data_2g5m_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2g5m _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 56.9 mtt . . . . . 0 N--CA 1.433 -1.292 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . 0.54 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 27.0 mt-10 -79.95 98.82 7.32 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.462 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 1.0 OUTLIER -82.67 89.84 6.78 Favored 'General case' 0 C--N 1.311 -1.105 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 174.602 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 13.5 p90 -110.59 142.11 25.42 Favored Pre-proline 0 C--N 1.286 -2.158 0 CA-C-N 116.038 -0.528 . . . . 0.0 112.128 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -68.78 129.46 18.7 Favored 'Trans proline' 0 N--CA 1.451 -1.024 0 C-N-CA 122.67 2.247 . . . . 0.0 112.482 178.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.481 HG13 ' HG3' ' B' ' 53' ' ' ARG . 79.1 t -120.88 122.91 69.01 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.515 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.725 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . 0.423 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 31.3 tt0 -123.11 113.84 19.53 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 mt -104.26 160.4 14.91 Favored 'General case' 0 C--N 1.283 -2.309 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.342 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.454 ' HB3' ' NH2' ' B' ' 86' ' ' ARG . 8.5 pt-20 -123.55 113.68 19.04 Favored 'General case' 0 C--N 1.271 -2.821 0 CA-C-N 114.271 -1.331 . . . . 0.0 108.421 173.019 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.4 ptpt -79.82 156.93 27.16 Favored 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.421 -0.808 . . . . 0.0 110.496 -175.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -89.18 -173.13 3.92 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.163 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 35.8 t -68.99 -21.15 64.17 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 173.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -69.7 -46.82 65.14 Favored 'General case' 0 N--CA 1.44 -0.929 0 CA-C-N 114.318 -1.31 . . . . 0.0 108.48 173.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.3 -132.73 8.66 Favored Glycine 0 N--CA 1.419 -2.496 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -176.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 90.7 mt -95.65 179.0 5.28 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . 0.457 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -151.3 66.59 0.35 Allowed Glycine 0 CA--C 1.481 -2.07 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . 0.526 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 3.5 pt -151.71 -177.6 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.104 0 C-N-CA 124.608 1.163 . . . . 0.0 108.246 -177.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' SER . . . . . 0.424 ' HB2' HG21 ' B' ' 41' ' ' THR . 49.3 m -153.73 162.7 41.01 Favored 'General case' 0 C--N 1.261 -3.243 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.236 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 19.0 pt -127.92 164.4 29.43 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 -178.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -144.0 138.57 24.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 178.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -83.61 96.03 1.92 Allowed Glycine 0 N--CA 1.426 -2.028 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.936 178.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 24.8 mmt . . . . . 0 C--N 1.307 -1.281 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 177.341 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 96.6 mt . . . . . 0 CA--C 1.495 -1.165 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -136.9 109.58 0.73 Allowed Glycine 0 N--CA 1.411 -3.02 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.627 -178.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 33.8 mm -89.62 84.55 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.89 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 175.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.493 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 90.4 m-85 -82.91 164.97 20.13 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.192 -1.367 . . . . 0.0 109.235 -176.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 52.1 t -73.21 126.47 33.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 176.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -86.87 -36.7 18.28 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.052 -176.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 41' ' ' THR . . . . . 0.424 HG21 ' HB2' ' B' ' 20' ' ' SER . 1.3 t -160.88 165.87 29.41 Favored 'General case' 0 N--CA 1.423 -1.791 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.208 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.3 p -139.1 94.22 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-O 122.562 1.173 . . . . 0.0 109.077 177.109 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 45.6 m -65.74 126.79 29.54 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-N 113.064 -1.88 . . . . 0.0 113.038 -173.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . 0.452 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 9.2 pt-20 -53.13 -31.4 42.15 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 125.218 1.407 . . . . 0.0 113.254 -179.089 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -64.65 -29.69 75.9 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 121.427 -0.416 . . . . 0.0 112.908 -179.503 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.457 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -95.98 165.79 24.43 Favored Glycine 0 N--CA 1.422 -2.298 0 C-N-CA 119.884 -1.15 . . . . 0.0 113.527 -176.031 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -58.45 -33.66 69.98 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 113.358 -1.421 . . . . 0.0 113.48 -175.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -59.51 -38.87 82.08 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -175.565 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . 0.452 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 7.9 t60 -75.06 -38.49 61.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.11 0.481 . . . . 0.0 110.145 -178.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 22.5 mtm-85 -77.89 -29.55 50.28 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.682 -175.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . 0.549 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 23.9 t70 -80.0 -53.78 6.41 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 176.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.39 39.66 4.16 Favored Glycine 0 CA--C 1.497 -1.077 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 179.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.549 ' HD3' ' OD2' ' B' ' 51' ' ' ASP . 0.5 OUTLIER -103.07 -69.41 0.79 Allowed 'General case' 0 N--CA 1.425 -1.717 0 CA-C-N 114.618 -0.791 . . . . 0.0 109.532 -174.26 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.598 HD11 ' CE2' ' B' ' 89' ' ' PHE . 52.1 mt -85.61 108.34 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 174.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 32.5 mt-30 -101.9 167.7 9.89 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -176.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 9.5 p -70.73 -4.54 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.568 1.641 0 CA-C-O 121.79 0.805 . . . . 0.0 112.3 -173.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -114.16 7.05 16.51 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.889 0.852 . . . . 0.0 109.232 -175.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -95.21 165.01 12.61 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.809 -176.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . 0.493 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 23.8 tp -136.5 133.98 37.1 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.668 -176.773 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 69.3 mt -80.48 96.51 6.78 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 176.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.517 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 38.8 t -78.4 -45.67 25.99 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-O 121.66 0.743 . . . . 0.0 109.917 178.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -154.11 151.69 29.57 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 114.968 -1.015 . . . . 0.0 109.931 174.167 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . 0.417 HG11 ' HB ' ' B' ' 66' ' ' THR . 4.3 p -95.28 -173.49 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 178.224 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . 0.445 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 13.0 t70 -47.26 -49.62 23.09 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -139.6 43.06 1.18 Allowed Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 119.29 -1.433 . . . . 0.0 113.964 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 66' ' ' THR . . . . . 0.417 ' HB ' HG11 ' B' ' 63' ' ' VAL . 31.8 m -160.64 115.66 2.21 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 178.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 43.4 m -76.75 133.76 39.36 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-O 121.133 0.492 . . . . 0.0 110.891 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.517 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 4.1 mm? -87.42 -68.06 0.78 Allowed 'General case' 0 N--CA 1.434 -1.228 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.995 177.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 59.9 t 70.05 -40.46 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 124.456 1.102 . . . . 0.0 111.52 -177.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . 0.404 ' H ' ' C ' ' B' ' 68' ' ' LEU . . . 157.44 85.22 0.05 OUTLIER Glycine 0 N--CA 1.417 -2.628 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.31 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . 0.441 HG22 ' O ' ' B' ' 72' ' ' THR . 35.5 m -105.58 -172.73 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 123.543 0.737 . . . . 0.0 109.49 -178.311 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 72' ' ' THR . . . . . 0.441 ' O ' HG22 ' B' ' 71' ' ' VAL . 19.8 p -81.64 157.03 24.81 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 172.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -61.49 -35.59 78.11 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.194 0.521 . . . . 0.0 110.735 -176.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 25.4 m -62.65 -38.02 88.66 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.915 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -63.83 -49.13 74.04 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.521 ' O ' HG13 ' B' ' 79' ' ' VAL . . . -61.64 -42.95 99.62 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.793 -178.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.04 -32.51 73.02 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.278 0.561 . . . . 0.0 110.696 178.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 8.1 t -82.38 -28.45 31.47 Favored 'General case' 0 N--CA 1.428 -1.56 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.059 -177.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.521 HG13 ' O ' ' B' ' 76' ' ' ALA . 7.2 p -71.44 -33.01 48.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 O-C-N 121.412 -0.805 . . . . 0.0 109.714 -174.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 29.1 mt -69.81 -16.88 63.35 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.573 -1.194 . . . . 0.0 111.02 176.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -96.14 -24.22 16.39 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.049 0.452 . . . . 0.0 110.787 178.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 29.2 m-80 -82.68 -21.5 34.89 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 121.373 0.606 . . . . 0.0 111.351 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.406 ' HB ' HG13 ' B' ' 87' ' ' VAL . 7.4 p -85.32 167.75 15.31 Favored 'General case' 0 N--CA 1.425 -1.683 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.928 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 37.4 mmtm -67.89 -173.76 0.39 Allowed 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 123.425 0.69 . . . . 0.0 112.422 179.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -75.16 -30.61 58.67 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.17 -0.923 . . . . 0.0 112.064 -178.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . 0.454 ' NH2' ' HB3' ' B' ' 11' ' ' GLU . 21.4 ttm-85 -130.62 116.09 17.62 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.062 0.458 . . . . 0.0 110.003 175.067 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . 0.445 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 5.8 m -136.71 144.64 31.93 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.737 179.172 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . 0.423 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 99.7 mtt180 -91.8 129.12 37.82 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 175.735 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.598 ' CE2' HD11 ' B' ' 54' ' ' ILE . 2.0 m-85 -105.93 161.0 14.84 Favored 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 178.674 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.484 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 62.1 mtt -109.14 106.64 16.62 Favored 'General case' 0 C--N 1.286 -2.167 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 169.449 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.486 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.3 mp -87.57 135.48 25.28 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 CA-C-N 114.459 -1.246 . . . . 0.0 107.648 178.492 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . 0.54 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -127.0 104.06 0.69 Allowed Glycine 0 CA--C 1.465 -3.088 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 177.186 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 11.2 ptp180 . . . . . 0 C--N 1.271 -2.809 0 N-CA-C 108.963 -0.754 . . . . 0.0 108.963 -179.892 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 24.7 mmt . . . . . 0 N--CA 1.434 -1.23 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . 0.501 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 19.0 mt-10 -89.85 100.25 13.1 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -95.46 93.93 7.5 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 177.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -118.53 141.48 29.87 Favored Pre-proline 0 C--N 1.283 -2.323 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.067 178.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -79.51 143.51 17.15 Favored 'Trans proline' 0 N--CA 1.446 -1.268 0 C-N-CA 122.151 1.901 . . . . 0.0 112.306 -179.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.414 ' CG1' ' HB3' ' B' ' 53' ' ' ARG . 53.8 t -131.49 127.7 59.99 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.981 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 176.599 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . 0.428 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 32.0 tt0 -110.4 121.61 45.72 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -177.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.469 HD23 ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -114.61 165.6 12.6 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 121.515 0.674 . . . . 0.0 110.707 178.685 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -115.52 126.63 54.52 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 105.728 -1.953 . . . . 0.0 105.728 175.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -79.85 160.45 26.08 Favored 'General case' 0 N--CA 1.417 -2.092 0 C-N-CA 117.627 -1.629 . . . . 0.0 107.022 170.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -115.75 178.31 4.36 Favored 'General case' 0 C--N 1.258 -3.391 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 -178.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 13.1 t -67.32 -20.54 65.62 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 179.398 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -92.61 7.24 44.22 Favored 'General case' 0 CA--C 1.555 1.168 0 CA-C-O 121.869 0.843 . . . . 0.0 109.42 176.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.57 -115.93 4.63 Favored Glycine 0 N--CA 1.435 -1.421 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.493 178.506 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -103.05 -173.19 2.25 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 121.42 0.629 . . . . 0.0 110.483 -177.282 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . 0.419 ' CA ' ' HA3' ' B' ' 46' ' ' GLY . . . -149.44 53.75 0.51 Allowed Glycine 0 CA--C 1.491 -1.433 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 178.291 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 2.6 pt -154.3 -179.99 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-O 121.961 0.886 . . . . 0.0 111.407 -175.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 51.0 m -152.49 131.45 12.56 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 175.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . 0.445 ' HB ' HG21 ' B' ' 37' ' ' ILE . 15.6 pt -108.66 162.53 6.51 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 C-N-CA 122.713 0.405 . . . . 0.0 109.946 -178.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . 0.449 ' HB ' ' HB2' ' B' ' 40' ' ' LYS . 9.5 tp -136.22 136.69 49.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 CA-C-O 121.134 0.493 . . . . 0.0 110.673 -178.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -82.58 105.63 2.64 Favored Glycine 0 N--CA 1.426 -2.022 0 CA-C-N 115.663 -0.699 . . . . 0.0 112.527 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 24' ' ' MET . . . . . 0.525 ' O ' ' HG ' ' B' ' 35' ' ' LEU . 26.3 mmt . . . . . 0 C--N 1.306 -1.322 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 176.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . 0.525 ' HG ' ' O ' ' B' ' 24' ' ' MET . 15.4 tp . . . . . 0 N--CA 1.429 -1.491 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . 0.438 ' H ' ' HG ' ' B' ' 35' ' ' LEU . . . -137.06 87.72 0.22 Allowed Glycine 0 N--CA 1.422 -2.296 0 C-N-CA 119.882 -1.151 . . . . 0.0 111.724 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . 0.445 HG21 ' HB ' ' B' ' 21' ' ' ILE . 34.5 mm -84.62 80.32 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 176.233 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -77.17 169.93 17.45 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.172 -176.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 49.1 t -80.36 135.46 25.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . 0.449 ' HB2' ' HB ' ' B' ' 22' ' ' ILE . 2.4 ttpm? -95.84 -41.47 8.81 Favored 'General case' 0 CA--C 1.482 -1.652 0 CA-C-O 121.187 0.517 . . . . 0.0 109.899 -178.125 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 1.1 m -154.83 146.98 23.72 Favored 'General case' 1 N--CA 1.369 -4.483 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -174.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 39.5 t -114.76 105.69 19.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 175.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 7.2 m -64.41 122.68 17.3 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.215 -174.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . 0.486 ' HG2' ' CE1' ' B' ' 49' ' ' HIS . 36.1 mt-10 -66.8 -28.36 68.31 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.457 -175.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.3 -1.11 85.4 Favored Glycine 0 N--CA 1.435 -1.401 0 CA-C-N 115.042 -0.981 . . . . 0.0 113.396 -179.266 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.419 ' HA3' ' CA ' ' B' ' 18' ' ' GLY . . . -117.07 170.29 13.38 Favored Glycine 0 N--CA 1.411 -2.972 0 C-N-CA 119.933 -1.127 . . . . 0.0 112.818 -178.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -60.72 -35.79 77.23 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 114.088 1.144 . . . . 0.0 114.088 -174.249 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . 0.469 ' HA ' HD23 ' B' ' 10' ' ' LEU . . . -63.28 -38.74 92.35 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 113.199 0.815 . . . . 0.0 113.199 -174.277 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . 0.486 ' CE1' ' HG2' ' B' ' 44' ' ' GLU . 4.1 t60 -74.15 -39.34 63.33 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.659 0.742 . . . . 0.0 109.342 -179.199 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 -76.63 -26.2 54.65 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 114.862 -1.063 . . . . 0.0 111.785 -175.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . 0.519 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 12.6 t70 -77.92 -46.18 22.0 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 176.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 97.08 16.34 35.76 Favored Glycine 0 CA--C 1.498 -1.03 0 CA-C-N 115.515 -0.766 . . . . 0.0 112.624 172.399 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.519 ' HD3' ' OD2' ' B' ' 51' ' ' ASP . 1.5 mpt_? -91.96 -63.46 1.24 Allowed 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 113.335 0.865 . . . . 0.0 113.335 -177.124 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.489 HD13 ' CE2' ' B' ' 89' ' ' PHE . 39.4 mt -69.3 133.09 32.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 C-N-CA 119.805 -0.758 . . . . 0.0 110.53 176.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 30.7 mm-40 -113.37 153.66 28.19 Favored 'General case' 0 CA--C 1.511 -0.543 0 C-N-CA 122.408 0.283 . . . . 0.0 110.634 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.3 p -73.6 -7.48 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.86 0 CA-C-O 121.709 0.766 . . . . 0.0 111.986 -176.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -114.35 9.83 16.97 Favored 'General case' 0 C--N 1.293 -1.879 0 O-C-N 121.581 -0.699 . . . . 0.0 111.95 -175.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -112.42 177.78 4.52 Favored 'General case' 0 C--O 1.244 0.784 0 CA-C-O 120.979 0.418 . . . . 0.0 111.767 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 24.9 tp -126.91 128.22 46.12 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.739 -176.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 31.7 mt -90.15 107.68 19.28 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 105.569 -2.011 . . . . 0.0 105.569 175.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.492 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 41.4 t -79.2 -74.36 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.19 -2.03 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -118.6 165.2 14.24 Favored 'General case' 0 C--N 1.269 -2.903 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.032 -173.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 4.6 p -113.34 -175.19 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -174.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . 0.428 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 12.6 t70 -40.18 -63.35 0.62 Allowed 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 125.76 1.624 . . . . 0.0 113.918 -178.709 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -134.68 41.01 1.5 Allowed Glycine 0 CA--C 1.496 -1.133 0 C-N-CA 119.333 -1.413 . . . . 0.0 113.401 -178.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 37.7 m -150.35 126.24 10.44 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 178.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 2.3 p -84.18 133.18 34.61 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 115.457 -0.792 . . . . 0.0 112.047 -177.09 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.492 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 4.2 mm? -118.69 141.91 48.16 Favored 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 175.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 44.6 t -123.47 -42.59 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 175.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 175.49 81.0 0.05 OUTLIER Glycine 0 N--CA 1.409 -3.164 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.552 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 27.1 m -100.91 -177.39 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.217 0 CA-C-N 114.197 -1.002 . . . . 0.0 109.532 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 72.0 p -76.1 163.4 27.15 Favored 'General case' 0 N--CA 1.432 -1.359 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 177.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -61.93 -31.85 72.2 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.651 0.739 . . . . 0.0 109.412 177.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 28.1 t -72.69 -42.6 64.05 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.872 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 19.4 t80 -62.46 -47.81 82.4 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.577 ' O ' HG11 ' B' ' 79' ' ' VAL . . . -61.72 -40.32 94.64 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.577 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.73 -28.84 69.35 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.499 0.666 . . . . 0.0 110.959 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.8 m -85.16 -16.94 38.75 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.171 -177.4 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.577 HG11 ' O ' ' B' ' 76' ' ' ALA . 4.2 p -72.91 -28.25 26.5 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.518 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 -179.236 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 55.2 mt -71.81 -7.14 46.48 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 114.09 -1.414 . . . . 0.0 110.815 177.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 88.3 mtt180 -103.65 -14.7 16.03 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 121.37 0.605 . . . . 0.0 109.707 178.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 -86.59 -29.03 22.91 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.471 176.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.481 ' HB ' HG11 ' B' ' 87' ' ' VAL . 9.3 p -69.49 170.08 11.27 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 115.402 1.63 . . . . 0.0 115.402 -173.392 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 35.1 mttp -73.56 -162.4 0.13 Allowed 'General case' 0 C--O 1.241 0.622 0 CA-C-N 114.845 -1.07 . . . . 0.0 110.253 173.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -80.0 -38.5 19.06 Favored Glycine 0 N--CA 1.437 -1.291 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.871 178.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 41.0 ttm180 -120.96 123.52 42.65 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . 0.481 HG11 ' HB ' ' B' ' 83' ' ' THR . 26.7 m -139.71 142.76 31.88 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 CA-C-O 120.867 0.365 . . . . 0.0 111.543 -177.767 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . 0.428 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 52.2 mtt180 -99.4 116.68 32.13 Favored 'General case' 0 CA--C 1.485 -1.556 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.164 176.528 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.489 ' CE2' HD13 ' B' ' 54' ' ' ILE . 6.8 m-85 -92.91 152.44 19.37 Favored 'General case' 0 C--N 1.285 -2.234 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.507 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 90' ' ' MET . . . . . . . . . . . . . 86.0 mtp -102.1 106.98 17.93 Favored 'General case' 0 C--N 1.286 -2.177 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 171.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.433 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.4 mp -84.77 120.86 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.942 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . 0.501 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -117.27 109.95 1.97 Allowed Glycine 1 CA--C 1.445 -4.283 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 179.219 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 7.3 tpp180 . . . . . 0 C--N 1.279 -2.475 0 CA-C-N 114.6 -0.8 . . . . 0.0 109.431 177.122 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 19.7 ptp . . . . . 0 N--CA 1.425 -1.709 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -84.99 104.93 15.37 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 -177.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -79.55 83.73 5.5 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 173.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -102.58 143.02 25.76 Favored Pre-proline 0 C--N 1.294 -1.845 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.396 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . 0.508 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 51.1 Cg_endo -79.28 134.61 11.53 Favored 'Trans proline' 0 N--CA 1.429 -2.267 0 C-N-CA 121.634 1.556 . . . . 0.0 112.291 177.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 73.4 t -115.22 127.54 72.75 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 175.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . 0.48 ' O ' ' HD2' ' B' ' 53' ' ' ARG . 43.3 tt0 -119.59 116.12 25.38 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 -176.291 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.519 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 0.5 OUTLIER -102.41 153.27 20.19 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.766 0.793 . . . . 0.0 110.761 -177.949 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -99.68 103.36 15.03 Favored 'General case' 0 C--N 1.276 -2.607 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 174.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . 0.426 ' HB2' ' O ' ' B' ' 85' ' ' GLY . 6.5 mmmm -81.61 157.02 24.86 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 114.301 1.223 . . . . 0.0 114.301 -171.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . 0.409 ' H ' ' HA3' ' B' ' 16' ' ' GLY . 22.1 m-20 -128.47 178.82 6.02 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 171.184 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 14.7 m -74.61 -19.56 60.26 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.652 0.739 . . . . 0.0 110.033 177.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 9.2 tp10 -128.56 31.49 4.98 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 105.762 -1.94 . . . . 0.0 105.762 176.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . 0.409 ' HA3' ' H ' ' B' ' 13' ' ' ASP . . . -71.21 -5.03 58.16 Favored Glycine 0 CA--C 1.494 -1.263 0 CA-C-N 113.662 -1.608 . . . . 0.0 116.481 -169.181 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -75.16 86.45 2.41 Favored 'General case' 0 N--CA 1.429 -1.488 0 C-N-CA 119.302 -0.959 . . . . 0.0 111.096 177.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -96.78 55.45 1.37 Allowed Glycine 0 CA--C 1.484 -1.85 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 6.6 pt -161.67 -177.49 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 C-N-CA 124.7 1.2 . . . . 0.0 107.92 -175.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' SER . . . . . 0.404 ' HB2' HG23 ' B' ' 41' ' ' THR . 43.2 m -149.65 145.61 26.83 Favored 'General case' 0 C--N 1.27 -2.865 0 N-CA-C 105.425 -2.065 . . . . 0.0 105.425 172.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . 0.416 ' HB ' HG22 ' B' ' 37' ' ' ILE . 16.0 pt -115.95 154.1 17.48 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.297 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.3 tp -127.08 136.79 59.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 CA-C-O 120.884 0.374 . . . . 0.0 110.764 -176.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.58 98.08 2.38 Favored Glycine 0 N--CA 1.434 -1.438 0 C-N-CA 121.058 -0.591 . . . . 0.0 111.791 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 95.4 mmm . . . . . 0 C--N 1.302 -1.492 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 178.408 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 74.9 mt . . . . . 0 N--CA 1.431 -1.399 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -107.75 98.27 1.24 Allowed Glycine 0 N--CA 1.404 -3.437 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 176.443 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . 0.416 HG22 ' HB ' ' B' ' 21' ' ' ILE . 27.9 mm -87.35 87.78 2.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 177.058 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -85.69 166.54 16.06 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.399 -1.273 . . . . 0.0 108.705 -176.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 57.4 t -77.9 136.47 24.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 175.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -96.04 -42.07 8.44 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -178.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 41' ' ' THR . . . . . 0.404 HG23 ' HB2' ' B' ' 20' ' ' SER . 3.5 t -157.05 168.8 26.41 Favored 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 21.3 t -130.47 97.35 3.19 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 178.265 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 40.5 m -73.89 124.64 26.54 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 124.281 1.033 . . . . 0.0 111.709 -176.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . 0.504 ' HA ' ' CB ' ' B' ' 49' ' ' HIS . 1.7 pm0 -65.53 -22.41 66.71 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 124.44 1.096 . . . . 0.0 113.904 -178.042 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.54 -23.87 72.23 Favored Glycine 0 N--CA 1.439 -1.128 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.243 176.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -104.4 173.15 21.01 Favored Glycine 0 N--CA 1.424 -2.163 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.837 -177.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -58.54 -41.34 85.34 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 125.205 1.402 . . . . 0.0 114.265 -175.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . 0.481 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -57.19 -37.52 72.28 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -173.39 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . 0.504 ' CB ' ' HA ' ' B' ' 44' ' ' GLU . 8.4 t60 -74.97 -35.4 62.07 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -178.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 68.9 mtt180 -68.43 -47.74 66.41 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 -178.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -60.41 -61.39 2.63 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 114.456 -1.247 . . . . 0.0 110.722 176.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 91.02 6.14 67.23 Favored Glycine 0 N--CA 1.433 -1.528 0 N-CA-C 114.824 0.69 . . . . 0.0 114.824 175.144 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.48 ' HD2' ' O ' ' B' ' 9' ' ' GLU . 65.4 mtt180 -83.3 -33.64 25.9 Favored 'General case' 0 N--CA 1.441 -0.892 0 CA-C-N 118.392 1.096 . . . . 0.0 111.316 179.107 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.437 HD12 ' CE2' ' B' ' 89' ' ' PHE . 28.8 mt -83.29 117.03 28.4 Favored 'Isoleucine or valine' 0 C--O 1.248 0.984 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 174.116 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 22.7 mt-30 -91.45 163.96 13.99 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 121.356 0.598 . . . . 0.0 110.47 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 13.2 p -75.51 -2.11 3.79 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.854 0 CA-C-O 122.488 1.137 . . . . 0.0 109.976 178.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -114.02 0.06 14.21 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.058 -175.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -82.29 174.34 11.23 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 112.926 0.713 . . . . 0.0 112.926 -174.076 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 25.8 tp -141.6 131.15 23.91 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.54 -0.755 . . . . 0.0 110.521 -175.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -81.71 95.63 7.29 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.688 0.756 . . . . 0.0 110.22 178.227 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.566 ' HB ' ' O ' ' B' ' 90' ' ' MET . 27.8 t -86.95 -40.73 14.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.695 177.03 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . 0.481 ' HG3' ' HA ' ' B' ' 67' ' ' SER . 32.4 tt0 -156.2 148.75 23.72 Favored 'General case' 0 C--N 1.273 -2.727 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.48 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . 0.479 ' O ' ' HG2' ' B' ' 62' ' ' GLU . 9.9 p -102.39 -168.45 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 104.912 -2.255 . . . . 0.0 104.912 176.419 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -50.19 -54.21 22.47 Favored 'General case' 0 N--CA 1.479 1.004 0 CA-C-N 119.189 0.904 . . . . 0.0 112.27 178.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -106.16 -53.78 0.73 Allowed Glycine 0 C--N 1.308 -0.989 0 C-N-CA 119.538 -1.315 . . . . 0.0 114.088 -178.3 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 6.1 m -72.37 120.81 18.51 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 123.101 0.56 . . . . 0.0 112.492 -174.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 67' ' ' SER . . . . . 0.481 ' HA ' ' HG3' ' B' ' 62' ' ' GLU . 64.9 m -86.12 121.15 28.31 Favored 'General case' 0 N--CA 1.435 -1.204 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 174.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.523 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 28.9 mt -83.3 100.23 10.51 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-O 121.087 0.47 . . . . 0.0 110.226 -179.308 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 29.0 m -89.48 12.5 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-O 121.759 0.79 . . . . 0.0 109.463 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 111.71 90.23 1.94 Allowed Glycine 0 N--CA 1.402 -3.615 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -174.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 26.4 m -117.15 174.4 3.73 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.28 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 20.7 p -76.87 159.86 29.7 Favored 'General case' 0 N--CA 1.413 -2.281 0 CA-C-O 120.957 0.408 . . . . 0.0 110.051 177.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 60.6 tt0 -58.66 -35.28 72.29 Favored 'General case' 0 C--N 1.311 -1.096 0 C-N-CA 123.788 0.835 . . . . 0.0 109.824 178.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 19.7 m -70.96 -39.14 72.73 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.576 179.559 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -62.56 -48.9 77.45 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.068 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.51 ' O ' HG11 ' B' ' 79' ' ' VAL . . . -57.81 -45.42 86.11 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.258 179.304 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.01 -39.19 91.42 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.641 0.734 . . . . 0.0 110.792 178.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 50.6 m -71.83 -27.5 62.95 Favored 'General case' 0 N--CA 1.433 -1.32 0 CA-C-N 115.377 -0.829 . . . . 0.0 112.511 -177.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.51 HG11 ' O ' ' B' ' 76' ' ' ALA . 5.0 p -77.25 -30.4 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 C-N-CA 119.546 -0.862 . . . . 0.0 108.852 -177.164 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . 0.477 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 77.1 mt -67.46 -35.85 80.01 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.306 176.08 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 79.4 mtp180 -78.05 -32.74 51.01 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.275 178.317 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -72.3 -36.71 69.0 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 123.234 0.614 . . . . 0.0 111.478 -179.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.434 ' HB ' HG13 ' B' ' 87' ' ' VAL . 8.5 p -67.82 159.81 29.57 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 113.693 0.997 . . . . 0.0 113.693 -177.117 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -66.56 -166.07 0.04 OUTLIER 'General case' 0 C--O 1.255 1.371 0 C-N-CA 125.729 1.612 . . . . 0.0 114.806 -174.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . 0.426 ' O ' ' HB2' ' B' ' 12' ' ' LYS . . . -70.86 -17.12 75.03 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 114.631 -1.168 . . . . 0.0 113.3 -177.514 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . 0.519 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 57.1 ttp180 -157.49 118.3 3.54 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 121.165 0.507 . . . . 0.0 111.016 174.465 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . 0.434 HG13 ' HB ' ' B' ' 83' ' ' THR . 14.8 m -132.1 145.72 34.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.237 179.351 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -98.05 128.89 44.85 Favored 'General case' 0 CA--C 1.482 -1.654 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.518 178.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.508 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 4.8 m-85 -105.38 157.36 17.39 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 106.965 -1.495 . . . . 0.0 106.965 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.566 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 63.0 mtt -109.87 117.51 34.02 Favored 'General case' 0 C--N 1.282 -2.352 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 172.134 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 1.4 mp -105.96 122.38 59.5 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 -179.157 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.37 103.76 2.51 Favored Glycine 0 CA--C 1.464 -3.11 0 N-CA-C 109.169 -1.573 . . . . 0.0 109.169 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 9.3 tpp180 . . . . . 0 C--N 1.265 -3.073 0 CA-C-N 114.214 -0.993 . . . . 0.0 110.572 -175.749 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 92.8 mmm . . . . . 0 CA--C 1.469 -2.171 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . 0.48 ' OE2' ' HD2' ' B' ' 93' ' ' ARG . 12.0 mt-10 -98.62 96.4 7.92 Favored 'General case' 0 C--N 1.275 -2.643 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.013 -175.614 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -84.38 97.51 9.52 Favored 'General case' 0 N--CA 1.427 -1.606 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 177.201 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -130.85 147.48 66.39 Favored Pre-proline 0 C--N 1.279 -2.495 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.481 177.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . 0.424 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 49.7 Cg_endo -75.84 136.89 19.28 Favored 'Trans proline' 0 N--CA 1.44 -1.65 0 C-N-CA 121.868 1.712 . . . . 0.0 111.625 175.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 91.4 t -121.56 148.54 24.93 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.071 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -126.98 143.65 51.23 Favored 'General case' 0 C--N 1.279 -2.469 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -177.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.421 HD11 ' CB ' ' B' ' 48' ' ' ALA . 0.8 OUTLIER -141.04 157.18 45.67 Favored 'General case' 0 CA--C 1.478 -1.789 0 CA-C-O 121.05 0.452 . . . . 0.0 109.908 174.431 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -127.15 112.59 15.32 Favored 'General case' 0 C--N 1.275 -2.632 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 177.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 5.4 ptpp? -77.14 150.77 35.55 Favored 'General case' 0 C--N 1.283 -2.317 0 CA-C-N 115.143 -0.935 . . . . 0.0 113.357 -172.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -93.78 -172.93 3.01 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 177.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 12.3 t -71.25 -25.65 62.57 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.954 -1.499 . . . . 0.0 106.954 173.09 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 11.9 tp10 -67.27 -20.87 65.71 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.444 172.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.07 -116.06 4.83 Favored Glycine 0 N--CA 1.416 -2.657 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -177.188 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -101.2 -175.06 2.76 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -178.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . 0.422 ' CA ' ' HA3' ' B' ' 46' ' ' GLY . . . -150.45 67.99 0.34 Allowed Glycine 0 CA--C 1.477 -2.325 0 N-CA-C 110.931 -0.868 . . . . 0.0 110.931 -179.754 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 4.3 pt -162.59 169.98 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 C-N-CA 125.277 1.431 . . . . 0.0 107.867 -176.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.4 m -131.76 141.99 49.65 Favored 'General case' 0 C--N 1.253 -3.611 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 174.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . 0.43 ' HB ' HG21 ' B' ' 37' ' ' ILE . 8.6 pt -115.23 149.37 17.47 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.012 0 O-C-N 123.45 0.469 . . . . 0.0 109.81 -178.188 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.1 tp -119.22 134.88 61.42 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -177.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.74 94.58 1.55 Allowed Glycine 0 N--CA 1.43 -1.707 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.688 -177.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 88.9 mmm . . . . . 0 C--O 1.253 1.268 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.934 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 78.6 mt . . . . . 0 C--O 1.235 0.331 0 N-CA-C 113.955 1.094 . . . . 0.0 113.955 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -111.18 103.64 1.61 Allowed Glycine 0 N--CA 1.423 -2.212 0 N-CA-C 108.614 -1.794 . . . . 0.0 108.614 175.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . 0.43 HG21 ' HB ' ' B' ' 21' ' ' ILE . 26.3 mm -94.15 90.38 2.8 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-O 121.674 0.749 . . . . 0.0 109.403 -177.759 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -88.79 167.07 13.59 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.207 -178.128 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 64.7 t -80.77 130.3 36.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 CA-C-O 121.28 0.562 . . . . 0.0 109.641 175.387 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -94.42 -41.11 9.56 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.218 -176.681 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -156.57 164.0 38.7 Favored 'General case' 0 N--CA 1.437 -1.082 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 21.3 t -112.05 102.52 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.031 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 174.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 31.2 m -69.73 122.04 18.38 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 124.112 0.965 . . . . 0.0 111.825 -174.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . 0.461 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 32.8 mt-10 -58.23 -41.45 84.15 Favored 'General case' 0 CA--C 1.507 -0.695 0 C-N-CA 124.662 1.185 . . . . 0.0 111.736 -175.568 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -67.22 -12.24 60.37 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 115.197 -0.911 . . . . 0.0 114.237 -177.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.422 ' HA3' ' CA ' ' B' ' 18' ' ' GLY . . . -112.23 170.0 13.35 Favored Glycine 0 N--CA 1.41 -3.078 0 C-N-CA 120.124 -1.036 . . . . 0.0 113.797 -175.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -57.64 -35.07 70.02 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 115.045 1.498 . . . . 0.0 115.045 -171.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . 0.421 ' CB ' HD11 ' B' ' 10' ' ' LEU . . . -67.53 -35.46 79.12 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 119.952 -0.699 . . . . 0.0 112.695 -174.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . 0.461 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 5.4 t60 -78.53 -39.62 37.38 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 64.4 mtp180 -67.13 -39.48 86.6 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.683 -177.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -79.56 -48.63 13.51 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 177.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 94.15 51.22 2.1 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -178.452 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 13.1 mmt180 -109.75 -79.44 0.58 Allowed 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 111.85 0.315 . . . . 0.0 111.85 -175.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.478 HD12 ' CE2' ' B' ' 89' ' ' PHE . 62.7 mt -71.16 132.7 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.977 -179.203 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 -103.58 173.51 6.27 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.234 0.54 . . . . 0.0 110.996 -177.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.1 p -79.27 2.43 2.17 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.145 0 CA-C-O 121.949 0.88 . . . . 0.0 111.638 -174.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -121.46 11.36 10.65 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 122.218 1.009 . . . . 0.0 108.683 -175.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 19.2 m-20 -89.07 168.49 12.29 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.929 -175.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . 0.497 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 23.5 tp -144.69 131.47 20.14 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 124.008 0.923 . . . . 0.0 108.83 -177.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 76.6 mt -85.08 94.23 8.8 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.561 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.2 t -80.09 -39.96 19.89 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 CA-C-O 121.739 0.78 . . . . 0.0 110.147 177.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -160.0 156.73 27.53 Favored 'General case' 0 C--N 1.28 -2.451 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.41 173.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 5.7 p -102.01 -173.74 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 N-CA-C 105.455 -2.054 . . . . 0.0 105.455 177.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -53.79 -48.75 69.49 Favored 'General case' 0 C--N 1.311 -1.093 0 C-N-CA 122.992 0.517 . . . . 0.0 112.387 -179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -101.87 -60.21 0.77 Allowed Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 120.22 -0.991 . . . . 0.0 114.187 -179.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 9.1 m -77.57 129.66 35.93 Favored 'General case' 0 CA--C 1.557 1.248 0 CA-C-O 121.164 0.507 . . . . 0.0 112.201 -176.119 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 49.4 m -94.44 121.84 36.39 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.058 178.358 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.561 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 32.0 mt -88.9 111.89 22.64 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.105 0.478 . . . . 0.0 111.838 -175.352 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 43.6 t -85.57 -23.67 7.06 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 174.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 147.63 68.6 0.01 OUTLIER Glycine 0 CA--C 1.475 -2.42 0 N-CA-C 109.396 -1.481 . . . . 0.0 109.396 -177.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 28.2 m -85.22 172.08 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 CA-C-N 114.467 -0.867 . . . . 0.0 109.383 -177.094 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 24.6 p -71.7 157.2 38.36 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 120.93 0.395 . . . . 0.0 110.138 177.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -57.43 -39.4 76.13 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 123.345 0.658 . . . . 0.0 110.458 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 40.0 t -68.17 -37.8 81.38 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.01 179.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -66.44 -45.45 79.79 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -179.124 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.582 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.2 -44.02 97.95 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.505 178.426 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.98 -34.12 75.58 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 121.756 0.788 . . . . 0.0 110.599 177.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 39.3 m -79.31 -27.68 42.16 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 115.489 -0.778 . . . . 0.0 112.094 -178.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.582 HG12 ' O ' ' B' ' 76' ' ' ALA . 4.5 p -71.53 -31.97 44.43 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-O 121.906 0.86 . . . . 0.0 109.07 -175.711 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 53.9 mt -66.03 -29.44 69.8 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 114.528 -1.214 . . . . 0.0 110.553 176.425 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 71.4 mtt180 -90.74 -16.85 27.71 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.373 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -90.38 -14.65 32.58 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.038 0.447 . . . . 0.0 111.268 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.494 ' HB ' HG13 ' B' ' 87' ' ' VAL . 6.7 p -90.63 171.76 9.16 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 77.1 mttt -60.37 -178.7 0.09 Allowed 'General case' 0 C--O 1.245 0.817 0 C-N-CA 124.612 1.165 . . . . 0.0 114.077 -179.06 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.38 -52.06 46.98 Favored Glycine 0 N--CA 1.44 -1.049 0 CA-C-N 114.208 -1.36 . . . . 0.0 111.117 177.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 14.5 ttp180 -114.82 117.64 31.31 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 177.068 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . 0.494 HG13 ' HB ' ' B' ' 83' ' ' THR . 14.0 m -132.13 157.57 43.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.353 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 15.9 mtm180 -108.5 152.64 24.45 Favored 'General case' 0 N--CA 1.422 -1.833 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 179.435 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.478 ' CE2' HD12 ' B' ' 54' ' ' ILE . 1.7 m-85 -133.5 164.99 25.91 Favored 'General case' 0 C--N 1.267 -3.004 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 179.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.47 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 84.3 mtp -112.82 117.43 32.14 Favored 'General case' 0 C--N 1.286 -2.195 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 170.571 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.497 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.5 mp -102.88 133.18 47.36 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.395 -177.11 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -113.6 93.86 0.68 Allowed Glycine 0 CA--C 1.463 -3.208 0 N-CA-C 108.18 -1.968 . . . . 0.0 108.18 172.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . 0.48 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 36.8 ttm180 . . . . . 0 C--N 1.273 -2.754 0 CA-C-N 114.244 -0.978 . . . . 0.0 111.152 -175.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 20.2 ptp . . . . . 0 N--CA 1.437 -1.086 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . 0.493 ' OE2' ' HG2' ' B' ' 93' ' ' ARG . 2.6 mt-10 -116.35 101.56 8.77 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -93.1 91.04 7.13 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 -179.125 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -117.67 146.52 38.9 Favored Pre-proline 0 C--N 1.29 -1.998 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.307 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -81.1 144.25 14.72 Favored 'Trans proline' 0 N--CA 1.449 -1.089 0 C-N-CA 122.5 2.133 . . . . 0.0 112.811 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.472 HG12 ' HB3' ' B' ' 53' ' ' ARG . 73.6 t -127.94 133.87 66.39 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.032 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -121.24 125.49 47.24 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 118.477 0.58 . . . . 0.0 110.173 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.424 ' CD1' ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -148.82 175.95 10.81 Favored 'General case' 0 N--CA 1.438 -1.037 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -178.188 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -147.03 178.02 8.69 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.086 -178.622 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -93.02 153.85 18.48 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.248 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . 0.549 ' HB2' ' N ' ' B' ' 47' ' ' ALA . 10.8 t70 -103.17 -164.37 1.07 Allowed 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' SER . . . . . 0.403 ' H ' ' CG ' ' B' ' 13' ' ' ASP . 22.8 p -55.43 -44.28 76.14 Favored 'General case' 0 C--O 1.243 0.756 0 C-N-CA 124.558 1.143 . . . . 0.0 111.57 -179.053 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -78.3 -48.72 15.06 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 177.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.08 -120.54 1.64 Allowed Glycine 0 N--CA 1.426 -2.006 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.831 178.171 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -89.23 101.4 14.06 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 121.397 0.618 . . . . 0.0 111.293 -178.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -92.12 59.84 2.7 Favored Glycine 0 C--O 1.21 -1.369 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 177.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . 0.442 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.0 pt -155.46 178.92 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 C-N-CA 125.406 1.482 . . . . 0.0 107.128 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' SER . . . . . 0.439 ' HB2' HG23 ' B' ' 41' ' ' THR . 51.0 m -158.19 155.81 29.71 Favored 'General case' 0 C--N 1.27 -2.88 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 176.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . 0.401 ' HB ' HG23 ' B' ' 37' ' ' ILE . 18.6 pt -115.71 161.12 14.69 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 O-C-N 123.445 0.466 . . . . 0.0 110.343 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . 0.443 ' HA ' ' NE2' ' B' ' 73' ' ' GLN . 8.1 tp -140.5 135.51 35.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.24 112.11 3.85 Favored Glycine 0 N--CA 1.428 -1.846 0 C-N-CA 120.494 -0.86 . . . . 0.0 111.982 -178.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 93.9 mmm . . . . . 0 C--N 1.302 -1.476 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 176.964 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . 0.5 ' O ' ' HA2' ' B' ' 70' ' ' GLY . 3.0 mm? . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 113.164 0.802 . . . . 0.0 113.164 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -99.0 103.82 2.8 Favored Glycine 0 N--CA 1.414 -2.805 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.854 -176.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . 0.401 HG23 ' HB ' ' B' ' 21' ' ' ILE . 30.2 mm -88.45 89.2 3.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.876 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.566 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.485 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 89.6 m-85 -82.3 173.45 12.06 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 114.674 -1.148 . . . . 0.0 109.981 -176.639 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 59.3 t -83.42 137.09 21.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 175.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 32.2 ttmt -93.77 -48.87 6.11 Favored 'General case' 0 N--CA 1.433 -1.289 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.784 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 41' ' ' THR . . . . . 0.45 ' HA ' HG21 ' B' ' 56' ' ' VAL . 5.2 t -150.03 170.79 18.05 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.442 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.7 p -156.42 113.25 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 C-N-CA 124.587 1.155 . . . . 0.0 108.005 -177.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 32.1 m -112.14 144.81 40.91 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 114.856 -1.066 . . . . 0.0 110.061 -171.199 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . 0.436 ' HA ' ' HB3' ' B' ' 49' ' ' HIS . 9.0 pt-20 -71.75 4.46 3.23 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -178.651 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.79 -19.5 79.89 Favored Glycine 0 N--CA 1.436 -1.329 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 172.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -113.03 169.49 12.97 Favored Glycine 0 N--CA 1.413 -2.86 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 175.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . 0.549 ' N ' ' HB2' ' B' ' 13' ' ' ASP . . . -75.18 -23.94 57.78 Favored 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 115.096 -0.552 . . . . 0.0 111.274 -175.251 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . 0.424 ' HA ' ' CD1' ' B' ' 10' ' ' LEU . . . -56.46 -44.56 80.67 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -176.111 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . 0.436 ' HB3' ' HA ' ' B' ' 44' ' ' GLU . 10.3 t60 -73.49 -41.27 63.32 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.381 -179.059 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 81.5 mtp180 -72.42 -34.88 68.15 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.43 0.633 . . . . 0.0 110.945 -174.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . 0.498 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 30.4 t70 -72.42 -49.99 29.55 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.889 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.7 27.49 9.64 Favored Glycine 0 CA--C 1.494 -1.259 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.486 172.132 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.498 ' HD3' ' OD2' ' B' ' 51' ' ' ASP . 5.4 mpt_? -101.39 -60.17 1.57 Allowed 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 112.008 0.373 . . . . 0.0 112.008 -179.276 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.554 HD13 ' CE2' ' B' ' 89' ' ' PHE . 58.7 mt -72.79 134.82 29.04 Favored 'Isoleucine or valine' 0 C--O 1.251 1.157 0 N-CA-C 107.1 -1.445 . . . . 0.0 107.1 169.61 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 15.3 mm100 -110.19 -170.74 1.7 Allowed 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -174.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.45 HG21 ' HA ' ' B' ' 41' ' ' THR . 8.0 p -100.39 4.87 10.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 CA-C-O 121.567 0.698 . . . . 0.0 110.083 174.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 19.9 t-20 -133.28 10.98 4.16 Favored 'General case' 0 C--N 1.311 -1.104 0 O-C-N 121.623 -0.673 . . . . 0.0 111.965 -174.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -94.86 -173.64 3.04 Favored 'General case' 0 C--N 1.318 -0.804 0 O-C-N 121.308 -0.87 . . . . 0.0 111.381 179.127 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . 0.485 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 25.8 tp -144.92 125.4 13.98 Favored 'General case' 0 C--N 1.318 -0.769 0 C-N-CA 123.194 0.598 . . . . 0.0 111.116 -172.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . 0.427 ' O ' HD12 ' B' ' 68' ' ' LEU . 68.9 mt -83.69 96.49 8.72 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.399 0.618 . . . . 0.0 109.369 178.799 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.627 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 9.2 t -79.28 -37.32 18.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-O 121.685 0.755 . . . . 0.0 111.133 178.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -157.02 153.51 28.09 Favored 'General case' 0 C--N 1.276 -2.608 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.506 176.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 5.2 p -100.52 -174.63 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.42 -1.975 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 178.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -53.18 -42.46 66.23 Favored 'General case' 0 C--N 1.311 -1.078 0 C-N-CA 124.138 0.975 . . . . 0.0 112.475 -178.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -106.91 -66.24 0.63 Allowed Glycine 0 N--CA 1.439 -1.161 0 C-N-CA 120.813 -0.708 . . . . 0.0 113.627 179.199 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 7.2 m -74.1 135.7 42.96 Favored 'General case' 0 CA--C 1.554 1.099 0 C-N-CA 122.882 0.473 . . . . 0.0 112.266 -175.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 15.9 m -96.31 126.49 41.55 Favored 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 177.116 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.627 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 28.9 mt -83.28 -69.86 0.6 Allowed 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 112.241 0.459 . . . . 0.0 112.241 -177.131 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 86.8 t 73.28 -27.2 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 124.189 0.995 . . . . 0.0 111.246 -175.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . 0.5 ' HA2' ' O ' ' B' ' 35' ' ' LEU . . . 153.16 81.39 0.03 OUTLIER Glycine 0 N--CA 1.42 -2.404 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -178.211 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.1 m -106.76 -179.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 39.9 p -78.63 156.51 29.03 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 175.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . 0.443 ' NE2' ' HA ' ' B' ' 22' ' ' ILE . 61.9 tt0 -58.4 -39.4 79.6 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.23 0.538 . . . . 0.0 110.637 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 14.9 m -66.82 -35.47 80.12 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.73 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -65.33 -49.36 69.71 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 179.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.548 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -59.51 -40.73 88.03 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.069 178.586 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.34 -32.65 73.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.331 0.586 . . . . 0.0 110.468 177.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.6 m -79.25 -28.44 42.43 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.454 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.548 HG12 ' O ' ' B' ' 76' ' ' ALA . 5.7 p -72.6 -36.31 53.23 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.889 0 C-N-CA 119.574 -0.851 . . . . 0.0 109.172 -176.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 26.3 mt -70.44 -7.14 40.97 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.848 178.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 68.5 mtp180 -108.66 -1.51 19.44 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 121.617 0.723 . . . . 0.0 110.102 177.438 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 32.2 m-80 -115.06 6.41 15.2 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.067 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.522 HG21 ' O ' ' B' ' 79' ' ' VAL . 7.7 p -87.2 175.81 7.87 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.323 -178.825 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 28.8 mmtm -75.64 -169.18 0.99 Allowed 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.472 0.709 . . . . 0.0 109.733 174.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.17 -38.97 45.93 Favored Glycine 0 N--CA 1.444 -0.827 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 177.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -124.31 131.56 53.52 Favored 'General case' 0 N--CA 1.431 -1.397 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 11.2 m -142.08 153.01 18.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 CA-C-O 121.53 0.681 . . . . 0.0 111.445 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 -96.05 164.07 12.86 Favored 'General case' 0 C--N 1.291 -1.975 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 174.05 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.554 ' CE2' HD13 ' B' ' 54' ' ' ILE . 8.9 m-85 -145.28 157.33 44.08 Favored 'General case' 0 C--N 1.284 -2.261 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 177.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.507 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 81.0 mtp -112.38 120.15 40.69 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 169.694 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.448 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -98.58 119.04 46.06 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.164 0 CA-C-N 114.246 -1.343 . . . . 0.0 109.485 -175.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -96.93 93.3 1.45 Allowed Glycine 0 CA--C 1.457 -3.57 0 N-CA-C 106.96 -2.456 . . . . 0.0 106.96 172.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . 0.493 ' HG2' ' OE2' ' B' ' 4' ' ' GLU . 5.9 tpt180 . . . . . 0 C--N 1.257 -3.429 0 CA-C-N 112.932 -1.634 . . . . 0.0 113.129 -174.278 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.438 -1.033 0 N-CA-C 104.704 -2.332 . . . . 0.0 104.704 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . 0.589 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 18.4 mt-10 -87.72 101.08 13.33 Favored 'General case' 0 C--N 1.293 -1.871 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.263 -171.128 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -85.62 85.73 7.4 Favored 'General case' 0 N--CA 1.428 -1.531 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 176.101 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -109.43 142.43 25.66 Favored Pre-proline 0 C--N 1.295 -1.801 0 C-N-CA 120.461 -0.496 . . . . 0.0 112.229 -178.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -80.34 126.4 6.17 Favored 'Trans proline' 0 N--CA 1.428 -2.371 0 C-N-CA 121.943 1.762 . . . . 0.0 112.541 177.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 95.2 t -107.08 151.94 8.78 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.82 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 175.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . 0.464 ' O ' ' HG2' ' B' ' 53' ' ' ARG . 45.0 tt0 -138.12 136.16 36.46 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 119.005 0.82 . . . . 0.0 109.696 -176.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.4 HD22 ' HA ' ' B' ' 48' ' ' ALA . 4.5 mt -139.34 165.31 27.54 Favored 'General case' 0 CA--C 1.475 -1.906 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 179.625 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -151.12 146.68 26.31 Favored 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 104.503 -2.406 . . . . 0.0 104.503 177.348 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.5 ptpt -88.41 171.33 10.2 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.883 0.849 . . . . 0.0 112.177 -174.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -99.92 176.61 5.37 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.804 -1.089 . . . . 0.0 108.214 176.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 7.0 m -59.66 -33.12 71.14 Favored 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 123.939 0.895 . . . . 0.0 109.261 175.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -77.15 -45.63 26.11 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 174.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.25 -138.36 7.65 Favored Glycine 0 N--CA 1.435 -1.406 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.273 179.255 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 91.8 mt -82.03 -176.24 6.04 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 123.033 0.533 . . . . 0.0 110.99 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -158.13 66.06 0.29 Allowed Glycine 0 CA--C 1.487 -1.665 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 pt -166.73 175.91 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.49 -1.361 0 C-N-CA 124.815 1.246 . . . . 0.0 108.408 -177.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 29.2 m -148.53 144.17 27.14 Favored 'General case' 0 C--N 1.27 -2.859 0 N-CA-C 105.784 -1.932 . . . . 0.0 105.784 174.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . 0.44 ' HB ' HG23 ' B' ' 37' ' ' ILE . 11.0 pt -115.09 158.13 15.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 CA-C-N 117.866 0.303 . . . . 0.0 110.395 -177.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 10.3 tp -139.32 140.75 37.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-O 120.636 0.255 . . . . 0.0 110.415 -176.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -91.24 109.53 3.72 Favored Glycine 0 N--CA 1.435 -1.398 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.687 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 66.2 mtt . . . . . 0 C--N 1.308 -1.226 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 177.084 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 70.1 mt . . . . . 0 N--CA 1.433 -1.286 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -96.85 109.97 3.95 Favored Glycine 0 N--CA 1.419 -2.46 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . 0.44 HG23 ' HB ' ' B' ' 21' ' ' ILE . 28.4 mm -89.09 92.04 3.85 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -85.68 169.01 13.87 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.106 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 59.5 t -82.77 136.57 22.6 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.496 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 174.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 31.1 ttpt -96.57 -35.9 10.92 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.085 0.469 . . . . 0.0 110.088 -176.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 2.8 t -161.27 165.28 29.44 Favored 'General case' 0 C--O 1.251 1.182 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 20.4 t -126.8 93.24 2.21 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.025 0 N-CA-C 106.843 -1.539 . . . . 0.0 106.843 177.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 20.8 m -60.91 123.32 17.24 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 115.207 -0.906 . . . . 0.0 111.282 -177.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . 0.429 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 12.7 pt-20 -70.43 -23.77 62.79 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-N 115.804 -0.634 . . . . 0.0 112.478 -174.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.32 -11.77 82.11 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 121.075 -0.584 . . . . 0.0 112.729 179.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -110.29 172.82 15.89 Favored Glycine 0 N--CA 1.413 -2.847 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.007 -178.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -61.34 -35.7 78.15 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 114.998 1.481 . . . . 0.0 114.998 -172.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . 0.4 ' HA ' HD22 ' B' ' 10' ' ' LEU . . . -61.37 -42.17 98.27 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -172.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . 0.429 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 5.0 t60 -71.22 -40.85 70.87 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 122.143 0.973 . . . . 0.0 108.864 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 71.1 mtp180 -69.05 -29.65 67.83 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.34 -177.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . 0.639 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 11.9 t70 -82.0 -45.44 15.32 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.61 35.28 6.57 Favored Glycine 0 CA--C 1.494 -1.263 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.637 173.529 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.639 ' HD3' ' OD2' ' B' ' 51' ' ' ASP . 5.3 mpt_? -107.82 -74.77 0.65 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.288 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . . . . . . . . . 27.9 mt -68.52 118.43 12.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 C-N-CA 120.051 -0.659 . . . . 0.0 110.033 177.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 14.8 mm100 -104.25 -179.48 3.96 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.1 p -80.82 2.02 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.173 0 CA-C-O 122.253 1.025 . . . . 0.0 111.099 -175.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 25.3 t-20 -110.76 1.29 17.72 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 122.138 0.971 . . . . 0.0 109.496 -177.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -78.93 155.01 29.2 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.233 -177.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 26.7 tp -139.3 126.68 21.51 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.735 -176.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 68.6 mt -79.3 91.47 5.03 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.258 0.551 . . . . 0.0 109.836 179.186 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.613 ' HB ' ' O ' ' B' ' 90' ' ' MET . 24.1 t -82.64 -39.28 15.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.997 0 CA-C-O 122.001 0.905 . . . . 0.0 110.053 177.272 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . 0.415 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 10.9 pt-20 -162.2 157.27 22.83 Favored 'General case' 0 C--N 1.28 -2.42 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.411 172.532 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . 0.452 HG11 ' HB ' ' B' ' 66' ' ' THR . 3.7 p -94.11 -177.86 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 N-CA-C 105.638 -1.986 . . . . 0.0 105.638 178.104 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . 0.511 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.2 t70 -44.54 -48.64 10.24 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 124.721 1.208 . . . . 0.0 112.975 -177.532 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -140.56 45.5 0.98 Allowed Glycine 0 CA--C 1.525 0.702 0 C-N-CA 119.991 -1.099 . . . . 0.0 113.847 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 66' ' ' THR . . . . . 0.452 ' HB ' HG11 ' B' ' 63' ' ' VAL . 45.5 m -158.42 119.51 3.42 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 177.375 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 67' ' ' SER . . . . . 0.408 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 45.8 m -85.48 133.18 34.1 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -175.788 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.568 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 23.9 mt -99.67 138.44 36.75 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.665 174.751 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -116.92 -26.77 2.63 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 CA-C-O 122.132 0.968 . . . . 0.0 109.146 173.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 160.45 87.75 0.06 OUTLIER Glycine 0 N--CA 1.399 -3.83 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 -176.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 m -111.58 173.17 2.54 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.667 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 41.7 p -75.21 160.2 30.68 Favored 'General case' 0 C--N 1.289 -2.039 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -59.57 -35.27 73.94 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 177.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 12.6 m -69.73 -41.03 75.82 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.632 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -63.54 -45.67 89.51 Favored 'General case' 0 CA--C 1.514 -0.429 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.529 ' O ' ' HG ' ' B' ' 80' ' ' LEU . . . -58.46 -46.26 86.95 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.487 178.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.39 -34.93 74.62 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.593 0.711 . . . . 0.0 110.736 178.067 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 45.5 m -80.37 -21.47 42.32 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 113.043 0.756 . . . . 0.0 113.043 -177.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.514 HG13 ' O ' ' B' ' 76' ' ' ALA . 8.4 p -78.52 -31.58 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.484 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . 0.529 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 63.4 mt -69.39 -13.54 62.42 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.656 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -107.88 -0.64 21.37 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.503 0.668 . . . . 0.0 110.898 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -99.0 -23.74 15.18 Favored 'General case' 0 C--O 1.248 0.981 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.021 178.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.437 ' HB ' HG12 ' B' ' 87' ' ' VAL . 2.1 p -68.47 169.42 10.88 Favored 'General case' 0 N--CA 1.422 -1.841 0 CA-C-N 114.517 -1.22 . . . . 0.0 114.01 -176.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 41.0 mmtm -70.58 -170.78 0.43 Allowed 'General case' 0 N--CA 1.437 -1.099 0 CA-C-N 115.132 -0.94 . . . . 0.0 112.488 178.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.38 -35.33 90.83 Favored Glycine 0 C--O 1.217 -0.946 0 CA-C-N 114.776 -1.102 . . . . 0.0 114.275 -176.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 34.3 ttp180 -143.0 125.04 15.26 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . 0.511 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 14.0 m -133.11 154.71 39.98 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.746 0 CA-C-O 121.804 0.812 . . . . 0.0 112.559 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 87.4 mtm180 -94.5 170.6 9.36 Favored 'General case' 0 N--CA 1.41 -2.429 0 CA-C-N 113.681 -1.6 . . . . 0.0 108.489 173.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.432 ' HB2' ' CD1' ' B' ' 91' ' ' ILE . 6.2 m-85 -145.55 149.11 34.0 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 175.486 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.613 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 1.1 mpt? -103.68 108.58 19.93 Favored 'General case' 0 C--N 1.276 -2.626 0 CA-C-O 121.604 0.716 . . . . 0.0 109.567 176.112 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.432 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.4 mp -98.84 110.92 27.18 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 114.329 -1.305 . . . . 0.0 107.95 -179.086 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . 0.589 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -104.15 103.71 2.33 Favored Glycine 0 CA--C 1.458 -3.514 0 N-CA-C 107.987 -2.045 . . . . 0.0 107.987 173.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . 0.424 ' HD2' ' OE1' ' B' ' 4' ' ' GLU . 1.9 ptp180 . . . . . 0 C--N 1.281 -2.37 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.232 -175.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 3' ' ' MET . . . . . 0.4 ' HG2' ' O ' ' B' ' 3' ' ' MET . 0.1 OUTLIER . . . . . 0 N--CA 1.415 -2.217 0 N-CA-C 105.5 -2.037 . . . . 0.0 105.5 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -91.34 92.86 8.78 Favored 'General case' 0 C--N 1.281 -2.4 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -174.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -88.56 86.04 6.94 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -107.49 140.93 22.01 Favored Pre-proline 0 C--N 1.297 -1.714 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.531 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -80.51 134.84 10.17 Favored 'Trans proline' 0 N--CA 1.432 -2.146 0 C-N-CA 122.086 1.857 . . . . 0.0 112.672 178.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.48 HG13 ' HB3' ' B' ' 53' ' ' ARG . 25.5 t -115.67 114.93 47.71 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.283 0 CA-C-N 114.374 -1.284 . . . . 0.0 108.554 176.121 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -105.59 105.84 16.06 Favored 'General case' 0 C--N 1.276 -2.611 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -178.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.443 HD11 HG13 ' B' ' 54' ' ' ILE . 0.9 OUTLIER -123.72 153.85 40.3 Favored 'General case' 0 N--CA 1.418 -2.073 0 CA-C-O 121.685 0.755 . . . . 0.0 111.692 178.995 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -122.23 143.16 49.76 Favored 'General case' 0 C--N 1.276 -2.588 0 CA-C-N 114.245 -1.343 . . . . 0.0 108.083 -173.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 45.5 mtmt -75.98 158.63 31.73 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 122.002 0.906 . . . . 0.0 112.276 -176.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . 0.457 ' HB2' ' H ' ' B' ' 16' ' ' GLY . 11.1 m-20 -83.52 177.13 8.57 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 113.717 -1.583 . . . . 0.0 107.963 173.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.9 m -73.46 -25.37 60.46 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 171.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -82.06 -30.85 31.13 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.7 -1.136 . . . . 0.0 109.779 177.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . 0.457 ' H ' ' HB2' ' B' ' 13' ' ' ASP . . . 134.34 -108.44 0.72 Allowed Glycine 0 N--CA 1.432 -1.6 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.122 179.117 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 84.7 mt -132.8 115.72 15.65 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 121.073 0.464 . . . . 0.0 111.481 -175.276 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . 0.468 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -86.96 60.99 4.39 Favored Glycine 0 C--O 1.213 -1.168 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 178.567 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . 0.495 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 5.7 pt -151.73 174.04 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 C-N-CA 125.137 1.375 . . . . 0.0 109.021 179.169 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 62.8 m -151.92 156.96 41.13 Favored 'General case' 0 C--N 1.271 -2.817 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 175.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 12.0 pt -124.33 161.24 27.71 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.129 0 O-C-N 123.437 0.461 . . . . 0.0 110.737 -177.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -143.11 133.55 22.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.6 119.0 6.36 Favored Glycine 0 N--CA 1.435 -1.388 0 C-N-CA 120.629 -0.796 . . . . 0.0 113.162 -177.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 68.9 mtm . . . . . 0 C--N 1.31 -1.144 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 177.424 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 18.8 tp . . . . . 0 N--CA 1.418 -2.069 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -142.44 117.72 1.18 Allowed Glycine 0 C--N 1.27 -3.128 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.351 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 28.9 mm -96.72 88.76 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 178.015 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.417 ' HA ' ' HA ' ' B' ' 59' ' ' LEU . 94.5 m-85 -81.83 168.76 17.64 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 114.386 -1.279 . . . . 0.0 109.225 -176.584 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.8 t -79.31 139.52 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.376 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 22.8 ttpp -101.12 -44.44 5.7 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.083 0.468 . . . . 0.0 109.829 -178.086 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -154.62 162.13 41.27 Favored 'General case' 0 N--CA 1.432 -1.351 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 -176.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.495 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.2 p -144.06 97.79 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 CA-C-O 122.408 1.099 . . . . 0.0 109.356 176.63 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 23.9 m -62.65 126.59 27.84 Favored 'General case' 0 N--CA 1.431 -1.417 0 CA-C-N 113.262 -1.79 . . . . 0.0 112.256 -174.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . 0.549 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 1.8 mp0 -55.57 -36.91 67.37 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.693 1.597 . . . . 0.0 110.775 -178.052 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.97 -0.48 56.12 Favored Glycine 0 N--CA 1.438 -1.173 0 CA-C-N 115.437 -0.802 . . . . 0.0 113.877 -179.191 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.468 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -112.56 162.01 12.52 Favored Glycine 0 N--CA 1.417 -2.605 0 C-N-CA 120.121 -1.037 . . . . 0.0 113.093 179.211 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -57.45 -36.36 71.3 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 125.688 1.595 . . . . 0.0 112.06 -175.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -63.01 -34.54 77.77 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . 0.549 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 6.4 t60 -82.14 -39.12 23.73 Favored 'General case' 0 C--O 1.24 0.575 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 59.5 mtp180 -61.94 -39.56 92.49 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.137 179.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -74.68 -69.65 0.45 Allowed 'General case' 0 C--N 1.309 -1.174 0 C-N-CA 124.11 0.964 . . . . 0.0 109.382 175.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 110.99 -2.08 28.57 Favored Glycine 0 N--CA 1.436 -1.346 0 C-N-CA 120.21 -0.995 . . . . 0.0 114.565 177.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.48 ' HB3' HG13 ' B' ' 8' ' ' VAL . 39.5 mmt180 -72.24 -50.9 23.77 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 118.503 1.151 . . . . 0.0 113.054 177.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.495 HD11 ' CE2' ' B' ' 89' ' ' PHE . 54.6 mt -72.97 123.02 26.92 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 C-N-CA 119.034 -1.066 . . . . 0.0 108.891 173.141 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -116.47 146.96 42.18 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -178.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 13.2 p -56.54 -23.45 17.01 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.067 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -168.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -109.3 -3.53 17.1 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 120.875 -1.141 . . . . 0.0 111.469 -174.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -87.49 179.15 6.61 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 113.693 0.998 . . . . 0.0 113.693 -174.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . 0.417 ' HA ' ' HA ' ' B' ' 38' ' ' PHE . 24.6 tp -124.46 126.08 45.31 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.372 -172.239 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 82.0 mt -83.7 104.31 13.71 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 106.063 -1.829 . . . . 0.0 106.063 173.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.747 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 0.5 OUTLIER -91.09 -27.65 4.92 Favored 'Isoleucine or valine' 0 C--O 1.198 -1.627 0 C-N-CA 119.667 -0.813 . . . . 0.0 110.117 -174.625 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . 0.463 ' HB2' ' HA ' ' B' ' 67' ' ' SER . 13.2 pt-20 -158.35 166.11 33.08 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-N 114.725 -1.125 . . . . 0.0 111.389 176.122 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 6.4 p -105.57 -174.39 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.023 0 N-CA-C 106.549 -1.649 . . . . 0.0 106.549 178.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . 0.43 ' HB2' ' H ' ' B' ' 88' ' ' ARG . 18.9 t70 -56.55 -39.44 73.44 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 123.272 0.629 . . . . 0.0 112.479 -177.037 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -107.55 -65.29 0.6 Allowed Glycine 0 C--N 1.309 -0.945 0 C-N-CA 120.581 -0.818 . . . . 0.0 113.511 179.444 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 7.0 m -69.5 115.44 8.76 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 122.882 0.473 . . . . 0.0 112.059 -177.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 67' ' ' SER . . . . . 0.463 ' HA ' ' HB2' ' B' ' 62' ' ' GLU . 48.6 m -87.36 114.93 24.42 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 174.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.747 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 75.5 mt -85.46 140.48 30.67 Favored 'General case' 0 N--CA 1.435 -1.176 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.402 -177.606 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 p -100.09 -18.72 6.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 144.63 70.84 0.02 OUTLIER Glycine 0 N--CA 1.426 -1.985 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 -176.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.3 m -83.76 173.66 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 CA-C-N 114.478 -0.861 . . . . 0.0 110.021 -178.254 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 37.7 p -71.93 160.29 32.79 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 177.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.5 tt0 -61.14 -37.1 81.65 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.35 0.595 . . . . 0.0 110.437 -178.024 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.7 m -73.18 -30.27 63.43 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.664 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 51.1 t80 -71.6 -41.79 68.49 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.595 ' O ' HG13 ' B' ' 79' ' ' VAL . . . -64.46 -40.98 96.75 Favored 'General case' 0 N--CA 1.435 -1.182 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.828 177.768 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.01 -41.91 93.18 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.049 0.452 . . . . 0.0 110.829 177.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.1 p -76.75 -23.24 52.98 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 112.957 0.725 . . . . 0.0 112.957 -178.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.595 HG13 ' O ' ' B' ' 76' ' ' ALA . 6.7 p -72.47 -35.12 50.49 Favored 'Isoleucine or valine' 0 C--N 1.345 0.4 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -177.595 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 51.2 mt -68.35 -18.39 64.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 114.551 -1.204 . . . . 0.0 110.349 178.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -97.14 -9.95 26.89 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.534 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -96.35 -21.29 17.89 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-O 121.248 0.547 . . . . 0.0 110.203 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 83' ' ' THR . . . . . . . . . . . . . 17.9 p -80.67 174.27 11.78 Favored 'General case' 0 N--CA 1.425 -1.686 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.915 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 38.1 mttp -70.27 -168.03 0.2 Allowed 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.799 0.809 . . . . 0.0 112.393 178.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -72.62 -30.62 63.87 Favored Glycine 0 N--CA 1.437 -1.293 0 CA-C-N 114.932 -1.031 . . . . 0.0 111.989 178.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 50.4 ttp180 -135.16 123.37 23.0 Favored 'General case' 0 C--N 1.31 -1.129 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.3 m -137.44 160.01 35.1 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.131 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . 0.43 ' H ' ' HB2' ' B' ' 64' ' ' ASP . 81.3 mtm180 -107.82 110.99 22.91 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.635 -179.323 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.495 ' CE2' HD11 ' B' ' 54' ' ' ILE . 3.4 m-85 -92.29 156.18 17.44 Favored 'General case' 0 C--N 1.275 -2.664 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 179.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.408 ' O ' HG13 ' B' ' 61' ' ' VAL . 57.1 mtt -108.46 121.73 45.57 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.435 172.304 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.404 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -99.64 117.5 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.405 -2.682 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 179.507 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -105.45 104.04 2.25 Favored Glycine 0 CA--C 1.458 -3.505 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 178.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 13.8 tpp180 . . . . . 0 C--N 1.268 -2.977 0 CA-C-N 114.142 -1.029 . . . . 0.0 109.071 178.824 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 47.8 mtm . . . . . 0 N--CA 1.418 -2.063 0 N-CA-C 103.635 -2.728 . . . . 0.0 103.635 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . 0.475 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 16.2 mt-10 -88.4 97.29 10.97 Favored 'General case' 0 C--N 1.284 -2.276 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.263 -176.422 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -86.37 89.55 7.91 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 172.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 23.6 p90 -108.81 144.78 30.29 Favored Pre-proline 0 C--N 1.297 -1.7 0 CA-C-N 115.52 -0.764 . . . . 0.0 112.092 -177.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -73.85 138.59 26.3 Favored 'Trans proline' 0 N--CA 1.447 -1.255 0 C-N-CA 122.303 2.002 . . . . 0.0 113.314 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 74.8 t -129.49 126.55 63.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.824 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 175.219 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -108.39 135.75 49.17 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.668 -177.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.409 HD22 ' HA ' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -139.75 162.21 35.68 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.614 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -134.13 159.36 41.1 Favored 'General case' 0 C--N 1.285 -2.208 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.31 177.019 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -77.22 134.87 38.49 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.579 -178.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -87.61 -179.74 6.37 Favored 'General case' 0 C--N 1.292 -1.917 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 175.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.3 m -64.65 -29.8 70.8 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 176.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -91.66 -8.96 45.63 Favored 'General case' 0 CA--C 1.548 0.891 0 CA-C-O 121.661 0.743 . . . . 0.0 109.975 177.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 106.51 -100.07 1.57 Allowed Glycine 0 N--CA 1.44 -1.038 0 C-N-CA 121.068 -0.586 . . . . 0.0 113.02 177.594 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.509 ' HG ' ' H ' ' B' ' 18' ' ' GLY . 17.7 tp -98.85 -173.28 2.48 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -177.255 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . 0.509 ' H ' ' HG ' ' B' ' 17' ' ' LEU . . . -164.91 58.18 0.26 Allowed Glycine 0 N--CA 1.435 -1.371 0 C-N-CA 120.262 -0.971 . . . . 0.0 112.688 177.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . 0.453 HG21 ' HB1' ' B' ' 48' ' ' ALA . 5.7 pt -162.93 177.46 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.487 -1.473 0 C-N-CA 124.662 1.185 . . . . 0.0 108.228 -179.134 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.2 m -138.83 147.25 42.25 Favored 'General case' 0 C--N 1.262 -3.21 0 N-CA-C 105.522 -2.029 . . . . 0.0 105.522 174.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 9.3 pt -114.85 167.17 7.72 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.827 0 O-C-N 123.36 0.412 . . . . 0.0 109.931 -178.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 10.1 tp -142.82 135.81 26.06 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -90.12 110.31 3.75 Favored Glycine 0 N--CA 1.435 -1.392 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.615 -178.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 89.1 mtp . . . . . 0 C--N 1.303 -1.429 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 177.252 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 91.8 mt . . . . . 0 N--CA 1.425 -1.709 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -112.12 95.17 0.78 Allowed Glycine 0 N--CA 1.398 -3.843 0 C-N-CA 120.63 -0.795 . . . . 0.0 111.467 -176.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 30.8 mm -86.99 86.01 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.824 0 N-CA-C 106.428 -1.693 . . . . 0.0 106.428 172.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -84.1 166.85 17.31 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 114.335 -1.302 . . . . 0.0 108.727 -175.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.1 t -79.67 133.05 30.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 175.084 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -95.41 -41.76 8.83 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 120.932 0.396 . . . . 0.0 110.008 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -156.88 163.03 39.63 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -179.603 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 21.9 t -118.62 108.69 24.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 177.255 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 43' ' ' THR . . . . . 0.43 ' O ' ' HB2' ' B' ' 49' ' ' HIS . 24.3 m -64.92 123.68 20.05 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 123.422 0.689 . . . . 0.0 111.088 -176.188 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . 0.424 ' HG2' ' CE1' ' B' ' 49' ' ' HIS . 32.8 mt-10 -67.72 -33.7 75.4 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 124.588 1.155 . . . . 0.0 109.839 -175.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.46 16.82 47.36 Favored Glycine 0 N--CA 1.431 -1.633 0 CA-C-N 114.761 -1.108 . . . . 0.0 112.114 178.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -127.07 174.75 18.23 Favored Glycine 0 N--CA 1.405 -3.422 0 C-N-CA 120.81 -0.71 . . . . 0.0 113.464 -178.648 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -56.84 -54.84 41.79 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -173.612 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . 0.453 ' HB1' HG21 ' B' ' 19' ' ' ILE . . . -61.13 -27.14 68.18 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 114.017 1.117 . . . . 0.0 114.017 -171.105 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . 0.43 ' HB2' ' O ' ' B' ' 43' ' ' THR . 2.4 t60 -78.98 -38.7 36.19 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -179.197 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 92.1 mtt180 -73.5 -38.82 65.23 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.373 -178.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -66.85 -67.1 0.48 Allowed 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.088 173.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.84 3.49 52.17 Favored Glycine 0 N--CA 1.439 -1.104 0 N-CA-C 114.722 0.649 . . . . 0.0 114.722 175.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -81.2 -45.94 15.59 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 118.489 1.144 . . . . 0.0 112.061 -179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.522 HD13 ' CE2' ' B' ' 89' ' ' PHE . 19.7 mt -78.56 127.89 38.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.142 174.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 50.7 mt-30 -110.92 167.07 10.52 Favored 'General case' 0 N--CA 1.436 -1.165 0 CA-C-O 121.07 0.462 . . . . 0.0 110.396 176.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.6 p -70.71 -2.1 2.42 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.704 0 N-CA-C 114.191 1.182 . . . . 0.0 114.191 -171.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -119.85 15.01 12.57 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.723 -1.236 . . . . 0.0 110.546 179.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -90.47 168.76 11.6 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.783 -178.2 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . 0.484 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 22.8 tp -133.23 132.59 41.66 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.716 -176.637 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 78.2 mt -86.06 99.54 11.55 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 177.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.601 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.3 t -83.52 -42.42 17.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 CA-C-O 121.461 0.648 . . . . 0.0 110.647 177.546 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . 0.523 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 15.9 pt-20 -159.67 158.53 31.63 Favored 'General case' 0 C--N 1.282 -2.332 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.546 175.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . 0.414 HG11 ' HB ' ' B' ' 66' ' ' THR . 4.0 p -100.74 -173.58 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.228 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . 0.403 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 22.8 t70 -51.49 -47.73 63.13 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 113.126 0.787 . . . . 0.0 113.126 -178.431 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -137.4 44.56 1.13 Allowed Glycine 0 C--N 1.314 -0.678 0 C-N-CA 119.362 -1.399 . . . . 0.0 114.207 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 66' ' ' THR . . . . . 0.414 ' HB ' HG11 ' B' ' 63' ' ' VAL . 94.9 m -161.31 119.43 2.38 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.027 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 67' ' ' SER . . . . . 0.523 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 21.2 m -97.92 132.48 43.46 Favored 'General case' 0 N--CA 1.431 -1.394 0 CA-C-O 121.075 0.464 . . . . 0.0 111.853 -176.486 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.601 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 42.4 mt -96.06 115.42 27.4 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.108 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 40.1 t -81.85 -23.51 9.78 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 174.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 145.75 75.76 0.02 OUTLIER Glycine 0 N--CA 1.424 -2.124 0 N-CA-C 108.871 -1.692 . . . . 0.0 108.871 -177.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 m -93.53 -178.32 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-N 115.554 -0.323 . . . . 0.0 110.557 -175.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 41.3 p -82.6 165.32 20.17 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 176.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.0 tt0 -63.15 -33.91 76.48 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.23 0.538 . . . . 0.0 109.596 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.3 m -66.28 -44.93 82.19 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.991 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -60.19 -48.2 82.75 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.49 ' O ' HG13 ' B' ' 79' ' ' VAL . . . -59.08 -44.2 91.87 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.122 178.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.4 -37.27 80.3 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-O 121.204 0.526 . . . . 0.0 110.324 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 36.0 m -66.84 -35.96 81.24 Favored 'General case' 0 N--CA 1.435 -1.182 0 CA-C-N 115.366 -0.834 . . . . 0.0 111.344 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.49 HG13 ' O ' ' B' ' 76' ' ' ALA . 4.2 p -75.66 -34.17 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 C-N-CA 119.558 -0.857 . . . . 0.0 109.81 -174.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 25.0 mt -64.82 -42.29 95.09 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.261 -0.882 . . . . 0.0 111.167 176.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 39.1 mtp180 -77.64 -30.16 52.03 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.819 0.342 . . . . 0.0 111.922 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 6.5 t30 -74.8 -27.09 60.16 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 83' ' ' THR . . . . . . . . . . . . . 16.3 p -71.88 158.69 35.59 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 -178.114 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -66.74 -168.04 0.06 Allowed 'General case' 0 C--O 1.251 1.163 0 C-N-CA 124.708 1.203 . . . . 0.0 112.933 -178.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.12 -49.95 64.7 Favored Glycine 0 N--CA 1.431 -1.689 0 CA-C-N 114.644 -1.162 . . . . 0.0 112.828 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 23.0 ttp180 -135.04 121.65 20.7 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.981 -0.688 . . . . 0.0 111.961 -177.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . 0.403 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 15.8 m -138.24 149.56 24.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 114.879 -1.055 . . . . 0.0 109.383 -179.361 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -94.6 155.95 16.66 Favored 'General case' 0 C--N 1.295 -1.796 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.755 174.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.522 ' CE2' HD13 ' B' ' 54' ' ' ILE . 9.1 m-85 -126.99 162.33 26.25 Favored 'General case' 0 C--N 1.276 -2.63 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 176.689 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.482 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 24.5 mmt -111.58 113.1 25.28 Favored 'General case' 0 C--N 1.28 -2.448 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.597 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.484 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -97.21 129.23 47.58 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -179.331 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -109.45 116.28 4.5 Favored Glycine 0 CA--C 1.468 -2.858 0 C-N-CA 120.19 -1.005 . . . . 0.0 112.079 -178.792 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 8.7 tpp180 . . . . . 0 C--N 1.284 -2.257 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 176.023 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 3' ' ' MET . . . . . 0.425 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 65.6 mtt . . . . . 0 N--CA 1.424 -1.752 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -77.47 103.98 7.73 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -176.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -78.05 91.39 4.27 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 124.106 0.878 . . . . 0.0 108.822 176.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -113.22 142.99 28.37 Favored Pre-proline 0 C--N 1.281 -2.371 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.646 176.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . 0.477 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 34.2 Cg_endo -75.01 128.84 11.79 Favored 'Trans proline' 0 N--CA 1.438 -1.791 0 C-N-CA 121.943 1.762 . . . . 0.0 112.843 179.327 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 72.0 t -113.41 122.78 68.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . 0.533 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 36.5 tt0 -106.86 132.15 53.15 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -174.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.423 HD22 ' HA ' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -127.4 158.27 37.75 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 177.548 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -134.41 138.51 44.88 Favored 'General case' 0 C--N 1.279 -2.481 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 176.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 34.7 mmtp -68.54 152.97 44.63 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 114.876 1.435 . . . . 0.0 114.876 -174.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -92.76 177.33 6.13 Favored 'General case' 0 C--O 1.247 0.922 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 173.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 13.2 p -69.62 -28.76 66.19 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 118.327 0.512 . . . . 0.0 110.356 178.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -80.24 -53.04 7.03 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 173.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 147.92 -96.98 0.18 Allowed Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.34 179.091 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 96.3 mt -128.36 175.48 8.46 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 122.928 0.491 . . . . 0.0 109.996 -178.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . 0.427 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -156.38 69.05 0.28 Allowed Glycine 0 CA--C 1.482 -1.977 0 N-CA-C 108.254 -1.938 . . . . 0.0 108.254 179.166 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . 0.457 HG23 ' HB ' ' B' ' 42' ' ' VAL . 12.7 pt -145.22 -179.09 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.281 -2.393 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 -177.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' SER . . . . . 0.443 ' HB2' HG22 ' B' ' 41' ' ' THR . 28.5 m -154.88 155.46 34.38 Favored 'General case' 0 C--N 1.253 -3.627 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 174.829 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . 0.423 ' HB ' HG21 ' B' ' 37' ' ' ILE . 7.9 pt -127.58 154.5 38.07 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.892 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -129.26 132.13 67.08 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -179.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.78 103.18 2.28 Favored Glycine 0 N--CA 1.423 -2.231 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.192 -176.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 72.6 mtm . . . . . 0 C--N 1.303 -1.438 0 CA-C-O 121.085 0.469 . . . . 0.0 110.672 -179.829 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 83.6 mt . . . . . 0 CA--C 1.493 -1.218 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -87.64 91.67 1.75 Allowed Glycine 0 N--CA 1.41 -3.063 0 C-N-CA 120.365 -0.921 . . . . 0.0 111.982 -177.146 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . 0.423 HG21 ' HB ' ' B' ' 21' ' ' ILE . 20.1 mm -87.38 84.91 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.549 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 173.467 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -84.71 165.01 18.22 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 114.636 -1.165 . . . . 0.0 108.695 -178.031 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 56.9 t -75.8 133.12 31.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 176.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -92.71 -46.4 7.59 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.622 -177.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 41' ' ' THR . . . . . 0.443 HG22 ' HB2' ' B' ' 20' ' ' SER . 6.3 t -155.14 174.58 15.0 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.457 ' HB ' HG23 ' B' ' 19' ' ' ILE . 2.4 p -158.81 98.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 C-N-CA 124.793 1.237 . . . . 0.0 109.201 -177.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 26.5 m -87.76 143.27 27.24 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 113.915 -1.493 . . . . 0.0 110.32 -174.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -56.78 -19.89 19.48 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 124.593 1.157 . . . . 0.0 112.744 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.98 -12.44 79.14 Favored Glycine 0 N--CA 1.439 -1.102 0 CA-C-N 116.11 -0.496 . . . . 0.0 113.363 -178.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.427 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -116.5 169.0 12.87 Favored Glycine 0 N--CA 1.422 -2.3 0 C-N-CA 119.438 -1.363 . . . . 0.0 113.328 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -56.77 -41.25 77.31 Favored 'General case' 0 C--O 1.19 -2.066 0 CA-C-N 113.977 -1.111 . . . . 0.0 113.568 -175.078 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . 0.423 ' HA ' HD22 ' B' ' 10' ' ' LEU . . . -59.87 -35.94 75.84 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -173.516 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 4.9 t60 -81.45 -38.76 25.91 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -179.574 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -69.29 -46.17 67.82 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.07 -178.411 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -70.89 -36.01 72.58 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.81 47.68 7.05 Favored Glycine 0 CA--C 1.494 -1.276 0 CA-C-N 114.102 -1.408 . . . . 0.0 112.463 173.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.533 ' HG3' ' O ' ' B' ' 9' ' ' GLU . 35.2 mmt180 -116.14 -60.78 1.82 Allowed 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -177.244 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.458 HD11 ' CE2' ' B' ' 89' ' ' PHE . 43.9 mt -77.28 125.73 37.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 C-N-CA 120.255 -0.578 . . . . 0.0 109.735 178.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 65.4 mt-30 -99.74 159.04 15.35 Favored 'General case' 0 C--N 1.287 -2.144 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.435 HG21 ' HA ' ' B' ' 41' ' ' THR . 11.8 p -70.03 -4.83 4.43 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.699 0 CA-C-O 121.804 0.812 . . . . 0.0 112.027 -177.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -113.15 10.14 18.6 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.451 -0.78 . . . . 0.0 110.824 -177.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 87.9 m-20 -85.01 175.31 9.12 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.293 0.568 . . . . 0.0 112.379 -177.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 26.6 tp -143.05 130.97 21.61 Favored 'General case' 0 C--N 1.315 -0.908 0 C-N-CA 123.894 0.878 . . . . 0.0 109.752 -177.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 71.7 mt -87.49 98.12 11.21 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 178.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.615 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 36.6 t -81.97 -41.41 18.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 CA-C-O 121.941 0.877 . . . . 0.0 110.477 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -157.26 158.95 37.08 Favored 'General case' 0 C--N 1.275 -2.633 0 CA-C-N 114.858 -1.065 . . . . 0.0 109.763 173.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . 0.457 HG13 ' O ' ' B' ' 66' ' ' THR . 3.3 p -101.57 -173.89 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 105.825 -1.917 . . . . 0.0 105.825 178.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . 0.436 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.2 t70 -55.34 -58.68 6.74 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 113.092 0.775 . . . . 0.0 113.092 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -119.23 33.43 4.7 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 119.818 -1.182 . . . . 0.0 114.535 -176.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 66' ' ' THR . . . . . 0.457 ' O ' HG13 ' B' ' 63' ' ' VAL . 18.8 m -160.71 128.53 4.43 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 179.002 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 39.0 m -93.91 136.77 33.85 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.899 -0.501 . . . . 0.0 111.092 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.615 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 17.2 mt -93.34 -77.39 0.45 Allowed 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.373 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 61.4 t 70.49 -29.4 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 125.34 1.456 . . . . 0.0 111.181 -175.206 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . 0.488 ' H ' ' C ' ' B' ' 68' ' ' LEU . . . 164.59 89.29 0.07 OUTLIER Glycine 1 N--CA 1.395 -4.085 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -177.226 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 33.6 m -118.42 -178.74 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.282 -2.356 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 175.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 36.7 p -79.92 161.8 25.33 Favored 'General case' 0 C--N 1.292 -1.931 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 177.226 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -60.42 -35.03 74.84 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 121.287 0.565 . . . . 0.0 110.129 -177.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 50.0 m -74.22 -36.44 63.94 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.831 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -63.25 -46.22 87.91 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.526 ' O ' HG11 ' B' ' 79' ' ' VAL . . . -63.01 -38.92 93.11 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.279 179.534 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.67 -38.33 88.98 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.489 0.661 . . . . 0.0 110.122 178.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 34.7 t -64.49 -39.28 93.5 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.956 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.526 HG11 ' O ' ' B' ' 76' ' ' ALA . 2.6 p -70.31 -27.94 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 121.947 0.879 . . . . 0.0 110.374 -172.047 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 55.8 mt -72.51 -6.6 44.99 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.376 178.672 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 67.6 mtt180 -116.88 -17.48 10.42 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-O 120.852 0.358 . . . . 0.0 111.948 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.9 m-20 -87.76 -8.36 56.11 Favored 'General case' 0 C--O 1.241 0.645 0 C-N-CA 123.308 0.643 . . . . 0.0 111.378 179.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.465 ' HB ' HG11 ' B' ' 87' ' ' VAL . 1.4 p -87.25 -175.16 5.18 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 113.873 1.064 . . . . 0.0 113.873 -178.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -77.34 -171.5 2.12 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.879 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -75.97 -38.27 36.1 Favored Glycine 0 N--CA 1.44 -1.067 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.927 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . 0.402 ' HA ' ' O ' ' B' ' 10' ' ' LEU . 13.0 ttp180 -127.69 118.49 23.92 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.397 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . 0.465 HG11 ' HB ' ' B' ' 83' ' ' THR . 15.6 m -135.5 154.82 35.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -175.165 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -109.66 126.19 53.4 Favored 'General case' 0 CA--C 1.49 -1.345 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.115 179.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.477 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 3.1 m-85 -105.58 155.05 19.58 Favored 'General case' 0 C--N 1.28 -2.45 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 178.023 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.416 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 19.6 mmt -98.74 109.69 22.4 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 173.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.463 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.5 mp -98.06 119.92 46.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.943 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.53 111.89 4.07 Favored Glycine 0 CA--C 1.466 -3.007 0 N-CA-C 108.726 -1.75 . . . . 0.0 108.726 175.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . 0.425 ' O ' ' HA ' ' B' ' 3' ' ' MET . 8.3 tpp180 . . . . . 0 C--N 1.285 -2.224 0 CA-C-N 114.637 -0.781 . . . . 0.0 111.679 -178.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 20.6 ptp . . . . . 0 N--CA 1.429 -1.482 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . 0.535 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 17.1 mt-10 -89.85 100.09 12.97 Favored 'General case' 0 C--N 1.289 -2.037 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -177.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -91.4 89.94 7.47 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 175.021 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -119.14 143.88 34.97 Favored Pre-proline 0 C--N 1.29 -1.997 0 C-N-CA 120.736 -0.386 . . . . 0.0 111.946 178.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . 0.46 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 56.7 Cg_endo -75.15 139.49 23.97 Favored 'Trans proline' 0 N--CA 1.439 -1.716 0 C-N-CA 122.076 1.851 . . . . 0.0 111.73 176.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 90.5 t -128.33 123.34 59.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -179.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . 0.493 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 38.9 tt0 -103.24 129.6 50.24 Favored 'General case' 0 C--N 1.285 -2.196 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.196 -178.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . . . . . . . . . 2.0 mt -142.81 165.37 27.55 Favored 'General case' 0 CA--C 1.478 -1.812 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.812 175.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -135.58 164.67 27.3 Favored 'General case' 0 C--N 1.283 -2.324 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.726 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -82.38 163.14 21.89 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 121.616 0.722 . . . . 0.0 112.156 -179.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -111.44 -159.54 0.68 Allowed 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 104.12 -2.548 . . . . 0.0 104.12 173.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 22.8 t -75.17 -25.45 58.32 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 169.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -86.73 -60.83 1.88 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.977 176.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 122.84 75.45 0.32 Allowed Glycine 0 N--CA 1.439 -1.108 0 C-N-CA 120.223 -0.989 . . . . 0.0 112.143 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp 77.12 172.04 0.22 Allowed 'General case' 0 CA--C 1.507 -0.678 0 C-N-CA 124.576 1.15 . . . . 0.0 112.402 178.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -141.83 74.44 0.35 Allowed Glycine 0 CA--C 1.471 -2.675 0 N-CA-C 109.097 -1.601 . . . . 0.0 109.097 -178.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . 0.417 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 14.2 pt -157.51 -177.53 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 -178.673 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 24.0 t -149.08 142.31 25.05 Favored 'General case' 0 C--N 1.272 -2.793 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 176.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 20.6 pt -109.17 152.87 11.11 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -129.76 136.14 59.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.65 97.85 2.15 Favored Glycine 0 N--CA 1.434 -1.472 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.025 179.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 26.5 ptm . . . . . 0 C--N 1.308 -1.216 0 CA-C-O 120.894 0.378 . . . . 0.0 110.025 -179.044 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 20.2 tp . . . . . 0 N--CA 1.413 -2.286 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -110.49 89.5 0.55 Allowed Glycine 0 N--CA 1.398 -3.849 0 C-N-CA 119.99 -1.1 . . . . 0.0 111.982 -176.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 29.6 mm -90.21 78.4 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.212 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 171.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -86.05 167.63 14.83 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-N 113.911 -1.495 . . . . 0.0 109.137 -176.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 51.1 t -81.07 131.34 34.14 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 176.2 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 36.4 ttpt -91.9 -40.97 10.86 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.771 -175.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -156.63 162.73 39.84 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 -177.012 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.417 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 21.8 t -127.53 92.11 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 178.29 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 10.5 m -72.31 132.55 44.16 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 123.541 0.736 . . . . 0.0 111.672 -176.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -67.83 -3.52 9.83 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 123.886 0.874 . . . . 0.0 113.208 -179.163 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.1 3.23 85.72 Favored Glycine 0 N--CA 1.44 -1.098 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.133 -177.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -139.36 170.94 23.94 Favored Glycine 0 N--CA 1.407 -3.273 0 C-N-CA 119.862 -1.161 . . . . 0.0 113.556 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.94 -35.05 44.54 Favored 'General case' 0 C--O 1.195 -1.812 0 C-N-CA 126.235 1.814 . . . . 0.0 114.726 -174.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -64.63 -45.28 87.53 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 120.284 -0.566 . . . . 0.0 112.348 -174.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 5.1 t60 -73.44 -41.09 63.65 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 108.679 -0.859 . . . . 0.0 108.679 177.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -59.81 -42.76 94.2 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.71 -178.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . 0.574 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 9.7 t70 -78.19 -51.85 9.58 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.279 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.95 42.71 3.23 Favored Glycine 0 N--CA 1.434 -1.463 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.595 ' HA ' ' NE ' ' B' ' 53' ' ' ARG . 4.9 mmp_? -104.97 -82.77 0.51 Allowed 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -178.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.46 HD11 ' CE2' ' B' ' 89' ' ' PHE . 49.9 mt -61.28 122.94 13.1 Favored 'Isoleucine or valine' 0 C--O 1.244 0.785 0 C-N-CA 120.165 -0.614 . . . . 0.0 110.435 176.574 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . 0.411 ' HB2' ' OD1' ' B' ' 58' ' ' ASP . 48.0 mt-30 -100.81 173.45 6.5 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.845 0.355 . . . . 0.0 111.039 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.8 p -77.83 -1.97 4.36 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 CA-C-O 121.374 0.607 . . . . 0.0 112.388 -174.022 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -124.07 24.55 8.16 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-O 122.053 0.93 . . . . 0.0 109.584 -178.461 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . 0.411 ' OD1' ' HB2' ' B' ' 55' ' ' GLN . 11.1 m-20 -98.21 166.36 11.44 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 114.345 -1.298 . . . . 0.0 110.421 -177.411 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . 0.543 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 24.8 tp -140.39 133.35 29.27 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 123.423 0.689 . . . . 0.0 109.851 -177.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 71.1 mt -82.72 99.75 9.83 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 177.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.535 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.1 t -85.02 -40.81 15.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 122.0 0.905 . . . . 0.0 110.676 178.51 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . 0.411 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 10.2 pt-20 -155.51 154.25 31.51 Favored 'General case' 0 C--N 1.27 -2.883 0 CA-C-N 115.17 -0.923 . . . . 0.0 109.633 173.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . 0.416 HG11 ' HB ' ' B' ' 66' ' ' THR . 6.6 p -100.4 -171.86 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 N-CA-C 105.825 -1.917 . . . . 0.0 105.825 178.65 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 8.6 t70 -44.14 -55.21 4.95 Favored 'General case' 0 N--CA 1.482 1.125 0 C-N-CA 124.117 0.967 . . . . 0.0 112.959 177.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -136.21 43.39 1.24 Allowed Glycine 0 C--N 1.304 -1.234 0 C-N-CA 119.07 -1.538 . . . . 0.0 114.98 -179.214 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 66' ' ' THR . . . . . 0.416 ' HB ' HG11 ' B' ' 63' ' ' VAL . 88.5 m -155.09 123.5 5.98 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 117.558 0.679 . . . . 0.0 109.326 177.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 5.7 m -87.58 125.02 34.11 Favored 'General case' 0 N--CA 1.441 -0.909 0 C-N-CA 123.091 0.557 . . . . 0.0 109.782 -177.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.535 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 25.1 mt -90.38 99.54 12.55 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 122.21 1.005 . . . . 0.0 110.856 179.327 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 58.1 t -69.22 -33.07 56.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-N 114.759 -1.109 . . . . 0.0 108.046 175.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 149.35 66.46 0.01 OUTLIER Glycine 0 CA--C 1.468 -2.845 0 N-CA-C 108.901 -1.68 . . . . 0.0 108.901 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 29.8 m -83.06 171.97 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.878 0 CA-C-N 113.694 -1.253 . . . . 0.0 109.188 -177.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 25.4 p -77.91 163.79 25.7 Favored 'General case' 0 N--CA 1.412 -2.339 0 C-N-CA 121.042 -0.263 . . . . 0.0 110.465 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -59.74 -37.53 79.22 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.314 0.578 . . . . 0.0 109.899 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 32.9 t -65.23 -41.36 94.48 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.776 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -64.57 -48.1 76.25 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.589 ' O ' ' HG ' ' B' ' 80' ' ' LEU . . . -55.78 -43.29 76.63 Favored 'General case' 0 C--O 1.217 -0.642 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.772 178.794 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.62 -39.1 91.12 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.28 0.562 . . . . 0.0 111.033 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.1 t -72.17 -29.41 63.99 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.9 -177.099 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.443 HG12 ' O ' ' B' ' 76' ' ' ALA . 9.8 p -75.69 -33.85 27.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 -176.173 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . 0.589 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 70.2 mt -68.19 -12.02 60.24 Favored 'General case' 0 C--O 1.214 -0.794 0 CA-C-N 114.517 -1.22 . . . . 0.0 110.789 176.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 96.6 mtt180 -106.16 -5.78 19.05 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.467 0.651 . . . . 0.0 111.036 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 13.0 m-80 -96.95 -24.04 16.02 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.546 177.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.468 ' HB ' HG13 ' B' ' 87' ' ' VAL . 3.9 p -68.44 179.74 1.57 Allowed 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -178.132 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 66.3 mmtt -72.03 -170.33 0.58 Allowed 'General case' 0 C--O 1.239 0.514 0 C-N-CA 123.462 0.705 . . . . 0.0 110.921 176.045 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.95 -36.09 47.99 Favored Glycine 0 N--CA 1.445 -0.759 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.648 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 26.3 ttm180 -127.52 122.48 33.45 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . 0.486 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 13.6 m -133.75 150.14 31.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.085 0 CA-C-O 121.085 0.469 . . . . 0.0 111.051 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 69.6 mtp85 -108.36 118.63 37.28 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.459 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.46 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 1.3 m-85 -98.73 170.74 8.56 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -177.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.411 ' HB2' ' CG ' ' B' ' 62' ' ' GLU . 48.5 mtt -113.54 116.88 30.24 Favored 'General case' 0 CA--C 1.473 -1.992 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 167.535 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.543 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.3 mp -94.49 121.72 45.34 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 177.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . 0.535 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -112.67 96.45 0.83 Allowed Glycine 0 CA--C 1.461 -3.321 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 177.557 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . 0.512 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 36.6 ttm180 . . . . . 0 C--N 1.257 -3.435 0 CA-C-N 114.761 -0.719 . . . . 0.0 110.512 -176.077 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 3' ' ' MET . . . . . 0.504 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 66.8 mtt . . . . . 0 CA--C 1.505 -0.765 0 CA-C-O 120.901 0.381 . . . . 0.0 110.734 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . 0.447 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 19.7 mt-10 -84.85 105.6 15.75 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -85.34 93.59 8.75 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 174.517 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -117.02 141.5 28.47 Favored Pre-proline 0 C--N 1.288 -2.068 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.196 179.398 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . 0.495 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 61.0 Cg_endo -79.32 137.79 13.57 Favored 'Trans proline' 0 N--CA 1.444 -1.411 0 C-N-CA 122.379 2.052 . . . . 0.0 112.984 178.413 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 79.0 t -125.61 142.19 43.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 N-CA-C 106.855 -1.535 . . . . 0.0 106.855 177.659 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -127.97 123.2 34.24 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 118.659 0.663 . . . . 0.0 110.708 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.442 ' O ' ' HD3' ' B' ' 86' ' ' ARG . 1.2 mt -113.7 163.94 14.35 Favored 'General case' 0 CA--C 1.486 -1.503 0 CA-C-O 121.589 0.709 . . . . 0.0 111.478 178.812 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -124.88 145.89 49.58 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 174.309 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -91.02 164.14 14.07 Favored 'General case' 0 N--CA 1.418 -2.026 0 CA-C-O 121.874 0.845 . . . . 0.0 110.36 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . 0.401 ' HB2' ' HB1' ' B' ' 47' ' ' ALA . 25.3 t70 -111.44 -179.41 3.71 Favored 'General case' 0 C--N 1.274 -2.683 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 178.073 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 16.1 m -69.54 -25.92 64.25 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 176.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 8.3 tp10 -85.89 1.71 48.85 Favored 'General case' 0 CA--C 1.548 0.876 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.443 178.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.45 -138.75 14.6 Favored Glycine 0 N--CA 1.437 -1.285 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.573 179.751 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 93.9 mt -95.54 -177.94 4.25 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 177.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -138.42 58.04 0.63 Allowed Glycine 0 CA--C 1.478 -2.23 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.453 -178.356 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . 0.506 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 7.0 pt -150.4 179.13 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 C-N-CA 123.52 0.728 . . . . 0.0 109.396 -177.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 20' ' ' SER . . . . . 0.41 ' HB2' HG22 ' B' ' 41' ' ' THR . 70.0 m -150.97 160.92 43.61 Favored 'General case' 0 C--N 1.269 -2.93 0 N-CA-C 105.14 -2.171 . . . . 0.0 105.14 175.673 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . 0.415 ' HB ' HG21 ' B' ' 37' ' ' ILE . 10.3 pt -130.73 159.96 42.32 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.621 0 CA-C-N 117.877 0.308 . . . . 0.0 110.226 -177.607 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.2 tp -136.5 135.86 48.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-O 120.985 0.421 . . . . 0.0 110.348 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -83.63 99.16 2.16 Favored Glycine 0 N--CA 1.437 -1.24 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.591 -178.082 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 24' ' ' MET . . . . . 0.418 ' HA ' ' HE3' ' B' ' 24' ' ' MET . 3.8 mmt . . . . . 0 C--N 1.3 -1.583 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.473 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 94.7 mt . . . . . 0 N--CA 1.427 -1.588 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -124.69 102.8 0.71 Allowed Glycine 0 N--CA 1.414 -2.803 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 -178.301 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . 0.415 HG21 ' HB ' ' B' ' 21' ' ' ILE . 23.7 mm -88.18 88.84 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 178.297 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -83.9 163.46 20.03 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.689 -1.141 . . . . 0.0 109.342 -178.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 65.8 t -71.49 130.99 35.09 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 174.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -90.31 -48.73 6.96 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.42 -177.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 41' ' ' THR . . . . . 0.41 HG22 ' HB2' ' B' ' 20' ' ' SER . 0.6 OUTLIER -150.05 163.86 37.04 Favored 'General case' 0 N--CA 1.428 -1.529 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -177.875 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.506 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.0 p -139.01 93.7 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 CA-C-O 122.693 1.235 . . . . 0.0 109.29 178.63 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 10.3 m -75.6 130.91 39.55 Favored 'General case' 0 N--CA 1.44 -0.974 0 CA-C-N 113.443 -1.708 . . . . 0.0 112.72 -172.44 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -57.93 -24.12 56.45 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 124.22 1.008 . . . . 0.0 112.901 179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.47 -1.26 81.67 Favored Glycine 0 N--CA 1.436 -1.313 0 CA-C-N 115.97 -0.559 . . . . 0.0 113.465 -178.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -122.28 170.23 15.08 Favored Glycine 0 N--CA 1.421 -2.354 0 C-N-CA 120.229 -0.986 . . . . 0.0 112.733 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . 0.401 ' HB1' ' HB2' ' B' ' 13' ' ' ASP . . . -59.94 -39.41 85.45 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 114.261 1.208 . . . . 0.0 114.261 -173.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -64.34 -39.82 94.65 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -173.003 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -72.36 -44.53 62.44 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.509 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 17.2 mtp180 -62.24 -45.49 93.1 Favored 'General case' 0 CA--C 1.511 -0.536 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.188 -177.047 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . 0.49 ' OD2' ' HD2' ' B' ' 53' ' ' ARG . 19.1 t70 -65.54 -51.4 60.2 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 176.692 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 95.04 39.48 4.56 Favored Glycine 0 CA--C 1.478 -2.278 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.548 ' HA ' ' NE ' ' B' ' 53' ' ' ARG . 0.0 OUTLIER -99.66 -73.18 0.64 Allowed 'General case' 0 N--CA 1.419 -2.023 0 CA-C-N 114.221 -0.989 . . . . 0.0 110.483 -170.965 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.553 HD13 ' CE2' ' B' ' 89' ' ' PHE . 47.1 mt -82.78 125.1 39.95 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 175.725 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . 0.499 ' HG2' ' OD2' ' B' ' 58' ' ' ASP . 24.2 pt20 -100.42 169.52 9.04 Favored 'General case' 0 C--N 1.309 -1.196 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -178.26 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.1 p -66.82 -2.28 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.507 0 C-N-CA 123.964 0.906 . . . . 0.0 113.361 -174.182 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -127.27 19.39 6.93 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.044 -1.035 . . . . 0.0 110.769 -178.349 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . 0.499 ' OD2' ' HG2' ' B' ' 55' ' ' GLN . 80.8 m-20 -84.66 168.24 15.46 Favored 'General case' 0 C--N 1.312 -1.038 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.595 176.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . 0.43 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 28.6 tp -136.06 127.45 28.48 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.393 -176.303 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 82.5 mt -81.73 90.91 6.39 Favored 'General case' 0 N--CA 1.434 -1.236 0 CA-C-O 121.534 0.683 . . . . 0.0 109.875 178.401 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.653 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 10.9 t -74.25 -39.6 49.56 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.126 175.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . 0.463 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 11.9 pt-20 -164.56 159.66 19.42 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.862 171.009 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . 0.441 HG13 ' HB ' ' B' ' 66' ' ' THR . 3.0 p -96.95 178.19 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . 0.516 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 19.9 t70 -42.59 -54.34 4.01 Favored 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 125.409 1.484 . . . . 0.0 113.762 -176.185 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -132.56 43.85 1.25 Allowed Glycine 0 C--N 1.304 -1.232 0 C-N-CA 119.581 -1.295 . . . . 0.0 113.682 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 66' ' ' THR . . . . . 0.441 ' HB ' HG13 ' B' ' 63' ' ' VAL . 51.6 m -157.43 114.34 2.99 Favored 'General case' 0 C--O 1.247 0.923 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 175.867 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 67' ' ' SER . . . . . 0.463 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 44.6 m -81.99 111.65 18.36 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 112.476 0.547 . . . . 0.0 112.476 -177.177 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.653 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 44.2 mt -79.52 110.48 14.88 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.887 176.496 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 14.7 p -75.84 -24.98 16.98 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 177.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 142.54 64.04 0.03 OUTLIER Glycine 0 CA--C 1.484 -1.87 0 N-CA-C 108.928 -1.669 . . . . 0.0 108.928 -177.172 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.9 m -82.26 -178.59 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 114.366 -0.917 . . . . 0.0 110.406 -176.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 40.4 p -82.89 166.29 19.04 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 120.926 0.393 . . . . 0.0 110.93 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.7 tt0 -59.55 -42.89 93.4 Favored 'General case' 0 C--N 1.324 -0.539 0 C-N-CA 123.237 0.615 . . . . 0.0 110.168 -179.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 23.2 t -66.49 -38.96 88.41 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.247 -178.632 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -63.13 -50.22 71.33 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.547 ' O ' HG13 ' B' ' 79' ' ' VAL . . . -61.3 -37.59 83.75 Favored 'General case' 0 CA--C 1.539 0.526 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.261 178.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.34 -30.54 71.24 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.657 0.741 . . . . 0.0 110.502 177.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.4 m -82.36 -27.48 32.12 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.521 -178.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.547 HG13 ' O ' ' B' ' 76' ' ' ALA . 3.9 p -72.03 -31.34 39.88 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.453 0 CA-C-O 121.396 0.617 . . . . 0.0 109.56 -176.126 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 19.4 mt -67.12 -17.35 64.82 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.918 -1.037 . . . . 0.0 111.322 176.519 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 22.1 mtm180 -100.72 -7.9 23.34 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-O 121.292 0.568 . . . . 0.0 110.31 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -89.99 -15.01 32.78 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 121.744 0.783 . . . . 0.0 109.655 176.255 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.453 ' HB ' HG11 ' B' ' 87' ' ' VAL . 9.3 p -92.06 167.2 12.24 Favored 'General case' 0 N--CA 1.412 -2.351 0 CA-C-N 115.261 -0.881 . . . . 0.0 111.855 179.191 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -76.88 -167.49 0.86 Allowed 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.277 -0.874 . . . . 0.0 112.876 177.242 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.26 -13.33 79.09 Favored Glycine 0 C--O 1.207 -1.555 0 CA-C-N 114.738 -1.119 . . . . 0.0 112.732 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . 0.442 ' HD3' ' O ' ' B' ' 10' ' ' LEU . 4.4 tpp180 -137.74 116.3 12.08 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 175.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . 0.516 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 6.3 m -149.12 157.59 6.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 122.969 0.508 . . . . 0.0 110.534 -179.06 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 77.0 mtm180 -96.18 170.18 9.44 Favored 'General case' 0 C--N 1.287 -2.145 0 CA-C-N 114.545 -1.207 . . . . 0.0 108.246 176.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.553 ' CE2' HD13 ' B' ' 54' ' ' ILE . 3.4 m-85 -150.9 162.16 41.32 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 105.163 -2.162 . . . . 0.0 105.163 175.397 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.535 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 66.4 mtm -115.54 114.45 24.99 Favored 'General case' 0 C--N 1.286 -2.195 0 CA-C-O 121.721 0.772 . . . . 0.0 110.139 170.548 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.43 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -97.38 127.33 49.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.73 0 CA-C-N 113.819 -1.537 . . . . 0.0 108.024 -176.566 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . 0.447 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -106.83 118.05 5.51 Favored Glycine 0 CA--C 1.466 -3.014 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 176.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . 0.504 ' O ' ' HA ' ' B' ' 3' ' ' MET . 9.9 tpp180 . . . . . 0 C--N 1.288 -2.084 0 CA-C-N 115.067 -0.567 . . . . 0.0 110.416 178.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 68.5 mtm . . . . . 0 N--CA 1.424 -1.752 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -76.03 102.12 5.53 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.528 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 0.6 OUTLIER -85.93 84.64 7.48 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.056 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -113.49 142.93 28.42 Favored Pre-proline 0 C--N 1.301 -1.522 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.906 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . 0.426 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 59.0 Cg_endo -80.0 131.59 9.03 Favored 'Trans proline' 0 N--CA 1.444 -1.391 0 C-N-CA 122.115 1.877 . . . . 0.0 113.396 179.238 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.405 ' CG1' ' HB3' ' B' ' 53' ' ' ARG . 75.9 t -119.08 141.23 39.97 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.998 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.502 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -129.82 139.67 51.18 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.447 HD12 HG13 ' B' ' 54' ' ' ILE . 1.0 OUTLIER -144.09 157.68 44.17 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.001 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.596 ' OE2' ' HD3' ' B' ' 86' ' ' ARG . 68.4 mm-40 -95.11 133.14 39.26 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 114.061 -1.427 . . . . 0.0 107.71 177.138 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.73 135.3 35.97 Favored 'General case' 0 N--CA 1.426 -1.664 0 C-N-CA 118.928 -1.109 . . . . 0.0 108.491 173.815 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -85.76 -178.12 6.54 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -174.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 18.9 m -68.93 -26.39 65.05 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.394 -175.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -81.91 -46.61 13.83 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 176.492 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 168.25 -85.07 0.09 OUTLIER Glycine 0 N--CA 1.423 -2.225 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 177.569 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 27.2 tp -164.15 108.28 0.97 Allowed 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 175.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . 0.442 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -67.7 59.22 0.33 Allowed Glycine 0 C--O 1.215 -1.077 0 C-N-CA 124.704 1.145 . . . . 0.0 115.581 -173.858 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . 0.446 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.8 pt -144.8 -178.42 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.267 -3.006 0 C-N-CA 125.565 1.546 . . . . 0.0 107.365 173.265 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.4 m -156.69 161.68 39.84 Favored 'General case' 0 C--N 1.272 -2.804 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.141 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 26.3 pt -124.43 153.52 31.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-N 117.99 0.359 . . . . 0.0 110.278 -179.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.2 tp -137.64 135.15 46.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.87 103.63 2.93 Favored Glycine 0 N--CA 1.421 -2.311 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.179 -178.616 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 25.9 mmt . . . . . 0 C--N 1.298 -1.657 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 176.49 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 2.9 mm? . . . . . 0 CA--C 1.48 -1.74 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -94.68 87.64 1.1 Allowed Glycine 0 N--CA 1.4 -3.764 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 20.7 mm -82.99 78.38 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.362 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 173.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -81.56 169.77 16.67 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 114.193 -1.367 . . . . 0.0 109.371 -172.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 79.4 t -75.69 128.98 37.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-O 121.372 0.606 . . . . 0.0 109.814 176.231 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 9.2 tmtm? -84.5 -54.42 4.76 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.11 -177.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 7.9 t -145.7 175.2 10.56 Favored 'General case' 0 N--CA 1.429 -1.508 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 179.182 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.5 p -154.88 96.4 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 -179.378 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 6.0 m -78.25 134.96 37.48 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 113.59 -1.641 . . . . 0.0 111.514 -170.621 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -61.87 -12.8 19.46 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.004 0.922 . . . . 0.0 113.238 178.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.18 -2.05 85.98 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 116.528 -0.306 . . . . 0.0 112.455 177.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.442 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -115.88 169.97 13.15 Favored Glycine 0 N--CA 1.418 -2.544 0 C-N-CA 120.291 -0.957 . . . . 0.0 111.823 179.169 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -69.28 -36.26 76.88 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 114.882 -0.659 . . . . 0.0 111.745 -175.088 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -57.03 -40.52 76.9 Favored 'General case' 0 CA--C 1.542 0.657 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -175.417 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -71.34 -42.46 68.51 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.213 0.53 . . . . 0.0 110.209 -179.081 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -75.09 -28.52 60.32 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.952 -175.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -80.75 -41.79 22.92 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.723 -177.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 83.78 43.24 7.33 Favored Glycine 0 C--N 1.309 -0.924 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.576 176.447 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.51 ' HE ' ' HA ' ' B' ' 53' ' ' ARG . 1.4 mmp_? -115.22 -69.72 0.84 Allowed 'General case' 0 C--N 1.301 -1.537 0 CA-C-O 119.091 -0.48 . . . . 0.0 110.848 178.847 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.583 HD11 ' CE2' ' B' ' 89' ' ' PHE . 77.7 mt -73.55 136.97 24.25 Favored 'Isoleucine or valine' 0 C--O 1.253 1.241 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 171.755 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 19.6 mt-30 -118.21 162.51 18.12 Favored 'General case' 0 C--N 1.289 -2.04 0 C-N-CA 123.909 0.884 . . . . 0.0 109.639 -174.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 9.7 p -73.6 -4.34 5.29 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-O 121.695 0.76 . . . . 0.0 111.075 -178.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -116.55 -5.49 11.68 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -176.144 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -91.39 -175.39 4.22 Favored 'General case' 0 C--O 1.247 0.958 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 -175.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . 0.507 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 35.6 tp -139.35 128.07 23.29 Favored 'General case' 0 N--CA 1.435 -1.212 0 CA-C-N 114.775 -1.102 . . . . 0.0 109.883 -174.043 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 57.0 mt -87.09 95.38 9.93 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.455 -0.942 . . . . 0.0 108.455 178.141 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.496 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 36.3 t -75.65 -43.07 41.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 CA-C-O 121.843 0.83 . . . . 0.0 111.301 -178.445 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . 0.41 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 12.2 pt-20 -146.63 160.95 41.53 Favored 'General case' 0 C--N 1.267 -2.997 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 173.511 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 4.8 p -113.18 -177.44 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -49.53 -45.73 47.75 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -176.369 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -132.29 31.33 3.03 Favored Glycine 0 CA--C 1.522 0.525 0 C-N-CA 119.687 -1.244 . . . . 0.0 114.607 -177.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 36.1 m -159.73 135.47 8.51 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.125 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 67' ' ' SER . . . . . 0.41 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 30.5 m -108.64 146.83 32.78 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.496 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 43.6 mt -104.31 115.05 29.7 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-O 120.938 0.399 . . . . 0.0 110.66 176.49 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 12.3 p -81.38 -20.39 10.95 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 N-CA-C 108.544 -0.909 . . . . 0.0 108.544 174.529 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 140.79 71.27 0.04 OUTLIER Glycine 0 CA--C 1.487 -1.672 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 -177.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.9 m -92.79 179.33 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 114.856 -0.672 . . . . 0.0 110.681 -175.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 43.5 p -82.86 165.28 19.93 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 177.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -59.45 -42.11 91.2 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.949 0.404 . . . . 0.0 110.108 179.37 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 48.5 m -66.5 -35.92 81.46 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.473 -179.413 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -66.61 -46.67 75.09 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.52 -41.56 94.65 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.132 178.149 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.25 -34.96 75.99 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.072 178.268 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 24.5 m -76.9 -20.92 55.66 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.984 -179.018 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . . . . . . . . . 24.3 t -71.37 -57.11 8.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 16.6 mt -57.79 -18.59 22.74 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 125.325 1.45 . . . . 0.0 112.964 178.205 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 69.9 mtp180 -88.94 -18.09 28.2 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-O 121.279 0.561 . . . . 0.0 110.813 176.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -99.71 -6.19 27.54 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.729 0.776 . . . . 0.0 110.749 -176.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 83' ' ' THR . . . . . . . . . . . . . 18.9 p -82.41 165.96 19.81 Favored 'General case' 0 C--O 1.249 1.07 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 -178.482 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 57.7 mmtt -73.1 -167.58 0.41 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 124.594 1.158 . . . . 0.0 112.012 179.052 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.05 -34.23 55.87 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-N 115.509 -0.769 . . . . 0.0 112.516 -179.307 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . 0.596 ' HD3' ' OE2' ' B' ' 11' ' ' GLU . 45.5 ttp180 -134.69 124.69 25.68 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 175.621 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 13.7 m -137.13 160.32 36.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.915 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -102.15 163.11 12.42 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 176.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.583 ' CE2' HD11 ' B' ' 54' ' ' ILE . 4.9 m-85 -140.44 155.99 46.52 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 179.072 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.45 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 9.5 ttt -110.22 115.07 29.05 Favored 'General case' 0 C--N 1.275 -2.631 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 174.082 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.528 ' O ' ' HA ' ' B' ' 5' ' ' LEU . 1.4 mp -92.29 138.45 19.92 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.342 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -177.679 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.26 112.99 1.29 Allowed Glycine 0 CA--C 1.486 -1.742 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 175.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 18.1 tpp180 . . . . . 0 C--N 1.286 -2.156 0 CA-C-N 115.099 -0.55 . . . . 0.0 109.757 -179.126 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 64.4 mtm . . . . . 0 N--CA 1.423 -1.779 0 N-CA-C 104.466 -2.42 . . . . 0.0 104.466 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . 0.494 ' HB2' ' HB3' ' B' ' 93' ' ' ARG . 12.0 mt-10 -94.3 93.36 7.68 Favored 'General case' 0 C--N 1.289 -2.036 0 C-N-CA 118.46 -1.296 . . . . 0.0 110.4 -175.581 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -82.52 95.85 7.85 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 177.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 7.1 p90 -119.46 144.33 36.41 Favored Pre-proline 0 C--N 1.279 -2.48 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.128 176.575 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . 0.579 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 30.4 Cg_endo -72.87 129.46 14.39 Favored 'Trans proline' 0 N--CA 1.432 -2.099 0 C-N-CA 122.005 1.803 . . . . 0.0 112.242 176.719 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.403 ' HB ' HD13 ' B' ' 91' ' ' ILE . 70.5 t -115.02 122.02 68.28 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.046 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 177.527 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . 0.423 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 31.8 tt0 -105.58 132.22 52.0 Favored 'General case' 0 C--N 1.269 -2.895 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -176.574 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.43 HD23 ' HA ' ' B' ' 48' ' ' ALA . 0.6 OUTLIER -124.09 159.77 29.21 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 175.264 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -132.12 125.81 32.2 Favored 'General case' 0 C--N 1.26 -3.322 0 CA-C-N 113.919 -1.491 . . . . 0.0 107.187 178.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt -66.14 151.88 45.98 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 121.938 0.875 . . . . 0.0 112.608 -178.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -102.66 178.34 4.6 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 14.7 m -67.79 -26.5 66.12 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 121.7 0.762 . . . . 0.0 109.035 175.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -72.74 -21.28 61.05 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-N 114.62 -1.173 . . . . 0.0 109.607 173.763 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.62 -105.12 2.7 Favored Glycine 0 N--CA 1.422 -2.236 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -176.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 94.8 mt -109.79 -176.87 3.12 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.1 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -156.19 61.62 0.35 Allowed Glycine 0 CA--C 1.476 -2.383 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.22 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . 0.543 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 3.1 pt -161.46 175.78 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.481 -1.693 0 C-N-CA 124.557 1.143 . . . . 0.0 108.157 -176.654 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 20' ' ' SER . . . . . 0.418 ' HB2' HG23 ' B' ' 41' ' ' THR . 54.9 m -148.59 151.7 35.49 Favored 'General case' 0 C--N 1.262 -3.2 0 N-CA-C 105.854 -1.906 . . . . 0.0 105.854 174.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . 0.431 ' HB ' HG22 ' B' ' 37' ' ' ILE . 16.6 pt -116.94 162.06 15.2 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.537 0 O-C-N 123.421 0.45 . . . . 0.0 110.613 -176.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.5 tp -146.84 137.61 17.92 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.19 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.98 111.41 3.73 Favored Glycine 0 N--CA 1.431 -1.668 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.482 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 85.9 mtp . . . . . 0 C--N 1.305 -1.341 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 176.993 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . 0.609 ' O ' ' HA2' ' B' ' 70' ' ' GLY . 85.9 mt . . . . . 0 N--CA 1.442 -0.844 0 CA-C-O 121.881 0.848 . . . . 0.0 111.764 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -101.7 115.48 5.27 Favored Glycine 0 N--CA 1.4 -3.722 0 N-CA-C 106.903 -2.479 . . . . 0.0 106.903 176.11 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . 0.431 HG22 ' HB ' ' B' ' 21' ' ' ILE . 29.1 mm -89.03 88.17 2.9 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 -177.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.468 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 73.5 m-85 -83.32 171.72 13.26 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 114.716 -1.129 . . . . 0.0 109.419 -177.664 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 58.9 t -78.19 136.22 24.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.67 0.748 . . . . 0.0 110.053 176.448 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -92.68 -48.13 6.74 Favored 'General case' 0 N--CA 1.426 -1.672 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.131 177.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 41' ' ' THR . . . . . 0.418 HG23 ' HB2' ' B' ' 20' ' ' SER . 1.0 OUTLIER -154.13 167.27 30.43 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -178.44 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.543 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.4 p -133.92 96.66 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.065 0 CA-C-O 122.389 1.09 . . . . 0.0 109.821 176.697 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 27.9 m -59.87 125.57 24.17 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 113.257 -1.792 . . . . 0.0 112.2 -175.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . 0.457 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 45.4 mt-10 -61.27 -35.07 76.31 Favored 'General case' 0 CA--C 1.516 -0.35 0 C-N-CA 124.21 1.004 . . . . 0.0 111.889 -176.122 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.79 -10.13 84.95 Favored Glycine 0 N--CA 1.441 -1.015 0 CA-C-N 115.861 -0.609 . . . . 0.0 113.415 -179.295 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.472 ' O ' ' HG3' ' B' ' 50' ' ' ARG . . . -106.23 171.2 17.38 Favored Glycine 0 N--CA 1.417 -2.629 0 C-N-CA 119.828 -1.177 . . . . 0.0 113.85 -175.452 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.26 -50.59 38.21 Favored 'General case' 0 C--O 1.208 -1.131 0 C-N-CA 125.213 1.405 . . . . 0.0 114.788 -173.52 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . 0.43 ' HA ' HD23 ' B' ' 10' ' ' LEU . . . -63.96 -32.44 73.97 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 113.88 1.067 . . . . 0.0 113.88 -172.018 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . 0.457 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 2.7 t60 -83.75 -38.8 20.89 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.128 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . 0.472 ' HG3' ' O ' ' B' ' 46' ' ' GLY . 74.9 mtp180 -70.32 -42.52 71.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.072 -178.683 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -74.09 -43.08 58.97 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 89.98 51.49 2.8 Favored Glycine 0 CA--C 1.504 -0.608 0 CA-C-N 115.113 -0.949 . . . . 0.0 112.406 175.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 34.0 mmt180 -112.94 -82.84 0.59 Allowed 'General case' 0 N--CA 1.442 -0.868 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.053 -177.356 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.452 HD13 ' CE2' ' B' ' 89' ' ' PHE . 70.7 mt -65.52 134.87 29.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 O-C-N 123.774 0.671 . . . . 0.0 109.396 179.648 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 24.4 mm-40 -111.95 164.77 12.74 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.9 p -65.0 -8.34 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.578 2.028 0 N-CA-C 113.093 0.775 . . . . 0.0 113.093 -175.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -115.3 -6.09 12.37 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 -172.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -94.25 179.2 5.38 Favored 'General case' 0 N--CA 1.432 -1.373 0 N-CA-C 114.998 1.481 . . . . 0.0 114.998 -178.513 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . 0.468 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 25.8 tp -135.25 136.69 41.89 Favored 'General case' 0 C--O 1.247 0.933 0 CA-C-N 114.958 -1.019 . . . . 0.0 110.954 -172.269 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 52.6 mt -83.82 96.84 8.89 Favored 'General case' 0 N--CA 1.425 -1.69 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 176.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.503 ' HB ' ' O ' ' B' ' 90' ' ' MET . 35.0 t -69.74 -42.75 80.28 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-O 122.159 0.98 . . . . 0.0 109.752 179.314 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -156.94 158.87 37.43 Favored 'General case' 0 C--N 1.277 -2.572 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.821 173.056 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 5.0 p -106.36 -175.9 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.099 0 N-CA-C 104.796 -2.298 . . . . 0.0 104.796 178.297 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . 0.437 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 8.9 t70 -52.44 -54.47 31.77 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 112.792 0.664 . . . . 0.0 112.792 178.459 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -122.29 35.73 3.4 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 119.81 -1.186 . . . . 0.0 115.277 -177.072 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 19.2 m -160.9 141.64 11.5 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 47.3 t -107.02 151.37 25.42 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 -178.628 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.47 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.6 mm? -116.27 106.28 13.5 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 120.98 0.419 . . . . 0.0 110.434 178.609 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 42.6 t -103.51 -8.09 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-O 122.221 1.01 . . . . 0.0 109.096 176.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . 0.609 ' HA2' ' O ' ' B' ' 35' ' ' LEU . . . 131.52 78.02 0.16 Allowed Glycine 0 CA--C 1.484 -1.898 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -177.47 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . 0.434 HG21 ' O ' ' B' ' 72' ' ' THR . 26.4 m -106.13 -175.08 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.098 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -175.836 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 72' ' ' THR . . . . . 0.434 ' O ' HG21 ' B' ' 71' ' ' VAL . 45.7 p -83.86 159.8 21.28 Favored 'General case' 0 N--CA 1.426 -1.655 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 175.061 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.0 tt0 -63.26 -31.37 72.51 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-O 121.519 0.676 . . . . 0.0 109.567 178.564 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 9.7 m -64.89 -43.18 93.75 Favored 'General case' 0 C--O 1.247 0.948 0 CA-C-N 115.052 -0.977 . . . . 0.0 110.051 177.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -62.27 -51.89 65.9 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 115.212 -0.904 . . . . 0.0 108.782 177.46 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.661 ' O ' ' HB ' ' B' ' 79' ' ' VAL . . . -57.61 -37.55 73.45 Favored 'General case' 0 C--O 1.214 -0.814 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.434 -178.131 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.84 -32.64 73.31 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.174 0.512 . . . . 0.0 111.037 178.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 19.0 m -79.36 -19.65 49.71 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.767 179.535 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.661 ' HB ' ' O ' ' B' ' 76' ' ' ALA . 3.9 t -57.15 -57.46 9.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.447 1.099 . . . . 0.0 111.843 177.072 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -58.62 -30.15 67.04 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 122.822 0.449 . . . . 0.0 111.781 178.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 31.6 mtp85 -80.76 -16.76 52.99 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.785 -179.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -81.97 -27.91 32.97 Favored 'General case' 0 N--CA 1.44 -0.973 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.451 ' HB ' HG13 ' B' ' 87' ' ' VAL . 12.5 p -88.99 159.86 17.4 Favored 'General case' 0 N--CA 1.417 -2.088 0 CA-C-N 114.882 -1.054 . . . . 0.0 112.887 179.05 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 72.5 mttt -64.6 -174.91 0.15 Allowed 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 124.914 1.286 . . . . 0.0 113.682 -177.114 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.94 -42.53 94.78 Favored Glycine 0 N--CA 1.445 -0.762 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.985 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 56.9 ttm-85 -123.13 118.46 27.73 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 176.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . 0.451 HG13 ' HB ' ' B' ' 83' ' ' THR . 6.2 m -146.41 156.3 11.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.786 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.256 -178.037 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . 0.423 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 95.5 mtt180 -105.71 125.54 51.11 Favored 'General case' 0 N--CA 1.423 -1.799 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.47 177.452 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.579 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 1.8 m-85 -100.32 166.79 10.79 Favored 'General case' 0 C--N 1.27 -2.856 0 N-CA-C 106.026 -1.842 . . . . 0.0 106.026 176.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.503 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 64.3 mtt -113.3 112.92 24.52 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 171.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.403 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.4 mp -97.25 128.77 48.18 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -101.39 100.89 2.15 Favored Glycine 0 CA--C 1.46 -3.356 0 N-CA-C 108.522 -1.831 . . . . 0.0 108.522 176.338 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . 0.494 ' HB3' ' HB2' ' B' ' 4' ' ' GLU . 21.2 tpp180 . . . . . 0 C--N 1.277 -2.547 0 CA-C-N 114.398 -0.901 . . . . 0.0 109.991 -177.218 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 1.7 mpt? . . . . . 0 N--CA 1.432 -1.352 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -75.97 98.55 4.3 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 177.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -81.28 88.97 6.04 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 175.77 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -109.92 145.31 31.78 Favored Pre-proline 0 C--N 1.288 -2.077 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.672 178.781 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -75.91 129.92 11.94 Favored 'Trans proline' 0 N--CA 1.44 -1.66 0 C-N-CA 122.19 1.926 . . . . 0.0 111.97 177.65 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.44 HG11 ' HB3' ' B' ' 53' ' ' ARG . 84.9 t -116.61 126.2 73.96 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.401 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.331 -179.071 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . 0.479 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 41.4 tt0 -120.81 128.78 53.18 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -178.675 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.487 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -115.41 -162.59 0.84 Allowed 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.796 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.416 ' H ' ' CD2' ' B' ' 10' ' ' LEU . 2.3 mm-40 -156.67 167.69 29.69 Favored 'General case' 0 C--N 1.29 -1.998 0 C-N-CA 126.251 1.82 . . . . 0.0 106.145 176.353 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -92.81 -173.15 3.23 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 121.297 0.57 . . . . 0.0 111.35 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . 0.423 ' HB2' ' HB1' ' B' ' 47' ' ' ALA . 21.9 t70 -128.52 172.05 11.53 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 22.8 t -61.75 -30.98 71.14 Favored 'General case' 0 C--N 1.307 -1.251 0 O-C-N 123.789 0.681 . . . . 0.0 109.199 178.298 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -91.59 -51.95 5.0 Favored 'General case' 0 N--CA 1.446 -0.662 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 173.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 126.47 133.27 3.83 Favored Glycine 0 N--CA 1.428 -1.848 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.977 178.043 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mm? 63.66 -168.66 0.2 Allowed 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 176.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.19 54.29 0.05 OUTLIER Glycine 0 C--O 1.209 -1.43 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 179.035 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . 0.536 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 4.9 pt -166.91 177.62 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.493 -1.246 0 C-N-CA 125.068 1.347 . . . . 0.0 108.657 -173.707 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 39.1 m -151.95 144.92 24.47 Favored 'General case' 0 C--N 1.27 -2.853 0 N-CA-C 105.461 -2.051 . . . . 0.0 105.461 174.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . 0.414 ' HB ' HG21 ' B' ' 37' ' ' ILE . 12.3 pt -111.1 160.76 10.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.054 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 -178.361 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.8 tp -138.75 138.17 42.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-O 120.939 0.399 . . . . 0.0 110.177 -178.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.72 98.7 2.3 Favored Glycine 0 N--CA 1.423 -2.221 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 177.453 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 86.4 mtp . . . . . 0 C--N 1.306 -1.29 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 178.922 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 77.6 mt . . . . . 0 C--O 1.248 0.996 0 CA-C-O 121.091 0.472 . . . . 0.0 111.483 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -113.59 123.42 6.13 Favored Glycine 0 N--CA 1.412 -2.935 0 N-CA-C 108.892 -1.683 . . . . 0.0 108.892 177.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . 0.414 HG21 ' HB ' ' B' ' 21' ' ' ILE . 20.7 mm -93.81 89.21 2.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.375 -0.93 . . . . 0.0 108.91 -179.46 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.463 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 90.5 m-85 -89.69 169.6 11.17 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.598 -178.376 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 58.0 t -75.32 134.83 28.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 CA-C-O 121.29 0.567 . . . . 0.0 109.723 175.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -93.04 -45.71 7.79 Favored 'General case' 0 N--CA 1.435 -1.186 0 CA-C-N 115.337 -0.847 . . . . 0.0 108.835 -179.09 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 2.5 t -155.21 169.2 24.72 Favored 'General case' 0 N--CA 1.419 -2.003 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.536 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.3 p -140.47 99.67 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.279 -2.496 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 -179.709 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 9.8 m -61.13 124.46 20.6 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 113.804 -1.543 . . . . 0.0 111.549 -175.095 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -69.92 -20.93 63.33 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.256 0.551 . . . . 0.0 111.863 -177.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.95 4.76 85.54 Favored Glycine 0 N--CA 1.437 -1.292 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.673 175.245 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -113.29 172.09 14.24 Favored Glycine 0 N--CA 1.425 -2.044 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.92 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . 0.423 ' HB1' ' HB2' ' B' ' 13' ' ' ASP . . . -64.86 -42.05 95.19 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -173.581 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . 0.487 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -58.85 -38.09 77.96 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 113.649 0.981 . . . . 0.0 113.649 -173.601 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -75.79 -41.07 53.95 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.244 0.545 . . . . 0.0 109.581 -177.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 64.4 mtp180 -68.18 -44.04 76.81 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.717 -178.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -63.21 -59.4 4.79 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.909 176.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 110.83 -15.53 28.78 Favored Glycine 0 N--CA 1.437 -1.233 0 C-N-CA 120.286 -0.959 . . . . 0.0 114.279 176.171 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.479 ' HG3' ' O ' ' B' ' 9' ' ' GLU . 30.4 mmt180 -62.85 -52.33 63.55 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 114.131 1.16 . . . . 0.0 114.131 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.519 HD11 ' CE2' ' B' ' 89' ' ' PHE . 39.0 mt -95.7 119.01 43.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 C-N-CA 119.634 -0.826 . . . . 0.0 109.901 178.57 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 85.0 mm-40 -107.69 -179.92 4.05 Favored 'General case' 0 N--CA 1.433 -1.317 0 CA-C-O 121.269 0.557 . . . . 0.0 109.881 177.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 12.7 p -71.02 -5.46 5.75 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.329 0 N-CA-C 113.087 0.773 . . . . 0.0 113.087 -174.681 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -117.12 4.24 12.7 Favored 'General case' 0 C--N 1.313 -0.996 0 O-C-N 121.06 -1.025 . . . . 0.0 111.354 -175.214 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -79.09 164.22 24.47 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.504 -175.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . 0.463 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 23.2 tp -136.69 128.34 28.81 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 123.078 0.551 . . . . 0.0 110.349 -176.587 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 70.3 mt -79.78 92.36 5.43 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.532 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 40.8 t -76.31 -42.24 36.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-O 122.066 0.936 . . . . 0.0 109.749 178.394 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . 0.408 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 8.6 pt-20 -154.23 147.49 24.84 Favored 'General case' 0 C--N 1.274 -2.697 0 CA-C-N 114.843 -1.072 . . . . 0.0 109.348 174.809 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . 0.407 HG11 ' O ' ' B' ' 66' ' ' THR . 5.3 p -97.61 -174.98 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 104.349 -2.463 . . . . 0.0 104.349 174.524 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . 0.463 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 28.8 t70 -56.37 -44.11 79.83 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 118.643 0.656 . . . . 0.0 112.563 -179.259 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -103.88 -66.57 0.72 Allowed Glycine 0 CA--C 1.528 0.85 0 C-N-CA 120.391 -0.909 . . . . 0.0 113.277 178.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 66' ' ' THR . . . . . 0.407 ' O ' HG11 ' B' ' 63' ' ' VAL . 14.2 m -66.87 129.86 41.27 Favored 'General case' 0 CA--C 1.547 0.849 0 CA-C-O 121.135 0.493 . . . . 0.0 112.124 -177.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 4.4 m -95.15 139.48 31.43 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 177.157 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.532 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.3 mm? -101.44 125.97 48.15 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.696 0.76 . . . . 0.0 111.39 -179.009 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 8.8 p -125.13 9.57 4.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 115.163 -0.926 . . . . 0.0 109.104 178.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 120.09 87.89 1.05 Allowed Glycine 0 CA--C 1.499 -0.942 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -177.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.0 m -121.94 -179.11 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -177.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 32.3 p -83.88 164.16 19.62 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 175.543 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.3 tt0 -60.89 -41.23 95.63 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.278 0.561 . . . . 0.0 110.246 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 12.9 t -66.74 -36.41 82.38 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.282 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . 0.41 ' O ' HG11 ' B' ' 79' ' ' VAL . 38.0 t80 -62.29 -52.29 64.26 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -179.65 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.689 ' O ' HG21 ' B' ' 79' ' ' VAL . . . -65.93 -31.32 72.18 Favored 'General case' 0 C--O 1.218 -0.574 0 CA-C-O 120.978 0.418 . . . . 0.0 110.383 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.4 -34.54 77.96 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.757 0.789 . . . . 0.0 109.603 175.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.4 m -84.18 -17.14 40.94 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 115.194 -0.912 . . . . 0.0 112.112 -177.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.689 HG21 ' O ' ' B' ' 76' ' ' ALA . 23.5 m -68.81 -38.87 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 CA-C-O 121.53 0.681 . . . . 0.0 109.588 -178.439 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 23.5 mt -65.56 -21.31 66.59 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 125.193 1.397 . . . . 0.0 110.884 176.728 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 80.7 mtt180 -92.94 -14.36 27.65 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.491 -177.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -94.79 -22.28 18.17 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.669 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.47 ' HB ' HG11 ' B' ' 87' ' ' VAL . 6.6 p -80.77 -177.37 6.3 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.707 177.854 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -67.8 -171.48 0.21 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 123.484 0.714 . . . . 0.0 111.217 178.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -73.15 -42.05 44.94 Favored Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.134 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . 0.471 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 16.0 ttp180 -121.99 124.13 43.29 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 175.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . 0.47 HG11 ' HB ' ' B' ' 83' ' ' THR . 5.2 m -137.86 165.58 25.93 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 CA-C-O 121.055 0.455 . . . . 0.0 110.858 178.084 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 51.8 mtp85 -106.52 147.91 28.84 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.405 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.519 ' CE2' HD11 ' B' ' 54' ' ' ILE . 0.7 OUTLIER -129.83 170.38 13.97 Favored 'General case' 0 C--N 1.277 -2.578 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 -179.224 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.527 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 59.8 mtt -121.16 122.93 41.06 Favored 'General case' 0 C--N 1.292 -1.923 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 168.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 1.3 mp -105.7 133.31 50.4 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 CA-C-N 114.194 -1.366 . . . . 0.0 107.446 -178.307 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -117.69 101.14 0.9 Allowed Glycine 0 CA--C 1.48 -2.113 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 177.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 19.2 tpp180 . . . . . 0 C--N 1.274 -2.685 0 CA-C-N 114.435 -0.883 . . . . 0.0 110.099 -176.18 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 3' ' ' MET . . . . . 0.449 ' O ' HD23 ' B' ' 5' ' ' LEU . 25.5 mmt . . . . . 0 N--CA 1.432 -1.34 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -83.38 92.3 7.52 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 -175.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.449 HD23 ' O ' ' B' ' 3' ' ' MET . 0.7 OUTLIER -88.49 93.99 9.72 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 176.585 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -111.77 142.89 27.54 Favored Pre-proline 0 C--N 1.281 -2.395 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.539 179.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . 0.465 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 57.8 Cg_endo -78.64 132.82 11.17 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 122.319 2.013 . . . . 0.0 113.316 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.443 HG11 ' HB3' ' B' ' 53' ' ' ARG . 71.6 t -117.69 122.59 70.16 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -106.77 132.25 52.96 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.192 -175.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.421 HD23 ' HA ' ' B' ' 48' ' ' ALA . 1.0 OUTLIER -135.51 158.57 44.04 Favored 'General case' 0 N--CA 1.427 -1.607 0 CA-C-O 121.293 0.568 . . . . 0.0 110.743 176.606 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -145.37 161.37 39.82 Favored 'General case' 0 C--N 1.278 -2.515 0 CA-C-N 114.105 -1.407 . . . . 0.0 107.228 175.198 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . 0.478 ' HZ2' ' HA2' ' B' ' 85' ' ' GLY . 60.6 mttp -86.71 156.64 19.88 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-O 122.029 0.919 . . . . 0.0 113.259 -172.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -71.55 -69.95 0.35 Allowed 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 113.69 -1.595 . . . . 0.0 110.744 178.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 47.0 t -176.55 -39.62 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 105.398 -2.075 . . . . 0.0 105.398 -175.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -78.3 -57.02 4.0 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 172.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 161.61 -142.54 8.1 Favored Glycine 0 N--CA 1.428 -1.887 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 179.354 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -91.59 -174.47 3.88 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.392 0.615 . . . . 0.0 110.003 176.31 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -133.98 -113.78 1.42 Allowed Glycine 0 N--CA 1.419 -2.475 0 N-CA-C 108.411 -1.876 . . . . 0.0 108.411 176.443 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 24.0 pt 45.04 -177.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 C-N-CA 125.573 1.549 . . . . 0.0 114.993 178.22 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 43.8 m -157.87 146.39 19.13 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 104.823 -2.288 . . . . 0.0 104.823 173.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . 0.471 ' HB ' HG21 ' B' ' 37' ' ' ILE . 12.5 pt -119.58 161.02 19.27 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.364 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . 0.406 ' HB ' ' CG ' ' B' ' 40' ' ' LYS . 8.7 tp -136.75 135.32 48.61 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 CA-C-O 120.964 0.412 . . . . 0.0 110.446 -176.363 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.33 103.24 3.02 Favored Glycine 0 N--CA 1.426 -2.011 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.025 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 68.6 mtm . . . . . 0 C--N 1.311 -1.067 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.266 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 97.6 mt . . . . . 0 N--CA 1.438 -1.042 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -108.54 114.15 4.01 Favored Glycine 0 N--CA 1.422 -2.269 0 C-N-CA 120.235 -0.984 . . . . 0.0 111.571 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . 0.471 HG21 ' HB ' ' B' ' 21' ' ' ILE . 20.7 mm -95.32 88.19 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.521 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 175.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.427 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 96.1 m-85 -82.07 172.1 13.6 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 114.901 -1.045 . . . . 0.0 108.686 -178.192 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 45.5 t -79.17 142.58 13.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 175.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . 0.406 ' CG ' ' HB ' ' B' ' 22' ' ' ILE . 0.1 OUTLIER -103.08 -42.63 5.72 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 -178.363 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 41' ' ' THR . . . . . 0.418 ' HA ' HG21 ' B' ' 56' ' ' VAL . 1.5 t -155.78 164.8 38.08 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 179.108 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 16.9 t -124.63 94.73 2.91 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.512 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 6.3 m -54.61 124.9 17.71 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 123.34 0.656 . . . . 0.0 111.517 179.752 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -62.09 -30.6 71.11 Favored 'General case' 0 C--O 1.222 -0.345 0 O-C-N 124.415 1.072 . . . . 0.0 112.26 -177.298 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.46 -23.46 77.05 Favored Glycine 0 N--CA 1.438 -1.172 0 C-N-CA 121.221 -0.514 . . . . 0.0 112.464 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.08 159.79 30.36 Favored Glycine 0 N--CA 1.416 -2.669 0 C-N-CA 119.692 -1.242 . . . . 0.0 113.158 -175.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -56.01 -38.31 70.34 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.27 -1.465 . . . . 0.0 112.458 -176.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . 0.421 ' HA ' HD23 ' B' ' 10' ' ' LEU . . . -59.03 -35.32 73.09 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -175.645 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 4.2 t60 -78.17 -40.69 36.99 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.491 0.663 . . . . 0.0 109.38 -179.223 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 65.6 mtp180 -73.86 -39.46 63.95 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 114.508 -1.223 . . . . 0.0 110.072 -174.484 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . 0.459 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 9.9 t70 -68.06 -60.08 2.76 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 173.174 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 97.69 11.38 50.82 Favored Glycine 0 N--CA 1.427 -1.919 0 CA-C-O 119.073 -0.849 . . . . 0.0 114.964 175.101 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.534 ' HA ' ' NE ' ' B' ' 53' ' ' ARG . 3.6 mmp_? -76.09 -50.25 15.21 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 118.655 1.227 . . . . 0.0 112.492 174.551 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.482 HD13 ' CE2' ' B' ' 89' ' ' PHE . 33.4 mt -77.36 141.02 16.14 Favored 'Isoleucine or valine' 0 C--O 1.249 1.072 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 175.538 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 72.5 mm-40 -114.54 -177.17 3.06 Favored 'General case' 0 N--CA 1.433 -1.315 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 -178.159 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.418 HG21 ' HA ' ' B' ' 41' ' ' THR . 8.4 p -90.45 3.55 6.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 CA-C-O 121.436 0.636 . . . . 0.0 111.416 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -119.38 -16.4 8.98 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 -174.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -76.39 178.65 6.39 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 114.491 1.293 . . . . 0.0 114.491 -173.43 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . 0.441 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 27.8 tp -133.79 121.9 22.51 Favored 'General case' 0 N--CA 1.437 -1.113 0 CA-C-N 114.933 -1.03 . . . . 0.0 110.911 -172.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 74.6 mt -80.67 91.66 5.89 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.458 179.128 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.646 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 10.8 t -72.5 -37.43 57.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 123.189 0.596 . . . . 0.0 111.078 179.076 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . 0.536 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 12.8 pt-20 -160.43 157.64 28.08 Favored 'General case' 0 C--N 1.28 -2.413 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.001 171.806 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 5.6 p -101.82 -178.35 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 105.484 -2.043 . . . . 0.0 105.484 178.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -55.94 -53.64 54.39 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -178.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -112.17 22.14 18.71 Favored Glycine 0 C--N 1.318 -0.425 0 C-N-CA 120.151 -1.023 . . . . 0.0 114.703 -175.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 32.3 m -153.89 115.19 4.13 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 117.859 0.83 . . . . 0.0 109.709 178.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 67' ' ' SER . . . . . 0.536 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 45.6 m -87.09 138.05 31.82 Favored 'General case' 0 N--CA 1.433 -1.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.751 178.322 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.646 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 52.5 mt -107.71 101.54 10.84 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-O 120.918 0.39 . . . . 0.0 111.695 -178.294 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 12.2 p -71.39 -26.63 26.97 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 172.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 151.62 85.77 0.05 OUTLIER Glycine 0 N--CA 1.424 -2.165 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -178.406 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 33.0 m -105.72 -177.56 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 CA-C-N 115.141 -0.53 . . . . 0.0 109.82 -177.056 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 71.6 p -81.37 166.68 20.21 Favored 'General case' 0 N--CA 1.428 -1.559 0 CA-C-O 121.236 0.541 . . . . 0.0 110.112 177.148 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -62.18 -39.85 94.09 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.584 -0.735 . . . . 0.0 109.935 178.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 20.3 t -69.77 -39.02 76.9 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.092 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . 0.417 ' O ' HG13 ' B' ' 79' ' ' VAL . 17.8 t80 -60.4 -51.57 68.91 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 -179.611 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.646 ' O ' HG22 ' B' ' 79' ' ' VAL . . . -64.38 -33.56 76.13 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.113 179.426 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.46 -37.44 87.3 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.622 0.725 . . . . 0.0 109.709 176.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.6 p -79.1 -18.06 54.0 Favored 'General case' 0 N--CA 1.427 -1.592 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 178.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.646 HG22 ' O ' ' B' ' 76' ' ' ALA . 32.9 m -73.67 -36.17 46.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 121.976 0.894 . . . . 0.0 109.703 -178.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 51.9 mt -66.1 -26.69 67.58 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 114.245 -1.343 . . . . 0.0 110.914 177.151 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 23.0 mtp180 -96.1 -8.0 34.53 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -176.523 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 25.7 m-80 -102.28 -13.77 17.24 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 120.852 0.358 . . . . 0.0 111.634 178.072 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.507 ' HB ' HG11 ' B' ' 87' ' ' VAL . 2.6 p -81.79 173.29 12.42 Favored 'General case' 0 N--CA 1.426 -1.665 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.108 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 66.5 mmtt -65.06 -172.36 0.09 Allowed 'General case' 0 C--O 1.242 0.679 0 C-N-CA 124.151 0.98 . . . . 0.0 113.347 -176.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . 0.478 ' HA2' ' HZ2' ' B' ' 12' ' ' LYS . . . -65.06 -49.12 63.88 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.635 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 -125.51 121.27 33.21 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -178.208 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . 0.507 HG11 ' HB ' ' B' ' 83' ' ' THR . 12.5 m -138.78 154.55 26.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 123.945 0.778 . . . . 0.0 111.396 -175.521 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 89.5 mtt180 -110.48 124.37 51.66 Favored 'General case' 0 N--CA 1.429 -1.521 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.917 178.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.482 ' CE2' HD13 ' B' ' 54' ' ' ILE . 4.8 m-85 -97.27 160.66 14.2 Favored 'General case' 0 C--N 1.28 -2.423 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 179.446 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.479 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 63.1 mtt -110.5 117.35 33.31 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 171.64 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.441 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -100.77 129.92 50.9 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.128 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -114.97 119.15 4.54 Favored Glycine 0 CA--C 1.473 -2.574 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.376 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 . . . . . 0 C--N 1.278 -2.526 0 CA-C-N 114.728 -0.736 . . . . 0.0 110.551 177.827 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 3' ' ' MET . . . . . 0.484 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 25.4 ptp . . . . . 0 C--O 1.239 0.539 0 CA-C-O 121.421 0.629 . . . . 0.0 110.092 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -106.07 104.7 14.46 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -88.55 89.58 8.05 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 178.692 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -118.51 144.47 35.34 Favored Pre-proline 0 C--N 1.297 -1.699 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -178.518 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -80.95 127.8 6.3 Favored 'Trans proline' 0 N--CA 1.445 -1.38 0 C-N-CA 122.337 2.024 . . . . 0.0 112.629 177.531 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.49 ' CG1' ' HB3' ' B' ' 53' ' ' ARG . 76.0 t -112.49 134.73 54.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.032 0 CA-C-N 114.913 -1.039 . . . . 0.0 108.214 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . 0.446 ' OE2' ' HD3' ' B' ' 86' ' ' ARG . 34.9 tt0 -121.75 130.79 53.68 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -178.087 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.425 HD13 HG13 ' B' ' 54' ' ' ILE . 0.5 OUTLIER -143.78 162.66 35.45 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.116 0.484 . . . . 0.0 111.075 -179.606 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -86.97 156.75 19.66 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 125.172 1.389 . . . . 0.0 107.414 179.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 15.8 ptpt -79.28 -167.59 1.23 Allowed 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 122.11 0.957 . . . . 0.0 109.961 172.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . 0.425 ' HB3' ' N ' ' B' ' 17' ' ' LEU . 6.9 t70 -126.18 162.65 24.91 Favored 'General case' 0 C--N 1.285 -2.206 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 -179.036 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 31.0 t -61.54 -33.7 74.27 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 124.057 0.848 . . . . 0.0 110.658 -176.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -88.78 -51.86 5.43 Favored 'General case' 0 N--CA 1.437 -1.082 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 176.47 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.79 94.48 0.16 Allowed Glycine 0 N--CA 1.43 -1.7 0 CA-C-N 115.266 -0.879 . . . . 0.0 111.417 179.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.425 ' N ' ' HB3' ' B' ' 13' ' ' ASP . 3.8 mm? 59.64 98.02 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 124.605 1.162 . . . . 0.0 113.941 178.203 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -83.15 59.9 4.94 Favored Glycine 0 C--O 1.219 -0.843 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . 0.544 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 6.7 pt -148.79 -175.51 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 C-N-CA 126.416 1.887 . . . . 0.0 107.072 179.024 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 66.7 m -151.27 146.99 26.43 Favored 'General case' 0 C--N 1.261 -3.271 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 176.293 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . 0.4 ' HB ' HG23 ' B' ' 37' ' ' ILE . 13.9 pt -113.49 157.86 14.04 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 O-C-N 123.405 0.44 . . . . 0.0 110.072 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.5 tp -131.94 130.24 61.22 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.84 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.67 89.85 1.62 Allowed Glycine 0 N--CA 1.408 -3.186 0 C-N-CA 120.926 -0.654 . . . . 0.0 111.819 -177.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 25.4 mmt . . . . . 0 N--CA 1.434 -1.262 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 176.146 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 88.3 mt . . . . . 0 N--CA 1.437 -1.111 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -112.44 95.01 0.76 Allowed Glycine 0 N--CA 1.429 -1.815 0 C-N-CA 120.021 -1.085 . . . . 0.0 110.882 179.409 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . 0.4 HG23 ' HB ' ' B' ' 21' ' ' ILE . 16.4 mm -87.84 85.33 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 CA-C-O 121.905 0.86 . . . . 0.0 109.237 179.65 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.42 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 87.0 m-85 -84.71 175.47 9.17 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.898 -178.544 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 48.5 t -79.92 142.35 14.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 175.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -100.82 -51.84 3.46 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.654 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -149.53 162.88 39.29 Favored 'General case' 0 N--CA 1.417 -2.102 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -175.537 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.544 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.4 p -140.84 105.48 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.04 0 CA-C-O 121.836 0.826 . . . . 0.0 109.839 178.271 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 16.5 m -62.95 125.97 25.77 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-N 114.355 -1.293 . . . . 0.0 111.566 -175.414 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . 0.448 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 11.1 pt-20 -65.47 -23.2 66.85 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.395 -178.063 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -83.65 3.96 83.57 Favored Glycine 0 N--CA 1.441 -0.992 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.23 177.033 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -108.07 164.49 12.82 Favored Glycine 0 N--CA 1.424 -2.156 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.208 179.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -65.57 -36.33 83.46 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-N 114.279 -0.96 . . . . 0.0 112.357 -176.501 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.72 -38.44 90.49 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -175.046 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . 0.448 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 7.9 t60 -69.91 -41.9 74.08 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 121.499 0.666 . . . . 0.0 109.713 -178.398 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 23.9 mtp180 -75.49 -35.76 60.74 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.697 -174.74 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -64.4 -63.64 1.08 Allowed 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.088 175.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 117.88 -20.25 10.86 Favored Glycine 0 N--CA 1.428 -1.9 0 C-N-CA 119.871 -1.157 . . . . 0.0 114.027 178.185 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.49 ' HB3' ' CG1' ' B' ' 8' ' ' VAL . 12.9 mmt180 -62.11 -62.83 1.5 Allowed 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 113.718 1.006 . . . . 0.0 113.718 179.588 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.624 HD12 ' CE2' ' B' ' 89' ' ' PHE . 62.9 mt -77.36 109.0 11.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 C-N-CA 119.374 -0.93 . . . . 0.0 109.137 174.43 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 79.6 mm-40 -102.01 173.89 6.18 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 121.163 0.506 . . . . 0.0 110.549 175.012 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.5 p -63.88 -12.97 12.6 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 114.165 1.172 . . . . 0.0 114.165 -173.381 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -125.62 16.89 8.15 Favored 'General case' 0 C--N 1.311 -1.091 0 O-C-N 120.976 -1.078 . . . . 0.0 111.145 -176.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 25.7 m-20 -83.22 172.6 12.44 Favored 'General case' 0 C--N 1.317 -0.812 0 O-C-N 121.362 -0.836 . . . . 0.0 111.084 179.098 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 29.7 tp -128.51 116.06 19.11 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 120.563 0.221 . . . . 0.0 110.808 -175.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 32.8 mt -93.17 95.29 9.31 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 179.126 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.64 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 96.3 t -73.19 -65.3 0.68 Allowed 'Isoleucine or valine' 0 C--O 1.175 -2.845 0 C-N-CA 120.607 -0.437 . . . . 0.0 109.83 178.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . 0.463 ' O ' ' HA ' ' B' ' 89' ' ' PHE . 8.6 pt-20 -129.05 157.26 42.22 Favored 'General case' 0 C--N 1.272 -2.787 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -177.019 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 5.0 p -103.51 -176.19 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.554 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 -178.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . 0.438 ' HB2' ' H ' ' B' ' 88' ' ' ARG . 27.5 t70 -51.25 -54.9 21.44 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 114.174 1.176 . . . . 0.0 114.174 -177.082 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -121.53 27.67 6.22 Favored Glycine 0 C--N 1.315 -0.591 0 C-N-CA 120.252 -0.975 . . . . 0.0 114.486 -175.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 51.4 m -152.57 120.67 6.22 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 176.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 19.7 m -94.21 111.38 23.11 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.168 -175.61 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.64 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 51.3 mt -89.57 121.36 31.7 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 176.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 14.8 p -83.74 -22.18 8.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.372 0.605 . . . . 0.0 109.565 177.451 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 145.88 69.16 0.01 OUTLIER Glycine 0 CA--C 1.487 -1.706 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 -177.318 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 34.9 m -90.6 -178.66 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 CA-C-N 114.563 -0.819 . . . . 0.0 109.742 -177.125 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 32.3 p -78.19 164.66 24.75 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 120.825 0.345 . . . . 0.0 111.066 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.3 tt0 -58.9 -40.43 84.45 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 123.429 0.692 . . . . 0.0 110.15 179.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 30.3 t -66.83 -36.48 82.45 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.323 -179.386 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -68.37 -47.84 66.35 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -179.649 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.531 ' O ' HG13 ' B' ' 79' ' ' VAL . . . -62.6 -39.31 93.35 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.929 178.814 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.33 -39.77 91.76 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-O 121.178 0.513 . . . . 0.0 111.153 178.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 13.3 p -82.1 -10.76 59.09 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -177.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.531 HG13 ' O ' ' B' ' 76' ' ' ALA . 5.3 p -86.18 -34.65 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.383 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 58.9 mt -69.87 -20.22 63.4 Favored 'General case' 0 C--O 1.213 -0.848 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.437 176.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 77.0 mtp180 -94.57 4.11 54.26 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.588 0.709 . . . . 0.0 110.244 177.429 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.2 t30 -113.6 0.86 14.76 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.734 0.778 . . . . 0.0 110.424 -176.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.455 HG23 ' O ' ' B' ' 79' ' ' VAL . 23.1 p -91.78 170.76 9.63 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.001 1.112 . . . . 0.0 114.001 -174.117 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.7 mmtt -73.88 -167.38 0.47 Allowed 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 124.795 1.238 . . . . 0.0 111.82 176.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.09 -33.93 84.95 Favored Glycine 0 C--O 1.225 -0.434 0 CA-C-N 115.628 -0.714 . . . . 0.0 113.274 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . 0.446 ' HD3' ' OE2' ' B' ' 9' ' ' GLU . 16.6 ttm180 -140.99 133.48 28.47 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 178.173 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 11.9 m -139.02 164.51 25.27 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.031 0 CA-C-O 121.167 0.508 . . . . 0.0 111.591 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . 0.438 ' H ' ' HB2' ' B' ' 64' ' ' ASP . 54.3 mtm180 -100.01 159.03 15.4 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-N 114.649 -1.159 . . . . 0.0 108.221 176.448 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.624 ' CE2' HD12 ' B' ' 54' ' ' ILE . 4.9 m-85 -141.82 152.92 44.13 Favored 'General case' 0 C--N 1.283 -2.306 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 175.551 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 90' ' ' MET . . . . . . . . . . . . . 87.3 mmm -98.41 112.89 24.75 Favored 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 120.101 -0.64 . . . . 0.0 109.913 173.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.467 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.5 mp -101.8 117.2 46.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -179.159 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.89 101.28 2.07 Favored Glycine 0 CA--C 1.458 -3.498 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 174.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . 0.484 ' O ' ' HA ' ' B' ' 3' ' ' MET . 19.9 tpp180 . . . . . 0 C--N 1.276 -2.59 0 CA-C-N 114.478 -0.861 . . . . 0.0 109.884 178.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 3' ' ' MET . . . . . 0.486 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 66.2 mtt . . . . . 0 N--CA 1.427 -1.605 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . 0.409 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 17.5 mt-10 -94.54 101.55 13.45 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.276 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.46 90.71 8.47 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.33 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -119.29 144.59 36.66 Favored Pre-proline 0 C--N 1.29 -1.985 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.109 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . 0.403 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 56.4 Cg_endo -75.49 139.23 22.83 Favored 'Trans proline' 0 N--CA 1.446 -1.297 0 C-N-CA 122.271 1.981 . . . . 0.0 111.767 177.36 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 87.5 t -129.73 128.99 66.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -179.298 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . 0.454 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 38.6 tt0 -114.99 123.26 48.65 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 mt -132.93 164.05 27.79 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 178.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -123.56 137.49 54.75 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 174.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . 0.412 ' HB2' ' O ' ' B' ' 16' ' ' GLY . 18.3 ptmt -74.96 162.48 28.56 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.189 179.143 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -134.78 -166.13 1.77 Allowed 'General case' 0 C--N 1.291 -1.965 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.5 m -66.49 -22.31 66.19 Favored 'General case' 0 C--N 1.313 -1.003 0 C-N-CA 123.666 0.786 . . . . 0.0 111.598 -178.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -86.06 2.34 46.89 Favored 'General case' 0 CA--C 1.55 0.952 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 177.543 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . 0.412 ' O ' ' HB2' ' B' ' 12' ' ' LYS . . . 85.06 -91.57 1.7 Allowed Glycine 0 N--CA 1.417 -2.58 0 N-CA-C 107.34 -2.304 . . . . 0.0 107.34 -175.077 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -124.75 134.14 52.91 Favored 'General case' 0 C--N 1.281 -2.396 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 174.719 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -83.45 53.3 4.84 Favored Glycine 0 C--O 1.216 -1.005 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.0 pt -161.87 176.56 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 C-N-CA 126.126 1.77 . . . . 0.0 107.491 -177.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 27.3 m -143.41 146.21 33.28 Favored 'General case' 0 C--N 1.268 -2.951 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 173.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . 0.424 ' HB ' HG21 ' B' ' 37' ' ' ILE . 10.1 pt -114.31 162.56 12.33 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -179.164 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 10.8 tp -137.89 138.37 44.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-O 121.041 0.448 . . . . 0.0 110.362 -177.714 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.54 108.58 3.45 Favored Glycine 0 N--CA 1.427 -1.94 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.662 178.304 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 22.7 mmt . . . . . 0 C--N 1.304 -1.371 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 177.65 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . 0.428 HD23 ' O ' ' B' ' 71' ' ' VAL . 14.5 tp . . . . . 0 N--CA 1.419 -2.017 0 N-CA-C 104.797 -2.297 . . . . 0.0 104.797 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -138.94 120.36 1.9 Allowed Glycine 0 C--N 1.273 -2.929 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.051 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . 0.424 HG21 ' HB ' ' B' ' 21' ' ' ILE . 32.0 mm -96.84 89.22 2.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 179.23 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -84.31 170.88 13.2 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.55 -1.204 . . . . 0.0 108.192 -179.176 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 49.8 t -75.86 145.22 10.92 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 174.151 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 2.0 tmmm? -105.08 -41.26 5.63 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 -179.522 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -158.39 164.15 36.58 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 -179.533 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 15.3 t -119.0 95.15 3.46 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 175.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 7.0 m -64.09 121.03 13.21 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 123.976 0.91 . . . . 0.0 112.159 -175.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -69.59 -18.18 63.6 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.18 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.45 -11.77 84.09 Favored Glycine 0 N--CA 1.436 -1.313 0 C-N-CA 120.978 -0.629 . . . . 0.0 112.354 178.094 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -115.69 172.43 14.21 Favored Glycine 0 N--CA 1.426 -1.982 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.303 -178.591 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -67.53 -27.03 66.63 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 114.698 1.37 . . . . 0.0 114.698 -172.171 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -63.72 -41.89 98.0 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 112.486 0.551 . . . . 0.0 112.486 -175.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -70.83 -38.01 73.23 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 121.807 0.813 . . . . 0.0 109.276 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 -72.7 -34.08 66.89 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 114.197 -1.365 . . . . 0.0 110.626 -174.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . 0.524 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 15.5 t0 -75.81 -52.87 9.44 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 175.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.82 29.62 8.03 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.546 -177.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.524 ' HG2' ' OD1' ' B' ' 51' ' ' ASP . 32.6 mmt180 -90.0 -81.74 0.28 Allowed 'General case' 0 CA--C 1.513 -0.478 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.41 HD12 ' CE2' ' B' ' 89' ' ' PHE . 81.3 mt -67.01 125.41 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 O-C-N 123.293 0.37 . . . . 0.0 110.197 176.48 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . 0.499 ' NE2' HH12 ' B' ' 93' ' ' ARG . 0.9 OUTLIER -104.39 161.61 13.93 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.635 -176.677 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.3 p -62.43 -21.32 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 N-CA-C 115.771 1.767 . . . . 0.0 115.771 -168.22 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 -122.57 22.63 9.85 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.936 -1.106 . . . . 0.0 109.066 -176.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . 0.448 ' OD2' ' HB2' ' B' ' 55' ' ' GLN . 78.5 m-20 -87.96 170.9 10.74 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.976 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 28.2 tp -132.12 131.22 42.12 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.626 -178.157 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 78.9 mt -83.2 95.03 8.0 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 176.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.473 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 21.4 t -74.0 -40.96 52.7 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.886 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . 0.428 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 11.3 pt-20 -160.56 149.66 17.07 Favored 'General case' 0 C--N 1.283 -2.307 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.482 176.22 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 4.8 p -98.27 -179.27 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 105.037 -2.209 . . . . 0.0 105.037 176.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . 0.464 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 16.6 t70 -53.52 -53.33 53.04 Favored 'General case' 0 C--N 1.311 -1.076 0 N-CA-C 114.081 1.141 . . . . 0.0 114.081 -177.567 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -105.23 -1.77 41.4 Favored Glycine 0 C--N 1.312 -0.768 0 C-N-CA 119.408 -1.377 . . . . 0.0 115.509 -175.632 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 13.8 m -142.89 133.29 24.82 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 118.163 0.982 . . . . 0.0 110.011 -175.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 67' ' ' SER . . . . . 0.428 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 13.0 t -94.15 157.15 16.21 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.72 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.473 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.3 mm? -118.25 115.21 24.27 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.956 0.408 . . . . 0.0 111.062 -179.075 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 13.8 p -97.52 -20.28 5.7 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-O 121.918 0.866 . . . . 0.0 109.497 175.437 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 143.52 86.15 0.08 OUTLIER Glycine 0 CA--C 1.485 -1.791 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -178.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . 0.428 ' O ' HD23 ' B' ' 35' ' ' LEU . 33.5 m -109.46 -179.04 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.301 0 CA-C-N 115.032 -0.584 . . . . 0.0 109.515 -175.665 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 71.2 p -75.24 159.56 31.41 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 109.173 -0.676 . . . . 0.0 109.173 176.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.6 tt0 -62.17 -33.38 74.41 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.469 0.652 . . . . 0.0 110.046 -179.116 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 22.3 m -73.24 -37.37 66.38 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.004 178.159 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -62.41 -46.1 90.12 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.334 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.478 ' O ' HG11 ' B' ' 79' ' ' VAL . . . -62.6 -42.42 99.57 Favored 'General case' 0 C--O 1.209 -1.075 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.747 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.0 -31.02 71.35 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 121.719 0.771 . . . . 0.0 111.057 178.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 33.4 t -90.47 -4.85 56.68 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.893 -179.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.478 HG11 ' O ' ' B' ' 76' ' ' ALA . 1.2 p -76.27 -31.98 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 C-N-CA 119.776 -0.77 . . . . 0.0 109.494 -177.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -67.86 -30.81 70.27 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.574 174.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -82.09 -7.59 59.62 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.648 -178.278 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -92.17 -23.11 19.49 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.989 178.259 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.438 ' HB ' HG13 ' B' ' 87' ' ' VAL . 11.6 p -97.46 -178.76 4.25 Favored 'General case' 0 N--CA 1.428 -1.535 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.241 177.479 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 65.3 mmtt -70.93 -171.56 0.56 Allowed 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 123.245 0.618 . . . . 0.0 111.387 177.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -78.39 -35.71 32.5 Favored Glycine 0 N--CA 1.442 -0.932 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.716 -178.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 29.5 ttt180 -123.13 117.33 25.15 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 176.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . 0.464 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 7.8 m -148.5 160.02 6.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 123.878 0.736 . . . . 0.0 110.009 -177.371 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . 0.454 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 96.3 mtt180 -103.49 134.12 47.38 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.708 177.761 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.41 ' CE2' HD12 ' B' ' 54' ' ' ILE . 0.7 OUTLIER -112.93 166.37 11.46 Favored 'General case' 0 C--N 1.281 -2.407 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 178.879 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.463 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 85.0 mtp -111.66 114.55 27.65 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 171.381 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 1.4 mp -97.76 130.0 47.11 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.188 -179.292 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . 0.409 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -118.65 95.23 0.61 Allowed Glycine 0 CA--C 1.45 -3.97 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 177.003 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . 0.499 HH12 ' NE2' ' B' ' 55' ' ' GLN . 24.4 ttp180 . . . . . 0 C--N 1.268 -2.953 0 CA-C-N 114.322 -0.939 . . . . 0.0 111.716 -178.256 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 22.3 ptt? . . . . . 0 N--CA 1.421 -1.884 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . 0.498 ' OE2' ' HD2' ' B' ' 93' ' ' ARG . 15.4 mt-10 -87.07 101.3 13.33 Favored 'General case' 0 C--N 1.294 -1.831 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.038 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -90.34 88.49 7.22 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 174.09 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -110.82 145.15 31.78 Favored Pre-proline 0 C--N 1.29 -1.985 0 CA-C-N 116.119 -0.491 . . . . 0.0 112.027 -177.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . 0.494 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 60.1 Cg_endo -81.89 134.65 8.45 Favored 'Trans proline' 0 N--CA 1.439 -1.707 0 C-N-CA 122.142 1.894 . . . . 0.0 113.526 178.09 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 65.4 t -121.97 130.76 74.31 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 176.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -115.22 132.95 56.45 Favored 'General case' 0 C--N 1.294 -1.84 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.165 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.41 HD22 ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -121.15 161.21 22.21 Favored 'General case' 0 CA--C 1.493 -1.231 0 CA-C-O 121.403 0.62 . . . . 0.0 111.251 179.562 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -132.94 132.99 42.61 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 107.41 -1.329 . . . . 0.0 107.41 174.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . 0.488 ' HA ' ' CB ' ' B' ' 47' ' ' ALA . 36.0 mtmm -97.43 160.31 14.4 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 121.467 0.651 . . . . 0.0 112.468 -171.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 m-20 -113.27 -168.27 1.31 Allowed 'General case' 0 C--N 1.308 -1.2 0 CA-C-N 114.882 -1.054 . . . . 0.0 109.652 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.1 m -60.27 -35.93 76.67 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 113.618 0.969 . . . . 0.0 113.618 -174.624 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -79.6 -22.08 44.15 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-O 121.641 0.734 . . . . 0.0 109.364 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.06 -132.02 10.78 Favored Glycine 0 N--CA 1.423 -2.205 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.139 178.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 24.0 tp -82.83 169.71 15.81 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -178.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . 0.436 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -149.54 66.24 0.38 Allowed Glycine 0 CA--C 1.48 -2.122 0 C-N-CA 119.805 -1.188 . . . . 0.0 112.442 -177.647 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.4 pt -160.14 172.17 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.486 -1.482 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 56.7 m -133.39 151.57 51.84 Favored 'General case' 0 C--N 1.257 -3.444 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 174.578 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . 0.457 ' HB ' HG23 ' B' ' 37' ' ' ILE . 13.2 pt -121.59 148.2 25.15 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.681 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 -178.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.6 tp -119.02 132.49 68.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -179.374 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -96.56 97.97 2.11 Favored Glycine 0 N--CA 1.427 -1.951 0 C-N-CA 120.231 -0.985 . . . . 0.0 113.689 -174.408 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 82.3 mtp . . . . . 0 C--N 1.301 -1.537 0 N-CA-C 108.083 -1.081 . . . . 0.0 108.083 175.672 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 9.4 mp . . . . . 0 CA--C 1.488 -1.423 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -116.18 97.77 0.79 Allowed Glycine 0 N--CA 1.413 -2.858 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.917 -177.095 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . 0.457 HG23 ' HB ' ' B' ' 21' ' ' ILE . 23.3 mm -92.98 87.69 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 174.771 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -85.17 164.44 18.11 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.614 -175.238 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 94.2 t -77.65 128.31 38.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 174.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -93.45 -37.45 11.95 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.123 0.487 . . . . 0.0 110.556 -176.003 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -158.4 163.46 37.22 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 -178.51 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 19.4 t -120.54 96.22 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.71 0 N-CA-C 106.468 -1.679 . . . . 0.0 106.468 176.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 17.1 m -59.99 124.31 19.8 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 124.186 0.995 . . . . 0.0 112.183 -175.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . 0.552 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 36.0 mt-10 -55.14 -33.83 63.25 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 124.767 1.227 . . . . 0.0 112.628 -176.709 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.67 -18.79 78.87 Favored Glycine 0 N--CA 1.438 -1.214 0 CA-C-N 115.674 -0.694 . . . . 0.0 114.521 -177.016 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.436 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -106.03 170.37 16.74 Favored Glycine 0 N--CA 1.423 -2.228 0 C-N-CA 118.497 -1.811 . . . . 0.0 114.719 -173.602 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . 0.488 ' CB ' ' HA ' ' B' ' 12' ' ' LYS . . . -59.53 -33.64 71.65 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 113.605 -1.298 . . . . 0.0 114.401 -174.14 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . 0.41 ' HA ' HD22 ' B' ' 10' ' ' LEU . . . -65.69 -33.0 74.86 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.243 -176.596 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . 0.552 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 12.2 t60 -77.31 -40.6 43.75 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.532 178.147 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 40.0 mtp-105 -66.97 -39.61 87.25 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.602 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . 0.507 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 12.0 t70 -78.0 -58.22 3.38 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.136 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.71 -4.87 36.9 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.628 -0.796 . . . . 0.0 113.662 179.146 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.507 ' HG2' ' OD1' ' B' ' 51' ' ' ASP . 0.4 OUTLIER -54.16 -62.13 1.86 Allowed 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 179.183 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.541 HD11 ' CE2' ' B' ' 89' ' ' PHE . 35.1 mt -81.31 126.46 39.8 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.227 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -103.29 168.51 9.12 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.162 177.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.1 p -73.53 4.46 0.84 Allowed 'Isoleucine or valine' 0 CA--C 1.57 1.725 0 CA-C-O 121.981 0.896 . . . . 0.0 111.533 -177.109 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -117.85 5.58 12.21 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.281 1.039 . . . . 0.0 109.529 -177.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -87.34 161.68 17.79 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.701 -177.536 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . 0.616 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 25.5 tp -138.31 127.21 23.88 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 123.494 0.717 . . . . 0.0 109.742 -175.471 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 66.0 mt -88.01 97.48 10.98 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.613 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 0.8 OUTLIER -92.9 -21.42 6.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-O 122.219 1.009 . . . . 0.0 109.5 -177.277 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . 0.553 ' HG2' ' O ' ' B' ' 63' ' ' VAL . 30.9 tt0 -164.64 150.99 10.65 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 113.133 -1.848 . . . . 0.0 108.701 175.013 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . 0.553 ' O ' ' HG2' ' B' ' 62' ' ' GLU . 6.2 p -93.18 -162.6 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.202 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 176.367 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . 0.521 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 11.7 t70 -56.59 -54.31 47.41 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 123.277 0.631 . . . . 0.0 111.687 -178.749 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -113.64 -54.18 0.44 Allowed Glycine 0 N--CA 1.439 -1.162 0 C-N-CA 120.478 -0.868 . . . . 0.0 113.213 -178.643 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 25.6 m -62.87 115.25 4.2 Favored 'General case' 0 C--O 1.246 0.909 0 CA-C-O 121.744 0.783 . . . . 0.0 112.731 -175.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 67' ' ' SER . . . . . 0.433 ' HA ' ' HG3' ' B' ' 62' ' ' GLU . 25.1 m -77.72 109.87 12.09 Favored 'General case' 0 N--CA 1.424 -1.75 0 C-N-CA 124.992 1.317 . . . . 0.0 113.397 -176.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.613 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 54.8 mt -90.88 -164.74 1.22 Allowed 'General case' 0 N--CA 1.421 -1.911 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 174.003 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 p 175.73 -30.86 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 106.236 -1.765 . . . . 0.0 106.236 178.368 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 169.02 77.06 0.04 OUTLIER Glycine 1 N--CA 1.39 -4.373 0 CA-C-N 114.48 -1.236 . . . . 0.0 111.227 -179.279 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 27.0 m -99.74 178.1 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.277 -2.581 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 34.6 p -76.84 161.74 28.19 Favored 'General case' 0 C--N 1.291 -1.95 0 C-N-CA 120.415 -0.514 . . . . 0.0 109.892 175.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -57.99 -40.77 81.55 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 123.829 0.851 . . . . 0.0 109.614 178.675 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 22.3 m -68.46 -38.57 81.22 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.077 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -62.93 -47.92 81.13 Favored 'General case' 0 C--O 1.24 0.566 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 178.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.565 ' O ' HG13 ' B' ' 79' ' ' VAL . . . -58.75 -45.37 89.86 Favored 'General case' 0 C--O 1.208 -1.105 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.845 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.91 -36.82 77.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.982 0.42 . . . . 0.0 111.749 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 15.4 p -77.88 -14.83 59.43 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 112.967 0.729 . . . . 0.0 112.967 -179.5 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.565 HG13 ' O ' ' B' ' 76' ' ' ALA . 2.8 p -73.31 -37.3 51.36 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.952 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.071 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -59.64 -18.81 44.76 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.97 0.908 . . . . 0.0 112.433 176.541 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 6.6 mtp180 -100.21 -6.66 25.73 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 121.213 0.53 . . . . 0.0 111.918 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -114.95 10.69 16.37 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.41 0.624 . . . . 0.0 111.245 179.153 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.511 HG22 ' O ' ' B' ' 79' ' ' VAL . 7.9 p -92.46 -173.42 3.38 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 115.491 -0.777 . . . . 0.0 112.298 178.513 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 44.9 mttm -76.67 -169.0 1.12 Allowed 'General case' 0 N--CA 1.437 -1.111 0 C-N-CA 123.506 0.722 . . . . 0.0 111.113 175.163 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -73.37 -49.69 14.52 Favored Glycine 0 N--CA 1.437 -1.274 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.056 176.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 16.2 ttm180 -118.38 121.44 40.37 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 176.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . 0.521 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 8.8 m -130.13 151.98 36.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 71.7 mtm180 -94.96 169.66 9.97 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 113.788 -1.551 . . . . 0.0 108.006 173.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.541 ' CE2' HD11 ' B' ' 54' ' ' ILE . 4.7 m-85 -144.14 151.1 39.1 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 176.053 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 90' ' ' MET . . . . . . . . . . . . . 48.0 mtm -100.43 115.12 29.3 Favored 'General case' 0 N--CA 1.425 -1.698 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 173.443 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.616 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.5 mp -96.93 127.84 48.72 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.002 -179.142 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . 0.402 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -108.36 120.87 6.1 Favored Glycine 0 N--CA 1.427 -1.962 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 177.312 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . 0.498 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 35.5 ttm180 . . . . . 0 C--N 1.281 -2.377 0 CA-C-N 115.207 -0.497 . . . . 0.0 109.731 178.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 66.8 mtt . . . . . 0 N--CA 1.431 -1.377 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . 0.421 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 14.0 mt-10 -90.81 97.77 11.38 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 120.43 -0.508 . . . . 0.0 109.931 -173.044 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -86.87 93.56 9.34 Favored 'General case' 0 N--CA 1.439 -0.977 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 177.339 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -114.59 143.56 30.18 Favored Pre-proline 0 C--N 1.283 -2.286 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.851 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -74.21 132.89 17.11 Favored 'Trans proline' 0 N--CA 1.45 -1.054 0 C-N-CA 122.331 2.02 . . . . 0.0 113.493 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.447 ' CG1' ' HB3' ' B' ' 53' ' ' ARG . 77.6 t -124.66 123.82 66.79 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 CA-C-N 114.783 -1.099 . . . . 0.0 108.316 178.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -111.3 123.62 50.58 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -176.192 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.417 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 1.6 mt -117.46 177.01 4.9 Favored 'General case' 0 CA--C 1.489 -1.389 0 CA-C-O 121.233 0.539 . . . . 0.0 111.218 177.22 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -155.18 166.55 33.21 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . 0.45 ' HZ3' ' HB2' ' B' ' 12' ' ' LYS . 10.1 mtmp? -116.11 160.72 19.96 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 118.407 0.549 . . . . 0.0 112.264 -176.157 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -97.79 -160.22 0.79 Allowed 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 169.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 17.6 m -69.6 -27.06 64.76 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 120.993 0.425 . . . . 0.0 110.221 177.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -75.9 -64.42 1.09 Allowed 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.96 75.63 0.68 Allowed Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.209 -0.996 . . . . 0.0 112.628 179.683 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.418 ' CD1' ' HG2' ' B' ' 12' ' ' LYS . 10.7 mp 71.92 172.82 0.31 Allowed 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 124.309 1.044 . . . . 0.0 112.916 179.289 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . 0.447 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -172.59 88.88 0.08 OUTLIER Glycine 0 CA--C 1.488 -1.612 0 N-CA-C 107.806 -2.118 . . . . 0.0 107.806 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . 0.555 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.8 pt -157.62 -173.65 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 -176.421 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 20' ' ' SER . . . . . 0.453 ' HB2' HG21 ' B' ' 41' ' ' THR . 40.5 m -152.72 144.61 23.67 Favored 'General case' 0 C--N 1.257 -3.452 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 173.656 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . 0.448 ' HB ' HG21 ' B' ' 37' ' ' ILE . 16.3 pt -116.74 162.93 14.34 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.584 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 179.282 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.1 tp -140.81 136.77 35.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 CA-C-O 120.98 0.419 . . . . 0.0 110.665 -178.806 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . 0.418 ' HA2' ' CD1' ' B' ' 37' ' ' ILE . . . -67.13 101.92 0.73 Allowed Glycine 0 N--CA 1.435 -1.372 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.1 178.862 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 91.7 mtp . . . . . 0 N--CA 1.431 -1.411 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 -178.95 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 91.1 mt . . . . . 0 N--CA 1.417 -2.083 0 N-CA-C 104.174 -2.528 . . . . 0.0 104.174 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . 0.427 ' HA3' HD13 ' B' ' 59' ' ' LEU . . . -99.67 -13.78 36.72 Favored Glycine 0 C--N 1.291 -1.968 0 C-N-CA 118.881 -1.628 . . . . 0.0 111.048 -175.223 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . 0.448 HG21 ' HB ' ' B' ' 21' ' ' ILE . 31.2 mm 64.64 98.02 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.557 1.241 0 C-N-CA 124.396 1.078 . . . . 0.0 111.08 -179.145 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 62.4 m-85 -76.36 164.91 25.56 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.823 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 47.8 t -76.61 142.54 14.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 177.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 31.9 ttmt -98.36 -46.34 5.82 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.331 -179.614 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 41' ' ' THR . . . . . 0.453 HG21 ' HB2' ' B' ' 20' ' ' SER . 1.1 t -161.15 166.79 27.36 Favored 'General case' 0 N--CA 1.428 -1.55 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -178.355 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.555 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.8 p -137.71 97.26 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.282 -2.342 0 CA-C-O 122.102 0.953 . . . . 0.0 109.381 177.694 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 12.8 m -54.61 129.67 37.31 Favored 'General case' 0 N--CA 1.435 -1.2 0 CA-C-N 113.453 -1.703 . . . . 0.0 111.1 -176.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . 0.447 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 38.7 mt-10 -60.55 -27.17 67.45 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 123.537 0.735 . . . . 0.0 111.407 -177.13 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.63 -7.85 88.13 Favored Glycine 0 N--CA 1.434 -1.434 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.843 178.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.447 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -93.02 161.08 25.37 Favored Glycine 0 CA--C 1.485 -1.788 0 C-N-CA 120.326 -0.94 . . . . 0.0 114.243 -175.516 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -62.57 -34.6 77.3 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 113.614 -1.293 . . . . 0.0 111.642 -178.103 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . 0.417 ' HA ' HD23 ' B' ' 10' ' ' LEU . . . -66.15 -31.89 73.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.762 -0.199 . . . . 0.0 111.36 -177.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . 0.447 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 4.6 t60 -80.46 -42.6 22.32 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.568 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . 0.411 ' HG3' ' O ' ' B' ' 46' ' ' GLY . 82.5 mtp180 -64.59 -42.63 95.48 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.836 -179.632 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -76.52 -43.42 39.46 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 88.24 52.48 2.88 Favored Glycine 0 CA--C 1.503 -0.657 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.787 178.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.447 ' HB3' ' CG1' ' B' ' 8' ' ' VAL . 30.8 mmt180 -118.76 -74.29 0.61 Allowed 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -175.4 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.4 HD12 ' CE2' ' B' ' 89' ' ' PHE . 60.9 mt -72.24 107.81 3.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 176.586 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -97.25 153.52 17.97 Favored 'General case' 0 N--CA 1.425 -1.709 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.703 -175.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.438 HG21 ' HA ' ' B' ' 41' ' ' THR . 10.0 p -55.05 -24.07 14.0 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.56 0 N-CA-C 115.747 1.758 . . . . 0.0 115.747 -171.236 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -114.43 9.31 16.77 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 120.966 -1.084 . . . . 0.0 111.54 -172.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . 0.401 ' HB3' ' CG2' ' B' ' 91' ' ' ILE . 5.9 m-20 -99.49 -177.74 3.68 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 119.804 -0.759 . . . . 0.0 112.559 -176.85 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . 0.47 ' HB3' ' O ' ' B' ' 92' ' ' GLY . 29.3 tp -133.67 139.26 46.34 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 112.445 0.535 . . . . 0.0 112.445 -170.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 67.1 mt -89.27 101.76 14.43 Favored 'General case' 0 C--O 1.208 -1.104 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 176.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.598 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 24.8 t -83.46 -42.91 17.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-O 121.84 0.828 . . . . 0.0 111.509 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . 0.478 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 11.8 pt-20 -154.98 150.12 27.01 Favored 'General case' 0 C--N 1.272 -2.8 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.559 176.653 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 5.0 p -96.1 -178.51 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.07 0 N-CA-C 105.909 -1.885 . . . . 0.0 105.909 178.623 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . 0.414 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.8 t70 -49.47 -54.89 15.34 Favored 'General case' 0 C--N 1.315 -0.919 0 C-N-CA 124.16 0.984 . . . . 0.0 113.344 -176.381 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -121.12 24.2 7.46 Favored Glycine 0 C--N 1.32 -0.354 0 C-N-CA 119.372 -1.394 . . . . 0.0 114.254 -177.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 25.8 m -152.61 126.54 9.02 Favored 'General case' 0 C--N 1.316 -0.889 0 O-C-N 121.732 -0.864 . . . . 0.0 109.693 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 67' ' ' SER . . . . . 0.41 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 23.4 m -91.82 132.19 36.62 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 120.889 0.376 . . . . 0.0 110.757 -179.531 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.598 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 26.9 mt -81.69 95.66 7.29 Favored 'General case' 0 N--CA 1.431 -1.4 0 CA-C-O 121.374 0.607 . . . . 0.0 110.509 177.326 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 10.3 p -92.56 16.73 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 CA-C-O 122.317 1.056 . . . . 0.0 108.943 178.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 117.54 87.46 1.24 Allowed Glycine 0 CA--C 1.474 -2.493 0 C-N-CA 120.328 -0.939 . . . . 0.0 111.543 178.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 15.5 m -120.44 174.2 5.57 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -178.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 62.9 p -85.51 164.62 17.71 Favored 'General case' 0 N--CA 1.42 -1.928 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 176.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -60.97 -38.28 85.4 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 177.12 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.1 m -64.15 -41.28 97.23 Favored 'General case' 0 N--CA 1.433 -1.324 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.951 178.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -65.62 -46.72 78.18 Favored 'General case' 0 CA--C 1.521 -0.138 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.529 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.508 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -56.82 -43.43 81.03 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-O 120.999 0.428 . . . . 0.0 110.773 179.121 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.18 -24.54 66.65 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.605 0.716 . . . . 0.0 111.056 178.173 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 32.6 m -85.79 -26.43 25.78 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.821 -178.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.508 HG12 ' O ' ' B' ' 76' ' ' ALA . 9.0 p -73.69 -32.54 35.54 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.679 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . 0.421 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 64.5 mt -65.78 -23.12 66.64 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.485 177.04 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 59.7 mtm180 -99.53 -0.4 40.65 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.834 179.457 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -100.78 -29.38 12.29 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.203 177.497 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.468 ' HB ' HG13 ' B' ' 87' ' ' VAL . 7.8 p -74.38 164.03 27.08 Favored 'General case' 0 N--CA 1.425 -1.699 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.87 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 68.5 mmtt -68.83 -166.78 0.08 Allowed 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.102 1.361 . . . . 0.0 112.771 -179.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.93 -39.18 93.27 Favored Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.562 -0.744 . . . . 0.0 113.186 -179.161 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . 0.417 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 41.7 ttm180 -128.19 124.56 37.06 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 -179.614 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . 0.468 HG13 ' HB ' ' B' ' 83' ' ' THR . 13.6 m -135.2 147.68 29.06 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 CA-C-O 121.138 0.494 . . . . 0.0 111.448 178.075 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 36.2 mtp85 -108.87 120.37 42.31 Favored 'General case' 0 N--CA 1.428 -1.536 0 CA-C-N 114.925 -1.034 . . . . 0.0 109.086 -179.08 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.427 ' HB2' ' CD1' ' B' ' 91' ' ' ILE . 2.9 m-85 -103.82 159.36 15.7 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 -177.124 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.478 ' HB2' ' CG ' ' B' ' 62' ' ' GLU . 0.5 OUTLIER -104.34 109.35 21.16 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 168.939 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.452 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.3 mp -89.79 129.92 39.92 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.158 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 178.757 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . 0.47 ' O ' ' HB3' ' B' ' 59' ' ' LEU . . . -112.38 104.31 1.59 Allowed Glycine 0 CA--C 1.458 -3.483 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 178.512 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 . . . . . 0 C--N 1.27 -2.849 0 CA-C-N 114.913 -0.644 . . . . 0.0 109.664 178.566 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 67.8 mtm . . . . . 0 N--CA 1.432 -1.347 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -85.26 108.34 17.72 Favored 'General case' 0 N--CA 1.426 -1.652 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 179.136 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.557 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 1.1 mm? -85.35 89.46 7.68 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 174.219 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -111.7 142.6 26.93 Favored Pre-proline 0 C--N 1.288 -2.094 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.295 -179.37 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -75.8 132.88 14.83 Favored 'Trans proline' 0 N--CA 1.44 -1.632 0 C-N-CA 122.223 1.949 . . . . 0.0 111.878 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.429 HG13 ' HB3' ' B' ' 53' ' ' ARG . 76.4 t -120.83 120.77 63.39 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.389 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.178 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 9' ' ' GLU . . . . . 0.409 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 38.4 tt0 -115.29 120.18 38.8 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.704 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.465 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 0.9 OUTLIER -108.34 -173.58 2.31 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 178.832 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.408 ' H ' ' CD2' ' B' ' 10' ' ' LEU . 10.6 tp10 -158.83 155.85 28.59 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 105.046 -2.205 . . . . 0.0 105.046 176.528 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 10.6 ptpp? -84.96 163.38 18.95 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-O 121.743 0.782 . . . . 0.0 112.991 -173.346 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -111.34 -176.35 2.93 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 104.697 -2.334 . . . . 0.0 104.697 170.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 34.3 m -63.8 -30.33 71.44 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 119.278 0.944 . . . . 0.0 111.575 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -88.91 -13.0 40.12 Favored 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 121.711 0.767 . . . . 0.0 109.64 178.12 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.01 -108.11 2.43 Favored Glycine 0 N--CA 1.433 -1.505 0 C-N-CA 120.862 -0.685 . . . . 0.0 111.78 179.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -95.63 172.63 7.93 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 120.954 0.407 . . . . 0.0 110.105 -178.285 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -137.12 53.86 0.73 Allowed Glycine 0 CA--C 1.486 -1.744 0 N-CA-C 109.944 -1.263 . . . . 0.0 109.944 -179.519 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . 0.463 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 6.9 pt -157.95 -178.64 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.489 -1.369 0 C-N-CA 124.84 1.256 . . . . 0.0 108.282 -174.204 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 20' ' ' SER . . . . . 0.401 ' HB2' HG21 ' B' ' 41' ' ' THR . 46.8 m -152.58 156.21 38.87 Favored 'General case' 0 C--N 1.27 -2.853 0 N-CA-C 105.106 -2.183 . . . . 0.0 105.106 174.361 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 29.5 pt -117.3 158.96 17.71 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 CA-C-N 118.181 0.446 . . . . 0.0 110.287 -177.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -148.48 136.26 14.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 CA-C-O 121.422 0.629 . . . . 0.0 110.181 178.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -75.19 122.15 6.78 Favored Glycine 0 N--CA 1.423 -2.232 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.044 178.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 24' ' ' MET . . . . . 0.66 ' HB2' ' CD1' ' B' ' 38' ' ' PHE . 64.6 mtt . . . . . 0 CA--C 1.491 -1.298 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 174.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 10.8 mp . . . . . 0 N--CA 1.429 -1.486 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -170.99 1.63 0.03 OUTLIER Glycine 0 C--N 1.292 -1.892 0 C-N-CA 119.817 -1.183 . . . . 0.0 111.067 174.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 40.9 mm 65.39 114.64 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 CA-C-O 122.495 1.141 . . . . 0.0 110.543 -173.649 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.66 ' CD1' ' HB2' ' B' ' 24' ' ' MET . 29.0 m-85 -88.55 176.19 7.25 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.103 -0.953 . . . . 0.0 108.881 -175.205 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 64.6 t -83.93 142.9 12.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-O 121.654 0.74 . . . . 0.0 110.759 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 16.3 ttmm -94.34 -47.03 6.78 Favored 'General case' 0 N--CA 1.434 -1.261 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.769 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 41' ' ' THR . . . . . 0.401 HG21 ' HB2' ' B' ' 20' ' ' SER . 3.1 t -162.32 171.76 16.73 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 -178.64 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.463 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.2 p -147.9 91.51 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.861 0 CA-C-O 122.35 1.071 . . . . 0.0 109.193 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 8.2 m -59.3 128.94 39.61 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 113.557 -1.656 . . . . 0.0 111.528 -176.518 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 44' ' ' GLU . . . . . 0.561 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 8.1 pt-20 -68.01 -17.2 64.35 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 112.558 0.577 . . . . 0.0 112.558 -177.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.26 -0.04 85.27 Favored Glycine 0 N--CA 1.436 -1.351 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.486 177.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -111.14 169.59 13.36 Favored Glycine 0 N--CA 1.418 -2.503 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.923 -177.492 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -55.08 -54.67 40.11 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 113.911 -1.144 . . . . 0.0 113.651 -174.198 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 48' ' ' ALA . . . . . 0.461 ' HA ' HD23 ' B' ' 10' ' ' LEU . . . -56.24 -35.37 67.29 Favored 'General case' 0 C--O 1.243 0.75 0 N-CA-C 114.051 1.13 . . . . 0.0 114.051 -172.246 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 49' ' ' HIS . . . . . 0.561 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 6.6 t60 -75.39 -46.8 30.71 Favored 'General case' 0 C--N 1.312 -1.037 0 O-C-N 123.656 0.597 . . . . 0.0 109.953 -177.003 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 65.7 mtp180 -73.49 -34.98 65.57 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.422 -175.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -66.01 -51.36 59.06 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.419 178.549 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 95.13 52.77 1.7 Allowed Glycine 0 N--CA 1.432 -1.571 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 53' ' ' ARG . . . . . 0.429 ' HB3' HG13 ' B' ' 8' ' ' VAL . 21.6 mmt180 -129.78 -72.78 0.57 Allowed 'General case' 0 N--CA 1.432 -1.328 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -178.629 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.581 HD12 ' CE2' ' B' ' 89' ' ' PHE . 45.4 mt -80.06 129.15 38.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 C-N-CA 119.288 -0.965 . . . . 0.0 108.925 178.278 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 55' ' ' GLN . . . . . 0.733 ' HB2' ' OD1' ' B' ' 58' ' ' ASP . 6.9 mt-30 -116.78 164.15 15.09 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 -176.624 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.8 p -59.14 -33.95 52.01 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.276 0 N-CA-C 115.949 1.833 . . . . 0.0 115.949 -171.511 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -105.52 5.46 31.47 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.112 -0.993 . . . . 0.0 112.421 -172.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 58' ' ' ASP . . . . . 0.733 ' OD1' ' HB2' ' B' ' 55' ' ' GLN . 5.2 m-20 -82.01 171.09 14.8 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-O 121.318 0.58 . . . . 0.0 111.984 -175.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 59' ' ' LEU . . . . . 0.451 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 23.1 tp -131.54 133.11 44.72 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.312 -174.318 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 66.0 mt -87.25 96.36 10.31 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 178.095 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 61' ' ' VAL . . . . . 0.681 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 16.1 t -73.94 -38.46 49.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 CA-C-O 121.589 0.709 . . . . 0.0 110.928 179.092 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . 0.548 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 10.0 pt-20 -159.95 156.67 27.56 Favored 'General case' 0 C--N 1.282 -2.357 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.653 174.662 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 6.2 p -100.53 177.35 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 177.479 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 64' ' ' ASP . . . . . . . . . . . . . 27.3 t70 -46.65 -56.67 5.74 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 114.156 1.169 . . . . 0.0 114.156 -173.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -117.98 27.44 7.44 Favored Glycine 0 C--N 1.31 -0.877 0 C-N-CA 119.392 -1.385 . . . . 0.0 114.072 -177.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 29.6 m -154.11 123.86 6.71 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 117.754 0.777 . . . . 0.0 109.788 179.193 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 67' ' ' SER . . . . . 0.548 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 11.1 t -96.46 129.19 43.87 Favored 'General case' 0 N--CA 1.426 -1.671 0 CA-C-O 121.078 0.466 . . . . 0.0 110.607 -177.25 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.681 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 62.7 mt -92.03 124.2 35.95 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.081 179.212 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 14.4 p -93.05 -25.39 4.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 174.164 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 149.26 75.13 0.02 OUTLIER Glycine 0 N--CA 1.423 -2.176 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 -176.648 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 31.3 m -93.15 178.45 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 CA-C-N 114.912 -0.644 . . . . 0.0 110.691 -175.368 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 36.6 p -80.88 160.98 24.6 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 175.482 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -62.59 -35.42 79.47 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 120.944 0.402 . . . . 0.0 110.307 -178.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 19.2 m -66.41 -40.18 89.42 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.279 178.122 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -64.31 -46.35 83.95 Favored 'General case' 0 C--N 1.338 0.101 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 76' ' ' ALA . . . . . 0.413 ' O ' HG11 ' B' ' 79' ' ' VAL . . . -57.89 -46.91 84.2 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.382 178.293 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.49 -42.01 86.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.005 0.431 . . . . 0.0 110.687 178.345 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 22.8 t -68.73 -32.68 72.64 Favored 'General case' 0 N--CA 1.431 -1.377 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.736 -178.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 79' ' ' VAL . . . . . 0.413 HG11 ' O ' ' B' ' 76' ' ' ALA . 9.8 p -78.09 -39.13 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 119.582 -0.847 . . . . 0.0 109.921 -174.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 45.6 mt -63.93 -34.02 77.02 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.822 177.647 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -87.66 -5.02 58.9 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.344 179.446 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -89.07 -37.04 15.41 Favored 'General case' 0 N--CA 1.431 -1.387 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 175.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 83' ' ' THR . . . . . 0.506 ' HB ' HG13 ' B' ' 87' ' ' VAL . 12.8 p -77.11 172.24 13.54 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.463 177.058 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt -69.11 -173.74 0.55 Allowed 'General case' 0 N--CA 1.444 -0.748 0 CA-C-O 121.738 0.78 . . . . 0.0 111.725 177.607 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -81.4 -28.66 43.16 Favored Glycine 0 N--CA 1.431 -1.661 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 175.634 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . 0.465 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 21.9 ttm-85 -106.76 111.3 23.76 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 121.406 0.622 . . . . 0.0 110.162 175.804 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 87' ' ' VAL . . . . . 0.506 HG13 ' HB ' ' B' ' 83' ' ' THR . 2.6 m -147.63 151.68 13.44 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-N 114.58 -1.191 . . . . 0.0 109.679 178.348 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' B' ' 8' ' ' VAL . 10.3 mtm-85 -101.28 110.31 22.3 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 123.992 0.808 . . . . 0.0 109.726 -179.718 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 89' ' ' PHE . . . . . 0.581 ' CE2' HD12 ' B' ' 54' ' ' ILE . 3.0 m-85 -95.23 158.97 15.23 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 179.426 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 90' ' ' MET . . . . . 0.489 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 86.3 mtp -107.8 114.04 27.71 Favored 'General case' 0 C--N 1.29 -1.993 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 170.273 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . 0.557 ' O ' ' HA ' ' B' ' 5' ' ' LEU . 1.4 mp -95.45 136.78 25.39 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 -179.006 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.93 100.9 0.73 Allowed Glycine 0 CA--C 1.474 -2.506 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 175.283 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 16.4 tpp180 . . . . . 0 C--N 1.275 -2.652 0 CA-C-N 113.824 -1.188 . . . . 0.0 108.726 -178.73 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.298 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 45.2 p-80 -167.56 166.28 14.2 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 117.876 0.838 . . . . 0.0 109.095 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 56.9 mtt -95.09 128.57 42.02 Favored 'General case' 0 N--CA 1.433 -1.292 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 171.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . 0.54 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 27.0 mt-10 -79.95 98.82 7.32 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.462 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 1.0 OUTLIER -82.67 89.84 6.78 Favored 'General case' 0 C--N 1.311 -1.105 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 174.602 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 13.5 p90 -110.59 142.11 25.42 Favored Pre-proline 0 C--N 1.286 -2.158 0 CA-C-N 116.038 -0.528 . . . . 0.0 112.128 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -68.78 129.46 18.7 Favored 'Trans proline' 0 N--CA 1.451 -1.024 0 C-N-CA 122.67 2.247 . . . . 0.0 112.482 178.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.481 HG13 ' HG3' ' B' ' 53' ' ' ARG . 79.1 t -120.88 122.91 69.01 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.515 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.725 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . 0.423 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 31.3 tt0 -123.11 113.84 19.53 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 mt -104.26 160.4 14.91 Favored 'General case' 0 C--N 1.283 -2.309 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.342 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.454 ' HB3' ' NH2' ' B' ' 86' ' ' ARG . 8.5 pt-20 -123.55 113.68 19.04 Favored 'General case' 0 C--N 1.271 -2.821 0 CA-C-N 114.271 -1.331 . . . . 0.0 108.421 173.019 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.4 ptpt -79.82 156.93 27.16 Favored 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.421 -0.808 . . . . 0.0 110.496 -175.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -89.18 -173.13 3.92 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.163 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 35.8 t -68.99 -21.15 64.17 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 173.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -69.7 -46.82 65.14 Favored 'General case' 0 N--CA 1.44 -0.929 0 CA-C-N 114.318 -1.31 . . . . 0.0 108.48 173.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.3 -132.73 8.66 Favored Glycine 0 N--CA 1.419 -2.496 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -176.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 90.7 mt -95.65 179.0 5.28 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . 0.457 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -151.3 66.59 0.35 Allowed Glycine 0 CA--C 1.481 -2.07 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . 0.526 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 3.5 pt -151.71 -177.6 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.104 0 C-N-CA 124.608 1.163 . . . . 0.0 108.246 -177.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' SER . . . . . 0.424 ' HB2' HG21 ' B' ' 41' ' ' THR . 49.3 m -153.73 162.7 41.01 Favored 'General case' 0 C--N 1.261 -3.243 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.236 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 19.0 pt -127.92 164.4 29.43 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 -178.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -144.0 138.57 24.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 178.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -83.61 96.03 1.92 Allowed Glycine 0 N--CA 1.426 -2.028 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.936 178.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 24.8 mmt -113.05 175.83 5.27 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 177.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 105.93 164.92 23.19 Favored Glycine 0 N--CA 1.428 -1.881 0 C-N-CA 120.156 -1.021 . . . . 0.0 110.645 -179.072 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.59 138.25 23.31 Favored 'General case' 0 C--N 1.284 -2.262 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 177.565 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 125.65 62.36 0.17 Allowed Glycine 0 N--CA 1.421 -2.339 0 C-N-CA 120.197 -1.001 . . . . 0.0 112.35 178.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.15 82.91 6.12 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 175.289 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.405 ' HB3' ' HB3' ' B' ' 32' ' ' LEU . 18.5 t70 -79.17 -7.04 57.9 Favored 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 113.522 -1.672 . . . . 0.0 113.383 -170.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 63.5 mtt 61.89 77.85 0.31 Allowed 'General case' 0 CA--C 1.496 -1.113 0 CA-C-O 121.85 0.833 . . . . 0.0 111.38 -176.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.66 45.89 1.47 Allowed Glycine 0 C--N 1.294 -1.772 0 CA-C-N 114.931 -1.032 . . . . 0.0 112.346 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . 0.405 ' HB3' ' HB3' ' B' ' 29' ' ' ASP . 3.3 tm? 178.44 -64.24 0.01 OUTLIER 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 104.802 -2.296 . . . . 0.0 104.802 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 45.86 86.86 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 125.352 1.461 . . . . 0.0 114.876 172.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 8.6 ptmm? -80.92 76.83 7.84 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.436 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 96.6 mt -115.39 162.2 17.47 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 114.399 -1.273 . . . . 0.0 108.787 179.272 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -136.9 109.58 0.73 Allowed Glycine 0 N--CA 1.411 -3.02 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.627 -178.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 33.8 mm -89.62 84.55 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.89 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 175.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.493 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 90.4 m-85 -82.91 164.97 20.13 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.192 -1.367 . . . . 0.0 109.235 -176.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 52.1 t -73.21 126.47 33.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 176.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -86.87 -36.7 18.28 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.052 -176.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' THR . . . . . 0.424 HG21 ' HB2' ' B' ' 20' ' ' SER . 1.3 t -160.88 165.87 29.41 Favored 'General case' 0 N--CA 1.423 -1.791 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.208 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.3 p -139.1 94.22 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-O 122.562 1.173 . . . . 0.0 109.077 177.109 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 45.6 m -65.74 126.79 29.54 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-N 113.064 -1.88 . . . . 0.0 113.038 -173.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . 0.452 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 9.2 pt-20 -53.13 -31.4 42.15 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 125.218 1.407 . . . . 0.0 113.254 -179.089 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -64.65 -29.69 75.9 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 121.427 -0.416 . . . . 0.0 112.908 -179.503 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.457 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -95.98 165.79 24.43 Favored Glycine 0 N--CA 1.422 -2.298 0 C-N-CA 119.884 -1.15 . . . . 0.0 113.527 -176.031 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -58.45 -33.66 69.98 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 113.358 -1.421 . . . . 0.0 113.48 -175.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -59.51 -38.87 82.08 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -175.565 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . 0.452 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 7.9 t60 -75.06 -38.49 61.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.11 0.481 . . . . 0.0 110.145 -178.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 22.5 mtm-85 -77.89 -29.55 50.28 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.682 -175.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . 0.549 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 23.9 t70 -80.0 -53.78 6.41 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 176.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.39 39.66 4.16 Favored Glycine 0 CA--C 1.497 -1.077 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 179.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.549 ' HD3' ' OD2' ' B' ' 51' ' ' ASP . 0.5 OUTLIER -103.07 -69.41 0.79 Allowed 'General case' 0 N--CA 1.425 -1.717 0 CA-C-N 114.618 -0.791 . . . . 0.0 109.532 -174.26 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.598 HD11 ' CE2' ' B' ' 89' ' ' PHE . 52.1 mt -85.61 108.34 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 174.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 32.5 mt-30 -101.9 167.7 9.89 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -176.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 9.5 p -70.73 -4.54 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.568 1.641 0 CA-C-O 121.79 0.805 . . . . 0.0 112.3 -173.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -114.16 7.05 16.51 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.889 0.852 . . . . 0.0 109.232 -175.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -95.21 165.01 12.61 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.809 -176.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . 0.493 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 23.8 tp -136.5 133.98 37.1 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.668 -176.773 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 69.3 mt -80.48 96.51 6.78 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 176.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.517 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 38.8 t -78.4 -45.67 25.99 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-O 121.66 0.743 . . . . 0.0 109.917 178.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -154.11 151.69 29.57 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 114.968 -1.015 . . . . 0.0 109.931 174.167 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . 0.417 HG11 ' HB ' ' B' ' 66' ' ' THR . 4.3 p -95.28 -173.49 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 178.224 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . 0.445 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 13.0 t70 -47.26 -49.62 23.09 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -139.6 43.06 1.18 Allowed Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 119.29 -1.433 . . . . 0.0 113.964 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 66' ' ' THR . . . . . 0.417 ' HB ' HG11 ' B' ' 63' ' ' VAL . 31.8 m -160.64 115.66 2.21 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 178.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 43.4 m -76.75 133.76 39.36 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-O 121.133 0.492 . . . . 0.0 110.891 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.517 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 4.1 mm? -87.42 -68.06 0.78 Allowed 'General case' 0 N--CA 1.434 -1.228 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.995 177.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 59.9 t 70.05 -40.46 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 124.456 1.102 . . . . 0.0 111.52 -177.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . 0.404 ' H ' ' C ' ' B' ' 68' ' ' LEU . . . 157.44 85.22 0.05 OUTLIER Glycine 0 N--CA 1.417 -2.628 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.31 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . 0.441 HG22 ' O ' ' B' ' 72' ' ' THR . 35.5 m -105.58 -172.73 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 123.543 0.737 . . . . 0.0 109.49 -178.311 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 72' ' ' THR . . . . . 0.441 ' O ' HG22 ' B' ' 71' ' ' VAL . 19.8 p -81.64 157.03 24.81 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 172.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -61.49 -35.59 78.11 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.194 0.521 . . . . 0.0 110.735 -176.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 25.4 m -62.65 -38.02 88.66 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.915 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -63.83 -49.13 74.04 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.521 ' O ' HG13 ' B' ' 79' ' ' VAL . . . -61.64 -42.95 99.62 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.793 -178.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.04 -32.51 73.02 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.278 0.561 . . . . 0.0 110.696 178.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 8.1 t -82.38 -28.45 31.47 Favored 'General case' 0 N--CA 1.428 -1.56 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.059 -177.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.521 HG13 ' O ' ' B' ' 76' ' ' ALA . 7.2 p -71.44 -33.01 48.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 O-C-N 121.412 -0.805 . . . . 0.0 109.714 -174.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 29.1 mt -69.81 -16.88 63.35 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.573 -1.194 . . . . 0.0 111.02 176.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -96.14 -24.22 16.39 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.049 0.452 . . . . 0.0 110.787 178.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 29.2 m-80 -82.68 -21.5 34.89 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 121.373 0.606 . . . . 0.0 111.351 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.406 ' HB ' HG13 ' B' ' 87' ' ' VAL . 7.4 p -85.32 167.75 15.31 Favored 'General case' 0 N--CA 1.425 -1.683 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.928 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 37.4 mmtm -67.89 -173.76 0.39 Allowed 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 123.425 0.69 . . . . 0.0 112.422 179.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -75.16 -30.61 58.67 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.17 -0.923 . . . . 0.0 112.064 -178.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . 0.454 ' NH2' ' HB3' ' B' ' 11' ' ' GLU . 21.4 ttm-85 -130.62 116.09 17.62 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.062 0.458 . . . . 0.0 110.003 175.067 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . 0.445 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 5.8 m -136.71 144.64 31.93 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.737 179.172 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . 0.423 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 99.7 mtt180 -91.8 129.12 37.82 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 175.735 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.598 ' CE2' HD11 ' B' ' 54' ' ' ILE . 2.0 m-85 -105.93 161.0 14.84 Favored 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 178.674 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.484 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 62.1 mtt -109.14 106.64 16.62 Favored 'General case' 0 C--N 1.286 -2.167 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 169.449 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.486 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.3 mp -87.57 135.48 25.28 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 CA-C-N 114.459 -1.246 . . . . 0.0 107.648 178.492 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . 0.54 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -127.0 104.06 0.69 Allowed Glycine 0 CA--C 1.465 -3.088 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 177.186 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 11.2 ptp180 -104.88 148.96 26.1 Favored 'General case' 0 C--N 1.271 -2.809 0 N-CA-C 108.963 -0.754 . . . . 0.0 108.963 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -94.95 77.49 3.58 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 174.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 45.4 ttt180 -64.0 -59.36 11.48 Favored Pre-proline 0 C--N 1.3 -1.568 0 CA-C-N 113.69 -1.596 . . . . 0.0 112.623 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -73.5 161.61 41.95 Favored 'Trans proline' 0 C--N 1.37 1.661 0 C-N-CA 121.298 1.332 . . . . 0.0 112.92 -179.056 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . 0.412 ' C ' ' H ' ' B' ' 99' ' ' GLN . . . 153.63 -46.55 0.55 Allowed Glycine 0 CA--C 1.492 -1.387 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 176.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -79.29 23.27 0.39 Allowed 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 123.088 0.555 . . . . 0.0 111.017 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . 0.412 ' H ' ' C ' ' B' ' 97' ' ' GLY . 39.6 mt-30 -66.2 -54.64 22.71 Favored 'General case' 0 N--CA 1.436 -1.136 0 C-N-CA 124.073 0.949 . . . . 0.0 111.076 -175.378 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 19.6 m -156.05 175.77 13.52 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 -177.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 67.59 17.83 9.94 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 124.058 0.943 . . . . 0.0 111.583 175.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 30.0 m -90.84 144.76 8.47 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.166 -0.959 . . . . 0.0 110.798 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . 67.5 -65.68 0.23 Allowed 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 125.579 1.552 . . . . 0.0 114.089 178.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 35.0 tt0 -85.02 -23.26 28.7 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.298 -178.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 11.1 mp 60.47 -172.26 0.13 Allowed 'General case' 0 C--O 1.242 0.701 0 C-N-CA 123.869 0.868 . . . . 0.0 110.657 -173.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 38.6 mm -76.39 -64.38 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 176.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 28.1 tp60 55.94 94.61 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.483 0 O-C-N 124.665 1.228 . . . . 0.0 113.001 173.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -76.72 77.99 3.35 Favored 'General case' 0 CA--C 1.515 -0.382 0 C-N-CA 119.916 -0.714 . . . . 0.0 109.351 177.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 8.1 t -89.51 -29.61 18.83 Favored 'General case' 0 N--CA 1.423 -1.791 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.589 -177.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 90.0 mt -83.63 12.87 5.17 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.57 0.7 . . . . 0.0 111.485 -176.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -135.87 98.85 4.0 Favored 'General case' 0 N--CA 1.426 -1.644 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 175.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.39 16.25 6.57 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.087 0.47 . . . . 0.0 111.742 177.25 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 16.2 mp0 . . . . . 0 CA--C 1.513 -0.445 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 172.833 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.171 0 N-CA-C 110.121 -1.192 . . . . 0.0 110.121 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 32.8 p-80 -144.06 145.26 32.06 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 118.047 0.924 . . . . 0.0 111.408 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 3' ' ' MET . . . . . 0.497 ' SD ' ' HA ' ' B' ' 94' ' ' GLU . 24.7 mmt -105.93 118.69 37.25 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 175.602 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . 0.501 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 19.0 mt-10 -89.85 100.25 13.1 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -95.46 93.93 7.5 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 177.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -118.53 141.48 29.87 Favored Pre-proline 0 C--N 1.283 -2.323 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.067 178.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -79.51 143.51 17.15 Favored 'Trans proline' 0 N--CA 1.446 -1.268 0 C-N-CA 122.151 1.901 . . . . 0.0 112.306 -179.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.414 ' CG1' ' HB3' ' B' ' 53' ' ' ARG . 53.8 t -131.49 127.7 59.99 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.981 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 176.599 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . 0.428 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 32.0 tt0 -110.4 121.61 45.72 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -177.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.469 HD23 ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -114.61 165.6 12.6 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 121.515 0.674 . . . . 0.0 110.707 178.685 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -115.52 126.63 54.52 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 105.728 -1.953 . . . . 0.0 105.728 175.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -79.85 160.45 26.08 Favored 'General case' 0 N--CA 1.417 -2.092 0 C-N-CA 117.627 -1.629 . . . . 0.0 107.022 170.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -115.75 178.31 4.36 Favored 'General case' 0 C--N 1.258 -3.391 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 -178.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 13.1 t -67.32 -20.54 65.62 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 179.398 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -92.61 7.24 44.22 Favored 'General case' 0 CA--C 1.555 1.168 0 CA-C-O 121.869 0.843 . . . . 0.0 109.42 176.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.57 -115.93 4.63 Favored Glycine 0 N--CA 1.435 -1.421 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.493 178.506 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -103.05 -173.19 2.25 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 121.42 0.629 . . . . 0.0 110.483 -177.282 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . 0.419 ' CA ' ' HA3' ' B' ' 46' ' ' GLY . . . -149.44 53.75 0.51 Allowed Glycine 0 CA--C 1.491 -1.433 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 178.291 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 2.6 pt -154.3 -179.99 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-O 121.961 0.886 . . . . 0.0 111.407 -175.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 51.0 m -152.49 131.45 12.56 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 175.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . 0.445 ' HB ' HG21 ' B' ' 37' ' ' ILE . 15.6 pt -108.66 162.53 6.51 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 C-N-CA 122.713 0.405 . . . . 0.0 109.946 -178.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . 0.449 ' HB ' ' HB2' ' B' ' 40' ' ' LYS . 9.5 tp -136.22 136.69 49.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 CA-C-O 121.134 0.493 . . . . 0.0 110.673 -178.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -82.58 105.63 2.64 Favored Glycine 0 N--CA 1.426 -2.022 0 CA-C-N 115.663 -0.699 . . . . 0.0 112.527 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' MET . . . . . 0.525 ' O ' ' HG ' ' B' ' 35' ' ' LEU . 26.3 mmt -131.07 178.22 6.85 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 176.196 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 121.14 -162.52 14.85 Favored Glycine 0 C--N 1.289 -2.033 0 C-N-CA 120.465 -0.874 . . . . 0.0 111.206 179.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -135.46 137.8 42.56 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 176.464 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.98 83.75 0.71 Allowed Glycine 0 N--CA 1.443 -0.856 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 179.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.91 79.26 0.31 Allowed 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.587 0.708 . . . . 0.0 112.065 -178.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.417 ' C ' ' H ' ' B' ' 31' ' ' GLY . 20.6 t70 -76.29 2.95 11.91 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-O 122.876 1.322 . . . . 0.0 110.687 -175.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 24.5 ptm -73.12 19.72 0.09 Allowed 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.207 -1.36 . . . . 0.0 111.801 175.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.417 ' H ' ' C ' ' B' ' 29' ' ' ASP . . . 97.0 17.55 32.05 Favored Glycine 0 N--CA 1.442 -0.935 0 C-N-CA 121.442 -0.408 . . . . 0.0 112.768 177.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -121.55 -53.62 1.99 Allowed 'General case' 0 C--N 1.312 -1.033 0 C-N-CA 119.87 -0.732 . . . . 0.0 112.288 -177.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . 0.463 ' O ' ' HA3' ' B' ' 70' ' ' GLY . 40.9 mt-10 59.66 24.81 13.68 Favored 'General case' 0 CA--C 1.502 -0.876 0 C-N-CA 125.381 1.472 . . . . 0.0 111.649 -173.34 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . 0.402 ' HA ' ' O ' ' B' ' 69' ' ' VAL . 14.1 ptmm? -72.21 124.29 24.73 Favored 'General case' 0 N--CA 1.423 -1.784 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 179.08 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . 0.525 ' HG ' ' O ' ' B' ' 24' ' ' MET . 15.4 tp -123.37 -172.44 2.51 Favored 'General case' 0 C--N 1.28 -2.447 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 -174.124 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . 0.438 ' H ' ' HG ' ' B' ' 35' ' ' LEU . . . -137.06 87.72 0.22 Allowed Glycine 0 N--CA 1.422 -2.296 0 C-N-CA 119.882 -1.151 . . . . 0.0 111.724 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . 0.445 HG21 ' HB ' ' B' ' 21' ' ' ILE . 34.5 mm -84.62 80.32 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 176.233 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -77.17 169.93 17.45 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.172 -176.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 49.1 t -80.36 135.46 25.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . 0.449 ' HB2' ' HB ' ' B' ' 22' ' ' ILE . 2.4 ttpm? -95.84 -41.47 8.81 Favored 'General case' 0 CA--C 1.482 -1.652 0 CA-C-O 121.187 0.517 . . . . 0.0 109.899 -178.125 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 1.1 m -154.83 146.98 23.72 Favored 'General case' 1 N--CA 1.369 -4.483 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -174.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 39.5 t -114.76 105.69 19.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 175.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 7.2 m -64.41 122.68 17.3 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.215 -174.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . 0.486 ' HG2' ' CE1' ' B' ' 49' ' ' HIS . 36.1 mt-10 -66.8 -28.36 68.31 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.457 -175.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.3 -1.11 85.4 Favored Glycine 0 N--CA 1.435 -1.401 0 CA-C-N 115.042 -0.981 . . . . 0.0 113.396 -179.266 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.419 ' HA3' ' CA ' ' B' ' 18' ' ' GLY . . . -117.07 170.29 13.38 Favored Glycine 0 N--CA 1.411 -2.972 0 C-N-CA 119.933 -1.127 . . . . 0.0 112.818 -178.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -60.72 -35.79 77.23 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 114.088 1.144 . . . . 0.0 114.088 -174.249 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . 0.469 ' HA ' HD23 ' B' ' 10' ' ' LEU . . . -63.28 -38.74 92.35 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 113.199 0.815 . . . . 0.0 113.199 -174.277 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . 0.486 ' CE1' ' HG2' ' B' ' 44' ' ' GLU . 4.1 t60 -74.15 -39.34 63.33 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.659 0.742 . . . . 0.0 109.342 -179.199 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 -76.63 -26.2 54.65 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 114.862 -1.063 . . . . 0.0 111.785 -175.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . 0.519 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 12.6 t70 -77.92 -46.18 22.0 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 176.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 97.08 16.34 35.76 Favored Glycine 0 CA--C 1.498 -1.03 0 CA-C-N 115.515 -0.766 . . . . 0.0 112.624 172.399 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.519 ' HD3' ' OD2' ' B' ' 51' ' ' ASP . 1.5 mpt_? -91.96 -63.46 1.24 Allowed 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 113.335 0.865 . . . . 0.0 113.335 -177.124 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.489 HD13 ' CE2' ' B' ' 89' ' ' PHE . 39.4 mt -69.3 133.09 32.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 C-N-CA 119.805 -0.758 . . . . 0.0 110.53 176.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 30.7 mm-40 -113.37 153.66 28.19 Favored 'General case' 0 CA--C 1.511 -0.543 0 C-N-CA 122.408 0.283 . . . . 0.0 110.634 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.3 p -73.6 -7.48 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.86 0 CA-C-O 121.709 0.766 . . . . 0.0 111.986 -176.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -114.35 9.83 16.97 Favored 'General case' 0 C--N 1.293 -1.879 0 O-C-N 121.581 -0.699 . . . . 0.0 111.95 -175.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -112.42 177.78 4.52 Favored 'General case' 0 C--O 1.244 0.784 0 CA-C-O 120.979 0.418 . . . . 0.0 111.767 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 24.9 tp -126.91 128.22 46.12 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.739 -176.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 31.7 mt -90.15 107.68 19.28 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 105.569 -2.011 . . . . 0.0 105.569 175.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.492 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 41.4 t -79.2 -74.36 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.19 -2.03 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -118.6 165.2 14.24 Favored 'General case' 0 C--N 1.269 -2.903 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.032 -173.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 4.6 p -113.34 -175.19 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -174.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . 0.428 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 12.6 t70 -40.18 -63.35 0.62 Allowed 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 125.76 1.624 . . . . 0.0 113.918 -178.709 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -134.68 41.01 1.5 Allowed Glycine 0 CA--C 1.496 -1.133 0 C-N-CA 119.333 -1.413 . . . . 0.0 113.401 -178.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 37.7 m -150.35 126.24 10.44 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 178.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 2.3 p -84.18 133.18 34.61 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 115.457 -0.792 . . . . 0.0 112.047 -177.09 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.492 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 4.2 mm? -118.69 141.91 48.16 Favored 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 175.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . 0.402 ' O ' ' HA ' ' B' ' 34' ' ' LYS . 44.6 t -123.47 -42.59 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 175.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . 0.463 ' HA3' ' O ' ' B' ' 33' ' ' GLU . . . 175.49 81.0 0.05 OUTLIER Glycine 0 N--CA 1.409 -3.164 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.552 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 27.1 m -100.91 -177.39 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.217 0 CA-C-N 114.197 -1.002 . . . . 0.0 109.532 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 72.0 p -76.1 163.4 27.15 Favored 'General case' 0 N--CA 1.432 -1.359 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 177.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -61.93 -31.85 72.2 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.651 0.739 . . . . 0.0 109.412 177.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 28.1 t -72.69 -42.6 64.05 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.872 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 19.4 t80 -62.46 -47.81 82.4 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.577 ' O ' HG11 ' B' ' 79' ' ' VAL . . . -61.72 -40.32 94.64 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.577 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.73 -28.84 69.35 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.499 0.666 . . . . 0.0 110.959 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.8 m -85.16 -16.94 38.75 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.171 -177.4 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.577 HG11 ' O ' ' B' ' 76' ' ' ALA . 4.2 p -72.91 -28.25 26.5 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.518 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 -179.236 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 55.2 mt -71.81 -7.14 46.48 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 114.09 -1.414 . . . . 0.0 110.815 177.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 88.3 mtt180 -103.65 -14.7 16.03 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 121.37 0.605 . . . . 0.0 109.707 178.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 -86.59 -29.03 22.91 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.471 176.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.481 ' HB ' HG11 ' B' ' 87' ' ' VAL . 9.3 p -69.49 170.08 11.27 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 115.402 1.63 . . . . 0.0 115.402 -173.392 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 35.1 mttp -73.56 -162.4 0.13 Allowed 'General case' 0 C--O 1.241 0.622 0 CA-C-N 114.845 -1.07 . . . . 0.0 110.253 173.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -80.0 -38.5 19.06 Favored Glycine 0 N--CA 1.437 -1.291 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.871 178.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 41.0 ttm180 -120.96 123.52 42.65 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . 0.481 HG11 ' HB ' ' B' ' 83' ' ' THR . 26.7 m -139.71 142.76 31.88 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 CA-C-O 120.867 0.365 . . . . 0.0 111.543 -177.767 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . 0.428 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 52.2 mtt180 -99.4 116.68 32.13 Favored 'General case' 0 CA--C 1.485 -1.556 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.164 176.528 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.489 ' CE2' HD13 ' B' ' 54' ' ' ILE . 6.8 m-85 -92.91 152.44 19.37 Favored 'General case' 0 C--N 1.285 -2.234 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.507 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 90' ' ' MET . . . . . . . . . . . . . 86.0 mtp -102.1 106.98 17.93 Favored 'General case' 0 C--N 1.286 -2.177 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 171.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.433 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.4 mp -84.77 120.86 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.942 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . 0.501 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -117.27 109.95 1.97 Allowed Glycine 1 CA--C 1.445 -4.283 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 179.219 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 7.3 tpp180 -69.72 94.57 0.81 Allowed 'General case' 0 C--N 1.279 -2.475 0 CA-C-N 114.6 -0.8 . . . . 0.0 109.431 177.122 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . 0.497 ' HA ' ' SD ' ' B' ' 3' ' ' MET . 31.8 tt0 -81.88 77.79 8.66 Favored 'General case' 0 N--CA 1.408 -2.549 0 CA-C-O 122.783 1.278 . . . . 0.0 107.762 173.654 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 28.3 ttm105 -78.71 -58.09 0.77 Allowed Pre-proline 0 N--CA 1.408 -2.55 0 CA-C-N 112.774 -2.012 . . . . 0.0 109.309 176.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -72.89 117.27 5.05 Favored 'Trans proline' 0 N--CA 1.424 -2.578 0 C-N-CA 121.376 1.384 . . . . 0.0 112.853 178.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . 0.403 ' C ' ' H ' ' B' ' 99' ' ' GLN . . . -149.1 -37.16 0.04 OUTLIER Glycine 0 C--N 1.267 -3.277 0 CA-C-N 113.045 -1.888 . . . . 0.0 108.843 -179.453 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -80.59 22.5 0.57 Allowed 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 124.123 0.969 . . . . 0.0 110.904 176.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . 0.403 ' H ' ' C ' ' B' ' 97' ' ' GLY . 84.1 mm-40 -85.48 114.25 22.37 Favored 'General case' 0 N--CA 1.407 -2.584 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.664 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 24.4 m -114.57 170.56 8.23 Favored 'General case' 0 C--N 1.279 -2.458 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 177.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 66.29 31.21 8.62 Favored 'General case' 0 CA--C 1.555 1.157 0 CA-C-O 122.565 1.174 . . . . 0.0 109.8 177.197 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 35.2 m -99.36 172.9 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 114.744 -1.116 . . . . 0.0 110.605 -177.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -118.93 -91.73 0.55 Allowed 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 114.122 1.156 . . . . 0.0 114.122 -176.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 10.2 pt20 -82.04 25.51 0.57 Allowed 'General case' 0 N--CA 1.476 0.855 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 -173.318 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 73.8 mt -83.7 -3.3 57.65 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-O 122.25 1.024 . . . . 0.0 108.349 174.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 46.5 mm -79.79 -65.68 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 CA-C-N 113.875 -1.511 . . . . 0.0 107.967 174.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -118.68 115.89 25.45 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.265 175.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -91.36 89.61 7.34 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 177.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 7.9 t -106.44 150.81 25.69 Favored 'General case' 0 N--CA 1.412 -2.344 0 CA-C-N 115.087 -0.961 . . . . 0.0 109.455 -178.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 28.4 mt -96.13 -5.39 40.85 Favored 'General case' 0 C--N 1.285 -2.204 0 CA-C-N 115.244 -0.889 . . . . 0.0 108.962 -178.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -135.3 79.05 1.76 Allowed 'General case' 0 N--CA 1.432 -1.346 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.417 178.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 59.9 tt0 -100.05 99.31 10.02 Favored 'General case' 0 C--N 1.306 -1.315 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 174.007 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 . . . . . 0 C--N 1.285 -2.228 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -173.288 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.502 -0.777 0 N-CA-C 110.226 -1.15 . . . . 0.0 110.226 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 60.5 m-70 -83.47 -45.14 13.97 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 171.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 19.7 ptp -96.44 149.68 21.45 Favored 'General case' 0 N--CA 1.425 -1.709 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 173.08 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -84.99 104.93 15.37 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 -177.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -79.55 83.73 5.5 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 173.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -102.58 143.02 25.76 Favored Pre-proline 0 C--N 1.294 -1.845 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.396 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . 0.508 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 51.1 Cg_endo -79.28 134.61 11.53 Favored 'Trans proline' 0 N--CA 1.429 -2.267 0 C-N-CA 121.634 1.556 . . . . 0.0 112.291 177.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 73.4 t -115.22 127.54 72.75 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 175.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . 0.48 ' O ' ' HD2' ' B' ' 53' ' ' ARG . 43.3 tt0 -119.59 116.12 25.38 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 -176.291 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.519 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 0.5 OUTLIER -102.41 153.27 20.19 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.766 0.793 . . . . 0.0 110.761 -177.949 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -99.68 103.36 15.03 Favored 'General case' 0 C--N 1.276 -2.607 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 174.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . 0.426 ' HB2' ' O ' ' B' ' 85' ' ' GLY . 6.5 mmmm -81.61 157.02 24.86 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 114.301 1.223 . . . . 0.0 114.301 -171.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . 0.409 ' H ' ' HA3' ' B' ' 16' ' ' GLY . 22.1 m-20 -128.47 178.82 6.02 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 171.184 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 14.7 m -74.61 -19.56 60.26 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.652 0.739 . . . . 0.0 110.033 177.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 9.2 tp10 -128.56 31.49 4.98 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 105.762 -1.94 . . . . 0.0 105.762 176.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . 0.409 ' HA3' ' H ' ' B' ' 13' ' ' ASP . . . -71.21 -5.03 58.16 Favored Glycine 0 CA--C 1.494 -1.263 0 CA-C-N 113.662 -1.608 . . . . 0.0 116.481 -169.181 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -75.16 86.45 2.41 Favored 'General case' 0 N--CA 1.429 -1.488 0 C-N-CA 119.302 -0.959 . . . . 0.0 111.096 177.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -96.78 55.45 1.37 Allowed Glycine 0 CA--C 1.484 -1.85 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 6.6 pt -161.67 -177.49 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 C-N-CA 124.7 1.2 . . . . 0.0 107.92 -175.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' SER . . . . . 0.404 ' HB2' HG23 ' B' ' 41' ' ' THR . 43.2 m -149.65 145.61 26.83 Favored 'General case' 0 C--N 1.27 -2.865 0 N-CA-C 105.425 -2.065 . . . . 0.0 105.425 172.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . 0.416 ' HB ' HG22 ' B' ' 37' ' ' ILE . 16.0 pt -115.95 154.1 17.48 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.297 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.3 tp -127.08 136.79 59.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 CA-C-O 120.884 0.374 . . . . 0.0 110.764 -176.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.58 98.08 2.38 Favored Glycine 0 N--CA 1.434 -1.438 0 C-N-CA 121.058 -0.591 . . . . 0.0 111.791 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 95.4 mmm -102.95 118.9 37.85 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 178.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 144.92 177.83 20.05 Favored Glycine 0 N--CA 1.425 -2.043 0 C-N-CA 119.959 -1.115 . . . . 0.0 113.099 177.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -159.29 154.49 25.31 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 177.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 164.82 -162.06 35.24 Favored Glycine 0 N--CA 1.434 -1.433 0 C-N-CA 120.072 -1.061 . . . . 0.0 112.542 178.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.69 98.45 10.7 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-O 120.835 0.35 . . . . 0.0 111.118 -179.11 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.423 ' HA ' ' HB3' ' B' ' 33' ' ' GLU . 9.7 p-10 -75.24 49.89 0.48 Allowed 'General case' 0 N--CA 1.445 -0.68 0 C-N-CA 125.056 1.342 . . . . 0.0 112.345 -177.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 25.9 ptt? -128.31 26.32 5.72 Favored 'General case' 0 C--N 1.29 -2.012 0 CA-C-N 115.067 -0.97 . . . . 0.0 109.423 -178.29 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.37 16.68 12.68 Favored Glycine 0 N--CA 1.444 -0.778 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.755 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 26.3 mt -150.5 26.91 0.75 Allowed 'General case' 0 C--O 1.25 1.12 0 C-N-CA 123.253 0.621 . . . . 0.0 111.134 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . 0.474 ' O ' ' HG ' ' B' ' 35' ' ' LEU . 2.4 pm0 -79.94 71.62 6.65 Favored 'General case' 0 N--CA 1.421 -1.921 0 CA-C-O 122.007 0.908 . . . . 0.0 108.654 175.664 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 22.5 pttp -64.91 86.58 0.05 Allowed 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 114.202 -1.363 . . . . 0.0 109.452 176.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . 0.474 ' HG ' ' O ' ' B' ' 33' ' ' GLU . 74.9 mt -107.93 158.49 17.31 Favored 'General case' 0 N--CA 1.431 -1.399 0 CA-C-N 113.759 -1.564 . . . . 0.0 109.522 -175.679 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -107.75 98.27 1.24 Allowed Glycine 0 N--CA 1.404 -3.437 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 176.443 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . 0.416 HG22 ' HB ' ' B' ' 21' ' ' ILE . 27.9 mm -87.35 87.78 2.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 177.058 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -85.69 166.54 16.06 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.399 -1.273 . . . . 0.0 108.705 -176.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 57.4 t -77.9 136.47 24.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 175.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -96.04 -42.07 8.44 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -178.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 41' ' ' THR . . . . . 0.404 HG23 ' HB2' ' B' ' 20' ' ' SER . 3.5 t -157.05 168.8 26.41 Favored 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 21.3 t -130.47 97.35 3.19 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 178.265 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 40.5 m -73.89 124.64 26.54 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 124.281 1.033 . . . . 0.0 111.709 -176.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . 0.504 ' HA ' ' CB ' ' B' ' 49' ' ' HIS . 1.7 pm0 -65.53 -22.41 66.71 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 124.44 1.096 . . . . 0.0 113.904 -178.042 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.54 -23.87 72.23 Favored Glycine 0 N--CA 1.439 -1.128 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.243 176.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -104.4 173.15 21.01 Favored Glycine 0 N--CA 1.424 -2.163 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.837 -177.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -58.54 -41.34 85.34 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 125.205 1.402 . . . . 0.0 114.265 -175.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . 0.481 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -57.19 -37.52 72.28 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -173.39 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . 0.504 ' CB ' ' HA ' ' B' ' 44' ' ' GLU . 8.4 t60 -74.97 -35.4 62.07 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -178.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 68.9 mtt180 -68.43 -47.74 66.41 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 -178.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -60.41 -61.39 2.63 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 114.456 -1.247 . . . . 0.0 110.722 176.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 91.02 6.14 67.23 Favored Glycine 0 N--CA 1.433 -1.528 0 N-CA-C 114.824 0.69 . . . . 0.0 114.824 175.144 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.48 ' HD2' ' O ' ' B' ' 9' ' ' GLU . 65.4 mtt180 -83.3 -33.64 25.9 Favored 'General case' 0 N--CA 1.441 -0.892 0 CA-C-N 118.392 1.096 . . . . 0.0 111.316 179.107 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.437 HD12 ' CE2' ' B' ' 89' ' ' PHE . 28.8 mt -83.29 117.03 28.4 Favored 'Isoleucine or valine' 0 C--O 1.248 0.984 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 174.116 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 22.7 mt-30 -91.45 163.96 13.99 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 121.356 0.598 . . . . 0.0 110.47 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 13.2 p -75.51 -2.11 3.79 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.854 0 CA-C-O 122.488 1.137 . . . . 0.0 109.976 178.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -114.02 0.06 14.21 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.058 -175.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -82.29 174.34 11.23 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 112.926 0.713 . . . . 0.0 112.926 -174.076 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 25.8 tp -141.6 131.15 23.91 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.54 -0.755 . . . . 0.0 110.521 -175.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -81.71 95.63 7.29 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.688 0.756 . . . . 0.0 110.22 178.227 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.566 ' HB ' ' O ' ' B' ' 90' ' ' MET . 27.8 t -86.95 -40.73 14.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.695 177.03 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . 0.481 ' HG3' ' HA ' ' B' ' 67' ' ' SER . 32.4 tt0 -156.2 148.75 23.72 Favored 'General case' 0 C--N 1.273 -2.727 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.48 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . 0.479 ' O ' ' HG2' ' B' ' 62' ' ' GLU . 9.9 p -102.39 -168.45 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 104.912 -2.255 . . . . 0.0 104.912 176.419 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -50.19 -54.21 22.47 Favored 'General case' 0 N--CA 1.479 1.004 0 CA-C-N 119.189 0.904 . . . . 0.0 112.27 178.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -106.16 -53.78 0.73 Allowed Glycine 0 C--N 1.308 -0.989 0 C-N-CA 119.538 -1.315 . . . . 0.0 114.088 -178.3 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 6.1 m -72.37 120.81 18.51 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 123.101 0.56 . . . . 0.0 112.492 -174.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 67' ' ' SER . . . . . 0.481 ' HA ' ' HG3' ' B' ' 62' ' ' GLU . 64.9 m -86.12 121.15 28.31 Favored 'General case' 0 N--CA 1.435 -1.204 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 174.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.523 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 28.9 mt -83.3 100.23 10.51 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-O 121.087 0.47 . . . . 0.0 110.226 -179.308 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 29.0 m -89.48 12.5 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-O 121.759 0.79 . . . . 0.0 109.463 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 111.71 90.23 1.94 Allowed Glycine 0 N--CA 1.402 -3.615 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -174.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 26.4 m -117.15 174.4 3.73 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.28 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 20.7 p -76.87 159.86 29.7 Favored 'General case' 0 N--CA 1.413 -2.281 0 CA-C-O 120.957 0.408 . . . . 0.0 110.051 177.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 60.6 tt0 -58.66 -35.28 72.29 Favored 'General case' 0 C--N 1.311 -1.096 0 C-N-CA 123.788 0.835 . . . . 0.0 109.824 178.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 19.7 m -70.96 -39.14 72.73 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.576 179.559 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -62.56 -48.9 77.45 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.068 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.51 ' O ' HG11 ' B' ' 79' ' ' VAL . . . -57.81 -45.42 86.11 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.258 179.304 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.01 -39.19 91.42 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.641 0.734 . . . . 0.0 110.792 178.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 50.6 m -71.83 -27.5 62.95 Favored 'General case' 0 N--CA 1.433 -1.32 0 CA-C-N 115.377 -0.829 . . . . 0.0 112.511 -177.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.51 HG11 ' O ' ' B' ' 76' ' ' ALA . 5.0 p -77.25 -30.4 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 C-N-CA 119.546 -0.862 . . . . 0.0 108.852 -177.164 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . 0.477 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 77.1 mt -67.46 -35.85 80.01 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.306 176.08 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 79.4 mtp180 -78.05 -32.74 51.01 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.275 178.317 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -72.3 -36.71 69.0 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 123.234 0.614 . . . . 0.0 111.478 -179.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.434 ' HB ' HG13 ' B' ' 87' ' ' VAL . 8.5 p -67.82 159.81 29.57 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 113.693 0.997 . . . . 0.0 113.693 -177.117 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -66.56 -166.07 0.04 OUTLIER 'General case' 0 C--O 1.255 1.371 0 C-N-CA 125.729 1.612 . . . . 0.0 114.806 -174.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . 0.426 ' O ' ' HB2' ' B' ' 12' ' ' LYS . . . -70.86 -17.12 75.03 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 114.631 -1.168 . . . . 0.0 113.3 -177.514 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . 0.519 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 57.1 ttp180 -157.49 118.3 3.54 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 121.165 0.507 . . . . 0.0 111.016 174.465 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . 0.434 HG13 ' HB ' ' B' ' 83' ' ' THR . 14.8 m -132.1 145.72 34.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.237 179.351 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -98.05 128.89 44.85 Favored 'General case' 0 CA--C 1.482 -1.654 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.518 178.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.508 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 4.8 m-85 -105.38 157.36 17.39 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 106.965 -1.495 . . . . 0.0 106.965 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.566 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 63.0 mtt -109.87 117.51 34.02 Favored 'General case' 0 C--N 1.282 -2.352 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 172.134 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 1.4 mp -105.96 122.38 59.5 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 -179.157 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.37 103.76 2.51 Favored Glycine 0 CA--C 1.464 -3.11 0 N-CA-C 109.169 -1.573 . . . . 0.0 109.169 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 9.3 tpp180 -141.81 121.41 13.36 Favored 'General case' 0 C--N 1.265 -3.073 0 CA-C-N 114.214 -0.993 . . . . 0.0 110.572 -175.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -83.97 86.79 7.13 Favored 'General case' 0 N--CA 1.429 -1.519 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 168.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 45.6 ttt180 -65.96 -61.63 5.32 Favored Pre-proline 0 C--N 1.302 -1.488 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.612 179.099 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -74.69 136.47 21.13 Favored 'Trans proline' 0 N--CA 1.444 -1.438 0 C-N-CA 121.888 1.725 . . . . 0.0 114.379 -178.183 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -143.13 -94.85 0.2 Allowed Glycine 0 C--N 1.286 -2.246 0 N-CA-C 107.343 -2.303 . . . . 0.0 107.343 174.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -103.53 77.45 1.5 Allowed 'General case' 0 N--CA 1.421 -1.9 0 CA-C-O 122.659 1.218 . . . . 0.0 109.881 173.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -129.72 -66.69 0.78 Allowed 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 12.3 m -94.65 169.64 10.03 Favored 'General case' 0 N--CA 1.425 -1.682 0 N-CA-C 105.651 -1.981 . . . . 0.0 105.651 169.225 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 6.1 tm-20 70.28 8.76 6.77 Favored 'General case' 0 N--CA 1.479 0.986 0 CA-C-O 121.686 0.755 . . . . 0.0 111.457 176.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 15.8 m -65.3 113.78 2.32 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-O 121.965 0.888 . . . . 0.0 112.077 -178.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -118.44 -33.01 4.45 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.797 -1.092 . . . . 0.0 109.984 -177.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -78.63 93.27 4.84 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 175.127 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 82.0 mt -119.03 120.99 38.83 Favored 'General case' 0 C--N 1.297 -1.715 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.024 -173.068 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 1.7 mp -91.08 -56.37 5.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 174.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 13.1 mm100 -96.03 100.03 11.73 Favored 'General case' 0 N--CA 1.438 -1.066 0 CA-C-N 115.325 -0.852 . . . . 0.0 108.771 175.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 52.7 mt-30 -84.04 34.8 0.51 Allowed 'General case' 0 C--N 1.31 -1.113 0 C-N-CA 123.153 0.581 . . . . 0.0 111.752 -177.225 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 9.7 t -63.77 -25.41 68.17 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 122.979 0.512 . . . . 0.0 112.163 -177.037 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -81.22 -7.61 59.6 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -100.2 129.1 46.18 Favored 'General case' 0 N--CA 1.44 -0.961 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 175.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 45.2 mt-30 -82.85 148.26 27.84 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-O 120.935 0.397 . . . . 0.0 111.223 -174.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 . . . . . 0 C--N 1.302 -1.478 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.771 -177.949 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.205 0 CA-C-O 119.715 -0.492 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 15.0 t-80 -71.33 -69.92 0.35 Allowed 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 122.989 0.516 . . . . 0.0 109.835 -176.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 92.8 mmm -104.09 106.11 16.5 Favored 'General case' 0 CA--C 1.469 -2.171 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 177.126 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . 0.48 ' OE2' ' HD2' ' B' ' 93' ' ' ARG . 12.0 mt-10 -98.62 96.4 7.92 Favored 'General case' 0 C--N 1.275 -2.643 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.013 -175.614 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -84.38 97.51 9.52 Favored 'General case' 0 N--CA 1.427 -1.606 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 177.201 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -130.85 147.48 66.39 Favored Pre-proline 0 C--N 1.279 -2.495 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.481 177.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . 0.424 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 49.7 Cg_endo -75.84 136.89 19.28 Favored 'Trans proline' 0 N--CA 1.44 -1.65 0 C-N-CA 121.868 1.712 . . . . 0.0 111.625 175.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 91.4 t -121.56 148.54 24.93 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.071 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -126.98 143.65 51.23 Favored 'General case' 0 C--N 1.279 -2.469 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -177.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.421 HD11 ' CB ' ' B' ' 48' ' ' ALA . 0.8 OUTLIER -141.04 157.18 45.67 Favored 'General case' 0 CA--C 1.478 -1.789 0 CA-C-O 121.05 0.452 . . . . 0.0 109.908 174.431 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -127.15 112.59 15.32 Favored 'General case' 0 C--N 1.275 -2.632 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 177.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 5.4 ptpp? -77.14 150.77 35.55 Favored 'General case' 0 C--N 1.283 -2.317 0 CA-C-N 115.143 -0.935 . . . . 0.0 113.357 -172.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -93.78 -172.93 3.01 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 177.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 12.3 t -71.25 -25.65 62.57 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.954 -1.499 . . . . 0.0 106.954 173.09 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 11.9 tp10 -67.27 -20.87 65.71 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.444 172.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.07 -116.06 4.83 Favored Glycine 0 N--CA 1.416 -2.657 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -177.188 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -101.2 -175.06 2.76 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -178.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . 0.422 ' CA ' ' HA3' ' B' ' 46' ' ' GLY . . . -150.45 67.99 0.34 Allowed Glycine 0 CA--C 1.477 -2.325 0 N-CA-C 110.931 -0.868 . . . . 0.0 110.931 -179.754 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 4.3 pt -162.59 169.98 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 C-N-CA 125.277 1.431 . . . . 0.0 107.867 -176.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.4 m -131.76 141.99 49.65 Favored 'General case' 0 C--N 1.253 -3.611 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 174.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . 0.43 ' HB ' HG21 ' B' ' 37' ' ' ILE . 8.6 pt -115.23 149.37 17.47 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.012 0 O-C-N 123.45 0.469 . . . . 0.0 109.81 -178.188 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.1 tp -119.22 134.88 61.42 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -177.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.74 94.58 1.55 Allowed Glycine 0 N--CA 1.43 -1.707 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.688 -177.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 88.9 mmm -84.05 113.23 20.87 Favored 'General case' 0 C--O 1.253 1.268 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -83.22 68.17 3.61 Favored Glycine 0 CA--C 1.481 -2.052 0 CA-C-O 122.268 0.926 . . . . 0.0 113.163 -175.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -163.72 -45.95 0.03 OUTLIER 'General case' 0 C--N 1.251 -3.692 0 CA-C-N 112.528 -1.836 . . . . 0.0 108.383 178.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 49.59 -119.58 6.7 Favored Glycine 0 C--N 1.27 -3.123 0 CA-C-N 111.358 -2.656 . . . . 0.0 113.206 178.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -121.79 89.09 3.05 Favored 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.484 ' HA ' ' HA ' ' B' ' 33' ' ' GLU . 17.6 t70 -69.0 -41.28 78.02 Favored 'General case' 0 CA--C 1.492 -1.284 0 N-CA-C 112.851 0.686 . . . . 0.0 112.851 -176.022 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 23.0 ptp -91.74 45.75 1.24 Allowed 'General case' 0 C--N 1.274 -2.675 0 CA-C-O 122.75 1.262 . . . . 0.0 108.899 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -161.01 -63.96 0.02 OUTLIER Glycine 0 N--CA 1.42 -2.376 0 CA-C-N 113.221 -1.809 . . . . 0.0 112.12 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -129.07 -3.97 5.05 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -174.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . 0.484 ' HA ' ' HA ' ' B' ' 29' ' ' ASP . 8.6 pt-20 49.01 22.04 0.54 Allowed 'General case' 0 N--CA 1.503 2.206 0 C-N-CA 126.439 1.895 . . . . 0.0 114.553 -175.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -130.85 175.46 9.03 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 112.115 0.413 . . . . 0.0 112.115 -177.112 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 78.6 mt -52.61 140.74 22.37 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 125.403 1.481 . . . . 0.0 113.955 -175.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -111.18 103.64 1.61 Allowed Glycine 0 N--CA 1.423 -2.212 0 N-CA-C 108.614 -1.794 . . . . 0.0 108.614 175.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . 0.43 HG21 ' HB ' ' B' ' 21' ' ' ILE . 26.3 mm -94.15 90.38 2.8 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-O 121.674 0.749 . . . . 0.0 109.403 -177.759 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -88.79 167.07 13.59 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.207 -178.128 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 64.7 t -80.77 130.3 36.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 CA-C-O 121.28 0.562 . . . . 0.0 109.641 175.387 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -94.42 -41.11 9.56 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.218 -176.681 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -156.57 164.0 38.7 Favored 'General case' 0 N--CA 1.437 -1.082 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 21.3 t -112.05 102.52 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.031 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 174.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 31.2 m -69.73 122.04 18.38 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 124.112 0.965 . . . . 0.0 111.825 -174.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . 0.461 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 32.8 mt-10 -58.23 -41.45 84.15 Favored 'General case' 0 CA--C 1.507 -0.695 0 C-N-CA 124.662 1.185 . . . . 0.0 111.736 -175.568 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -67.22 -12.24 60.37 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 115.197 -0.911 . . . . 0.0 114.237 -177.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.422 ' HA3' ' CA ' ' B' ' 18' ' ' GLY . . . -112.23 170.0 13.35 Favored Glycine 0 N--CA 1.41 -3.078 0 C-N-CA 120.124 -1.036 . . . . 0.0 113.797 -175.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -57.64 -35.07 70.02 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 115.045 1.498 . . . . 0.0 115.045 -171.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . 0.421 ' CB ' HD11 ' B' ' 10' ' ' LEU . . . -67.53 -35.46 79.12 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 119.952 -0.699 . . . . 0.0 112.695 -174.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . 0.461 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 5.4 t60 -78.53 -39.62 37.38 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 64.4 mtp180 -67.13 -39.48 86.6 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.683 -177.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -79.56 -48.63 13.51 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 177.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 94.15 51.22 2.1 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -178.452 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 13.1 mmt180 -109.75 -79.44 0.58 Allowed 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 111.85 0.315 . . . . 0.0 111.85 -175.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.478 HD12 ' CE2' ' B' ' 89' ' ' PHE . 62.7 mt -71.16 132.7 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.977 -179.203 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 -103.58 173.51 6.27 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.234 0.54 . . . . 0.0 110.996 -177.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.1 p -79.27 2.43 2.17 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.145 0 CA-C-O 121.949 0.88 . . . . 0.0 111.638 -174.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -121.46 11.36 10.65 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 122.218 1.009 . . . . 0.0 108.683 -175.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 19.2 m-20 -89.07 168.49 12.29 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.929 -175.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . 0.497 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 23.5 tp -144.69 131.47 20.14 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 124.008 0.923 . . . . 0.0 108.83 -177.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 76.6 mt -85.08 94.23 8.8 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.561 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.2 t -80.09 -39.96 19.89 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 CA-C-O 121.739 0.78 . . . . 0.0 110.147 177.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -160.0 156.73 27.53 Favored 'General case' 0 C--N 1.28 -2.451 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.41 173.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 5.7 p -102.01 -173.74 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 N-CA-C 105.455 -2.054 . . . . 0.0 105.455 177.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -53.79 -48.75 69.49 Favored 'General case' 0 C--N 1.311 -1.093 0 C-N-CA 122.992 0.517 . . . . 0.0 112.387 -179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -101.87 -60.21 0.77 Allowed Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 120.22 -0.991 . . . . 0.0 114.187 -179.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 9.1 m -77.57 129.66 35.93 Favored 'General case' 0 CA--C 1.557 1.248 0 CA-C-O 121.164 0.507 . . . . 0.0 112.201 -176.119 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 49.4 m -94.44 121.84 36.39 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.058 178.358 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.561 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 32.0 mt -88.9 111.89 22.64 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.105 0.478 . . . . 0.0 111.838 -175.352 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 43.6 t -85.57 -23.67 7.06 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 174.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 147.63 68.6 0.01 OUTLIER Glycine 0 CA--C 1.475 -2.42 0 N-CA-C 109.396 -1.481 . . . . 0.0 109.396 -177.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 28.2 m -85.22 172.08 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 CA-C-N 114.467 -0.867 . . . . 0.0 109.383 -177.094 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 24.6 p -71.7 157.2 38.36 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 120.93 0.395 . . . . 0.0 110.138 177.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -57.43 -39.4 76.13 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 123.345 0.658 . . . . 0.0 110.458 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 40.0 t -68.17 -37.8 81.38 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.01 179.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -66.44 -45.45 79.79 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -179.124 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.582 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.2 -44.02 97.95 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.505 178.426 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.98 -34.12 75.58 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 121.756 0.788 . . . . 0.0 110.599 177.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 39.3 m -79.31 -27.68 42.16 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 115.489 -0.778 . . . . 0.0 112.094 -178.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.582 HG12 ' O ' ' B' ' 76' ' ' ALA . 4.5 p -71.53 -31.97 44.43 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-O 121.906 0.86 . . . . 0.0 109.07 -175.711 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 53.9 mt -66.03 -29.44 69.8 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 114.528 -1.214 . . . . 0.0 110.553 176.425 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 71.4 mtt180 -90.74 -16.85 27.71 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.373 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -90.38 -14.65 32.58 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.038 0.447 . . . . 0.0 111.268 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.494 ' HB ' HG13 ' B' ' 87' ' ' VAL . 6.7 p -90.63 171.76 9.16 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 77.1 mttt -60.37 -178.7 0.09 Allowed 'General case' 0 C--O 1.245 0.817 0 C-N-CA 124.612 1.165 . . . . 0.0 114.077 -179.06 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.38 -52.06 46.98 Favored Glycine 0 N--CA 1.44 -1.049 0 CA-C-N 114.208 -1.36 . . . . 0.0 111.117 177.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 14.5 ttp180 -114.82 117.64 31.31 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 177.068 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . 0.494 HG13 ' HB ' ' B' ' 83' ' ' THR . 14.0 m -132.13 157.57 43.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.353 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 15.9 mtm180 -108.5 152.64 24.45 Favored 'General case' 0 N--CA 1.422 -1.833 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 179.435 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.478 ' CE2' HD12 ' B' ' 54' ' ' ILE . 1.7 m-85 -133.5 164.99 25.91 Favored 'General case' 0 C--N 1.267 -3.004 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 179.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.47 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 84.3 mtp -112.82 117.43 32.14 Favored 'General case' 0 C--N 1.286 -2.195 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 170.571 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.497 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.5 mp -102.88 133.18 47.36 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.395 -177.11 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -113.6 93.86 0.68 Allowed Glycine 0 CA--C 1.463 -3.208 0 N-CA-C 108.18 -1.968 . . . . 0.0 108.18 172.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . 0.48 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 36.8 ttm180 -71.34 126.71 30.34 Favored 'General case' 0 C--N 1.273 -2.754 0 CA-C-N 114.244 -0.978 . . . . 0.0 111.152 -175.846 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -87.7 74.26 9.19 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 172.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 10.9 ttm180 -56.07 -59.36 11.97 Favored Pre-proline 0 C--O 1.239 0.532 0 CA-C-N 115.002 -0.999 . . . . 0.0 112.779 -178.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -60.21 111.95 1.16 Allowed 'Trans proline' 0 N--CA 1.424 -2.608 0 C-N-CA 121.4 1.4 . . . . 0.0 112.514 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -177.97 -59.35 0.07 OUTLIER Glycine 0 C--N 1.263 -3.506 1 N-CA-C 102.862 -4.095 . . . . 0.0 102.862 -176.48 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -94.15 85.9 4.81 Favored 'General case' 0 N--CA 1.428 -1.565 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 166.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . 0.416 ' HA ' HE21 ' B' ' 99' ' ' GLN . 0.0 OUTLIER -157.16 -51.13 0.07 Allowed 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 102.678 -3.082 . . . . 0.0 102.678 -179.365 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 19.9 m -86.16 -179.09 6.66 Favored 'General case' 0 N--CA 1.427 -1.617 0 N-CA-C 103.847 -2.649 . . . . 0.0 103.847 161.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 54.4 73.45 0.4 Allowed 'General case' 0 N--CA 1.441 -0.92 0 CA-C-N 118.741 0.7 . . . . 0.0 109.649 -173.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 9.0 p -137.97 171.36 15.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 -175.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . 71.86 86.84 0.11 Allowed 'General case' 0 N--CA 1.442 -0.857 0 C-N-CA 125.298 1.439 . . . . 0.0 113.041 177.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 55.71 88.51 0.04 OUTLIER 'General case' 0 C--O 1.246 0.878 0 C-N-CA 124.851 1.26 . . . . 0.0 111.573 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . 0.273 36.0 mt -75.72 75.59 2.7 Favored 'General case' 0 CA--C 1.508 -0.656 0 N-CA-C 115.176 1.547 . . . . 0.0 115.176 -173.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 15.5 mm -150.81 -57.71 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.283 -2.318 0 N-CA-C 102.386 -3.19 . . . . 0.0 102.386 170.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 9.3 tt0 49.92 65.92 1.28 Allowed 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 113.13 -1.85 . . . . 0.0 112.252 175.215 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -92.53 -21.55 20.06 Favored 'General case' 0 C--N 1.312 -1.043 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 174.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 12.5 t -90.25 163.14 14.89 Favored 'General case' 0 N--CA 1.411 -2.403 0 N-CA-C 105.605 -1.998 . . . . 0.0 105.605 172.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 92.2 mt 68.12 -79.7 0.04 OUTLIER 'General case' 0 C--N 1.309 -1.193 0 C-N-CA 123.979 0.912 . . . . 0.0 111.591 -178.204 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 65.34 -49.34 0.37 Allowed 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 126.242 1.817 . . . . 0.0 111.858 -175.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 27.1 tp60 -123.59 101.03 7.09 Favored 'General case' 0 N--CA 1.418 -2.05 0 N-CA-C 108.309 -0.996 . . . . 0.0 108.309 176.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 . . . . . 0 C--N 1.292 -1.93 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 175.273 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.49 -1.484 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 25.6 t-80 -63.57 -44.6 93.61 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 174.46 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 20.2 ptp -102.07 142.04 33.96 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 172.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . 0.493 ' OE2' ' HG2' ' B' ' 93' ' ' ARG . 2.6 mt-10 -116.35 101.56 8.77 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -93.1 91.04 7.13 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 -179.125 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -117.67 146.52 38.9 Favored Pre-proline 0 C--N 1.29 -1.998 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.307 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -81.1 144.25 14.72 Favored 'Trans proline' 0 N--CA 1.449 -1.089 0 C-N-CA 122.5 2.133 . . . . 0.0 112.811 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.472 HG12 ' HB3' ' B' ' 53' ' ' ARG . 73.6 t -127.94 133.87 66.39 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.032 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -121.24 125.49 47.24 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 118.477 0.58 . . . . 0.0 110.173 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.424 ' CD1' ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -148.82 175.95 10.81 Favored 'General case' 0 N--CA 1.438 -1.037 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -178.188 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -147.03 178.02 8.69 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.086 -178.622 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -93.02 153.85 18.48 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.248 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . 0.549 ' HB2' ' N ' ' B' ' 47' ' ' ALA . 10.8 t70 -103.17 -164.37 1.07 Allowed 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' SER . . . . . 0.403 ' H ' ' CG ' ' B' ' 13' ' ' ASP . 22.8 p -55.43 -44.28 76.14 Favored 'General case' 0 C--O 1.243 0.756 0 C-N-CA 124.558 1.143 . . . . 0.0 111.57 -179.053 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -78.3 -48.72 15.06 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 177.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.08 -120.54 1.64 Allowed Glycine 0 N--CA 1.426 -2.006 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.831 178.171 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -89.23 101.4 14.06 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 121.397 0.618 . . . . 0.0 111.293 -178.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -92.12 59.84 2.7 Favored Glycine 0 C--O 1.21 -1.369 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 177.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . 0.442 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.0 pt -155.46 178.92 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 C-N-CA 125.406 1.482 . . . . 0.0 107.128 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' SER . . . . . 0.439 ' HB2' HG23 ' B' ' 41' ' ' THR . 51.0 m -158.19 155.81 29.71 Favored 'General case' 0 C--N 1.27 -2.88 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 176.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . 0.401 ' HB ' HG23 ' B' ' 37' ' ' ILE . 18.6 pt -115.71 161.12 14.69 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 O-C-N 123.445 0.466 . . . . 0.0 110.343 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . 0.443 ' HA ' ' NE2' ' B' ' 73' ' ' GLN . 8.1 tp -140.5 135.51 35.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.24 112.11 3.85 Favored Glycine 0 N--CA 1.428 -1.846 0 C-N-CA 120.494 -0.86 . . . . 0.0 111.982 -178.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 93.9 mmm -111.8 141.89 44.85 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 176.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.18 134.66 12.91 Favored Glycine 0 N--CA 1.423 -2.228 0 C-N-CA 119.599 -1.286 . . . . 0.0 111.624 -179.138 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -132.44 128.13 36.8 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 176.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -123.32 32.92 4.17 Favored Glycine 0 N--CA 1.427 -1.96 0 C-N-CA 119.338 -1.41 . . . . 0.0 113.955 -172.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.485 ' HB2' ' HB2' ' B' ' 33' ' ' GLU . . . -84.58 69.6 10.63 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 122.688 1.232 . . . . 0.0 108.546 177.457 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -74.63 -24.45 58.85 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 113.443 -1.708 . . . . 0.0 110.735 -174.18 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 23.2 ptp -63.62 -23.6 67.45 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 114.436 -1.256 . . . . 0.0 110.203 178.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -105.02 -73.45 0.91 Allowed Glycine 0 N--CA 1.416 -2.667 0 N-CA-C 110.106 -1.198 . . . . 0.0 110.106 177.29 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . 0.517 ' HG ' ' O ' ' B' ' 32' ' ' LEU . 18.7 tp 167.4 18.11 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 123.471 0.709 . . . . 0.0 110.647 -176.717 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . 0.485 ' HB2' ' HB2' ' B' ' 28' ' ' ALA . 16.4 mm-40 -100.98 82.98 2.45 Favored 'General case' 0 C--N 1.295 -1.764 0 O-C-N 120.84 -1.162 . . . . 0.0 108.328 -172.255 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? -82.15 -171.35 3.36 Favored 'General case' 0 C--N 1.278 -2.512 0 CA-C-N 112.991 -1.913 . . . . 0.0 110.235 175.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . 0.5 ' O ' ' HA2' ' B' ' 70' ' ' GLY . 3.0 mm? -35.7 119.37 0.54 Allowed 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 124.882 1.273 . . . . 0.0 113.164 -178.149 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -99.0 103.82 2.8 Favored Glycine 0 N--CA 1.414 -2.805 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.854 -176.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . 0.401 HG23 ' HB ' ' B' ' 21' ' ' ILE . 30.2 mm -88.45 89.2 3.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.876 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.566 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.485 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 89.6 m-85 -82.3 173.45 12.06 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 114.674 -1.148 . . . . 0.0 109.981 -176.639 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 59.3 t -83.42 137.09 21.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 175.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 32.2 ttmt -93.77 -48.87 6.11 Favored 'General case' 0 N--CA 1.433 -1.289 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.784 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 41' ' ' THR . . . . . 0.45 ' HA ' HG21 ' B' ' 56' ' ' VAL . 5.2 t -150.03 170.79 18.05 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.442 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.7 p -156.42 113.25 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 C-N-CA 124.587 1.155 . . . . 0.0 108.005 -177.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 32.1 m -112.14 144.81 40.91 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 114.856 -1.066 . . . . 0.0 110.061 -171.199 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . 0.436 ' HA ' ' HB3' ' B' ' 49' ' ' HIS . 9.0 pt-20 -71.75 4.46 3.23 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -178.651 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.79 -19.5 79.89 Favored Glycine 0 N--CA 1.436 -1.329 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 172.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -113.03 169.49 12.97 Favored Glycine 0 N--CA 1.413 -2.86 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 175.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . 0.549 ' N ' ' HB2' ' B' ' 13' ' ' ASP . . . -75.18 -23.94 57.78 Favored 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 115.096 -0.552 . . . . 0.0 111.274 -175.251 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . 0.424 ' HA ' ' CD1' ' B' ' 10' ' ' LEU . . . -56.46 -44.56 80.67 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -176.111 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . 0.436 ' HB3' ' HA ' ' B' ' 44' ' ' GLU . 10.3 t60 -73.49 -41.27 63.32 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.381 -179.059 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 81.5 mtp180 -72.42 -34.88 68.15 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.43 0.633 . . . . 0.0 110.945 -174.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . 0.498 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 30.4 t70 -72.42 -49.99 29.55 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.889 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.7 27.49 9.64 Favored Glycine 0 CA--C 1.494 -1.259 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.486 172.132 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.498 ' HD3' ' OD2' ' B' ' 51' ' ' ASP . 5.4 mpt_? -101.39 -60.17 1.57 Allowed 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 112.008 0.373 . . . . 0.0 112.008 -179.276 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.554 HD13 ' CE2' ' B' ' 89' ' ' PHE . 58.7 mt -72.79 134.82 29.04 Favored 'Isoleucine or valine' 0 C--O 1.251 1.157 0 N-CA-C 107.1 -1.445 . . . . 0.0 107.1 169.61 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 15.3 mm100 -110.19 -170.74 1.7 Allowed 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -174.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.45 HG21 ' HA ' ' B' ' 41' ' ' THR . 8.0 p -100.39 4.87 10.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 CA-C-O 121.567 0.698 . . . . 0.0 110.083 174.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 19.9 t-20 -133.28 10.98 4.16 Favored 'General case' 0 C--N 1.311 -1.104 0 O-C-N 121.623 -0.673 . . . . 0.0 111.965 -174.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -94.86 -173.64 3.04 Favored 'General case' 0 C--N 1.318 -0.804 0 O-C-N 121.308 -0.87 . . . . 0.0 111.381 179.127 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . 0.485 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 25.8 tp -144.92 125.4 13.98 Favored 'General case' 0 C--N 1.318 -0.769 0 C-N-CA 123.194 0.598 . . . . 0.0 111.116 -172.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . 0.427 ' O ' HD12 ' B' ' 68' ' ' LEU . 68.9 mt -83.69 96.49 8.72 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.399 0.618 . . . . 0.0 109.369 178.799 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.627 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 9.2 t -79.28 -37.32 18.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-O 121.685 0.755 . . . . 0.0 111.133 178.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -157.02 153.51 28.09 Favored 'General case' 0 C--N 1.276 -2.608 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.506 176.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 5.2 p -100.52 -174.63 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.42 -1.975 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 178.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -53.18 -42.46 66.23 Favored 'General case' 0 C--N 1.311 -1.078 0 C-N-CA 124.138 0.975 . . . . 0.0 112.475 -178.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -106.91 -66.24 0.63 Allowed Glycine 0 N--CA 1.439 -1.161 0 C-N-CA 120.813 -0.708 . . . . 0.0 113.627 179.199 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 7.2 m -74.1 135.7 42.96 Favored 'General case' 0 CA--C 1.554 1.099 0 C-N-CA 122.882 0.473 . . . . 0.0 112.266 -175.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 15.9 m -96.31 126.49 41.55 Favored 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 177.116 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.627 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 28.9 mt -83.28 -69.86 0.6 Allowed 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 112.241 0.459 . . . . 0.0 112.241 -177.131 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 86.8 t 73.28 -27.2 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 124.189 0.995 . . . . 0.0 111.246 -175.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . 0.5 ' HA2' ' O ' ' B' ' 35' ' ' LEU . . . 153.16 81.39 0.03 OUTLIER Glycine 0 N--CA 1.42 -2.404 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -178.211 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.1 m -106.76 -179.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 39.9 p -78.63 156.51 29.03 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 175.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . 0.443 ' NE2' ' HA ' ' B' ' 22' ' ' ILE . 61.9 tt0 -58.4 -39.4 79.6 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.23 0.538 . . . . 0.0 110.637 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 14.9 m -66.82 -35.47 80.12 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.73 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -65.33 -49.36 69.71 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 179.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.548 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -59.51 -40.73 88.03 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.069 178.586 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.34 -32.65 73.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.331 0.586 . . . . 0.0 110.468 177.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.6 m -79.25 -28.44 42.43 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.454 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.548 HG12 ' O ' ' B' ' 76' ' ' ALA . 5.7 p -72.6 -36.31 53.23 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.889 0 C-N-CA 119.574 -0.851 . . . . 0.0 109.172 -176.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 26.3 mt -70.44 -7.14 40.97 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.848 178.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 68.5 mtp180 -108.66 -1.51 19.44 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 121.617 0.723 . . . . 0.0 110.102 177.438 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 32.2 m-80 -115.06 6.41 15.2 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.067 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.522 HG21 ' O ' ' B' ' 79' ' ' VAL . 7.7 p -87.2 175.81 7.87 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.323 -178.825 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 28.8 mmtm -75.64 -169.18 0.99 Allowed 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.472 0.709 . . . . 0.0 109.733 174.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.17 -38.97 45.93 Favored Glycine 0 N--CA 1.444 -0.827 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 177.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -124.31 131.56 53.52 Favored 'General case' 0 N--CA 1.431 -1.397 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 11.2 m -142.08 153.01 18.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 CA-C-O 121.53 0.681 . . . . 0.0 111.445 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 -96.05 164.07 12.86 Favored 'General case' 0 C--N 1.291 -1.975 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 174.05 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.554 ' CE2' HD13 ' B' ' 54' ' ' ILE . 8.9 m-85 -145.28 157.33 44.08 Favored 'General case' 0 C--N 1.284 -2.261 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 177.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.507 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 81.0 mtp -112.38 120.15 40.69 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 169.694 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.448 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -98.58 119.04 46.06 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.164 0 CA-C-N 114.246 -1.343 . . . . 0.0 109.485 -175.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -96.93 93.3 1.45 Allowed Glycine 0 CA--C 1.457 -3.57 0 N-CA-C 106.96 -2.456 . . . . 0.0 106.96 172.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . 0.493 ' HG2' ' OE2' ' B' ' 4' ' ' GLU . 5.9 tpt180 -62.81 107.84 1.06 Allowed 'General case' 0 C--N 1.257 -3.429 0 CA-C-N 112.932 -1.634 . . . . 0.0 113.129 -174.278 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -79.41 94.34 5.52 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 104.642 -2.355 . . . . 0.0 104.642 165.75 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . 0.476 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 49.4 ttt180 -88.85 -55.87 0.3 Allowed Pre-proline 0 N--CA 1.398 -3.074 0 CA-C-N 113.098 -1.865 . . . . 0.0 108.827 173.227 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . 0.476 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 84.9 Cg_endo -88.81 108.56 0.49 Allowed 'Trans proline' 0 N--CA 1.426 -2.49 0 CA-C-O 123.448 1.353 . . . . 0.0 114.927 174.256 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -113.44 -11.46 13.24 Favored Glycine 1 C--N 1.251 -4.163 0 CA-C-N 112.467 -2.152 . . . . 0.0 108.255 174.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -89.45 11.03 20.5 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.482 -1.359 . . . . 0.0 109.466 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 52.3 mt-30 -126.82 135.21 50.71 Favored 'General case' 0 N--CA 1.402 -2.847 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 175.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 11.0 m -79.57 175.51 10.55 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 123.869 0.731 . . . . 0.0 111.995 -175.443 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -85.39 69.6 10.72 Favored 'General case' 0 N--CA 1.442 -0.862 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 -178.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -134.99 133.03 53.67 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.196 0 CA-C-N 114.185 -1.371 . . . . 0.0 112.461 179.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -141.92 -65.83 0.41 Allowed 'General case' 0 C--N 1.294 -1.836 0 CA-C-N 114.47 -1.241 . . . . 0.0 108.038 175.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -162.82 120.73 2.03 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.601 175.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -109.35 138.15 46.13 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 116.326 -0.397 . . . . 0.0 109.959 -179.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 31.5 mm -78.47 -56.39 7.55 Favored 'Isoleucine or valine' 0 C--O 1.246 0.875 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 176.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -67.11 109.34 2.99 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 170.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 15.7 tp60 167.5 -23.27 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 127.605 2.362 . . . . 0.0 105.091 -165.588 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 8.9 t -69.55 -12.43 61.64 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 113.043 -1.89 . . . . 0.0 111.531 178.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 49.6 mt 73.7 33.07 1.07 Allowed 'General case' 0 C--N 1.342 0.242 0 C-N-CA 123.926 0.89 . . . . 0.0 112.33 173.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -80.41 -12.2 59.6 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 121.99 0.9 . . . . 0.0 108.975 174.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 9.9 pt20 -176.85 -35.86 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 127.19 2.196 . . . . 0.0 105.504 178.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 . . . . . 0 N--CA 1.407 -2.591 0 N-CA-C 105.636 -1.986 . . . . 0.0 105.636 175.289 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.84 0 N-CA-C 111.671 -0.571 . . . . 0.0 111.671 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 84.2 m-70 -154.19 -162.84 1.49 Allowed 'General case' 0 C--O 1.243 0.721 0 N-CA-C 105.871 -1.9 . . . . 0.0 105.871 -178.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -68.15 129.5 40.12 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 104.704 -2.332 . . . . 0.0 104.704 164.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . 0.589 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 18.4 mt-10 -87.72 101.08 13.33 Favored 'General case' 0 C--N 1.293 -1.871 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.263 -171.128 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -85.62 85.73 7.4 Favored 'General case' 0 N--CA 1.428 -1.531 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 176.101 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -109.43 142.43 25.66 Favored Pre-proline 0 C--N 1.295 -1.801 0 C-N-CA 120.461 -0.496 . . . . 0.0 112.229 -178.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -80.34 126.4 6.17 Favored 'Trans proline' 0 N--CA 1.428 -2.371 0 C-N-CA 121.943 1.762 . . . . 0.0 112.541 177.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 95.2 t -107.08 151.94 8.78 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.82 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 175.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . 0.464 ' O ' ' HG2' ' B' ' 53' ' ' ARG . 45.0 tt0 -138.12 136.16 36.46 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 119.005 0.82 . . . . 0.0 109.696 -176.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.4 HD22 ' HA ' ' B' ' 48' ' ' ALA . 4.5 mt -139.34 165.31 27.54 Favored 'General case' 0 CA--C 1.475 -1.906 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 179.625 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -151.12 146.68 26.31 Favored 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 104.503 -2.406 . . . . 0.0 104.503 177.348 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.5 ptpt -88.41 171.33 10.2 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.883 0.849 . . . . 0.0 112.177 -174.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -99.92 176.61 5.37 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.804 -1.089 . . . . 0.0 108.214 176.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 7.0 m -59.66 -33.12 71.14 Favored 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 123.939 0.895 . . . . 0.0 109.261 175.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -77.15 -45.63 26.11 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 174.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.25 -138.36 7.65 Favored Glycine 0 N--CA 1.435 -1.406 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.273 179.255 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 91.8 mt -82.03 -176.24 6.04 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 123.033 0.533 . . . . 0.0 110.99 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -158.13 66.06 0.29 Allowed Glycine 0 CA--C 1.487 -1.665 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 pt -166.73 175.91 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.49 -1.361 0 C-N-CA 124.815 1.246 . . . . 0.0 108.408 -177.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 29.2 m -148.53 144.17 27.14 Favored 'General case' 0 C--N 1.27 -2.859 0 N-CA-C 105.784 -1.932 . . . . 0.0 105.784 174.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . 0.44 ' HB ' HG23 ' B' ' 37' ' ' ILE . 11.0 pt -115.09 158.13 15.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 CA-C-N 117.866 0.303 . . . . 0.0 110.395 -177.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 10.3 tp -139.32 140.75 37.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-O 120.636 0.255 . . . . 0.0 110.415 -176.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -91.24 109.53 3.72 Favored Glycine 0 N--CA 1.435 -1.398 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.687 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 66.2 mtt -122.7 114.92 21.22 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 177.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 162.15 -157.38 29.21 Favored Glycine 0 C--N 1.284 -2.359 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 -177.194 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -144.48 107.7 4.56 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 177.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.73 53.44 4.71 Favored Glycine 0 CA--C 1.488 -1.63 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.569 -177.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -160.57 86.71 0.74 Allowed 'General case' 0 N--CA 1.408 -2.537 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 177.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -129.0 21.5 5.81 Favored 'General case' 0 C--N 1.277 -2.573 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -177.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . 0.318 20.7 ptm 42.53 58.88 2.94 Favored 'General case' 0 CA--C 1.506 -0.735 0 CA-C-N 112.982 -1.917 . . . . 0.0 113.241 -174.156 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 146.91 -66.6 0.41 Allowed Glycine 0 N--CA 1.431 -1.656 0 CA-C-N 114.024 -1.444 . . . . 0.0 111.906 177.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 86.9 mt -71.17 -34.31 70.82 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 111.871 0.323 . . . . 0.0 111.871 -177.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 46.93 53.41 10.5 Favored 'General case' 0 C--N 1.349 0.578 0 C-N-CA 124.669 1.188 . . . . 0.0 108.661 -176.145 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 14.1 ptmm? -77.75 105.7 9.09 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 115.515 1.672 . . . . 0.0 115.515 -166.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 70.1 mt -108.78 129.34 55.38 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 114.504 -1.225 . . . . 0.0 108.583 172.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -96.85 109.97 3.95 Favored Glycine 0 N--CA 1.419 -2.46 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . 0.44 HG23 ' HB ' ' B' ' 21' ' ' ILE . 28.4 mm -89.09 92.04 3.85 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -85.68 169.01 13.87 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.106 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 59.5 t -82.77 136.57 22.6 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.496 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 174.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 31.1 ttpt -96.57 -35.9 10.92 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.085 0.469 . . . . 0.0 110.088 -176.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 2.8 t -161.27 165.28 29.44 Favored 'General case' 0 C--O 1.251 1.182 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 20.4 t -126.8 93.24 2.21 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.025 0 N-CA-C 106.843 -1.539 . . . . 0.0 106.843 177.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 20.8 m -60.91 123.32 17.24 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 115.207 -0.906 . . . . 0.0 111.282 -177.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . 0.429 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 12.7 pt-20 -70.43 -23.77 62.79 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-N 115.804 -0.634 . . . . 0.0 112.478 -174.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.32 -11.77 82.11 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 121.075 -0.584 . . . . 0.0 112.729 179.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -110.29 172.82 15.89 Favored Glycine 0 N--CA 1.413 -2.847 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.007 -178.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -61.34 -35.7 78.15 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 114.998 1.481 . . . . 0.0 114.998 -172.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . 0.4 ' HA ' HD22 ' B' ' 10' ' ' LEU . . . -61.37 -42.17 98.27 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -172.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . 0.429 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 5.0 t60 -71.22 -40.85 70.87 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 122.143 0.973 . . . . 0.0 108.864 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 71.1 mtp180 -69.05 -29.65 67.83 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.34 -177.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . 0.639 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 11.9 t70 -82.0 -45.44 15.32 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.61 35.28 6.57 Favored Glycine 0 CA--C 1.494 -1.263 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.637 173.529 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.639 ' HD3' ' OD2' ' B' ' 51' ' ' ASP . 5.3 mpt_? -107.82 -74.77 0.65 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.288 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . . . . . . . . . 27.9 mt -68.52 118.43 12.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 C-N-CA 120.051 -0.659 . . . . 0.0 110.033 177.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 14.8 mm100 -104.25 -179.48 3.96 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.1 p -80.82 2.02 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.173 0 CA-C-O 122.253 1.025 . . . . 0.0 111.099 -175.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 25.3 t-20 -110.76 1.29 17.72 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 122.138 0.971 . . . . 0.0 109.496 -177.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -78.93 155.01 29.2 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.233 -177.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 26.7 tp -139.3 126.68 21.51 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.735 -176.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 68.6 mt -79.3 91.47 5.03 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.258 0.551 . . . . 0.0 109.836 179.186 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.613 ' HB ' ' O ' ' B' ' 90' ' ' MET . 24.1 t -82.64 -39.28 15.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.997 0 CA-C-O 122.001 0.905 . . . . 0.0 110.053 177.272 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . 0.415 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 10.9 pt-20 -162.2 157.27 22.83 Favored 'General case' 0 C--N 1.28 -2.42 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.411 172.532 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . 0.452 HG11 ' HB ' ' B' ' 66' ' ' THR . 3.7 p -94.11 -177.86 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 N-CA-C 105.638 -1.986 . . . . 0.0 105.638 178.104 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . 0.511 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.2 t70 -44.54 -48.64 10.24 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 124.721 1.208 . . . . 0.0 112.975 -177.532 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -140.56 45.5 0.98 Allowed Glycine 0 CA--C 1.525 0.702 0 C-N-CA 119.991 -1.099 . . . . 0.0 113.847 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 66' ' ' THR . . . . . 0.452 ' HB ' HG11 ' B' ' 63' ' ' VAL . 45.5 m -158.42 119.51 3.42 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 177.375 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 67' ' ' SER . . . . . 0.408 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 45.8 m -85.48 133.18 34.1 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -175.788 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.568 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 23.9 mt -99.67 138.44 36.75 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.665 174.751 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -116.92 -26.77 2.63 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 CA-C-O 122.132 0.968 . . . . 0.0 109.146 173.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 160.45 87.75 0.06 OUTLIER Glycine 0 N--CA 1.399 -3.83 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 -176.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 m -111.58 173.17 2.54 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.667 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 41.7 p -75.21 160.2 30.68 Favored 'General case' 0 C--N 1.289 -2.039 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -59.57 -35.27 73.94 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 177.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 12.6 m -69.73 -41.03 75.82 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.632 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -63.54 -45.67 89.51 Favored 'General case' 0 CA--C 1.514 -0.429 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.529 ' O ' ' HG ' ' B' ' 80' ' ' LEU . . . -58.46 -46.26 86.95 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.487 178.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.39 -34.93 74.62 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.593 0.711 . . . . 0.0 110.736 178.067 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 45.5 m -80.37 -21.47 42.32 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 113.043 0.756 . . . . 0.0 113.043 -177.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.514 HG13 ' O ' ' B' ' 76' ' ' ALA . 8.4 p -78.52 -31.58 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.484 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . 0.529 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 63.4 mt -69.39 -13.54 62.42 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.656 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -107.88 -0.64 21.37 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.503 0.668 . . . . 0.0 110.898 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -99.0 -23.74 15.18 Favored 'General case' 0 C--O 1.248 0.981 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.021 178.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.437 ' HB ' HG12 ' B' ' 87' ' ' VAL . 2.1 p -68.47 169.42 10.88 Favored 'General case' 0 N--CA 1.422 -1.841 0 CA-C-N 114.517 -1.22 . . . . 0.0 114.01 -176.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 41.0 mmtm -70.58 -170.78 0.43 Allowed 'General case' 0 N--CA 1.437 -1.099 0 CA-C-N 115.132 -0.94 . . . . 0.0 112.488 178.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.38 -35.33 90.83 Favored Glycine 0 C--O 1.217 -0.946 0 CA-C-N 114.776 -1.102 . . . . 0.0 114.275 -176.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 34.3 ttp180 -143.0 125.04 15.26 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . 0.511 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 14.0 m -133.11 154.71 39.98 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.746 0 CA-C-O 121.804 0.812 . . . . 0.0 112.559 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 87.4 mtm180 -94.5 170.6 9.36 Favored 'General case' 0 N--CA 1.41 -2.429 0 CA-C-N 113.681 -1.6 . . . . 0.0 108.489 173.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.432 ' HB2' ' CD1' ' B' ' 91' ' ' ILE . 6.2 m-85 -145.55 149.11 34.0 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 175.486 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.613 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 1.1 mpt? -103.68 108.58 19.93 Favored 'General case' 0 C--N 1.276 -2.626 0 CA-C-O 121.604 0.716 . . . . 0.0 109.567 176.112 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.432 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.4 mp -98.84 110.92 27.18 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 114.329 -1.305 . . . . 0.0 107.95 -179.086 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . 0.589 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -104.15 103.71 2.33 Favored Glycine 0 CA--C 1.458 -3.514 0 N-CA-C 107.987 -2.045 . . . . 0.0 107.987 173.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . 0.424 ' HD2' ' OE1' ' B' ' 4' ' ' GLU . 1.9 ptp180 -84.39 150.02 25.62 Favored 'General case' 0 C--N 1.281 -2.37 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.232 -175.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -82.29 73.57 9.32 Favored 'General case' 0 N--CA 1.411 -2.408 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 175.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . 0.419 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 27.2 ttt180 -65.91 -57.52 13.49 Favored Pre-proline 0 N--CA 1.426 -1.63 0 CA-C-N 114.283 -1.326 . . . . 0.0 109.141 174.121 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . 0.419 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 69.6 Cg_endo -89.3 148.63 5.39 Favored 'Trans proline' 0 N--CA 1.441 -1.616 0 C-N-CA 121.513 1.475 . . . . 0.0 111.199 172.195 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 163.72 -31.63 0.27 Allowed Glycine 0 C--N 1.294 -1.76 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.265 -179.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -95.43 3.2 54.52 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.158 0.504 . . . . 0.0 109.761 179.347 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 7.3 tp60 64.97 115.17 0.03 OUTLIER 'General case' 0 N--CA 1.444 -0.744 0 C-N-CA 126.238 1.815 . . . . 0.0 113.678 179.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 22.6 m -127.41 -162.85 1.2 Allowed 'General case' 0 C--N 1.281 -2.412 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 177.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -74.32 -15.24 60.96 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.865 0.841 . . . . 0.0 111.482 178.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 15.0 m -77.27 78.99 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.29 -2.008 0 CA-C-O 123.052 1.406 . . . . 0.0 111.034 174.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -127.62 -53.83 1.34 Allowed 'General case' 0 C--N 1.29 -2.015 0 CA-C-N 112.947 -1.933 . . . . 0.0 106.912 178.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -88.9 97.72 11.34 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 172.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 68.5 mt -84.64 113.89 21.61 Favored 'General case' 0 C--N 1.295 -1.789 0 CA-C-N 115.131 -0.941 . . . . 0.0 111.435 -172.019 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 44.7 mm -66.06 -68.86 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 174.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 56.9 tp60 66.71 -28.61 0.13 Allowed 'General case' 0 CA--C 1.551 1.019 0 N-CA-C 115.743 1.757 . . . . 0.0 115.743 170.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 84.1 mm-40 73.96 75.42 0.12 Allowed 'General case' 0 CA--C 1.493 -1.225 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 -170.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 12.9 t -77.62 65.65 3.17 Favored 'General case' 0 N--CA 1.436 -1.14 0 CA-C-O 123.509 1.623 . . . . 0.0 110.298 -174.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 58.5 mt -111.64 -39.63 4.55 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 114.131 -1.395 . . . . 0.0 108.999 -177.529 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 52.31 73.59 0.33 Allowed 'General case' 0 C--O 1.24 0.596 0 O-C-N 124.355 1.035 . . . . 0.0 110.769 179.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 9.5 tt0 -91.04 -24.39 20.07 Favored 'General case' 0 C--N 1.298 -1.671 0 CA-C-N 114.631 -1.168 . . . . 0.0 108.845 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 . . . . . 0 N--CA 1.424 -1.729 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 179.649 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.489 -1.571 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 17.5 t-80 -78.42 -60.69 2.27 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 178.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 3' ' ' MET . . . . . 0.4 ' HG2' ' O ' ' B' ' 3' ' ' MET . 0.1 OUTLIER -103.3 115.67 31.0 Favored 'General case' 0 C--N 1.281 -2.412 0 N-CA-C 105.5 -2.037 . . . . 0.0 105.5 168.109 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -91.34 92.86 8.78 Favored 'General case' 0 C--N 1.281 -2.4 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -174.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -88.56 86.04 6.94 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -107.49 140.93 22.01 Favored Pre-proline 0 C--N 1.297 -1.714 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.531 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -80.51 134.84 10.17 Favored 'Trans proline' 0 N--CA 1.432 -2.146 0 C-N-CA 122.086 1.857 . . . . 0.0 112.672 178.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.48 HG13 ' HB3' ' B' ' 53' ' ' ARG . 25.5 t -115.67 114.93 47.71 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.283 0 CA-C-N 114.374 -1.284 . . . . 0.0 108.554 176.121 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -105.59 105.84 16.06 Favored 'General case' 0 C--N 1.276 -2.611 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -178.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.443 HD11 HG13 ' B' ' 54' ' ' ILE . 0.9 OUTLIER -123.72 153.85 40.3 Favored 'General case' 0 N--CA 1.418 -2.073 0 CA-C-O 121.685 0.755 . . . . 0.0 111.692 178.995 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -122.23 143.16 49.76 Favored 'General case' 0 C--N 1.276 -2.588 0 CA-C-N 114.245 -1.343 . . . . 0.0 108.083 -173.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 45.5 mtmt -75.98 158.63 31.73 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 122.002 0.906 . . . . 0.0 112.276 -176.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . 0.457 ' HB2' ' H ' ' B' ' 16' ' ' GLY . 11.1 m-20 -83.52 177.13 8.57 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 113.717 -1.583 . . . . 0.0 107.963 173.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.9 m -73.46 -25.37 60.46 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 171.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -82.06 -30.85 31.13 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.7 -1.136 . . . . 0.0 109.779 177.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . 0.457 ' H ' ' HB2' ' B' ' 13' ' ' ASP . . . 134.34 -108.44 0.72 Allowed Glycine 0 N--CA 1.432 -1.6 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.122 179.117 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 84.7 mt -132.8 115.72 15.65 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 121.073 0.464 . . . . 0.0 111.481 -175.276 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . 0.468 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -86.96 60.99 4.39 Favored Glycine 0 C--O 1.213 -1.168 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 178.567 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . 0.495 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 5.7 pt -151.73 174.04 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 C-N-CA 125.137 1.375 . . . . 0.0 109.021 179.169 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 62.8 m -151.92 156.96 41.13 Favored 'General case' 0 C--N 1.271 -2.817 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 175.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 12.0 pt -124.33 161.24 27.71 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.129 0 O-C-N 123.437 0.461 . . . . 0.0 110.737 -177.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -143.11 133.55 22.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.6 119.0 6.36 Favored Glycine 0 N--CA 1.435 -1.388 0 C-N-CA 120.629 -0.796 . . . . 0.0 113.162 -177.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 68.9 mtm -134.05 156.72 47.73 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 177.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 132.08 -148.99 19.3 Favored Glycine 0 C--N 1.306 -1.13 0 C-N-CA 120.244 -0.979 . . . . 0.0 111.222 -178.203 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -128.02 99.96 5.7 Favored 'General case' 0 C--O 1.245 0.817 0 CA-C-O 121.242 0.544 . . . . 0.0 110.458 178.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.04 57.64 5.03 Favored Glycine 0 N--CA 1.45 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 112.15 -177.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.16 107.47 17.89 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 179.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.459 ' C ' ' H ' ' B' ' 31' ' ' GLY . 26.1 t70 -72.45 -6.29 42.64 Favored 'General case' 0 N--CA 1.48 1.056 0 C-N-CA 124.584 1.153 . . . . 0.0 112.127 -172.538 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 27.0 ptm -73.57 30.59 0.07 Allowed 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 125.42 1.488 . . . . 0.0 112.006 -178.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.459 ' H ' ' C ' ' B' ' 29' ' ' ASP . . . 90.66 18.22 49.07 Favored Glycine 0 C--N 1.294 -1.771 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.673 177.158 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 83.4 mt -108.3 -67.92 0.94 Allowed 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 49.61 34.56 7.27 Favored 'General case' 0 C--O 1.216 -0.683 0 C-N-CA 125.131 1.372 . . . . 0.0 113.216 176.263 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -88.54 78.2 7.87 Favored 'General case' 0 N--CA 1.426 -1.668 0 CA-C-O 122.815 1.293 . . . . 0.0 110.792 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 18.8 tp -107.59 172.67 6.7 Favored 'General case' 0 C--N 1.286 -2.194 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 178.124 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -142.44 117.72 1.18 Allowed Glycine 0 C--N 1.27 -3.128 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.351 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 28.9 mm -96.72 88.76 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 178.015 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.417 ' HA ' ' HA ' ' B' ' 59' ' ' LEU . 94.5 m-85 -81.83 168.76 17.64 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 114.386 -1.279 . . . . 0.0 109.225 -176.584 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.8 t -79.31 139.52 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.376 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 22.8 ttpp -101.12 -44.44 5.7 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.083 0.468 . . . . 0.0 109.829 -178.086 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -154.62 162.13 41.27 Favored 'General case' 0 N--CA 1.432 -1.351 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 -176.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.495 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.2 p -144.06 97.79 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 CA-C-O 122.408 1.099 . . . . 0.0 109.356 176.63 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 23.9 m -62.65 126.59 27.84 Favored 'General case' 0 N--CA 1.431 -1.417 0 CA-C-N 113.262 -1.79 . . . . 0.0 112.256 -174.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . 0.549 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 1.8 mp0 -55.57 -36.91 67.37 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.693 1.597 . . . . 0.0 110.775 -178.052 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.97 -0.48 56.12 Favored Glycine 0 N--CA 1.438 -1.173 0 CA-C-N 115.437 -0.802 . . . . 0.0 113.877 -179.191 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.468 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -112.56 162.01 12.52 Favored Glycine 0 N--CA 1.417 -2.605 0 C-N-CA 120.121 -1.037 . . . . 0.0 113.093 179.211 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -57.45 -36.36 71.3 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 125.688 1.595 . . . . 0.0 112.06 -175.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -63.01 -34.54 77.77 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . 0.549 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 6.4 t60 -82.14 -39.12 23.73 Favored 'General case' 0 C--O 1.24 0.575 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 59.5 mtp180 -61.94 -39.56 92.49 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.137 179.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -74.68 -69.65 0.45 Allowed 'General case' 0 C--N 1.309 -1.174 0 C-N-CA 124.11 0.964 . . . . 0.0 109.382 175.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 110.99 -2.08 28.57 Favored Glycine 0 N--CA 1.436 -1.346 0 C-N-CA 120.21 -0.995 . . . . 0.0 114.565 177.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.48 ' HB3' HG13 ' B' ' 8' ' ' VAL . 39.5 mmt180 -72.24 -50.9 23.77 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 118.503 1.151 . . . . 0.0 113.054 177.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.495 HD11 ' CE2' ' B' ' 89' ' ' PHE . 54.6 mt -72.97 123.02 26.92 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 C-N-CA 119.034 -1.066 . . . . 0.0 108.891 173.141 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -116.47 146.96 42.18 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -178.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 13.2 p -56.54 -23.45 17.01 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.067 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -168.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -109.3 -3.53 17.1 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 120.875 -1.141 . . . . 0.0 111.469 -174.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -87.49 179.15 6.61 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 113.693 0.998 . . . . 0.0 113.693 -174.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . 0.417 ' HA ' ' HA ' ' B' ' 38' ' ' PHE . 24.6 tp -124.46 126.08 45.31 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.372 -172.239 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 82.0 mt -83.7 104.31 13.71 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 106.063 -1.829 . . . . 0.0 106.063 173.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.747 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 0.5 OUTLIER -91.09 -27.65 4.92 Favored 'Isoleucine or valine' 0 C--O 1.198 -1.627 0 C-N-CA 119.667 -0.813 . . . . 0.0 110.117 -174.625 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . 0.463 ' HB2' ' HA ' ' B' ' 67' ' ' SER . 13.2 pt-20 -158.35 166.11 33.08 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-N 114.725 -1.125 . . . . 0.0 111.389 176.122 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 6.4 p -105.57 -174.39 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.023 0 N-CA-C 106.549 -1.649 . . . . 0.0 106.549 178.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . 0.43 ' HB2' ' H ' ' B' ' 88' ' ' ARG . 18.9 t70 -56.55 -39.44 73.44 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 123.272 0.629 . . . . 0.0 112.479 -177.037 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -107.55 -65.29 0.6 Allowed Glycine 0 C--N 1.309 -0.945 0 C-N-CA 120.581 -0.818 . . . . 0.0 113.511 179.444 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 7.0 m -69.5 115.44 8.76 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 122.882 0.473 . . . . 0.0 112.059 -177.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 67' ' ' SER . . . . . 0.463 ' HA ' ' HB2' ' B' ' 62' ' ' GLU . 48.6 m -87.36 114.93 24.42 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 174.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.747 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 75.5 mt -85.46 140.48 30.67 Favored 'General case' 0 N--CA 1.435 -1.176 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.402 -177.606 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 p -100.09 -18.72 6.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 144.63 70.84 0.02 OUTLIER Glycine 0 N--CA 1.426 -1.985 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 -176.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.3 m -83.76 173.66 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 CA-C-N 114.478 -0.861 . . . . 0.0 110.021 -178.254 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 37.7 p -71.93 160.29 32.79 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 177.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.5 tt0 -61.14 -37.1 81.65 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.35 0.595 . . . . 0.0 110.437 -178.024 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.7 m -73.18 -30.27 63.43 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.664 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 51.1 t80 -71.6 -41.79 68.49 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.595 ' O ' HG13 ' B' ' 79' ' ' VAL . . . -64.46 -40.98 96.75 Favored 'General case' 0 N--CA 1.435 -1.182 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.828 177.768 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.01 -41.91 93.18 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.049 0.452 . . . . 0.0 110.829 177.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.1 p -76.75 -23.24 52.98 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 112.957 0.725 . . . . 0.0 112.957 -178.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.595 HG13 ' O ' ' B' ' 76' ' ' ALA . 6.7 p -72.47 -35.12 50.49 Favored 'Isoleucine or valine' 0 C--N 1.345 0.4 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -177.595 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 51.2 mt -68.35 -18.39 64.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 114.551 -1.204 . . . . 0.0 110.349 178.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -97.14 -9.95 26.89 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.534 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -96.35 -21.29 17.89 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-O 121.248 0.547 . . . . 0.0 110.203 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 83' ' ' THR . . . . . . . . . . . . . 17.9 p -80.67 174.27 11.78 Favored 'General case' 0 N--CA 1.425 -1.686 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.915 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 38.1 mttp -70.27 -168.03 0.2 Allowed 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.799 0.809 . . . . 0.0 112.393 178.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -72.62 -30.62 63.87 Favored Glycine 0 N--CA 1.437 -1.293 0 CA-C-N 114.932 -1.031 . . . . 0.0 111.989 178.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 50.4 ttp180 -135.16 123.37 23.0 Favored 'General case' 0 C--N 1.31 -1.129 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 3.3 m -137.44 160.01 35.1 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.131 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . 0.43 ' H ' ' HB2' ' B' ' 64' ' ' ASP . 81.3 mtm180 -107.82 110.99 22.91 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.635 -179.323 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.495 ' CE2' HD11 ' B' ' 54' ' ' ILE . 3.4 m-85 -92.29 156.18 17.44 Favored 'General case' 0 C--N 1.275 -2.664 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 179.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.408 ' O ' HG13 ' B' ' 61' ' ' VAL . 57.1 mtt -108.46 121.73 45.57 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.435 172.304 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.404 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -99.64 117.5 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.405 -2.682 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 179.507 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -105.45 104.04 2.25 Favored Glycine 0 CA--C 1.458 -3.505 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 178.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 13.8 tpp180 -96.62 99.06 10.7 Favored 'General case' 0 C--N 1.268 -2.977 0 CA-C-N 114.142 -1.029 . . . . 0.0 109.071 178.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -81.91 84.3 6.96 Favored 'General case' 0 C--N 1.287 -2.121 0 N-CA-C 104.842 -2.281 . . . . 0.0 104.842 171.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 14.0 ttm180 -54.08 -60.98 6.08 Favored Pre-proline 0 N--CA 1.442 -0.851 0 CA-C-N 114.032 -1.44 . . . . 0.0 111.536 -175.127 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -80.29 149.04 19.18 Favored 'Trans proline' 0 N--CA 1.443 -1.483 0 C-N-CA 121.236 1.291 . . . . 0.0 110.092 172.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -136.58 59.83 0.63 Allowed Glycine 0 C--N 1.297 -1.624 0 C-N-CA 119.624 -1.274 . . . . 0.0 113.339 -174.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 39.2 61.04 1.38 Allowed 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 125.237 1.415 . . . . 0.0 113.374 -178.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -138.39 30.07 2.41 Favored 'General case' 0 N--CA 1.425 -1.698 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 -176.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 57.9 p -101.08 166.74 10.65 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 114.478 -1.237 . . . . 0.0 110.38 -179.273 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -107.84 2.31 23.41 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.916 0.865 . . . . 0.0 109.937 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 31.1 m -85.77 93.84 3.91 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-O 122.35 1.071 . . . . 0.0 111.725 -178.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -154.45 127.46 8.28 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 176.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 98.3 mt-30 59.43 84.47 0.11 Allowed 'General case' 0 C--O 1.239 0.514 0 O-C-N 124.318 1.011 . . . . 0.0 111.401 -178.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 75.0 mt -139.66 179.78 6.37 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 -177.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 35.7 mm -88.2 -72.81 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 173.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 50.17 -87.82 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 126.045 1.738 . . . . 0.0 112.41 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 52.7 mt-30 55.8 89.11 0.04 OUTLIER 'General case' 0 C--O 1.24 0.602 0 C-N-CA 124.193 0.997 . . . . 0.0 110.309 -176.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 14.3 t -124.79 -174.43 3.03 Favored 'General case' 0 N--CA 1.404 -2.772 0 CA-C-N 114.652 -1.158 . . . . 0.0 108.684 -172.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . 0.431 ' O ' HD12 ' B' ' 110' ' ' LEU . 0.6 OUTLIER -101.27 104.69 15.72 Favored 'General case' 0 C--N 1.269 -2.916 0 CA-C-N 114.832 -1.076 . . . . 0.0 109.937 179.449 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 65.97 99.22 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 114.375 -1.284 . . . . 0.0 111.63 178.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 7.3 tp60 -108.05 -44.19 4.24 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 -178.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 . . . . . 0 N--CA 1.42 -1.949 0 CA-C-N 114.306 -1.316 . . . . 0.0 110.791 179.674 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.505 -0.554 0 N-CA-C 112.121 -0.392 . . . . 0.0 112.121 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 36.1 m80 -69.7 -42.77 73.64 Favored 'General case' 0 CA--C 1.503 -0.837 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 174.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 47.8 mtm -112.42 129.9 56.16 Favored 'General case' 0 N--CA 1.418 -2.063 0 N-CA-C 103.635 -2.728 . . . . 0.0 103.635 168.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . 0.475 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 16.2 mt-10 -88.4 97.29 10.97 Favored 'General case' 0 C--N 1.284 -2.276 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.263 -176.422 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -86.37 89.55 7.91 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 172.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 23.6 p90 -108.81 144.78 30.29 Favored Pre-proline 0 C--N 1.297 -1.7 0 CA-C-N 115.52 -0.764 . . . . 0.0 112.092 -177.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -73.85 138.59 26.3 Favored 'Trans proline' 0 N--CA 1.447 -1.255 0 C-N-CA 122.303 2.002 . . . . 0.0 113.314 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 74.8 t -129.49 126.55 63.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.824 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 175.219 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -108.39 135.75 49.17 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.668 -177.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.409 HD22 ' HA ' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -139.75 162.21 35.68 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.614 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -134.13 159.36 41.1 Favored 'General case' 0 C--N 1.285 -2.208 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.31 177.019 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -77.22 134.87 38.49 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.579 -178.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -87.61 -179.74 6.37 Favored 'General case' 0 C--N 1.292 -1.917 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 175.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.3 m -64.65 -29.8 70.8 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 176.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -91.66 -8.96 45.63 Favored 'General case' 0 CA--C 1.548 0.891 0 CA-C-O 121.661 0.743 . . . . 0.0 109.975 177.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 106.51 -100.07 1.57 Allowed Glycine 0 N--CA 1.44 -1.038 0 C-N-CA 121.068 -0.586 . . . . 0.0 113.02 177.594 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.509 ' HG ' ' H ' ' B' ' 18' ' ' GLY . 17.7 tp -98.85 -173.28 2.48 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -177.255 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . 0.509 ' H ' ' HG ' ' B' ' 17' ' ' LEU . . . -164.91 58.18 0.26 Allowed Glycine 0 N--CA 1.435 -1.371 0 C-N-CA 120.262 -0.971 . . . . 0.0 112.688 177.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . 0.453 HG21 ' HB1' ' B' ' 48' ' ' ALA . 5.7 pt -162.93 177.46 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.487 -1.473 0 C-N-CA 124.662 1.185 . . . . 0.0 108.228 -179.134 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.2 m -138.83 147.25 42.25 Favored 'General case' 0 C--N 1.262 -3.21 0 N-CA-C 105.522 -2.029 . . . . 0.0 105.522 174.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 9.3 pt -114.85 167.17 7.72 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.827 0 O-C-N 123.36 0.412 . . . . 0.0 109.931 -178.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 10.1 tp -142.82 135.81 26.06 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -90.12 110.31 3.75 Favored Glycine 0 N--CA 1.435 -1.392 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.615 -178.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 89.1 mtp -130.05 -178.85 4.91 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 177.252 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 118.84 145.73 7.78 Favored Glycine 0 C--N 1.302 -1.338 0 C-N-CA 120.318 -0.944 . . . . 0.0 113.003 176.268 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -166.98 166.17 15.49 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 176.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 143.28 -138.4 8.19 Favored Glycine 0 N--CA 1.438 -1.207 0 C-N-CA 120.803 -0.713 . . . . 0.0 111.542 177.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.35 89.28 2.09 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 177.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.478 ' O ' ' HB3' ' B' ' 33' ' ' GLU . 30.6 t70 -71.56 -39.23 70.77 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 121.521 0.676 . . . . 0.0 112.342 -175.823 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 23.5 ptp -85.58 -8.4 58.3 Favored 'General case' 0 C--N 1.272 -2.793 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.345 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -104.8 -51.46 0.9 Allowed Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 120.801 -0.714 . . . . 0.0 113.395 -179.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 77.9 mt -119.25 -35.49 3.59 Favored 'General case' 0 C--O 1.211 -0.958 0 O-C-N 122.62 -0.341 . . . . 0.0 111.416 -174.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . 0.478 ' HB3' ' O ' ' B' ' 29' ' ' ASP . 11.3 pt-20 50.98 30.12 5.05 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 126.138 1.775 . . . . 0.0 112.254 -178.492 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . 0.403 ' HA ' ' O ' ' B' ' 69' ' ' VAL . 0.1 OUTLIER -70.83 103.03 2.49 Favored 'General case' 0 N--CA 1.425 -1.685 0 CA-C-O 122.614 1.197 . . . . 0.0 110.734 -177.426 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 91.8 mt -97.48 151.8 19.63 Favored 'General case' 0 C--N 1.284 -2.24 0 CA-C-N 114.655 -1.157 . . . . 0.0 108.583 176.703 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -112.12 95.17 0.78 Allowed Glycine 0 N--CA 1.398 -3.843 0 C-N-CA 120.63 -0.795 . . . . 0.0 111.467 -176.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 30.8 mm -86.99 86.01 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.824 0 N-CA-C 106.428 -1.693 . . . . 0.0 106.428 172.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -84.1 166.85 17.31 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 114.335 -1.302 . . . . 0.0 108.727 -175.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.1 t -79.67 133.05 30.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 175.084 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -95.41 -41.76 8.83 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 120.932 0.396 . . . . 0.0 110.008 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -156.88 163.03 39.63 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -179.603 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 21.9 t -118.62 108.69 24.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 177.255 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 43' ' ' THR . . . . . 0.43 ' O ' ' HB2' ' B' ' 49' ' ' HIS . 24.3 m -64.92 123.68 20.05 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 123.422 0.689 . . . . 0.0 111.088 -176.188 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . 0.424 ' HG2' ' CE1' ' B' ' 49' ' ' HIS . 32.8 mt-10 -67.72 -33.7 75.4 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 124.588 1.155 . . . . 0.0 109.839 -175.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.46 16.82 47.36 Favored Glycine 0 N--CA 1.431 -1.633 0 CA-C-N 114.761 -1.108 . . . . 0.0 112.114 178.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -127.07 174.75 18.23 Favored Glycine 0 N--CA 1.405 -3.422 0 C-N-CA 120.81 -0.71 . . . . 0.0 113.464 -178.648 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -56.84 -54.84 41.79 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -173.612 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . 0.453 ' HB1' HG21 ' B' ' 19' ' ' ILE . . . -61.13 -27.14 68.18 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 114.017 1.117 . . . . 0.0 114.017 -171.105 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . 0.43 ' HB2' ' O ' ' B' ' 43' ' ' THR . 2.4 t60 -78.98 -38.7 36.19 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -179.197 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 92.1 mtt180 -73.5 -38.82 65.23 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.373 -178.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -66.85 -67.1 0.48 Allowed 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.088 173.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.84 3.49 52.17 Favored Glycine 0 N--CA 1.439 -1.104 0 N-CA-C 114.722 0.649 . . . . 0.0 114.722 175.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -81.2 -45.94 15.59 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 118.489 1.144 . . . . 0.0 112.061 -179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.522 HD13 ' CE2' ' B' ' 89' ' ' PHE . 19.7 mt -78.56 127.89 38.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.142 174.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 50.7 mt-30 -110.92 167.07 10.52 Favored 'General case' 0 N--CA 1.436 -1.165 0 CA-C-O 121.07 0.462 . . . . 0.0 110.396 176.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.6 p -70.71 -2.1 2.42 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.704 0 N-CA-C 114.191 1.182 . . . . 0.0 114.191 -171.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -119.85 15.01 12.57 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.723 -1.236 . . . . 0.0 110.546 179.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -90.47 168.76 11.6 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.783 -178.2 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . 0.484 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 22.8 tp -133.23 132.59 41.66 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.716 -176.637 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 78.2 mt -86.06 99.54 11.55 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 177.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.601 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.3 t -83.52 -42.42 17.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 CA-C-O 121.461 0.648 . . . . 0.0 110.647 177.546 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . 0.523 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 15.9 pt-20 -159.67 158.53 31.63 Favored 'General case' 0 C--N 1.282 -2.332 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.546 175.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . 0.414 HG11 ' HB ' ' B' ' 66' ' ' THR . 4.0 p -100.74 -173.58 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.228 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . 0.403 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 22.8 t70 -51.49 -47.73 63.13 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 113.126 0.787 . . . . 0.0 113.126 -178.431 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -137.4 44.56 1.13 Allowed Glycine 0 C--N 1.314 -0.678 0 C-N-CA 119.362 -1.399 . . . . 0.0 114.207 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 66' ' ' THR . . . . . 0.414 ' HB ' HG11 ' B' ' 63' ' ' VAL . 94.9 m -161.31 119.43 2.38 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.027 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 67' ' ' SER . . . . . 0.523 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 21.2 m -97.92 132.48 43.46 Favored 'General case' 0 N--CA 1.431 -1.394 0 CA-C-O 121.075 0.464 . . . . 0.0 111.853 -176.486 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.601 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 42.4 mt -96.06 115.42 27.4 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.108 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' B' ' 34' ' ' LYS . 40.1 t -81.85 -23.51 9.78 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 174.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 145.75 75.76 0.02 OUTLIER Glycine 0 N--CA 1.424 -2.124 0 N-CA-C 108.871 -1.692 . . . . 0.0 108.871 -177.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 m -93.53 -178.32 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-N 115.554 -0.323 . . . . 0.0 110.557 -175.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 41.3 p -82.6 165.32 20.17 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 176.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.0 tt0 -63.15 -33.91 76.48 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.23 0.538 . . . . 0.0 109.596 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.3 m -66.28 -44.93 82.19 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.991 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -60.19 -48.2 82.75 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.49 ' O ' HG13 ' B' ' 79' ' ' VAL . . . -59.08 -44.2 91.87 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.122 178.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.4 -37.27 80.3 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-O 121.204 0.526 . . . . 0.0 110.324 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 36.0 m -66.84 -35.96 81.24 Favored 'General case' 0 N--CA 1.435 -1.182 0 CA-C-N 115.366 -0.834 . . . . 0.0 111.344 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.49 HG13 ' O ' ' B' ' 76' ' ' ALA . 4.2 p -75.66 -34.17 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 C-N-CA 119.558 -0.857 . . . . 0.0 109.81 -174.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 25.0 mt -64.82 -42.29 95.09 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.261 -0.882 . . . . 0.0 111.167 176.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 39.1 mtp180 -77.64 -30.16 52.03 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.819 0.342 . . . . 0.0 111.922 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 6.5 t30 -74.8 -27.09 60.16 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 83' ' ' THR . . . . . . . . . . . . . 16.3 p -71.88 158.69 35.59 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 -178.114 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -66.74 -168.04 0.06 Allowed 'General case' 0 C--O 1.251 1.163 0 C-N-CA 124.708 1.203 . . . . 0.0 112.933 -178.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.12 -49.95 64.7 Favored Glycine 0 N--CA 1.431 -1.689 0 CA-C-N 114.644 -1.162 . . . . 0.0 112.828 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 23.0 ttp180 -135.04 121.65 20.7 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.981 -0.688 . . . . 0.0 111.961 -177.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . 0.403 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 15.8 m -138.24 149.56 24.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 114.879 -1.055 . . . . 0.0 109.383 -179.361 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -94.6 155.95 16.66 Favored 'General case' 0 C--N 1.295 -1.796 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.755 174.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.522 ' CE2' HD13 ' B' ' 54' ' ' ILE . 9.1 m-85 -126.99 162.33 26.25 Favored 'General case' 0 C--N 1.276 -2.63 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 176.689 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.482 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 24.5 mmt -111.58 113.1 25.28 Favored 'General case' 0 C--N 1.28 -2.448 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.597 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.484 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -97.21 129.23 47.58 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -179.331 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -109.45 116.28 4.5 Favored Glycine 0 CA--C 1.468 -2.858 0 C-N-CA 120.19 -1.005 . . . . 0.0 112.079 -178.792 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 8.7 tpp180 -83.86 118.25 23.84 Favored 'General case' 0 C--N 1.284 -2.257 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 176.023 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -105.15 79.61 1.51 Allowed 'General case' 0 N--CA 1.407 -2.605 0 C-N-CA 119.002 -1.079 . . . . 0.0 108.17 171.595 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 30.0 ttt180 -62.78 -58.1 18.44 Favored Pre-proline 0 CA--C 1.562 1.41 0 CA-C-N 114.602 -1.181 . . . . 0.0 110.164 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -77.05 145.59 24.85 Favored 'Trans proline' 0 C--N 1.387 2.602 0 C-N-CA 122.169 1.912 . . . . 0.0 112.898 178.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 154.11 43.86 0.02 OUTLIER Glycine 0 C--N 1.288 -2.136 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 -178.406 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 55.0 mm-40 54.53 23.5 4.64 Favored 'General case' 0 N--CA 1.436 -1.151 0 N-CA-C 115.385 1.624 . . . . 0.0 115.385 -173.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 10.1 tt0 -74.35 -43.71 55.42 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 104.988 -2.227 . . . . 0.0 104.988 170.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 43.7 p 56.49 156.97 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 127.202 2.201 . . . . 0.0 116.448 175.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -90.64 21.88 3.79 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.98 -177.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 21.6 t -83.28 137.06 21.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -106.52 -73.42 0.69 Allowed 'General case' 0 C--N 1.311 -1.107 0 CA-C-O 120.813 0.34 . . . . 0.0 110.855 178.049 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 95.8 mt-30 -123.68 74.83 1.29 Allowed 'General case' 0 C--N 1.309 -1.171 0 N-CA-C 112.906 0.706 . . . . 0.0 112.906 -178.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -140.67 170.07 16.45 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 174.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 1.7 mp -77.88 -57.86 5.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 174.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 4.3 tp60 -166.39 143.68 5.15 Favored 'General case' 0 N--CA 1.421 -1.909 0 CA-C-N 114.233 -1.349 . . . . 0.0 107.834 173.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -108.53 68.32 0.69 Allowed 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 122.536 1.16 . . . . 0.0 108.915 176.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 13.4 t -83.66 -26.78 29.58 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 114.547 -1.206 . . . . 0.0 109.245 -177.007 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 92.3 mt -86.89 30.76 0.73 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.28 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -59.04 -42.59 90.6 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.376 178.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 58.25 33.27 22.99 Favored 'General case' 0 C--N 1.354 0.765 0 CA-C-O 122.118 0.961 . . . . 0.0 111.744 176.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 20.6 mm-40 . . . . . 0 N--CA 1.435 -1.192 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.653 177.131 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.499 -0.957 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 28.6 t-80 -83.21 -44.31 15.15 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 3' ' ' MET . . . . . 0.425 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 65.6 mtt -110.11 109.28 19.76 Favored 'General case' 0 N--CA 1.424 -1.752 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 172.393 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -77.47 103.98 7.73 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -176.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -78.05 91.39 4.27 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 124.106 0.878 . . . . 0.0 108.822 176.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -113.22 142.99 28.37 Favored Pre-proline 0 C--N 1.281 -2.371 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.646 176.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . 0.477 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 34.2 Cg_endo -75.01 128.84 11.79 Favored 'Trans proline' 0 N--CA 1.438 -1.791 0 C-N-CA 121.943 1.762 . . . . 0.0 112.843 179.327 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 72.0 t -113.41 122.78 68.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . 0.533 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 36.5 tt0 -106.86 132.15 53.15 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -174.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.423 HD22 ' HA ' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -127.4 158.27 37.75 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 177.548 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -134.41 138.51 44.88 Favored 'General case' 0 C--N 1.279 -2.481 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 176.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 34.7 mmtp -68.54 152.97 44.63 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 114.876 1.435 . . . . 0.0 114.876 -174.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -92.76 177.33 6.13 Favored 'General case' 0 C--O 1.247 0.922 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 173.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 13.2 p -69.62 -28.76 66.19 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 118.327 0.512 . . . . 0.0 110.356 178.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -80.24 -53.04 7.03 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 173.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 147.92 -96.98 0.18 Allowed Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.34 179.091 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 96.3 mt -128.36 175.48 8.46 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 122.928 0.491 . . . . 0.0 109.996 -178.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . 0.427 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -156.38 69.05 0.28 Allowed Glycine 0 CA--C 1.482 -1.977 0 N-CA-C 108.254 -1.938 . . . . 0.0 108.254 179.166 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . 0.457 HG23 ' HB ' ' B' ' 42' ' ' VAL . 12.7 pt -145.22 -179.09 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.281 -2.393 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 -177.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' SER . . . . . 0.443 ' HB2' HG22 ' B' ' 41' ' ' THR . 28.5 m -154.88 155.46 34.38 Favored 'General case' 0 C--N 1.253 -3.627 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 174.829 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . 0.423 ' HB ' HG21 ' B' ' 37' ' ' ILE . 7.9 pt -127.58 154.5 38.07 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.892 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -129.26 132.13 67.08 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -179.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.78 103.18 2.28 Favored Glycine 0 N--CA 1.423 -2.231 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.192 -176.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 72.6 mtm -127.57 140.32 52.19 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-O 121.085 0.469 . . . . 0.0 110.672 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.95 -178.64 43.3 Favored Glycine 0 N--CA 1.425 -2.052 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 -178.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -125.15 24.82 7.37 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.992 0.901 . . . . 0.0 109.075 179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 86.6 -72.91 2.56 Favored Glycine 0 N--CA 1.436 -1.345 0 CA-C-N 114.572 -1.194 . . . . 0.0 111.442 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . 50.43 59.23 4.72 Favored 'General case' 0 C--O 1.244 0.773 0 CA-C-O 122.274 1.035 . . . . 0.0 110.739 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' B' ' 33' ' ' GLU . 6.0 p-10 -63.09 -26.3 68.77 Favored 'General case' 0 N--CA 1.422 -1.856 0 CA-C-N 113.937 -1.483 . . . . 0.0 112.922 -174.136 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 26.6 ptm -66.08 -26.57 67.55 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.817 -178.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.449 ' HA3' ' HE3' ' B' ' 34' ' ' LYS . . . -106.81 53.43 0.62 Allowed Glycine 0 N--CA 1.425 -2.076 0 C-N-CA 120.509 -0.853 . . . . 0.0 111.156 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 28.8 mt 67.86 29.74 6.52 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 124.284 1.034 . . . . 0.0 110.89 176.254 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . 0.43 ' HA ' ' HA ' ' B' ' 29' ' ' ASP 0.271 13.6 pt-20 46.11 64.93 1.3 Allowed 'General case' 0 N--CA 1.475 0.792 0 CA-C-O 122.791 1.281 . . . . 0.0 111.656 -174.698 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . 0.449 ' HE3' ' HA3' ' B' ' 31' ' ' GLY . 19.0 ptpt -78.99 110.31 14.09 Favored 'General case' 0 N--CA 1.427 -1.605 0 CA-C-N 113.171 -1.831 . . . . 0.0 111.806 -173.103 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 83.6 mt -115.07 130.12 56.86 Favored 'General case' 0 C--N 1.297 -1.686 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 176.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -87.64 91.67 1.75 Allowed Glycine 0 N--CA 1.41 -3.063 0 C-N-CA 120.365 -0.921 . . . . 0.0 111.982 -177.146 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . 0.423 HG21 ' HB ' ' B' ' 21' ' ' ILE . 20.1 mm -87.38 84.91 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.549 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 173.467 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -84.71 165.01 18.22 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 114.636 -1.165 . . . . 0.0 108.695 -178.031 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 56.9 t -75.8 133.12 31.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 176.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -92.71 -46.4 7.59 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.622 -177.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 41' ' ' THR . . . . . 0.443 HG22 ' HB2' ' B' ' 20' ' ' SER . 6.3 t -155.14 174.58 15.0 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.457 ' HB ' HG23 ' B' ' 19' ' ' ILE . 2.4 p -158.81 98.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 C-N-CA 124.793 1.237 . . . . 0.0 109.201 -177.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 26.5 m -87.76 143.27 27.24 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 113.915 -1.493 . . . . 0.0 110.32 -174.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -56.78 -19.89 19.48 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 124.593 1.157 . . . . 0.0 112.744 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.98 -12.44 79.14 Favored Glycine 0 N--CA 1.439 -1.102 0 CA-C-N 116.11 -0.496 . . . . 0.0 113.363 -178.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.427 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -116.5 169.0 12.87 Favored Glycine 0 N--CA 1.422 -2.3 0 C-N-CA 119.438 -1.363 . . . . 0.0 113.328 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -56.77 -41.25 77.31 Favored 'General case' 0 C--O 1.19 -2.066 0 CA-C-N 113.977 -1.111 . . . . 0.0 113.568 -175.078 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . 0.423 ' HA ' HD22 ' B' ' 10' ' ' LEU . . . -59.87 -35.94 75.84 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -173.516 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 4.9 t60 -81.45 -38.76 25.91 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -179.574 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -69.29 -46.17 67.82 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.07 -178.411 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -70.89 -36.01 72.58 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.81 47.68 7.05 Favored Glycine 0 CA--C 1.494 -1.276 0 CA-C-N 114.102 -1.408 . . . . 0.0 112.463 173.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.533 ' HG3' ' O ' ' B' ' 9' ' ' GLU . 35.2 mmt180 -116.14 -60.78 1.82 Allowed 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -177.244 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.458 HD11 ' CE2' ' B' ' 89' ' ' PHE . 43.9 mt -77.28 125.73 37.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 C-N-CA 120.255 -0.578 . . . . 0.0 109.735 178.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 65.4 mt-30 -99.74 159.04 15.35 Favored 'General case' 0 C--N 1.287 -2.144 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.435 HG21 ' HA ' ' B' ' 41' ' ' THR . 11.8 p -70.03 -4.83 4.43 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.699 0 CA-C-O 121.804 0.812 . . . . 0.0 112.027 -177.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -113.15 10.14 18.6 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.451 -0.78 . . . . 0.0 110.824 -177.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 87.9 m-20 -85.01 175.31 9.12 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.293 0.568 . . . . 0.0 112.379 -177.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 26.6 tp -143.05 130.97 21.61 Favored 'General case' 0 C--N 1.315 -0.908 0 C-N-CA 123.894 0.878 . . . . 0.0 109.752 -177.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 71.7 mt -87.49 98.12 11.21 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 178.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.615 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 36.6 t -81.97 -41.41 18.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 CA-C-O 121.941 0.877 . . . . 0.0 110.477 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -157.26 158.95 37.08 Favored 'General case' 0 C--N 1.275 -2.633 0 CA-C-N 114.858 -1.065 . . . . 0.0 109.763 173.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . 0.457 HG13 ' O ' ' B' ' 66' ' ' THR . 3.3 p -101.57 -173.89 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 105.825 -1.917 . . . . 0.0 105.825 178.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . 0.436 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.2 t70 -55.34 -58.68 6.74 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 113.092 0.775 . . . . 0.0 113.092 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -119.23 33.43 4.7 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 119.818 -1.182 . . . . 0.0 114.535 -176.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 66' ' ' THR . . . . . 0.457 ' O ' HG13 ' B' ' 63' ' ' VAL . 18.8 m -160.71 128.53 4.43 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 179.002 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 39.0 m -93.91 136.77 33.85 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.899 -0.501 . . . . 0.0 111.092 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.615 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 17.2 mt -93.34 -77.39 0.45 Allowed 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.373 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 61.4 t 70.49 -29.4 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 125.34 1.456 . . . . 0.0 111.181 -175.206 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . 0.488 ' H ' ' C ' ' B' ' 68' ' ' LEU . . . 164.59 89.29 0.07 OUTLIER Glycine 1 N--CA 1.395 -4.085 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -177.226 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 33.6 m -118.42 -178.74 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.282 -2.356 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 175.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 36.7 p -79.92 161.8 25.33 Favored 'General case' 0 C--N 1.292 -1.931 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 177.226 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -60.42 -35.03 74.84 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 121.287 0.565 . . . . 0.0 110.129 -177.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 50.0 m -74.22 -36.44 63.94 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.831 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -63.25 -46.22 87.91 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.526 ' O ' HG11 ' B' ' 79' ' ' VAL . . . -63.01 -38.92 93.11 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.279 179.534 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.67 -38.33 88.98 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.489 0.661 . . . . 0.0 110.122 178.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 34.7 t -64.49 -39.28 93.5 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.956 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.526 HG11 ' O ' ' B' ' 76' ' ' ALA . 2.6 p -70.31 -27.94 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 121.947 0.879 . . . . 0.0 110.374 -172.047 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 55.8 mt -72.51 -6.6 44.99 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.376 178.672 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 67.6 mtt180 -116.88 -17.48 10.42 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-O 120.852 0.358 . . . . 0.0 111.948 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.9 m-20 -87.76 -8.36 56.11 Favored 'General case' 0 C--O 1.241 0.645 0 C-N-CA 123.308 0.643 . . . . 0.0 111.378 179.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.465 ' HB ' HG11 ' B' ' 87' ' ' VAL . 1.4 p -87.25 -175.16 5.18 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 113.873 1.064 . . . . 0.0 113.873 -178.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -77.34 -171.5 2.12 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.879 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -75.97 -38.27 36.1 Favored Glycine 0 N--CA 1.44 -1.067 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.927 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . 0.402 ' HA ' ' O ' ' B' ' 10' ' ' LEU . 13.0 ttp180 -127.69 118.49 23.92 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.397 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . 0.465 HG11 ' HB ' ' B' ' 83' ' ' THR . 15.6 m -135.5 154.82 35.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -175.165 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -109.66 126.19 53.4 Favored 'General case' 0 CA--C 1.49 -1.345 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.115 179.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.477 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 3.1 m-85 -105.58 155.05 19.58 Favored 'General case' 0 C--N 1.28 -2.45 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 178.023 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.416 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 19.6 mmt -98.74 109.69 22.4 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 173.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.463 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.5 mp -98.06 119.92 46.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.943 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.53 111.89 4.07 Favored Glycine 0 CA--C 1.466 -3.007 0 N-CA-C 108.726 -1.75 . . . . 0.0 108.726 175.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . 0.425 ' O ' ' HA ' ' B' ' 3' ' ' MET . 8.3 tpp180 -68.63 114.43 7.0 Favored 'General case' 0 C--N 1.285 -2.224 0 CA-C-N 114.637 -0.781 . . . . 0.0 111.679 -178.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -79.74 82.04 5.9 Favored 'General case' 0 N--CA 1.413 -2.316 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 170.008 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 24.2 ttm180 -59.27 -57.95 23.16 Favored Pre-proline 0 CA--C 1.562 1.436 0 CA-C-N 115.193 -0.912 . . . . 0.0 112.208 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -74.54 166.62 28.99 Favored 'Trans proline' 0 C--N 1.358 1.046 0 C-N-CA 122.056 1.837 . . . . 0.0 112.097 177.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -132.58 19.99 4.43 Favored Glycine 0 C--N 1.295 -1.716 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.13 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -87.08 -27.68 23.0 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 52.6 tp60 -84.89 -51.62 6.6 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-N 114.784 -1.098 . . . . 0.0 112.503 -170.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 73.2 m 58.77 -179.27 0.08 Allowed 'General case' 0 CA--C 1.558 1.277 0 C-N-CA 124.19 0.996 . . . . 0.0 112.217 -174.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -75.98 -45.93 32.21 Favored 'General case' 0 CA--C 1.495 -1.146 0 CA-C-O 122.895 1.331 . . . . 0.0 109.0 -178.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . 0.483 ' CG2' ' HG ' ' B' ' 105' ' ' LEU . 3.9 p -77.25 140.9 16.35 Favored 'Isoleucine or valine' 0 C--N 1.261 -3.243 0 CA-C-N 111.936 -2.393 . . . . 0.0 111.523 -175.631 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -98.52 -62.16 1.28 Allowed 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.612 177.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 21.5 tp60 -162.74 117.77 1.79 Allowed 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 179.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . 0.483 ' HG ' ' CG2' ' B' ' 102' ' ' VAL . 83.2 mt -114.35 110.68 20.28 Favored 'General case' 0 C--N 1.309 -1.158 0 C-N-CA 120.578 -0.449 . . . . 0.0 111.4 179.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 46.8 mm -81.84 -65.05 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 171.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 53.7 mt-30 -98.97 133.21 43.56 Favored 'General case' 0 N--CA 1.431 -1.412 0 N-CA-C 104.231 -2.507 . . . . 0.0 104.231 166.406 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -76.83 -77.94 0.13 Allowed 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 114.22 1.192 . . . . 0.0 114.22 -174.016 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 109' ' ' THR . . . . . 0.402 HG23 ' H ' ' B' ' 111' ' ' GLU . 15.1 t -81.96 -14.61 55.8 Favored 'General case' 0 C--N 1.282 -2.352 0 CA-C-N 115.235 -0.893 . . . . 0.0 111.553 -173.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 38.8 mt 69.82 16.3 7.82 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.812 0.845 . . . . 0.0 111.333 175.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . 0.402 ' H ' HG23 ' B' ' 109' ' ' THR . 9.3 tp10 -101.3 49.86 0.87 Allowed 'General case' 0 N--CA 1.433 -1.275 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -177.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 12.3 mm100 60.44 -102.09 0.13 Allowed 'General case' 0 C--O 1.246 0.883 0 CA-C-N 114.207 -1.36 . . . . 0.0 111.175 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 . . . . . 0 N--CA 1.423 -1.786 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 177.02 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.496 -1.145 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 56.5 t60 -68.43 -51.8 39.73 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 176.082 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 20.6 ptp -94.44 135.05 36.3 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 173.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . 0.535 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 17.1 mt-10 -89.85 100.09 12.97 Favored 'General case' 0 C--N 1.289 -2.037 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -177.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -91.4 89.94 7.47 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 175.021 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -119.14 143.88 34.97 Favored Pre-proline 0 C--N 1.29 -1.997 0 C-N-CA 120.736 -0.386 . . . . 0.0 111.946 178.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . 0.46 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 56.7 Cg_endo -75.15 139.49 23.97 Favored 'Trans proline' 0 N--CA 1.439 -1.716 0 C-N-CA 122.076 1.851 . . . . 0.0 111.73 176.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 90.5 t -128.33 123.34 59.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -179.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . 0.493 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 38.9 tt0 -103.24 129.6 50.24 Favored 'General case' 0 C--N 1.285 -2.196 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.196 -178.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . . . . . . . . . 2.0 mt -142.81 165.37 27.55 Favored 'General case' 0 CA--C 1.478 -1.812 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.812 175.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -135.58 164.67 27.3 Favored 'General case' 0 C--N 1.283 -2.324 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.726 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -82.38 163.14 21.89 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 121.616 0.722 . . . . 0.0 112.156 -179.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -111.44 -159.54 0.68 Allowed 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 104.12 -2.548 . . . . 0.0 104.12 173.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 22.8 t -75.17 -25.45 58.32 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 169.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -86.73 -60.83 1.88 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.977 176.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 122.84 75.45 0.32 Allowed Glycine 0 N--CA 1.439 -1.108 0 C-N-CA 120.223 -0.989 . . . . 0.0 112.143 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp 77.12 172.04 0.22 Allowed 'General case' 0 CA--C 1.507 -0.678 0 C-N-CA 124.576 1.15 . . . . 0.0 112.402 178.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -141.83 74.44 0.35 Allowed Glycine 0 CA--C 1.471 -2.675 0 N-CA-C 109.097 -1.601 . . . . 0.0 109.097 -178.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . 0.417 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 14.2 pt -157.51 -177.53 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 -178.673 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 24.0 t -149.08 142.31 25.05 Favored 'General case' 0 C--N 1.272 -2.793 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 176.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 20.6 pt -109.17 152.87 11.11 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -129.76 136.14 59.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.65 97.85 2.15 Favored Glycine 0 N--CA 1.434 -1.472 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.025 179.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 26.5 ptm -110.69 130.62 55.52 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 120.894 0.378 . . . . 0.0 110.025 -179.044 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -164.35 -133.41 1.49 Allowed Glycine 0 N--CA 1.431 -1.672 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.012 -178.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . 62.46 26.76 15.94 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.587 1.155 . . . . 0.0 111.021 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -117.04 -75.49 0.55 Allowed Glycine 0 N--CA 1.43 -1.752 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 179.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -109.9 90.21 3.24 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 121.474 0.654 . . . . 0.0 111.6 -178.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 19.5 p-10 -86.89 -35.25 19.09 Favored 'General case' 0 CA--C 1.491 -1.319 0 CA-C-O 122.249 1.023 . . . . 0.0 109.795 177.13 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 25.3 ptm -76.01 2.17 13.43 Favored 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 113.406 -1.725 . . . . 0.0 110.361 178.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -98.13 38.63 3.02 Favored Glycine 0 N--CA 1.421 -2.363 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 176.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 8.5 mp 73.01 27.53 2.05 Favored 'General case' 0 CA--C 1.502 -0.903 0 C-N-CA 123.732 0.813 . . . . 0.0 110.282 175.045 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . 0.695 ' O ' ' HA3' ' B' ' 70' ' ' GLY . 32.0 mt-10 56.25 32.25 19.98 Favored 'General case' 0 CA--C 1.504 -0.817 0 CA-C-N 115.22 -0.9 . . . . 0.0 113.377 -177.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . 0.426 ' HD3' ' O ' ' B' ' 69' ' ' VAL . 70.1 mmtt -67.86 88.55 0.26 Allowed 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 122.324 1.059 . . . . 0.0 110.18 176.255 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 20.2 tp -87.47 159.11 18.78 Favored 'General case' 0 N--CA 1.413 -2.286 0 CA-C-N 113.808 -1.542 . . . . 0.0 107.674 -178.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -110.49 89.5 0.55 Allowed Glycine 0 N--CA 1.398 -3.849 0 C-N-CA 119.99 -1.1 . . . . 0.0 111.982 -176.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 29.6 mm -90.21 78.4 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.212 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 171.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -86.05 167.63 14.83 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-N 113.911 -1.495 . . . . 0.0 109.137 -176.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 51.1 t -81.07 131.34 34.14 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 176.2 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 36.4 ttpt -91.9 -40.97 10.86 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.771 -175.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -156.63 162.73 39.84 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 -177.012 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.417 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 21.8 t -127.53 92.11 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 178.29 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 10.5 m -72.31 132.55 44.16 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 123.541 0.736 . . . . 0.0 111.672 -176.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -67.83 -3.52 9.83 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 123.886 0.874 . . . . 0.0 113.208 -179.163 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.1 3.23 85.72 Favored Glycine 0 N--CA 1.44 -1.098 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.133 -177.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -139.36 170.94 23.94 Favored Glycine 0 N--CA 1.407 -3.273 0 C-N-CA 119.862 -1.161 . . . . 0.0 113.556 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.94 -35.05 44.54 Favored 'General case' 0 C--O 1.195 -1.812 0 C-N-CA 126.235 1.814 . . . . 0.0 114.726 -174.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -64.63 -45.28 87.53 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 120.284 -0.566 . . . . 0.0 112.348 -174.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 5.1 t60 -73.44 -41.09 63.65 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 108.679 -0.859 . . . . 0.0 108.679 177.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -59.81 -42.76 94.2 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.71 -178.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . 0.574 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 9.7 t70 -78.19 -51.85 9.58 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.279 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.95 42.71 3.23 Favored Glycine 0 N--CA 1.434 -1.463 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.595 ' HA ' ' NE ' ' B' ' 53' ' ' ARG . 4.9 mmp_? -104.97 -82.77 0.51 Allowed 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -178.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.46 HD11 ' CE2' ' B' ' 89' ' ' PHE . 49.9 mt -61.28 122.94 13.1 Favored 'Isoleucine or valine' 0 C--O 1.244 0.785 0 C-N-CA 120.165 -0.614 . . . . 0.0 110.435 176.574 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . 0.411 ' HB2' ' OD1' ' B' ' 58' ' ' ASP . 48.0 mt-30 -100.81 173.45 6.5 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.845 0.355 . . . . 0.0 111.039 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.8 p -77.83 -1.97 4.36 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 CA-C-O 121.374 0.607 . . . . 0.0 112.388 -174.022 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -124.07 24.55 8.16 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-O 122.053 0.93 . . . . 0.0 109.584 -178.461 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . 0.411 ' OD1' ' HB2' ' B' ' 55' ' ' GLN . 11.1 m-20 -98.21 166.36 11.44 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 114.345 -1.298 . . . . 0.0 110.421 -177.411 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . 0.543 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 24.8 tp -140.39 133.35 29.27 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 123.423 0.689 . . . . 0.0 109.851 -177.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 71.1 mt -82.72 99.75 9.83 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 177.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.535 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.1 t -85.02 -40.81 15.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 122.0 0.905 . . . . 0.0 110.676 178.51 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . 0.411 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 10.2 pt-20 -155.51 154.25 31.51 Favored 'General case' 0 C--N 1.27 -2.883 0 CA-C-N 115.17 -0.923 . . . . 0.0 109.633 173.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . 0.416 HG11 ' HB ' ' B' ' 66' ' ' THR . 6.6 p -100.4 -171.86 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 N-CA-C 105.825 -1.917 . . . . 0.0 105.825 178.65 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 8.6 t70 -44.14 -55.21 4.95 Favored 'General case' 0 N--CA 1.482 1.125 0 C-N-CA 124.117 0.967 . . . . 0.0 112.959 177.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -136.21 43.39 1.24 Allowed Glycine 0 C--N 1.304 -1.234 0 C-N-CA 119.07 -1.538 . . . . 0.0 114.98 -179.214 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 66' ' ' THR . . . . . 0.416 ' HB ' HG11 ' B' ' 63' ' ' VAL . 88.5 m -155.09 123.5 5.98 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 117.558 0.679 . . . . 0.0 109.326 177.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 5.7 m -87.58 125.02 34.11 Favored 'General case' 0 N--CA 1.441 -0.909 0 C-N-CA 123.091 0.557 . . . . 0.0 109.782 -177.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.535 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 25.1 mt -90.38 99.54 12.55 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 122.21 1.005 . . . . 0.0 110.856 179.327 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . 0.426 ' O ' ' HD3' ' B' ' 34' ' ' LYS . 58.1 t -69.22 -33.07 56.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-N 114.759 -1.109 . . . . 0.0 108.046 175.189 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . 0.695 ' HA3' ' O ' ' B' ' 33' ' ' GLU . . . 149.35 66.46 0.01 OUTLIER Glycine 0 CA--C 1.468 -2.845 0 N-CA-C 108.901 -1.68 . . . . 0.0 108.901 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 29.8 m -83.06 171.97 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.878 0 CA-C-N 113.694 -1.253 . . . . 0.0 109.188 -177.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 25.4 p -77.91 163.79 25.7 Favored 'General case' 0 N--CA 1.412 -2.339 0 C-N-CA 121.042 -0.263 . . . . 0.0 110.465 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -59.74 -37.53 79.22 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.314 0.578 . . . . 0.0 109.899 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 32.9 t -65.23 -41.36 94.48 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.776 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -64.57 -48.1 76.25 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.589 ' O ' ' HG ' ' B' ' 80' ' ' LEU . . . -55.78 -43.29 76.63 Favored 'General case' 0 C--O 1.217 -0.642 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.772 178.794 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.62 -39.1 91.12 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.28 0.562 . . . . 0.0 111.033 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.1 t -72.17 -29.41 63.99 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.9 -177.099 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.443 HG12 ' O ' ' B' ' 76' ' ' ALA . 9.8 p -75.69 -33.85 27.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 -176.173 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . 0.589 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 70.2 mt -68.19 -12.02 60.24 Favored 'General case' 0 C--O 1.214 -0.794 0 CA-C-N 114.517 -1.22 . . . . 0.0 110.789 176.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 96.6 mtt180 -106.16 -5.78 19.05 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.467 0.651 . . . . 0.0 111.036 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 13.0 m-80 -96.95 -24.04 16.02 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.546 177.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.468 ' HB ' HG13 ' B' ' 87' ' ' VAL . 3.9 p -68.44 179.74 1.57 Allowed 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -178.132 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 66.3 mmtt -72.03 -170.33 0.58 Allowed 'General case' 0 C--O 1.239 0.514 0 C-N-CA 123.462 0.705 . . . . 0.0 110.921 176.045 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.95 -36.09 47.99 Favored Glycine 0 N--CA 1.445 -0.759 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.648 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 26.3 ttm180 -127.52 122.48 33.45 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . 0.486 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 13.6 m -133.75 150.14 31.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.085 0 CA-C-O 121.085 0.469 . . . . 0.0 111.051 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 69.6 mtp85 -108.36 118.63 37.28 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.459 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.46 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 1.3 m-85 -98.73 170.74 8.56 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -177.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.411 ' HB2' ' CG ' ' B' ' 62' ' ' GLU . 48.5 mtt -113.54 116.88 30.24 Favored 'General case' 0 CA--C 1.473 -1.992 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 167.535 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.543 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.3 mp -94.49 121.72 45.34 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 177.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . 0.535 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -112.67 96.45 0.83 Allowed Glycine 0 CA--C 1.461 -3.321 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 177.557 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . 0.512 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 36.6 ttm180 -96.51 120.36 36.67 Favored 'General case' 0 C--N 1.257 -3.435 0 CA-C-N 114.761 -0.719 . . . . 0.0 110.512 -176.077 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -85.6 79.03 9.51 Favored 'General case' 0 N--CA 1.423 -1.808 0 N-CA-C 106.529 -1.656 . . . . 0.0 106.529 170.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 12.5 ttm180 -57.89 -62.31 5.69 Favored Pre-proline 0 CA--C 1.551 1.003 0 CA-C-N 113.572 -1.649 . . . . 0.0 112.535 -179.166 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -61.14 144.91 99.29 Favored 'Trans proline' 0 C--N 1.371 1.715 0 C-N-CA 121.613 1.542 . . . . 0.0 111.331 179.321 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 129.36 -50.43 0.89 Allowed Glycine 0 N--CA 1.419 -2.491 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -176.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -75.69 -35.51 60.31 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.689 0.28 . . . . 0.0 111.142 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 18.7 tt0 -78.65 106.76 10.84 Favored 'General case' 0 N--CA 1.436 -1.139 0 CA-C-O 121.127 0.489 . . . . 0.0 111.339 -174.013 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 29.2 m -78.37 -178.07 5.55 Favored 'General case' 0 N--CA 1.426 -1.664 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 172.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 69.4 mm-40 -81.08 55.0 2.36 Favored 'General case' 0 C--N 1.306 -1.307 0 CA-C-O 121.963 0.887 . . . . 0.0 111.601 -178.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 25.3 m -95.24 112.34 27.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 CA-C-N 114.887 -1.051 . . . . 0.0 109.031 176.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -121.86 33.91 5.35 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 114.941 -1.027 . . . . 0.0 108.685 -176.418 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 5.6 tp60 79.49 117.34 0.06 Allowed 'General case' 0 CA--C 1.508 -0.669 0 C-N-CA 125.606 1.562 . . . . 0.0 110.403 -175.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 6.3 mp -87.17 -179.66 6.48 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.386 -175.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 1.7 mp -74.46 -56.26 9.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -138.3 125.05 20.98 Favored 'General case' 0 N--CA 1.429 -1.487 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 176.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 12.1 tp60 -87.0 92.9 9.2 Favored 'General case' 0 N--CA 1.434 -1.239 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 178.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 12.4 t -64.5 -17.67 64.08 Favored 'General case' 0 CA--C 1.551 0.982 0 N-CA-C 114.53 1.307 . . . . 0.0 114.53 -171.055 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 94.0 mt -108.56 14.06 24.85 Favored 'General case' 0 C--N 1.317 -0.844 0 O-C-N 121.923 -0.485 . . . . 0.0 110.895 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 63.1 -87.56 0.02 OUTLIER 'General case' 0 C--O 1.21 -0.974 0 C-N-CA 124.588 1.155 . . . . 0.0 110.592 -177.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 25.6 mt-30 -162.51 155.26 19.54 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 178.098 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 . . . . . 0 C--N 1.294 -1.826 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 178.406 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.488 -1.627 0 N-CA-C 110.465 -1.054 . . . . 0.0 110.465 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 66.45 -163.86 0.23 Allowed 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.145 0.978 . . . . 0.0 110.483 178.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 3' ' ' MET . . . . . 0.504 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 66.8 mtt -77.09 95.41 4.22 Favored 'General case' 0 CA--C 1.505 -0.765 0 CA-C-O 120.901 0.381 . . . . 0.0 110.734 178.777 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . 0.447 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 19.7 mt-10 -84.85 105.6 15.75 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -85.34 93.59 8.75 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 174.517 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -117.02 141.5 28.47 Favored Pre-proline 0 C--N 1.288 -2.068 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.196 179.398 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . 0.495 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 61.0 Cg_endo -79.32 137.79 13.57 Favored 'Trans proline' 0 N--CA 1.444 -1.411 0 C-N-CA 122.379 2.052 . . . . 0.0 112.984 178.413 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 79.0 t -125.61 142.19 43.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 N-CA-C 106.855 -1.535 . . . . 0.0 106.855 177.659 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -127.97 123.2 34.24 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 118.659 0.663 . . . . 0.0 110.708 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.442 ' O ' ' HD3' ' B' ' 86' ' ' ARG . 1.2 mt -113.7 163.94 14.35 Favored 'General case' 0 CA--C 1.486 -1.503 0 CA-C-O 121.589 0.709 . . . . 0.0 111.478 178.812 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -124.88 145.89 49.58 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 174.309 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -91.02 164.14 14.07 Favored 'General case' 0 N--CA 1.418 -2.026 0 CA-C-O 121.874 0.845 . . . . 0.0 110.36 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . 0.401 ' HB2' ' HB1' ' B' ' 47' ' ' ALA . 25.3 t70 -111.44 -179.41 3.71 Favored 'General case' 0 C--N 1.274 -2.683 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 178.073 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 16.1 m -69.54 -25.92 64.25 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 176.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 8.3 tp10 -85.89 1.71 48.85 Favored 'General case' 0 CA--C 1.548 0.876 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.443 178.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.45 -138.75 14.6 Favored Glycine 0 N--CA 1.437 -1.285 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.573 179.751 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 93.9 mt -95.54 -177.94 4.25 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 177.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -138.42 58.04 0.63 Allowed Glycine 0 CA--C 1.478 -2.23 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.453 -178.356 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . 0.506 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 7.0 pt -150.4 179.13 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 C-N-CA 123.52 0.728 . . . . 0.0 109.396 -177.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 20' ' ' SER . . . . . 0.41 ' HB2' HG22 ' B' ' 41' ' ' THR . 70.0 m -150.97 160.92 43.61 Favored 'General case' 0 C--N 1.269 -2.93 0 N-CA-C 105.14 -2.171 . . . . 0.0 105.14 175.673 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . 0.415 ' HB ' HG21 ' B' ' 37' ' ' ILE . 10.3 pt -130.73 159.96 42.32 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.621 0 CA-C-N 117.877 0.308 . . . . 0.0 110.226 -177.607 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.2 tp -136.5 135.86 48.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-O 120.985 0.421 . . . . 0.0 110.348 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -83.63 99.16 2.16 Favored Glycine 0 N--CA 1.437 -1.24 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.591 -178.082 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 24' ' ' MET . . . . . 0.418 ' HA ' ' HE3' ' B' ' 24' ' ' MET . 3.8 mmt -113.83 175.59 5.4 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.473 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.03 170.54 47.54 Favored Glycine 0 N--CA 1.435 -1.418 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 174.167 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . 0.41 ' HB2' ' HG3' ' B' ' 34' ' ' LYS . . . -123.96 164.96 18.26 Favored 'General case' 0 C--N 1.295 -1.775 0 CA-C-N 117.394 0.597 . . . . 0.0 109.879 179.759 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.79 -28.74 41.26 Favored Glycine 0 N--CA 1.439 -1.153 0 C-N-CA 120.93 -0.652 . . . . 0.0 113.428 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.14 54.88 0.19 Allowed 'General case' 0 N--CA 1.484 1.248 0 N-CA-C 114.311 1.226 . . . . 0.0 114.311 -175.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.45 ' HA ' ' HA ' ' B' ' 33' ' ' GLU . 16.6 t70 -73.97 -33.26 63.81 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.659 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 13.0 ptp -60.6 -34.41 74.17 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 114.451 -1.25 . . . . 0.0 111.18 -177.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -105.88 -49.81 0.93 Allowed Glycine 0 N--CA 1.421 -2.327 0 C-N-CA 120.232 -0.985 . . . . 0.0 114.078 -175.199 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 93.9 mt -119.02 -10.56 9.81 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 114.323 1.231 . . . . 0.0 114.323 -171.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . 0.45 ' HA ' ' HA ' ' B' ' 29' ' ' ASP . 48.0 mt-10 52.13 41.69 30.19 Favored 'General case' 0 N--CA 1.481 1.099 0 CA-C-O 122.494 1.14 . . . . 0.0 108.436 -176.397 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . 0.41 ' HG3' ' HB2' ' B' ' 26' ' ' ALA . 21.8 ptmt -90.23 172.45 8.78 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-N 114.147 -1.388 . . . . 0.0 114.464 -167.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 94.7 mt -106.93 161.81 14.38 Favored 'General case' 0 N--CA 1.427 -1.588 0 CA-C-N 113.504 -1.68 . . . . 0.0 107.627 176.094 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -124.69 102.8 0.71 Allowed Glycine 0 N--CA 1.414 -2.803 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 -178.301 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . 0.415 HG21 ' HB ' ' B' ' 21' ' ' ILE . 23.7 mm -88.18 88.84 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 178.297 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -83.9 163.46 20.03 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.689 -1.141 . . . . 0.0 109.342 -178.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 65.8 t -71.49 130.99 35.09 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 174.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -90.31 -48.73 6.96 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.42 -177.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 41' ' ' THR . . . . . 0.41 HG22 ' HB2' ' B' ' 20' ' ' SER . 0.6 OUTLIER -150.05 163.86 37.04 Favored 'General case' 0 N--CA 1.428 -1.529 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -177.875 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.506 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.0 p -139.01 93.7 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 CA-C-O 122.693 1.235 . . . . 0.0 109.29 178.63 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 10.3 m -75.6 130.91 39.55 Favored 'General case' 0 N--CA 1.44 -0.974 0 CA-C-N 113.443 -1.708 . . . . 0.0 112.72 -172.44 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -57.93 -24.12 56.45 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 124.22 1.008 . . . . 0.0 112.901 179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.47 -1.26 81.67 Favored Glycine 0 N--CA 1.436 -1.313 0 CA-C-N 115.97 -0.559 . . . . 0.0 113.465 -178.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -122.28 170.23 15.08 Favored Glycine 0 N--CA 1.421 -2.354 0 C-N-CA 120.229 -0.986 . . . . 0.0 112.733 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . 0.401 ' HB1' ' HB2' ' B' ' 13' ' ' ASP . . . -59.94 -39.41 85.45 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 114.261 1.208 . . . . 0.0 114.261 -173.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -64.34 -39.82 94.65 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -173.003 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -72.36 -44.53 62.44 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.509 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 17.2 mtp180 -62.24 -45.49 93.1 Favored 'General case' 0 CA--C 1.511 -0.536 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.188 -177.047 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . 0.49 ' OD2' ' HD2' ' B' ' 53' ' ' ARG . 19.1 t70 -65.54 -51.4 60.2 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 176.692 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 95.04 39.48 4.56 Favored Glycine 0 CA--C 1.478 -2.278 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.548 ' HA ' ' NE ' ' B' ' 53' ' ' ARG . 0.0 OUTLIER -99.66 -73.18 0.64 Allowed 'General case' 0 N--CA 1.419 -2.023 0 CA-C-N 114.221 -0.989 . . . . 0.0 110.483 -170.965 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.553 HD13 ' CE2' ' B' ' 89' ' ' PHE . 47.1 mt -82.78 125.1 39.95 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 175.725 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . 0.499 ' HG2' ' OD2' ' B' ' 58' ' ' ASP . 24.2 pt20 -100.42 169.52 9.04 Favored 'General case' 0 C--N 1.309 -1.196 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -178.26 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.1 p -66.82 -2.28 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.507 0 C-N-CA 123.964 0.906 . . . . 0.0 113.361 -174.182 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -127.27 19.39 6.93 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.044 -1.035 . . . . 0.0 110.769 -178.349 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . 0.499 ' OD2' ' HG2' ' B' ' 55' ' ' GLN . 80.8 m-20 -84.66 168.24 15.46 Favored 'General case' 0 C--N 1.312 -1.038 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.595 176.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . 0.43 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 28.6 tp -136.06 127.45 28.48 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.393 -176.303 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 82.5 mt -81.73 90.91 6.39 Favored 'General case' 0 N--CA 1.434 -1.236 0 CA-C-O 121.534 0.683 . . . . 0.0 109.875 178.401 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.653 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 10.9 t -74.25 -39.6 49.56 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.126 175.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . 0.463 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 11.9 pt-20 -164.56 159.66 19.42 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.862 171.009 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . 0.441 HG13 ' HB ' ' B' ' 66' ' ' THR . 3.0 p -96.95 178.19 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . 0.516 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 19.9 t70 -42.59 -54.34 4.01 Favored 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 125.409 1.484 . . . . 0.0 113.762 -176.185 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -132.56 43.85 1.25 Allowed Glycine 0 C--N 1.304 -1.232 0 C-N-CA 119.581 -1.295 . . . . 0.0 113.682 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 66' ' ' THR . . . . . 0.441 ' HB ' HG13 ' B' ' 63' ' ' VAL . 51.6 m -157.43 114.34 2.99 Favored 'General case' 0 C--O 1.247 0.923 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 175.867 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 67' ' ' SER . . . . . 0.463 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 44.6 m -81.99 111.65 18.36 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 112.476 0.547 . . . . 0.0 112.476 -177.177 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.653 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 44.2 mt -79.52 110.48 14.88 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.887 176.496 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 14.7 p -75.84 -24.98 16.98 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 177.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 142.54 64.04 0.03 OUTLIER Glycine 0 CA--C 1.484 -1.87 0 N-CA-C 108.928 -1.669 . . . . 0.0 108.928 -177.172 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.9 m -82.26 -178.59 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 114.366 -0.917 . . . . 0.0 110.406 -176.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 40.4 p -82.89 166.29 19.04 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 120.926 0.393 . . . . 0.0 110.93 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.7 tt0 -59.55 -42.89 93.4 Favored 'General case' 0 C--N 1.324 -0.539 0 C-N-CA 123.237 0.615 . . . . 0.0 110.168 -179.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 23.2 t -66.49 -38.96 88.41 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.247 -178.632 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -63.13 -50.22 71.33 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.547 ' O ' HG13 ' B' ' 79' ' ' VAL . . . -61.3 -37.59 83.75 Favored 'General case' 0 CA--C 1.539 0.526 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.261 178.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.34 -30.54 71.24 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.657 0.741 . . . . 0.0 110.502 177.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.4 m -82.36 -27.48 32.12 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.521 -178.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.547 HG13 ' O ' ' B' ' 76' ' ' ALA . 3.9 p -72.03 -31.34 39.88 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.453 0 CA-C-O 121.396 0.617 . . . . 0.0 109.56 -176.126 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 19.4 mt -67.12 -17.35 64.82 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.918 -1.037 . . . . 0.0 111.322 176.519 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 22.1 mtm180 -100.72 -7.9 23.34 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-O 121.292 0.568 . . . . 0.0 110.31 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -89.99 -15.01 32.78 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 121.744 0.783 . . . . 0.0 109.655 176.255 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.453 ' HB ' HG11 ' B' ' 87' ' ' VAL . 9.3 p -92.06 167.2 12.24 Favored 'General case' 0 N--CA 1.412 -2.351 0 CA-C-N 115.261 -0.881 . . . . 0.0 111.855 179.191 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -76.88 -167.49 0.86 Allowed 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.277 -0.874 . . . . 0.0 112.876 177.242 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.26 -13.33 79.09 Favored Glycine 0 C--O 1.207 -1.555 0 CA-C-N 114.738 -1.119 . . . . 0.0 112.732 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . 0.442 ' HD3' ' O ' ' B' ' 10' ' ' LEU . 4.4 tpp180 -137.74 116.3 12.08 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 175.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . 0.516 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 6.3 m -149.12 157.59 6.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 122.969 0.508 . . . . 0.0 110.534 -179.06 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 77.0 mtm180 -96.18 170.18 9.44 Favored 'General case' 0 C--N 1.287 -2.145 0 CA-C-N 114.545 -1.207 . . . . 0.0 108.246 176.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.553 ' CE2' HD13 ' B' ' 54' ' ' ILE . 3.4 m-85 -150.9 162.16 41.32 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 105.163 -2.162 . . . . 0.0 105.163 175.397 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.535 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 66.4 mtm -115.54 114.45 24.99 Favored 'General case' 0 C--N 1.286 -2.195 0 CA-C-O 121.721 0.772 . . . . 0.0 110.139 170.548 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.43 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -97.38 127.33 49.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.73 0 CA-C-N 113.819 -1.537 . . . . 0.0 108.024 -176.566 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . 0.447 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -106.83 118.05 5.51 Favored Glycine 0 CA--C 1.466 -3.014 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 176.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . 0.504 ' O ' ' HA ' ' B' ' 3' ' ' MET . 9.9 tpp180 -72.94 91.23 1.53 Allowed 'General case' 0 C--N 1.288 -2.084 0 CA-C-N 115.067 -0.567 . . . . 0.0 110.416 178.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -85.2 73.53 10.59 Favored 'General case' 0 N--CA 1.424 -1.762 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 172.063 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . 0.445 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 36.6 ttt180 -81.09 -57.26 0.57 Allowed Pre-proline 0 N--CA 1.424 -1.762 0 CA-C-N 113.585 -1.643 . . . . 0.0 110.533 179.295 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . 0.445 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 60.5 Cg_endo -87.78 163.55 7.65 Favored 'Trans proline' 0 C--N 1.364 1.378 0 C-N-CA 122.289 1.993 . . . . 0.0 113.591 178.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -137.21 -75.75 0.07 OUTLIER Glycine 0 N--CA 1.423 -2.208 0 N-CA-C 108.457 -1.857 . . . . 0.0 108.457 174.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -82.35 68.8 8.93 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-O 122.479 1.133 . . . . 0.0 111.207 175.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 21.4 mm-40 -141.49 -160.36 1.07 Allowed 'General case' 0 N--CA 1.417 -2.085 0 C-N-CA 126.754 2.022 . . . . 0.0 106.473 176.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 7.4 m -62.32 158.5 17.21 Favored 'General case' 0 C--O 1.248 0.993 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 176.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 62.54 76.07 0.38 Allowed 'General case' 0 CA--C 1.506 -0.724 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 -170.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 15.8 m -71.9 86.86 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 114.44 -1.255 . . . . 0.0 112.871 -173.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -116.25 109.66 17.71 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.96 -176.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 8.1 tp-100 55.85 86.03 0.06 Allowed 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 124.404 1.082 . . . . 0.0 112.737 177.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -103.91 153.73 20.45 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 176.495 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 48.9 mm -81.02 -75.9 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 120.739 -0.384 . . . . 0.0 111.022 -177.726 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 56.87 101.24 0.02 OUTLIER 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.151 0.981 . . . . 0.0 111.537 -175.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 46.5 tt0 -96.61 1.87 51.66 Favored 'General case' 0 C--N 1.288 -2.096 0 CA-C-O 121.787 0.803 . . . . 0.0 109.554 -177.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 6.3 t -114.18 173.23 6.55 Favored 'General case' 0 C--N 1.305 -1.331 0 O-C-N 121.912 -0.492 . . . . 0.0 110.981 -176.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 95.5 mt 60.19 -94.78 0.05 OUTLIER 'General case' 0 N--CA 1.469 0.516 0 C-N-CA 125.14 1.376 . . . . 0.0 111.991 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -84.35 78.95 9.71 Favored 'General case' 0 N--CA 1.426 -1.658 0 CA-C-O 122.468 1.128 . . . . 0.0 108.969 175.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -105.95 22.57 15.4 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 114.234 -1.348 . . . . 0.0 110.653 -175.7 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 . . . . . 0 N--CA 1.432 -1.336 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 175.817 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.491 -1.461 0 N-CA-C 110.851 -0.899 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 76.52 156.27 0.17 Allowed 'General case' 0 C--O 1.246 0.918 0 C-N-CA 124.834 1.254 . . . . 0.0 111.777 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 68.5 mtm -73.86 129.71 38.44 Favored 'General case' 0 N--CA 1.424 -1.752 0 CA-C-N 115.236 -0.893 . . . . 0.0 109.161 178.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -76.03 102.12 5.53 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.528 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 0.6 OUTLIER -85.93 84.64 7.48 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.056 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -113.49 142.93 28.42 Favored Pre-proline 0 C--N 1.301 -1.522 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.906 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . 0.426 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 59.0 Cg_endo -80.0 131.59 9.03 Favored 'Trans proline' 0 N--CA 1.444 -1.391 0 C-N-CA 122.115 1.877 . . . . 0.0 113.396 179.238 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.405 ' CG1' ' HB3' ' B' ' 53' ' ' ARG . 75.9 t -119.08 141.23 39.97 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.998 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.502 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -129.82 139.67 51.18 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.447 HD12 HG13 ' B' ' 54' ' ' ILE . 1.0 OUTLIER -144.09 157.68 44.17 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.001 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.596 ' OE2' ' HD3' ' B' ' 86' ' ' ARG . 68.4 mm-40 -95.11 133.14 39.26 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 114.061 -1.427 . . . . 0.0 107.71 177.138 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.73 135.3 35.97 Favored 'General case' 0 N--CA 1.426 -1.664 0 C-N-CA 118.928 -1.109 . . . . 0.0 108.491 173.815 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -85.76 -178.12 6.54 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -174.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 18.9 m -68.93 -26.39 65.05 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.394 -175.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -81.91 -46.61 13.83 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 176.492 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 168.25 -85.07 0.09 OUTLIER Glycine 0 N--CA 1.423 -2.225 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 177.569 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 27.2 tp -164.15 108.28 0.97 Allowed 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 175.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . 0.442 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -67.7 59.22 0.33 Allowed Glycine 0 C--O 1.215 -1.077 0 C-N-CA 124.704 1.145 . . . . 0.0 115.581 -173.858 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . 0.446 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.8 pt -144.8 -178.42 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.267 -3.006 0 C-N-CA 125.565 1.546 . . . . 0.0 107.365 173.265 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.4 m -156.69 161.68 39.84 Favored 'General case' 0 C--N 1.272 -2.804 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.141 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 26.3 pt -124.43 153.52 31.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-N 117.99 0.359 . . . . 0.0 110.278 -179.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.2 tp -137.64 135.15 46.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.87 103.63 2.93 Favored Glycine 0 N--CA 1.421 -2.311 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.179 -178.616 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 25.9 mmt -106.45 116.46 31.96 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 176.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 135.85 151.9 6.26 Favored Glycine 0 N--CA 1.414 -2.827 0 C-N-CA 120.22 -0.991 . . . . 0.0 112.14 179.087 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -143.86 106.67 4.47 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 175.095 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -171.92 32.4 0.13 Allowed Glycine 0 N--CA 1.436 -1.333 0 C-N-CA 119.729 -1.224 . . . . 0.0 113.55 -177.489 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.54 75.19 10.19 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 176.774 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -106.24 13.95 28.17 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 114.468 -1.242 . . . . 0.0 109.671 -174.613 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 89.2 mtp 64.19 9.16 4.56 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.118 0.967 . . . . 0.0 112.959 -178.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -157.13 29.61 0.53 Allowed Glycine 0 C--O 1.217 -0.922 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 75.1 mt -146.24 -69.37 0.26 Allowed 'General case' 0 CA--C 1.486 -1.506 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 179.617 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . 0.288 6.2 pt-20 40.43 70.79 0.22 Allowed 'General case' 0 C--N 1.352 0.699 0 O-C-N 124.862 1.351 . . . . 0.0 114.421 175.124 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -132.74 85.66 2.24 Favored 'General case' 0 N--CA 1.431 -1.403 0 CA-C-N 113.857 -1.519 . . . . 0.0 107.089 176.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -111.52 129.24 56.12 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-N 114.883 -1.053 . . . . 0.0 108.78 -179.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -94.68 87.64 1.1 Allowed Glycine 0 N--CA 1.4 -3.764 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 20.7 mm -82.99 78.38 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.362 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 173.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -81.56 169.77 16.67 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 114.193 -1.367 . . . . 0.0 109.371 -172.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 79.4 t -75.69 128.98 37.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-O 121.372 0.606 . . . . 0.0 109.814 176.231 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 9.2 tmtm? -84.5 -54.42 4.76 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.11 -177.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 7.9 t -145.7 175.2 10.56 Favored 'General case' 0 N--CA 1.429 -1.508 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 179.182 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.5 p -154.88 96.4 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 -179.378 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 6.0 m -78.25 134.96 37.48 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 113.59 -1.641 . . . . 0.0 111.514 -170.621 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -61.87 -12.8 19.46 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.004 0.922 . . . . 0.0 113.238 178.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.18 -2.05 85.98 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 116.528 -0.306 . . . . 0.0 112.455 177.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.442 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -115.88 169.97 13.15 Favored Glycine 0 N--CA 1.418 -2.544 0 C-N-CA 120.291 -0.957 . . . . 0.0 111.823 179.169 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -69.28 -36.26 76.88 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 114.882 -0.659 . . . . 0.0 111.745 -175.088 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -57.03 -40.52 76.9 Favored 'General case' 0 CA--C 1.542 0.657 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -175.417 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -71.34 -42.46 68.51 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.213 0.53 . . . . 0.0 110.209 -179.081 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -75.09 -28.52 60.32 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.952 -175.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -80.75 -41.79 22.92 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.723 -177.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 83.78 43.24 7.33 Favored Glycine 0 C--N 1.309 -0.924 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.576 176.447 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.51 ' HE ' ' HA ' ' B' ' 53' ' ' ARG . 1.4 mmp_? -115.22 -69.72 0.84 Allowed 'General case' 0 C--N 1.301 -1.537 0 CA-C-O 119.091 -0.48 . . . . 0.0 110.848 178.847 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.583 HD11 ' CE2' ' B' ' 89' ' ' PHE . 77.7 mt -73.55 136.97 24.25 Favored 'Isoleucine or valine' 0 C--O 1.253 1.241 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 171.755 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 19.6 mt-30 -118.21 162.51 18.12 Favored 'General case' 0 C--N 1.289 -2.04 0 C-N-CA 123.909 0.884 . . . . 0.0 109.639 -174.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 9.7 p -73.6 -4.34 5.29 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-O 121.695 0.76 . . . . 0.0 111.075 -178.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -116.55 -5.49 11.68 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -176.144 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -91.39 -175.39 4.22 Favored 'General case' 0 C--O 1.247 0.958 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 -175.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . 0.507 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 35.6 tp -139.35 128.07 23.29 Favored 'General case' 0 N--CA 1.435 -1.212 0 CA-C-N 114.775 -1.102 . . . . 0.0 109.883 -174.043 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 57.0 mt -87.09 95.38 9.93 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.455 -0.942 . . . . 0.0 108.455 178.141 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.496 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 36.3 t -75.65 -43.07 41.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 CA-C-O 121.843 0.83 . . . . 0.0 111.301 -178.445 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . 0.41 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 12.2 pt-20 -146.63 160.95 41.53 Favored 'General case' 0 C--N 1.267 -2.997 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 173.511 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 4.8 p -113.18 -177.44 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -49.53 -45.73 47.75 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -176.369 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -132.29 31.33 3.03 Favored Glycine 0 CA--C 1.522 0.525 0 C-N-CA 119.687 -1.244 . . . . 0.0 114.607 -177.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 36.1 m -159.73 135.47 8.51 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.125 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 67' ' ' SER . . . . . 0.41 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 30.5 m -108.64 146.83 32.78 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.496 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 43.6 mt -104.31 115.05 29.7 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-O 120.938 0.399 . . . . 0.0 110.66 176.49 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 12.3 p -81.38 -20.39 10.95 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 N-CA-C 108.544 -0.909 . . . . 0.0 108.544 174.529 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 140.79 71.27 0.04 OUTLIER Glycine 0 CA--C 1.487 -1.672 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 -177.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.9 m -92.79 179.33 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 114.856 -0.672 . . . . 0.0 110.681 -175.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 43.5 p -82.86 165.28 19.93 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 177.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -59.45 -42.11 91.2 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.949 0.404 . . . . 0.0 110.108 179.37 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 48.5 m -66.5 -35.92 81.46 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.473 -179.413 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -66.61 -46.67 75.09 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . . . . . . . . . . . -60.52 -41.56 94.65 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.132 178.149 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.25 -34.96 75.99 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.072 178.268 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 24.5 m -76.9 -20.92 55.66 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.984 -179.018 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . . . . . . . . . 24.3 t -71.37 -57.11 8.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 16.6 mt -57.79 -18.59 22.74 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 125.325 1.45 . . . . 0.0 112.964 178.205 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 69.9 mtp180 -88.94 -18.09 28.2 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-O 121.279 0.561 . . . . 0.0 110.813 176.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -99.71 -6.19 27.54 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.729 0.776 . . . . 0.0 110.749 -176.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 83' ' ' THR . . . . . . . . . . . . . 18.9 p -82.41 165.96 19.81 Favored 'General case' 0 C--O 1.249 1.07 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 -178.482 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 57.7 mmtt -73.1 -167.58 0.41 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 124.594 1.158 . . . . 0.0 112.012 179.052 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.05 -34.23 55.87 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-N 115.509 -0.769 . . . . 0.0 112.516 -179.307 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . 0.596 ' HD3' ' OE2' ' B' ' 11' ' ' GLU . 45.5 ttp180 -134.69 124.69 25.68 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 175.621 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 13.7 m -137.13 160.32 36.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.915 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -102.15 163.11 12.42 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 176.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.583 ' CE2' HD11 ' B' ' 54' ' ' ILE . 4.9 m-85 -140.44 155.99 46.52 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 179.072 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.45 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 9.5 ttt -110.22 115.07 29.05 Favored 'General case' 0 C--N 1.275 -2.631 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 174.082 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.528 ' O ' ' HA ' ' B' ' 5' ' ' LEU . 1.4 mp -92.29 138.45 19.92 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.342 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -177.679 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.26 112.99 1.29 Allowed Glycine 0 CA--C 1.486 -1.742 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 175.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 18.1 tpp180 -148.87 125.92 11.34 Favored 'General case' 0 C--N 1.286 -2.156 0 CA-C-N 115.099 -0.55 . . . . 0.0 109.757 -179.126 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -92.36 78.03 5.09 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 173.484 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . 0.421 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 32.7 ttm180 -77.92 -59.96 0.73 Allowed Pre-proline 0 N--CA 1.421 -1.876 0 CA-C-N 114.331 -1.304 . . . . 0.0 110.056 178.078 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . 0.421 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 91.7 Cg_endo -84.46 169.53 10.94 Favored 'Trans proline' 0 C--N 1.363 1.338 0 C-N-CA 122.166 1.911 . . . . 0.0 111.285 177.567 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 99.14 18.57 24.0 Favored Glycine 0 N--CA 1.428 -1.855 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.476 -177.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -77.27 -58.57 3.2 Favored 'General case' 0 N--CA 1.442 -0.841 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 178.37 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 63.44 -71.71 0.06 Allowed 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.952 1.301 . . . . 0.0 112.597 178.322 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 100' ' ' SER . . . . . 0.449 ' C ' ' H ' ' B' ' 102' ' ' VAL . 23.1 t -98.32 -155.06 0.48 Allowed 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -80.89 20.76 0.74 Allowed 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 123.626 0.77 . . . . 0.0 109.798 177.302 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . 0.449 ' H ' ' C ' ' B' ' 100' ' ' SER . 58.8 t -111.47 146.14 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 124.611 1.164 . . . . 0.0 108.374 -174.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -142.94 -77.17 0.25 Allowed 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 173.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -107.0 134.3 50.35 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 177.219 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 83.8 mt -115.24 109.78 18.47 Favored 'General case' 0 C--N 1.296 -1.731 0 CA-C-O 120.984 0.421 . . . . 0.0 111.259 179.344 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 1.7 mp -88.72 -62.24 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.073 178.14 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 5.5 pm0 -99.86 127.6 46.02 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 176.399 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 48.1 mt-30 -127.17 111.85 14.46 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 -178.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 11.5 t -104.93 -32.57 8.71 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 120.386 -0.525 . . . . 0.0 111.21 -178.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 96.2 mt -138.24 88.67 2.33 Favored 'General case' 0 C--O 1.242 0.684 0 CA-C-O 121.064 0.459 . . . . 0.0 112.064 -177.551 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 8.3 tp10 -92.36 -29.77 16.15 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 168.105 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 4.6 pp0? -158.33 158.83 35.08 Favored 'General case' 0 N--CA 1.43 -1.432 0 CA-C-N 113.839 -1.528 . . . . 0.0 107.163 174.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 . . . . . 0 C--N 1.294 -1.845 0 CA-C-O 118.786 -0.626 . . . . 0.0 110.618 -173.911 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.514 0 CA-C-O 120.007 -0.33 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 56.8 m80 -70.75 -42.14 70.86 Favored 'General case' 0 CA--C 1.507 -0.695 0 N-CA-C 107.409 -1.33 . . . . 0.0 107.409 175.705 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 64.4 mtm -125.85 133.08 52.07 Favored 'General case' 0 N--CA 1.423 -1.779 0 N-CA-C 104.466 -2.42 . . . . 0.0 104.466 171.272 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . 0.494 ' HB2' ' HB3' ' B' ' 93' ' ' ARG . 12.0 mt-10 -94.3 93.36 7.68 Favored 'General case' 0 C--N 1.289 -2.036 0 C-N-CA 118.46 -1.296 . . . . 0.0 110.4 -175.581 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -82.52 95.85 7.85 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 177.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 7.1 p90 -119.46 144.33 36.41 Favored Pre-proline 0 C--N 1.279 -2.48 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.128 176.575 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . 0.579 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 30.4 Cg_endo -72.87 129.46 14.39 Favored 'Trans proline' 0 N--CA 1.432 -2.099 0 C-N-CA 122.005 1.803 . . . . 0.0 112.242 176.719 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.403 ' HB ' HD13 ' B' ' 91' ' ' ILE . 70.5 t -115.02 122.02 68.28 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.046 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 177.527 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . 0.423 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 31.8 tt0 -105.58 132.22 52.0 Favored 'General case' 0 C--N 1.269 -2.895 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -176.574 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.43 HD23 ' HA ' ' B' ' 48' ' ' ALA . 0.6 OUTLIER -124.09 159.77 29.21 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 175.264 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -132.12 125.81 32.2 Favored 'General case' 0 C--N 1.26 -3.322 0 CA-C-N 113.919 -1.491 . . . . 0.0 107.187 178.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt -66.14 151.88 45.98 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 121.938 0.875 . . . . 0.0 112.608 -178.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -102.66 178.34 4.6 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 14.7 m -67.79 -26.5 66.12 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 121.7 0.762 . . . . 0.0 109.035 175.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -72.74 -21.28 61.05 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-N 114.62 -1.173 . . . . 0.0 109.607 173.763 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.62 -105.12 2.7 Favored Glycine 0 N--CA 1.422 -2.236 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -176.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 94.8 mt -109.79 -176.87 3.12 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.1 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -156.19 61.62 0.35 Allowed Glycine 0 CA--C 1.476 -2.383 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.22 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . 0.543 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 3.1 pt -161.46 175.78 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.481 -1.693 0 C-N-CA 124.557 1.143 . . . . 0.0 108.157 -176.654 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 20' ' ' SER . . . . . 0.418 ' HB2' HG23 ' B' ' 41' ' ' THR . 54.9 m -148.59 151.7 35.49 Favored 'General case' 0 C--N 1.262 -3.2 0 N-CA-C 105.854 -1.906 . . . . 0.0 105.854 174.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . 0.431 ' HB ' HG22 ' B' ' 37' ' ' ILE . 16.6 pt -116.94 162.06 15.2 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.537 0 O-C-N 123.421 0.45 . . . . 0.0 110.613 -176.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.5 tp -146.84 137.61 17.92 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.19 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.98 111.41 3.73 Favored Glycine 0 N--CA 1.431 -1.668 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.482 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 85.9 mtp -105.74 138.62 41.63 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 176.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 152.39 155.02 6.88 Favored Glycine 0 C--N 1.297 -1.619 0 C-N-CA 119.74 -1.219 . . . . 0.0 112.305 179.252 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -165.34 98.62 0.71 Allowed 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 124.62 1.168 . . . . 0.0 108.666 179.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.08 161.06 20.71 Favored Glycine 0 CA--C 1.487 -1.699 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -176.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.589 ' HA ' ' O ' ' B' ' 33' ' ' GLU . . . -136.38 107.95 6.97 Favored 'General case' 0 N--CA 1.422 -1.869 0 CA-C-O 121.758 0.79 . . . . 0.0 112.628 179.304 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.519 ' HB3' ' HB2' ' B' ' 33' ' ' GLU . 22.4 t70 -92.38 -10.07 39.44 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 114.33 -1.304 . . . . 0.0 108.18 173.062 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . 0.337 21.5 ptm 59.27 -6.54 0.06 Allowed 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 128.083 2.553 . . . . 0.0 114.404 -173.175 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.447 ' H ' ' C ' ' B' ' 29' ' ' ASP . . . -105.52 69.09 0.24 Allowed Glycine 0 N--CA 1.434 -1.483 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 174.263 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . 0.275 4.4 mm? 77.95 -8.76 1.62 Allowed 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 114.68 1.363 . . . . 0.0 114.68 179.473 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . 0.589 ' O ' ' HA ' ' B' ' 28' ' ' ALA . 29.9 mm-40 -103.21 74.27 1.28 Allowed 'General case' 0 N--CA 1.413 -2.31 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 177.517 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 12.6 mtmt -144.95 -171.65 3.68 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.146 -2.168 . . . . 0.0 105.146 176.15 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . 0.609 ' O ' ' HA2' ' B' ' 70' ' ' GLY . 85.9 mt -63.75 115.94 5.26 Favored 'General case' 0 C--N 1.291 -1.95 0 CA-C-O 121.881 0.848 . . . . 0.0 111.764 177.265 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -101.7 115.48 5.27 Favored Glycine 0 N--CA 1.4 -3.722 0 N-CA-C 106.903 -2.479 . . . . 0.0 106.903 176.11 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . 0.431 HG22 ' HB ' ' B' ' 21' ' ' ILE . 29.1 mm -89.03 88.17 2.9 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 -177.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.468 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 73.5 m-85 -83.32 171.72 13.26 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 114.716 -1.129 . . . . 0.0 109.419 -177.664 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 58.9 t -78.19 136.22 24.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.67 0.748 . . . . 0.0 110.053 176.448 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -92.68 -48.13 6.74 Favored 'General case' 0 N--CA 1.426 -1.672 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.131 177.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 41' ' ' THR . . . . . 0.418 HG23 ' HB2' ' B' ' 20' ' ' SER . 1.0 OUTLIER -154.13 167.27 30.43 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -178.44 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.543 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.4 p -133.92 96.66 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.065 0 CA-C-O 122.389 1.09 . . . . 0.0 109.821 176.697 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 27.9 m -59.87 125.57 24.17 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 113.257 -1.792 . . . . 0.0 112.2 -175.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . 0.457 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 45.4 mt-10 -61.27 -35.07 76.31 Favored 'General case' 0 CA--C 1.516 -0.35 0 C-N-CA 124.21 1.004 . . . . 0.0 111.889 -176.122 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.79 -10.13 84.95 Favored Glycine 0 N--CA 1.441 -1.015 0 CA-C-N 115.861 -0.609 . . . . 0.0 113.415 -179.295 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.472 ' O ' ' HG3' ' B' ' 50' ' ' ARG . . . -106.23 171.2 17.38 Favored Glycine 0 N--CA 1.417 -2.629 0 C-N-CA 119.828 -1.177 . . . . 0.0 113.85 -175.452 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.26 -50.59 38.21 Favored 'General case' 0 C--O 1.208 -1.131 0 C-N-CA 125.213 1.405 . . . . 0.0 114.788 -173.52 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . 0.43 ' HA ' HD23 ' B' ' 10' ' ' LEU . . . -63.96 -32.44 73.97 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 113.88 1.067 . . . . 0.0 113.88 -172.018 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . 0.457 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 2.7 t60 -83.75 -38.8 20.89 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.128 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . 0.472 ' HG3' ' O ' ' B' ' 46' ' ' GLY . 74.9 mtp180 -70.32 -42.52 71.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.072 -178.683 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -74.09 -43.08 58.97 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 89.98 51.49 2.8 Favored Glycine 0 CA--C 1.504 -0.608 0 CA-C-N 115.113 -0.949 . . . . 0.0 112.406 175.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 34.0 mmt180 -112.94 -82.84 0.59 Allowed 'General case' 0 N--CA 1.442 -0.868 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.053 -177.356 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.452 HD13 ' CE2' ' B' ' 89' ' ' PHE . 70.7 mt -65.52 134.87 29.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 O-C-N 123.774 0.671 . . . . 0.0 109.396 179.648 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 24.4 mm-40 -111.95 164.77 12.74 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.9 p -65.0 -8.34 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.578 2.028 0 N-CA-C 113.093 0.775 . . . . 0.0 113.093 -175.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -115.3 -6.09 12.37 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 -172.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -94.25 179.2 5.38 Favored 'General case' 0 N--CA 1.432 -1.373 0 N-CA-C 114.998 1.481 . . . . 0.0 114.998 -178.513 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . 0.468 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 25.8 tp -135.25 136.69 41.89 Favored 'General case' 0 C--O 1.247 0.933 0 CA-C-N 114.958 -1.019 . . . . 0.0 110.954 -172.269 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 52.6 mt -83.82 96.84 8.89 Favored 'General case' 0 N--CA 1.425 -1.69 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 176.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.503 ' HB ' ' O ' ' B' ' 90' ' ' MET . 35.0 t -69.74 -42.75 80.28 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-O 122.159 0.98 . . . . 0.0 109.752 179.314 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -156.94 158.87 37.43 Favored 'General case' 0 C--N 1.277 -2.572 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.821 173.056 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 5.0 p -106.36 -175.9 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.099 0 N-CA-C 104.796 -2.298 . . . . 0.0 104.796 178.297 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . 0.437 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 8.9 t70 -52.44 -54.47 31.77 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 112.792 0.664 . . . . 0.0 112.792 178.459 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -122.29 35.73 3.4 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 119.81 -1.186 . . . . 0.0 115.277 -177.072 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 19.2 m -160.9 141.64 11.5 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 47.3 t -107.02 151.37 25.42 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 -178.628 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.47 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.6 mm? -116.27 106.28 13.5 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 120.98 0.419 . . . . 0.0 110.434 178.609 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 42.6 t -103.51 -8.09 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-O 122.221 1.01 . . . . 0.0 109.096 176.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . 0.609 ' HA2' ' O ' ' B' ' 35' ' ' LEU . . . 131.52 78.02 0.16 Allowed Glycine 0 CA--C 1.484 -1.898 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -177.47 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . 0.434 HG21 ' O ' ' B' ' 72' ' ' THR . 26.4 m -106.13 -175.08 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.098 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -175.836 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 72' ' ' THR . . . . . 0.434 ' O ' HG21 ' B' ' 71' ' ' VAL . 45.7 p -83.86 159.8 21.28 Favored 'General case' 0 N--CA 1.426 -1.655 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 175.061 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.0 tt0 -63.26 -31.37 72.51 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-O 121.519 0.676 . . . . 0.0 109.567 178.564 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 9.7 m -64.89 -43.18 93.75 Favored 'General case' 0 C--O 1.247 0.948 0 CA-C-N 115.052 -0.977 . . . . 0.0 110.051 177.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -62.27 -51.89 65.9 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 115.212 -0.904 . . . . 0.0 108.782 177.46 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.661 ' O ' ' HB ' ' B' ' 79' ' ' VAL . . . -57.61 -37.55 73.45 Favored 'General case' 0 C--O 1.214 -0.814 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.434 -178.131 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.84 -32.64 73.31 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.174 0.512 . . . . 0.0 111.037 178.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 19.0 m -79.36 -19.65 49.71 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.767 179.535 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.661 ' HB ' ' O ' ' B' ' 76' ' ' ALA . 3.9 t -57.15 -57.46 9.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.447 1.099 . . . . 0.0 111.843 177.072 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -58.62 -30.15 67.04 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 122.822 0.449 . . . . 0.0 111.781 178.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 31.6 mtp85 -80.76 -16.76 52.99 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.785 -179.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -81.97 -27.91 32.97 Favored 'General case' 0 N--CA 1.44 -0.973 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.451 ' HB ' HG13 ' B' ' 87' ' ' VAL . 12.5 p -88.99 159.86 17.4 Favored 'General case' 0 N--CA 1.417 -2.088 0 CA-C-N 114.882 -1.054 . . . . 0.0 112.887 179.05 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 72.5 mttt -64.6 -174.91 0.15 Allowed 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 124.914 1.286 . . . . 0.0 113.682 -177.114 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.94 -42.53 94.78 Favored Glycine 0 N--CA 1.445 -0.762 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.985 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 56.9 ttm-85 -123.13 118.46 27.73 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 176.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . 0.451 HG13 ' HB ' ' B' ' 83' ' ' THR . 6.2 m -146.41 156.3 11.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.786 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.256 -178.037 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . 0.423 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 95.5 mtt180 -105.71 125.54 51.11 Favored 'General case' 0 N--CA 1.423 -1.799 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.47 177.452 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.579 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 1.8 m-85 -100.32 166.79 10.79 Favored 'General case' 0 C--N 1.27 -2.856 0 N-CA-C 106.026 -1.842 . . . . 0.0 106.026 176.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.503 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 64.3 mtt -113.3 112.92 24.52 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 171.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.403 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.4 mp -97.25 128.77 48.18 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -101.39 100.89 2.15 Favored Glycine 0 CA--C 1.46 -3.356 0 N-CA-C 108.522 -1.831 . . . . 0.0 108.522 176.338 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . 0.494 ' HB3' ' HB2' ' B' ' 4' ' ' GLU . 21.2 tpp180 -69.39 118.79 12.72 Favored 'General case' 0 C--N 1.277 -2.547 0 CA-C-N 114.398 -0.901 . . . . 0.0 109.991 -177.218 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -87.06 79.99 8.51 Favored 'General case' 0 N--CA 1.409 -2.521 0 N-CA-C 104.826 -2.287 . . . . 0.0 104.826 172.035 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 16.4 ttm180 -57.46 -59.48 12.75 Favored Pre-proline 0 CA--C 1.549 0.939 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.865 -179.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -82.92 -177.65 3.46 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.163 1.909 . . . . 0.0 111.625 175.167 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -121.99 -38.21 0.62 Allowed Glycine 0 C--N 1.297 -1.589 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 175.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 19.0 mt-10 -82.43 -14.51 55.01 Favored 'General case' 0 C--N 1.315 -0.892 0 C-N-CA 123.656 0.782 . . . . 0.0 108.974 178.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 58.9 tp60 63.32 -95.4 0.05 OUTLIER 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 125.384 1.473 . . . . 0.0 109.452 -173.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 72.5 m -170.46 166.18 8.46 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 126.084 1.754 . . . . 0.0 106.271 176.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -117.19 3.69 12.65 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 121.537 0.684 . . . . 0.0 110.857 177.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 21.1 m -120.14 144.72 27.97 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-N 115.038 -0.983 . . . . 0.0 109.506 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -152.96 -80.45 0.1 Allowed 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 177.162 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 5.9 tp-100 -130.61 115.1 16.26 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 107.213 -1.402 . . . . 0.0 107.213 -179.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 5.8 mp -96.76 69.74 2.48 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.527 0.68 . . . . 0.0 111.202 -175.665 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 31.9 mm -111.1 -59.99 3.03 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.796 178.103 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -72.2 -16.87 61.96 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.658 0.742 . . . . 0.0 109.355 177.528 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 54.9 mt-30 -73.76 79.88 1.57 Allowed 'General case' 0 N--CA 1.433 -1.306 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.168 178.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 15.3 t -129.71 -4.06 4.69 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 107.286 -1.375 . . . . 0.0 107.286 170.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 95.1 mt -134.37 83.24 2.02 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 114.546 -1.206 . . . . 0.0 107.924 177.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.27 149.58 33.64 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 -179.83 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 23.6 tt0 -90.85 87.45 6.66 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 179.405 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 . . . . . 0 C--N 1.296 -1.747 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.792 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.272 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . 0.481 ' O ' ' HB2' ' B' ' 94' ' ' GLU . 22.9 p-80 -138.89 165.97 25.69 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 -177.443 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 1.7 mpt? -88.95 121.72 31.59 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 176.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -75.97 98.55 4.3 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 177.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -81.28 88.97 6.04 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 175.77 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -109.92 145.31 31.78 Favored Pre-proline 0 C--N 1.288 -2.077 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.672 178.781 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -75.91 129.92 11.94 Favored 'Trans proline' 0 N--CA 1.44 -1.66 0 C-N-CA 122.19 1.926 . . . . 0.0 111.97 177.65 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.44 HG11 ' HB3' ' B' ' 53' ' ' ARG . 84.9 t -116.61 126.2 73.96 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.401 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.331 -179.071 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . 0.479 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 41.4 tt0 -120.81 128.78 53.18 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -178.675 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.487 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -115.41 -162.59 0.84 Allowed 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.796 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.416 ' H ' ' CD2' ' B' ' 10' ' ' LEU . 2.3 mm-40 -156.67 167.69 29.69 Favored 'General case' 0 C--N 1.29 -1.998 0 C-N-CA 126.251 1.82 . . . . 0.0 106.145 176.353 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -92.81 -173.15 3.23 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 121.297 0.57 . . . . 0.0 111.35 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . 0.423 ' HB2' ' HB1' ' B' ' 47' ' ' ALA . 21.9 t70 -128.52 172.05 11.53 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 22.8 t -61.75 -30.98 71.14 Favored 'General case' 0 C--N 1.307 -1.251 0 O-C-N 123.789 0.681 . . . . 0.0 109.199 178.298 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -91.59 -51.95 5.0 Favored 'General case' 0 N--CA 1.446 -0.662 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 173.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 126.47 133.27 3.83 Favored Glycine 0 N--CA 1.428 -1.848 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.977 178.043 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mm? 63.66 -168.66 0.2 Allowed 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 176.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.19 54.29 0.05 OUTLIER Glycine 0 C--O 1.209 -1.43 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 179.035 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . 0.536 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 4.9 pt -166.91 177.62 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.493 -1.246 0 C-N-CA 125.068 1.347 . . . . 0.0 108.657 -173.707 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 39.1 m -151.95 144.92 24.47 Favored 'General case' 0 C--N 1.27 -2.853 0 N-CA-C 105.461 -2.051 . . . . 0.0 105.461 174.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . 0.414 ' HB ' HG21 ' B' ' 37' ' ' ILE . 12.3 pt -111.1 160.76 10.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.054 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 -178.361 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.8 tp -138.75 138.17 42.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-O 120.939 0.399 . . . . 0.0 110.177 -178.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.72 98.7 2.3 Favored Glycine 0 N--CA 1.423 -2.221 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 177.453 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 86.4 mtp -91.97 157.24 16.91 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 178.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.3 173.36 14.68 Favored Glycine 1 N--CA 1.388 -4.555 0 N-CA-C 107.359 -2.296 . . . . 0.0 107.359 179.665 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . 64.94 73.12 0.42 Allowed 'General case' 0 C--N 1.287 -2.148 0 CA-C-O 122.192 0.996 . . . . 0.0 111.319 -177.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -128.16 60.98 0.66 Allowed Glycine 0 N--CA 1.428 -1.859 0 CA-C-N 114.923 -1.035 . . . . 0.0 111.014 -178.425 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.16 75.14 8.14 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 121.868 0.842 . . . . 0.0 109.626 178.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 11.7 p-10 -89.61 -9.66 48.88 Favored 'General case' 0 N--CA 1.42 -1.957 0 C-N-CA 125.049 1.34 . . . . 0.0 110.034 -176.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 61.1 mtt 67.56 73.78 0.32 Allowed 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 114.266 -1.334 . . . . 0.0 109.743 -172.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.428 ' H ' ' HG3' ' B' ' 33' ' ' GLU . . . 168.51 -59.74 0.2 Allowed Glycine 0 N--CA 1.437 -1.256 0 CA-C-N 113.673 -1.603 . . . . 0.0 109.511 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . 0.419 ' HG ' ' HA ' ' B' ' 69' ' ' VAL . 9.3 mp -88.92 -53.31 4.66 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 176.527 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . 0.428 ' HG3' ' H ' ' B' ' 31' ' ' GLY . 47.5 mt-10 54.29 29.45 10.79 Favored 'General case' 0 C--N 1.349 0.555 0 C-N-CA 124.733 1.213 . . . . 0.0 112.241 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 37.2 mtmm -147.0 -168.79 3.14 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.15 -175.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 77.6 mt -47.54 129.92 13.69 Favored 'General case' 0 C--O 1.248 0.996 0 O-C-N 124.926 1.391 . . . . 0.0 111.483 177.303 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -113.59 123.42 6.13 Favored Glycine 0 N--CA 1.412 -2.935 0 N-CA-C 108.892 -1.683 . . . . 0.0 108.892 177.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . 0.414 HG21 ' HB ' ' B' ' 21' ' ' ILE . 20.7 mm -93.81 89.21 2.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.375 -0.93 . . . . 0.0 108.91 -179.46 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.463 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 90.5 m-85 -89.69 169.6 11.17 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.598 -178.376 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 58.0 t -75.32 134.83 28.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 CA-C-O 121.29 0.567 . . . . 0.0 109.723 175.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -93.04 -45.71 7.79 Favored 'General case' 0 N--CA 1.435 -1.186 0 CA-C-N 115.337 -0.847 . . . . 0.0 108.835 -179.09 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 2.5 t -155.21 169.2 24.72 Favored 'General case' 0 N--CA 1.419 -2.003 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.536 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.3 p -140.47 99.67 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.279 -2.496 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 -179.709 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 9.8 m -61.13 124.46 20.6 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 113.804 -1.543 . . . . 0.0 111.549 -175.095 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -69.92 -20.93 63.33 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.256 0.551 . . . . 0.0 111.863 -177.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.95 4.76 85.54 Favored Glycine 0 N--CA 1.437 -1.292 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.673 175.245 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -113.29 172.09 14.24 Favored Glycine 0 N--CA 1.425 -2.044 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.92 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . 0.423 ' HB1' ' HB2' ' B' ' 13' ' ' ASP . . . -64.86 -42.05 95.19 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -173.581 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . 0.487 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -58.85 -38.09 77.96 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 113.649 0.981 . . . . 0.0 113.649 -173.601 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -75.79 -41.07 53.95 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.244 0.545 . . . . 0.0 109.581 -177.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 64.4 mtp180 -68.18 -44.04 76.81 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.717 -178.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -63.21 -59.4 4.79 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.909 176.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 110.83 -15.53 28.78 Favored Glycine 0 N--CA 1.437 -1.233 0 C-N-CA 120.286 -0.959 . . . . 0.0 114.279 176.171 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.479 ' HG3' ' O ' ' B' ' 9' ' ' GLU . 30.4 mmt180 -62.85 -52.33 63.55 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 114.131 1.16 . . . . 0.0 114.131 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.519 HD11 ' CE2' ' B' ' 89' ' ' PHE . 39.0 mt -95.7 119.01 43.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 C-N-CA 119.634 -0.826 . . . . 0.0 109.901 178.57 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 85.0 mm-40 -107.69 -179.92 4.05 Favored 'General case' 0 N--CA 1.433 -1.317 0 CA-C-O 121.269 0.557 . . . . 0.0 109.881 177.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 12.7 p -71.02 -5.46 5.75 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.329 0 N-CA-C 113.087 0.773 . . . . 0.0 113.087 -174.681 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -117.12 4.24 12.7 Favored 'General case' 0 C--N 1.313 -0.996 0 O-C-N 121.06 -1.025 . . . . 0.0 111.354 -175.214 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -79.09 164.22 24.47 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.504 -175.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . 0.463 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 23.2 tp -136.69 128.34 28.81 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 123.078 0.551 . . . . 0.0 110.349 -176.587 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 70.3 mt -79.78 92.36 5.43 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.532 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 40.8 t -76.31 -42.24 36.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-O 122.066 0.936 . . . . 0.0 109.749 178.394 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . 0.408 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 8.6 pt-20 -154.23 147.49 24.84 Favored 'General case' 0 C--N 1.274 -2.697 0 CA-C-N 114.843 -1.072 . . . . 0.0 109.348 174.809 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . 0.407 HG11 ' O ' ' B' ' 66' ' ' THR . 5.3 p -97.61 -174.98 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 104.349 -2.463 . . . . 0.0 104.349 174.524 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . 0.463 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 28.8 t70 -56.37 -44.11 79.83 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 118.643 0.656 . . . . 0.0 112.563 -179.259 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -103.88 -66.57 0.72 Allowed Glycine 0 CA--C 1.528 0.85 0 C-N-CA 120.391 -0.909 . . . . 0.0 113.277 178.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 66' ' ' THR . . . . . 0.407 ' O ' HG11 ' B' ' 63' ' ' VAL . 14.2 m -66.87 129.86 41.27 Favored 'General case' 0 CA--C 1.547 0.849 0 CA-C-O 121.135 0.493 . . . . 0.0 112.124 -177.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 4.4 m -95.15 139.48 31.43 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 177.157 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.532 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.3 mm? -101.44 125.97 48.15 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.696 0.76 . . . . 0.0 111.39 -179.009 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . 0.419 ' HA ' ' HG ' ' B' ' 32' ' ' LEU . 8.8 p -125.13 9.57 4.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 115.163 -0.926 . . . . 0.0 109.104 178.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 120.09 87.89 1.05 Allowed Glycine 0 CA--C 1.499 -0.942 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -177.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.0 m -121.94 -179.11 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -177.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 32.3 p -83.88 164.16 19.62 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 175.543 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.3 tt0 -60.89 -41.23 95.63 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.278 0.561 . . . . 0.0 110.246 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 12.9 t -66.74 -36.41 82.38 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.282 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . 0.41 ' O ' HG11 ' B' ' 79' ' ' VAL . 38.0 t80 -62.29 -52.29 64.26 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -179.65 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.689 ' O ' HG21 ' B' ' 79' ' ' VAL . . . -65.93 -31.32 72.18 Favored 'General case' 0 C--O 1.218 -0.574 0 CA-C-O 120.978 0.418 . . . . 0.0 110.383 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.4 -34.54 77.96 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.757 0.789 . . . . 0.0 109.603 175.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.4 m -84.18 -17.14 40.94 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 115.194 -0.912 . . . . 0.0 112.112 -177.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.689 HG21 ' O ' ' B' ' 76' ' ' ALA . 23.5 m -68.81 -38.87 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 CA-C-O 121.53 0.681 . . . . 0.0 109.588 -178.439 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 23.5 mt -65.56 -21.31 66.59 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 125.193 1.397 . . . . 0.0 110.884 176.728 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 80.7 mtt180 -92.94 -14.36 27.65 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.491 -177.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -94.79 -22.28 18.17 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.669 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.47 ' HB ' HG11 ' B' ' 87' ' ' VAL . 6.6 p -80.77 -177.37 6.3 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.707 177.854 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -67.8 -171.48 0.21 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 123.484 0.714 . . . . 0.0 111.217 178.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -73.15 -42.05 44.94 Favored Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.134 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . 0.471 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 16.0 ttp180 -121.99 124.13 43.29 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 175.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . 0.47 HG11 ' HB ' ' B' ' 83' ' ' THR . 5.2 m -137.86 165.58 25.93 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 CA-C-O 121.055 0.455 . . . . 0.0 110.858 178.084 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 51.8 mtp85 -106.52 147.91 28.84 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.405 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.519 ' CE2' HD11 ' B' ' 54' ' ' ILE . 0.7 OUTLIER -129.83 170.38 13.97 Favored 'General case' 0 C--N 1.277 -2.578 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 -179.224 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.527 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 59.8 mtt -121.16 122.93 41.06 Favored 'General case' 0 C--N 1.292 -1.923 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 168.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 1.3 mp -105.7 133.31 50.4 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 CA-C-N 114.194 -1.366 . . . . 0.0 107.446 -178.307 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -117.69 101.14 0.9 Allowed Glycine 0 CA--C 1.48 -2.113 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 177.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 19.2 tpp180 -147.98 128.21 13.83 Favored 'General case' 0 C--N 1.274 -2.685 0 CA-C-N 114.435 -0.883 . . . . 0.0 110.099 -176.18 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . 0.481 ' HB2' ' O ' ' B' ' 2' ' ' HIS . 45.1 tt0 -101.29 84.57 2.65 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 172.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 46.4 ttt180 -80.28 -57.15 0.66 Allowed Pre-proline 0 C--N 1.295 -1.765 0 CA-C-N 114.722 -1.127 . . . . 0.0 110.995 178.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_endo -86.54 -178.48 2.7 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 122.2 1.933 . . . . 0.0 110.888 176.284 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -105.67 -33.97 3.43 Favored Glycine 0 C--N 1.295 -1.702 0 C-N-CA 120.441 -0.885 . . . . 0.0 110.956 176.018 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -144.1 -28.88 0.5 Allowed 'General case' 0 N--CA 1.425 -1.695 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -178.591 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 -84.86 79.83 9.49 Favored 'General case' 0 N--CA 1.426 -1.648 0 CA-C-O 122.012 0.911 . . . . 0.0 112.413 -178.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 19.5 m -105.94 170.64 7.79 Favored 'General case' 0 C--N 1.288 -2.069 0 CA-C-N 114.28 -1.327 . . . . 0.0 108.178 177.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -98.12 -39.16 9.03 Favored 'General case' 0 CA--C 1.485 -1.527 0 C-N-CA 119.219 -0.993 . . . . 0.0 110.074 175.473 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 20.5 t -94.46 78.38 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.262 -3.204 0 CA-C-N 114.255 -1.339 . . . . 0.0 108.069 -179.64 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -102.75 -68.91 0.81 Allowed 'General case' 0 C--N 1.264 -3.115 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.036 178.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 76.1 mm-40 -106.69 19.79 19.96 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.19 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -91.45 21.35 4.61 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.295 0.569 . . . . 0.0 111.184 -179.136 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 36.5 mm -78.41 -60.24 2.43 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 178.234 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . 0.499 HE21 ' HA ' ' B' ' 107' ' ' GLN . 0.0 OUTLIER 35.86 91.24 0.01 OUTLIER 'General case' 0 C--O 1.235 0.329 0 C-N-CA 127.314 2.246 . . . . 0.0 114.264 173.241 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 49.8 tp60 -141.85 97.73 3.2 Favored 'General case' 0 C--N 1.311 -1.093 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.457 -179.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 5.7 t -153.04 161.12 42.9 Favored 'General case' 0 N--CA 1.427 -1.591 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 176.328 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 96.0 mt 63.09 30.23 16.18 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 123.835 0.854 . . . . 0.0 111.121 174.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -158.34 -50.77 0.06 Allowed 'General case' 0 C--N 1.313 -0.978 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -176.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 32.7 tt0 -94.82 -59.36 1.93 Allowed 'General case' 0 C--N 1.308 -1.204 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 176.068 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 11.2 tp10 . . . . . 0 N--CA 1.414 -2.257 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 175.363 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.488 -1.609 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 76.5 m-70 58.5 -89.23 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.406 1.082 . . . . 0.0 109.669 -175.1 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 3' ' ' MET . . . . . 0.449 ' O ' HD23 ' B' ' 5' ' ' LEU . 25.5 mmt -95.03 97.6 10.07 Favored 'General case' 0 N--CA 1.432 -1.34 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 169.824 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -83.38 92.3 7.52 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 -175.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.449 HD23 ' O ' ' B' ' 3' ' ' MET . 0.7 OUTLIER -88.49 93.99 9.72 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 176.585 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -111.77 142.89 27.54 Favored Pre-proline 0 C--N 1.281 -2.395 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.539 179.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . 0.465 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 57.8 Cg_endo -78.64 132.82 11.17 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 122.319 2.013 . . . . 0.0 113.316 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.443 HG11 ' HB3' ' B' ' 53' ' ' ARG . 71.6 t -117.69 122.59 70.16 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -106.77 132.25 52.96 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.192 -175.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.421 HD23 ' HA ' ' B' ' 48' ' ' ALA . 1.0 OUTLIER -135.51 158.57 44.04 Favored 'General case' 0 N--CA 1.427 -1.607 0 CA-C-O 121.293 0.568 . . . . 0.0 110.743 176.606 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -145.37 161.37 39.82 Favored 'General case' 0 C--N 1.278 -2.515 0 CA-C-N 114.105 -1.407 . . . . 0.0 107.228 175.198 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . 0.478 ' HZ2' ' HA2' ' B' ' 85' ' ' GLY . 60.6 mttp -86.71 156.64 19.88 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-O 122.029 0.919 . . . . 0.0 113.259 -172.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -71.55 -69.95 0.35 Allowed 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 113.69 -1.595 . . . . 0.0 110.744 178.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 47.0 t -176.55 -39.62 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 105.398 -2.075 . . . . 0.0 105.398 -175.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -78.3 -57.02 4.0 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 172.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 161.61 -142.54 8.1 Favored Glycine 0 N--CA 1.428 -1.887 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 179.354 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -91.59 -174.47 3.88 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.392 0.615 . . . . 0.0 110.003 176.31 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -133.98 -113.78 1.42 Allowed Glycine 0 N--CA 1.419 -2.475 0 N-CA-C 108.411 -1.876 . . . . 0.0 108.411 176.443 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 24.0 pt 45.04 -177.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 C-N-CA 125.573 1.549 . . . . 0.0 114.993 178.22 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 43.8 m -157.87 146.39 19.13 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 104.823 -2.288 . . . . 0.0 104.823 173.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . 0.471 ' HB ' HG21 ' B' ' 37' ' ' ILE . 12.5 pt -119.58 161.02 19.27 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.364 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . 0.406 ' HB ' ' CG ' ' B' ' 40' ' ' LYS . 8.7 tp -136.75 135.32 48.61 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 CA-C-O 120.964 0.412 . . . . 0.0 110.446 -176.363 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.33 103.24 3.02 Favored Glycine 0 N--CA 1.426 -2.011 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.025 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 68.6 mtm -129.3 107.48 9.56 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.266 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -163.15 154.09 24.88 Favored Glycine 0 N--CA 1.42 -2.397 0 C-N-CA 120.34 -0.933 . . . . 0.0 111.568 -177.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -136.15 94.2 3.01 Favored 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 176.637 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -176.42 33.85 0.09 OUTLIER Glycine 0 N--CA 1.43 -1.732 0 C-N-CA 120.633 -0.794 . . . . 0.0 113.222 -177.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -76.96 117.63 18.75 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 174.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -143.12 30.59 1.41 Allowed 'General case' 0 C--N 1.288 -2.081 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -173.375 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 15.6 ptt? 45.48 44.31 9.6 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 125.021 1.328 . . . . 0.0 112.973 -179.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.09 -51.3 0.26 Allowed Glycine 0 N--CA 1.443 -0.865 0 CA-C-N 114.98 -1.009 . . . . 0.0 112.126 -179.12 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 91.1 mt -66.57 -48.55 69.26 Favored 'General case' 0 CA--C 1.512 -0.512 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 178.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . 0.617 ' O ' ' HA3' ' B' ' 70' ' ' GLY . 5.0 mm-40 46.49 40.88 8.78 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 126.185 1.794 . . . . 0.0 113.472 177.81 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 56.9 pttt -76.71 82.07 3.34 Favored 'General case' 0 N--CA 1.438 -1.069 0 CA-C-O 122.195 0.998 . . . . 0.0 113.21 -175.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 97.6 mt -108.15 142.59 38.14 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 114.065 -1.425 . . . . 0.0 108.142 176.528 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -108.54 114.15 4.01 Favored Glycine 0 N--CA 1.422 -2.269 0 C-N-CA 120.235 -0.984 . . . . 0.0 111.571 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . 0.471 HG21 ' HB ' ' B' ' 21' ' ' ILE . 20.7 mm -95.32 88.19 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.521 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 175.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.427 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 96.1 m-85 -82.07 172.1 13.6 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 114.901 -1.045 . . . . 0.0 108.686 -178.192 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 45.5 t -79.17 142.58 13.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 175.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . 0.406 ' CG ' ' HB ' ' B' ' 22' ' ' ILE . 0.1 OUTLIER -103.08 -42.63 5.72 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 -178.363 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 41' ' ' THR . . . . . 0.418 ' HA ' HG21 ' B' ' 56' ' ' VAL . 1.5 t -155.78 164.8 38.08 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 179.108 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 16.9 t -124.63 94.73 2.91 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.512 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 6.3 m -54.61 124.9 17.71 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 123.34 0.656 . . . . 0.0 111.517 179.752 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -62.09 -30.6 71.11 Favored 'General case' 0 C--O 1.222 -0.345 0 O-C-N 124.415 1.072 . . . . 0.0 112.26 -177.298 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.46 -23.46 77.05 Favored Glycine 0 N--CA 1.438 -1.172 0 C-N-CA 121.221 -0.514 . . . . 0.0 112.464 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.08 159.79 30.36 Favored Glycine 0 N--CA 1.416 -2.669 0 C-N-CA 119.692 -1.242 . . . . 0.0 113.158 -175.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -56.01 -38.31 70.34 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.27 -1.465 . . . . 0.0 112.458 -176.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . 0.421 ' HA ' HD23 ' B' ' 10' ' ' LEU . . . -59.03 -35.32 73.09 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -175.645 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 4.2 t60 -78.17 -40.69 36.99 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.491 0.663 . . . . 0.0 109.38 -179.223 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 65.6 mtp180 -73.86 -39.46 63.95 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 114.508 -1.223 . . . . 0.0 110.072 -174.484 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . 0.459 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 9.9 t70 -68.06 -60.08 2.76 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 173.174 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 97.69 11.38 50.82 Favored Glycine 0 N--CA 1.427 -1.919 0 CA-C-O 119.073 -0.849 . . . . 0.0 114.964 175.101 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.534 ' HA ' ' NE ' ' B' ' 53' ' ' ARG . 3.6 mmp_? -76.09 -50.25 15.21 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 118.655 1.227 . . . . 0.0 112.492 174.551 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.482 HD13 ' CE2' ' B' ' 89' ' ' PHE . 33.4 mt -77.36 141.02 16.14 Favored 'Isoleucine or valine' 0 C--O 1.249 1.072 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 175.538 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 72.5 mm-40 -114.54 -177.17 3.06 Favored 'General case' 0 N--CA 1.433 -1.315 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 -178.159 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.418 HG21 ' HA ' ' B' ' 41' ' ' THR . 8.4 p -90.45 3.55 6.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 CA-C-O 121.436 0.636 . . . . 0.0 111.416 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -119.38 -16.4 8.98 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 -174.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -76.39 178.65 6.39 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 114.491 1.293 . . . . 0.0 114.491 -173.43 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . 0.441 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 27.8 tp -133.79 121.9 22.51 Favored 'General case' 0 N--CA 1.437 -1.113 0 CA-C-N 114.933 -1.03 . . . . 0.0 110.911 -172.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 74.6 mt -80.67 91.66 5.89 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.458 179.128 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.646 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 10.8 t -72.5 -37.43 57.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 123.189 0.596 . . . . 0.0 111.078 179.076 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . 0.536 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 12.8 pt-20 -160.43 157.64 28.08 Favored 'General case' 0 C--N 1.28 -2.413 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.001 171.806 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 5.6 p -101.82 -178.35 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 105.484 -2.043 . . . . 0.0 105.484 178.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -55.94 -53.64 54.39 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -178.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -112.17 22.14 18.71 Favored Glycine 0 C--N 1.318 -0.425 0 C-N-CA 120.151 -1.023 . . . . 0.0 114.703 -175.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 32.3 m -153.89 115.19 4.13 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 117.859 0.83 . . . . 0.0 109.709 178.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 67' ' ' SER . . . . . 0.536 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 45.6 m -87.09 138.05 31.82 Favored 'General case' 0 N--CA 1.433 -1.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.751 178.322 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.646 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 52.5 mt -107.71 101.54 10.84 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-O 120.918 0.39 . . . . 0.0 111.695 -178.294 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 12.2 p -71.39 -26.63 26.97 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 172.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . 0.617 ' HA3' ' O ' ' B' ' 33' ' ' GLU . . . 151.62 85.77 0.05 OUTLIER Glycine 0 N--CA 1.424 -2.165 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -178.406 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 33.0 m -105.72 -177.56 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 CA-C-N 115.141 -0.53 . . . . 0.0 109.82 -177.056 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 71.6 p -81.37 166.68 20.21 Favored 'General case' 0 N--CA 1.428 -1.559 0 CA-C-O 121.236 0.541 . . . . 0.0 110.112 177.148 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -62.18 -39.85 94.09 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.584 -0.735 . . . . 0.0 109.935 178.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 20.3 t -69.77 -39.02 76.9 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.092 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . 0.417 ' O ' HG13 ' B' ' 79' ' ' VAL . 17.8 t80 -60.4 -51.57 68.91 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 -179.611 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.646 ' O ' HG22 ' B' ' 79' ' ' VAL . . . -64.38 -33.56 76.13 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.113 179.426 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.46 -37.44 87.3 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.622 0.725 . . . . 0.0 109.709 176.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.6 p -79.1 -18.06 54.0 Favored 'General case' 0 N--CA 1.427 -1.592 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 178.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.646 HG22 ' O ' ' B' ' 76' ' ' ALA . 32.9 m -73.67 -36.17 46.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 121.976 0.894 . . . . 0.0 109.703 -178.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 51.9 mt -66.1 -26.69 67.58 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 114.245 -1.343 . . . . 0.0 110.914 177.151 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 23.0 mtp180 -96.1 -8.0 34.53 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -176.523 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 25.7 m-80 -102.28 -13.77 17.24 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 120.852 0.358 . . . . 0.0 111.634 178.072 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.507 ' HB ' HG11 ' B' ' 87' ' ' VAL . 2.6 p -81.79 173.29 12.42 Favored 'General case' 0 N--CA 1.426 -1.665 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.108 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 66.5 mmtt -65.06 -172.36 0.09 Allowed 'General case' 0 C--O 1.242 0.679 0 C-N-CA 124.151 0.98 . . . . 0.0 113.347 -176.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . 0.478 ' HA2' ' HZ2' ' B' ' 12' ' ' LYS . . . -65.06 -49.12 63.88 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.635 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 -125.51 121.27 33.21 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -178.208 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . 0.507 HG11 ' HB ' ' B' ' 83' ' ' THR . 12.5 m -138.78 154.55 26.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 123.945 0.778 . . . . 0.0 111.396 -175.521 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 89.5 mtt180 -110.48 124.37 51.66 Favored 'General case' 0 N--CA 1.429 -1.521 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.917 178.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.482 ' CE2' HD13 ' B' ' 54' ' ' ILE . 4.8 m-85 -97.27 160.66 14.2 Favored 'General case' 0 C--N 1.28 -2.423 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 179.446 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.479 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 63.1 mtt -110.5 117.35 33.31 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 171.64 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.441 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -100.77 129.92 50.9 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.128 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -114.97 119.15 4.54 Favored Glycine 0 CA--C 1.473 -2.574 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.376 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 -107.72 114.57 28.63 Favored 'General case' 0 C--N 1.278 -2.526 0 CA-C-N 114.728 -0.736 . . . . 0.0 110.551 177.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -82.21 86.35 6.66 Favored 'General case' 0 N--CA 1.424 -1.744 0 N-CA-C 105.996 -1.853 . . . . 0.0 105.996 168.005 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 59.1 ttt180 -70.14 -59.34 4.32 Favored Pre-proline 0 C--N 1.294 -1.84 0 CA-C-N 114.094 -1.412 . . . . 0.0 111.183 -178.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . 0.554 ' HB2' ' O ' ' B' ' 99' ' ' GLN . 98.3 Cg_endo -79.95 -169.37 0.78 Allowed 'Trans proline' 0 N--CA 1.437 -1.825 0 C-N-CA 121.88 1.72 . . . . 0.0 112.218 175.556 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 153.03 -58.4 0.41 Allowed Glycine 0 C--N 1.288 -2.135 0 N-CA-C 108.181 -1.968 . . . . 0.0 108.181 -175.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -74.19 -27.05 60.63 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 171.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . 0.554 ' O ' ' HB2' ' B' ' 96' ' ' PRO . 8.3 tt0 -94.73 111.9 23.66 Favored 'General case' 0 N--CA 1.422 -1.851 0 N-CA-C 105.734 -1.95 . . . . 0.0 105.734 170.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 100' ' ' SER . . . . . 0.455 ' OG ' HG12 ' B' ' 102' ' ' VAL . 12.1 p -92.48 -162.98 0.98 Allowed 'General case' 0 C--N 1.292 -1.934 0 CA-C-O 120.596 0.236 . . . . 0.0 111.258 -176.304 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -87.74 5.25 40.86 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 121.087 0.47 . . . . 0.0 111.325 -177.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . 0.455 HG12 ' OG ' ' B' ' 100' ' ' SER . 7.1 p -82.25 110.57 17.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 CA-C-O 122.755 1.264 . . . . 0.0 111.513 -178.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -154.63 37.79 0.42 Allowed 'General case' 0 C--N 1.283 -2.289 0 CA-C-N 113.08 -1.873 . . . . 0.0 107.316 -177.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 36.4 tt0 69.36 93.74 0.08 Allowed 'General case' 0 C--O 1.243 0.726 0 CA-C-N 114.194 -1.366 . . . . 0.0 109.698 -171.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 6.0 mp -77.72 146.17 36.12 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 115.025 -0.988 . . . . 0.0 109.683 -178.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 35.3 mm -84.32 -62.24 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 176.252 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . 0.446 ' HG2' HG21 ' B' ' 109' ' ' THR . 23.8 tt0 51.87 94.66 0.02 OUTLIER 'General case' 0 C--O 1.242 0.678 0 C-N-CA 125.579 1.551 . . . . 0.0 111.553 176.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 28.9 pt20 -66.47 -13.55 60.99 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -173.57 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 109' ' ' THR . . . . . 0.446 HG21 ' HG2' ' B' ' 107' ' ' GLN . 11.7 t -83.19 -13.41 55.48 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 120.3 -0.56 . . . . 0.0 110.644 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 41.6 mt 61.54 29.78 18.45 Favored 'General case' 0 N--CA 1.477 0.884 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 172.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 49.7 mt-10 -89.47 -9.18 51.04 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 112.449 0.537 . . . . 0.0 112.449 -177.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 25.4 pt20 -76.32 144.39 40.22 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.167 178.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 56.7 mm-40 . . . . . 0 C--N 1.302 -1.463 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 175.52 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.636 0 N-CA-C 112.32 -0.312 . . . . 0.0 112.32 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 11.6 p80 -143.8 -172.54 3.76 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -178.47 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 3' ' ' MET . . . . . 0.484 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 25.4 ptp -65.05 117.31 7.49 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 121.421 0.629 . . . . 0.0 110.092 175.675 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -106.07 104.7 14.46 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -88.55 89.58 8.05 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 178.692 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -118.51 144.47 35.34 Favored Pre-proline 0 C--N 1.297 -1.699 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -178.518 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -80.95 127.8 6.3 Favored 'Trans proline' 0 N--CA 1.445 -1.38 0 C-N-CA 122.337 2.024 . . . . 0.0 112.629 177.531 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.49 ' CG1' ' HB3' ' B' ' 53' ' ' ARG . 76.0 t -112.49 134.73 54.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.032 0 CA-C-N 114.913 -1.039 . . . . 0.0 108.214 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . 0.446 ' OE2' ' HD3' ' B' ' 86' ' ' ARG . 34.9 tt0 -121.75 130.79 53.68 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -178.087 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.425 HD13 HG13 ' B' ' 54' ' ' ILE . 0.5 OUTLIER -143.78 162.66 35.45 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.116 0.484 . . . . 0.0 111.075 -179.606 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -86.97 156.75 19.66 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 125.172 1.389 . . . . 0.0 107.414 179.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 15.8 ptpt -79.28 -167.59 1.23 Allowed 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 122.11 0.957 . . . . 0.0 109.961 172.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . 0.425 ' HB3' ' N ' ' B' ' 17' ' ' LEU . 6.9 t70 -126.18 162.65 24.91 Favored 'General case' 0 C--N 1.285 -2.206 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 -179.036 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 31.0 t -61.54 -33.7 74.27 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 124.057 0.848 . . . . 0.0 110.658 -176.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -88.78 -51.86 5.43 Favored 'General case' 0 N--CA 1.437 -1.082 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 176.47 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.79 94.48 0.16 Allowed Glycine 0 N--CA 1.43 -1.7 0 CA-C-N 115.266 -0.879 . . . . 0.0 111.417 179.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.425 ' N ' ' HB3' ' B' ' 13' ' ' ASP . 3.8 mm? 59.64 98.02 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 124.605 1.162 . . . . 0.0 113.941 178.203 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -83.15 59.9 4.94 Favored Glycine 0 C--O 1.219 -0.843 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . 0.544 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 6.7 pt -148.79 -175.51 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 C-N-CA 126.416 1.887 . . . . 0.0 107.072 179.024 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 66.7 m -151.27 146.99 26.43 Favored 'General case' 0 C--N 1.261 -3.271 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 176.293 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . 0.4 ' HB ' HG23 ' B' ' 37' ' ' ILE . 13.9 pt -113.49 157.86 14.04 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 O-C-N 123.405 0.44 . . . . 0.0 110.072 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.5 tp -131.94 130.24 61.22 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.84 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.67 89.85 1.62 Allowed Glycine 0 N--CA 1.408 -3.186 0 C-N-CA 120.926 -0.654 . . . . 0.0 111.819 -177.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 25.4 mmt -72.86 108.41 5.79 Favored 'General case' 0 N--CA 1.434 -1.262 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 176.146 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.02 67.56 3.37 Favored Glycine 0 CA--C 1.465 -3.063 0 CA-C-O 122.291 0.94 . . . . 0.0 112.928 -174.726 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -111.68 75.75 0.94 Allowed 'General case' 1 C--N 1.239 -4.22 0 CA-C-N 112.628 -1.786 . . . . 0.0 106.242 174.447 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.73 104.2 1.34 Allowed Glycine 0 N--CA 1.426 -2.032 0 CA-C-N 114.382 -1.281 . . . . 0.0 111.748 -175.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.61 105.56 3.17 Favored 'General case' 0 C--O 1.256 1.403 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 177.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -82.8 67.44 8.87 Favored 'General case' 0 N--CA 1.434 -1.267 0 CA-C-O 122.988 1.375 . . . . 0.0 110.555 -176.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 24.4 ptm -112.83 26.59 10.37 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 112.916 -1.947 . . . . 0.0 109.28 178.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.06 10.34 59.86 Favored Glycine 0 CA--C 1.495 -1.204 0 CA-C-N 114.901 -1.045 . . . . 0.0 111.595 179.271 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 88.9 mt -132.19 -19.19 2.53 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 119.336 -0.364 . . . . 0.0 111.867 -177.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 42.11 36.93 0.75 Allowed 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 125.036 1.334 . . . . 0.0 111.355 -172.05 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -62.91 122.18 15.35 Favored 'General case' 0 N--CA 1.437 -1.094 0 CA-C-N 114.226 -1.352 . . . . 0.0 112.687 -174.225 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 88.3 mt -85.58 160.54 19.61 Favored 'General case' 0 C--N 1.3 -1.567 0 CA-C-N 114.404 -1.271 . . . . 0.0 108.147 175.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -112.44 95.01 0.76 Allowed Glycine 0 N--CA 1.429 -1.815 0 C-N-CA 120.021 -1.085 . . . . 0.0 110.882 179.409 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . 0.4 HG23 ' HB ' ' B' ' 21' ' ' ILE . 16.4 mm -87.84 85.33 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 CA-C-O 121.905 0.86 . . . . 0.0 109.237 179.65 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.42 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 87.0 m-85 -84.71 175.47 9.17 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.898 -178.544 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 48.5 t -79.92 142.35 14.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 175.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -100.82 -51.84 3.46 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.654 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -149.53 162.88 39.29 Favored 'General case' 0 N--CA 1.417 -2.102 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -175.537 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.544 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.4 p -140.84 105.48 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.04 0 CA-C-O 121.836 0.826 . . . . 0.0 109.839 178.271 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 16.5 m -62.95 125.97 25.77 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-N 114.355 -1.293 . . . . 0.0 111.566 -175.414 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . 0.448 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 11.1 pt-20 -65.47 -23.2 66.85 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.395 -178.063 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -83.65 3.96 83.57 Favored Glycine 0 N--CA 1.441 -0.992 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.23 177.033 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -108.07 164.49 12.82 Favored Glycine 0 N--CA 1.424 -2.156 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.208 179.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -65.57 -36.33 83.46 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-N 114.279 -0.96 . . . . 0.0 112.357 -176.501 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.72 -38.44 90.49 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -175.046 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . 0.448 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 7.9 t60 -69.91 -41.9 74.08 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 121.499 0.666 . . . . 0.0 109.713 -178.398 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 23.9 mtp180 -75.49 -35.76 60.74 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.697 -174.74 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -64.4 -63.64 1.08 Allowed 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.088 175.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 117.88 -20.25 10.86 Favored Glycine 0 N--CA 1.428 -1.9 0 C-N-CA 119.871 -1.157 . . . . 0.0 114.027 178.185 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.49 ' HB3' ' CG1' ' B' ' 8' ' ' VAL . 12.9 mmt180 -62.11 -62.83 1.5 Allowed 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 113.718 1.006 . . . . 0.0 113.718 179.588 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.624 HD12 ' CE2' ' B' ' 89' ' ' PHE . 62.9 mt -77.36 109.0 11.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 C-N-CA 119.374 -0.93 . . . . 0.0 109.137 174.43 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 79.6 mm-40 -102.01 173.89 6.18 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 121.163 0.506 . . . . 0.0 110.549 175.012 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.5 p -63.88 -12.97 12.6 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 114.165 1.172 . . . . 0.0 114.165 -173.381 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -125.62 16.89 8.15 Favored 'General case' 0 C--N 1.311 -1.091 0 O-C-N 120.976 -1.078 . . . . 0.0 111.145 -176.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 25.7 m-20 -83.22 172.6 12.44 Favored 'General case' 0 C--N 1.317 -0.812 0 O-C-N 121.362 -0.836 . . . . 0.0 111.084 179.098 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 29.7 tp -128.51 116.06 19.11 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 120.563 0.221 . . . . 0.0 110.808 -175.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 32.8 mt -93.17 95.29 9.31 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 179.126 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.64 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 96.3 t -73.19 -65.3 0.68 Allowed 'Isoleucine or valine' 0 C--O 1.175 -2.845 0 C-N-CA 120.607 -0.437 . . . . 0.0 109.83 178.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . 0.463 ' O ' ' HA ' ' B' ' 89' ' ' PHE . 8.6 pt-20 -129.05 157.26 42.22 Favored 'General case' 0 C--N 1.272 -2.787 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -177.019 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 5.0 p -103.51 -176.19 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.554 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 -178.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . 0.438 ' HB2' ' H ' ' B' ' 88' ' ' ARG . 27.5 t70 -51.25 -54.9 21.44 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 114.174 1.176 . . . . 0.0 114.174 -177.082 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -121.53 27.67 6.22 Favored Glycine 0 C--N 1.315 -0.591 0 C-N-CA 120.252 -0.975 . . . . 0.0 114.486 -175.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 51.4 m -152.57 120.67 6.22 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 176.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 19.7 m -94.21 111.38 23.11 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.168 -175.61 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.64 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 51.3 mt -89.57 121.36 31.7 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 176.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 14.8 p -83.74 -22.18 8.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.372 0.605 . . . . 0.0 109.565 177.451 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 145.88 69.16 0.01 OUTLIER Glycine 0 CA--C 1.487 -1.706 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 -177.318 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 34.9 m -90.6 -178.66 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 CA-C-N 114.563 -0.819 . . . . 0.0 109.742 -177.125 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 32.3 p -78.19 164.66 24.75 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 120.825 0.345 . . . . 0.0 111.066 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.3 tt0 -58.9 -40.43 84.45 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 123.429 0.692 . . . . 0.0 110.15 179.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 30.3 t -66.83 -36.48 82.45 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.323 -179.386 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -68.37 -47.84 66.35 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -179.649 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.531 ' O ' HG13 ' B' ' 79' ' ' VAL . . . -62.6 -39.31 93.35 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.929 178.814 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.33 -39.77 91.76 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-O 121.178 0.513 . . . . 0.0 111.153 178.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 13.3 p -82.1 -10.76 59.09 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -177.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.531 HG13 ' O ' ' B' ' 76' ' ' ALA . 5.3 p -86.18 -34.65 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.383 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 58.9 mt -69.87 -20.22 63.4 Favored 'General case' 0 C--O 1.213 -0.848 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.437 176.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 77.0 mtp180 -94.57 4.11 54.26 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.588 0.709 . . . . 0.0 110.244 177.429 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.2 t30 -113.6 0.86 14.76 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.734 0.778 . . . . 0.0 110.424 -176.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.455 HG23 ' O ' ' B' ' 79' ' ' VAL . 23.1 p -91.78 170.76 9.63 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.001 1.112 . . . . 0.0 114.001 -174.117 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.7 mmtt -73.88 -167.38 0.47 Allowed 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 124.795 1.238 . . . . 0.0 111.82 176.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.09 -33.93 84.95 Favored Glycine 0 C--O 1.225 -0.434 0 CA-C-N 115.628 -0.714 . . . . 0.0 113.274 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . 0.446 ' HD3' ' OE2' ' B' ' 9' ' ' GLU . 16.6 ttm180 -140.99 133.48 28.47 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 178.173 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . . . . . . . . . 11.9 m -139.02 164.51 25.27 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.031 0 CA-C-O 121.167 0.508 . . . . 0.0 111.591 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . 0.438 ' H ' ' HB2' ' B' ' 64' ' ' ASP . 54.3 mtm180 -100.01 159.03 15.4 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-N 114.649 -1.159 . . . . 0.0 108.221 176.448 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.624 ' CE2' HD12 ' B' ' 54' ' ' ILE . 4.9 m-85 -141.82 152.92 44.13 Favored 'General case' 0 C--N 1.283 -2.306 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 175.551 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 90' ' ' MET . . . . . . . . . . . . . 87.3 mmm -98.41 112.89 24.75 Favored 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 120.101 -0.64 . . . . 0.0 109.913 173.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.467 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.5 mp -101.8 117.2 46.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -179.159 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.89 101.28 2.07 Favored Glycine 0 CA--C 1.458 -3.498 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 174.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . 0.484 ' O ' ' HA ' ' B' ' 3' ' ' MET . 19.9 tpp180 -76.09 93.74 3.36 Favored 'General case' 0 C--N 1.276 -2.59 0 CA-C-N 114.478 -0.861 . . . . 0.0 109.884 178.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -83.71 80.67 9.05 Favored 'General case' 0 N--CA 1.403 -2.783 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 173.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 31.7 ttm180 -62.91 -58.24 17.5 Favored Pre-proline 0 C--N 1.304 -1.401 0 CA-C-N 114.086 -1.415 . . . . 0.0 110.796 176.135 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -82.35 -159.01 0.1 OUTLIER 'Trans proline' 0 C--N 1.357 0.993 0 C-N-CA 122.252 1.968 . . . . 0.0 111.254 173.425 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 121.36 35.85 0.78 Allowed Glycine 0 C--N 1.29 -2.014 0 C-N-CA 120.781 -0.724 . . . . 0.0 111.853 176.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 54.55 15.21 0.98 Allowed 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 115.834 1.791 . . . . 0.0 115.834 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 7.1 tp-100 -77.72 -29.86 51.43 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 173.205 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 23.9 m -128.27 158.87 36.96 Favored 'General case' 0 N--CA 1.414 -2.253 0 N-CA-C 105.289 -2.115 . . . . 0.0 105.289 174.09 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -108.9 75.34 0.95 Allowed 'General case' 0 C--N 1.291 -1.954 0 CA-C-O 122.091 0.948 . . . . 0.0 110.799 -173.541 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 20.7 t -90.82 119.25 37.64 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.539 0 N-CA-C 104.706 -2.331 . . . . 0.0 104.706 170.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -139.18 102.77 4.59 Favored 'General case' 0 C--N 1.283 -2.316 0 O-C-N 123.238 0.336 . . . . 0.0 111.839 -172.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 7.1 tp60 59.49 97.61 0.03 OUTLIER 'General case' 0 C--O 1.249 1.034 0 C-N-CA 125.025 1.33 . . . . 0.0 112.874 178.196 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 89.7 mt -85.64 119.05 25.56 Favored 'General case' 0 C--N 1.278 -2.543 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 176.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 40.1 mm -61.81 -60.56 2.51 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.697 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 60.26 95.54 0.03 OUTLIER 'General case' 0 N--CA 1.435 -1.194 0 O-C-N 125.029 1.456 . . . . 0.0 112.422 174.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . 0.454 ' HB3' ' HA ' ' B' ' 111' ' ' GLU . 98.2 mt-30 -66.71 103.64 1.14 Allowed 'General case' 0 N--CA 1.437 -1.121 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 174.223 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 12.7 t -70.07 -27.99 65.06 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.018 -172.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 58.3 mt -98.11 -27.35 14.23 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 176.083 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . 0.454 ' HA ' ' HB3' ' B' ' 108' ' ' GLN . 29.1 tt0 64.24 78.95 0.27 Allowed 'General case' 0 C--O 1.251 1.137 0 CA-C-N 113.78 -1.555 . . . . 0.0 110.988 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 66.0 mt-30 65.78 -177.31 0.19 Allowed 'General case' 0 C--O 1.242 0.703 0 CA-C-N 113.827 -1.533 . . . . 0.0 110.736 -179.589 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 15.4 mm-40 . . . . . 0 C--N 1.303 -1.433 0 CA-C-O 118.765 -0.636 . . . . 0.0 109.403 179.718 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.201 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -79.13 -50.17 11.44 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 178.406 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 3' ' ' MET . . . . . 0.486 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 66.2 mtt -125.58 125.98 44.05 Favored 'General case' 0 N--CA 1.427 -1.605 0 CA-C-N 114.235 -1.348 . . . . 0.0 110.045 178.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . 0.409 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 17.5 mt-10 -94.54 101.55 13.45 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.276 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.46 90.71 8.47 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.33 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -119.29 144.59 36.66 Favored Pre-proline 0 C--N 1.29 -1.985 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.109 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . 0.403 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 56.4 Cg_endo -75.49 139.23 22.83 Favored 'Trans proline' 0 N--CA 1.446 -1.297 0 C-N-CA 122.271 1.981 . . . . 0.0 111.767 177.36 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 87.5 t -129.73 128.99 66.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -179.298 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . 0.454 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 38.6 tt0 -114.99 123.26 48.65 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 mt -132.93 164.05 27.79 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 178.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -123.56 137.49 54.75 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 174.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . 0.412 ' HB2' ' O ' ' B' ' 16' ' ' GLY . 18.3 ptmt -74.96 162.48 28.56 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.189 179.143 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -134.78 -166.13 1.77 Allowed 'General case' 0 C--N 1.291 -1.965 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.5 m -66.49 -22.31 66.19 Favored 'General case' 0 C--N 1.313 -1.003 0 C-N-CA 123.666 0.786 . . . . 0.0 111.598 -178.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -86.06 2.34 46.89 Favored 'General case' 0 CA--C 1.55 0.952 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 177.543 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . 0.412 ' O ' ' HB2' ' B' ' 12' ' ' LYS . . . 85.06 -91.57 1.7 Allowed Glycine 0 N--CA 1.417 -2.58 0 N-CA-C 107.34 -2.304 . . . . 0.0 107.34 -175.077 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -124.75 134.14 52.91 Favored 'General case' 0 C--N 1.281 -2.396 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 174.719 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -83.45 53.3 4.84 Favored Glycine 0 C--O 1.216 -1.005 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.0 pt -161.87 176.56 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 C-N-CA 126.126 1.77 . . . . 0.0 107.491 -177.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 27.3 m -143.41 146.21 33.28 Favored 'General case' 0 C--N 1.268 -2.951 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 173.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . 0.424 ' HB ' HG21 ' B' ' 37' ' ' ILE . 10.1 pt -114.31 162.56 12.33 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -179.164 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 10.8 tp -137.89 138.37 44.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-O 121.041 0.448 . . . . 0.0 110.362 -177.714 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.54 108.58 3.45 Favored Glycine 0 N--CA 1.427 -1.94 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.662 178.304 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 22.7 mmt -124.33 149.36 46.67 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 177.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 135.1 168.4 11.62 Favored Glycine 0 N--CA 1.426 -1.979 0 C-N-CA 120.205 -0.998 . . . . 0.0 111.612 178.4 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -171.77 161.51 5.96 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 179.685 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 144.51 -149.11 21.17 Favored Glycine 0 N--CA 1.426 -2.031 0 C-N-CA 120.297 -0.954 . . . . 0.0 111.984 178.7 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.38 101.17 2.33 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-O 121.204 0.526 . . . . 0.0 111.133 179.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -100.43 -7.58 24.16 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-O 121.962 0.886 . . . . 0.0 109.186 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 24.0 ptm -60.09 -33.97 72.82 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 114.255 -1.339 . . . . 0.0 112.949 -178.552 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -171.22 56.25 0.18 Allowed Glycine 0 N--CA 1.445 -0.737 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 177.57 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 65.5 tp -171.01 -51.45 0.02 OUTLIER 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 -178.19 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . 0.356 10.0 pt-20 51.8 68.66 0.77 Allowed 'General case' 0 CA--C 1.504 -0.804 0 O-C-N 125.22 1.575 . . . . 0.0 113.387 -178.813 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . 0.419 ' HB2' ' HZ2' ' B' ' 34' ' ' LYS . 0.0 OUTLIER -79.11 101.91 8.15 Favored 'General case' 0 N--CA 1.42 -1.937 0 CA-C-N 113.341 -1.754 . . . . 0.0 110.271 179.037 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . 0.428 HD23 ' O ' ' B' ' 71' ' ' VAL . 14.5 tp -135.35 165.42 25.49 Favored 'General case' 0 C--N 1.282 -2.34 0 N-CA-C 104.797 -2.297 . . . . 0.0 104.797 179.348 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -138.94 120.36 1.9 Allowed Glycine 0 C--N 1.273 -2.929 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.051 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . 0.424 HG21 ' HB ' ' B' ' 21' ' ' ILE . 32.0 mm -96.84 89.22 2.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 179.23 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -84.31 170.88 13.2 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.55 -1.204 . . . . 0.0 108.192 -179.176 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 49.8 t -75.86 145.22 10.92 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 174.151 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 2.0 tmmm? -105.08 -41.26 5.63 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 -179.522 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -158.39 164.15 36.58 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 -179.533 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 15.3 t -119.0 95.15 3.46 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 175.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 7.0 m -64.09 121.03 13.21 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 123.976 0.91 . . . . 0.0 112.159 -175.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -69.59 -18.18 63.6 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.18 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.45 -11.77 84.09 Favored Glycine 0 N--CA 1.436 -1.313 0 C-N-CA 120.978 -0.629 . . . . 0.0 112.354 178.094 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -115.69 172.43 14.21 Favored Glycine 0 N--CA 1.426 -1.982 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.303 -178.591 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -67.53 -27.03 66.63 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 114.698 1.37 . . . . 0.0 114.698 -172.171 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -63.72 -41.89 98.0 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 112.486 0.551 . . . . 0.0 112.486 -175.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -70.83 -38.01 73.23 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 121.807 0.813 . . . . 0.0 109.276 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 -72.7 -34.08 66.89 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 114.197 -1.365 . . . . 0.0 110.626 -174.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . 0.524 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 15.5 t0 -75.81 -52.87 9.44 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 175.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.82 29.62 8.03 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.546 -177.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.524 ' HG2' ' OD1' ' B' ' 51' ' ' ASP . 32.6 mmt180 -90.0 -81.74 0.28 Allowed 'General case' 0 CA--C 1.513 -0.478 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.41 HD12 ' CE2' ' B' ' 89' ' ' PHE . 81.3 mt -67.01 125.41 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 O-C-N 123.293 0.37 . . . . 0.0 110.197 176.48 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . 0.499 ' NE2' HH12 ' B' ' 93' ' ' ARG . 0.9 OUTLIER -104.39 161.61 13.93 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.635 -176.677 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.3 p -62.43 -21.32 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 N-CA-C 115.771 1.767 . . . . 0.0 115.771 -168.22 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.627 ' ND2' ' HA ' ' B' ' 98' ' ' GLU . 15.6 t-20 -122.57 22.63 9.85 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.936 -1.106 . . . . 0.0 109.066 -176.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . 0.448 ' OD2' ' HB2' ' B' ' 55' ' ' GLN . 78.5 m-20 -87.96 170.9 10.74 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.976 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 28.2 tp -132.12 131.22 42.12 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.626 -178.157 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 78.9 mt -83.2 95.03 8.0 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 176.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.473 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 21.4 t -74.0 -40.96 52.7 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.886 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . 0.428 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 11.3 pt-20 -160.56 149.66 17.07 Favored 'General case' 0 C--N 1.283 -2.307 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.482 176.22 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 4.8 p -98.27 -179.27 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 105.037 -2.209 . . . . 0.0 105.037 176.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . 0.464 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 16.6 t70 -53.52 -53.33 53.04 Favored 'General case' 0 C--N 1.311 -1.076 0 N-CA-C 114.081 1.141 . . . . 0.0 114.081 -177.567 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -105.23 -1.77 41.4 Favored Glycine 0 C--N 1.312 -0.768 0 C-N-CA 119.408 -1.377 . . . . 0.0 115.509 -175.632 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 13.8 m -142.89 133.29 24.82 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 118.163 0.982 . . . . 0.0 110.011 -175.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 67' ' ' SER . . . . . 0.428 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 13.0 t -94.15 157.15 16.21 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.72 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.473 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.3 mm? -118.25 115.21 24.27 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.956 0.408 . . . . 0.0 111.062 -179.075 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 13.8 p -97.52 -20.28 5.7 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-O 121.918 0.866 . . . . 0.0 109.497 175.437 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 143.52 86.15 0.08 OUTLIER Glycine 0 CA--C 1.485 -1.791 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -178.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . 0.428 ' O ' HD23 ' B' ' 35' ' ' LEU . 33.5 m -109.46 -179.04 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.301 0 CA-C-N 115.032 -0.584 . . . . 0.0 109.515 -175.665 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 71.2 p -75.24 159.56 31.41 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 109.173 -0.676 . . . . 0.0 109.173 176.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.6 tt0 -62.17 -33.38 74.41 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.469 0.652 . . . . 0.0 110.046 -179.116 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 22.3 m -73.24 -37.37 66.38 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.004 178.159 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -62.41 -46.1 90.12 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.334 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.478 ' O ' HG11 ' B' ' 79' ' ' VAL . . . -62.6 -42.42 99.57 Favored 'General case' 0 C--O 1.209 -1.075 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.747 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.0 -31.02 71.35 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 121.719 0.771 . . . . 0.0 111.057 178.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 33.4 t -90.47 -4.85 56.68 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.893 -179.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.478 HG11 ' O ' ' B' ' 76' ' ' ALA . 1.2 p -76.27 -31.98 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 C-N-CA 119.776 -0.77 . . . . 0.0 109.494 -177.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -67.86 -30.81 70.27 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.574 174.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -82.09 -7.59 59.62 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.648 -178.278 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -92.17 -23.11 19.49 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.989 178.259 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.438 ' HB ' HG13 ' B' ' 87' ' ' VAL . 11.6 p -97.46 -178.76 4.25 Favored 'General case' 0 N--CA 1.428 -1.535 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.241 177.479 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 65.3 mmtt -70.93 -171.56 0.56 Allowed 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 123.245 0.618 . . . . 0.0 111.387 177.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -78.39 -35.71 32.5 Favored Glycine 0 N--CA 1.442 -0.932 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.716 -178.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 29.5 ttt180 -123.13 117.33 25.15 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 176.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . 0.464 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 7.8 m -148.5 160.02 6.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 123.878 0.736 . . . . 0.0 110.009 -177.371 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . 0.454 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 96.3 mtt180 -103.49 134.12 47.38 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.708 177.761 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.41 ' CE2' HD12 ' B' ' 54' ' ' ILE . 0.7 OUTLIER -112.93 166.37 11.46 Favored 'General case' 0 C--N 1.281 -2.407 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 178.879 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.463 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 85.0 mtp -111.66 114.55 27.65 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 171.381 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 1.4 mp -97.76 130.0 47.11 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.188 -179.292 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . 0.409 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -118.65 95.23 0.61 Allowed Glycine 0 CA--C 1.45 -3.97 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 177.003 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . 0.499 HH12 ' NE2' ' B' ' 55' ' ' GLN . 24.4 ttp180 -84.93 125.93 33.08 Favored 'General case' 0 C--N 1.268 -2.953 0 CA-C-N 114.322 -0.939 . . . . 0.0 111.716 -178.256 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -87.04 89.86 8.15 Favored 'General case' 0 N--CA 1.406 -2.655 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 170.177 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 24.0 ttt180 -39.17 -58.46 1.82 Allowed Pre-proline 0 CA--C 1.554 1.116 0 C-N-CA 126.282 1.833 . . . . 0.0 112.956 -177.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -70.39 139.05 37.19 Favored 'Trans proline' 0 N--CA 1.449 -1.093 0 C-N-CA 122.005 1.803 . . . . 0.0 110.888 174.324 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . 0.424 ' HA2' ' OG ' ' B' ' 100' ' ' SER . . . 118.73 7.29 10.75 Favored Glycine 0 C--N 1.286 -2.211 0 C-N-CA 120.059 -1.067 . . . . 0.0 112.299 -177.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . 0.627 ' HA ' ' ND2' ' B' ' 57' ' ' ASN . 5.4 pt-20 -82.22 -41.86 19.71 Favored 'General case' 0 N--CA 1.438 -1.042 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.381 176.766 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . 0.412 ' HG2' ' HG3' ' B' ' 98' ' ' GLU . 81.5 mm-40 -92.04 -60.91 1.74 Allowed 'General case' 0 N--CA 1.421 -1.897 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 100' ' ' SER . . . . . 0.424 ' OG ' ' HA2' ' B' ' 97' ' ' GLY . 73.5 m 53.12 -175.64 0.03 OUTLIER 'General case' 0 C--O 1.246 0.888 0 C-N-CA 125.117 1.367 . . . . 0.0 113.821 -179.567 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -121.31 72.12 0.98 Allowed 'General case' 0 N--CA 1.423 -1.796 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 175.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . 0.411 ' HB ' HD12 ' B' ' 105' ' ' LEU . 14.2 m -126.53 97.72 4.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.686 -178.575 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -113.42 -54.22 2.63 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.943 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 22.3 mt-30 -122.7 95.01 4.46 Favored 'General case' 0 C--N 1.29 -1.989 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 178.543 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . 0.411 HD12 ' HB ' ' B' ' 102' ' ' VAL . 5.7 mp -78.93 76.87 5.41 Favored 'General case' 0 C--N 1.31 -1.12 0 CA-C-O 121.261 0.553 . . . . 0.0 110.895 -177.683 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 45.9 mm -101.66 -71.67 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 175.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -159.82 115.07 2.39 Favored 'General case' 0 N--CA 1.438 -1.046 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 176.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 80.2 mt-30 -87.0 102.09 14.07 Favored 'General case' 0 N--CA 1.425 -1.708 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 177.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 7.4 t -82.59 -22.81 34.67 Favored 'General case' 0 N--CA 1.431 -1.386 0 CA-C-N 114.661 -1.154 . . . . 0.0 108.093 -177.49 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 92.3 mt -96.68 91.35 5.67 Favored 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 174.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -69.48 115.28 8.56 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 176.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 29.2 tt0 -111.82 -57.18 2.29 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.136 -174.196 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 55.9 mm-40 . . . . . 0 N--CA 1.432 -1.367 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.541 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.503 -0.696 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . 0.408 ' O ' ' HD2' ' B' ' 96' ' ' PRO . 42.9 t-80 -72.18 -46.83 54.71 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 176.452 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 22.3 ptt? -103.31 115.99 31.61 Favored 'General case' 0 N--CA 1.421 -1.884 0 CA-C-N 114.601 -1.181 . . . . 0.0 107.813 172.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . 0.498 ' OE2' ' HD2' ' B' ' 93' ' ' ARG . 15.4 mt-10 -87.07 101.3 13.33 Favored 'General case' 0 C--N 1.294 -1.831 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.038 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -90.34 88.49 7.22 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 174.09 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -110.82 145.15 31.78 Favored Pre-proline 0 C--N 1.29 -1.985 0 CA-C-N 116.119 -0.491 . . . . 0.0 112.027 -177.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . 0.494 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 60.1 Cg_endo -81.89 134.65 8.45 Favored 'Trans proline' 0 N--CA 1.439 -1.707 0 C-N-CA 122.142 1.894 . . . . 0.0 113.526 178.09 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 65.4 t -121.97 130.76 74.31 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 176.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -115.22 132.95 56.45 Favored 'General case' 0 C--N 1.294 -1.84 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.165 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.41 HD22 ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -121.15 161.21 22.21 Favored 'General case' 0 CA--C 1.493 -1.231 0 CA-C-O 121.403 0.62 . . . . 0.0 111.251 179.562 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -132.94 132.99 42.61 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 107.41 -1.329 . . . . 0.0 107.41 174.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . 0.488 ' HA ' ' CB ' ' B' ' 47' ' ' ALA . 36.0 mtmm -97.43 160.31 14.4 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 121.467 0.651 . . . . 0.0 112.468 -171.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 m-20 -113.27 -168.27 1.31 Allowed 'General case' 0 C--N 1.308 -1.2 0 CA-C-N 114.882 -1.054 . . . . 0.0 109.652 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.1 m -60.27 -35.93 76.67 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 113.618 0.969 . . . . 0.0 113.618 -174.624 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -79.6 -22.08 44.15 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-O 121.641 0.734 . . . . 0.0 109.364 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.06 -132.02 10.78 Favored Glycine 0 N--CA 1.423 -2.205 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.139 178.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 24.0 tp -82.83 169.71 15.81 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -178.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . 0.436 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -149.54 66.24 0.38 Allowed Glycine 0 CA--C 1.48 -2.122 0 C-N-CA 119.805 -1.188 . . . . 0.0 112.442 -177.647 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.4 pt -160.14 172.17 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.486 -1.482 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 56.7 m -133.39 151.57 51.84 Favored 'General case' 0 C--N 1.257 -3.444 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 174.578 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . 0.457 ' HB ' HG23 ' B' ' 37' ' ' ILE . 13.2 pt -121.59 148.2 25.15 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.681 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 -178.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.6 tp -119.02 132.49 68.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -179.374 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -96.56 97.97 2.11 Favored Glycine 0 N--CA 1.427 -1.951 0 C-N-CA 120.231 -0.985 . . . . 0.0 113.689 -174.408 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 82.3 mtp -95.89 112.94 24.54 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.083 -1.081 . . . . 0.0 108.083 175.672 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.449 ' HA3' ' HG ' ' B' ' 35' ' ' LEU . . . 149.95 173.26 20.15 Favored Glycine 0 N--CA 1.414 -2.809 0 C-N-CA 120.367 -0.921 . . . . 0.0 111.935 -178.374 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -152.76 -168.79 3.15 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 -178.562 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.36 113.55 5.42 Favored Glycine 0 N--CA 1.437 -1.234 0 O-C-N 123.673 0.608 . . . . 0.0 112.924 -178.25 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -132.85 45.0 2.79 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 105.748 -1.945 . . . . 0.0 105.748 176.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -79.63 2.5 22.27 Favored 'General case' 0 C--N 1.301 -1.529 0 CA-C-N 112.433 -2.167 . . . . 0.0 111.777 -171.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 26.5 ptm -75.45 11.71 1.18 Allowed 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.476 177.607 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 111.22 27.06 4.36 Favored Glycine 0 N--CA 1.435 -1.375 0 C-N-CA 121.369 -0.443 . . . . 0.0 112.818 177.602 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 95.3 mt -124.89 -69.99 0.77 Allowed 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 116.936 0.368 . . . . 0.0 110.536 -178.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . 0.295 10.4 pt-20 43.02 62.74 1.71 Allowed 'General case' 0 C--O 1.213 -0.821 0 C-N-CA 125.086 1.354 . . . . 0.0 114.285 -176.504 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . 0.435 ' HZ2' ' HB3' ' B' ' 34' ' ' LYS . 9.3 mtpm? -107.06 89.13 2.9 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 175.753 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . 0.449 ' HG ' ' HA3' ' B' ' 25' ' ' GLY . 9.4 mp -113.75 155.22 26.02 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.748 -175.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -116.18 97.77 0.79 Allowed Glycine 0 N--CA 1.413 -2.858 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.917 -177.095 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . 0.457 HG23 ' HB ' ' B' ' 21' ' ' ILE . 23.3 mm -92.98 87.69 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 174.771 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -85.17 164.44 18.11 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.614 -175.238 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 94.2 t -77.65 128.31 38.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 174.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -93.45 -37.45 11.95 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.123 0.487 . . . . 0.0 110.556 -176.003 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -158.4 163.46 37.22 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 -178.51 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 19.4 t -120.54 96.22 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.71 0 N-CA-C 106.468 -1.679 . . . . 0.0 106.468 176.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 17.1 m -59.99 124.31 19.8 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 124.186 0.995 . . . . 0.0 112.183 -175.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . 0.552 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 36.0 mt-10 -55.14 -33.83 63.25 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 124.767 1.227 . . . . 0.0 112.628 -176.709 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.67 -18.79 78.87 Favored Glycine 0 N--CA 1.438 -1.214 0 CA-C-N 115.674 -0.694 . . . . 0.0 114.521 -177.016 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.436 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -106.03 170.37 16.74 Favored Glycine 0 N--CA 1.423 -2.228 0 C-N-CA 118.497 -1.811 . . . . 0.0 114.719 -173.602 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . 0.488 ' CB ' ' HA ' ' B' ' 12' ' ' LYS . . . -59.53 -33.64 71.65 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 113.605 -1.298 . . . . 0.0 114.401 -174.14 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . 0.41 ' HA ' HD22 ' B' ' 10' ' ' LEU . . . -65.69 -33.0 74.86 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.243 -176.596 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . 0.552 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 12.2 t60 -77.31 -40.6 43.75 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.532 178.147 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 40.0 mtp-105 -66.97 -39.61 87.25 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.602 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . 0.507 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 12.0 t70 -78.0 -58.22 3.38 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.136 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.71 -4.87 36.9 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.628 -0.796 . . . . 0.0 113.662 179.146 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.507 ' HG2' ' OD1' ' B' ' 51' ' ' ASP . 0.4 OUTLIER -54.16 -62.13 1.86 Allowed 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 179.183 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.541 HD11 ' CE2' ' B' ' 89' ' ' PHE . 35.1 mt -81.31 126.46 39.8 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.227 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -103.29 168.51 9.12 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.162 177.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.1 p -73.53 4.46 0.84 Allowed 'Isoleucine or valine' 0 CA--C 1.57 1.725 0 CA-C-O 121.981 0.896 . . . . 0.0 111.533 -177.109 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -117.85 5.58 12.21 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.281 1.039 . . . . 0.0 109.529 -177.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -87.34 161.68 17.79 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.701 -177.536 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . 0.616 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 25.5 tp -138.31 127.21 23.88 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 123.494 0.717 . . . . 0.0 109.742 -175.471 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 66.0 mt -88.01 97.48 10.98 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.613 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 0.8 OUTLIER -92.9 -21.42 6.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-O 122.219 1.009 . . . . 0.0 109.5 -177.277 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . 0.553 ' HG2' ' O ' ' B' ' 63' ' ' VAL . 30.9 tt0 -164.64 150.99 10.65 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 113.133 -1.848 . . . . 0.0 108.701 175.013 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . 0.553 ' O ' ' HG2' ' B' ' 62' ' ' GLU . 6.2 p -93.18 -162.6 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.202 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 176.367 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . 0.521 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 11.7 t70 -56.59 -54.31 47.41 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 123.277 0.631 . . . . 0.0 111.687 -178.749 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -113.64 -54.18 0.44 Allowed Glycine 0 N--CA 1.439 -1.162 0 C-N-CA 120.478 -0.868 . . . . 0.0 113.213 -178.643 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 25.6 m -62.87 115.25 4.2 Favored 'General case' 0 C--O 1.246 0.909 0 CA-C-O 121.744 0.783 . . . . 0.0 112.731 -175.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 67' ' ' SER . . . . . 0.433 ' HA ' ' HG3' ' B' ' 62' ' ' GLU . 25.1 m -77.72 109.87 12.09 Favored 'General case' 0 N--CA 1.424 -1.75 0 C-N-CA 124.992 1.317 . . . . 0.0 113.397 -176.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.613 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 54.8 mt -90.88 -164.74 1.22 Allowed 'General case' 0 N--CA 1.421 -1.911 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 174.003 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 p 175.73 -30.86 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 106.236 -1.765 . . . . 0.0 106.236 178.368 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 169.02 77.06 0.04 OUTLIER Glycine 1 N--CA 1.39 -4.373 0 CA-C-N 114.48 -1.236 . . . . 0.0 111.227 -179.279 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 27.0 m -99.74 178.1 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.277 -2.581 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 34.6 p -76.84 161.74 28.19 Favored 'General case' 0 C--N 1.291 -1.95 0 C-N-CA 120.415 -0.514 . . . . 0.0 109.892 175.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -57.99 -40.77 81.55 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 123.829 0.851 . . . . 0.0 109.614 178.675 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 22.3 m -68.46 -38.57 81.22 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.077 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -62.93 -47.92 81.13 Favored 'General case' 0 C--O 1.24 0.566 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 178.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.565 ' O ' HG13 ' B' ' 79' ' ' VAL . . . -58.75 -45.37 89.86 Favored 'General case' 0 C--O 1.208 -1.105 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.845 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.91 -36.82 77.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.982 0.42 . . . . 0.0 111.749 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 15.4 p -77.88 -14.83 59.43 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 112.967 0.729 . . . . 0.0 112.967 -179.5 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.565 HG13 ' O ' ' B' ' 76' ' ' ALA . 2.8 p -73.31 -37.3 51.36 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.952 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.071 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -59.64 -18.81 44.76 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.97 0.908 . . . . 0.0 112.433 176.541 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 6.6 mtp180 -100.21 -6.66 25.73 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 121.213 0.53 . . . . 0.0 111.918 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -114.95 10.69 16.37 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.41 0.624 . . . . 0.0 111.245 179.153 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.511 HG22 ' O ' ' B' ' 79' ' ' VAL . 7.9 p -92.46 -173.42 3.38 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 115.491 -0.777 . . . . 0.0 112.298 178.513 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 44.9 mttm -76.67 -169.0 1.12 Allowed 'General case' 0 N--CA 1.437 -1.111 0 C-N-CA 123.506 0.722 . . . . 0.0 111.113 175.163 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -73.37 -49.69 14.52 Favored Glycine 0 N--CA 1.437 -1.274 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.056 176.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 16.2 ttm180 -118.38 121.44 40.37 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 176.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . 0.521 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 8.8 m -130.13 151.98 36.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 71.7 mtm180 -94.96 169.66 9.97 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 113.788 -1.551 . . . . 0.0 108.006 173.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.541 ' CE2' HD11 ' B' ' 54' ' ' ILE . 4.7 m-85 -144.14 151.1 39.1 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 176.053 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 90' ' ' MET . . . . . . . . . . . . . 48.0 mtm -100.43 115.12 29.3 Favored 'General case' 0 N--CA 1.425 -1.698 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 173.443 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.616 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.5 mp -96.93 127.84 48.72 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.002 -179.142 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . 0.402 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -108.36 120.87 6.1 Favored Glycine 0 N--CA 1.427 -1.962 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 177.312 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . 0.498 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 35.5 ttm180 -120.85 123.25 42.1 Favored 'General case' 0 C--N 1.281 -2.377 0 CA-C-N 115.207 -0.497 . . . . 0.0 109.731 178.218 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -87.88 81.72 7.47 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 171.445 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 13.8 ttm-85 -63.05 -64.38 3.08 Favored Pre-proline 0 CA--C 1.556 1.192 0 CA-C-N 115.136 -0.938 . . . . 0.0 113.387 -178.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . 0.408 ' HD2' ' O ' ' B' ' 2' ' ' HIS . 30.9 Cg_endo -67.13 159.92 49.86 Favored 'Trans proline' 0 C--N 1.364 1.368 0 C-N-CA 122.015 1.81 . . . . 0.0 113.952 -176.313 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 155.33 -47.21 0.51 Allowed Glycine 0 N--CA 1.436 -1.366 0 CA-C-N 114.716 -1.129 . . . . 0.0 110.34 -178.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -68.58 -32.49 72.44 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.308 -0.446 . . . . 0.0 111.056 178.427 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 8.9 tp-100 52.32 74.56 0.27 Allowed 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 124.856 1.262 . . . . 0.0 110.838 -177.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 71.0 m -93.45 158.43 15.72 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.524 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -87.68 -21.48 25.22 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-O 122.708 1.242 . . . . 0.0 109.798 -176.544 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 12.9 m -114.68 71.01 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.269 -2.918 0 CA-C-N 113.946 -1.479 . . . . 0.0 112.721 178.477 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -139.99 13.3 2.45 Favored 'General case' 0 C--N 1.282 -2.333 0 CA-C-N 113.342 -1.754 . . . . 0.0 108.078 175.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 55.2 tp60 -161.48 93.64 0.94 Allowed 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 -179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 3.8 mp -121.63 93.8 4.12 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 120.957 0.408 . . . . 0.0 110.269 -176.139 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 32.7 mm -96.94 -61.87 2.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 175.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 29.8 tt0 68.54 -33.39 0.24 Allowed 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 125.828 1.651 . . . . 0.0 114.486 174.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 12.5 mm-40 64.34 78.08 0.3 Allowed 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 124.075 0.95 . . . . 0.0 110.614 -179.562 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 5.2 t -81.17 -48.85 11.55 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.061 -177.365 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 89.7 mt -91.19 -14.31 31.27 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-O 121.277 0.561 . . . . 0.0 110.467 -178.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -96.78 102.6 14.41 Favored 'General case' 0 N--CA 1.418 -2.052 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.435 179.444 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.22 103.59 8.87 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 174.703 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 . . . . . 0 N--CA 1.42 -1.972 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -177.336 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.505 -0.552 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 14.9 p-80 -103.84 160.6 14.66 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 116.809 0.305 . . . . 0.0 110.841 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 66.8 mtt -81.82 137.0 35.35 Favored 'General case' 0 N--CA 1.431 -1.377 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 172.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . 0.421 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 14.0 mt-10 -90.81 97.77 11.38 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 120.43 -0.508 . . . . 0.0 109.931 -173.044 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -86.87 93.56 9.34 Favored 'General case' 0 N--CA 1.439 -0.977 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 177.339 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -114.59 143.56 30.18 Favored Pre-proline 0 C--N 1.283 -2.286 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.851 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -74.21 132.89 17.11 Favored 'Trans proline' 0 N--CA 1.45 -1.054 0 C-N-CA 122.331 2.02 . . . . 0.0 113.493 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.447 ' CG1' ' HB3' ' B' ' 53' ' ' ARG . 77.6 t -124.66 123.82 66.79 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 CA-C-N 114.783 -1.099 . . . . 0.0 108.316 178.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -111.3 123.62 50.58 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -176.192 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.417 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 1.6 mt -117.46 177.01 4.9 Favored 'General case' 0 CA--C 1.489 -1.389 0 CA-C-O 121.233 0.539 . . . . 0.0 111.218 177.22 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -155.18 166.55 33.21 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . 0.45 ' HZ3' ' HB2' ' B' ' 12' ' ' LYS . 10.1 mtmp? -116.11 160.72 19.96 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 118.407 0.549 . . . . 0.0 112.264 -176.157 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -97.79 -160.22 0.79 Allowed 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 169.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 17.6 m -69.6 -27.06 64.76 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 120.993 0.425 . . . . 0.0 110.221 177.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -75.9 -64.42 1.09 Allowed 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.96 75.63 0.68 Allowed Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.209 -0.996 . . . . 0.0 112.628 179.683 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.418 ' CD1' ' HG2' ' B' ' 12' ' ' LYS . 10.7 mp 71.92 172.82 0.31 Allowed 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 124.309 1.044 . . . . 0.0 112.916 179.289 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . 0.447 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -172.59 88.88 0.08 OUTLIER Glycine 0 CA--C 1.488 -1.612 0 N-CA-C 107.806 -2.118 . . . . 0.0 107.806 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . 0.555 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.8 pt -157.62 -173.65 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 -176.421 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 20' ' ' SER . . . . . 0.453 ' HB2' HG21 ' B' ' 41' ' ' THR . 40.5 m -152.72 144.61 23.67 Favored 'General case' 0 C--N 1.257 -3.452 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 173.656 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . 0.448 ' HB ' HG21 ' B' ' 37' ' ' ILE . 16.3 pt -116.74 162.93 14.34 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.584 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 179.282 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.1 tp -140.81 136.77 35.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 CA-C-O 120.98 0.419 . . . . 0.0 110.665 -178.806 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . 0.418 ' HA2' ' CD1' ' B' ' 37' ' ' ILE . . . -67.13 101.92 0.73 Allowed Glycine 0 N--CA 1.435 -1.372 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.1 178.862 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 91.7 mtp -145.93 159.37 43.34 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 -178.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 167.68 -148.51 13.0 Favored Glycine 0 N--CA 1.42 -2.421 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 -177.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -142.97 168.68 19.15 Favored 'General case' 0 C--N 1.289 -2.059 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.38 69.75 2.73 Favored Glycine 0 N--CA 1.442 -0.922 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 174.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.81 81.05 6.13 Favored 'General case' 0 N--CA 1.42 -1.934 0 N-CA-C 113.129 0.788 . . . . 0.0 113.129 -173.39 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -72.5 -24.64 61.19 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 123.059 1.409 . . . . 0.0 107.32 173.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 25.6 ptt? -80.8 4.3 19.56 Favored 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 112.318 -2.219 . . . . 0.0 110.057 176.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -153.68 40.93 0.67 Allowed Glycine 0 C--O 1.206 -1.603 0 C-N-CA 119.973 -1.108 . . . . 0.0 113.839 -177.485 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 2.8 mm? 62.6 26.09 15.49 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 112.727 0.64 . . . . 0.0 112.727 171.602 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 61.84 26.58 16.13 Favored 'General case' 0 C--O 1.243 0.733 0 C-N-CA 124.622 1.169 . . . . 0.0 111.529 -179.071 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -71.0 126.46 29.64 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 114.788 1.403 . . . . 0.0 114.788 -172.214 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 91.1 mt -100.0 129.2 46.03 Favored 'General case' 0 N--CA 1.417 -2.083 0 N-CA-C 104.174 -2.528 . . . . 0.0 104.174 167.052 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . 0.427 ' HA3' HD13 ' B' ' 59' ' ' LEU . . . -99.67 -13.78 36.72 Favored Glycine 0 C--N 1.291 -1.968 0 C-N-CA 118.881 -1.628 . . . . 0.0 111.048 -175.223 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . 0.448 HG21 ' HB ' ' B' ' 21' ' ' ILE . 31.2 mm 64.64 98.02 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.557 1.241 0 C-N-CA 124.396 1.078 . . . . 0.0 111.08 -179.145 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 62.4 m-85 -76.36 164.91 25.56 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.823 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 47.8 t -76.61 142.54 14.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 177.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 31.9 ttmt -98.36 -46.34 5.82 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.331 -179.614 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 41' ' ' THR . . . . . 0.453 HG21 ' HB2' ' B' ' 20' ' ' SER . 1.1 t -161.15 166.79 27.36 Favored 'General case' 0 N--CA 1.428 -1.55 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -178.355 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.555 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.8 p -137.71 97.26 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.282 -2.342 0 CA-C-O 122.102 0.953 . . . . 0.0 109.381 177.694 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 12.8 m -54.61 129.67 37.31 Favored 'General case' 0 N--CA 1.435 -1.2 0 CA-C-N 113.453 -1.703 . . . . 0.0 111.1 -176.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . 0.447 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 38.7 mt-10 -60.55 -27.17 67.45 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 123.537 0.735 . . . . 0.0 111.407 -177.13 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.63 -7.85 88.13 Favored Glycine 0 N--CA 1.434 -1.434 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.843 178.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.447 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -93.02 161.08 25.37 Favored Glycine 0 CA--C 1.485 -1.788 0 C-N-CA 120.326 -0.94 . . . . 0.0 114.243 -175.516 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -62.57 -34.6 77.3 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 113.614 -1.293 . . . . 0.0 111.642 -178.103 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . 0.417 ' HA ' HD23 ' B' ' 10' ' ' LEU . . . -66.15 -31.89 73.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.762 -0.199 . . . . 0.0 111.36 -177.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . 0.447 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 4.6 t60 -80.46 -42.6 22.32 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.568 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . 0.411 ' HG3' ' O ' ' B' ' 46' ' ' GLY . 82.5 mtp180 -64.59 -42.63 95.48 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.836 -179.632 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -76.52 -43.42 39.46 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 88.24 52.48 2.88 Favored Glycine 0 CA--C 1.503 -0.657 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.787 178.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.447 ' HB3' ' CG1' ' B' ' 8' ' ' VAL . 30.8 mmt180 -118.76 -74.29 0.61 Allowed 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -175.4 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.4 HD12 ' CE2' ' B' ' 89' ' ' PHE . 60.9 mt -72.24 107.81 3.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 176.586 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -97.25 153.52 17.97 Favored 'General case' 0 N--CA 1.425 -1.709 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.703 -175.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.438 HG21 ' HA ' ' B' ' 41' ' ' THR . 10.0 p -55.05 -24.07 14.0 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.56 0 N-CA-C 115.747 1.758 . . . . 0.0 115.747 -171.236 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -114.43 9.31 16.77 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 120.966 -1.084 . . . . 0.0 111.54 -172.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . 0.401 ' HB3' ' CG2' ' B' ' 91' ' ' ILE . 5.9 m-20 -99.49 -177.74 3.68 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 119.804 -0.759 . . . . 0.0 112.559 -176.85 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . 0.47 ' HB3' ' O ' ' B' ' 92' ' ' GLY . 29.3 tp -133.67 139.26 46.34 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 112.445 0.535 . . . . 0.0 112.445 -170.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 67.1 mt -89.27 101.76 14.43 Favored 'General case' 0 C--O 1.208 -1.104 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 176.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.598 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 24.8 t -83.46 -42.91 17.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-O 121.84 0.828 . . . . 0.0 111.509 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . 0.478 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 11.8 pt-20 -154.98 150.12 27.01 Favored 'General case' 0 C--N 1.272 -2.8 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.559 176.653 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 5.0 p -96.1 -178.51 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.07 0 N-CA-C 105.909 -1.885 . . . . 0.0 105.909 178.623 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . 0.414 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.8 t70 -49.47 -54.89 15.34 Favored 'General case' 0 C--N 1.315 -0.919 0 C-N-CA 124.16 0.984 . . . . 0.0 113.344 -176.381 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -121.12 24.2 7.46 Favored Glycine 0 C--N 1.32 -0.354 0 C-N-CA 119.372 -1.394 . . . . 0.0 114.254 -177.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 25.8 m -152.61 126.54 9.02 Favored 'General case' 0 C--N 1.316 -0.889 0 O-C-N 121.732 -0.864 . . . . 0.0 109.693 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 67' ' ' SER . . . . . 0.41 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 23.4 m -91.82 132.19 36.62 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 120.889 0.376 . . . . 0.0 110.757 -179.531 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.598 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 26.9 mt -81.69 95.66 7.29 Favored 'General case' 0 N--CA 1.431 -1.4 0 CA-C-O 121.374 0.607 . . . . 0.0 110.509 177.326 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 10.3 p -92.56 16.73 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 CA-C-O 122.317 1.056 . . . . 0.0 108.943 178.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 117.54 87.46 1.24 Allowed Glycine 0 CA--C 1.474 -2.493 0 C-N-CA 120.328 -0.939 . . . . 0.0 111.543 178.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 15.5 m -120.44 174.2 5.57 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -178.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 62.9 p -85.51 164.62 17.71 Favored 'General case' 0 N--CA 1.42 -1.928 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 176.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -60.97 -38.28 85.4 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 177.12 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.1 m -64.15 -41.28 97.23 Favored 'General case' 0 N--CA 1.433 -1.324 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.951 178.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -65.62 -46.72 78.18 Favored 'General case' 0 CA--C 1.521 -0.138 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.529 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.508 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -56.82 -43.43 81.03 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-O 120.999 0.428 . . . . 0.0 110.773 179.121 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.18 -24.54 66.65 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.605 0.716 . . . . 0.0 111.056 178.173 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 32.6 m -85.79 -26.43 25.78 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.821 -178.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.508 HG12 ' O ' ' B' ' 76' ' ' ALA . 9.0 p -73.69 -32.54 35.54 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.679 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . 0.421 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 64.5 mt -65.78 -23.12 66.64 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.485 177.04 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 59.7 mtm180 -99.53 -0.4 40.65 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.834 179.457 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -100.78 -29.38 12.29 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.203 177.497 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.468 ' HB ' HG13 ' B' ' 87' ' ' VAL . 7.8 p -74.38 164.03 27.08 Favored 'General case' 0 N--CA 1.425 -1.699 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.87 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 68.5 mmtt -68.83 -166.78 0.08 Allowed 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.102 1.361 . . . . 0.0 112.771 -179.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.93 -39.18 93.27 Favored Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.562 -0.744 . . . . 0.0 113.186 -179.161 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . 0.417 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 41.7 ttm180 -128.19 124.56 37.06 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 -179.614 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . 0.468 HG13 ' HB ' ' B' ' 83' ' ' THR . 13.6 m -135.2 147.68 29.06 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 CA-C-O 121.138 0.494 . . . . 0.0 111.448 178.075 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 36.2 mtp85 -108.87 120.37 42.31 Favored 'General case' 0 N--CA 1.428 -1.536 0 CA-C-N 114.925 -1.034 . . . . 0.0 109.086 -179.08 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.427 ' HB2' ' CD1' ' B' ' 91' ' ' ILE . 2.9 m-85 -103.82 159.36 15.7 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 -177.124 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.478 ' HB2' ' CG ' ' B' ' 62' ' ' GLU . 0.5 OUTLIER -104.34 109.35 21.16 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 168.939 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.452 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.3 mp -89.79 129.92 39.92 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.158 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 178.757 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . 0.47 ' O ' ' HB3' ' B' ' 59' ' ' LEU . . . -112.38 104.31 1.59 Allowed Glycine 0 CA--C 1.458 -3.483 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 178.512 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 -73.87 118.43 16.82 Favored 'General case' 0 C--N 1.27 -2.849 0 CA-C-N 114.913 -0.644 . . . . 0.0 109.664 178.566 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -76.46 75.74 3.2 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 173.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 31.5 ttt180 -71.05 -56.42 5.63 Favored Pre-proline 0 C--N 1.294 -1.814 0 CA-C-N 113.312 -1.767 . . . . 0.0 111.354 177.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.95 167.31 27.53 Favored 'Trans proline' 0 C--N 1.364 1.358 0 C-N-CA 121.855 1.704 . . . . 0.0 112.038 177.429 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -146.89 66.88 0.4 Allowed Glycine 0 N--CA 1.435 -1.385 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.348 -178.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 49.33 25.15 1.19 Allowed 'General case' 0 CA--C 1.539 0.522 0 N-CA-C 115.287 1.588 . . . . 0.0 115.287 177.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 23.9 tp60 -95.7 -17.8 20.98 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 178.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 28.5 m -77.68 157.98 29.9 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.952 -178.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 52.94 81.78 0.08 Allowed 'General case' 0 C--O 1.251 1.144 0 C-N-CA 125.584 1.554 . . . . 0.0 112.46 178.059 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 4.0 p -114.79 132.48 63.85 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.044 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.194 176.025 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -101.21 -74.5 0.61 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.495 -179.084 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -154.69 99.0 2.12 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-O 121.691 0.758 . . . . 0.0 110.92 -177.04 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 78.0 mt -100.84 -13.82 18.23 Favored 'General case' 0 CA--C 1.502 -0.885 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.871 -177.106 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 38.3 mm -88.17 -60.43 2.28 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.017 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.272 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 28.1 tt0 -102.14 105.17 15.83 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.943 177.454 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 24.5 mt-30 -105.26 112.38 25.47 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 9.2 t -80.28 -41.55 24.75 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 120.59 -0.444 . . . . 0.0 111.397 -176.071 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 96.5 mt -133.53 -24.32 1.79 Allowed 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.121 -179.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 68.91 123.16 0.03 OUTLIER 'General case' 0 C--O 1.235 0.325 0 C-N-CA 124.914 1.285 . . . . 0.0 112.073 -177.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 89.4 mt-30 -115.66 -76.34 0.58 Allowed 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 105.842 -1.91 . . . . 0.0 105.842 175.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 . . . . . 0 N--CA 1.434 -1.245 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 169.017 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.241 0.583 0 N-CA-C 111.489 -0.645 . . . . 0.0 111.489 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 57.9 m80 -90.57 -56.76 3.07 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 179.104 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 67.8 mtm -127.31 151.98 48.05 Favored 'General case' 0 N--CA 1.432 -1.347 0 CA-C-N 115.254 -0.884 . . . . 0.0 109.0 178.194 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -85.26 108.34 17.72 Favored 'General case' 0 N--CA 1.426 -1.652 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 179.136 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.557 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 1.1 mm? -85.35 89.46 7.68 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 174.219 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -111.7 142.6 26.93 Favored Pre-proline 0 C--N 1.288 -2.094 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.295 -179.37 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -75.8 132.88 14.83 Favored 'Trans proline' 0 N--CA 1.44 -1.632 0 C-N-CA 122.223 1.949 . . . . 0.0 111.878 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.429 HG13 ' HB3' ' B' ' 53' ' ' ARG . 76.4 t -120.83 120.77 63.39 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.389 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.178 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 9' ' ' GLU . . . . . 0.409 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 38.4 tt0 -115.29 120.18 38.8 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.704 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.465 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 0.9 OUTLIER -108.34 -173.58 2.31 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 178.832 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.408 ' H ' ' CD2' ' B' ' 10' ' ' LEU . 10.6 tp10 -158.83 155.85 28.59 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 105.046 -2.205 . . . . 0.0 105.046 176.528 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 10.6 ptpp? -84.96 163.38 18.95 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-O 121.743 0.782 . . . . 0.0 112.991 -173.346 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -111.34 -176.35 2.93 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 104.697 -2.334 . . . . 0.0 104.697 170.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 34.3 m -63.8 -30.33 71.44 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 119.278 0.944 . . . . 0.0 111.575 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -88.91 -13.0 40.12 Favored 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 121.711 0.767 . . . . 0.0 109.64 178.12 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.01 -108.11 2.43 Favored Glycine 0 N--CA 1.433 -1.505 0 C-N-CA 120.862 -0.685 . . . . 0.0 111.78 179.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -95.63 172.63 7.93 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 120.954 0.407 . . . . 0.0 110.105 -178.285 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -137.12 53.86 0.73 Allowed Glycine 0 CA--C 1.486 -1.744 0 N-CA-C 109.944 -1.263 . . . . 0.0 109.944 -179.519 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . 0.463 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 6.9 pt -157.95 -178.64 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.489 -1.369 0 C-N-CA 124.84 1.256 . . . . 0.0 108.282 -174.204 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 20' ' ' SER . . . . . 0.401 ' HB2' HG21 ' B' ' 41' ' ' THR . 46.8 m -152.58 156.21 38.87 Favored 'General case' 0 C--N 1.27 -2.853 0 N-CA-C 105.106 -2.183 . . . . 0.0 105.106 174.361 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 29.5 pt -117.3 158.96 17.71 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 CA-C-N 118.181 0.446 . . . . 0.0 110.287 -177.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -148.48 136.26 14.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 CA-C-O 121.422 0.629 . . . . 0.0 110.181 178.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -75.19 122.15 6.78 Favored Glycine 0 N--CA 1.423 -2.232 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.044 178.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 24' ' ' MET . . . . . 0.66 ' HB2' ' CD1' ' B' ' 38' ' ' PHE . 64.6 mtt -126.34 144.75 50.7 Favored 'General case' 0 CA--C 1.491 -1.298 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 174.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 145.08 -170.37 26.53 Favored Glycine 0 N--CA 1.42 -2.389 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 -177.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -138.98 169.41 17.84 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.98 69.41 1.88 Allowed Glycine 0 N--CA 1.449 -0.467 0 O-C-N 123.412 0.445 . . . . 0.0 113.669 -176.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -99.34 54.1 0.96 Allowed 'General case' 0 C--N 1.298 -1.663 0 CA-C-O 122.193 0.997 . . . . 0.0 109.142 177.53 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -84.05 19.94 1.67 Allowed 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 113.97 -1.468 . . . . 0.0 111.618 -175.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 23.5 ptp -88.75 23.72 2.23 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 123.428 0.691 . . . . 0.0 110.597 -178.149 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.04 36.27 3.71 Favored Glycine 0 N--CA 1.437 -1.247 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 -178.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 48.6 tp -140.63 -77.11 0.31 Allowed 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.061 -177.566 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . 0.611 ' O ' ' HA3' ' B' ' 70' ' ' GLY . 45.7 mt-10 47.66 42.41 15.19 Favored 'General case' 0 C--O 1.215 -0.726 0 C-N-CA 124.922 1.289 . . . . 0.0 114.472 -179.355 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 34' ' ' LYS . . . . . 0.453 ' HA ' ' O ' ' B' ' 69' ' ' VAL . 65.2 mttm -73.46 87.16 1.57 Allowed 'General case' 0 CA--C 1.512 -0.492 0 CA-C-O 122.366 1.079 . . . . 0.0 112.847 178.684 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 10.8 mp -125.84 -171.47 2.39 Favored 'General case' 0 C--N 1.296 -1.749 0 CA-C-N 113.181 -1.827 . . . . 0.0 106.662 178.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -170.99 1.63 0.03 OUTLIER Glycine 0 C--N 1.292 -1.892 0 C-N-CA 119.817 -1.183 . . . . 0.0 111.067 174.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 40.9 mm 65.39 114.64 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 CA-C-O 122.495 1.141 . . . . 0.0 110.543 -173.649 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.66 ' CD1' ' HB2' ' B' ' 24' ' ' MET . 29.0 m-85 -88.55 176.19 7.25 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.103 -0.953 . . . . 0.0 108.881 -175.205 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 64.6 t -83.93 142.9 12.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-O 121.654 0.74 . . . . 0.0 110.759 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 16.3 ttmm -94.34 -47.03 6.78 Favored 'General case' 0 N--CA 1.434 -1.261 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.769 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 41' ' ' THR . . . . . 0.401 HG21 ' HB2' ' B' ' 20' ' ' SER . 3.1 t -162.32 171.76 16.73 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 -178.64 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.463 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.2 p -147.9 91.51 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.861 0 CA-C-O 122.35 1.071 . . . . 0.0 109.193 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 8.2 m -59.3 128.94 39.61 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 113.557 -1.656 . . . . 0.0 111.528 -176.518 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 44' ' ' GLU . . . . . 0.561 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 8.1 pt-20 -68.01 -17.2 64.35 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 112.558 0.577 . . . . 0.0 112.558 -177.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.26 -0.04 85.27 Favored Glycine 0 N--CA 1.436 -1.351 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.486 177.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -111.14 169.59 13.36 Favored Glycine 0 N--CA 1.418 -2.503 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.923 -177.492 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -55.08 -54.67 40.11 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 113.911 -1.144 . . . . 0.0 113.651 -174.198 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 48' ' ' ALA . . . . . 0.461 ' HA ' HD23 ' B' ' 10' ' ' LEU . . . -56.24 -35.37 67.29 Favored 'General case' 0 C--O 1.243 0.75 0 N-CA-C 114.051 1.13 . . . . 0.0 114.051 -172.246 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 49' ' ' HIS . . . . . 0.561 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 6.6 t60 -75.39 -46.8 30.71 Favored 'General case' 0 C--N 1.312 -1.037 0 O-C-N 123.656 0.597 . . . . 0.0 109.953 -177.003 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 65.7 mtp180 -73.49 -34.98 65.57 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.422 -175.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -66.01 -51.36 59.06 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.419 178.549 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 95.13 52.77 1.7 Allowed Glycine 0 N--CA 1.432 -1.571 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 53' ' ' ARG . . . . . 0.429 ' HB3' HG13 ' B' ' 8' ' ' VAL . 21.6 mmt180 -129.78 -72.78 0.57 Allowed 'General case' 0 N--CA 1.432 -1.328 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -178.629 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.581 HD12 ' CE2' ' B' ' 89' ' ' PHE . 45.4 mt -80.06 129.15 38.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 C-N-CA 119.288 -0.965 . . . . 0.0 108.925 178.278 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 55' ' ' GLN . . . . . 0.733 ' HB2' ' OD1' ' B' ' 58' ' ' ASP . 6.9 mt-30 -116.78 164.15 15.09 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 -176.624 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.8 p -59.14 -33.95 52.01 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.276 0 N-CA-C 115.949 1.833 . . . . 0.0 115.949 -171.511 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -105.52 5.46 31.47 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.112 -0.993 . . . . 0.0 112.421 -172.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 58' ' ' ASP . . . . . 0.733 ' OD1' ' HB2' ' B' ' 55' ' ' GLN . 5.2 m-20 -82.01 171.09 14.8 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-O 121.318 0.58 . . . . 0.0 111.984 -175.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 59' ' ' LEU . . . . . 0.451 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 23.1 tp -131.54 133.11 44.72 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.312 -174.318 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 66.0 mt -87.25 96.36 10.31 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 178.095 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 61' ' ' VAL . . . . . 0.681 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 16.1 t -73.94 -38.46 49.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 CA-C-O 121.589 0.709 . . . . 0.0 110.928 179.092 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . 0.548 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 10.0 pt-20 -159.95 156.67 27.56 Favored 'General case' 0 C--N 1.282 -2.357 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.653 174.662 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 63' ' ' VAL . . . . . . . . . . . . . 6.2 p -100.53 177.35 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 177.479 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 64' ' ' ASP . . . . . . . . . . . . . 27.3 t70 -46.65 -56.67 5.74 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 114.156 1.169 . . . . 0.0 114.156 -173.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -117.98 27.44 7.44 Favored Glycine 0 C--N 1.31 -0.877 0 C-N-CA 119.392 -1.385 . . . . 0.0 114.072 -177.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 29.6 m -154.11 123.86 6.71 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 117.754 0.777 . . . . 0.0 109.788 179.193 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 67' ' ' SER . . . . . 0.548 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 11.1 t -96.46 129.19 43.87 Favored 'General case' 0 N--CA 1.426 -1.671 0 CA-C-O 121.078 0.466 . . . . 0.0 110.607 -177.25 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.681 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 62.7 mt -92.03 124.2 35.95 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.081 179.212 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 69' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' B' ' 34' ' ' LYS . 14.4 p -93.05 -25.39 4.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 174.164 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 70' ' ' GLY . . . . . 0.611 ' HA3' ' O ' ' B' ' 33' ' ' GLU . . . 149.26 75.13 0.02 OUTLIER Glycine 0 N--CA 1.423 -2.176 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 -176.648 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 31.3 m -93.15 178.45 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 CA-C-N 114.912 -0.644 . . . . 0.0 110.691 -175.368 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 36.6 p -80.88 160.98 24.6 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 175.482 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -62.59 -35.42 79.47 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 120.944 0.402 . . . . 0.0 110.307 -178.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 19.2 m -66.41 -40.18 89.42 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.279 178.122 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -64.31 -46.35 83.95 Favored 'General case' 0 C--N 1.338 0.101 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 76' ' ' ALA . . . . . 0.413 ' O ' HG11 ' B' ' 79' ' ' VAL . . . -57.89 -46.91 84.2 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.382 178.293 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.49 -42.01 86.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.005 0.431 . . . . 0.0 110.687 178.345 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 22.8 t -68.73 -32.68 72.64 Favored 'General case' 0 N--CA 1.431 -1.377 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.736 -178.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 79' ' ' VAL . . . . . 0.413 HG11 ' O ' ' B' ' 76' ' ' ALA . 9.8 p -78.09 -39.13 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 119.582 -0.847 . . . . 0.0 109.921 -174.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 45.6 mt -63.93 -34.02 77.02 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.822 177.647 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -87.66 -5.02 58.9 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.344 179.446 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -89.07 -37.04 15.41 Favored 'General case' 0 N--CA 1.431 -1.387 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 175.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 83' ' ' THR . . . . . 0.506 ' HB ' HG13 ' B' ' 87' ' ' VAL . 12.8 p -77.11 172.24 13.54 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.463 177.058 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt -69.11 -173.74 0.55 Allowed 'General case' 0 N--CA 1.444 -0.748 0 CA-C-O 121.738 0.78 . . . . 0.0 111.725 177.607 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -81.4 -28.66 43.16 Favored Glycine 0 N--CA 1.431 -1.661 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 175.634 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . 0.465 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 21.9 ttm-85 -106.76 111.3 23.76 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 121.406 0.622 . . . . 0.0 110.162 175.804 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 87' ' ' VAL . . . . . 0.506 HG13 ' HB ' ' B' ' 83' ' ' THR . 2.6 m -147.63 151.68 13.44 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-N 114.58 -1.191 . . . . 0.0 109.679 178.348 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' B' ' 8' ' ' VAL . 10.3 mtm-85 -101.28 110.31 22.3 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 123.992 0.808 . . . . 0.0 109.726 -179.718 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 89' ' ' PHE . . . . . 0.581 ' CE2' HD12 ' B' ' 54' ' ' ILE . 3.0 m-85 -95.23 158.97 15.23 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 179.426 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 90' ' ' MET . . . . . 0.489 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 86.3 mtp -107.8 114.04 27.71 Favored 'General case' 0 C--N 1.29 -1.993 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 170.273 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . 0.557 ' O ' ' HA ' ' B' ' 5' ' ' LEU . 1.4 mp -95.45 136.78 25.39 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 -179.006 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.93 100.9 0.73 Allowed Glycine 0 CA--C 1.474 -2.506 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 175.283 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 16.4 tpp180 -163.61 132.78 3.96 Favored 'General case' 0 C--N 1.275 -2.652 0 CA-C-N 113.824 -1.188 . . . . 0.0 108.726 -178.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 94' ' ' GLU . . . . . 0.458 ' HG2' ' O ' ' B' ' 96' ' ' PRO . 41.6 tt0 -99.39 91.14 4.8 Favored 'General case' 0 N--CA 1.415 -2.19 0 N-CA-C 106.352 -1.721 . . . . 0.0 106.352 170.066 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 45.0 ttt180 -58.13 -59.15 14.24 Favored Pre-proline 0 CA--C 1.554 1.12 0 CA-C-N 114.209 -1.36 . . . . 0.0 111.881 -177.633 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 96' ' ' PRO . . . . . 0.458 ' O ' ' HG2' ' B' ' 94' ' ' GLU . 41.6 Cg_endo -87.96 -172.38 0.8 Allowed 'Trans proline' 0 N--CA 1.448 -1.181 0 C-N-CA 122.005 1.804 . . . . 0.0 109.993 174.755 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -106.34 -85.45 1.8 Allowed Glycine 0 C--N 1.28 -2.537 0 N-CA-C 107.436 -2.266 . . . . 0.0 107.436 171.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 30.0 mt-10 -115.06 80.64 1.45 Allowed 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 174.065 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 35.0 tt0 -72.06 148.84 45.41 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.942 -178.022 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 64.5 m 62.79 152.66 0.03 OUTLIER 'General case' 0 N--CA 1.437 -1.087 0 C-N-CA 126.514 1.925 . . . . 0.0 114.948 179.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -124.87 20.6 8.38 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-N 114.976 -1.011 . . . . 0.0 109.584 -174.549 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 66.7 t -120.5 124.97 73.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 CA-C-O 122.075 0.941 . . . . 0.0 112.805 -171.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -94.02 -76.33 0.48 Allowed 'General case' 0 C--N 1.277 -2.583 0 CA-C-N 114.639 -1.164 . . . . 0.0 108.346 173.215 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 20.9 mm-40 -127.08 24.52 6.36 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.093 176.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -82.4 61.26 5.49 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 177.443 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 106' ' ' ILE . . . . . 0.415 ' HB ' ' OE1' ' B' ' 107' ' ' GLN . 38.2 mm -126.48 -60.44 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 N-CA-C 106.345 -1.724 . . . . 0.0 106.345 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . 0.415 ' OE1' ' HB ' ' B' ' 106' ' ' ILE . 0.3 OUTLIER -74.0 159.13 33.15 Favored 'General case' 0 N--CA 1.44 -0.953 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 172.879 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -140.73 138.34 34.11 Favored 'General case' 0 C--N 1.274 -2.711 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 176.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 10.2 t -74.73 124.18 26.31 Favored 'General case' 0 N--CA 1.417 -2.106 0 CA-C-O 121.711 0.767 . . . . 0.0 109.707 179.23 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 31.3 mt -105.35 5.48 31.88 Favored 'General case' 0 C--N 1.281 -2.39 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 179.558 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -102.21 66.93 1.03 Allowed 'General case' 0 N--CA 1.417 -2.112 0 N-CA-C 105.649 -1.982 . . . . 0.0 105.649 174.32 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -144.8 93.2 2.37 Favored 'General case' 0 N--CA 1.427 -1.619 0 CA-C-N 114.376 -1.283 . . . . 0.0 107.726 -178.126 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 . . . . . 0 C--N 1.286 -2.158 0 CA-C-N 114.519 -1.219 . . . . 0.0 108.553 -176.217 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 56.9 mtt . . . . . 0 N--CA 1.433 -1.292 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 4' ' ' GLU . . . . . 0.548 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 27.0 mt-10 -79.95 98.82 7.32 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.423 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 1.0 OUTLIER -82.67 89.84 6.78 Favored 'General case' 0 C--N 1.311 -1.105 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 174.602 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 13.5 p90 -110.59 142.11 25.42 Favored Pre-proline 0 C--N 1.286 -2.158 0 CA-C-N 116.038 -0.528 . . . . 0.0 112.128 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -68.78 129.46 18.7 Favored 'Trans proline' 0 N--CA 1.451 -1.024 0 C-N-CA 122.67 2.247 . . . . 0.0 112.482 178.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.703 HG13 ' HG3' ' B' ' 53' ' ' ARG . 79.1 t -120.88 122.91 69.01 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.515 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.725 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 9' ' ' GLU . . . . . 0.468 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 31.3 tt0 -123.11 113.84 19.53 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 mt -104.26 160.4 14.91 Favored 'General case' 0 C--N 1.283 -2.309 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.342 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.464 ' HB3' ' NH2' ' B' ' 86' ' ' ARG . 8.5 pt-20 -123.55 113.68 19.04 Favored 'General case' 0 C--N 1.271 -2.821 0 CA-C-N 114.271 -1.331 . . . . 0.0 108.421 173.019 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.4 ptpt -79.82 156.93 27.16 Favored 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.421 -0.808 . . . . 0.0 110.496 -175.653 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -89.18 -173.13 3.92 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.163 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 35.8 t -68.99 -21.15 64.17 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 173.424 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -69.7 -46.82 65.14 Favored 'General case' 0 N--CA 1.44 -0.929 0 CA-C-N 114.318 -1.31 . . . . 0.0 108.48 173.601 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.3 -132.73 8.66 Favored Glycine 0 N--CA 1.419 -2.496 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -176.346 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 90.7 mt -95.65 179.0 5.28 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 18' ' ' GLY . . . . . 0.531 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -151.3 66.59 0.35 Allowed Glycine 0 CA--C 1.481 -2.07 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.524 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 3.5 pt -151.71 -177.6 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.104 0 C-N-CA 124.608 1.163 . . . . 0.0 108.246 -177.226 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 20' ' ' SER . . . . . 0.457 ' HB2' HG22 ' B' ' 41' ' ' THR . 49.3 m -153.73 162.7 41.01 Favored 'General case' 0 C--N 1.261 -3.243 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.236 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.419 ' HB ' HG22 ' B' ' 37' ' ' ILE . 19.0 pt -127.92 164.4 29.43 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 -178.403 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -144.0 138.57 24.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 178.883 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 23' ' ' GLY . . . . . 0.419 ' HA2' ' CD1' ' B' ' 37' ' ' ILE . . . -83.61 96.03 1.92 Allowed Glycine 0 N--CA 1.426 -2.028 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.936 178.209 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 24.8 mmt . . . . . 0 C--N 1.307 -1.281 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 177.341 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 96.6 mt . . . . . 0 CA--C 1.495 -1.165 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -136.9 109.58 0.73 Allowed Glycine 0 N--CA 1.411 -3.02 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.627 -178.522 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.419 ' CD1' ' HA2' ' B' ' 23' ' ' GLY . 33.8 mm -89.62 84.55 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.89 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 175.352 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.487 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 90.4 m-85 -82.91 164.97 20.13 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.192 -1.367 . . . . 0.0 109.235 -176.819 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 52.1 t -73.21 126.47 33.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 176.499 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -86.87 -36.7 18.28 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.052 -176.458 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 41' ' ' THR . . . . . 0.457 HG22 ' HB2' ' B' ' 20' ' ' SER . 1.3 t -160.88 165.87 29.41 Favored 'General case' 0 N--CA 1.423 -1.791 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.208 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.524 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.3 p -139.1 94.22 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-O 122.562 1.173 . . . . 0.0 109.077 177.109 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.417 HG22 ' H ' ' B' ' 45' ' ' GLY . 45.6 m -65.74 126.79 29.54 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-N 113.064 -1.88 . . . . 0.0 113.038 -173.238 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 44' ' ' GLU . . . . . 0.453 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 9.2 pt-20 -53.13 -31.4 42.15 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 125.218 1.407 . . . . 0.0 113.254 -179.089 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 45' ' ' GLY . . . . . 0.417 ' H ' HG22 ' B' ' 43' ' ' THR . . . -64.65 -29.69 75.9 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 121.427 -0.416 . . . . 0.0 112.908 -179.503 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.531 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -95.98 165.79 24.43 Favored Glycine 0 N--CA 1.422 -2.298 0 C-N-CA 119.884 -1.15 . . . . 0.0 113.527 -176.031 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -58.45 -33.66 69.98 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 113.358 -1.421 . . . . 0.0 113.48 -175.687 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -59.51 -38.87 82.08 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -175.565 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 49' ' ' HIS . . . . . 0.453 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 7.9 t60 -75.06 -38.49 61.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.11 0.481 . . . . 0.0 110.145 -178.784 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 22.5 mtm-85 -77.89 -29.55 50.28 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.682 -175.189 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 51' ' ' ASP . . . . . 0.547 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 23.9 t70 -80.0 -53.78 6.41 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 176.78 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.39 39.66 4.16 Favored Glycine 0 CA--C 1.497 -1.077 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 179.004 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.703 ' HG3' HG13 ' B' ' 8' ' ' VAL . 0.5 OUTLIER -103.07 -69.41 0.79 Allowed 'General case' 0 N--CA 1.425 -1.717 0 CA-C-N 114.618 -0.791 . . . . 0.0 109.532 -174.26 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.609 HD11 ' CE2' ' B' ' 89' ' ' PHE . 52.1 mt -85.61 108.34 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 174.676 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 32.5 mt-30 -101.9 167.7 9.89 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -176.606 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 9.5 p -70.73 -4.54 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.568 1.641 0 CA-C-O 121.79 0.805 . . . . 0.0 112.3 -173.527 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 61.9 t30 -114.16 7.05 16.51 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.889 0.852 . . . . 0.0 109.232 -175.17 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -95.21 165.01 12.61 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.809 -176.546 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.515 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 23.8 tp -136.5 133.98 37.1 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.668 -176.773 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 69.3 mt -80.48 96.51 6.78 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 176.846 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.505 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 38.8 t -78.4 -45.67 25.99 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-O 121.66 0.743 . . . . 0.0 109.917 178.696 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -154.11 151.69 29.57 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 114.968 -1.015 . . . . 0.0 109.931 174.167 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.53 HG12 ' HB ' ' B' ' 66' ' ' THR . 4.3 p -95.28 -173.49 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 178.224 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.513 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 13.0 t70 -47.26 -49.62 23.09 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -139.6 43.06 1.18 Allowed Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 119.29 -1.433 . . . . 0.0 113.964 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 66' ' ' THR . . . . . 0.53 ' HB ' HG12 ' B' ' 63' ' ' VAL . 31.8 m -160.64 115.66 2.21 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 178.301 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 43.4 m -76.75 133.76 39.36 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-O 121.133 0.492 . . . . 0.0 110.891 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.515 HD12 ' CG2' ' B' ' 71' ' ' VAL . 4.1 mm? -87.42 -68.06 0.78 Allowed 'General case' 0 N--CA 1.434 -1.228 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.995 177.858 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 59.9 t 70.05 -40.46 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 124.456 1.102 . . . . 0.0 111.52 -177.132 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 157.44 85.22 0.05 OUTLIER Glycine 0 N--CA 1.417 -2.628 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.31 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.515 ' CG2' HD12 ' B' ' 68' ' ' LEU . 35.5 m -105.58 -172.73 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 123.543 0.737 . . . . 0.0 109.49 -178.311 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 72' ' ' THR . . . . . 0.437 ' O ' HG23 ' B' ' 71' ' ' VAL . 19.8 p -81.64 157.03 24.81 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 172.527 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -61.49 -35.59 78.11 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.194 0.521 . . . . 0.0 110.735 -176.707 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 25.4 m -62.65 -38.02 88.66 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.915 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -63.83 -49.13 74.04 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.527 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.64 -42.95 99.62 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.793 -178.765 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.04 -32.51 73.02 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.278 0.561 . . . . 0.0 110.696 178.388 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 8.1 t -82.38 -28.45 31.47 Favored 'General case' 0 N--CA 1.428 -1.56 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.059 -177.011 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.527 HG12 ' O ' ' B' ' 76' ' ' ALA . 7.2 p -71.44 -33.01 48.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 O-C-N 121.412 -0.805 . . . . 0.0 109.714 -174.673 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 29.1 mt -69.81 -16.88 63.35 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.573 -1.194 . . . . 0.0 111.02 176.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -96.14 -24.22 16.39 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.049 0.452 . . . . 0.0 110.787 178.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 29.2 m-80 -82.68 -21.5 34.89 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 121.373 0.606 . . . . 0.0 111.351 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.524 ' HB ' HG11 ' B' ' 87' ' ' VAL . 7.4 p -85.32 167.75 15.31 Favored 'General case' 0 N--CA 1.425 -1.683 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.928 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 37.4 mmtm -67.89 -173.76 0.39 Allowed 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 123.425 0.69 . . . . 0.0 112.422 179.005 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -75.16 -30.61 58.67 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.17 -0.923 . . . . 0.0 112.064 -178.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 86' ' ' ARG . . . . . 0.464 ' NH2' ' HB3' ' B' ' 11' ' ' GLU . 21.4 ttm-85 -130.62 116.09 17.62 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.062 0.458 . . . . 0.0 110.003 175.067 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.524 HG11 ' HB ' ' B' ' 83' ' ' THR . 5.8 m -136.71 144.64 31.93 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.737 179.172 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 88' ' ' ARG . . . . . 0.468 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 99.7 mtt180 -91.8 129.12 37.82 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 175.735 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.609 ' CE2' HD11 ' B' ' 54' ' ' ILE . 2.0 m-85 -105.93 161.0 14.84 Favored 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 178.674 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.486 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 62.1 mtt -109.14 106.64 16.62 Favored 'General case' 0 C--N 1.286 -2.167 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 169.449 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.515 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.3 mp -87.57 135.48 25.28 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 CA-C-N 114.459 -1.246 . . . . 0.0 107.648 178.492 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 92' ' ' GLY . . . . . 0.548 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -127.0 104.06 0.69 Allowed Glycine 0 CA--C 1.465 -3.088 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 177.186 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 11.2 ptp180 . . . . . 0 C--N 1.271 -2.809 0 N-CA-C 108.963 -0.754 . . . . 0.0 108.963 -179.892 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 24.7 mmt . . . . . 0 N--CA 1.434 -1.23 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 4' ' ' GLU . . . . . 0.464 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 19.0 mt-10 -89.85 100.25 13.1 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -95.46 93.93 7.5 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 177.917 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -118.53 141.48 29.87 Favored Pre-proline 0 C--N 1.283 -2.323 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.067 178.071 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 7' ' ' PRO . . . . . 0.413 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 79.2 Cg_endo -79.51 143.51 17.15 Favored 'Trans proline' 0 N--CA 1.446 -1.268 0 C-N-CA 122.151 1.901 . . . . 0.0 112.306 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.449 HG13 ' HB3' ' B' ' 53' ' ' ARG . 53.8 t -131.49 127.7 59.99 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.981 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 176.599 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 9' ' ' GLU . . . . . 0.488 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 32.0 tt0 -110.4 121.61 45.72 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -177.837 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.523 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -114.61 165.6 12.6 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 121.515 0.674 . . . . 0.0 110.707 178.685 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -115.52 126.63 54.52 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 105.728 -1.953 . . . . 0.0 105.728 175.25 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 12' ' ' LYS . . . . . 0.412 ' HG2' ' HA2' ' B' ' 85' ' ' GLY . 21.1 ptmt -79.85 160.45 26.08 Favored 'General case' 0 N--CA 1.417 -2.092 0 C-N-CA 117.627 -1.629 . . . . 0.0 107.022 170.838 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 13' ' ' ASP . . . . . 0.407 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 22.2 t70 -115.75 178.31 4.36 Favored 'General case' 0 C--N 1.258 -3.391 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 -178.8 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 13.1 t -67.32 -20.54 65.62 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 179.398 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -92.61 7.24 44.22 Favored 'General case' 0 CA--C 1.555 1.168 0 CA-C-O 121.869 0.843 . . . . 0.0 109.42 176.066 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.57 -115.93 4.63 Favored Glycine 0 N--CA 1.435 -1.421 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.493 178.506 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -103.05 -173.19 2.25 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 121.42 0.629 . . . . 0.0 110.483 -177.282 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 18' ' ' GLY . . . . . 0.462 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -149.44 53.75 0.51 Allowed Glycine 0 CA--C 1.491 -1.433 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 178.291 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 2.6 pt -154.3 -179.99 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-O 121.961 0.886 . . . . 0.0 111.407 -175.885 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 51.0 m -152.49 131.45 12.56 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 175.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.505 ' HB ' HG22 ' B' ' 37' ' ' ILE . 15.6 pt -108.66 162.53 6.51 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 C-N-CA 122.713 0.405 . . . . 0.0 109.946 -178.832 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 22' ' ' ILE . . . . . 0.479 ' HB ' ' HB2' ' B' ' 40' ' ' LYS . 9.5 tp -136.22 136.69 49.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 CA-C-O 121.134 0.493 . . . . 0.0 110.673 -178.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -82.58 105.63 2.64 Favored Glycine 0 N--CA 1.426 -2.022 0 CA-C-N 115.663 -0.699 . . . . 0.0 112.527 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 24' ' ' MET . . . . . 0.531 ' O ' ' HG ' ' B' ' 35' ' ' LEU . 26.3 mmt . . . . . 0 C--N 1.306 -1.322 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 176.196 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 35' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' B' ' 24' ' ' MET . 15.4 tp . . . . . 0 N--CA 1.429 -1.491 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 36' ' ' GLY . . . . . 0.475 ' H ' ' HG ' ' B' ' 35' ' ' LEU . . . -137.06 87.72 0.22 Allowed Glycine 0 N--CA 1.422 -2.296 0 C-N-CA 119.882 -1.151 . . . . 0.0 111.724 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.505 HG22 ' HB ' ' B' ' 21' ' ' ILE . 34.5 mm -84.62 80.32 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 176.233 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.413 ' CD1' ' HB2' ' B' ' 59' ' ' LEU . 96.9 m-85 -77.17 169.93 17.45 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.172 -176.38 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 49.1 t -80.36 135.46 25.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 40' ' ' LYS . . . . . 0.479 ' HB2' ' HB ' ' B' ' 22' ' ' ILE . 2.4 ttpm? -95.84 -41.47 8.81 Favored 'General case' 0 CA--C 1.482 -1.652 0 CA-C-O 121.187 0.517 . . . . 0.0 109.899 -178.125 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 1.1 m -154.83 146.98 23.72 Favored 'General case' 1 N--CA 1.369 -4.483 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -174.904 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 39.5 t -114.76 105.69 19.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 175.519 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 7.2 m -64.41 122.68 17.3 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.215 -174.538 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 44' ' ' GLU . . . . . 0.505 ' HG2' ' CE1' ' B' ' 49' ' ' HIS . 36.1 mt-10 -66.8 -28.36 68.31 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.457 -175.74 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.3 -1.11 85.4 Favored Glycine 0 N--CA 1.435 -1.401 0 CA-C-N 115.042 -0.981 . . . . 0.0 113.396 -179.266 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.462 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -117.07 170.29 13.38 Favored Glycine 0 N--CA 1.411 -2.972 0 C-N-CA 119.933 -1.127 . . . . 0.0 112.818 -178.51 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 47' ' ' ALA . . . . . 0.407 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -60.72 -35.79 77.23 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 114.088 1.144 . . . . 0.0 114.088 -174.249 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 48' ' ' ALA . . . . . 0.523 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -63.28 -38.74 92.35 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 113.199 0.815 . . . . 0.0 113.199 -174.277 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 49' ' ' HIS . . . . . 0.505 ' CE1' ' HG2' ' B' ' 44' ' ' GLU . 4.1 t60 -74.15 -39.34 63.33 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.659 0.742 . . . . 0.0 109.342 -179.199 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 -76.63 -26.2 54.65 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 114.862 -1.063 . . . . 0.0 111.785 -175.314 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 51' ' ' ASP . . . . . 0.523 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 12.6 t70 -77.92 -46.18 22.0 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 176.52 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 97.08 16.34 35.76 Favored Glycine 0 CA--C 1.498 -1.03 0 CA-C-N 115.515 -0.766 . . . . 0.0 112.624 172.399 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.523 ' HD3' ' OD2' ' B' ' 51' ' ' ASP . 1.5 mpt_? -91.96 -63.46 1.24 Allowed 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 113.335 0.865 . . . . 0.0 113.335 -177.124 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.5 HD11 ' CE2' ' B' ' 89' ' ' PHE . 39.4 mt -69.3 133.09 32.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 C-N-CA 119.805 -0.758 . . . . 0.0 110.53 176.757 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 30.7 mm-40 -113.37 153.66 28.19 Favored 'General case' 0 CA--C 1.511 -0.543 0 C-N-CA 122.408 0.283 . . . . 0.0 110.634 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.3 p -73.6 -7.48 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.86 0 CA-C-O 121.709 0.766 . . . . 0.0 111.986 -176.015 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -114.35 9.83 16.97 Favored 'General case' 0 C--N 1.293 -1.879 0 O-C-N 121.581 -0.699 . . . . 0.0 111.95 -175.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -112.42 177.78 4.52 Favored 'General case' 0 C--O 1.244 0.784 0 CA-C-O 120.979 0.418 . . . . 0.0 111.767 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.413 ' HB2' ' CD1' ' B' ' 38' ' ' PHE . 24.9 tp -126.91 128.22 46.12 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.739 -176.638 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 31.7 mt -90.15 107.68 19.28 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 105.569 -2.011 . . . . 0.0 105.569 175.229 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.534 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 41.4 t -79.2 -74.36 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.19 -2.03 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.45 ' HA ' HD23 ' B' ' 68' ' ' LEU . 10.9 pt-20 -118.6 165.2 14.24 Favored 'General case' 0 C--N 1.269 -2.903 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.032 -173.766 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.485 HG22 ' H ' ' B' ' 64' ' ' ASP . 4.6 p -113.34 -175.19 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -174.705 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.491 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 12.6 t70 -40.18 -63.35 0.62 Allowed 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 125.76 1.624 . . . . 0.0 113.918 -178.709 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -134.68 41.01 1.5 Allowed Glycine 0 CA--C 1.496 -1.133 0 C-N-CA 119.333 -1.413 . . . . 0.0 113.401 -178.097 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 37.7 m -150.35 126.24 10.44 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 178.159 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 2.3 p -84.18 133.18 34.61 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 115.457 -0.792 . . . . 0.0 112.047 -177.09 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.534 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 4.2 mm? -118.69 141.91 48.16 Favored 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 175.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 44.6 t -123.47 -42.59 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 175.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 175.49 81.0 0.05 OUTLIER Glycine 0 N--CA 1.409 -3.164 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.552 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 27.1 m -100.91 -177.39 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.217 0 CA-C-N 114.197 -1.002 . . . . 0.0 109.532 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 72.0 p -76.1 163.4 27.15 Favored 'General case' 0 N--CA 1.432 -1.359 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 177.304 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -61.93 -31.85 72.2 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.651 0.739 . . . . 0.0 109.412 177.013 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 28.1 t -72.69 -42.6 64.05 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.872 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 19.4 t80 -62.46 -47.81 82.4 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.586 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.72 -40.32 94.64 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.577 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.73 -28.84 69.35 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.499 0.666 . . . . 0.0 110.959 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.8 m -85.16 -16.94 38.75 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.171 -177.4 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.586 HG12 ' O ' ' B' ' 76' ' ' ALA . 4.2 p -72.91 -28.25 26.5 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.518 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 -179.236 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 55.2 mt -71.81 -7.14 46.48 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 114.09 -1.414 . . . . 0.0 110.815 177.264 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 88.3 mtt180 -103.65 -14.7 16.03 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 121.37 0.605 . . . . 0.0 109.707 178.192 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 -86.59 -29.03 22.91 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.471 176.717 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.674 ' HB ' HG11 ' B' ' 87' ' ' VAL . 9.3 p -69.49 170.08 11.27 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 115.402 1.63 . . . . 0.0 115.402 -173.392 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 35.1 mttp -73.56 -162.4 0.13 Allowed 'General case' 0 C--O 1.241 0.622 0 CA-C-N 114.845 -1.07 . . . . 0.0 110.253 173.384 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 85' ' ' GLY . . . . . 0.412 ' HA2' ' HG2' ' B' ' 12' ' ' LYS . . . -80.0 -38.5 19.06 Favored Glycine 0 N--CA 1.437 -1.291 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.871 178.277 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 41.0 ttm180 -120.96 123.52 42.65 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.674 HG11 ' HB ' ' B' ' 83' ' ' THR . 26.7 m -139.71 142.76 31.88 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 CA-C-O 120.867 0.365 . . . . 0.0 111.543 -177.767 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 88' ' ' ARG . . . . . 0.488 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 52.2 mtt180 -99.4 116.68 32.13 Favored 'General case' 0 CA--C 1.485 -1.556 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.164 176.528 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.5 ' CE2' HD11 ' B' ' 54' ' ' ILE . 6.8 m-85 -92.91 152.44 19.37 Favored 'General case' 0 C--N 1.285 -2.234 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.507 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 90' ' ' MET . . . . . . . . . . . . . 86.0 mtp -102.1 106.98 17.93 Favored 'General case' 0 C--N 1.286 -2.177 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 171.27 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.454 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.4 mp -84.77 120.86 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.942 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 92' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -117.27 109.95 1.97 Allowed Glycine 1 CA--C 1.445 -4.283 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 179.219 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 7.3 tpp180 . . . . . 0 C--N 1.279 -2.475 0 CA-C-N 114.6 -0.8 . . . . 0.0 109.431 177.122 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 19.7 ptp . . . . . 0 N--CA 1.425 -1.709 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -84.99 104.93 15.37 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 -177.636 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -79.55 83.73 5.5 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 173.527 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -102.58 143.02 25.76 Favored Pre-proline 0 C--N 1.294 -1.845 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.396 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 7' ' ' PRO . . . . . 0.536 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 51.1 Cg_endo -79.28 134.61 11.53 Favored 'Trans proline' 0 N--CA 1.429 -2.267 0 C-N-CA 121.634 1.556 . . . . 0.0 112.291 177.77 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 73.4 t -115.22 127.54 72.75 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 175.272 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 9' ' ' GLU . . . . . 0.497 ' O ' ' HD2' ' B' ' 53' ' ' ARG . 43.3 tt0 -119.59 116.12 25.38 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 -176.291 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.626 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -102.41 153.27 20.19 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.766 0.793 . . . . 0.0 110.761 -177.949 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.443 ' H ' HD23 ' B' ' 10' ' ' LEU . 80.4 mm-40 -99.68 103.36 15.03 Favored 'General case' 0 C--N 1.276 -2.607 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 174.718 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 12' ' ' LYS . . . . . 0.438 ' HE2' ' HB3' ' B' ' 12' ' ' LYS . 6.5 mmmm -81.61 157.02 24.86 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 114.301 1.223 . . . . 0.0 114.301 -171.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 13' ' ' ASP . . . . . 0.498 ' H ' ' HA3' ' B' ' 16' ' ' GLY . 22.1 m-20 -128.47 178.82 6.02 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 171.184 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 14.7 m -74.61 -19.56 60.26 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.652 0.739 . . . . 0.0 110.033 177.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 9.2 tp10 -128.56 31.49 4.98 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 105.762 -1.94 . . . . 0.0 105.762 176.04 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.498 ' HA3' ' H ' ' B' ' 13' ' ' ASP . . . -71.21 -5.03 58.16 Favored Glycine 0 CA--C 1.494 -1.263 0 CA-C-N 113.662 -1.608 . . . . 0.0 116.481 -169.181 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -75.16 86.45 2.41 Favored 'General case' 0 N--CA 1.429 -1.488 0 C-N-CA 119.302 -0.959 . . . . 0.0 111.096 177.851 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -96.78 55.45 1.37 Allowed Glycine 0 CA--C 1.484 -1.85 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 6.6 pt -161.67 -177.49 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 C-N-CA 124.7 1.2 . . . . 0.0 107.92 -175.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 20' ' ' SER . . . . . 0.434 ' HB2' HG22 ' B' ' 41' ' ' THR . 43.2 m -149.65 145.61 26.83 Favored 'General case' 0 C--N 1.27 -2.865 0 N-CA-C 105.425 -2.065 . . . . 0.0 105.425 172.791 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.458 ' HB ' HG22 ' B' ' 37' ' ' ILE . 16.0 pt -115.95 154.1 17.48 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.297 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.3 tp -127.08 136.79 59.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 CA-C-O 120.884 0.374 . . . . 0.0 110.764 -176.044 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.58 98.08 2.38 Favored Glycine 0 N--CA 1.434 -1.438 0 C-N-CA 121.058 -0.591 . . . . 0.0 111.791 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 95.4 mmm . . . . . 0 C--N 1.302 -1.492 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 178.408 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 74.9 mt . . . . . 0 N--CA 1.431 -1.399 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -107.75 98.27 1.24 Allowed Glycine 0 N--CA 1.404 -3.437 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 176.443 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.458 HG22 ' HB ' ' B' ' 21' ' ' ILE . 27.9 mm -87.35 87.78 2.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 177.058 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -85.69 166.54 16.06 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.399 -1.273 . . . . 0.0 108.705 -176.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 57.4 t -77.9 136.47 24.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 175.107 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -96.04 -42.07 8.44 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -178.309 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 41' ' ' THR . . . . . 0.463 ' HA ' HG23 ' B' ' 56' ' ' VAL . 3.5 t -157.05 168.8 26.41 Favored 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 21.3 t -130.47 97.35 3.19 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 178.265 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 40.5 m -73.89 124.64 26.54 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 124.281 1.033 . . . . 0.0 111.709 -176.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 44' ' ' GLU . . . . . 0.579 ' HA ' ' HB3' ' B' ' 49' ' ' HIS . 1.7 pm0 -65.53 -22.41 66.71 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 124.44 1.096 . . . . 0.0 113.904 -178.042 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.54 -23.87 72.23 Favored Glycine 0 N--CA 1.439 -1.128 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.243 176.214 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -104.4 173.15 21.01 Favored Glycine 0 N--CA 1.424 -2.163 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.837 -177.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 47' ' ' ALA . . . . . 0.404 ' HB2' ' OD2' ' B' ' 13' ' ' ASP . . . -58.54 -41.34 85.34 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 125.205 1.402 . . . . 0.0 114.265 -175.647 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 48' ' ' ALA . . . . . 0.626 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -57.19 -37.52 72.28 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -173.39 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 49' ' ' HIS . . . . . 0.579 ' HB3' ' HA ' ' B' ' 44' ' ' GLU . 8.4 t60 -74.97 -35.4 62.07 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -178.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 68.9 mtt180 -68.43 -47.74 66.41 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 -178.452 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -60.41 -61.39 2.63 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 114.456 -1.247 . . . . 0.0 110.722 176.476 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 91.02 6.14 67.23 Favored Glycine 0 N--CA 1.433 -1.528 0 N-CA-C 114.824 0.69 . . . . 0.0 114.824 175.144 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.497 ' HD2' ' O ' ' B' ' 9' ' ' GLU . 65.4 mtt180 -83.3 -33.64 25.9 Favored 'General case' 0 N--CA 1.441 -0.892 0 CA-C-N 118.392 1.096 . . . . 0.0 111.316 179.107 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.445 HD11 ' CE2' ' B' ' 89' ' ' PHE . 28.8 mt -83.29 117.03 28.4 Favored 'Isoleucine or valine' 0 C--O 1.248 0.984 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 174.116 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 22.7 mt-30 -91.45 163.96 13.99 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 121.356 0.598 . . . . 0.0 110.47 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.463 HG23 ' HA ' ' B' ' 41' ' ' THR . 13.2 p -75.51 -2.11 3.79 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.854 0 CA-C-O 122.488 1.137 . . . . 0.0 109.976 178.361 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -114.02 0.06 14.21 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.058 -175.597 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -82.29 174.34 11.23 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 112.926 0.713 . . . . 0.0 112.926 -174.076 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 25.8 tp -141.6 131.15 23.91 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.54 -0.755 . . . . 0.0 110.521 -175.539 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -81.71 95.63 7.29 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.688 0.756 . . . . 0.0 110.22 178.227 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.569 ' HB ' ' O ' ' B' ' 90' ' ' MET . 27.8 t -86.95 -40.73 14.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.695 177.03 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.536 ' HG3' ' HA ' ' B' ' 67' ' ' SER . 32.4 tt0 -156.2 148.75 23.72 Favored 'General case' 0 C--N 1.273 -2.727 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.48 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.513 ' O ' ' HG2' ' B' ' 62' ' ' GLU . 9.9 p -102.39 -168.45 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 104.912 -2.255 . . . . 0.0 104.912 176.419 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.425 ' H ' HG22 ' B' ' 63' ' ' VAL . 12.2 t70 -50.19 -54.21 22.47 Favored 'General case' 0 N--CA 1.479 1.004 0 CA-C-N 119.189 0.904 . . . . 0.0 112.27 178.369 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -106.16 -53.78 0.73 Allowed Glycine 0 C--N 1.308 -0.989 0 C-N-CA 119.538 -1.315 . . . . 0.0 114.088 -178.3 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 6.1 m -72.37 120.81 18.51 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 123.101 0.56 . . . . 0.0 112.492 -174.732 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 67' ' ' SER . . . . . 0.536 ' HA ' ' HG3' ' B' ' 62' ' ' GLU . 64.9 m -86.12 121.15 28.31 Favored 'General case' 0 N--CA 1.435 -1.204 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 174.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.471 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 28.9 mt -83.3 100.23 10.51 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-O 121.087 0.47 . . . . 0.0 110.226 -179.308 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 29.0 m -89.48 12.5 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-O 121.759 0.79 . . . . 0.0 109.463 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 111.71 90.23 1.94 Allowed Glycine 0 N--CA 1.402 -3.615 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -174.84 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 26.4 m -117.15 174.4 3.73 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.28 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 20.7 p -76.87 159.86 29.7 Favored 'General case' 0 N--CA 1.413 -2.281 0 CA-C-O 120.957 0.408 . . . . 0.0 110.051 177.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 60.6 tt0 -58.66 -35.28 72.29 Favored 'General case' 0 C--N 1.311 -1.096 0 C-N-CA 123.788 0.835 . . . . 0.0 109.824 178.768 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 19.7 m -70.96 -39.14 72.73 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.576 179.559 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -62.56 -48.9 77.45 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.068 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.516 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -57.81 -45.42 86.11 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.258 179.304 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.01 -39.19 91.42 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.641 0.734 . . . . 0.0 110.792 178.553 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 50.6 m -71.83 -27.5 62.95 Favored 'General case' 0 N--CA 1.433 -1.32 0 CA-C-N 115.377 -0.829 . . . . 0.0 112.511 -177.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.516 HG12 ' O ' ' B' ' 76' ' ' ALA . 5.0 p -77.25 -30.4 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 C-N-CA 119.546 -0.862 . . . . 0.0 108.852 -177.164 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 80' ' ' LEU . . . . . 0.491 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 77.1 mt -67.46 -35.85 80.01 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.306 176.08 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 79.4 mtp180 -78.05 -32.74 51.01 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.275 178.317 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -72.3 -36.71 69.0 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 123.234 0.614 . . . . 0.0 111.478 -179.081 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.667 ' HB ' HG11 ' B' ' 87' ' ' VAL . 8.5 p -67.82 159.81 29.57 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 113.693 0.997 . . . . 0.0 113.693 -177.117 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -66.56 -166.07 0.04 OUTLIER 'General case' 0 C--O 1.255 1.371 0 C-N-CA 125.729 1.612 . . . . 0.0 114.806 -174.848 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 85' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' B' ' 12' ' ' LYS . . . -70.86 -17.12 75.03 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 114.631 -1.168 . . . . 0.0 113.3 -177.514 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 86' ' ' ARG . . . . . 0.522 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 57.1 ttp180 -157.49 118.3 3.54 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 121.165 0.507 . . . . 0.0 111.016 174.465 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.667 HG11 ' HB ' ' B' ' 83' ' ' THR . 14.8 m -132.1 145.72 34.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.237 179.351 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -98.05 128.89 44.85 Favored 'General case' 0 CA--C 1.482 -1.654 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.518 178.402 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.536 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 4.8 m-85 -105.38 157.36 17.39 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 106.965 -1.495 . . . . 0.0 106.965 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.569 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 63.0 mtt -109.87 117.51 34.02 Favored 'General case' 0 C--N 1.282 -2.352 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 172.134 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 1.4 mp -105.96 122.38 59.5 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 -179.157 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.37 103.76 2.51 Favored Glycine 0 CA--C 1.464 -3.11 0 N-CA-C 109.169 -1.573 . . . . 0.0 109.169 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 9.3 tpp180 . . . . . 0 C--N 1.265 -3.073 0 CA-C-N 114.214 -0.993 . . . . 0.0 110.572 -175.749 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 92.8 mmm . . . . . 0 CA--C 1.469 -2.171 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 4' ' ' GLU . . . . . 0.491 ' OE2' ' HD2' ' B' ' 93' ' ' ARG . 12.0 mt-10 -98.62 96.4 7.92 Favored 'General case' 0 C--N 1.275 -2.643 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.013 -175.614 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -84.38 97.51 9.52 Favored 'General case' 0 N--CA 1.427 -1.606 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 177.201 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -130.85 147.48 66.39 Favored Pre-proline 0 C--N 1.279 -2.495 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.481 177.534 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 7' ' ' PRO . . . . . 0.442 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 49.7 Cg_endo -75.84 136.89 19.28 Favored 'Trans proline' 0 N--CA 1.44 -1.65 0 C-N-CA 121.868 1.712 . . . . 0.0 111.625 175.831 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 91.4 t -121.56 148.54 24.93 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.071 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.091 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -126.98 143.65 51.23 Favored 'General case' 0 C--N 1.279 -2.469 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -177.451 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.55 HD11 ' HB2' ' B' ' 48' ' ' ALA . 0.8 OUTLIER -141.04 157.18 45.67 Favored 'General case' 0 CA--C 1.478 -1.789 0 CA-C-O 121.05 0.452 . . . . 0.0 109.908 174.431 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -127.15 112.59 15.32 Favored 'General case' 0 C--N 1.275 -2.632 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 177.491 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 5.4 ptpp? -77.14 150.77 35.55 Favored 'General case' 0 C--N 1.283 -2.317 0 CA-C-N 115.143 -0.935 . . . . 0.0 113.357 -172.017 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -93.78 -172.93 3.01 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 177.698 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 12.3 t -71.25 -25.65 62.57 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.954 -1.499 . . . . 0.0 106.954 173.09 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 11.9 tp10 -67.27 -20.87 65.71 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.444 172.411 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.07 -116.06 4.83 Favored Glycine 0 N--CA 1.416 -2.657 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -177.188 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -101.2 -175.06 2.76 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -178.684 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 18' ' ' GLY . . . . . 0.432 ' CA ' ' HA3' ' B' ' 46' ' ' GLY . . . -150.45 67.99 0.34 Allowed Glycine 0 CA--C 1.477 -2.325 0 N-CA-C 110.931 -0.868 . . . . 0.0 110.931 -179.754 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.466 ' HA ' ' H ' ' B' ' 43' ' ' THR . 4.3 pt -162.59 169.98 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 C-N-CA 125.277 1.431 . . . . 0.0 107.867 -176.527 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.4 m -131.76 141.99 49.65 Favored 'General case' 0 C--N 1.253 -3.611 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 174.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.502 ' HB ' HG22 ' B' ' 37' ' ' ILE . 8.6 pt -115.23 149.37 17.47 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.012 0 O-C-N 123.45 0.469 . . . . 0.0 109.81 -178.188 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.1 tp -119.22 134.88 61.42 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -177.465 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.74 94.58 1.55 Allowed Glycine 0 N--CA 1.43 -1.707 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.688 -177.271 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 88.9 mmm . . . . . 0 C--O 1.253 1.268 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.934 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 78.6 mt . . . . . 0 C--O 1.235 0.331 0 N-CA-C 113.955 1.094 . . . . 0.0 113.955 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -111.18 103.64 1.61 Allowed Glycine 0 N--CA 1.423 -2.212 0 N-CA-C 108.614 -1.794 . . . . 0.0 108.614 175.789 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.502 HG22 ' HB ' ' B' ' 21' ' ' ILE . 26.3 mm -94.15 90.38 2.8 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-O 121.674 0.749 . . . . 0.0 109.403 -177.759 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -88.79 167.07 13.59 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.207 -178.128 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 64.7 t -80.77 130.3 36.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 CA-C-O 121.28 0.562 . . . . 0.0 109.641 175.387 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -94.42 -41.11 9.56 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.218 -176.681 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -156.57 164.0 38.7 Favored 'General case' 0 N--CA 1.437 -1.082 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.412 ' HA ' HG22 ' B' ' 19' ' ' ILE . 21.3 t -112.05 102.52 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.031 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 174.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.466 ' H ' ' HA ' ' B' ' 19' ' ' ILE . 31.2 m -69.73 122.04 18.38 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 124.112 0.965 . . . . 0.0 111.825 -174.357 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 44' ' ' GLU . . . . . 0.473 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 32.8 mt-10 -58.23 -41.45 84.15 Favored 'General case' 0 CA--C 1.507 -0.695 0 C-N-CA 124.662 1.185 . . . . 0.0 111.736 -175.568 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -67.22 -12.24 60.37 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 115.197 -0.911 . . . . 0.0 114.237 -177.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.432 ' HA3' ' CA ' ' B' ' 18' ' ' GLY . . . -112.23 170.0 13.35 Favored Glycine 0 N--CA 1.41 -3.078 0 C-N-CA 120.124 -1.036 . . . . 0.0 113.797 -175.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -57.64 -35.07 70.02 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 115.045 1.498 . . . . 0.0 115.045 -171.863 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 48' ' ' ALA . . . . . 0.55 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -67.53 -35.46 79.12 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 119.952 -0.699 . . . . 0.0 112.695 -174.396 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 49' ' ' HIS . . . . . 0.473 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 5.4 t60 -78.53 -39.62 37.38 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 64.4 mtp180 -67.13 -39.48 86.6 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.683 -177.68 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -79.56 -48.63 13.51 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 177.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 94.15 51.22 2.1 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -178.452 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 13.1 mmt180 -109.75 -79.44 0.58 Allowed 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 111.85 0.315 . . . . 0.0 111.85 -175.673 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.488 HD11 ' CE2' ' B' ' 89' ' ' PHE . 62.7 mt -71.16 132.7 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.977 -179.203 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 -103.58 173.51 6.27 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.234 0.54 . . . . 0.0 110.996 -177.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.1 p -79.27 2.43 2.17 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.145 0 CA-C-O 121.949 0.88 . . . . 0.0 111.638 -174.662 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -121.46 11.36 10.65 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 122.218 1.009 . . . . 0.0 108.683 -175.316 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 19.2 m-20 -89.07 168.49 12.29 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.929 -175.858 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.511 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 23.5 tp -144.69 131.47 20.14 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 124.008 0.923 . . . . 0.0 108.83 -177.877 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 76.6 mt -85.08 94.23 8.8 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.506 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.2 t -80.09 -39.96 19.89 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 CA-C-O 121.739 0.78 . . . . 0.0 110.147 177.864 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -160.0 156.73 27.53 Favored 'General case' 0 C--N 1.28 -2.451 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.41 173.046 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.426 HG22 ' H ' ' B' ' 64' ' ' ASP . 5.7 p -102.01 -173.74 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 N-CA-C 105.455 -2.054 . . . . 0.0 105.455 177.635 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.436 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 18.0 t70 -53.79 -48.75 69.49 Favored 'General case' 0 C--N 1.311 -1.093 0 C-N-CA 122.992 0.517 . . . . 0.0 112.387 -179.471 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -101.87 -60.21 0.77 Allowed Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 120.22 -0.991 . . . . 0.0 114.187 -179.278 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 9.1 m -77.57 129.66 35.93 Favored 'General case' 0 CA--C 1.557 1.248 0 CA-C-O 121.164 0.507 . . . . 0.0 112.201 -176.119 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 49.4 m -94.44 121.84 36.39 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.058 178.358 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.506 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 32.0 mt -88.9 111.89 22.64 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.105 0.478 . . . . 0.0 111.838 -175.352 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 43.6 t -85.57 -23.67 7.06 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 174.597 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 147.63 68.6 0.01 OUTLIER Glycine 0 CA--C 1.475 -2.42 0 N-CA-C 109.396 -1.481 . . . . 0.0 109.396 -177.471 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 28.2 m -85.22 172.08 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 CA-C-N 114.467 -0.867 . . . . 0.0 109.383 -177.094 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 24.6 p -71.7 157.2 38.36 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 120.93 0.395 . . . . 0.0 110.138 177.502 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -57.43 -39.4 76.13 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 123.345 0.658 . . . . 0.0 110.458 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 40.0 t -68.17 -37.8 81.38 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.01 179.742 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -66.44 -45.45 79.79 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -179.124 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.591 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.2 -44.02 97.95 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.505 178.426 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.98 -34.12 75.58 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 121.756 0.788 . . . . 0.0 110.599 177.756 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 39.3 m -79.31 -27.68 42.16 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 115.489 -0.778 . . . . 0.0 112.094 -178.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.591 HG12 ' O ' ' B' ' 76' ' ' ALA . 4.5 p -71.53 -31.97 44.43 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-O 121.906 0.86 . . . . 0.0 109.07 -175.711 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 53.9 mt -66.03 -29.44 69.8 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 114.528 -1.214 . . . . 0.0 110.553 176.425 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 71.4 mtt180 -90.74 -16.85 27.71 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.373 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -90.38 -14.65 32.58 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.038 0.447 . . . . 0.0 111.268 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.722 ' HB ' HG11 ' B' ' 87' ' ' VAL . 6.7 p -90.63 171.76 9.16 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 77.1 mttt -60.37 -178.7 0.09 Allowed 'General case' 0 C--O 1.245 0.817 0 C-N-CA 124.612 1.165 . . . . 0.0 114.077 -179.06 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.38 -52.06 46.98 Favored Glycine 0 N--CA 1.44 -1.049 0 CA-C-N 114.208 -1.36 . . . . 0.0 111.117 177.367 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 14.5 ttp180 -114.82 117.64 31.31 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 177.068 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.722 HG11 ' HB ' ' B' ' 83' ' ' THR . 14.0 m -132.13 157.57 43.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.353 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 15.9 mtm180 -108.5 152.64 24.45 Favored 'General case' 0 N--CA 1.422 -1.833 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 179.435 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.488 ' CE2' HD11 ' B' ' 54' ' ' ILE . 1.7 m-85 -133.5 164.99 25.91 Favored 'General case' 0 C--N 1.267 -3.004 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 179.555 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.457 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 84.3 mtp -112.82 117.43 32.14 Favored 'General case' 0 C--N 1.286 -2.195 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 170.571 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.511 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.5 mp -102.88 133.18 47.36 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.395 -177.11 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -113.6 93.86 0.68 Allowed Glycine 0 CA--C 1.463 -3.208 0 N-CA-C 108.18 -1.968 . . . . 0.0 108.18 172.401 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 93' ' ' ARG . . . . . 0.491 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 36.8 ttm180 . . . . . 0 C--N 1.273 -2.754 0 CA-C-N 114.244 -0.978 . . . . 0.0 111.152 -175.846 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 20.2 ptp . . . . . 0 N--CA 1.437 -1.086 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 4' ' ' GLU . . . . . 0.489 ' OE2' ' HG2' ' B' ' 93' ' ' ARG . 2.6 mt-10 -116.35 101.56 8.77 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -93.1 91.04 7.13 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 -179.125 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -117.67 146.52 38.9 Favored Pre-proline 0 C--N 1.29 -1.998 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.307 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -81.1 144.25 14.72 Favored 'Trans proline' 0 N--CA 1.449 -1.089 0 C-N-CA 122.5 2.133 . . . . 0.0 112.811 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.588 HG13 ' HB3' ' B' ' 53' ' ' ARG . 73.6 t -127.94 133.87 66.39 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.032 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.73 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -121.24 125.49 47.24 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 118.477 0.58 . . . . 0.0 110.173 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.449 ' CD1' ' H ' ' B' ' 54' ' ' ILE . 0.9 OUTLIER -148.82 175.95 10.81 Favored 'General case' 0 N--CA 1.438 -1.037 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -178.188 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -147.03 178.02 8.69 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.086 -178.622 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -93.02 153.85 18.48 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.248 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 13' ' ' ASP . . . . . 0.559 ' HB2' ' N ' ' B' ' 47' ' ' ALA . 10.8 t70 -103.17 -164.37 1.07 Allowed 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 22.8 p -55.43 -44.28 76.14 Favored 'General case' 0 C--O 1.243 0.756 0 C-N-CA 124.558 1.143 . . . . 0.0 111.57 -179.053 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -78.3 -48.72 15.06 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 177.78 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.08 -120.54 1.64 Allowed Glycine 0 N--CA 1.426 -2.006 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.831 178.171 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -89.23 101.4 14.06 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 121.397 0.618 . . . . 0.0 111.293 -178.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -92.12 59.84 2.7 Favored Glycine 0 C--O 1.21 -1.369 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 177.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.499 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.0 pt -155.46 178.92 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 C-N-CA 125.406 1.482 . . . . 0.0 107.128 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 20' ' ' SER . . . . . 0.472 ' HB2' HG22 ' B' ' 41' ' ' THR . 51.0 m -158.19 155.81 29.71 Favored 'General case' 0 C--N 1.27 -2.88 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 176.55 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.457 ' HB ' HG22 ' B' ' 37' ' ' ILE . 18.6 pt -115.71 161.12 14.69 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 O-C-N 123.445 0.466 . . . . 0.0 110.343 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 22' ' ' ILE . . . . . 0.429 ' HA ' ' NE2' ' B' ' 73' ' ' GLN . 8.1 tp -140.5 135.51 35.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.24 112.11 3.85 Favored Glycine 0 N--CA 1.428 -1.846 0 C-N-CA 120.494 -0.86 . . . . 0.0 111.982 -178.237 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 93.9 mmm . . . . . 0 C--N 1.302 -1.476 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 176.964 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 35' ' ' LEU . . . . . 0.514 ' O ' ' HA2' ' B' ' 70' ' ' GLY . 3.0 mm? . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 113.164 0.802 . . . . 0.0 113.164 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -99.0 103.82 2.8 Favored Glycine 0 N--CA 1.414 -2.805 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.854 -176.326 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.457 HG22 ' HB ' ' B' ' 21' ' ' ILE . 30.2 mm -88.45 89.2 3.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.876 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.566 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.477 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 89.6 m-85 -82.3 173.45 12.06 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 114.674 -1.148 . . . . 0.0 109.981 -176.639 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.41 HG11 ' O ' ' B' ' 55' ' ' GLN . 59.3 t -83.42 137.09 21.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 175.873 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 32.2 ttmt -93.77 -48.87 6.11 Favored 'General case' 0 N--CA 1.433 -1.289 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.784 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 41' ' ' THR . . . . . 0.495 ' HA ' HG23 ' B' ' 56' ' ' VAL . 5.2 t -150.03 170.79 18.05 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.499 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.7 p -156.42 113.25 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 C-N-CA 124.587 1.155 . . . . 0.0 108.005 -177.774 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.415 HG22 ' H ' ' B' ' 45' ' ' GLY . 32.1 m -112.14 144.81 40.91 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 114.856 -1.066 . . . . 0.0 110.061 -171.199 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 44' ' ' GLU . . . . . 0.478 ' HA ' ' HB3' ' B' ' 49' ' ' HIS . 9.0 pt-20 -71.75 4.46 3.23 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -178.651 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 45' ' ' GLY . . . . . 0.415 ' H ' HG22 ' B' ' 43' ' ' THR . . . -74.79 -19.5 79.89 Favored Glycine 0 N--CA 1.436 -1.329 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 172.753 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -113.03 169.49 12.97 Favored Glycine 0 N--CA 1.413 -2.86 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 175.532 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 47' ' ' ALA . . . . . 0.559 ' N ' ' HB2' ' B' ' 13' ' ' ASP . . . -75.18 -23.94 57.78 Favored 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 115.096 -0.552 . . . . 0.0 111.274 -175.251 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 48' ' ' ALA . . . . . 0.446 ' HA ' ' CD1' ' B' ' 10' ' ' LEU . . . -56.46 -44.56 80.67 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -176.111 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 49' ' ' HIS . . . . . 0.479 ' HB2' HG22 ' B' ' 42' ' ' VAL . 10.3 t60 -73.49 -41.27 63.32 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.381 -179.059 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 81.5 mtp180 -72.42 -34.88 68.15 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.43 0.633 . . . . 0.0 110.945 -174.771 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 51' ' ' ASP . . . . . 0.502 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 30.4 t70 -72.42 -49.99 29.55 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.889 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.7 27.49 9.64 Favored Glycine 0 CA--C 1.494 -1.259 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.486 172.132 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.588 ' HB3' HG13 ' B' ' 8' ' ' VAL . 5.4 mpt_? -101.39 -60.17 1.57 Allowed 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 112.008 0.373 . . . . 0.0 112.008 -179.276 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.567 HD11 ' CE2' ' B' ' 89' ' ' PHE . 58.7 mt -72.79 134.82 29.04 Favored 'Isoleucine or valine' 0 C--O 1.251 1.157 0 N-CA-C 107.1 -1.445 . . . . 0.0 107.1 169.61 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 55' ' ' GLN . . . . . 0.41 ' O ' HG11 ' B' ' 39' ' ' VAL . 15.3 mm100 -110.19 -170.74 1.7 Allowed 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -174.9 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.495 HG23 ' HA ' ' B' ' 41' ' ' THR . 8.0 p -100.39 4.87 10.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 CA-C-O 121.567 0.698 . . . . 0.0 110.083 174.877 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 19.9 t-20 -133.28 10.98 4.16 Favored 'General case' 0 C--N 1.311 -1.104 0 O-C-N 121.623 -0.673 . . . . 0.0 111.965 -174.757 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -94.86 -173.64 3.04 Favored 'General case' 0 C--N 1.318 -0.804 0 O-C-N 121.308 -0.87 . . . . 0.0 111.381 179.127 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.477 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 25.8 tp -144.92 125.4 13.98 Favored 'General case' 0 C--N 1.318 -0.769 0 C-N-CA 123.194 0.598 . . . . 0.0 111.116 -172.568 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 60' ' ' LEU . . . . . 0.438 ' O ' HD12 ' B' ' 68' ' ' LEU . 68.9 mt -83.69 96.49 8.72 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.399 0.618 . . . . 0.0 109.369 178.799 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.571 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 9.2 t -79.28 -37.32 18.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-O 121.685 0.755 . . . . 0.0 111.133 178.826 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.401 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 10.4 pt-20 -157.02 153.51 28.09 Favored 'General case' 0 C--N 1.276 -2.608 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.506 176.032 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.464 HG22 ' H ' ' B' ' 64' ' ' ASP . 5.2 p -100.52 -174.63 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.42 -1.975 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 178.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.464 ' H ' HG22 ' B' ' 63' ' ' VAL . 28.1 t70 -53.18 -42.46 66.23 Favored 'General case' 0 C--N 1.311 -1.078 0 C-N-CA 124.138 0.975 . . . . 0.0 112.475 -178.214 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -106.91 -66.24 0.63 Allowed Glycine 0 N--CA 1.439 -1.161 0 C-N-CA 120.813 -0.708 . . . . 0.0 113.627 179.199 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 7.2 m -74.1 135.7 42.96 Favored 'General case' 0 CA--C 1.554 1.099 0 C-N-CA 122.882 0.473 . . . . 0.0 112.266 -175.624 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 15.9 m -96.31 126.49 41.55 Favored 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 177.116 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.571 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 28.9 mt -83.28 -69.86 0.6 Allowed 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 112.241 0.459 . . . . 0.0 112.241 -177.131 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 86.8 t 73.28 -27.2 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 124.189 0.995 . . . . 0.0 111.246 -175.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 70' ' ' GLY . . . . . 0.514 ' HA2' ' O ' ' B' ' 35' ' ' LEU . . . 153.16 81.39 0.03 OUTLIER Glycine 0 N--CA 1.42 -2.404 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -178.211 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.1 m -106.76 -179.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.71 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 39.9 p -78.63 156.51 29.03 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 175.213 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 73' ' ' GLN . . . . . 0.429 ' NE2' ' HA ' ' B' ' 22' ' ' ILE . 61.9 tt0 -58.4 -39.4 79.6 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.23 0.538 . . . . 0.0 110.637 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 14.9 m -66.82 -35.47 80.12 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.73 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -65.33 -49.36 69.71 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 179.049 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.553 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -59.51 -40.73 88.03 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.069 178.586 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.34 -32.65 73.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.331 0.586 . . . . 0.0 110.468 177.674 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.6 m -79.25 -28.44 42.43 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.454 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.553 HG12 ' O ' ' B' ' 76' ' ' ALA . 5.7 p -72.6 -36.31 53.23 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.889 0 C-N-CA 119.574 -0.851 . . . . 0.0 109.172 -176.559 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 26.3 mt -70.44 -7.14 40.97 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.848 178.225 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 68.5 mtp180 -108.66 -1.51 19.44 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 121.617 0.723 . . . . 0.0 110.102 177.438 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 32.2 m-80 -115.06 6.41 15.2 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.067 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.53 HG23 ' O ' ' B' ' 79' ' ' VAL . 7.7 p -87.2 175.81 7.87 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.323 -178.825 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 28.8 mmtm -75.64 -169.18 0.99 Allowed 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.472 0.709 . . . . 0.0 109.733 174.357 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.17 -38.97 45.93 Favored Glycine 0 N--CA 1.444 -0.827 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 177.784 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -124.31 131.56 53.52 Favored 'General case' 0 N--CA 1.431 -1.397 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.51 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.516 HG11 ' HB ' ' B' ' 83' ' ' THR . 11.2 m -142.08 153.01 18.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 CA-C-O 121.53 0.681 . . . . 0.0 111.445 -179.584 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 -96.05 164.07 12.86 Favored 'General case' 0 C--N 1.291 -1.975 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 174.05 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.567 ' CE2' HD11 ' B' ' 54' ' ' ILE . 8.9 m-85 -145.28 157.33 44.08 Favored 'General case' 0 C--N 1.284 -2.261 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 177.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.505 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 81.0 mtp -112.38 120.15 40.69 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 169.694 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.464 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -98.58 119.04 46.06 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.164 0 CA-C-N 114.246 -1.343 . . . . 0.0 109.485 -175.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -96.93 93.3 1.45 Allowed Glycine 0 CA--C 1.457 -3.57 0 N-CA-C 106.96 -2.456 . . . . 0.0 106.96 172.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 93' ' ' ARG . . . . . 0.489 ' HG2' ' OE2' ' B' ' 4' ' ' GLU . 5.9 tpt180 . . . . . 0 C--N 1.257 -3.429 0 CA-C-N 112.932 -1.634 . . . . 0.0 113.129 -174.278 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.438 -1.033 0 N-CA-C 104.704 -2.332 . . . . 0.0 104.704 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 4' ' ' GLU . . . . . 0.57 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 18.4 mt-10 -87.72 101.08 13.33 Favored 'General case' 0 C--N 1.293 -1.871 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.263 -171.128 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -85.62 85.73 7.4 Favored 'General case' 0 N--CA 1.428 -1.531 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 176.101 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -109.43 142.43 25.66 Favored Pre-proline 0 C--N 1.295 -1.801 0 C-N-CA 120.461 -0.496 . . . . 0.0 112.229 -178.026 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 7' ' ' PRO . . . . . 0.422 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 42.0 Cg_endo -80.34 126.4 6.17 Favored 'Trans proline' 0 N--CA 1.428 -2.371 0 C-N-CA 121.943 1.762 . . . . 0.0 112.541 177.105 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 95.2 t -107.08 151.94 8.78 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.82 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 175.685 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 9' ' ' GLU . . . . . 0.464 ' O ' ' HG2' ' B' ' 53' ' ' ARG . 45.0 tt0 -138.12 136.16 36.46 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 119.005 0.82 . . . . 0.0 109.696 -176.085 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.523 HD21 ' HA ' ' B' ' 48' ' ' ALA . 4.5 mt -139.34 165.31 27.54 Favored 'General case' 0 CA--C 1.475 -1.906 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 179.625 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -151.12 146.68 26.31 Favored 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 104.503 -2.406 . . . . 0.0 104.503 177.348 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.5 ptpt -88.41 171.33 10.2 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.883 0.849 . . . . 0.0 112.177 -174.184 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 13' ' ' ASP . . . . . 0.412 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 19.5 t70 -99.92 176.61 5.37 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.804 -1.089 . . . . 0.0 108.214 176.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 7.0 m -59.66 -33.12 71.14 Favored 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 123.939 0.895 . . . . 0.0 109.261 175.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -77.15 -45.63 26.11 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 174.694 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.25 -138.36 7.65 Favored Glycine 0 N--CA 1.435 -1.406 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.273 179.255 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 91.8 mt -82.03 -176.24 6.04 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 123.033 0.533 . . . . 0.0 110.99 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 18' ' ' GLY . . . . . 0.418 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -158.13 66.06 0.29 Allowed Glycine 0 CA--C 1.487 -1.665 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.614 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 pt -166.73 175.91 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.49 -1.361 0 C-N-CA 124.815 1.246 . . . . 0.0 108.408 -177.55 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 20' ' ' SER . . . . . 0.406 ' HB2' HG22 ' B' ' 41' ' ' THR . 29.2 m -148.53 144.17 27.14 Favored 'General case' 0 C--N 1.27 -2.859 0 N-CA-C 105.784 -1.932 . . . . 0.0 105.784 174.011 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.497 ' HB ' HG22 ' B' ' 37' ' ' ILE . 11.0 pt -115.09 158.13 15.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 CA-C-N 117.866 0.303 . . . . 0.0 110.395 -177.764 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 10.3 tp -139.32 140.75 37.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-O 120.636 0.255 . . . . 0.0 110.415 -176.658 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -91.24 109.53 3.72 Favored Glycine 0 N--CA 1.435 -1.398 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.687 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 66.2 mtt . . . . . 0 C--N 1.308 -1.226 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 177.084 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 70.1 mt . . . . . 0 N--CA 1.433 -1.286 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -96.85 109.97 3.95 Favored Glycine 0 N--CA 1.419 -2.46 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.296 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.497 HG22 ' HB ' ' B' ' 21' ' ' ILE . 28.4 mm -89.09 92.04 3.85 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -85.68 169.01 13.87 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.106 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.436 HG21 HG23 ' B' ' 54' ' ' ILE . 59.5 t -82.77 136.57 22.6 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.496 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 174.685 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 31.1 ttpt -96.57 -35.9 10.92 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.085 0.469 . . . . 0.0 110.088 -176.459 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 41' ' ' THR . . . . . 0.406 HG22 ' HB2' ' B' ' 20' ' ' SER . 2.8 t -161.27 165.28 29.44 Favored 'General case' 0 C--O 1.251 1.182 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.871 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 20.4 t -126.8 93.24 2.21 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.025 0 N-CA-C 106.843 -1.539 . . . . 0.0 106.843 177.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 20.8 m -60.91 123.32 17.24 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 115.207 -0.906 . . . . 0.0 111.282 -177.257 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 44' ' ' GLU . . . . . 0.435 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 12.7 pt-20 -70.43 -23.77 62.79 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-N 115.804 -0.634 . . . . 0.0 112.478 -174.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.32 -11.77 82.11 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 121.075 -0.584 . . . . 0.0 112.729 179.379 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.418 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -110.29 172.82 15.89 Favored Glycine 0 N--CA 1.413 -2.847 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.007 -178.36 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 47' ' ' ALA . . . . . 0.412 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -61.34 -35.7 78.15 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 114.998 1.481 . . . . 0.0 114.998 -172.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 48' ' ' ALA . . . . . 0.523 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -61.37 -42.17 98.27 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -172.932 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 49' ' ' HIS . . . . . 0.435 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 5.0 t60 -71.22 -40.85 70.87 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 122.143 0.973 . . . . 0.0 108.864 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 71.1 mtp180 -69.05 -29.65 67.83 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.34 -177.75 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 51' ' ' ASP . . . . . 0.64 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 11.9 t70 -82.0 -45.44 15.32 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.61 35.28 6.57 Favored Glycine 0 CA--C 1.494 -1.263 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.637 173.529 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.64 ' HD3' ' OD2' ' B' ' 51' ' ' ASP . 5.3 mpt_? -107.82 -74.77 0.65 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.288 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.436 HG23 HG21 ' B' ' 39' ' ' VAL . 27.9 mt -68.52 118.43 12.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 C-N-CA 120.051 -0.659 . . . . 0.0 110.033 177.187 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 80.0 mm-40 -104.25 -179.48 3.96 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.1 p -80.82 2.02 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.173 0 CA-C-O 122.253 1.025 . . . . 0.0 111.099 -175.541 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 25.3 t-20 -110.76 1.29 17.72 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 122.138 0.971 . . . . 0.0 109.496 -177.426 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -78.93 155.01 29.2 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.233 -177.694 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 26.7 tp -139.3 126.68 21.51 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.735 -176.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 68.6 mt -79.3 91.47 5.03 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.258 0.551 . . . . 0.0 109.836 179.186 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.616 ' HB ' ' O ' ' B' ' 90' ' ' MET . 24.1 t -82.64 -39.28 15.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.997 0 CA-C-O 122.001 0.905 . . . . 0.0 110.053 177.272 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.426 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 10.9 pt-20 -162.2 157.27 22.83 Favored 'General case' 0 C--N 1.28 -2.42 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.411 172.532 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.621 HG12 ' HB ' ' B' ' 66' ' ' THR . 3.7 p -94.11 -177.86 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 N-CA-C 105.638 -1.986 . . . . 0.0 105.638 178.104 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.584 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.2 t70 -44.54 -48.64 10.24 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 124.721 1.208 . . . . 0.0 112.975 -177.532 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -140.56 45.5 0.98 Allowed Glycine 0 CA--C 1.525 0.702 0 C-N-CA 119.991 -1.099 . . . . 0.0 113.847 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 66' ' ' THR . . . . . 0.621 ' HB ' HG12 ' B' ' 63' ' ' VAL . 45.5 m -158.42 119.51 3.42 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 177.375 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 67' ' ' SER . . . . . 0.419 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 45.8 m -85.48 133.18 34.1 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -175.788 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.521 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 23.9 mt -99.67 138.44 36.75 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.665 174.751 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -116.92 -26.77 2.63 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 CA-C-O 122.132 0.968 . . . . 0.0 109.146 173.591 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 160.45 87.75 0.06 OUTLIER Glycine 0 N--CA 1.399 -3.83 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 -176.629 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 m -111.58 173.17 2.54 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.667 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 41.7 p -75.21 160.2 30.68 Favored 'General case' 0 C--N 1.289 -2.039 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -59.57 -35.27 73.94 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 177.326 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 12.6 m -69.73 -41.03 75.82 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.632 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -63.54 -45.67 89.51 Favored 'General case' 0 CA--C 1.514 -0.429 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.139 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.538 ' O ' ' HG ' ' B' ' 80' ' ' LEU . . . -58.46 -46.26 86.95 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.487 178.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.39 -34.93 74.62 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.593 0.711 . . . . 0.0 110.736 178.067 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 45.5 m -80.37 -21.47 42.32 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 113.043 0.756 . . . . 0.0 113.043 -177.452 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.52 HG12 ' O ' ' B' ' 76' ' ' ALA . 8.4 p -78.52 -31.58 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.484 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 80' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 63.4 mt -69.39 -13.54 62.42 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.656 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -107.88 -0.64 21.37 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.503 0.668 . . . . 0.0 110.898 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -99.0 -23.74 15.18 Favored 'General case' 0 C--O 1.248 0.981 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.021 178.621 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.646 ' HB ' HG11 ' B' ' 87' ' ' VAL . 2.1 p -68.47 169.42 10.88 Favored 'General case' 0 N--CA 1.422 -1.841 0 CA-C-N 114.517 -1.22 . . . . 0.0 114.01 -176.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 41.0 mmtm -70.58 -170.78 0.43 Allowed 'General case' 0 N--CA 1.437 -1.099 0 CA-C-N 115.132 -0.94 . . . . 0.0 112.488 178.554 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.38 -35.33 90.83 Favored Glycine 0 C--O 1.217 -0.946 0 CA-C-N 114.776 -1.102 . . . . 0.0 114.275 -176.008 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 34.3 ttp180 -143.0 125.04 15.26 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.619 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.646 HG11 ' HB ' ' B' ' 83' ' ' THR . 14.0 m -133.11 154.71 39.98 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.746 0 CA-C-O 121.804 0.812 . . . . 0.0 112.559 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 87.4 mtm180 -94.5 170.6 9.36 Favored 'General case' 0 N--CA 1.41 -2.429 0 CA-C-N 113.681 -1.6 . . . . 0.0 108.489 173.782 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.459 ' HB2' ' CD1' ' B' ' 91' ' ' ILE . 6.2 m-85 -145.55 149.11 34.0 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 175.486 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.616 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 1.1 mpt? -103.68 108.58 19.93 Favored 'General case' 0 C--N 1.276 -2.626 0 CA-C-O 121.604 0.716 . . . . 0.0 109.567 176.112 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.459 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.4 mp -98.84 110.92 27.18 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 114.329 -1.305 . . . . 0.0 107.95 -179.086 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 92' ' ' GLY . . . . . 0.57 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -104.15 103.71 2.33 Favored Glycine 0 CA--C 1.458 -3.514 0 N-CA-C 107.987 -2.045 . . . . 0.0 107.987 173.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 93' ' ' ARG . . . . . 0.416 ' HD2' ' OE1' ' B' ' 4' ' ' GLU . 1.9 ptp180 . . . . . 0 C--N 1.281 -2.37 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.232 -175.7 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.415 -2.217 0 N-CA-C 105.5 -2.037 . . . . 0.0 105.5 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -91.34 92.86 8.78 Favored 'General case' 0 C--N 1.281 -2.4 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -174.907 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -88.56 86.04 6.94 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -107.49 140.93 22.01 Favored Pre-proline 0 C--N 1.297 -1.714 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.531 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -80.51 134.84 10.17 Favored 'Trans proline' 0 N--CA 1.432 -2.146 0 C-N-CA 122.086 1.857 . . . . 0.0 112.672 178.828 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.668 HG13 ' HB3' ' B' ' 53' ' ' ARG . 25.5 t -115.67 114.93 47.71 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.283 0 CA-C-N 114.374 -1.284 . . . . 0.0 108.554 176.121 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -105.59 105.84 16.06 Favored 'General case' 0 C--N 1.276 -2.611 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -178.88 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.514 HD23 ' H ' ' B' ' 11' ' ' GLU . 0.9 OUTLIER -123.72 153.85 40.3 Favored 'General case' 0 N--CA 1.418 -2.073 0 CA-C-O 121.685 0.755 . . . . 0.0 111.692 178.995 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.514 ' H ' HD23 ' B' ' 10' ' ' LEU . 40.7 tt0 -122.23 143.16 49.76 Favored 'General case' 0 C--N 1.276 -2.588 0 CA-C-N 114.245 -1.343 . . . . 0.0 108.083 -173.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 12' ' ' LYS . . . . . 0.421 ' HG2' HD21 ' B' ' 17' ' ' LEU . 45.5 mtmt -75.98 158.63 31.73 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 122.002 0.906 . . . . 0.0 112.276 -176.739 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 13' ' ' ASP . . . . . 0.568 ' HB2' ' H ' ' B' ' 16' ' ' GLY . 11.1 m-20 -83.52 177.13 8.57 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 113.717 -1.583 . . . . 0.0 107.963 173.91 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.9 m -73.46 -25.37 60.46 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 171.542 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -82.06 -30.85 31.13 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.7 -1.136 . . . . 0.0 109.779 177.63 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.568 ' H ' ' HB2' ' B' ' 13' ' ' ASP . . . 134.34 -108.44 0.72 Allowed Glycine 0 N--CA 1.432 -1.6 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.122 179.117 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.421 HD21 ' HG2' ' B' ' 12' ' ' LYS . 84.7 mt -132.8 115.72 15.65 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 121.073 0.464 . . . . 0.0 111.481 -175.276 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 18' ' ' GLY . . . . . 0.537 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -86.96 60.99 4.39 Favored Glycine 0 C--O 1.213 -1.168 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 178.567 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.534 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 5.7 pt -151.73 174.04 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 C-N-CA 125.137 1.375 . . . . 0.0 109.021 179.169 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 20' ' ' SER . . . . . 0.407 ' HB2' HG22 ' B' ' 41' ' ' THR . 62.8 m -151.92 156.96 41.13 Favored 'General case' 0 C--N 1.271 -2.817 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 175.496 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.429 ' HB ' HG22 ' B' ' 37' ' ' ILE . 12.0 pt -124.33 161.24 27.71 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.129 0 O-C-N 123.437 0.461 . . . . 0.0 110.737 -177.761 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -143.11 133.55 22.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.6 119.0 6.36 Favored Glycine 0 N--CA 1.435 -1.388 0 C-N-CA 120.629 -0.796 . . . . 0.0 113.162 -177.595 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 68.9 mtm . . . . . 0 C--N 1.31 -1.144 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 177.424 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 18.8 tp . . . . . 0 N--CA 1.418 -2.069 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -142.44 117.72 1.18 Allowed Glycine 0 C--N 1.27 -3.128 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.351 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.429 HG22 ' HB ' ' B' ' 21' ' ' ILE . 28.9 mm -96.72 88.76 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 178.015 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.415 ' HA ' ' HA ' ' B' ' 59' ' ' LEU . 94.5 m-85 -81.83 168.76 17.64 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 114.386 -1.279 . . . . 0.0 109.225 -176.584 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.8 t -79.31 139.52 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.376 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.551 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 22.8 ttpp -101.12 -44.44 5.7 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.083 0.468 . . . . 0.0 109.829 -178.086 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 41' ' ' THR . . . . . 0.407 HG22 ' HB2' ' B' ' 20' ' ' SER . 0.6 OUTLIER -154.62 162.13 41.27 Favored 'General case' 0 N--CA 1.432 -1.351 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 -176.781 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.534 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.2 p -144.06 97.79 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 CA-C-O 122.408 1.099 . . . . 0.0 109.356 176.63 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 23.9 m -62.65 126.59 27.84 Favored 'General case' 0 N--CA 1.431 -1.417 0 CA-C-N 113.262 -1.79 . . . . 0.0 112.256 -174.713 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 44' ' ' GLU . . . . . 0.572 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 1.8 mp0 -55.57 -36.91 67.37 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.693 1.597 . . . . 0.0 110.775 -178.052 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.97 -0.48 56.12 Favored Glycine 0 N--CA 1.438 -1.173 0 CA-C-N 115.437 -0.802 . . . . 0.0 113.877 -179.191 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.537 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -112.56 162.01 12.52 Favored Glycine 0 N--CA 1.417 -2.605 0 C-N-CA 120.121 -1.037 . . . . 0.0 113.093 179.211 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 47' ' ' ALA . . . . . 0.406 ' H ' ' CG ' ' B' ' 13' ' ' ASP . . . -57.45 -36.36 71.3 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 125.688 1.595 . . . . 0.0 112.06 -175.026 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -63.01 -34.54 77.77 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 49' ' ' HIS . . . . . 0.572 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 6.4 t60 -82.14 -39.12 23.73 Favored 'General case' 0 C--O 1.24 0.575 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.473 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 59.5 mtp180 -61.94 -39.56 92.49 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.137 179.277 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -74.68 -69.65 0.45 Allowed 'General case' 0 C--N 1.309 -1.174 0 C-N-CA 124.11 0.964 . . . . 0.0 109.382 175.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 110.99 -2.08 28.57 Favored Glycine 0 N--CA 1.436 -1.346 0 C-N-CA 120.21 -0.995 . . . . 0.0 114.565 177.363 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.668 ' HB3' HG13 ' B' ' 8' ' ' VAL . 39.5 mmt180 -72.24 -50.9 23.77 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 118.503 1.151 . . . . 0.0 113.054 177.293 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.509 HD11 ' CE2' ' B' ' 89' ' ' PHE . 54.6 mt -72.97 123.02 26.92 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 C-N-CA 119.034 -1.066 . . . . 0.0 108.891 173.141 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -116.47 146.96 42.18 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -178.709 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 13.2 p -56.54 -23.45 17.01 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.067 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -168.605 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -109.3 -3.53 17.1 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 120.875 -1.141 . . . . 0.0 111.469 -174.785 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -87.49 179.15 6.61 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 113.693 0.998 . . . . 0.0 113.693 -174.649 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.439 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 24.6 tp -124.46 126.08 45.31 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.372 -172.239 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 82.0 mt -83.7 104.31 13.71 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 106.063 -1.829 . . . . 0.0 106.063 173.569 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.735 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 0.5 OUTLIER -91.09 -27.65 4.92 Favored 'Isoleucine or valine' 0 C--O 1.198 -1.627 0 C-N-CA 119.667 -0.813 . . . . 0.0 110.117 -174.625 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.585 ' HB2' ' HA ' ' B' ' 67' ' ' SER . 13.2 pt-20 -158.35 166.11 33.08 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-N 114.725 -1.125 . . . . 0.0 111.389 176.122 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.515 HG22 ' H ' ' B' ' 64' ' ' ASP . 6.4 p -105.57 -174.39 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.023 0 N-CA-C 106.549 -1.649 . . . . 0.0 106.549 178.239 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.515 ' H ' HG22 ' B' ' 63' ' ' VAL . 18.9 t70 -56.55 -39.44 73.44 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 123.272 0.629 . . . . 0.0 112.479 -177.037 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -107.55 -65.29 0.6 Allowed Glycine 0 C--N 1.309 -0.945 0 C-N-CA 120.581 -0.818 . . . . 0.0 113.511 179.444 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 7.0 m -69.5 115.44 8.76 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 122.882 0.473 . . . . 0.0 112.059 -177.036 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 67' ' ' SER . . . . . 0.585 ' HA ' ' HB2' ' B' ' 62' ' ' GLU . 48.6 m -87.36 114.93 24.42 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 174.749 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.735 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 75.5 mt -85.46 140.48 30.67 Favored 'General case' 0 N--CA 1.435 -1.176 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.402 -177.606 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 p -100.09 -18.72 6.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 144.63 70.84 0.02 OUTLIER Glycine 0 N--CA 1.426 -1.985 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 -176.345 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.419 HG11 HD22 ' B' ' 68' ' ' LEU . 35.3 m -83.76 173.66 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 CA-C-N 114.478 -0.861 . . . . 0.0 110.021 -178.254 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 37.7 p -71.93 160.29 32.79 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 177.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.5 tt0 -61.14 -37.1 81.65 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.35 0.595 . . . . 0.0 110.437 -178.024 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.7 m -73.18 -30.27 63.43 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.664 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 51.1 t80 -71.6 -41.79 68.49 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.507 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.601 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -64.46 -40.98 96.75 Favored 'General case' 0 N--CA 1.435 -1.182 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.828 177.768 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.01 -41.91 93.18 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.049 0.452 . . . . 0.0 110.829 177.803 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.1 p -76.75 -23.24 52.98 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 112.957 0.725 . . . . 0.0 112.957 -178.109 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.601 HG12 ' O ' ' B' ' 76' ' ' ALA . 6.7 p -72.47 -35.12 50.49 Favored 'Isoleucine or valine' 0 C--N 1.345 0.4 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -177.595 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 80' ' ' LEU . . . . . 0.493 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 51.2 mt -68.35 -18.39 64.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 114.551 -1.204 . . . . 0.0 110.349 178.186 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -97.14 -9.95 26.89 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.534 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -96.35 -21.29 17.89 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-O 121.248 0.547 . . . . 0.0 110.203 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.537 ' HB ' HG11 ' B' ' 87' ' ' VAL . 17.9 p -80.67 174.27 11.78 Favored 'General case' 0 N--CA 1.425 -1.686 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.915 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 38.1 mttp -70.27 -168.03 0.2 Allowed 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.799 0.809 . . . . 0.0 112.393 178.706 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -72.62 -30.62 63.87 Favored Glycine 0 N--CA 1.437 -1.293 0 CA-C-N 114.932 -1.031 . . . . 0.0 111.989 178.661 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 50.4 ttp180 -135.16 123.37 23.0 Favored 'General case' 0 C--N 1.31 -1.129 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.537 HG11 ' HB ' ' B' ' 83' ' ' THR . 3.3 m -137.44 160.01 35.1 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.131 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 88' ' ' ARG . . . . . 0.446 ' H ' ' HB2' ' B' ' 64' ' ' ASP . 81.3 mtm180 -107.82 110.99 22.91 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.635 -179.323 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.509 ' CE2' HD11 ' B' ' 54' ' ' ILE . 3.4 m-85 -92.29 156.18 17.44 Favored 'General case' 0 C--N 1.275 -2.664 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 179.802 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.436 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 57.1 mtt -108.46 121.73 45.57 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.435 172.304 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.461 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.4 mp -99.64 117.5 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.405 -2.682 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 179.507 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -105.45 104.04 2.25 Favored Glycine 0 CA--C 1.458 -3.505 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 178.828 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 13.8 tpp180 . . . . . 0 C--N 1.268 -2.977 0 CA-C-N 114.142 -1.029 . . . . 0.0 109.071 178.824 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 47.8 mtm . . . . . 0 N--CA 1.418 -2.063 0 N-CA-C 103.635 -2.728 . . . . 0.0 103.635 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 4' ' ' GLU . . . . . 0.444 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 16.2 mt-10 -88.4 97.29 10.97 Favored 'General case' 0 C--N 1.284 -2.276 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.263 -176.422 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -86.37 89.55 7.91 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 172.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 23.6 p90 -108.81 144.78 30.29 Favored Pre-proline 0 C--N 1.297 -1.7 0 CA-C-N 115.52 -0.764 . . . . 0.0 112.092 -177.783 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 7' ' ' PRO . . . . . 0.414 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 53.6 Cg_endo -73.85 138.59 26.3 Favored 'Trans proline' 0 N--CA 1.447 -1.255 0 C-N-CA 122.303 2.002 . . . . 0.0 113.314 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.458 ' HB ' HD13 ' B' ' 91' ' ' ILE . 74.8 t -129.49 126.55 63.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.824 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 175.219 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -108.39 135.75 49.17 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.668 -177.338 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.575 HD11 ' HB2' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -139.75 162.21 35.68 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.614 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.44 ' H ' HD23 ' B' ' 10' ' ' LEU . 11.9 pt-20 -134.13 159.36 41.1 Favored 'General case' 0 C--N 1.285 -2.208 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.31 177.019 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -77.22 134.87 38.49 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.579 -178.13 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 13' ' ' ASP . . . . . 0.55 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 15.6 t70 -87.61 -179.74 6.37 Favored 'General case' 0 C--N 1.292 -1.917 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 175.55 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.3 m -64.65 -29.8 70.8 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 176.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -91.66 -8.96 45.63 Favored 'General case' 0 CA--C 1.548 0.891 0 CA-C-O 121.661 0.743 . . . . 0.0 109.975 177.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 106.51 -100.07 1.57 Allowed Glycine 0 N--CA 1.44 -1.038 0 C-N-CA 121.068 -0.586 . . . . 0.0 113.02 177.594 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.55 ' HG ' ' H ' ' B' ' 18' ' ' GLY . 17.7 tp -98.85 -173.28 2.48 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -177.255 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 18' ' ' GLY . . . . . 0.55 ' H ' ' HG ' ' B' ' 17' ' ' LEU . . . -164.91 58.18 0.26 Allowed Glycine 0 N--CA 1.435 -1.371 0 C-N-CA 120.262 -0.971 . . . . 0.0 112.688 177.677 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.504 HG23 ' HB3' ' B' ' 48' ' ' ALA . 5.7 pt -162.93 177.46 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.487 -1.473 0 C-N-CA 124.662 1.185 . . . . 0.0 108.228 -179.134 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.2 m -138.83 147.25 42.25 Favored 'General case' 0 C--N 1.262 -3.21 0 N-CA-C 105.522 -2.029 . . . . 0.0 105.522 174.065 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 9.3 pt -114.85 167.17 7.72 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.827 0 O-C-N 123.36 0.412 . . . . 0.0 109.931 -178.647 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 10.1 tp -142.82 135.81 26.06 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.455 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -90.12 110.31 3.75 Favored Glycine 0 N--CA 1.435 -1.392 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.615 -178.205 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 89.1 mtp . . . . . 0 C--N 1.303 -1.429 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 177.252 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 91.8 mt . . . . . 0 N--CA 1.425 -1.709 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -112.12 95.17 0.78 Allowed Glycine 0 N--CA 1.398 -3.843 0 C-N-CA 120.63 -0.795 . . . . 0.0 111.467 -176.087 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 30.8 mm -86.99 86.01 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.824 0 N-CA-C 106.428 -1.693 . . . . 0.0 106.428 172.58 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -84.1 166.85 17.31 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 114.335 -1.302 . . . . 0.0 108.727 -175.374 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.1 t -79.67 133.05 30.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 175.084 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -95.41 -41.76 8.83 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 120.932 0.396 . . . . 0.0 110.008 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -156.88 163.03 39.63 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -179.603 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.451 ' HA ' HG22 ' B' ' 19' ' ' ILE . 21.9 t -118.62 108.69 24.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 177.255 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' B' ' 49' ' ' HIS . 24.3 m -64.92 123.68 20.05 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 123.422 0.689 . . . . 0.0 111.088 -176.188 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 44' ' ' GLU . . . . . 0.446 ' HG2' ' CE1' ' B' ' 49' ' ' HIS . 32.8 mt-10 -67.72 -33.7 75.4 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 124.588 1.155 . . . . 0.0 109.839 -175.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.46 16.82 47.36 Favored Glycine 0 N--CA 1.431 -1.633 0 CA-C-N 114.761 -1.108 . . . . 0.0 112.114 178.212 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -127.07 174.75 18.23 Favored Glycine 0 N--CA 1.405 -3.422 0 C-N-CA 120.81 -0.71 . . . . 0.0 113.464 -178.648 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 47' ' ' ALA . . . . . 0.55 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -56.84 -54.84 41.79 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -173.612 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 48' ' ' ALA . . . . . 0.575 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -61.13 -27.14 68.18 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 114.017 1.117 . . . . 0.0 114.017 -171.105 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 49' ' ' HIS . . . . . 0.446 ' CE1' ' HG2' ' B' ' 44' ' ' GLU . 2.4 t60 -78.98 -38.7 36.19 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -179.197 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 92.1 mtt180 -73.5 -38.82 65.23 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.373 -178.418 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -66.85 -67.1 0.48 Allowed 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.088 173.791 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.84 3.49 52.17 Favored Glycine 0 N--CA 1.439 -1.104 0 N-CA-C 114.722 0.649 . . . . 0.0 114.722 175.478 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -81.2 -45.94 15.59 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 118.489 1.144 . . . . 0.0 112.061 -179.543 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.516 HD11 ' CE2' ' B' ' 89' ' ' PHE . 19.7 mt -78.56 127.89 38.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.142 174.746 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 50.7 mt-30 -110.92 167.07 10.52 Favored 'General case' 0 N--CA 1.436 -1.165 0 CA-C-O 121.07 0.462 . . . . 0.0 110.396 176.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.6 p -70.71 -2.1 2.42 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.704 0 N-CA-C 114.191 1.182 . . . . 0.0 114.191 -171.423 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -119.85 15.01 12.57 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.723 -1.236 . . . . 0.0 110.546 179.565 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -90.47 168.76 11.6 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.783 -178.2 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.512 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 22.8 tp -133.23 132.59 41.66 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.716 -176.637 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 78.2 mt -86.06 99.54 11.55 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 177.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.53 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.3 t -83.52 -42.42 17.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 CA-C-O 121.461 0.648 . . . . 0.0 110.647 177.546 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.536 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 15.9 pt-20 -159.67 158.53 31.63 Favored 'General case' 0 C--N 1.282 -2.332 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.546 175.364 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.507 HG12 ' HB ' ' B' ' 66' ' ' THR . 4.0 p -100.74 -173.58 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.228 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.458 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 22.8 t70 -51.49 -47.73 63.13 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 113.126 0.787 . . . . 0.0 113.126 -178.431 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -137.4 44.56 1.13 Allowed Glycine 0 C--N 1.314 -0.678 0 C-N-CA 119.362 -1.399 . . . . 0.0 114.207 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 66' ' ' THR . . . . . 0.507 ' HB ' HG12 ' B' ' 63' ' ' VAL . 94.9 m -161.31 119.43 2.38 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.027 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 67' ' ' SER . . . . . 0.536 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 21.2 m -97.92 132.48 43.46 Favored 'General case' 0 N--CA 1.431 -1.394 0 CA-C-O 121.075 0.464 . . . . 0.0 111.853 -176.486 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.53 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 42.4 mt -96.06 115.42 27.4 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.108 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 40.1 t -81.85 -23.51 9.78 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 174.773 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 145.75 75.76 0.02 OUTLIER Glycine 0 N--CA 1.424 -2.124 0 N-CA-C 108.871 -1.692 . . . . 0.0 108.871 -177.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 m -93.53 -178.32 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-N 115.554 -0.323 . . . . 0.0 110.557 -175.577 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 41.3 p -82.6 165.32 20.17 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 176.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.0 tt0 -63.15 -33.91 76.48 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.23 0.538 . . . . 0.0 109.596 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.3 m -66.28 -44.93 82.19 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.991 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -60.19 -48.2 82.75 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.496 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -59.08 -44.2 91.87 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.122 178.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.4 -37.27 80.3 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-O 121.204 0.526 . . . . 0.0 110.324 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 36.0 m -66.84 -35.96 81.24 Favored 'General case' 0 N--CA 1.435 -1.182 0 CA-C-N 115.366 -0.834 . . . . 0.0 111.344 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.496 HG12 ' O ' ' B' ' 76' ' ' ALA . 4.2 p -75.66 -34.17 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 C-N-CA 119.558 -0.857 . . . . 0.0 109.81 -174.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 25.0 mt -64.82 -42.29 95.09 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.261 -0.882 . . . . 0.0 111.167 176.616 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 39.1 mtp180 -77.64 -30.16 52.03 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.819 0.342 . . . . 0.0 111.922 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 6.5 t30 -74.8 -27.09 60.16 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.412 ' HB ' HG11 ' B' ' 87' ' ' VAL . 16.3 p -71.88 158.69 35.59 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 -178.114 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -66.74 -168.04 0.06 Allowed 'General case' 0 C--O 1.251 1.163 0 C-N-CA 124.708 1.203 . . . . 0.0 112.933 -178.56 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.12 -49.95 64.7 Favored Glycine 0 N--CA 1.431 -1.689 0 CA-C-N 114.644 -1.162 . . . . 0.0 112.828 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 23.0 ttp180 -135.04 121.65 20.7 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.981 -0.688 . . . . 0.0 111.961 -177.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.458 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 15.8 m -138.24 149.56 24.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 114.879 -1.055 . . . . 0.0 109.383 -179.361 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -94.6 155.95 16.66 Favored 'General case' 0 C--N 1.295 -1.796 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.755 174.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.516 ' CE2' HD11 ' B' ' 54' ' ' ILE . 9.1 m-85 -126.99 162.33 26.25 Favored 'General case' 0 C--N 1.276 -2.63 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 176.689 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.505 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 24.5 mmt -111.58 113.1 25.28 Favored 'General case' 0 C--N 1.28 -2.448 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.597 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.512 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -97.21 129.23 47.58 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -179.331 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 92' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -109.45 116.28 4.5 Favored Glycine 0 CA--C 1.468 -2.858 0 C-N-CA 120.19 -1.005 . . . . 0.0 112.079 -178.792 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 8.7 tpp180 . . . . . 0 C--N 1.284 -2.257 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 176.023 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 3' ' ' MET . . . . . 0.439 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 65.6 mtt . . . . . 0 N--CA 1.424 -1.752 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -77.47 103.98 7.73 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -176.374 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -78.05 91.39 4.27 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 124.106 0.878 . . . . 0.0 108.822 176.628 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -113.22 142.99 28.37 Favored Pre-proline 0 C--N 1.281 -2.371 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.646 176.593 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 7' ' ' PRO . . . . . 0.517 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 34.2 Cg_endo -75.01 128.84 11.79 Favored 'Trans proline' 0 N--CA 1.438 -1.791 0 C-N-CA 121.943 1.762 . . . . 0.0 112.843 179.327 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.461 ' HB ' HD13 ' B' ' 91' ' ' ILE . 72.0 t -113.41 122.78 68.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.266 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 9' ' ' GLU . . . . . 0.532 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 36.5 tt0 -106.86 132.15 53.15 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -174.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.522 HD11 ' HB2' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -127.4 158.27 37.75 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 177.548 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.417 ' H ' HD23 ' B' ' 10' ' ' LEU . 45.7 tt0 -134.41 138.51 44.88 Favored 'General case' 0 C--N 1.279 -2.481 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 176.001 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 34.7 mmtp -68.54 152.97 44.63 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 114.876 1.435 . . . . 0.0 114.876 -174.33 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 13' ' ' ASP . . . . . 0.455 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 15.2 t70 -92.76 177.33 6.13 Favored 'General case' 0 C--O 1.247 0.922 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 173.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 13.2 p -69.62 -28.76 66.19 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 118.327 0.512 . . . . 0.0 110.356 178.715 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -80.24 -53.04 7.03 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 173.131 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 147.92 -96.98 0.18 Allowed Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.34 179.091 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 96.3 mt -128.36 175.48 8.46 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 122.928 0.491 . . . . 0.0 109.996 -178.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 18' ' ' GLY . . . . . 0.492 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -156.38 69.05 0.28 Allowed Glycine 0 CA--C 1.482 -1.977 0 N-CA-C 108.254 -1.938 . . . . 0.0 108.254 179.166 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.514 HG22 ' HB ' ' B' ' 42' ' ' VAL . 12.7 pt -145.22 -179.09 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.281 -2.393 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 -177.876 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 20' ' ' SER . . . . . 0.475 ' HB2' HG22 ' B' ' 41' ' ' THR . 28.5 m -154.88 155.46 34.38 Favored 'General case' 0 C--N 1.253 -3.627 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 174.829 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.473 ' HB ' HG22 ' B' ' 37' ' ' ILE . 7.9 pt -127.58 154.5 38.07 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.892 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -129.26 132.13 67.08 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -179.347 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.78 103.18 2.28 Favored Glycine 0 N--CA 1.423 -2.231 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.192 -176.826 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 72.6 mtm . . . . . 0 C--N 1.303 -1.438 0 CA-C-O 121.085 0.469 . . . . 0.0 110.672 -179.829 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 83.6 mt . . . . . 0 CA--C 1.493 -1.218 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -87.64 91.67 1.75 Allowed Glycine 0 N--CA 1.41 -3.063 0 C-N-CA 120.365 -0.921 . . . . 0.0 111.982 -177.146 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.473 HG22 ' HB ' ' B' ' 21' ' ' ILE . 20.1 mm -87.38 84.91 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.549 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 173.467 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -84.71 165.01 18.22 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 114.636 -1.165 . . . . 0.0 108.695 -178.031 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 56.9 t -75.8 133.12 31.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 176.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -92.71 -46.4 7.59 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.622 -177.535 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 41' ' ' THR . . . . . 0.525 ' HA ' HG23 ' B' ' 56' ' ' VAL . 6.3 t -155.14 174.58 15.0 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.84 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.514 ' HB ' HG22 ' B' ' 19' ' ' ILE . 2.4 p -158.81 98.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 C-N-CA 124.793 1.237 . . . . 0.0 109.201 -177.915 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.424 HG22 ' H ' ' B' ' 45' ' ' GLY . 26.5 m -87.76 143.27 27.24 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 113.915 -1.493 . . . . 0.0 110.32 -174.597 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -56.78 -19.89 19.48 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 124.593 1.157 . . . . 0.0 112.744 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 45' ' ' GLY . . . . . 0.424 ' H ' HG22 ' B' ' 43' ' ' THR . . . -72.98 -12.44 79.14 Favored Glycine 0 N--CA 1.439 -1.102 0 CA-C-N 116.11 -0.496 . . . . 0.0 113.363 -178.721 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.492 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -116.5 169.0 12.87 Favored Glycine 0 N--CA 1.422 -2.3 0 C-N-CA 119.438 -1.363 . . . . 0.0 113.328 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 47' ' ' ALA . . . . . 0.455 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -56.77 -41.25 77.31 Favored 'General case' 0 C--O 1.19 -2.066 0 CA-C-N 113.977 -1.111 . . . . 0.0 113.568 -175.078 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 48' ' ' ALA . . . . . 0.522 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -59.87 -35.94 75.84 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -173.516 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 4.9 t60 -81.45 -38.76 25.91 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -179.574 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -69.29 -46.17 67.82 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.07 -178.411 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -70.89 -36.01 72.58 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.81 47.68 7.05 Favored Glycine 0 CA--C 1.494 -1.276 0 CA-C-N 114.102 -1.408 . . . . 0.0 112.463 173.431 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.532 ' HG3' ' O ' ' B' ' 9' ' ' GLU . 35.2 mmt180 -116.14 -60.78 1.82 Allowed 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -177.244 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.463 HD11 ' CE2' ' B' ' 89' ' ' PHE . 43.9 mt -77.28 125.73 37.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 C-N-CA 120.255 -0.578 . . . . 0.0 109.735 178.695 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 65.4 mt-30 -99.74 159.04 15.35 Favored 'General case' 0 C--N 1.287 -2.144 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.525 HG23 ' HA ' ' B' ' 41' ' ' THR . 11.8 p -70.03 -4.83 4.43 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.699 0 CA-C-O 121.804 0.812 . . . . 0.0 112.027 -177.45 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -113.15 10.14 18.6 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.451 -0.78 . . . . 0.0 110.824 -177.015 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 87.9 m-20 -85.01 175.31 9.12 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.293 0.568 . . . . 0.0 112.379 -177.573 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.401 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 26.6 tp -143.05 130.97 21.61 Favored 'General case' 0 C--N 1.315 -0.908 0 C-N-CA 123.894 0.878 . . . . 0.0 109.752 -177.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 71.7 mt -87.49 98.12 11.21 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 178.847 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.575 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 36.6 t -81.97 -41.41 18.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 CA-C-O 121.941 0.877 . . . . 0.0 110.477 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.46 ' HG2' ' HB2' ' B' ' 90' ' ' MET . 9.7 pt-20 -157.26 158.95 37.08 Favored 'General case' 0 C--N 1.275 -2.633 0 CA-C-N 114.858 -1.065 . . . . 0.0 109.763 173.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.453 HG12 ' O ' ' B' ' 66' ' ' THR . 3.3 p -101.57 -173.89 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 105.825 -1.917 . . . . 0.0 105.825 178.61 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.511 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.2 t70 -55.34 -58.68 6.74 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 113.092 0.775 . . . . 0.0 113.092 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -119.23 33.43 4.7 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 119.818 -1.182 . . . . 0.0 114.535 -176.74 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 66' ' ' THR . . . . . 0.453 ' O ' HG12 ' B' ' 63' ' ' VAL . 18.8 m -160.71 128.53 4.43 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 179.002 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 67' ' ' SER . . . . . 0.405 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 39.0 m -93.91 136.77 33.85 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.899 -0.501 . . . . 0.0 111.092 -179.249 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.575 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 17.2 mt -93.34 -77.39 0.45 Allowed 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.373 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 61.4 t 70.49 -29.4 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 125.34 1.456 . . . . 0.0 111.181 -175.206 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 70' ' ' GLY . . . . . 0.467 ' H ' ' C ' ' B' ' 68' ' ' LEU . . . 164.59 89.29 0.07 OUTLIER Glycine 1 N--CA 1.395 -4.085 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -177.226 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.415 HG21 HD22 ' B' ' 68' ' ' LEU . 33.6 m -118.42 -178.74 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.282 -2.356 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 175.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 36.7 p -79.92 161.8 25.33 Favored 'General case' 0 C--N 1.292 -1.931 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 177.226 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -60.42 -35.03 74.84 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 121.287 0.565 . . . . 0.0 110.129 -177.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 50.0 m -74.22 -36.44 63.94 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.831 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -63.25 -46.22 87.91 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.533 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -63.01 -38.92 93.11 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.279 179.534 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.67 -38.33 88.98 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.489 0.661 . . . . 0.0 110.122 178.222 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 34.7 t -64.49 -39.28 93.5 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.956 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.533 HG12 ' O ' ' B' ' 76' ' ' ALA . 2.6 p -70.31 -27.94 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 121.947 0.879 . . . . 0.0 110.374 -172.047 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 80' ' ' LEU . . . . . 0.501 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 55.8 mt -72.51 -6.6 44.99 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.376 178.672 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 67.6 mtt180 -116.88 -17.48 10.42 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-O 120.852 0.358 . . . . 0.0 111.948 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.9 m-20 -87.76 -8.36 56.11 Favored 'General case' 0 C--O 1.241 0.645 0 C-N-CA 123.308 0.643 . . . . 0.0 111.378 179.644 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.612 ' HB ' HG11 ' B' ' 87' ' ' VAL . 1.4 p -87.25 -175.16 5.18 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 113.873 1.064 . . . . 0.0 113.873 -178.844 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -77.34 -171.5 2.12 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.879 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -75.97 -38.27 36.1 Favored Glycine 0 N--CA 1.44 -1.067 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.927 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 86' ' ' ARG . . . . . 0.427 ' HA ' ' O ' ' B' ' 10' ' ' LEU . 13.0 ttp180 -127.69 118.49 23.92 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.397 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.612 HG11 ' HB ' ' B' ' 83' ' ' THR . 15.6 m -135.5 154.82 35.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -175.165 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 88' ' ' ARG . . . . . 0.42 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 99.7 mtt180 -109.66 126.19 53.4 Favored 'General case' 0 CA--C 1.49 -1.345 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.115 179.307 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.517 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 3.1 m-85 -105.58 155.05 19.58 Favored 'General case' 0 C--N 1.28 -2.45 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 178.023 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.46 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 19.6 mmt -98.74 109.69 22.4 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 173.871 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.484 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.5 mp -98.06 119.92 46.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.943 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.53 111.89 4.07 Favored Glycine 0 CA--C 1.466 -3.007 0 N-CA-C 108.726 -1.75 . . . . 0.0 108.726 175.26 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 93' ' ' ARG . . . . . 0.439 ' O ' ' HA ' ' B' ' 3' ' ' MET . 8.3 tpp180 . . . . . 0 C--N 1.285 -2.224 0 CA-C-N 114.637 -0.781 . . . . 0.0 111.679 -178.906 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 20.6 ptp . . . . . 0 N--CA 1.429 -1.482 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 4' ' ' GLU . . . . . 0.522 ' OE2' ' HD2' ' B' ' 93' ' ' ARG . 17.1 mt-10 -89.85 100.09 12.97 Favored 'General case' 0 C--N 1.289 -2.037 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -177.647 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -91.4 89.94 7.47 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 175.021 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -119.14 143.88 34.97 Favored Pre-proline 0 C--N 1.29 -1.997 0 C-N-CA 120.736 -0.386 . . . . 0.0 111.946 178.845 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 7' ' ' PRO . . . . . 0.489 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 56.7 Cg_endo -75.15 139.49 23.97 Favored 'Trans proline' 0 N--CA 1.439 -1.716 0 C-N-CA 122.076 1.851 . . . . 0.0 111.73 176.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.45 ' HB ' HD13 ' B' ' 91' ' ' ILE . 90.5 t -128.33 123.34 59.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -179.592 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 9' ' ' GLU . . . . . 0.5 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 38.9 tt0 -103.24 129.6 50.24 Favored 'General case' 0 C--N 1.285 -2.196 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.196 -178.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.446 HD12 HG13 ' B' ' 54' ' ' ILE . 2.0 mt -142.81 165.37 27.55 Favored 'General case' 0 CA--C 1.478 -1.812 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.812 175.915 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -135.58 164.67 27.3 Favored 'General case' 0 C--N 1.283 -2.324 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.726 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -82.38 163.14 21.89 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 121.616 0.722 . . . . 0.0 112.156 -179.821 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -111.44 -159.54 0.68 Allowed 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 104.12 -2.548 . . . . 0.0 104.12 173.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 22.8 t -75.17 -25.45 58.32 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 169.473 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -86.73 -60.83 1.88 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.977 176.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 122.84 75.45 0.32 Allowed Glycine 0 N--CA 1.439 -1.108 0 C-N-CA 120.223 -0.989 . . . . 0.0 112.143 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp 77.12 172.04 0.22 Allowed 'General case' 0 CA--C 1.507 -0.678 0 C-N-CA 124.576 1.15 . . . . 0.0 112.402 178.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -141.83 74.44 0.35 Allowed Glycine 0 CA--C 1.471 -2.675 0 N-CA-C 109.097 -1.601 . . . . 0.0 109.097 -178.818 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.443 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 14.2 pt -157.51 -177.53 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 -178.673 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 24.0 t -149.08 142.31 25.05 Favored 'General case' 0 C--N 1.272 -2.793 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 176.006 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 20.6 pt -109.17 152.87 11.11 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -129.76 136.14 59.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.65 97.85 2.15 Favored Glycine 0 N--CA 1.434 -1.472 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.025 179.477 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 26.5 ptm . . . . . 0 C--N 1.308 -1.216 0 CA-C-O 120.894 0.378 . . . . 0.0 110.025 -179.044 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 20.2 tp . . . . . 0 N--CA 1.413 -2.286 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -110.49 89.5 0.55 Allowed Glycine 0 N--CA 1.398 -3.849 0 C-N-CA 119.99 -1.1 . . . . 0.0 111.982 -176.785 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 29.6 mm -90.21 78.4 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.212 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 171.574 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -86.05 167.63 14.83 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-N 113.911 -1.495 . . . . 0.0 109.137 -176.57 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.414 HG21 ' CG2' ' B' ' 54' ' ' ILE . 51.1 t -81.07 131.34 34.14 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 176.2 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 36.4 ttpt -91.9 -40.97 10.86 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.771 -175.778 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -156.63 162.73 39.84 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 -177.012 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 21.8 t -127.53 92.11 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 178.29 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 10.5 m -72.31 132.55 44.16 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 123.541 0.736 . . . . 0.0 111.672 -176.698 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 44' ' ' GLU . . . . . 0.45 ' HA ' ' HB3' ' B' ' 49' ' ' HIS . 11.3 pt-20 -67.83 -3.52 9.83 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 123.886 0.874 . . . . 0.0 113.208 -179.163 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.1 3.23 85.72 Favored Glycine 0 N--CA 1.44 -1.098 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.133 -177.793 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -139.36 170.94 23.94 Favored Glycine 0 N--CA 1.407 -3.273 0 C-N-CA 119.862 -1.161 . . . . 0.0 113.556 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.94 -35.05 44.54 Favored 'General case' 0 C--O 1.195 -1.812 0 C-N-CA 126.235 1.814 . . . . 0.0 114.726 -174.835 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -64.63 -45.28 87.53 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 120.284 -0.566 . . . . 0.0 112.348 -174.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 49' ' ' HIS . . . . . 0.45 ' HB3' ' HA ' ' B' ' 44' ' ' GLU . 5.1 t60 -73.44 -41.09 63.65 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 108.679 -0.859 . . . . 0.0 108.679 177.155 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -59.81 -42.76 94.2 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.71 -178.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 51' ' ' ASP . . . . . 0.601 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 9.7 t70 -78.19 -51.85 9.58 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.279 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.95 42.71 3.23 Favored Glycine 0 N--CA 1.434 -1.463 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.615 ' NE ' ' HA ' ' B' ' 53' ' ' ARG . 4.9 mmp_? -104.97 -82.77 0.51 Allowed 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -178.828 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.474 HD11 ' CE2' ' B' ' 89' ' ' PHE . 49.9 mt -61.28 122.94 13.1 Favored 'Isoleucine or valine' 0 C--O 1.244 0.785 0 C-N-CA 120.165 -0.614 . . . . 0.0 110.435 176.574 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 55' ' ' GLN . . . . . 0.419 ' HB2' ' OD1' ' B' ' 58' ' ' ASP . 48.0 mt-30 -100.81 173.45 6.5 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.845 0.355 . . . . 0.0 111.039 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.8 p -77.83 -1.97 4.36 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 CA-C-O 121.374 0.607 . . . . 0.0 112.388 -174.022 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -124.07 24.55 8.16 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-O 122.053 0.93 . . . . 0.0 109.584 -178.461 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 58' ' ' ASP . . . . . 0.419 ' OD1' ' HB2' ' B' ' 55' ' ' GLN . 11.1 m-20 -98.21 166.36 11.44 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 114.345 -1.298 . . . . 0.0 110.421 -177.411 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.577 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 24.8 tp -140.39 133.35 29.27 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 123.423 0.689 . . . . 0.0 109.851 -177.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 71.1 mt -82.72 99.75 9.83 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 177.401 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.472 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.1 t -85.02 -40.81 15.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 122.0 0.905 . . . . 0.0 110.676 178.51 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.481 ' HG2' ' HB2' ' B' ' 90' ' ' MET . 10.2 pt-20 -155.51 154.25 31.51 Favored 'General case' 0 C--N 1.27 -2.883 0 CA-C-N 115.17 -0.923 . . . . 0.0 109.633 173.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.538 HG12 ' HB ' ' B' ' 66' ' ' THR . 6.6 p -100.4 -171.86 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 N-CA-C 105.825 -1.917 . . . . 0.0 105.825 178.65 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.562 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 8.6 t70 -44.14 -55.21 4.95 Favored 'General case' 0 N--CA 1.482 1.125 0 C-N-CA 124.117 0.967 . . . . 0.0 112.959 177.719 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -136.21 43.39 1.24 Allowed Glycine 0 C--N 1.304 -1.234 0 C-N-CA 119.07 -1.538 . . . . 0.0 114.98 -179.214 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 66' ' ' THR . . . . . 0.538 ' HB ' HG12 ' B' ' 63' ' ' VAL . 88.5 m -155.09 123.5 5.98 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 117.558 0.679 . . . . 0.0 109.326 177.293 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 5.7 m -87.58 125.02 34.11 Favored 'General case' 0 N--CA 1.441 -0.909 0 C-N-CA 123.091 0.557 . . . . 0.0 109.782 -177.796 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.472 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 25.1 mt -90.38 99.54 12.55 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 122.21 1.005 . . . . 0.0 110.856 179.327 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 58.1 t -69.22 -33.07 56.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-N 114.759 -1.109 . . . . 0.0 108.046 175.189 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 149.35 66.46 0.01 OUTLIER Glycine 0 CA--C 1.468 -2.845 0 N-CA-C 108.901 -1.68 . . . . 0.0 108.901 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 29.8 m -83.06 171.97 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.878 0 CA-C-N 113.694 -1.253 . . . . 0.0 109.188 -177.379 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 25.4 p -77.91 163.79 25.7 Favored 'General case' 0 N--CA 1.412 -2.339 0 C-N-CA 121.042 -0.263 . . . . 0.0 110.465 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -59.74 -37.53 79.22 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.314 0.578 . . . . 0.0 109.899 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 32.9 t -65.23 -41.36 94.48 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.776 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -64.57 -48.1 76.25 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.596 ' O ' ' HG ' ' B' ' 80' ' ' LEU . . . -55.78 -43.29 76.63 Favored 'General case' 0 C--O 1.217 -0.642 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.772 178.794 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.62 -39.1 91.12 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.28 0.562 . . . . 0.0 111.033 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.1 t -72.17 -29.41 63.99 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.9 -177.099 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.446 HG12 ' O ' ' B' ' 76' ' ' ALA . 9.8 p -75.69 -33.85 27.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 -176.173 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 80' ' ' LEU . . . . . 0.596 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 70.2 mt -68.19 -12.02 60.24 Favored 'General case' 0 C--O 1.214 -0.794 0 CA-C-N 114.517 -1.22 . . . . 0.0 110.789 176.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 96.6 mtt180 -106.16 -5.78 19.05 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.467 0.651 . . . . 0.0 111.036 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 13.0 m-80 -96.95 -24.04 16.02 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.546 177.074 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.791 ' HB ' HG11 ' B' ' 87' ' ' VAL . 3.9 p -68.44 179.74 1.57 Allowed 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -178.132 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 66.3 mmtt -72.03 -170.33 0.58 Allowed 'General case' 0 C--O 1.239 0.514 0 C-N-CA 123.462 0.705 . . . . 0.0 110.921 176.045 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.95 -36.09 47.99 Favored Glycine 0 N--CA 1.445 -0.759 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.648 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 26.3 ttm180 -127.52 122.48 33.45 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.496 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.791 HG11 ' HB ' ' B' ' 83' ' ' THR . 13.6 m -133.75 150.14 31.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.085 0 CA-C-O 121.085 0.469 . . . . 0.0 111.051 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 69.6 mtp85 -108.36 118.63 37.28 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.459 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.489 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 1.3 m-85 -98.73 170.74 8.56 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -177.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.481 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 48.5 mtt -113.54 116.88 30.24 Favored 'General case' 0 CA--C 1.473 -1.992 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 167.535 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.577 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.3 mp -94.49 121.72 45.34 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 177.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 92' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -112.67 96.45 0.83 Allowed Glycine 0 CA--C 1.461 -3.321 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 177.557 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 93' ' ' ARG . . . . . 0.522 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 36.6 ttm180 . . . . . 0 C--N 1.257 -3.435 0 CA-C-N 114.761 -0.719 . . . . 0.0 110.512 -176.077 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 3' ' ' MET . . . . . 0.522 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 66.8 mtt . . . . . 0 CA--C 1.505 -0.765 0 CA-C-O 120.901 0.381 . . . . 0.0 110.734 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 4' ' ' GLU . . . . . 0.408 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 19.7 mt-10 -84.85 105.6 15.75 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -85.34 93.59 8.75 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 174.517 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -117.02 141.5 28.47 Favored Pre-proline 0 C--N 1.288 -2.068 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.196 179.398 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 7' ' ' PRO . . . . . 0.51 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 61.0 Cg_endo -79.32 137.79 13.57 Favored 'Trans proline' 0 N--CA 1.444 -1.411 0 C-N-CA 122.379 2.052 . . . . 0.0 112.984 178.413 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 79.0 t -125.61 142.19 43.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 N-CA-C 106.855 -1.535 . . . . 0.0 106.855 177.659 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -127.97 123.2 34.24 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 118.659 0.663 . . . . 0.0 110.708 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.453 ' O ' ' HD3' ' B' ' 86' ' ' ARG . 1.2 mt -113.7 163.94 14.35 Favored 'General case' 0 CA--C 1.486 -1.503 0 CA-C-O 121.589 0.709 . . . . 0.0 111.478 178.812 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -124.88 145.89 49.58 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 174.309 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -91.02 164.14 14.07 Favored 'General case' 0 N--CA 1.418 -2.026 0 CA-C-O 121.874 0.845 . . . . 0.0 110.36 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 13' ' ' ASP . . . . . 0.567 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 25.3 t70 -111.44 -179.41 3.71 Favored 'General case' 0 C--N 1.274 -2.683 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 178.073 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 16.1 m -69.54 -25.92 64.25 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 176.895 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 8.3 tp10 -85.89 1.71 48.85 Favored 'General case' 0 CA--C 1.548 0.876 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.443 178.651 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.45 -138.75 14.6 Favored Glycine 0 N--CA 1.437 -1.285 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.573 179.751 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 93.9 mt -95.54 -177.94 4.25 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 177.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -138.42 58.04 0.63 Allowed Glycine 0 CA--C 1.478 -2.23 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.453 -178.356 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.561 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 7.0 pt -150.4 179.13 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 C-N-CA 123.52 0.728 . . . . 0.0 109.396 -177.819 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 20' ' ' SER . . . . . 0.426 ' HB2' HG22 ' B' ' 41' ' ' THR . 70.0 m -150.97 160.92 43.61 Favored 'General case' 0 C--N 1.269 -2.93 0 N-CA-C 105.14 -2.171 . . . . 0.0 105.14 175.673 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.475 ' HB ' HG22 ' B' ' 37' ' ' ILE . 10.3 pt -130.73 159.96 42.32 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.621 0 CA-C-N 117.877 0.308 . . . . 0.0 110.226 -177.607 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.2 tp -136.5 135.86 48.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-O 120.985 0.421 . . . . 0.0 110.348 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 23' ' ' GLY . . . . . 0.412 ' HA2' ' CD1' ' B' ' 37' ' ' ILE . . . -83.63 99.16 2.16 Favored Glycine 0 N--CA 1.437 -1.24 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.591 -178.082 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 3.8 mmt . . . . . 0 C--N 1.3 -1.583 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.473 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 94.7 mt . . . . . 0 N--CA 1.427 -1.588 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -124.69 102.8 0.71 Allowed Glycine 0 N--CA 1.414 -2.803 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 -178.301 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.475 HG22 ' HB ' ' B' ' 21' ' ' ILE . 23.7 mm -88.18 88.84 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 178.297 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -83.9 163.46 20.03 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.689 -1.141 . . . . 0.0 109.342 -178.548 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 65.8 t -71.49 130.99 35.09 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 174.871 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -90.31 -48.73 6.96 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.42 -177.263 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 41' ' ' THR . . . . . 0.426 HG22 ' HB2' ' B' ' 20' ' ' SER . 0.6 OUTLIER -150.05 163.86 37.04 Favored 'General case' 0 N--CA 1.428 -1.529 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -177.875 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.0 p -139.01 93.7 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 CA-C-O 122.693 1.235 . . . . 0.0 109.29 178.63 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.429 HG22 ' H ' ' B' ' 45' ' ' GLY . 10.3 m -75.6 130.91 39.55 Favored 'General case' 0 N--CA 1.44 -0.974 0 CA-C-N 113.443 -1.708 . . . . 0.0 112.72 -172.44 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -57.93 -24.12 56.45 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 124.22 1.008 . . . . 0.0 112.901 179.831 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 45' ' ' GLY . . . . . 0.429 ' H ' HG22 ' B' ' 43' ' ' THR . . . -78.47 -1.26 81.67 Favored Glycine 0 N--CA 1.436 -1.313 0 CA-C-N 115.97 -0.559 . . . . 0.0 113.465 -178.129 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -122.28 170.23 15.08 Favored Glycine 0 N--CA 1.421 -2.354 0 C-N-CA 120.229 -0.986 . . . . 0.0 112.733 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 47' ' ' ALA . . . . . 0.567 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -59.94 -39.41 85.45 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 114.261 1.208 . . . . 0.0 114.261 -173.877 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 48' ' ' ALA . . . . . 0.4 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -64.34 -39.82 94.65 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -173.003 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -72.36 -44.53 62.44 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.509 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 17.2 mtp180 -62.24 -45.49 93.1 Favored 'General case' 0 CA--C 1.511 -0.536 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.188 -177.047 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 51' ' ' ASP . . . . . 0.484 ' OD2' ' HD2' ' B' ' 53' ' ' ARG . 19.1 t70 -65.54 -51.4 60.2 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 176.692 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 95.04 39.48 4.56 Favored Glycine 0 CA--C 1.478 -2.278 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.553 ' NE ' ' HA ' ' B' ' 53' ' ' ARG . 0.0 OUTLIER -99.66 -73.18 0.64 Allowed 'General case' 0 N--CA 1.419 -2.023 0 CA-C-N 114.221 -0.989 . . . . 0.0 110.483 -170.965 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.555 HD11 ' CE2' ' B' ' 89' ' ' PHE . 47.1 mt -82.78 125.1 39.95 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 175.725 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 55' ' ' GLN . . . . . 0.512 ' HG2' ' OD2' ' B' ' 58' ' ' ASP . 24.2 pt20 -100.42 169.52 9.04 Favored 'General case' 0 C--N 1.309 -1.196 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -178.26 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.1 p -66.82 -2.28 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.507 0 C-N-CA 123.964 0.906 . . . . 0.0 113.361 -174.182 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -127.27 19.39 6.93 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.044 -1.035 . . . . 0.0 110.769 -178.349 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 58' ' ' ASP . . . . . 0.512 ' OD2' ' HG2' ' B' ' 55' ' ' GLN . 80.8 m-20 -84.66 168.24 15.46 Favored 'General case' 0 C--N 1.312 -1.038 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.595 176.963 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 28.6 tp -136.06 127.45 28.48 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.393 -176.303 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 82.5 mt -81.73 90.91 6.39 Favored 'General case' 0 N--CA 1.434 -1.236 0 CA-C-O 121.534 0.683 . . . . 0.0 109.875 178.401 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.643 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 10.9 t -74.25 -39.6 49.56 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.126 175.869 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.486 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 11.9 pt-20 -164.56 159.66 19.42 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.862 171.009 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.566 HG12 ' HB ' ' B' ' 66' ' ' THR . 3.0 p -96.95 178.19 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.606 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 19.9 t70 -42.59 -54.34 4.01 Favored 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 125.409 1.484 . . . . 0.0 113.762 -176.185 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -132.56 43.85 1.25 Allowed Glycine 0 C--N 1.304 -1.232 0 C-N-CA 119.581 -1.295 . . . . 0.0 113.682 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 66' ' ' THR . . . . . 0.566 ' HB ' HG12 ' B' ' 63' ' ' VAL . 51.6 m -157.43 114.34 2.99 Favored 'General case' 0 C--O 1.247 0.923 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 175.867 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 67' ' ' SER . . . . . 0.486 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 44.6 m -81.99 111.65 18.36 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 112.476 0.547 . . . . 0.0 112.476 -177.177 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.643 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 44.2 mt -79.52 110.48 14.88 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.887 176.496 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 14.7 p -75.84 -24.98 16.98 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 177.677 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 142.54 64.04 0.03 OUTLIER Glycine 0 CA--C 1.484 -1.87 0 N-CA-C 108.928 -1.669 . . . . 0.0 108.928 -177.172 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.9 m -82.26 -178.59 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 114.366 -0.917 . . . . 0.0 110.406 -176.216 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 40.4 p -82.89 166.29 19.04 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 120.926 0.393 . . . . 0.0 110.93 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.7 tt0 -59.55 -42.89 93.4 Favored 'General case' 0 C--N 1.324 -0.539 0 C-N-CA 123.237 0.615 . . . . 0.0 110.168 -179.064 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 23.2 t -66.49 -38.96 88.41 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.247 -178.632 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -63.13 -50.22 71.33 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.554 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.3 -37.59 83.75 Favored 'General case' 0 CA--C 1.539 0.526 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.261 178.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.34 -30.54 71.24 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.657 0.741 . . . . 0.0 110.502 177.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.4 m -82.36 -27.48 32.12 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.521 -178.129 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.554 HG12 ' O ' ' B' ' 76' ' ' ALA . 3.9 p -72.03 -31.34 39.88 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.453 0 CA-C-O 121.396 0.617 . . . . 0.0 109.56 -176.126 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 19.4 mt -67.12 -17.35 64.82 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.918 -1.037 . . . . 0.0 111.322 176.519 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 22.1 mtm180 -100.72 -7.9 23.34 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-O 121.292 0.568 . . . . 0.0 110.31 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -89.99 -15.01 32.78 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 121.744 0.783 . . . . 0.0 109.655 176.255 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.655 ' HB ' HG11 ' B' ' 87' ' ' VAL . 9.3 p -92.06 167.2 12.24 Favored 'General case' 0 N--CA 1.412 -2.351 0 CA-C-N 115.261 -0.881 . . . . 0.0 111.855 179.191 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -76.88 -167.49 0.86 Allowed 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.277 -0.874 . . . . 0.0 112.876 177.242 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.26 -13.33 79.09 Favored Glycine 0 C--O 1.207 -1.555 0 CA-C-N 114.738 -1.119 . . . . 0.0 112.732 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 86' ' ' ARG . . . . . 0.453 ' HD3' ' O ' ' B' ' 10' ' ' LEU . 4.4 tpp180 -137.74 116.3 12.08 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 175.909 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.655 HG11 ' HB ' ' B' ' 83' ' ' THR . 6.3 m -149.12 157.59 6.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 122.969 0.508 . . . . 0.0 110.534 -179.06 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 77.0 mtm180 -96.18 170.18 9.44 Favored 'General case' 0 C--N 1.287 -2.145 0 CA-C-N 114.545 -1.207 . . . . 0.0 108.246 176.644 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.555 ' CE2' HD11 ' B' ' 54' ' ' ILE . 3.4 m-85 -150.9 162.16 41.32 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 105.163 -2.162 . . . . 0.0 105.163 175.397 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.543 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 66.4 mtm -115.54 114.45 24.99 Favored 'General case' 0 C--N 1.286 -2.195 0 CA-C-O 121.721 0.772 . . . . 0.0 110.139 170.548 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.45 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -97.38 127.33 49.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.73 0 CA-C-N 113.819 -1.537 . . . . 0.0 108.024 -176.566 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 92' ' ' GLY . . . . . 0.408 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -106.83 118.05 5.51 Favored Glycine 0 CA--C 1.466 -3.014 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 176.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 93' ' ' ARG . . . . . 0.522 ' O ' ' HA ' ' B' ' 3' ' ' MET . 9.9 tpp180 . . . . . 0 C--N 1.288 -2.084 0 CA-C-N 115.067 -0.567 . . . . 0.0 110.416 178.648 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 68.5 mtm . . . . . 0 N--CA 1.424 -1.752 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -76.03 102.12 5.53 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.507 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 0.6 OUTLIER -85.93 84.64 7.48 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.056 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -113.49 142.93 28.42 Favored Pre-proline 0 C--N 1.301 -1.522 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.906 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 7' ' ' PRO . . . . . 0.454 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 59.0 Cg_endo -80.0 131.59 9.03 Favored 'Trans proline' 0 N--CA 1.444 -1.391 0 C-N-CA 122.115 1.877 . . . . 0.0 113.396 179.238 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.469 HG13 ' HB3' ' B' ' 53' ' ' ARG . 75.9 t -119.08 141.23 39.97 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.998 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.502 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -129.82 139.67 51.18 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.496 HD12 HG13 ' B' ' 54' ' ' ILE . 1.0 OUTLIER -144.09 157.68 44.17 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.001 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.606 ' OE2' ' HD3' ' B' ' 86' ' ' ARG . 68.4 mm-40 -95.11 133.14 39.26 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 114.061 -1.427 . . . . 0.0 107.71 177.138 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 12' ' ' LYS . . . . . 0.429 ' HA ' HD13 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -80.73 135.3 35.97 Favored 'General case' 0 N--CA 1.426 -1.664 0 C-N-CA 118.928 -1.109 . . . . 0.0 108.491 173.815 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 13' ' ' ASP . . . . . 0.435 ' HB3' ' HB2' ' B' ' 47' ' ' ALA . 2.6 p30 -85.76 -178.12 6.54 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -174.059 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 18.9 m -68.93 -26.39 65.05 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.394 -175.814 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -81.91 -46.61 13.83 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 176.492 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 168.25 -85.07 0.09 OUTLIER Glycine 0 N--CA 1.423 -2.225 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 177.569 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.429 HD13 ' HA ' ' B' ' 12' ' ' LYS . 27.2 tp -164.15 108.28 0.97 Allowed 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 175.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 18' ' ' GLY . . . . . 0.479 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -67.7 59.22 0.33 Allowed Glycine 0 C--O 1.215 -1.077 0 C-N-CA 124.704 1.145 . . . . 0.0 115.581 -173.858 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.478 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.8 pt -144.8 -178.42 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.267 -3.006 0 C-N-CA 125.565 1.546 . . . . 0.0 107.365 173.265 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.4 m -156.69 161.68 39.84 Favored 'General case' 0 C--N 1.272 -2.804 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.141 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.443 ' HB ' HG22 ' B' ' 37' ' ' ILE . 26.3 pt -124.43 153.52 31.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-N 117.99 0.359 . . . . 0.0 110.278 -179.513 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.2 tp -137.64 135.15 46.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.676 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.87 103.63 2.93 Favored Glycine 0 N--CA 1.421 -2.311 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.179 -178.616 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 25.9 mmt . . . . . 0 C--N 1.298 -1.657 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 176.49 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 2.9 mm? . . . . . 0 CA--C 1.48 -1.74 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -94.68 87.64 1.1 Allowed Glycine 0 N--CA 1.4 -3.764 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.443 HG22 ' HB ' ' B' ' 21' ' ' ILE . 20.7 mm -82.99 78.38 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.362 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 173.942 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -81.56 169.77 16.67 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 114.193 -1.367 . . . . 0.0 109.371 -172.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 79.4 t -75.69 128.98 37.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-O 121.372 0.606 . . . . 0.0 109.814 176.231 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 9.2 tmtm? -84.5 -54.42 4.76 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.11 -177.823 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 7.9 t -145.7 175.2 10.56 Favored 'General case' 0 N--CA 1.429 -1.508 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 179.182 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.478 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.5 p -154.88 96.4 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 -179.378 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.425 HG22 ' H ' ' B' ' 45' ' ' GLY . 6.0 m -78.25 134.96 37.48 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 113.59 -1.641 . . . . 0.0 111.514 -170.621 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -61.87 -12.8 19.46 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.004 0.922 . . . . 0.0 113.238 178.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 45' ' ' GLY . . . . . 0.425 ' H ' HG22 ' B' ' 43' ' ' THR . . . -86.18 -2.05 85.98 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 116.528 -0.306 . . . . 0.0 112.455 177.688 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.479 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -115.88 169.97 13.15 Favored Glycine 0 N--CA 1.418 -2.544 0 C-N-CA 120.291 -0.957 . . . . 0.0 111.823 179.169 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 47' ' ' ALA . . . . . 0.435 ' HB2' ' HB3' ' B' ' 13' ' ' ASP . . . -69.28 -36.26 76.88 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 114.882 -0.659 . . . . 0.0 111.745 -175.088 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -57.03 -40.52 76.9 Favored 'General case' 0 CA--C 1.542 0.657 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -175.417 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -71.34 -42.46 68.51 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.213 0.53 . . . . 0.0 110.209 -179.081 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -75.09 -28.52 60.32 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.952 -175.345 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -80.75 -41.79 22.92 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.723 -177.582 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 83.78 43.24 7.33 Favored Glycine 0 C--N 1.309 -0.924 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.576 176.447 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.533 ' HE ' ' HA ' ' B' ' 53' ' ' ARG . 1.4 mmp_? -115.22 -69.72 0.84 Allowed 'General case' 0 C--N 1.301 -1.537 0 CA-C-O 119.091 -0.48 . . . . 0.0 110.848 178.847 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.601 HD11 ' CE2' ' B' ' 89' ' ' PHE . 77.7 mt -73.55 136.97 24.25 Favored 'Isoleucine or valine' 0 C--O 1.253 1.241 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 171.755 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 19.6 mt-30 -118.21 162.51 18.12 Favored 'General case' 0 C--N 1.289 -2.04 0 C-N-CA 123.909 0.884 . . . . 0.0 109.639 -174.718 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.478 ' HB ' HG12 ' B' ' 42' ' ' VAL . 9.7 p -73.6 -4.34 5.29 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-O 121.695 0.76 . . . . 0.0 111.075 -178.384 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -116.55 -5.49 11.68 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -176.144 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -91.39 -175.39 4.22 Favored 'General case' 0 C--O 1.247 0.958 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 -175.225 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.528 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 35.6 tp -139.35 128.07 23.29 Favored 'General case' 0 N--CA 1.435 -1.212 0 CA-C-N 114.775 -1.102 . . . . 0.0 109.883 -174.043 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 57.0 mt -87.09 95.38 9.93 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.455 -0.942 . . . . 0.0 108.455 178.141 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.441 ' HB ' ' O ' ' B' ' 90' ' ' MET . 36.3 t -75.65 -43.07 41.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 CA-C-O 121.843 0.83 . . . . 0.0 111.301 -178.445 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.419 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 12.2 pt-20 -146.63 160.95 41.53 Favored 'General case' 0 C--N 1.267 -2.997 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 173.511 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.554 HG21 HG21 ' B' ' 83' ' ' THR . 4.8 p -113.18 -177.44 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.728 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.505 ' H ' HG22 ' B' ' 63' ' ' VAL . 31.2 t70 -49.53 -45.73 47.75 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -176.369 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -132.29 31.33 3.03 Favored Glycine 0 CA--C 1.522 0.525 0 C-N-CA 119.687 -1.244 . . . . 0.0 114.607 -177.824 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 66' ' ' THR . . . . . 0.411 ' HB ' HG12 ' B' ' 63' ' ' VAL . 36.1 m -159.73 135.47 8.51 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 67' ' ' SER . . . . . 0.419 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 30.5 m -108.64 146.83 32.78 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.43 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 43.6 mt -104.31 115.05 29.7 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-O 120.938 0.399 . . . . 0.0 110.66 176.49 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 12.3 p -81.38 -20.39 10.95 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 N-CA-C 108.544 -0.909 . . . . 0.0 108.544 174.529 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 140.79 71.27 0.04 OUTLIER Glycine 0 CA--C 1.487 -1.672 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 -177.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.9 m -92.79 179.33 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 114.856 -0.672 . . . . 0.0 110.681 -175.051 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 43.5 p -82.86 165.28 19.93 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 177.192 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -59.45 -42.11 91.2 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.949 0.404 . . . . 0.0 110.108 179.37 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 48.5 m -66.5 -35.92 81.46 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.473 -179.413 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -66.61 -46.67 75.09 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.386 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.401 ' O ' ' HB ' ' B' ' 79' ' ' VAL . . . -60.52 -41.56 94.65 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.132 178.149 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.25 -34.96 75.99 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.072 178.268 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 24.5 m -76.9 -20.92 55.66 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.984 -179.018 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.401 ' HB ' ' O ' ' B' ' 76' ' ' ALA . 24.3 t -71.37 -57.11 8.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 16.6 mt -57.79 -18.59 22.74 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 125.325 1.45 . . . . 0.0 112.964 178.205 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 69.9 mtp180 -88.94 -18.09 28.2 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-O 121.279 0.561 . . . . 0.0 110.813 176.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -99.71 -6.19 27.54 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.729 0.776 . . . . 0.0 110.749 -176.747 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.554 HG21 HG21 ' B' ' 63' ' ' VAL . 18.9 p -82.41 165.96 19.81 Favored 'General case' 0 C--O 1.249 1.07 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 -178.482 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 57.7 mmtt -73.1 -167.58 0.41 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 124.594 1.158 . . . . 0.0 112.012 179.052 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.05 -34.23 55.87 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-N 115.509 -0.769 . . . . 0.0 112.516 -179.307 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 86' ' ' ARG . . . . . 0.606 ' HD3' ' OE2' ' B' ' 11' ' ' GLU . 45.5 ttp180 -134.69 124.69 25.68 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 175.621 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.539 HG11 ' HB ' ' B' ' 83' ' ' THR . 13.7 m -137.13 160.32 36.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.915 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -102.15 163.11 12.42 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 176.609 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.601 ' CE2' HD11 ' B' ' 54' ' ' ILE . 4.9 m-85 -140.44 155.99 46.52 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 179.072 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.441 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 9.5 ttt -110.22 115.07 29.05 Favored 'General case' 0 C--N 1.275 -2.631 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 174.082 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.528 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -92.29 138.45 19.92 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.342 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -177.679 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.26 112.99 1.29 Allowed Glycine 0 CA--C 1.486 -1.742 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 175.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 18.1 tpp180 . . . . . 0 C--N 1.286 -2.156 0 CA-C-N 115.099 -0.55 . . . . 0.0 109.757 -179.126 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 64.4 mtm . . . . . 0 N--CA 1.423 -1.779 0 N-CA-C 104.466 -2.42 . . . . 0.0 104.466 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 4' ' ' GLU . . . . . 0.533 ' HB2' ' HB3' ' B' ' 93' ' ' ARG . 12.0 mt-10 -94.3 93.36 7.68 Favored 'General case' 0 C--N 1.289 -2.036 0 C-N-CA 118.46 -1.296 . . . . 0.0 110.4 -175.581 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -82.52 95.85 7.85 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 177.443 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 7.1 p90 -119.46 144.33 36.41 Favored Pre-proline 0 C--N 1.279 -2.48 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.128 176.575 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 7' ' ' PRO . . . . . 0.596 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 30.4 Cg_endo -72.87 129.46 14.39 Favored 'Trans proline' 0 N--CA 1.432 -2.099 0 C-N-CA 122.005 1.803 . . . . 0.0 112.242 176.719 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.492 ' HB ' HD13 ' B' ' 91' ' ' ILE . 70.5 t -115.02 122.02 68.28 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.046 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 177.527 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 9' ' ' GLU . . . . . 0.485 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 31.8 tt0 -105.58 132.22 52.0 Favored 'General case' 0 C--N 1.269 -2.895 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -176.574 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.601 HD11 ' HB2' ' B' ' 48' ' ' ALA . 0.6 OUTLIER -124.09 159.77 29.21 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 175.264 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.411 ' H ' HD23 ' B' ' 10' ' ' LEU . 4.5 pt-20 -132.12 125.81 32.2 Favored 'General case' 0 C--N 1.26 -3.322 0 CA-C-N 113.919 -1.491 . . . . 0.0 107.187 178.187 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt -66.14 151.88 45.98 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 121.938 0.875 . . . . 0.0 112.608 -178.206 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -102.66 178.34 4.6 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 14.7 m -67.79 -26.5 66.12 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 121.7 0.762 . . . . 0.0 109.035 175.885 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -72.74 -21.28 61.05 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-N 114.62 -1.173 . . . . 0.0 109.607 173.763 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.62 -105.12 2.7 Favored Glycine 0 N--CA 1.422 -2.236 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -176.863 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 94.8 mt -109.79 -176.87 3.12 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.1 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 18' ' ' GLY . . . . . 0.409 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -156.19 61.62 0.35 Allowed Glycine 0 CA--C 1.476 -2.383 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.22 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.586 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 3.1 pt -161.46 175.78 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.481 -1.693 0 C-N-CA 124.557 1.143 . . . . 0.0 108.157 -176.654 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 20' ' ' SER . . . . . 0.443 ' HB2' HG22 ' B' ' 41' ' ' THR . 54.9 m -148.59 151.7 35.49 Favored 'General case' 0 C--N 1.262 -3.2 0 N-CA-C 105.854 -1.906 . . . . 0.0 105.854 174.813 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.494 ' HB ' HG22 ' B' ' 37' ' ' ILE . 16.6 pt -116.94 162.06 15.2 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.537 0 O-C-N 123.421 0.45 . . . . 0.0 110.613 -176.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.5 tp -146.84 137.61 17.92 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.19 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.98 111.41 3.73 Favored Glycine 0 N--CA 1.431 -1.668 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.482 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 85.9 mtp . . . . . 0 C--N 1.305 -1.341 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 176.993 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 35' ' ' LEU . . . . . 0.594 ' O ' ' HA2' ' B' ' 70' ' ' GLY . 85.9 mt . . . . . 0 N--CA 1.442 -0.844 0 CA-C-O 121.881 0.848 . . . . 0.0 111.764 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -101.7 115.48 5.27 Favored Glycine 0 N--CA 1.4 -3.722 0 N-CA-C 106.903 -2.479 . . . . 0.0 106.903 176.11 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.494 HG22 ' HB ' ' B' ' 21' ' ' ILE . 29.1 mm -89.03 88.17 2.9 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 -177.888 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.478 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 73.5 m-85 -83.32 171.72 13.26 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 114.716 -1.129 . . . . 0.0 109.419 -177.664 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 58.9 t -78.19 136.22 24.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.67 0.748 . . . . 0.0 110.053 176.448 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -92.68 -48.13 6.74 Favored 'General case' 0 N--CA 1.426 -1.672 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.131 177.873 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 41' ' ' THR . . . . . 0.443 HG22 ' HB2' ' B' ' 20' ' ' SER . 1.0 OUTLIER -154.13 167.27 30.43 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -178.44 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.586 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.4 p -133.92 96.66 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.065 0 CA-C-O 122.389 1.09 . . . . 0.0 109.821 176.697 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 27.9 m -59.87 125.57 24.17 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 113.257 -1.792 . . . . 0.0 112.2 -175.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 44' ' ' GLU . . . . . 0.47 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 45.4 mt-10 -61.27 -35.07 76.31 Favored 'General case' 0 CA--C 1.516 -0.35 0 C-N-CA 124.21 1.004 . . . . 0.0 111.889 -176.122 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.79 -10.13 84.95 Favored Glycine 0 N--CA 1.441 -1.015 0 CA-C-N 115.861 -0.609 . . . . 0.0 113.415 -179.295 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.478 ' O ' ' HG3' ' B' ' 50' ' ' ARG . . . -106.23 171.2 17.38 Favored Glycine 0 N--CA 1.417 -2.629 0 C-N-CA 119.828 -1.177 . . . . 0.0 113.85 -175.452 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.26 -50.59 38.21 Favored 'General case' 0 C--O 1.208 -1.131 0 C-N-CA 125.213 1.405 . . . . 0.0 114.788 -173.52 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 48' ' ' ALA . . . . . 0.601 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -63.96 -32.44 73.97 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 113.88 1.067 . . . . 0.0 113.88 -172.018 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 49' ' ' HIS . . . . . 0.47 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 2.7 t60 -83.75 -38.8 20.89 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.128 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 50' ' ' ARG . . . . . 0.478 ' HG3' ' O ' ' B' ' 46' ' ' GLY . 74.9 mtp180 -70.32 -42.52 71.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.072 -178.683 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -74.09 -43.08 58.97 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 89.98 51.49 2.8 Favored Glycine 0 CA--C 1.504 -0.608 0 CA-C-N 115.113 -0.949 . . . . 0.0 112.406 175.729 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 34.0 mmt180 -112.94 -82.84 0.59 Allowed 'General case' 0 N--CA 1.442 -0.868 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.053 -177.356 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.463 HD11 ' CE2' ' B' ' 89' ' ' PHE . 70.7 mt -65.52 134.87 29.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 O-C-N 123.774 0.671 . . . . 0.0 109.396 179.648 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 24.4 mm-40 -111.95 164.77 12.74 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.416 HG23 ' HA ' ' B' ' 41' ' ' THR . 14.9 p -65.0 -8.34 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.578 2.028 0 N-CA-C 113.093 0.775 . . . . 0.0 113.093 -175.853 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -115.3 -6.09 12.37 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 -172.603 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -94.25 179.2 5.38 Favored 'General case' 0 N--CA 1.432 -1.373 0 N-CA-C 114.998 1.481 . . . . 0.0 114.998 -178.513 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.478 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 25.8 tp -135.25 136.69 41.89 Favored 'General case' 0 C--O 1.247 0.933 0 CA-C-N 114.958 -1.019 . . . . 0.0 110.954 -172.269 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 52.6 mt -83.82 96.84 8.89 Favored 'General case' 0 N--CA 1.425 -1.69 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 176.556 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.501 ' HB ' ' O ' ' B' ' 90' ' ' MET . 35.0 t -69.74 -42.75 80.28 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-O 122.159 0.98 . . . . 0.0 109.752 179.314 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -156.94 158.87 37.43 Favored 'General case' 0 C--N 1.277 -2.572 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.821 173.056 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.449 HG23 ' CD1' ' B' ' 89' ' ' PHE . 5.0 p -106.36 -175.9 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.099 0 N-CA-C 104.796 -2.298 . . . . 0.0 104.796 178.297 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.524 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 8.9 t70 -52.44 -54.47 31.77 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 112.792 0.664 . . . . 0.0 112.792 178.459 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -122.29 35.73 3.4 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 119.81 -1.186 . . . . 0.0 115.277 -177.072 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 66' ' ' THR . . . . . 0.448 ' HB ' HG12 ' B' ' 63' ' ' VAL . 19.2 m -160.9 141.64 11.5 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 177.45 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 47.3 t -107.02 151.37 25.42 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 -178.628 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.456 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.6 mm? -116.27 106.28 13.5 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 120.98 0.419 . . . . 0.0 110.434 178.609 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 42.6 t -103.51 -8.09 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-O 122.221 1.01 . . . . 0.0 109.096 176.234 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 70' ' ' GLY . . . . . 0.594 ' HA2' ' O ' ' B' ' 35' ' ' LEU . . . 131.52 78.02 0.16 Allowed Glycine 0 CA--C 1.484 -1.898 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -177.47 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.431 HG22 HD12 ' B' ' 68' ' ' LEU . 26.4 m -106.13 -175.08 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.098 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -175.836 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 72' ' ' THR . . . . . 0.41 ' O ' HG23 ' B' ' 71' ' ' VAL . 45.7 p -83.86 159.8 21.28 Favored 'General case' 0 N--CA 1.426 -1.655 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 175.061 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.0 tt0 -63.26 -31.37 72.51 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-O 121.519 0.676 . . . . 0.0 109.567 178.564 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 9.7 m -64.89 -43.18 93.75 Favored 'General case' 0 C--O 1.247 0.948 0 CA-C-N 115.052 -0.977 . . . . 0.0 110.051 177.89 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -62.27 -51.89 65.9 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 115.212 -0.904 . . . . 0.0 108.782 177.46 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.673 ' O ' ' HB ' ' B' ' 79' ' ' VAL . . . -57.61 -37.55 73.45 Favored 'General case' 0 C--O 1.214 -0.814 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.434 -178.131 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.84 -32.64 73.31 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.174 0.512 . . . . 0.0 111.037 178.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 19.0 m -79.36 -19.65 49.71 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.767 179.535 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.673 ' HB ' ' O ' ' B' ' 76' ' ' ALA . 3.9 t -57.15 -57.46 9.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.447 1.099 . . . . 0.0 111.843 177.072 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 80' ' ' LEU . . . . . 0.511 ' H ' HD22 ' B' ' 80' ' ' LEU . 2.6 mm? -58.62 -30.15 67.04 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 122.822 0.449 . . . . 0.0 111.781 178.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 31.6 mtp85 -80.76 -16.76 52.99 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.785 -179.158 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -81.97 -27.91 32.97 Favored 'General case' 0 N--CA 1.44 -0.973 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.659 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.611 ' HB ' HG11 ' B' ' 87' ' ' VAL . 12.5 p -88.99 159.86 17.4 Favored 'General case' 0 N--CA 1.417 -2.088 0 CA-C-N 114.882 -1.054 . . . . 0.0 112.887 179.05 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 72.5 mttt -64.6 -174.91 0.15 Allowed 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 124.914 1.286 . . . . 0.0 113.682 -177.114 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.94 -42.53 94.78 Favored Glycine 0 N--CA 1.445 -0.762 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.985 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 56.9 ttm-85 -123.13 118.46 27.73 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 176.88 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.611 HG11 ' HB ' ' B' ' 83' ' ' THR . 6.2 m -146.41 156.3 11.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.786 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.256 -178.037 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 88' ' ' ARG . . . . . 0.485 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 95.5 mtt180 -105.71 125.54 51.11 Favored 'General case' 0 N--CA 1.423 -1.799 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.47 177.452 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.596 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 1.8 m-85 -100.32 166.79 10.79 Favored 'General case' 0 C--N 1.27 -2.856 0 N-CA-C 106.026 -1.842 . . . . 0.0 106.026 176.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.501 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 64.3 mtt -113.3 112.92 24.52 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 171.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.492 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.4 mp -97.25 128.77 48.18 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -101.39 100.89 2.15 Favored Glycine 0 CA--C 1.46 -3.356 0 N-CA-C 108.522 -1.831 . . . . 0.0 108.522 176.338 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 93' ' ' ARG . . . . . 0.533 ' HB3' ' HB2' ' B' ' 4' ' ' GLU . 21.2 tpp180 . . . . . 0 C--N 1.277 -2.547 0 CA-C-N 114.398 -0.901 . . . . 0.0 109.991 -177.218 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 1.7 mpt? . . . . . 0 N--CA 1.432 -1.352 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -75.97 98.55 4.3 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 177.435 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -81.28 88.97 6.04 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 175.77 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -109.92 145.31 31.78 Favored Pre-proline 0 C--N 1.288 -2.077 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.672 178.781 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -75.91 129.92 11.94 Favored 'Trans proline' 0 N--CA 1.44 -1.66 0 C-N-CA 122.19 1.926 . . . . 0.0 111.97 177.65 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.521 HG13 ' HB3' ' B' ' 53' ' ' ARG . 84.9 t -116.61 126.2 73.96 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.401 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.331 -179.071 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 9' ' ' GLU . . . . . 0.477 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 41.4 tt0 -120.81 128.78 53.18 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -178.675 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.557 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -115.41 -162.59 0.84 Allowed 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.796 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.518 ' H ' HD22 ' B' ' 10' ' ' LEU . 2.3 mm-40 -156.67 167.69 29.69 Favored 'General case' 0 C--N 1.29 -1.998 0 C-N-CA 126.251 1.82 . . . . 0.0 106.145 176.353 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -92.81 -173.15 3.23 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 121.297 0.57 . . . . 0.0 111.35 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 13' ' ' ASP . . . . . 0.47 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 21.9 t70 -128.52 172.05 11.53 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 22.8 t -61.75 -30.98 71.14 Favored 'General case' 0 C--N 1.307 -1.251 0 O-C-N 123.789 0.681 . . . . 0.0 109.199 178.298 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -91.59 -51.95 5.0 Favored 'General case' 0 N--CA 1.446 -0.662 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 173.377 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.461 ' H ' ' HB3' ' B' ' 13' ' ' ASP . . . 126.47 133.27 3.83 Favored Glycine 0 N--CA 1.428 -1.848 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.977 178.043 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mm? 63.66 -168.66 0.2 Allowed 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 176.648 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.19 54.29 0.05 OUTLIER Glycine 0 C--O 1.209 -1.43 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 179.035 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.599 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 4.9 pt -166.91 177.62 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.493 -1.246 0 C-N-CA 125.068 1.347 . . . . 0.0 108.657 -173.707 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 20' ' ' SER . . . . . 0.421 ' HB2' HG22 ' B' ' 41' ' ' THR . 39.1 m -151.95 144.92 24.47 Favored 'General case' 0 C--N 1.27 -2.853 0 N-CA-C 105.461 -2.051 . . . . 0.0 105.461 174.146 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.464 ' HB ' HG22 ' B' ' 37' ' ' ILE . 12.3 pt -111.1 160.76 10.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.054 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 -178.361 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.8 tp -138.75 138.17 42.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-O 120.939 0.399 . . . . 0.0 110.177 -178.375 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.72 98.7 2.3 Favored Glycine 0 N--CA 1.423 -2.221 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 177.453 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 86.4 mtp . . . . . 0 C--N 1.306 -1.29 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 178.922 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 77.6 mt . . . . . 0 C--O 1.248 0.996 0 CA-C-O 121.091 0.472 . . . . 0.0 111.483 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -113.59 123.42 6.13 Favored Glycine 0 N--CA 1.412 -2.935 0 N-CA-C 108.892 -1.683 . . . . 0.0 108.892 177.846 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.464 HG22 ' HB ' ' B' ' 21' ' ' ILE . 20.7 mm -93.81 89.21 2.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.375 -0.93 . . . . 0.0 108.91 -179.46 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.457 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 90.5 m-85 -89.69 169.6 11.17 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.598 -178.376 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 58.0 t -75.32 134.83 28.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 CA-C-O 121.29 0.567 . . . . 0.0 109.723 175.364 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -93.04 -45.71 7.79 Favored 'General case' 0 N--CA 1.435 -1.186 0 CA-C-N 115.337 -0.847 . . . . 0.0 108.835 -179.09 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 41' ' ' THR . . . . . 0.433 ' HA ' HG23 ' B' ' 56' ' ' VAL . 2.5 t -155.21 169.2 24.72 Favored 'General case' 0 N--CA 1.419 -2.003 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.455 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.599 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.3 p -140.47 99.67 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.279 -2.496 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 -179.709 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 9.8 m -61.13 124.46 20.6 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 113.804 -1.543 . . . . 0.0 111.549 -175.095 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -69.92 -20.93 63.33 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.256 0.551 . . . . 0.0 111.863 -177.725 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.95 4.76 85.54 Favored Glycine 0 N--CA 1.437 -1.292 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.673 175.245 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -113.29 172.09 14.24 Favored Glycine 0 N--CA 1.425 -2.044 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.92 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 47' ' ' ALA . . . . . 0.47 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -64.86 -42.05 95.19 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -173.581 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 48' ' ' ALA . . . . . 0.557 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -58.85 -38.09 77.96 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 113.649 0.981 . . . . 0.0 113.649 -173.601 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -75.79 -41.07 53.95 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.244 0.545 . . . . 0.0 109.581 -177.868 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 64.4 mtp180 -68.18 -44.04 76.81 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.717 -178.264 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -63.21 -59.4 4.79 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.909 176.595 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 110.83 -15.53 28.78 Favored Glycine 0 N--CA 1.437 -1.233 0 C-N-CA 120.286 -0.959 . . . . 0.0 114.279 176.171 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.521 ' HB3' HG13 ' B' ' 8' ' ' VAL . 30.4 mmt180 -62.85 -52.33 63.55 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 114.131 1.16 . . . . 0.0 114.131 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.522 HD11 ' CE2' ' B' ' 89' ' ' PHE . 39.0 mt -95.7 119.01 43.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 C-N-CA 119.634 -0.826 . . . . 0.0 109.901 178.57 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 85.0 mm-40 -107.69 -179.92 4.05 Favored 'General case' 0 N--CA 1.433 -1.317 0 CA-C-O 121.269 0.557 . . . . 0.0 109.881 177.22 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.433 HG23 ' HA ' ' B' ' 41' ' ' THR . 12.7 p -71.02 -5.46 5.75 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.329 0 N-CA-C 113.087 0.773 . . . . 0.0 113.087 -174.681 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 5.2 p-10 -117.12 4.24 12.7 Favored 'General case' 0 C--N 1.313 -0.996 0 O-C-N 121.06 -1.025 . . . . 0.0 111.354 -175.214 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -79.09 164.22 24.47 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.504 -175.93 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.457 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 23.2 tp -136.69 128.34 28.81 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 123.078 0.551 . . . . 0.0 110.349 -176.587 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 70.3 mt -79.78 92.36 5.43 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.749 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.529 ' HB ' ' O ' ' B' ' 90' ' ' MET . 40.8 t -76.31 -42.24 36.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-O 122.066 0.936 . . . . 0.0 109.749 178.394 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.415 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 8.6 pt-20 -154.23 147.49 24.84 Favored 'General case' 0 C--N 1.274 -2.697 0 CA-C-N 114.843 -1.072 . . . . 0.0 109.348 174.809 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.41 HG12 ' O ' ' B' ' 66' ' ' THR . 5.3 p -97.61 -174.98 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 104.349 -2.463 . . . . 0.0 104.349 174.524 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.55 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 28.8 t70 -56.37 -44.11 79.83 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 118.643 0.656 . . . . 0.0 112.563 -179.259 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -103.88 -66.57 0.72 Allowed Glycine 0 CA--C 1.528 0.85 0 C-N-CA 120.391 -0.909 . . . . 0.0 113.277 178.865 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 66' ' ' THR . . . . . 0.41 ' O ' HG12 ' B' ' 63' ' ' VAL . 14.2 m -66.87 129.86 41.27 Favored 'General case' 0 CA--C 1.547 0.849 0 CA-C-O 121.135 0.493 . . . . 0.0 112.124 -177.89 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 4.4 m -95.15 139.48 31.43 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 177.157 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.512 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.3 mm? -101.44 125.97 48.15 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.696 0.76 . . . . 0.0 111.39 -179.009 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 8.8 p -125.13 9.57 4.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 115.163 -0.926 . . . . 0.0 109.104 178.79 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 120.09 87.89 1.05 Allowed Glycine 0 CA--C 1.499 -0.942 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -177.356 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.0 m -121.94 -179.11 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -177.776 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 32.3 p -83.88 164.16 19.62 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 175.543 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.3 tt0 -60.89 -41.23 95.63 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.278 0.561 . . . . 0.0 110.246 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 12.9 t -66.74 -36.41 82.38 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.282 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 75' ' ' PHE . . . . . 0.416 ' O ' HG13 ' B' ' 79' ' ' VAL . 38.0 t80 -62.29 -52.29 64.26 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -179.65 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.698 ' O ' HG22 ' B' ' 79' ' ' VAL . . . -65.93 -31.32 72.18 Favored 'General case' 0 C--O 1.218 -0.574 0 CA-C-O 120.978 0.418 . . . . 0.0 110.383 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.4 -34.54 77.96 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.757 0.789 . . . . 0.0 109.603 175.811 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.4 m -84.18 -17.14 40.94 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 115.194 -0.912 . . . . 0.0 112.112 -177.761 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.698 HG22 ' O ' ' B' ' 76' ' ' ALA . 23.5 m -68.81 -38.87 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 CA-C-O 121.53 0.681 . . . . 0.0 109.588 -178.439 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 23.5 mt -65.56 -21.31 66.59 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 125.193 1.397 . . . . 0.0 110.884 176.728 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 80.7 mtt180 -92.94 -14.36 27.65 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.491 -177.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -94.79 -22.28 18.17 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.669 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.705 ' HB ' HG11 ' B' ' 87' ' ' VAL . 6.6 p -80.77 -177.37 6.3 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.707 177.854 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -67.8 -171.48 0.21 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 123.484 0.714 . . . . 0.0 111.217 178.21 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -73.15 -42.05 44.94 Favored Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.134 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 86' ' ' ARG . . . . . 0.483 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 16.0 ttp180 -121.99 124.13 43.29 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 175.909 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.705 HG11 ' HB ' ' B' ' 83' ' ' THR . 5.2 m -137.86 165.58 25.93 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 CA-C-O 121.055 0.455 . . . . 0.0 110.858 178.084 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 51.8 mtp85 -106.52 147.91 28.84 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.405 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.522 ' CE2' HD11 ' B' ' 54' ' ' ILE . 0.7 OUTLIER -129.83 170.38 13.97 Favored 'General case' 0 C--N 1.277 -2.578 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 -179.224 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.529 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 59.8 mtt -121.16 122.93 41.06 Favored 'General case' 0 C--N 1.292 -1.923 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 168.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 1.3 mp -105.7 133.31 50.4 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 CA-C-N 114.194 -1.366 . . . . 0.0 107.446 -178.307 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -117.69 101.14 0.9 Allowed Glycine 0 CA--C 1.48 -2.113 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 177.819 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 19.2 tpp180 . . . . . 0 C--N 1.274 -2.685 0 CA-C-N 114.435 -0.883 . . . . 0.0 110.099 -176.18 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 3' ' ' MET . . . . . 0.46 ' O ' HD22 ' B' ' 5' ' ' LEU . 25.5 mmt . . . . . 0 N--CA 1.432 -1.34 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -83.38 92.3 7.52 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 -175.45 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.46 HD22 ' O ' ' B' ' 3' ' ' MET . 0.7 OUTLIER -88.49 93.99 9.72 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 176.585 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -111.77 142.89 27.54 Favored Pre-proline 0 C--N 1.281 -2.395 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.539 179.562 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 7' ' ' PRO . . . . . 0.498 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 57.8 Cg_endo -78.64 132.82 11.17 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 122.319 2.013 . . . . 0.0 113.316 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.503 HG13 ' HB3' ' B' ' 53' ' ' ARG . 71.6 t -117.69 122.59 70.16 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.957 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -106.77 132.25 52.96 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.192 -175.21 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.434 HD21 ' HA ' ' B' ' 48' ' ' ALA . 1.0 OUTLIER -135.51 158.57 44.04 Favored 'General case' 0 N--CA 1.427 -1.607 0 CA-C-O 121.293 0.568 . . . . 0.0 110.743 176.606 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -145.37 161.37 39.82 Favored 'General case' 0 C--N 1.278 -2.515 0 CA-C-N 114.105 -1.407 . . . . 0.0 107.228 175.198 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 60.6 mttp -86.71 156.64 19.88 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-O 122.029 0.919 . . . . 0.0 113.259 -172.852 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -71.55 -69.95 0.35 Allowed 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 113.69 -1.595 . . . . 0.0 110.744 178.62 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 47.0 t -176.55 -39.62 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 105.398 -2.075 . . . . 0.0 105.398 -175.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -78.3 -57.02 4.0 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 172.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 161.61 -142.54 8.1 Favored Glycine 0 N--CA 1.428 -1.887 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 179.354 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -91.59 -174.47 3.88 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.392 0.615 . . . . 0.0 110.003 176.31 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -133.98 -113.78 1.42 Allowed Glycine 0 N--CA 1.419 -2.475 0 N-CA-C 108.411 -1.876 . . . . 0.0 108.411 176.443 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.56 HG22 ' HA ' ' B' ' 42' ' ' VAL . 24.0 pt 45.04 -177.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 C-N-CA 125.573 1.549 . . . . 0.0 114.993 178.22 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 43.8 m -157.87 146.39 19.13 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 104.823 -2.288 . . . . 0.0 104.823 173.758 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.525 ' HB ' HG22 ' B' ' 37' ' ' ILE . 12.5 pt -119.58 161.02 19.27 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.364 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 22' ' ' ILE . . . . . 0.415 ' HB ' ' CG ' ' B' ' 40' ' ' LYS . 8.7 tp -136.75 135.32 48.61 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 CA-C-O 120.964 0.412 . . . . 0.0 110.446 -176.363 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.33 103.24 3.02 Favored Glycine 0 N--CA 1.426 -2.011 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.025 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 68.6 mtm . . . . . 0 C--N 1.311 -1.067 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.266 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 97.6 mt . . . . . 0 N--CA 1.438 -1.042 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -108.54 114.15 4.01 Favored Glycine 0 N--CA 1.422 -2.269 0 C-N-CA 120.235 -0.984 . . . . 0.0 111.571 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.525 HG22 ' HB ' ' B' ' 21' ' ' ILE . 20.7 mm -95.32 88.19 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.521 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 175.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.411 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 96.1 m-85 -82.07 172.1 13.6 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 114.901 -1.045 . . . . 0.0 108.686 -178.192 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 45.5 t -79.17 142.58 13.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 175.645 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 40' ' ' LYS . . . . . 0.415 ' CG ' ' HB ' ' B' ' 22' ' ' ILE . 0.1 OUTLIER -103.08 -42.63 5.72 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 -178.363 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 41' ' ' THR . . . . . 0.452 ' HA ' HG23 ' B' ' 56' ' ' VAL . 1.5 t -155.78 164.8 38.08 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 179.108 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.56 ' HA ' HG22 ' B' ' 19' ' ' ILE . 16.9 t -124.63 94.73 2.91 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.512 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 6.3 m -54.61 124.9 17.71 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 123.34 0.656 . . . . 0.0 111.517 179.752 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -62.09 -30.6 71.11 Favored 'General case' 0 C--O 1.222 -0.345 0 O-C-N 124.415 1.072 . . . . 0.0 112.26 -177.298 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.46 -23.46 77.05 Favored Glycine 0 N--CA 1.438 -1.172 0 C-N-CA 121.221 -0.514 . . . . 0.0 112.464 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.08 159.79 30.36 Favored Glycine 0 N--CA 1.416 -2.669 0 C-N-CA 119.692 -1.242 . . . . 0.0 113.158 -175.284 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -56.01 -38.31 70.34 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.27 -1.465 . . . . 0.0 112.458 -176.475 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 48' ' ' ALA . . . . . 0.434 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -59.03 -35.32 73.09 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -175.645 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 4.2 t60 -78.17 -40.69 36.99 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.491 0.663 . . . . 0.0 109.38 -179.223 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 65.6 mtp180 -73.86 -39.46 63.95 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 114.508 -1.223 . . . . 0.0 110.072 -174.484 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 51' ' ' ASP . . . . . 0.462 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 9.9 t70 -68.06 -60.08 2.76 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 173.174 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 97.69 11.38 50.82 Favored Glycine 0 N--CA 1.427 -1.919 0 CA-C-O 119.073 -0.849 . . . . 0.0 114.964 175.101 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.567 ' NE ' ' HA ' ' B' ' 53' ' ' ARG . 3.6 mmp_? -76.09 -50.25 15.21 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 118.655 1.227 . . . . 0.0 112.492 174.551 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.487 HD11 ' CE2' ' B' ' 89' ' ' PHE . 33.4 mt -77.36 141.02 16.14 Favored 'Isoleucine or valine' 0 C--O 1.249 1.072 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 175.538 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 72.5 mm-40 -114.54 -177.17 3.06 Favored 'General case' 0 N--CA 1.433 -1.315 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 -178.159 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.452 HG23 ' HA ' ' B' ' 41' ' ' THR . 8.4 p -90.45 3.55 6.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 CA-C-O 121.436 0.636 . . . . 0.0 111.416 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -119.38 -16.4 8.98 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 -174.693 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -76.39 178.65 6.39 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 114.491 1.293 . . . . 0.0 114.491 -173.43 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.47 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 27.8 tp -133.79 121.9 22.51 Favored 'General case' 0 N--CA 1.437 -1.113 0 CA-C-N 114.933 -1.03 . . . . 0.0 110.911 -172.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 74.6 mt -80.67 91.66 5.89 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.458 179.128 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.583 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 10.8 t -72.5 -37.43 57.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 123.189 0.596 . . . . 0.0 111.078 179.076 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.558 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 12.8 pt-20 -160.43 157.64 28.08 Favored 'General case' 0 C--N 1.28 -2.413 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.001 171.806 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.461 HG12 ' HB ' ' B' ' 66' ' ' THR . 5.6 p -101.82 -178.35 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 105.484 -2.043 . . . . 0.0 105.484 178.434 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.415 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 9.4 t70 -55.94 -53.64 54.39 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -178.556 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -112.17 22.14 18.71 Favored Glycine 0 C--N 1.318 -0.425 0 C-N-CA 120.151 -1.023 . . . . 0.0 114.703 -175.883 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 66' ' ' THR . . . . . 0.461 ' HB ' HG12 ' B' ' 63' ' ' VAL . 32.3 m -153.89 115.19 4.13 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 117.859 0.83 . . . . 0.0 109.709 178.778 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 67' ' ' SER . . . . . 0.558 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 45.6 m -87.09 138.05 31.82 Favored 'General case' 0 N--CA 1.433 -1.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.751 178.322 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.583 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 52.5 mt -107.71 101.54 10.84 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-O 120.918 0.39 . . . . 0.0 111.695 -178.294 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 12.2 p -71.39 -26.63 26.97 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 172.675 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 151.62 85.77 0.05 OUTLIER Glycine 0 N--CA 1.424 -2.165 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -178.406 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 33.0 m -105.72 -177.56 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 CA-C-N 115.141 -0.53 . . . . 0.0 109.82 -177.056 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 71.6 p -81.37 166.68 20.21 Favored 'General case' 0 N--CA 1.428 -1.559 0 CA-C-O 121.236 0.541 . . . . 0.0 110.112 177.148 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -62.18 -39.85 94.09 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.584 -0.735 . . . . 0.0 109.935 178.788 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 20.3 t -69.77 -39.02 76.9 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.092 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 75' ' ' PHE . . . . . 0.437 ' O ' HG13 ' B' ' 79' ' ' VAL . 17.8 t80 -60.4 -51.57 68.91 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 -179.611 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.631 ' O ' HG22 ' B' ' 79' ' ' VAL . . . -64.38 -33.56 76.13 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.113 179.426 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.46 -37.44 87.3 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.622 0.725 . . . . 0.0 109.709 176.832 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.6 p -79.1 -18.06 54.0 Favored 'General case' 0 N--CA 1.427 -1.592 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 178.756 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.631 HG22 ' O ' ' B' ' 76' ' ' ALA . 32.9 m -73.67 -36.17 46.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 121.976 0.894 . . . . 0.0 109.703 -178.797 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 51.9 mt -66.1 -26.69 67.58 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 114.245 -1.343 . . . . 0.0 110.914 177.151 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 23.0 mtp180 -96.1 -8.0 34.53 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -176.523 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 25.7 m-80 -102.28 -13.77 17.24 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 120.852 0.358 . . . . 0.0 111.634 178.072 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.604 ' HB ' HG11 ' B' ' 87' ' ' VAL . 2.6 p -81.79 173.29 12.42 Favored 'General case' 0 N--CA 1.426 -1.665 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.108 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 66.5 mmtt -65.06 -172.36 0.09 Allowed 'General case' 0 C--O 1.242 0.679 0 C-N-CA 124.151 0.98 . . . . 0.0 113.347 -176.767 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.06 -49.12 63.88 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.635 179.691 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 -125.51 121.27 33.21 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -178.208 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.604 HG11 ' HB ' ' B' ' 83' ' ' THR . 12.5 m -138.78 154.55 26.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 123.945 0.778 . . . . 0.0 111.396 -175.521 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 89.5 mtt180 -110.48 124.37 51.66 Favored 'General case' 0 N--CA 1.429 -1.521 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.917 178.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.498 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 4.8 m-85 -97.27 160.66 14.2 Favored 'General case' 0 C--N 1.28 -2.423 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 179.446 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.487 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 63.1 mtt -110.5 117.35 33.31 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 171.64 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.47 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -100.77 129.92 50.9 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.128 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -114.97 119.15 4.54 Favored Glycine 0 CA--C 1.473 -2.574 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.376 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 . . . . . 0 C--N 1.278 -2.526 0 CA-C-N 114.728 -0.736 . . . . 0.0 110.551 177.827 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 3' ' ' MET . . . . . 0.474 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 25.4 ptp . . . . . 0 C--O 1.239 0.539 0 CA-C-O 121.421 0.629 . . . . 0.0 110.092 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -106.07 104.7 14.46 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -88.55 89.58 8.05 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 178.692 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -118.51 144.47 35.34 Favored Pre-proline 0 C--N 1.297 -1.699 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -178.518 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 7' ' ' PRO . . . . . 0.414 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 28.7 Cg_endo -80.95 127.8 6.3 Favored 'Trans proline' 0 N--CA 1.445 -1.38 0 C-N-CA 122.337 2.024 . . . . 0.0 112.629 177.531 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.561 HG13 ' HB3' ' B' ' 53' ' ' ARG . 76.0 t -112.49 134.73 54.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.032 0 CA-C-N 114.913 -1.039 . . . . 0.0 108.214 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 9' ' ' GLU . . . . . 0.46 ' OE2' ' HD3' ' B' ' 86' ' ' ARG . 34.9 tt0 -121.75 130.79 53.68 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -178.087 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.56 HD23 ' H ' ' B' ' 11' ' ' GLU . 0.5 OUTLIER -143.78 162.66 35.45 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.116 0.484 . . . . 0.0 111.075 -179.606 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.56 ' H ' HD23 ' B' ' 10' ' ' LEU . 6.7 mm-40 -86.97 156.75 19.66 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 125.172 1.389 . . . . 0.0 107.414 179.585 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 15.8 ptpt -79.28 -167.59 1.23 Allowed 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 122.11 0.957 . . . . 0.0 109.961 172.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 13' ' ' ASP . . . . . 0.433 ' HB3' ' N ' ' B' ' 17' ' ' LEU . 6.9 t70 -126.18 162.65 24.91 Favored 'General case' 0 C--N 1.285 -2.206 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 -179.036 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 31.0 t -61.54 -33.7 74.27 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 124.057 0.848 . . . . 0.0 110.658 -176.54 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -88.78 -51.86 5.43 Favored 'General case' 0 N--CA 1.437 -1.082 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 176.47 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.79 94.48 0.16 Allowed Glycine 0 N--CA 1.43 -1.7 0 CA-C-N 115.266 -0.879 . . . . 0.0 111.417 179.743 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.433 ' N ' ' HB3' ' B' ' 13' ' ' ASP . 3.8 mm? 59.64 98.02 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 124.605 1.162 . . . . 0.0 113.941 178.203 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -83.15 59.9 4.94 Favored Glycine 0 C--O 1.219 -0.843 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.576 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 6.7 pt -148.79 -175.51 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 C-N-CA 126.416 1.887 . . . . 0.0 107.072 179.024 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 66.7 m -151.27 146.99 26.43 Favored 'General case' 0 C--N 1.261 -3.271 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 176.293 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.44 ' HB ' HG22 ' B' ' 37' ' ' ILE . 13.9 pt -113.49 157.86 14.04 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 O-C-N 123.405 0.44 . . . . 0.0 110.072 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 22' ' ' ILE . . . . . 0.444 ' HB ' ' HB2' ' B' ' 40' ' ' LYS . 8.5 tp -131.94 130.24 61.22 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.84 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.67 89.85 1.62 Allowed Glycine 0 N--CA 1.408 -3.186 0 C-N-CA 120.926 -0.654 . . . . 0.0 111.819 -177.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 25.4 mmt . . . . . 0 N--CA 1.434 -1.262 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 176.146 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 88.3 mt . . . . . 0 N--CA 1.437 -1.111 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -112.44 95.01 0.76 Allowed Glycine 0 N--CA 1.429 -1.815 0 C-N-CA 120.021 -1.085 . . . . 0.0 110.882 179.409 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.44 HG22 ' HB ' ' B' ' 21' ' ' ILE . 16.4 mm -87.84 85.33 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 CA-C-O 121.905 0.86 . . . . 0.0 109.237 179.65 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -84.71 175.47 9.17 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.898 -178.544 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 48.5 t -79.92 142.35 14.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 175.344 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 40' ' ' LYS . . . . . 0.444 ' HB2' ' HB ' ' B' ' 22' ' ' ILE . 87.5 tttt -100.82 -51.84 3.46 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.654 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -149.53 162.88 39.29 Favored 'General case' 0 N--CA 1.417 -2.102 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -175.537 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.576 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.4 p -140.84 105.48 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.04 0 CA-C-O 121.836 0.826 . . . . 0.0 109.839 178.271 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 16.5 m -62.95 125.97 25.77 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-N 114.355 -1.293 . . . . 0.0 111.566 -175.414 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 44' ' ' GLU . . . . . 0.449 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 11.1 pt-20 -65.47 -23.2 66.85 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.395 -178.063 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -83.65 3.96 83.57 Favored Glycine 0 N--CA 1.441 -0.992 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.23 177.033 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -108.07 164.49 12.82 Favored Glycine 0 N--CA 1.424 -2.156 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.208 179.261 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -65.57 -36.33 83.46 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-N 114.279 -0.96 . . . . 0.0 112.357 -176.501 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.72 -38.44 90.49 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -175.046 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 49' ' ' HIS . . . . . 0.449 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 7.9 t60 -69.91 -41.9 74.08 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 121.499 0.666 . . . . 0.0 109.713 -178.398 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 23.9 mtp180 -75.49 -35.76 60.74 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.697 -174.74 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 51' ' ' ASP . . . . . 0.439 ' CB ' HD21 ' B' ' 10' ' ' LEU . 16.8 t70 -64.4 -63.64 1.08 Allowed 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.088 175.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 117.88 -20.25 10.86 Favored Glycine 0 N--CA 1.428 -1.9 0 C-N-CA 119.871 -1.157 . . . . 0.0 114.027 178.185 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.561 ' HB3' HG13 ' B' ' 8' ' ' VAL . 12.9 mmt180 -62.11 -62.83 1.5 Allowed 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 113.718 1.006 . . . . 0.0 113.718 179.588 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.644 HD11 ' CE2' ' B' ' 89' ' ' PHE . 62.9 mt -77.36 109.0 11.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 C-N-CA 119.374 -0.93 . . . . 0.0 109.137 174.43 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 79.6 mm-40 -102.01 173.89 6.18 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 121.163 0.506 . . . . 0.0 110.549 175.012 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.5 p -63.88 -12.97 12.6 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 114.165 1.172 . . . . 0.0 114.165 -173.381 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -125.62 16.89 8.15 Favored 'General case' 0 C--N 1.311 -1.091 0 O-C-N 120.976 -1.078 . . . . 0.0 111.145 -176.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 25.7 m-20 -83.22 172.6 12.44 Favored 'General case' 0 C--N 1.317 -0.812 0 O-C-N 121.362 -0.836 . . . . 0.0 111.084 179.098 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.494 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 29.7 tp -128.51 116.06 19.11 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 120.563 0.221 . . . . 0.0 110.808 -175.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 32.8 mt -93.17 95.29 9.31 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 179.126 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.709 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 96.3 t -73.19 -65.3 0.68 Allowed 'Isoleucine or valine' 0 C--O 1.175 -2.845 0 C-N-CA 120.607 -0.437 . . . . 0.0 109.83 178.647 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.461 ' O ' ' HA ' ' B' ' 89' ' ' PHE . 8.6 pt-20 -129.05 157.26 42.22 Favored 'General case' 0 C--N 1.272 -2.787 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -177.019 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.559 HG21 HG21 ' B' ' 83' ' ' THR . 5.0 p -103.51 -176.19 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.554 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 -178.358 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.516 ' H ' HG22 ' B' ' 63' ' ' VAL . 27.5 t70 -51.25 -54.9 21.44 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 114.174 1.176 . . . . 0.0 114.174 -177.082 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -121.53 27.67 6.22 Favored Glycine 0 C--N 1.315 -0.591 0 C-N-CA 120.252 -0.975 . . . . 0.0 114.486 -175.251 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 51.4 m -152.57 120.67 6.22 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 176.791 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 19.7 m -94.21 111.38 23.11 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.168 -175.61 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.709 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 51.3 mt -89.57 121.36 31.7 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 176.957 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 14.8 p -83.74 -22.18 8.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.372 0.605 . . . . 0.0 109.565 177.451 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 145.88 69.16 0.01 OUTLIER Glycine 0 CA--C 1.487 -1.706 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 -177.318 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 34.9 m -90.6 -178.66 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 CA-C-N 114.563 -0.819 . . . . 0.0 109.742 -177.125 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 32.3 p -78.19 164.66 24.75 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 120.825 0.345 . . . . 0.0 111.066 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.3 tt0 -58.9 -40.43 84.45 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 123.429 0.692 . . . . 0.0 110.15 179.646 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 30.3 t -66.83 -36.48 82.45 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.323 -179.386 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -68.37 -47.84 66.35 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -179.649 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.539 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -62.6 -39.31 93.35 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.929 178.814 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.33 -39.77 91.76 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-O 121.178 0.513 . . . . 0.0 111.153 178.826 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 13.3 p -82.1 -10.76 59.09 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -177.504 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.539 HG12 ' O ' ' B' ' 76' ' ' ALA . 5.3 p -86.18 -34.65 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.383 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 58.9 mt -69.87 -20.22 63.4 Favored 'General case' 0 C--O 1.213 -0.848 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.437 176.745 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 77.0 mtp180 -94.57 4.11 54.26 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.588 0.709 . . . . 0.0 110.244 177.429 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.2 t30 -113.6 0.86 14.76 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.734 0.778 . . . . 0.0 110.424 -176.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.559 HG21 HG21 ' B' ' 63' ' ' VAL . 23.1 p -91.78 170.76 9.63 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.001 1.112 . . . . 0.0 114.001 -174.117 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.7 mmtt -73.88 -167.38 0.47 Allowed 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 124.795 1.238 . . . . 0.0 111.82 176.733 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.09 -33.93 84.95 Favored Glycine 0 C--O 1.225 -0.434 0 CA-C-N 115.628 -0.714 . . . . 0.0 113.274 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 86' ' ' ARG . . . . . 0.46 ' HD3' ' OE2' ' B' ' 9' ' ' GLU . 16.6 ttm180 -140.99 133.48 28.47 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 178.173 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.468 HG11 ' HB ' ' B' ' 83' ' ' THR . 11.9 m -139.02 164.51 25.27 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.031 0 CA-C-O 121.167 0.508 . . . . 0.0 111.591 178.886 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 88' ' ' ARG . . . . . 0.473 ' H ' ' HB2' ' B' ' 64' ' ' ASP . 54.3 mtm180 -100.01 159.03 15.4 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-N 114.649 -1.159 . . . . 0.0 108.221 176.448 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.644 ' CE2' HD11 ' B' ' 54' ' ' ILE . 4.9 m-85 -141.82 152.92 44.13 Favored 'General case' 0 C--N 1.283 -2.306 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 175.551 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.402 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 87.3 mmm -98.41 112.89 24.75 Favored 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 120.101 -0.64 . . . . 0.0 109.913 173.839 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.555 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.5 mp -101.8 117.2 46.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -179.159 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.89 101.28 2.07 Favored Glycine 0 CA--C 1.458 -3.498 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 174.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 93' ' ' ARG . . . . . 0.474 ' O ' ' HA ' ' B' ' 3' ' ' MET . 19.9 tpp180 . . . . . 0 C--N 1.276 -2.59 0 CA-C-N 114.478 -0.861 . . . . 0.0 109.884 178.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 3' ' ' MET . . . . . 0.491 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 66.2 mtt . . . . . 0 N--CA 1.427 -1.605 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -94.54 101.55 13.45 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.276 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.46 90.71 8.47 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.33 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -119.29 144.59 36.66 Favored Pre-proline 0 C--N 1.29 -1.985 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.109 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 7' ' ' PRO . . . . . 0.433 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 56.4 Cg_endo -75.49 139.23 22.83 Favored 'Trans proline' 0 N--CA 1.446 -1.297 0 C-N-CA 122.271 1.981 . . . . 0.0 111.767 177.36 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.463 ' HB ' HD13 ' B' ' 91' ' ' ILE . 87.5 t -129.73 128.99 66.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -179.298 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 9' ' ' GLU . . . . . 0.52 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 38.6 tt0 -114.99 123.26 48.65 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.48 HD21 ' HA ' ' B' ' 48' ' ' ALA . 1.1 mt -132.93 164.05 27.79 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 178.143 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -123.56 137.49 54.75 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 174.949 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 12' ' ' LYS . . . . . 0.415 ' HB2' ' O ' ' B' ' 16' ' ' GLY . 18.3 ptmt -74.96 162.48 28.56 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.189 179.143 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -134.78 -166.13 1.77 Allowed 'General case' 0 C--N 1.291 -1.965 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.811 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.5 m -66.49 -22.31 66.19 Favored 'General case' 0 C--N 1.313 -1.003 0 C-N-CA 123.666 0.786 . . . . 0.0 111.598 -178.279 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -86.06 2.34 46.89 Favored 'General case' 0 CA--C 1.55 0.952 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 177.543 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.415 ' O ' ' HB2' ' B' ' 12' ' ' LYS . . . 85.06 -91.57 1.7 Allowed Glycine 0 N--CA 1.417 -2.58 0 N-CA-C 107.34 -2.304 . . . . 0.0 107.34 -175.077 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.405 ' HB3' HG12 ' B' ' 19' ' ' ILE . 3.5 mm? -124.75 134.14 52.91 Favored 'General case' 0 C--N 1.281 -2.396 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 174.719 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -83.45 53.3 4.84 Favored Glycine 0 C--O 1.216 -1.005 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.531 HG22 ' HA ' ' B' ' 42' ' ' VAL . 8.0 pt -161.87 176.56 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 C-N-CA 126.126 1.77 . . . . 0.0 107.491 -177.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 20' ' ' SER . . . . . 0.402 ' HB2' HG22 ' B' ' 41' ' ' THR . 27.3 m -143.41 146.21 33.28 Favored 'General case' 0 C--N 1.268 -2.951 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 173.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.475 ' HB ' HG22 ' B' ' 37' ' ' ILE . 10.1 pt -114.31 162.56 12.33 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -179.164 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 22' ' ' ILE . . . . . 0.43 ' HB ' ' HB2' ' B' ' 40' ' ' LYS . 10.8 tp -137.89 138.37 44.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-O 121.041 0.448 . . . . 0.0 110.362 -177.714 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.54 108.58 3.45 Favored Glycine 0 N--CA 1.427 -1.94 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.662 178.304 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 22.7 mmt . . . . . 0 C--N 1.304 -1.371 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 177.65 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 35' ' ' LEU . . . . . 0.434 HD23 ' O ' ' B' ' 71' ' ' VAL . 14.5 tp . . . . . 0 N--CA 1.419 -2.017 0 N-CA-C 104.797 -2.297 . . . . 0.0 104.797 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -138.94 120.36 1.9 Allowed Glycine 0 C--N 1.273 -2.929 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.051 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.475 HG22 ' HB ' ' B' ' 21' ' ' ILE . 32.0 mm -96.84 89.22 2.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 179.23 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -84.31 170.88 13.2 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.55 -1.204 . . . . 0.0 108.192 -179.176 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 49.8 t -75.86 145.22 10.92 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 174.151 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 40' ' ' LYS . . . . . 0.43 ' HB2' ' HB ' ' B' ' 22' ' ' ILE . 2.0 tmmm? -105.08 -41.26 5.63 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 -179.522 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 41' ' ' THR . . . . . 0.424 ' HA ' HG23 ' B' ' 56' ' ' VAL . 1.0 OUTLIER -158.39 164.15 36.58 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 -179.533 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.531 ' HA ' HG22 ' B' ' 19' ' ' ILE . 15.3 t -119.0 95.15 3.46 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 175.634 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.45 ' H ' ' HA ' ' B' ' 19' ' ' ILE . 7.0 m -64.09 121.03 13.21 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 123.976 0.91 . . . . 0.0 112.159 -175.67 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -69.59 -18.18 63.6 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.18 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.45 -11.77 84.09 Favored Glycine 0 N--CA 1.436 -1.313 0 C-N-CA 120.978 -0.629 . . . . 0.0 112.354 178.094 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -115.69 172.43 14.21 Favored Glycine 0 N--CA 1.426 -1.982 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.303 -178.591 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -67.53 -27.03 66.63 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 114.698 1.37 . . . . 0.0 114.698 -172.171 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 48' ' ' ALA . . . . . 0.48 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -63.72 -41.89 98.0 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 112.486 0.551 . . . . 0.0 112.486 -175.829 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -70.83 -38.01 73.23 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 121.807 0.813 . . . . 0.0 109.276 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 -72.7 -34.08 66.89 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 114.197 -1.365 . . . . 0.0 110.626 -174.843 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 51' ' ' ASP . . . . . 0.542 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 15.5 t0 -75.81 -52.87 9.44 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 175.742 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.82 29.62 8.03 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.546 -177.436 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.542 ' HG2' ' OD1' ' B' ' 51' ' ' ASP . 32.6 mmt180 -90.0 -81.74 0.28 Allowed 'General case' 0 CA--C 1.513 -0.478 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.455 HD11 ' CE2' ' B' ' 89' ' ' PHE . 81.3 mt -67.01 125.41 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 O-C-N 123.293 0.37 . . . . 0.0 110.197 176.48 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 55' ' ' GLN . . . . . 0.445 ' HB2' ' OD2' ' B' ' 58' ' ' ASP . 8.5 mt-30 -104.39 161.61 13.93 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.635 -176.677 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.424 HG23 ' HA ' ' B' ' 41' ' ' THR . 7.3 p -62.43 -21.32 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 N-CA-C 115.771 1.767 . . . . 0.0 115.771 -168.22 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 -122.57 22.63 9.85 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.936 -1.106 . . . . 0.0 109.066 -176.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 58' ' ' ASP . . . . . 0.445 ' OD2' ' HB2' ' B' ' 55' ' ' GLN . 78.5 m-20 -87.96 170.9 10.74 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.976 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 28.2 tp -132.12 131.22 42.12 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.626 -178.157 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 78.9 mt -83.2 95.03 8.0 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 176.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.478 ' HB ' ' O ' ' B' ' 90' ' ' MET . 21.4 t -74.0 -40.96 52.7 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.886 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.448 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 11.3 pt-20 -160.56 149.66 17.07 Favored 'General case' 0 C--N 1.283 -2.307 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.482 176.22 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.407 HG12 ' O ' ' B' ' 66' ' ' THR . 4.8 p -98.27 -179.27 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 105.037 -2.209 . . . . 0.0 105.037 176.67 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.57 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 16.6 t70 -53.52 -53.33 53.04 Favored 'General case' 0 C--N 1.311 -1.076 0 N-CA-C 114.081 1.141 . . . . 0.0 114.081 -177.567 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -105.23 -1.77 41.4 Favored Glycine 0 C--N 1.312 -0.768 0 C-N-CA 119.408 -1.377 . . . . 0.0 115.509 -175.632 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 66' ' ' THR . . . . . 0.407 ' O ' HG12 ' B' ' 63' ' ' VAL . 13.8 m -142.89 133.29 24.82 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 118.163 0.982 . . . . 0.0 110.011 -175.344 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 67' ' ' SER . . . . . 0.448 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 13.0 t -94.15 157.15 16.21 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.72 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.45 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.3 mm? -118.25 115.21 24.27 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.956 0.408 . . . . 0.0 111.062 -179.075 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 13.8 p -97.52 -20.28 5.7 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-O 121.918 0.866 . . . . 0.0 109.497 175.437 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 143.52 86.15 0.08 OUTLIER Glycine 0 CA--C 1.485 -1.791 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -178.812 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.434 ' O ' HD23 ' B' ' 35' ' ' LEU . 33.5 m -109.46 -179.04 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.301 0 CA-C-N 115.032 -0.584 . . . . 0.0 109.515 -175.665 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 71.2 p -75.24 159.56 31.41 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 109.173 -0.676 . . . . 0.0 109.173 176.651 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.6 tt0 -62.17 -33.38 74.41 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.469 0.652 . . . . 0.0 110.046 -179.116 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 22.3 m -73.24 -37.37 66.38 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.004 178.159 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -62.41 -46.1 90.12 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.334 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.477 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -62.6 -42.42 99.57 Favored 'General case' 0 C--O 1.209 -1.075 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.747 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.0 -31.02 71.35 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 121.719 0.771 . . . . 0.0 111.057 178.788 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 33.4 t -90.47 -4.85 56.68 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.893 -179.201 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.477 HG12 ' O ' ' B' ' 76' ' ' ALA . 1.2 p -76.27 -31.98 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 C-N-CA 119.776 -0.77 . . . . 0.0 109.494 -177.916 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -67.86 -30.81 70.27 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.574 174.388 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -82.09 -7.59 59.62 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.648 -178.278 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -92.17 -23.11 19.49 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.989 178.259 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.516 ' HB ' HG11 ' B' ' 87' ' ' VAL . 11.6 p -97.46 -178.76 4.25 Favored 'General case' 0 N--CA 1.428 -1.535 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.241 177.479 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 65.3 mmtt -70.93 -171.56 0.56 Allowed 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 123.245 0.618 . . . . 0.0 111.387 177.169 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -78.39 -35.71 32.5 Favored Glycine 0 N--CA 1.442 -0.932 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.716 -178.835 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 29.5 ttt180 -123.13 117.33 25.15 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 176.847 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.57 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 7.8 m -148.5 160.02 6.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 123.878 0.736 . . . . 0.0 110.009 -177.371 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 88' ' ' ARG . . . . . 0.52 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 96.3 mtt180 -103.49 134.12 47.38 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.708 177.761 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.455 ' CE2' HD11 ' B' ' 54' ' ' ILE . 0.7 OUTLIER -112.93 166.37 11.46 Favored 'General case' 0 C--N 1.281 -2.407 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 178.879 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.478 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 85.0 mtp -111.66 114.55 27.65 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 171.381 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.463 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.4 mp -97.76 130.0 47.11 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.188 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -118.65 95.23 0.61 Allowed Glycine 0 CA--C 1.45 -3.97 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 177.003 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 93' ' ' ARG . . . . . 0.491 ' O ' ' HA ' ' B' ' 3' ' ' MET . 24.4 ttp180 . . . . . 0 C--N 1.268 -2.953 0 CA-C-N 114.322 -0.939 . . . . 0.0 111.716 -178.256 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 22.3 ptt? . . . . . 0 N--CA 1.421 -1.884 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 4' ' ' GLU . . . . . 0.502 ' OE2' ' HD2' ' B' ' 93' ' ' ARG . 15.4 mt-10 -87.07 101.3 13.33 Favored 'General case' 0 C--N 1.294 -1.831 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.038 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -90.34 88.49 7.22 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 174.09 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -110.82 145.15 31.78 Favored Pre-proline 0 C--N 1.29 -1.985 0 CA-C-N 116.119 -0.491 . . . . 0.0 112.027 -177.804 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 7' ' ' PRO . . . . . 0.53 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 60.1 Cg_endo -81.89 134.65 8.45 Favored 'Trans proline' 0 N--CA 1.439 -1.707 0 C-N-CA 122.142 1.894 . . . . 0.0 113.526 178.09 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 65.4 t -121.97 130.76 74.31 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 176.447 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -115.22 132.95 56.45 Favored 'General case' 0 C--N 1.294 -1.84 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.165 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.424 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -121.15 161.21 22.21 Favored 'General case' 0 CA--C 1.493 -1.231 0 CA-C-O 121.403 0.62 . . . . 0.0 111.251 179.562 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -132.94 132.99 42.61 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 107.41 -1.329 . . . . 0.0 107.41 174.835 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 12' ' ' LYS . . . . . 0.502 ' HA ' ' CB ' ' B' ' 47' ' ' ALA . 36.0 mtmm -97.43 160.31 14.4 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 121.467 0.651 . . . . 0.0 112.468 -171.869 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 m-20 -113.27 -168.27 1.31 Allowed 'General case' 0 C--N 1.308 -1.2 0 CA-C-N 114.882 -1.054 . . . . 0.0 109.652 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.1 m -60.27 -35.93 76.67 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 113.618 0.969 . . . . 0.0 113.618 -174.624 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -79.6 -22.08 44.15 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-O 121.641 0.734 . . . . 0.0 109.364 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.06 -132.02 10.78 Favored Glycine 0 N--CA 1.423 -2.205 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.139 178.623 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.423 ' HG ' HG12 ' B' ' 19' ' ' ILE . 24.0 tp -82.83 169.71 15.81 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -178.804 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 18' ' ' GLY . . . . . 0.514 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -149.54 66.24 0.38 Allowed Glycine 0 CA--C 1.48 -2.122 0 C-N-CA 119.805 -1.188 . . . . 0.0 112.442 -177.647 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.468 HG22 ' HA ' ' B' ' 42' ' ' VAL . 8.4 pt -160.14 172.17 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.486 -1.482 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 179.488 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 20' ' ' SER . . . . . 0.424 ' HB2' HG22 ' B' ' 41' ' ' THR . 56.7 m -133.39 151.57 51.84 Favored 'General case' 0 C--N 1.257 -3.444 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 174.578 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.519 ' HB ' HG22 ' B' ' 37' ' ' ILE . 13.2 pt -121.59 148.2 25.15 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.681 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 -178.911 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.6 tp -119.02 132.49 68.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -179.374 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -96.56 97.97 2.11 Favored Glycine 0 N--CA 1.427 -1.951 0 C-N-CA 120.231 -0.985 . . . . 0.0 113.689 -174.408 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 82.3 mtp . . . . . 0 C--N 1.301 -1.537 0 N-CA-C 108.083 -1.081 . . . . 0.0 108.083 175.672 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 9.4 mp . . . . . 0 CA--C 1.488 -1.423 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -116.18 97.77 0.79 Allowed Glycine 0 N--CA 1.413 -2.858 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.917 -177.095 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.519 HG22 ' HB ' ' B' ' 21' ' ' ILE . 23.3 mm -92.98 87.69 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 174.771 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -85.17 164.44 18.11 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.614 -175.238 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 94.2 t -77.65 128.31 38.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 174.765 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -93.45 -37.45 11.95 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.123 0.487 . . . . 0.0 110.556 -176.003 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 41' ' ' THR . . . . . 0.424 HG22 ' HB2' ' B' ' 20' ' ' SER . 0.6 OUTLIER -158.4 163.46 37.22 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 -178.51 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.468 ' HA ' HG22 ' B' ' 19' ' ' ILE . 19.4 t -120.54 96.22 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.71 0 N-CA-C 106.468 -1.679 . . . . 0.0 106.468 176.441 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 17.1 m -59.99 124.31 19.8 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 124.186 0.995 . . . . 0.0 112.183 -175.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 44' ' ' GLU . . . . . 0.576 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 36.0 mt-10 -55.14 -33.83 63.25 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 124.767 1.227 . . . . 0.0 112.628 -176.709 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.67 -18.79 78.87 Favored Glycine 0 N--CA 1.438 -1.214 0 CA-C-N 115.674 -0.694 . . . . 0.0 114.521 -177.016 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.514 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -106.03 170.37 16.74 Favored Glycine 0 N--CA 1.423 -2.228 0 C-N-CA 118.497 -1.811 . . . . 0.0 114.719 -173.602 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 47' ' ' ALA . . . . . 0.502 ' CB ' ' HA ' ' B' ' 12' ' ' LYS . . . -59.53 -33.64 71.65 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 113.605 -1.298 . . . . 0.0 114.401 -174.14 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 48' ' ' ALA . . . . . 0.424 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -65.69 -33.0 74.86 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.243 -176.596 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 49' ' ' HIS . . . . . 0.576 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 12.2 t60 -77.31 -40.6 43.75 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.532 178.147 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 40.0 mtp-105 -66.97 -39.61 87.25 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.602 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 51' ' ' ASP . . . . . 0.528 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 12.0 t70 -78.0 -58.22 3.38 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.136 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.71 -4.87 36.9 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.628 -0.796 . . . . 0.0 113.662 179.146 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.528 ' HG2' ' OD1' ' B' ' 51' ' ' ASP . 0.4 OUTLIER -54.16 -62.13 1.86 Allowed 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 179.183 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.55 HD11 ' CE2' ' B' ' 89' ' ' PHE . 35.1 mt -81.31 126.46 39.8 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.227 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -103.29 168.51 9.12 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.162 177.929 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.1 p -73.53 4.46 0.84 Allowed 'Isoleucine or valine' 0 CA--C 1.57 1.725 0 CA-C-O 121.981 0.896 . . . . 0.0 111.533 -177.109 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -117.85 5.58 12.21 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.281 1.039 . . . . 0.0 109.529 -177.749 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -87.34 161.68 17.79 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.701 -177.536 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.626 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 25.5 tp -138.31 127.21 23.88 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 123.494 0.717 . . . . 0.0 109.742 -175.471 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 66.0 mt -88.01 97.48 10.98 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.619 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 0.8 OUTLIER -92.9 -21.42 6.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-O 122.219 1.009 . . . . 0.0 109.5 -177.277 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.561 ' HG2' ' O ' ' B' ' 63' ' ' VAL . 30.9 tt0 -164.64 150.99 10.65 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 113.133 -1.848 . . . . 0.0 108.701 175.013 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.561 ' O ' ' HG2' ' B' ' 62' ' ' GLU . 6.2 p -93.18 -162.6 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.202 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 176.367 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.587 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 11.7 t70 -56.59 -54.31 47.41 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 123.277 0.631 . . . . 0.0 111.687 -178.749 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -113.64 -54.18 0.44 Allowed Glycine 0 N--CA 1.439 -1.162 0 C-N-CA 120.478 -0.868 . . . . 0.0 113.213 -178.643 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 25.6 m -62.87 115.25 4.2 Favored 'General case' 0 C--O 1.246 0.909 0 CA-C-O 121.744 0.783 . . . . 0.0 112.731 -175.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 67' ' ' SER . . . . . 0.506 ' HA ' ' HG3' ' B' ' 62' ' ' GLU . 25.1 m -77.72 109.87 12.09 Favored 'General case' 0 N--CA 1.424 -1.75 0 C-N-CA 124.992 1.317 . . . . 0.0 113.397 -176.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.619 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 54.8 mt -90.88 -164.74 1.22 Allowed 'General case' 0 N--CA 1.421 -1.911 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 174.003 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 p 175.73 -30.86 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 106.236 -1.765 . . . . 0.0 106.236 178.368 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 169.02 77.06 0.04 OUTLIER Glycine 1 N--CA 1.39 -4.373 0 CA-C-N 114.48 -1.236 . . . . 0.0 111.227 -179.279 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 27.0 m -99.74 178.1 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.277 -2.581 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 34.6 p -76.84 161.74 28.19 Favored 'General case' 0 C--N 1.291 -1.95 0 C-N-CA 120.415 -0.514 . . . . 0.0 109.892 175.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -57.99 -40.77 81.55 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 123.829 0.851 . . . . 0.0 109.614 178.675 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 22.3 m -68.46 -38.57 81.22 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.077 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -62.93 -47.92 81.13 Favored 'General case' 0 C--O 1.24 0.566 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 178.747 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.572 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -58.75 -45.37 89.86 Favored 'General case' 0 C--O 1.208 -1.105 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.845 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.91 -36.82 77.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.982 0.42 . . . . 0.0 111.749 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 15.4 p -77.88 -14.83 59.43 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 112.967 0.729 . . . . 0.0 112.967 -179.5 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.572 HG12 ' O ' ' B' ' 76' ' ' ALA . 2.8 p -73.31 -37.3 51.36 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.952 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.071 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -59.64 -18.81 44.76 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.97 0.908 . . . . 0.0 112.433 176.541 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 6.6 mtp180 -100.21 -6.66 25.73 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 121.213 0.53 . . . . 0.0 111.918 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -114.95 10.69 16.37 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.41 0.624 . . . . 0.0 111.245 179.153 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.724 ' HB ' HG11 ' B' ' 87' ' ' VAL . 7.9 p -92.46 -173.42 3.38 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 115.491 -0.777 . . . . 0.0 112.298 178.513 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 44.9 mttm -76.67 -169.0 1.12 Allowed 'General case' 0 N--CA 1.437 -1.111 0 C-N-CA 123.506 0.722 . . . . 0.0 111.113 175.163 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -73.37 -49.69 14.52 Favored Glycine 0 N--CA 1.437 -1.274 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.056 176.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 16.2 ttm180 -118.38 121.44 40.37 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 176.846 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.724 HG11 ' HB ' ' B' ' 83' ' ' THR . 8.8 m -130.13 151.98 36.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 71.7 mtm180 -94.96 169.66 9.97 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 113.788 -1.551 . . . . 0.0 108.006 173.499 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.55 ' CE2' HD11 ' B' ' 54' ' ' ILE . 4.7 m-85 -144.14 151.1 39.1 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 176.053 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 90' ' ' MET . . . . . . . . . . . . . 48.0 mtm -100.43 115.12 29.3 Favored 'General case' 0 N--CA 1.425 -1.698 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 173.443 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.626 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.5 mp -96.93 127.84 48.72 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.002 -179.142 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -108.36 120.87 6.1 Favored Glycine 0 N--CA 1.427 -1.962 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 177.312 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 93' ' ' ARG . . . . . 0.502 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 35.5 ttm180 . . . . . 0 C--N 1.281 -2.377 0 CA-C-N 115.207 -0.497 . . . . 0.0 109.731 178.218 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 66.8 mtt . . . . . 0 N--CA 1.431 -1.377 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 14.0 mt-10 -90.81 97.77 11.38 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 120.43 -0.508 . . . . 0.0 109.931 -173.044 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -86.87 93.56 9.34 Favored 'General case' 0 N--CA 1.439 -0.977 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 177.339 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -114.59 143.56 30.18 Favored Pre-proline 0 C--N 1.283 -2.286 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.851 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -74.21 132.89 17.11 Favored 'Trans proline' 0 N--CA 1.45 -1.054 0 C-N-CA 122.331 2.02 . . . . 0.0 113.493 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.517 ' HB ' HD13 ' B' ' 91' ' ' ILE . 77.6 t -124.66 123.82 66.79 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 CA-C-N 114.783 -1.099 . . . . 0.0 108.316 178.951 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -111.3 123.62 50.58 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -176.192 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.468 HD11 ' HB2' ' B' ' 48' ' ' ALA . 1.6 mt -117.46 177.01 4.9 Favored 'General case' 0 CA--C 1.489 -1.389 0 CA-C-O 121.233 0.539 . . . . 0.0 111.218 177.22 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -155.18 166.55 33.21 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 12' ' ' LYS . . . . . 0.435 ' HG2' ' CD1' ' B' ' 17' ' ' LEU . 10.1 mtmp? -116.11 160.72 19.96 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 118.407 0.549 . . . . 0.0 112.264 -176.157 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -97.79 -160.22 0.79 Allowed 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 169.898 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 17.6 m -69.6 -27.06 64.76 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 120.993 0.425 . . . . 0.0 110.221 177.808 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -75.9 -64.42 1.09 Allowed 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.96 75.63 0.68 Allowed Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.209 -0.996 . . . . 0.0 112.628 179.683 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.435 ' CD1' ' HG2' ' B' ' 12' ' ' LYS . 10.7 mp 71.92 172.82 0.31 Allowed 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 124.309 1.044 . . . . 0.0 112.916 179.289 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 18' ' ' GLY . . . . . 0.486 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -172.59 88.88 0.08 OUTLIER Glycine 0 CA--C 1.488 -1.612 0 N-CA-C 107.806 -2.118 . . . . 0.0 107.806 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.549 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.8 pt -157.62 -173.65 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 -176.421 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 20' ' ' SER . . . . . 0.493 ' HB2' HG22 ' B' ' 41' ' ' THR . 40.5 m -152.72 144.61 23.67 Favored 'General case' 0 C--N 1.257 -3.452 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 173.656 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.511 ' HB ' HG22 ' B' ' 37' ' ' ILE . 16.3 pt -116.74 162.93 14.34 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.584 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 179.282 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.1 tp -140.81 136.77 35.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 CA-C-O 120.98 0.419 . . . . 0.0 110.665 -178.806 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 23' ' ' GLY . . . . . 0.464 ' HA2' ' CD1' ' B' ' 37' ' ' ILE . . . -67.13 101.92 0.73 Allowed Glycine 0 N--CA 1.435 -1.372 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.1 178.862 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 91.7 mtp . . . . . 0 N--CA 1.431 -1.411 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 -178.95 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 91.1 mt . . . . . 0 N--CA 1.417 -2.083 0 N-CA-C 104.174 -2.528 . . . . 0.0 104.174 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 36' ' ' GLY . . . . . 0.462 ' HA3' HD11 ' B' ' 59' ' ' LEU . . . -99.67 -13.78 36.72 Favored Glycine 0 C--N 1.291 -1.968 0 C-N-CA 118.881 -1.628 . . . . 0.0 111.048 -175.223 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.511 HG22 ' HB ' ' B' ' 21' ' ' ILE . 31.2 mm 64.64 98.02 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.557 1.241 0 C-N-CA 124.396 1.078 . . . . 0.0 111.08 -179.145 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 62.4 m-85 -76.36 164.91 25.56 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.823 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 47.8 t -76.61 142.54 14.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 177.9 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 31.9 ttmt -98.36 -46.34 5.82 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.331 -179.614 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 41' ' ' THR . . . . . 0.536 ' HA ' HG23 ' B' ' 56' ' ' VAL . 1.1 t -161.15 166.79 27.36 Favored 'General case' 0 N--CA 1.428 -1.55 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -178.355 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.549 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.8 p -137.71 97.26 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.282 -2.342 0 CA-C-O 122.102 0.953 . . . . 0.0 109.381 177.694 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 12.8 m -54.61 129.67 37.31 Favored 'General case' 0 N--CA 1.435 -1.2 0 CA-C-N 113.453 -1.703 . . . . 0.0 111.1 -176.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 44' ' ' GLU . . . . . 0.461 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 38.7 mt-10 -60.55 -27.17 67.45 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 123.537 0.735 . . . . 0.0 111.407 -177.13 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.63 -7.85 88.13 Favored Glycine 0 N--CA 1.434 -1.434 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.843 178.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.486 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -93.02 161.08 25.37 Favored Glycine 0 CA--C 1.485 -1.788 0 C-N-CA 120.326 -0.94 . . . . 0.0 114.243 -175.516 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -62.57 -34.6 77.3 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 113.614 -1.293 . . . . 0.0 111.642 -178.103 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 48' ' ' ALA . . . . . 0.468 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -66.15 -31.89 73.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.762 -0.199 . . . . 0.0 111.36 -177.881 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 49' ' ' HIS . . . . . 0.461 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 4.6 t60 -80.46 -42.6 22.32 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.568 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 50' ' ' ARG . . . . . 0.414 ' HG3' ' O ' ' B' ' 46' ' ' GLY . 82.5 mtp180 -64.59 -42.63 95.48 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.836 -179.632 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -76.52 -43.42 39.46 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 88.24 52.48 2.88 Favored Glycine 0 CA--C 1.503 -0.657 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.787 178.702 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.463 ' HB3' ' CG1' ' B' ' 8' ' ' VAL . 30.8 mmt180 -118.76 -74.29 0.61 Allowed 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -175.4 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.406 HD11 ' CE2' ' B' ' 89' ' ' PHE . 60.9 mt -72.24 107.81 3.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 176.586 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -97.25 153.52 17.97 Favored 'General case' 0 N--CA 1.425 -1.709 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.703 -175.707 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.536 HG23 ' HA ' ' B' ' 41' ' ' THR . 10.0 p -55.05 -24.07 14.0 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.56 0 N-CA-C 115.747 1.758 . . . . 0.0 115.747 -171.236 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -114.43 9.31 16.77 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 120.966 -1.084 . . . . 0.0 111.54 -172.304 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 58' ' ' ASP . . . . . 0.41 ' HB3' ' CG2' ' B' ' 91' ' ' ILE . 5.9 m-20 -99.49 -177.74 3.68 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 119.804 -0.759 . . . . 0.0 112.559 -176.85 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.482 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 29.3 tp -133.67 139.26 46.34 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 112.445 0.535 . . . . 0.0 112.445 -170.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 60' ' ' LEU . . . . . 0.407 ' O ' HD12 ' B' ' 68' ' ' LEU . 67.1 mt -89.27 101.76 14.43 Favored 'General case' 0 C--O 1.208 -1.104 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 176.781 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.552 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 24.8 t -83.46 -42.91 17.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-O 121.84 0.828 . . . . 0.0 111.509 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.494 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 11.8 pt-20 -154.98 150.12 27.01 Favored 'General case' 0 C--N 1.272 -2.8 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.559 176.653 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.438 HG22 ' H ' ' B' ' 64' ' ' ASP . 5.0 p -96.1 -178.51 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.07 0 N-CA-C 105.909 -1.885 . . . . 0.0 105.909 178.623 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.47 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.8 t70 -49.47 -54.89 15.34 Favored 'General case' 0 C--N 1.315 -0.919 0 C-N-CA 124.16 0.984 . . . . 0.0 113.344 -176.381 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -121.12 24.2 7.46 Favored Glycine 0 C--N 1.32 -0.354 0 C-N-CA 119.372 -1.394 . . . . 0.0 114.254 -177.754 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 66' ' ' THR . . . . . 0.431 ' HB ' HG12 ' B' ' 63' ' ' VAL . 25.8 m -152.61 126.54 9.02 Favored 'General case' 0 C--N 1.316 -0.889 0 O-C-N 121.732 -0.864 . . . . 0.0 109.693 179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 67' ' ' SER . . . . . 0.42 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 23.4 m -91.82 132.19 36.62 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 120.889 0.376 . . . . 0.0 110.757 -179.531 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.552 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 26.9 mt -81.69 95.66 7.29 Favored 'General case' 0 N--CA 1.431 -1.4 0 CA-C-O 121.374 0.607 . . . . 0.0 110.509 177.326 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 10.3 p -92.56 16.73 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 CA-C-O 122.317 1.056 . . . . 0.0 108.943 178.581 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 117.54 87.46 1.24 Allowed Glycine 0 CA--C 1.474 -2.493 0 C-N-CA 120.328 -0.939 . . . . 0.0 111.543 178.599 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 15.5 m -120.44 174.2 5.57 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -178.878 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 62.9 p -85.51 164.62 17.71 Favored 'General case' 0 N--CA 1.42 -1.928 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 176.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -60.97 -38.28 85.4 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 177.12 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.1 m -64.15 -41.28 97.23 Favored 'General case' 0 N--CA 1.433 -1.324 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.951 178.546 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -65.62 -46.72 78.18 Favored 'General case' 0 CA--C 1.521 -0.138 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.529 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.515 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -56.82 -43.43 81.03 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-O 120.999 0.428 . . . . 0.0 110.773 179.121 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.18 -24.54 66.65 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.605 0.716 . . . . 0.0 111.056 178.173 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 32.6 m -85.79 -26.43 25.78 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.821 -178.678 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.515 HG12 ' O ' ' B' ' 76' ' ' ALA . 9.0 p -73.69 -32.54 35.54 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.679 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 80' ' ' LEU . . . . . 0.428 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 64.5 mt -65.78 -23.12 66.64 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.485 177.04 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 59.7 mtm180 -99.53 -0.4 40.65 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.834 179.457 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -100.78 -29.38 12.29 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.203 177.497 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.727 ' HB ' HG11 ' B' ' 87' ' ' VAL . 7.8 p -74.38 164.03 27.08 Favored 'General case' 0 N--CA 1.425 -1.699 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.87 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 68.5 mmtt -68.83 -166.78 0.08 Allowed 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.102 1.361 . . . . 0.0 112.771 -179.092 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.93 -39.18 93.27 Favored Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.562 -0.744 . . . . 0.0 113.186 -179.161 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 86' ' ' ARG . . . . . 0.426 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 41.7 ttm180 -128.19 124.56 37.06 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 -179.614 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.727 HG11 ' HB ' ' B' ' 83' ' ' THR . 13.6 m -135.2 147.68 29.06 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 CA-C-O 121.138 0.494 . . . . 0.0 111.448 178.075 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 36.2 mtp85 -108.87 120.37 42.31 Favored 'General case' 0 N--CA 1.428 -1.536 0 CA-C-N 114.925 -1.034 . . . . 0.0 109.086 -179.08 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.443 ' HB2' ' CD1' ' B' ' 91' ' ' ILE . 2.9 m-85 -103.82 159.36 15.7 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 -177.124 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.494 ' HB2' ' CG ' ' B' ' 62' ' ' GLU . 0.5 OUTLIER -104.34 109.35 21.16 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 168.939 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.517 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.3 mp -89.79 129.92 39.92 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.158 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 178.757 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 92' ' ' GLY . . . . . 0.466 ' O ' ' HB3' ' B' ' 59' ' ' LEU . . . -112.38 104.31 1.59 Allowed Glycine 0 CA--C 1.458 -3.483 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 178.512 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 . . . . . 0 C--N 1.27 -2.849 0 CA-C-N 114.913 -0.644 . . . . 0.0 109.664 178.566 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 67.8 mtm . . . . . 0 N--CA 1.432 -1.347 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -85.26 108.34 17.72 Favored 'General case' 0 N--CA 1.426 -1.652 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 179.136 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.522 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 1.1 mm? -85.35 89.46 7.68 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 174.219 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -111.7 142.6 26.93 Favored Pre-proline 0 C--N 1.288 -2.094 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.295 -179.37 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -75.8 132.88 14.83 Favored 'Trans proline' 0 N--CA 1.44 -1.632 0 C-N-CA 122.223 1.949 . . . . 0.0 111.878 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.498 HG13 ' HB3' ' B' ' 53' ' ' ARG . 76.4 t -120.83 120.77 63.39 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.389 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.178 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 9' ' ' GLU . . . . . 0.414 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 38.4 tt0 -115.29 120.18 38.8 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.704 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.554 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -108.34 -173.58 2.31 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 178.832 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -158.83 155.85 28.59 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 105.046 -2.205 . . . . 0.0 105.046 176.528 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 10.6 ptpp? -84.96 163.38 18.95 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-O 121.743 0.782 . . . . 0.0 112.991 -173.346 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 13' ' ' ASP . . . . . 0.515 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 14.0 t70 -111.34 -176.35 2.93 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 104.697 -2.334 . . . . 0.0 104.697 170.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 34.3 m -63.8 -30.33 71.44 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 119.278 0.944 . . . . 0.0 111.575 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -88.91 -13.0 40.12 Favored 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 121.711 0.767 . . . . 0.0 109.64 178.12 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.01 -108.11 2.43 Favored Glycine 0 N--CA 1.433 -1.505 0 C-N-CA 120.862 -0.685 . . . . 0.0 111.78 179.55 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -95.63 172.63 7.93 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 120.954 0.407 . . . . 0.0 110.105 -178.285 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -137.12 53.86 0.73 Allowed Glycine 0 CA--C 1.486 -1.744 0 N-CA-C 109.944 -1.263 . . . . 0.0 109.944 -179.519 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.518 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 6.9 pt -157.95 -178.64 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.489 -1.369 0 C-N-CA 124.84 1.256 . . . . 0.0 108.282 -174.204 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 20' ' ' SER . . . . . 0.433 ' HB2' ' HB3' ' B' ' 40' ' ' LYS . 46.8 m -152.58 156.21 38.87 Favored 'General case' 0 C--N 1.27 -2.853 0 N-CA-C 105.106 -2.183 . . . . 0.0 105.106 174.361 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 21' ' ' ILE . . . . . 0.419 ' HB ' HG22 ' B' ' 37' ' ' ILE . 29.5 pt -117.3 158.96 17.71 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 CA-C-N 118.181 0.446 . . . . 0.0 110.287 -177.045 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -148.48 136.26 14.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 CA-C-O 121.422 0.629 . . . . 0.0 110.181 178.694 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -75.19 122.15 6.78 Favored Glycine 0 N--CA 1.423 -2.232 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.044 178.751 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 24' ' ' MET . . . . . 0.67 ' HB2' ' CD1' ' B' ' 38' ' ' PHE . 64.6 mtt . . . . . 0 CA--C 1.491 -1.298 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 174.908 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 10.8 mp . . . . . 0 N--CA 1.429 -1.486 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -170.99 1.63 0.03 OUTLIER Glycine 0 C--N 1.292 -1.892 0 C-N-CA 119.817 -1.183 . . . . 0.0 111.067 174.409 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 37' ' ' ILE . . . . . 0.419 HG22 ' HB ' ' B' ' 21' ' ' ILE . 40.9 mm 65.39 114.64 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 CA-C-O 122.495 1.141 . . . . 0.0 110.543 -173.649 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.67 ' CD1' ' HB2' ' B' ' 24' ' ' MET . 29.0 m-85 -88.55 176.19 7.25 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.103 -0.953 . . . . 0.0 108.881 -175.205 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 64.6 t -83.93 142.9 12.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-O 121.654 0.74 . . . . 0.0 110.759 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 40' ' ' LYS . . . . . 0.433 ' HB3' ' HB2' ' B' ' 20' ' ' SER . 16.3 ttmm -94.34 -47.03 6.78 Favored 'General case' 0 N--CA 1.434 -1.261 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.769 -179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 3.1 t -162.32 171.76 16.73 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 -178.64 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.518 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.2 p -147.9 91.51 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.861 0 CA-C-O 122.35 1.071 . . . . 0.0 109.193 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 8.2 m -59.3 128.94 39.61 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 113.557 -1.656 . . . . 0.0 111.528 -176.518 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 44' ' ' GLU . . . . . 0.576 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 8.1 pt-20 -68.01 -17.2 64.35 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 112.558 0.577 . . . . 0.0 112.558 -177.901 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.26 -0.04 85.27 Favored Glycine 0 N--CA 1.436 -1.351 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.486 177.532 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -111.14 169.59 13.36 Favored Glycine 0 N--CA 1.418 -2.503 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.923 -177.492 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 47' ' ' ALA . . . . . 0.515 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -55.08 -54.67 40.11 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 113.911 -1.144 . . . . 0.0 113.651 -174.198 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 48' ' ' ALA . . . . . 0.554 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -56.24 -35.37 67.29 Favored 'General case' 0 C--O 1.243 0.75 0 N-CA-C 114.051 1.13 . . . . 0.0 114.051 -172.246 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 49' ' ' HIS . . . . . 0.576 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 6.6 t60 -75.39 -46.8 30.71 Favored 'General case' 0 C--N 1.312 -1.037 0 O-C-N 123.656 0.597 . . . . 0.0 109.953 -177.003 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 65.7 mtp180 -73.49 -34.98 65.57 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.422 -175.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -66.01 -51.36 59.06 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.419 178.549 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 95.13 52.77 1.7 Allowed Glycine 0 N--CA 1.432 -1.571 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 53' ' ' ARG . . . . . 0.498 ' HB3' HG13 ' B' ' 8' ' ' VAL . 21.6 mmt180 -129.78 -72.78 0.57 Allowed 'General case' 0 N--CA 1.432 -1.328 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -178.629 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.596 HD11 ' CE2' ' B' ' 89' ' ' PHE . 45.4 mt -80.06 129.15 38.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 C-N-CA 119.288 -0.965 . . . . 0.0 108.925 178.278 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 55' ' ' GLN . . . . . 0.741 ' HB2' ' OD1' ' B' ' 58' ' ' ASP . 6.9 mt-30 -116.78 164.15 15.09 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 -176.624 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.8 p -59.14 -33.95 52.01 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.276 0 N-CA-C 115.949 1.833 . . . . 0.0 115.949 -171.511 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -105.52 5.46 31.47 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.112 -0.993 . . . . 0.0 112.421 -172.721 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 58' ' ' ASP . . . . . 0.741 ' OD1' ' HB2' ' B' ' 55' ' ' GLN . 5.2 m-20 -82.01 171.09 14.8 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-O 121.318 0.58 . . . . 0.0 111.984 -175.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 59' ' ' LEU . . . . . 0.473 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 23.1 tp -131.54 133.11 44.72 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.312 -174.318 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 66.0 mt -87.25 96.36 10.31 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 178.095 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 61' ' ' VAL . . . . . 0.621 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 16.1 t -73.94 -38.46 49.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 CA-C-O 121.589 0.709 . . . . 0.0 110.928 179.092 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.565 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 10.0 pt-20 -159.95 156.67 27.56 Favored 'General case' 0 C--N 1.282 -2.357 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.653 174.662 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 63' ' ' VAL . . . . . 0.468 HG22 ' H ' ' B' ' 64' ' ' ASP . 6.2 p -100.53 177.35 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 177.479 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 64' ' ' ASP . . . . . 0.468 ' H ' HG22 ' B' ' 63' ' ' VAL . 27.3 t70 -46.65 -56.67 5.74 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 114.156 1.169 . . . . 0.0 114.156 -173.808 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -117.98 27.44 7.44 Favored Glycine 0 C--N 1.31 -0.877 0 C-N-CA 119.392 -1.385 . . . . 0.0 114.072 -177.504 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 66' ' ' THR . . . . . 0.43 ' HB ' HG12 ' B' ' 63' ' ' VAL . 29.6 m -154.11 123.86 6.71 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 117.754 0.777 . . . . 0.0 109.788 179.193 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 67' ' ' SER . . . . . 0.565 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 11.1 t -96.46 129.19 43.87 Favored 'General case' 0 N--CA 1.426 -1.671 0 CA-C-O 121.078 0.466 . . . . 0.0 110.607 -177.25 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.621 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 62.7 mt -92.03 124.2 35.95 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.081 179.212 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 14.4 p -93.05 -25.39 4.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 174.164 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 149.26 75.13 0.02 OUTLIER Glycine 0 N--CA 1.423 -2.176 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 -176.648 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 31.3 m -93.15 178.45 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 CA-C-N 114.912 -0.644 . . . . 0.0 110.691 -175.368 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 36.6 p -80.88 160.98 24.6 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 175.482 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -62.59 -35.42 79.47 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 120.944 0.402 . . . . 0.0 110.307 -178.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 19.2 m -66.41 -40.18 89.42 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.279 178.122 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -64.31 -46.35 83.95 Favored 'General case' 0 C--N 1.338 0.101 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 76' ' ' ALA . . . . . 0.413 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -57.89 -46.91 84.2 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.382 178.293 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.49 -42.01 86.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.005 0.431 . . . . 0.0 110.687 178.345 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 22.8 t -68.73 -32.68 72.64 Favored 'General case' 0 N--CA 1.431 -1.377 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.736 -178.565 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 79' ' ' VAL . . . . . 0.413 HG12 ' O ' ' B' ' 76' ' ' ALA . 9.8 p -78.09 -39.13 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 119.582 -0.847 . . . . 0.0 109.921 -174.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 45.6 mt -63.93 -34.02 77.02 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.822 177.647 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -87.66 -5.02 58.9 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.344 179.446 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -89.07 -37.04 15.41 Favored 'General case' 0 N--CA 1.431 -1.387 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 175.609 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 83' ' ' THR . . . . . 0.68 ' HB ' HG11 ' B' ' 87' ' ' VAL . 12.8 p -77.11 172.24 13.54 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.463 177.058 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt -69.11 -173.74 0.55 Allowed 'General case' 0 N--CA 1.444 -0.748 0 CA-C-O 121.738 0.78 . . . . 0.0 111.725 177.607 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -81.4 -28.66 43.16 Favored Glycine 0 N--CA 1.431 -1.661 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 175.634 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 86' ' ' ARG . . . . . 0.459 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 21.9 ttm-85 -106.76 111.3 23.76 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 121.406 0.622 . . . . 0.0 110.162 175.804 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 87' ' ' VAL . . . . . 0.68 HG11 ' HB ' ' B' ' 83' ' ' THR . 2.6 m -147.63 151.68 13.44 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-N 114.58 -1.191 . . . . 0.0 109.679 178.348 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 88' ' ' ARG . . . . . 0.431 ' HA ' ' O ' ' B' ' 8' ' ' VAL . 10.3 mtm-85 -101.28 110.31 22.3 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 123.992 0.808 . . . . 0.0 109.726 -179.718 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 89' ' ' PHE . . . . . 0.596 ' CE2' HD11 ' B' ' 54' ' ' ILE . 3.0 m-85 -95.23 158.97 15.23 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 179.426 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 90' ' ' MET . . . . . 0.479 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 86.3 mtp -107.8 114.04 27.71 Favored 'General case' 0 C--N 1.29 -1.993 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 170.273 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.522 ' O ' ' HA ' ' B' ' 5' ' ' LEU . 1.4 mp -95.45 136.78 25.39 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 -179.006 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.93 100.9 0.73 Allowed Glycine 0 CA--C 1.474 -2.506 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 175.283 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 16.4 tpp180 . . . . . 0 C--N 1.275 -2.652 0 CA-C-N 113.824 -1.188 . . . . 0.0 108.726 -178.73 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.298 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 45.2 p-80 -167.56 166.28 14.2 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 117.876 0.838 . . . . 0.0 109.095 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 56.9 mtt -95.09 128.57 42.02 Favored 'General case' 0 N--CA 1.433 -1.292 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 171.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 4' ' ' GLU . . . . . 0.548 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 27.0 mt-10 -79.95 98.82 7.32 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.423 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 1.0 OUTLIER -82.67 89.84 6.78 Favored 'General case' 0 C--N 1.311 -1.105 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 174.602 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 13.5 p90 -110.59 142.11 25.42 Favored Pre-proline 0 C--N 1.286 -2.158 0 CA-C-N 116.038 -0.528 . . . . 0.0 112.128 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -68.78 129.46 18.7 Favored 'Trans proline' 0 N--CA 1.451 -1.024 0 C-N-CA 122.67 2.247 . . . . 0.0 112.482 178.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.703 HG13 ' HG3' ' B' ' 53' ' ' ARG . 79.1 t -120.88 122.91 69.01 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.515 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.725 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 9' ' ' GLU . . . . . 0.468 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 31.3 tt0 -123.11 113.84 19.53 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 mt -104.26 160.4 14.91 Favored 'General case' 0 C--N 1.283 -2.309 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.342 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.464 ' HB3' ' NH2' ' B' ' 86' ' ' ARG . 8.5 pt-20 -123.55 113.68 19.04 Favored 'General case' 0 C--N 1.271 -2.821 0 CA-C-N 114.271 -1.331 . . . . 0.0 108.421 173.019 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.4 ptpt -79.82 156.93 27.16 Favored 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.421 -0.808 . . . . 0.0 110.496 -175.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -89.18 -173.13 3.92 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.163 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 35.8 t -68.99 -21.15 64.17 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 173.424 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -69.7 -46.82 65.14 Favored 'General case' 0 N--CA 1.44 -0.929 0 CA-C-N 114.318 -1.31 . . . . 0.0 108.48 173.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.3 -132.73 8.66 Favored Glycine 0 N--CA 1.419 -2.496 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -176.346 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 90.7 mt -95.65 179.0 5.28 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' GLY . . . . . 0.531 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -151.3 66.59 0.35 Allowed Glycine 0 CA--C 1.481 -2.07 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.524 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 3.5 pt -151.71 -177.6 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.104 0 C-N-CA 124.608 1.163 . . . . 0.0 108.246 -177.226 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 20' ' ' SER . . . . . 0.457 ' HB2' HG22 ' B' ' 41' ' ' THR . 49.3 m -153.73 162.7 41.01 Favored 'General case' 0 C--N 1.261 -3.243 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.236 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.419 ' HB ' HG22 ' B' ' 37' ' ' ILE . 19.0 pt -127.92 164.4 29.43 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 -178.403 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -144.0 138.57 24.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 178.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 23' ' ' GLY . . . . . 0.419 ' HA2' ' CD1' ' B' ' 37' ' ' ILE . . . -83.61 96.03 1.92 Allowed Glycine 0 N--CA 1.426 -2.028 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.936 178.209 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 24.8 mmt -113.05 175.83 5.27 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 177.341 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 105.93 164.92 23.19 Favored Glycine 0 N--CA 1.428 -1.881 0 C-N-CA 120.156 -1.021 . . . . 0.0 110.645 -179.072 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.59 138.25 23.31 Favored 'General case' 0 C--N 1.284 -2.262 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 177.565 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.438 ' O ' ' HA ' ' B' ' 33' ' ' GLU . . . 125.65 62.36 0.17 Allowed Glycine 0 N--CA 1.421 -2.339 0 C-N-CA 120.197 -1.001 . . . . 0.0 112.35 178.373 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.15 82.91 6.12 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 175.289 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.44 ' HB3' ' HB3' ' B' ' 32' ' ' LEU . 18.5 t70 -79.17 -7.04 57.9 Favored 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 113.522 -1.672 . . . . 0.0 113.383 -170.5 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 63.5 mtt 61.89 77.85 0.31 Allowed 'General case' 0 CA--C 1.496 -1.113 0 CA-C-O 121.85 0.833 . . . . 0.0 111.38 -176.354 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.66 45.89 1.47 Allowed Glycine 0 C--N 1.294 -1.772 0 CA-C-N 114.931 -1.032 . . . . 0.0 112.346 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 32' ' ' LEU . . . . . 0.44 ' HB3' ' HB3' ' B' ' 29' ' ' ASP . 3.3 tm? 178.44 -64.24 0.01 OUTLIER 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 104.802 -2.296 . . . . 0.0 104.802 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 33' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' B' ' 27' ' ' GLY . 16.5 mt-10 45.86 86.86 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 125.352 1.461 . . . . 0.0 114.876 172.403 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 8.6 ptmm? -80.92 76.83 7.84 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.436 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 96.6 mt -115.39 162.2 17.47 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 114.399 -1.273 . . . . 0.0 108.787 179.272 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -136.9 109.58 0.73 Allowed Glycine 0 N--CA 1.411 -3.02 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.627 -178.522 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.419 ' CD1' ' HA2' ' B' ' 23' ' ' GLY . 33.8 mm -89.62 84.55 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.89 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 175.352 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.487 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 90.4 m-85 -82.91 164.97 20.13 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.192 -1.367 . . . . 0.0 109.235 -176.819 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 52.1 t -73.21 126.47 33.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 176.499 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -86.87 -36.7 18.28 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.052 -176.458 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 41' ' ' THR . . . . . 0.457 HG22 ' HB2' ' B' ' 20' ' ' SER . 1.3 t -160.88 165.87 29.41 Favored 'General case' 0 N--CA 1.423 -1.791 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.208 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.524 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.3 p -139.1 94.22 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-O 122.562 1.173 . . . . 0.0 109.077 177.109 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.417 HG22 ' H ' ' B' ' 45' ' ' GLY . 45.6 m -65.74 126.79 29.54 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-N 113.064 -1.88 . . . . 0.0 113.038 -173.238 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 44' ' ' GLU . . . . . 0.453 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 9.2 pt-20 -53.13 -31.4 42.15 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 125.218 1.407 . . . . 0.0 113.254 -179.089 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 45' ' ' GLY . . . . . 0.417 ' H ' HG22 ' B' ' 43' ' ' THR . . . -64.65 -29.69 75.9 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 121.427 -0.416 . . . . 0.0 112.908 -179.503 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.531 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -95.98 165.79 24.43 Favored Glycine 0 N--CA 1.422 -2.298 0 C-N-CA 119.884 -1.15 . . . . 0.0 113.527 -176.031 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -58.45 -33.66 69.98 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 113.358 -1.421 . . . . 0.0 113.48 -175.687 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -59.51 -38.87 82.08 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -175.565 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 49' ' ' HIS . . . . . 0.453 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 7.9 t60 -75.06 -38.49 61.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.11 0.481 . . . . 0.0 110.145 -178.784 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 22.5 mtm-85 -77.89 -29.55 50.28 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.682 -175.189 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 51' ' ' ASP . . . . . 0.547 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 23.9 t70 -80.0 -53.78 6.41 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 176.78 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.39 39.66 4.16 Favored Glycine 0 CA--C 1.497 -1.077 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 179.004 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.703 ' HG3' HG13 ' B' ' 8' ' ' VAL . 0.5 OUTLIER -103.07 -69.41 0.79 Allowed 'General case' 0 N--CA 1.425 -1.717 0 CA-C-N 114.618 -0.791 . . . . 0.0 109.532 -174.26 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.609 HD11 ' CE2' ' B' ' 89' ' ' PHE . 52.1 mt -85.61 108.34 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 174.676 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 32.5 mt-30 -101.9 167.7 9.89 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -176.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 9.5 p -70.73 -4.54 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.568 1.641 0 CA-C-O 121.79 0.805 . . . . 0.0 112.3 -173.527 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 61.9 t30 -114.16 7.05 16.51 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.889 0.852 . . . . 0.0 109.232 -175.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -95.21 165.01 12.61 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.809 -176.546 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.515 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 23.8 tp -136.5 133.98 37.1 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.668 -176.773 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 69.3 mt -80.48 96.51 6.78 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 176.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.505 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 38.8 t -78.4 -45.67 25.99 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-O 121.66 0.743 . . . . 0.0 109.917 178.696 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -154.11 151.69 29.57 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 114.968 -1.015 . . . . 0.0 109.931 174.167 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.53 HG12 ' HB ' ' B' ' 66' ' ' THR . 4.3 p -95.28 -173.49 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 178.224 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.513 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 13.0 t70 -47.26 -49.62 23.09 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -139.6 43.06 1.18 Allowed Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 119.29 -1.433 . . . . 0.0 113.964 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 66' ' ' THR . . . . . 0.53 ' HB ' HG12 ' B' ' 63' ' ' VAL . 31.8 m -160.64 115.66 2.21 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 178.301 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 43.4 m -76.75 133.76 39.36 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-O 121.133 0.492 . . . . 0.0 110.891 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.515 HD12 ' CG2' ' B' ' 71' ' ' VAL . 4.1 mm? -87.42 -68.06 0.78 Allowed 'General case' 0 N--CA 1.434 -1.228 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.995 177.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 59.9 t 70.05 -40.46 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 124.456 1.102 . . . . 0.0 111.52 -177.132 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 157.44 85.22 0.05 OUTLIER Glycine 0 N--CA 1.417 -2.628 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.31 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.515 ' CG2' HD12 ' B' ' 68' ' ' LEU . 35.5 m -105.58 -172.73 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 123.543 0.737 . . . . 0.0 109.49 -178.311 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 72' ' ' THR . . . . . 0.437 ' O ' HG23 ' B' ' 71' ' ' VAL . 19.8 p -81.64 157.03 24.81 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 172.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -61.49 -35.59 78.11 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.194 0.521 . . . . 0.0 110.735 -176.707 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 25.4 m -62.65 -38.02 88.66 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.915 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -63.83 -49.13 74.04 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.527 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.64 -42.95 99.62 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.793 -178.765 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.04 -32.51 73.02 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.278 0.561 . . . . 0.0 110.696 178.388 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 8.1 t -82.38 -28.45 31.47 Favored 'General case' 0 N--CA 1.428 -1.56 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.059 -177.011 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.527 HG12 ' O ' ' B' ' 76' ' ' ALA . 7.2 p -71.44 -33.01 48.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 O-C-N 121.412 -0.805 . . . . 0.0 109.714 -174.673 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 29.1 mt -69.81 -16.88 63.35 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.573 -1.194 . . . . 0.0 111.02 176.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -96.14 -24.22 16.39 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.049 0.452 . . . . 0.0 110.787 178.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 29.2 m-80 -82.68 -21.5 34.89 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 121.373 0.606 . . . . 0.0 111.351 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.524 ' HB ' HG11 ' B' ' 87' ' ' VAL . 7.4 p -85.32 167.75 15.31 Favored 'General case' 0 N--CA 1.425 -1.683 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.928 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 37.4 mmtm -67.89 -173.76 0.39 Allowed 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 123.425 0.69 . . . . 0.0 112.422 179.005 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -75.16 -30.61 58.67 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.17 -0.923 . . . . 0.0 112.064 -178.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 86' ' ' ARG . . . . . 0.464 ' NH2' ' HB3' ' B' ' 11' ' ' GLU . 21.4 ttm-85 -130.62 116.09 17.62 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.062 0.458 . . . . 0.0 110.003 175.067 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.524 HG11 ' HB ' ' B' ' 83' ' ' THR . 5.8 m -136.71 144.64 31.93 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.737 179.172 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 88' ' ' ARG . . . . . 0.468 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 99.7 mtt180 -91.8 129.12 37.82 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 175.735 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.609 ' CE2' HD11 ' B' ' 54' ' ' ILE . 2.0 m-85 -105.93 161.0 14.84 Favored 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 178.674 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.486 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 62.1 mtt -109.14 106.64 16.62 Favored 'General case' 0 C--N 1.286 -2.167 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 169.449 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.515 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.3 mp -87.57 135.48 25.28 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 CA-C-N 114.459 -1.246 . . . . 0.0 107.648 178.492 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 92' ' ' GLY . . . . . 0.548 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -127.0 104.06 0.69 Allowed Glycine 0 CA--C 1.465 -3.088 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 177.186 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 11.2 ptp180 -104.88 148.96 26.1 Favored 'General case' 0 C--N 1.271 -2.809 0 N-CA-C 108.963 -0.754 . . . . 0.0 108.963 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -94.95 77.49 3.58 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 174.288 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 45.4 ttt180 -64.0 -59.36 11.48 Favored Pre-proline 0 C--N 1.3 -1.568 0 CA-C-N 113.69 -1.596 . . . . 0.0 112.623 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -73.5 161.61 41.95 Favored 'Trans proline' 0 C--N 1.37 1.661 0 C-N-CA 121.298 1.332 . . . . 0.0 112.92 -179.056 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 153.63 -46.55 0.55 Allowed Glycine 0 CA--C 1.492 -1.387 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 176.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -79.29 23.27 0.39 Allowed 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 123.088 0.555 . . . . 0.0 111.017 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -66.2 -54.64 22.71 Favored 'General case' 0 N--CA 1.436 -1.136 0 C-N-CA 124.073 0.949 . . . . 0.0 111.076 -175.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 19.6 m -156.05 175.77 13.52 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 -177.238 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 67.59 17.83 9.94 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 124.058 0.943 . . . . 0.0 111.583 175.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 30.0 m -90.84 144.76 8.47 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.166 -0.959 . . . . 0.0 110.798 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . 67.5 -65.68 0.23 Allowed 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 125.579 1.552 . . . . 0.0 114.089 178.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 35.0 tt0 -85.02 -23.26 28.7 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.298 -178.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 11.1 mp 60.47 -172.26 0.13 Allowed 'General case' 0 C--O 1.242 0.701 0 C-N-CA 123.869 0.868 . . . . 0.0 110.657 -173.549 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 38.6 mm -76.39 -64.38 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 176.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 28.1 tp60 55.94 94.61 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.483 0 O-C-N 124.665 1.228 . . . . 0.0 113.001 173.714 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 27.3 mp0 -76.72 77.99 3.35 Favored 'General case' 0 CA--C 1.515 -0.382 0 C-N-CA 119.916 -0.714 . . . . 0.0 109.351 177.297 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 8.1 t -89.51 -29.61 18.83 Favored 'General case' 0 N--CA 1.423 -1.791 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.589 -177.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 90.0 mt -83.63 12.87 5.17 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.57 0.7 . . . . 0.0 111.485 -176.303 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -135.87 98.85 4.0 Favored 'General case' 0 N--CA 1.426 -1.644 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 175.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.39 16.25 6.57 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.087 0.47 . . . . 0.0 111.742 177.25 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 16.2 mp0 . . . . . 0 CA--C 1.513 -0.445 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 172.833 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.171 0 N-CA-C 110.121 -1.192 . . . . 0.0 110.121 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 32.8 p-80 -144.06 145.26 32.06 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 118.047 0.924 . . . . 0.0 111.408 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 3' ' ' MET . . . . . 0.526 ' SD ' ' HA ' ' B' ' 94' ' ' GLU . 24.7 mmt -105.93 118.69 37.25 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 175.602 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 4' ' ' GLU . . . . . 0.464 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 19.0 mt-10 -89.85 100.25 13.1 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -95.46 93.93 7.5 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 177.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -118.53 141.48 29.87 Favored Pre-proline 0 C--N 1.283 -2.323 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.067 178.071 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 7' ' ' PRO . . . . . 0.413 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 79.2 Cg_endo -79.51 143.51 17.15 Favored 'Trans proline' 0 N--CA 1.446 -1.268 0 C-N-CA 122.151 1.901 . . . . 0.0 112.306 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.449 HG13 ' HB3' ' B' ' 53' ' ' ARG . 53.8 t -131.49 127.7 59.99 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.981 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 176.599 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 9' ' ' GLU . . . . . 0.488 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 32.0 tt0 -110.4 121.61 45.72 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -177.837 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.523 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -114.61 165.6 12.6 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 121.515 0.674 . . . . 0.0 110.707 178.685 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -115.52 126.63 54.52 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 105.728 -1.953 . . . . 0.0 105.728 175.25 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 12' ' ' LYS . . . . . 0.412 ' HG2' ' HA2' ' B' ' 85' ' ' GLY . 21.1 ptmt -79.85 160.45 26.08 Favored 'General case' 0 N--CA 1.417 -2.092 0 C-N-CA 117.627 -1.629 . . . . 0.0 107.022 170.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 13' ' ' ASP . . . . . 0.407 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 22.2 t70 -115.75 178.31 4.36 Favored 'General case' 0 C--N 1.258 -3.391 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 -178.8 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 13.1 t -67.32 -20.54 65.62 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 179.398 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -92.61 7.24 44.22 Favored 'General case' 0 CA--C 1.555 1.168 0 CA-C-O 121.869 0.843 . . . . 0.0 109.42 176.066 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.57 -115.93 4.63 Favored Glycine 0 N--CA 1.435 -1.421 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.493 178.506 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -103.05 -173.19 2.25 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 121.42 0.629 . . . . 0.0 110.483 -177.282 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 18' ' ' GLY . . . . . 0.462 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -149.44 53.75 0.51 Allowed Glycine 0 CA--C 1.491 -1.433 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 178.291 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 2.6 pt -154.3 -179.99 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-O 121.961 0.886 . . . . 0.0 111.407 -175.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 51.0 m -152.49 131.45 12.56 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 175.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.505 ' HB ' HG22 ' B' ' 37' ' ' ILE . 15.6 pt -108.66 162.53 6.51 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 C-N-CA 122.713 0.405 . . . . 0.0 109.946 -178.832 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 22' ' ' ILE . . . . . 0.479 ' HB ' ' HB2' ' B' ' 40' ' ' LYS . 9.5 tp -136.22 136.69 49.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 CA-C-O 121.134 0.493 . . . . 0.0 110.673 -178.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -82.58 105.63 2.64 Favored Glycine 0 N--CA 1.426 -2.022 0 CA-C-N 115.663 -0.699 . . . . 0.0 112.527 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 24' ' ' MET . . . . . 0.531 ' O ' ' HG ' ' B' ' 35' ' ' LEU . 26.3 mmt -131.07 178.22 6.85 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 176.196 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 121.14 -162.52 14.85 Favored Glycine 0 C--N 1.289 -2.033 0 C-N-CA 120.465 -0.874 . . . . 0.0 111.206 179.245 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -135.46 137.8 42.56 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 176.464 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.98 83.75 0.71 Allowed Glycine 0 N--CA 1.443 -0.856 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 179.655 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.91 79.26 0.31 Allowed 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.587 0.708 . . . . 0.0 112.065 -178.733 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -76.29 2.95 11.91 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-O 122.876 1.322 . . . . 0.0 110.687 -175.632 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 30' ' ' MET . . . . . 0.429 ' HG3' HD23 ' B' ' 32' ' ' LEU . 24.5 ptm -73.12 19.72 0.09 Allowed 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.207 -1.36 . . . . 0.0 111.801 175.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.0 17.55 32.05 Favored Glycine 0 N--CA 1.442 -0.935 0 C-N-CA 121.442 -0.408 . . . . 0.0 112.768 177.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 32' ' ' LEU . . . . . 0.429 HD23 ' HG3' ' B' ' 30' ' ' MET . 4.4 mm? -121.55 -53.62 1.99 Allowed 'General case' 0 C--N 1.312 -1.033 0 C-N-CA 119.87 -0.732 . . . . 0.0 112.288 -177.676 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 33' ' ' GLU . . . . . 0.482 ' O ' ' HA3' ' B' ' 70' ' ' GLY . 40.9 mt-10 59.66 24.81 13.68 Favored 'General case' 0 CA--C 1.502 -0.876 0 C-N-CA 125.381 1.472 . . . . 0.0 111.649 -173.34 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 34' ' ' LYS . . . . . 0.442 ' HA ' ' O ' ' B' ' 69' ' ' VAL . 14.1 ptmm? -72.21 124.29 24.73 Favored 'General case' 0 N--CA 1.423 -1.784 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 179.08 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 35' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' B' ' 24' ' ' MET . 15.4 tp -123.37 -172.44 2.51 Favored 'General case' 0 C--N 1.28 -2.447 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 -174.124 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 36' ' ' GLY . . . . . 0.475 ' H ' ' HG ' ' B' ' 35' ' ' LEU . . . -137.06 87.72 0.22 Allowed Glycine 0 N--CA 1.422 -2.296 0 C-N-CA 119.882 -1.151 . . . . 0.0 111.724 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.505 HG22 ' HB ' ' B' ' 21' ' ' ILE . 34.5 mm -84.62 80.32 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 176.233 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.413 ' CD1' ' HB2' ' B' ' 59' ' ' LEU . 96.9 m-85 -77.17 169.93 17.45 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.172 -176.38 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 49.1 t -80.36 135.46 25.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 40' ' ' LYS . . . . . 0.479 ' HB2' ' HB ' ' B' ' 22' ' ' ILE . 2.4 ttpm? -95.84 -41.47 8.81 Favored 'General case' 0 CA--C 1.482 -1.652 0 CA-C-O 121.187 0.517 . . . . 0.0 109.899 -178.125 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 1.1 m -154.83 146.98 23.72 Favored 'General case' 1 N--CA 1.369 -4.483 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -174.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 39.5 t -114.76 105.69 19.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 175.519 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 7.2 m -64.41 122.68 17.3 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.215 -174.538 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 44' ' ' GLU . . . . . 0.505 ' HG2' ' CE1' ' B' ' 49' ' ' HIS . 36.1 mt-10 -66.8 -28.36 68.31 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.457 -175.74 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.3 -1.11 85.4 Favored Glycine 0 N--CA 1.435 -1.401 0 CA-C-N 115.042 -0.981 . . . . 0.0 113.396 -179.266 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.462 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -117.07 170.29 13.38 Favored Glycine 0 N--CA 1.411 -2.972 0 C-N-CA 119.933 -1.127 . . . . 0.0 112.818 -178.51 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 47' ' ' ALA . . . . . 0.407 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -60.72 -35.79 77.23 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 114.088 1.144 . . . . 0.0 114.088 -174.249 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 48' ' ' ALA . . . . . 0.523 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -63.28 -38.74 92.35 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 113.199 0.815 . . . . 0.0 113.199 -174.277 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 49' ' ' HIS . . . . . 0.505 ' CE1' ' HG2' ' B' ' 44' ' ' GLU . 4.1 t60 -74.15 -39.34 63.33 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.659 0.742 . . . . 0.0 109.342 -179.199 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 -76.63 -26.2 54.65 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 114.862 -1.063 . . . . 0.0 111.785 -175.314 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 51' ' ' ASP . . . . . 0.523 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 12.6 t70 -77.92 -46.18 22.0 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 176.52 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 97.08 16.34 35.76 Favored Glycine 0 CA--C 1.498 -1.03 0 CA-C-N 115.515 -0.766 . . . . 0.0 112.624 172.399 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.523 ' HD3' ' OD2' ' B' ' 51' ' ' ASP . 1.5 mpt_? -91.96 -63.46 1.24 Allowed 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 113.335 0.865 . . . . 0.0 113.335 -177.124 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.5 HD11 ' CE2' ' B' ' 89' ' ' PHE . 39.4 mt -69.3 133.09 32.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 C-N-CA 119.805 -0.758 . . . . 0.0 110.53 176.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 30.7 mm-40 -113.37 153.66 28.19 Favored 'General case' 0 CA--C 1.511 -0.543 0 C-N-CA 122.408 0.283 . . . . 0.0 110.634 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.3 p -73.6 -7.48 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.86 0 CA-C-O 121.709 0.766 . . . . 0.0 111.986 -176.015 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -114.35 9.83 16.97 Favored 'General case' 0 C--N 1.293 -1.879 0 O-C-N 121.581 -0.699 . . . . 0.0 111.95 -175.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -112.42 177.78 4.52 Favored 'General case' 0 C--O 1.244 0.784 0 CA-C-O 120.979 0.418 . . . . 0.0 111.767 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.413 ' HB2' ' CD1' ' B' ' 38' ' ' PHE . 24.9 tp -126.91 128.22 46.12 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.739 -176.638 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 31.7 mt -90.15 107.68 19.28 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 105.569 -2.011 . . . . 0.0 105.569 175.229 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.534 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 41.4 t -79.2 -74.36 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.19 -2.03 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.45 ' HA ' HD23 ' B' ' 68' ' ' LEU . 10.9 pt-20 -118.6 165.2 14.24 Favored 'General case' 0 C--N 1.269 -2.903 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.032 -173.766 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.485 HG22 ' H ' ' B' ' 64' ' ' ASP . 4.6 p -113.34 -175.19 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -174.705 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.491 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 12.6 t70 -40.18 -63.35 0.62 Allowed 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 125.76 1.624 . . . . 0.0 113.918 -178.709 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -134.68 41.01 1.5 Allowed Glycine 0 CA--C 1.496 -1.133 0 C-N-CA 119.333 -1.413 . . . . 0.0 113.401 -178.097 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 37.7 m -150.35 126.24 10.44 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 178.159 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 2.3 p -84.18 133.18 34.61 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 115.457 -0.792 . . . . 0.0 112.047 -177.09 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.534 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 4.2 mm? -118.69 141.91 48.16 Favored 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 175.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 69' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' B' ' 34' ' ' LYS . 44.6 t -123.47 -42.59 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 175.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 70' ' ' GLY . . . . . 0.482 ' HA3' ' O ' ' B' ' 33' ' ' GLU . . . 175.49 81.0 0.05 OUTLIER Glycine 0 N--CA 1.409 -3.164 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.552 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 27.1 m -100.91 -177.39 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.217 0 CA-C-N 114.197 -1.002 . . . . 0.0 109.532 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 72.0 p -76.1 163.4 27.15 Favored 'General case' 0 N--CA 1.432 -1.359 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 177.304 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -61.93 -31.85 72.2 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.651 0.739 . . . . 0.0 109.412 177.013 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 28.1 t -72.69 -42.6 64.05 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.872 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 19.4 t80 -62.46 -47.81 82.4 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.586 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.72 -40.32 94.64 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.577 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.73 -28.84 69.35 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.499 0.666 . . . . 0.0 110.959 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.8 m -85.16 -16.94 38.75 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.171 -177.4 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.586 HG12 ' O ' ' B' ' 76' ' ' ALA . 4.2 p -72.91 -28.25 26.5 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.518 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 -179.236 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 55.2 mt -71.81 -7.14 46.48 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 114.09 -1.414 . . . . 0.0 110.815 177.264 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 88.3 mtt180 -103.65 -14.7 16.03 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 121.37 0.605 . . . . 0.0 109.707 178.192 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 -86.59 -29.03 22.91 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.471 176.717 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.674 ' HB ' HG11 ' B' ' 87' ' ' VAL . 9.3 p -69.49 170.08 11.27 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 115.402 1.63 . . . . 0.0 115.402 -173.392 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 35.1 mttp -73.56 -162.4 0.13 Allowed 'General case' 0 C--O 1.241 0.622 0 CA-C-N 114.845 -1.07 . . . . 0.0 110.253 173.384 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 85' ' ' GLY . . . . . 0.412 ' HA2' ' HG2' ' B' ' 12' ' ' LYS . . . -80.0 -38.5 19.06 Favored Glycine 0 N--CA 1.437 -1.291 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.871 178.277 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 41.0 ttm180 -120.96 123.52 42.65 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.674 HG11 ' HB ' ' B' ' 83' ' ' THR . 26.7 m -139.71 142.76 31.88 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 CA-C-O 120.867 0.365 . . . . 0.0 111.543 -177.767 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 88' ' ' ARG . . . . . 0.488 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 52.2 mtt180 -99.4 116.68 32.13 Favored 'General case' 0 CA--C 1.485 -1.556 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.164 176.528 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.5 ' CE2' HD11 ' B' ' 54' ' ' ILE . 6.8 m-85 -92.91 152.44 19.37 Favored 'General case' 0 C--N 1.285 -2.234 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.507 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 90' ' ' MET . . . . . . . . . . . . . 86.0 mtp -102.1 106.98 17.93 Favored 'General case' 0 C--N 1.286 -2.177 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 171.27 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.454 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.4 mp -84.77 120.86 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.942 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 92' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -117.27 109.95 1.97 Allowed Glycine 1 CA--C 1.445 -4.283 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 179.219 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 7.3 tpp180 -69.72 94.57 0.81 Allowed 'General case' 0 C--N 1.279 -2.475 0 CA-C-N 114.6 -0.8 . . . . 0.0 109.431 177.122 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 94' ' ' GLU . . . . . 0.526 ' HA ' ' SD ' ' B' ' 3' ' ' MET . 31.8 tt0 -81.88 77.79 8.66 Favored 'General case' 0 N--CA 1.408 -2.549 0 CA-C-O 122.783 1.278 . . . . 0.0 107.762 173.654 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 28.3 ttm105 -78.71 -58.09 0.77 Allowed Pre-proline 0 N--CA 1.408 -2.55 0 CA-C-N 112.774 -2.012 . . . . 0.0 109.309 176.534 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -72.89 117.27 5.05 Favored 'Trans proline' 0 N--CA 1.424 -2.578 0 C-N-CA 121.376 1.384 . . . . 0.0 112.853 178.393 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -149.1 -37.16 0.04 OUTLIER Glycine 0 C--N 1.267 -3.277 0 CA-C-N 113.045 -1.888 . . . . 0.0 108.843 -179.453 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -80.59 22.5 0.57 Allowed 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 124.123 0.969 . . . . 0.0 110.904 176.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 84.1 mm-40 -85.48 114.25 22.37 Favored 'General case' 0 N--CA 1.407 -2.584 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.664 179.708 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 24.4 m -114.57 170.56 8.23 Favored 'General case' 0 C--N 1.279 -2.458 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 177.082 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 66.29 31.21 8.62 Favored 'General case' 0 CA--C 1.555 1.157 0 CA-C-O 122.565 1.174 . . . . 0.0 109.8 177.197 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 35.2 m -99.36 172.9 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 114.744 -1.116 . . . . 0.0 110.605 -177.882 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -118.93 -91.73 0.55 Allowed 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 114.122 1.156 . . . . 0.0 114.122 -176.856 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 10.2 pt20 -82.04 25.51 0.57 Allowed 'General case' 0 N--CA 1.476 0.855 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 -173.318 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 73.8 mt -83.7 -3.3 57.65 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-O 122.25 1.024 . . . . 0.0 108.349 174.749 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 46.5 mm -79.79 -65.68 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 CA-C-N 113.875 -1.511 . . . . 0.0 107.967 174.21 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 27.0 pt20 -118.68 115.89 25.45 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.265 175.817 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 53.1 tt0 -91.36 89.61 7.34 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 177.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 7.9 t -106.44 150.81 25.69 Favored 'General case' 0 N--CA 1.412 -2.344 0 CA-C-N 115.087 -0.961 . . . . 0.0 109.455 -178.617 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 28.4 mt -96.13 -5.39 40.85 Favored 'General case' 0 C--N 1.285 -2.204 0 CA-C-N 115.244 -0.889 . . . . 0.0 108.962 -178.643 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -135.3 79.05 1.76 Allowed 'General case' 0 N--CA 1.432 -1.346 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.417 178.12 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 59.9 tt0 -100.05 99.31 10.02 Favored 'General case' 0 C--N 1.306 -1.315 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 174.007 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 . . . . . 0 C--N 1.285 -2.228 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -173.288 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.502 -0.777 0 N-CA-C 110.226 -1.15 . . . . 0.0 110.226 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 60.5 m-70 -83.47 -45.14 13.97 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 171.608 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 19.7 ptp -96.44 149.68 21.45 Favored 'General case' 0 N--CA 1.425 -1.709 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 173.08 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -84.99 104.93 15.37 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 -177.636 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -79.55 83.73 5.5 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 173.527 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -102.58 143.02 25.76 Favored Pre-proline 0 C--N 1.294 -1.845 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.396 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 7' ' ' PRO . . . . . 0.536 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 51.1 Cg_endo -79.28 134.61 11.53 Favored 'Trans proline' 0 N--CA 1.429 -2.267 0 C-N-CA 121.634 1.556 . . . . 0.0 112.291 177.77 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 73.4 t -115.22 127.54 72.75 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 175.272 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 9' ' ' GLU . . . . . 0.497 ' O ' ' HD2' ' B' ' 53' ' ' ARG . 43.3 tt0 -119.59 116.12 25.38 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 -176.291 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.626 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -102.41 153.27 20.19 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.766 0.793 . . . . 0.0 110.761 -177.949 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.443 ' H ' HD23 ' B' ' 10' ' ' LEU . 80.4 mm-40 -99.68 103.36 15.03 Favored 'General case' 0 C--N 1.276 -2.607 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 174.718 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 12' ' ' LYS . . . . . 0.438 ' HE2' ' HB3' ' B' ' 12' ' ' LYS . 6.5 mmmm -81.61 157.02 24.86 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 114.301 1.223 . . . . 0.0 114.301 -171.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 13' ' ' ASP . . . . . 0.498 ' H ' ' HA3' ' B' ' 16' ' ' GLY . 22.1 m-20 -128.47 178.82 6.02 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 171.184 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 14.7 m -74.61 -19.56 60.26 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.652 0.739 . . . . 0.0 110.033 177.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 9.2 tp10 -128.56 31.49 4.98 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 105.762 -1.94 . . . . 0.0 105.762 176.04 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.498 ' HA3' ' H ' ' B' ' 13' ' ' ASP . . . -71.21 -5.03 58.16 Favored Glycine 0 CA--C 1.494 -1.263 0 CA-C-N 113.662 -1.608 . . . . 0.0 116.481 -169.181 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -75.16 86.45 2.41 Favored 'General case' 0 N--CA 1.429 -1.488 0 C-N-CA 119.302 -0.959 . . . . 0.0 111.096 177.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -96.78 55.45 1.37 Allowed Glycine 0 CA--C 1.484 -1.85 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 6.6 pt -161.67 -177.49 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 C-N-CA 124.7 1.2 . . . . 0.0 107.92 -175.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 20' ' ' SER . . . . . 0.434 ' HB2' HG22 ' B' ' 41' ' ' THR . 43.2 m -149.65 145.61 26.83 Favored 'General case' 0 C--N 1.27 -2.865 0 N-CA-C 105.425 -2.065 . . . . 0.0 105.425 172.791 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.458 ' HB ' HG22 ' B' ' 37' ' ' ILE . 16.0 pt -115.95 154.1 17.48 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.297 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.3 tp -127.08 136.79 59.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 CA-C-O 120.884 0.374 . . . . 0.0 110.764 -176.044 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.58 98.08 2.38 Favored Glycine 0 N--CA 1.434 -1.438 0 C-N-CA 121.058 -0.591 . . . . 0.0 111.791 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 95.4 mmm -102.95 118.9 37.85 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 178.408 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 144.92 177.83 20.05 Favored Glycine 0 N--CA 1.425 -2.043 0 C-N-CA 119.959 -1.115 . . . . 0.0 113.099 177.628 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -159.29 154.49 25.31 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 177.386 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 164.82 -162.06 35.24 Favored Glycine 0 N--CA 1.434 -1.433 0 C-N-CA 120.072 -1.061 . . . . 0.0 112.542 178.651 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.69 98.45 10.7 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-O 120.835 0.35 . . . . 0.0 111.118 -179.11 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.422 ' HA ' ' HB3' ' B' ' 33' ' ' GLU . 9.7 p-10 -75.24 49.89 0.48 Allowed 'General case' 0 N--CA 1.445 -0.68 0 C-N-CA 125.056 1.342 . . . . 0.0 112.345 -177.811 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 25.9 ptt? -128.31 26.32 5.72 Favored 'General case' 0 C--N 1.29 -2.012 0 CA-C-N 115.067 -0.97 . . . . 0.0 109.423 -178.29 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.37 16.68 12.68 Favored Glycine 0 N--CA 1.444 -0.778 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.755 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 26.3 mt -150.5 26.91 0.75 Allowed 'General case' 0 C--O 1.25 1.12 0 C-N-CA 123.253 0.621 . . . . 0.0 111.134 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 33' ' ' GLU . . . . . 0.485 ' O ' ' HG ' ' B' ' 35' ' ' LEU . 2.4 pm0 -79.94 71.62 6.65 Favored 'General case' 0 N--CA 1.421 -1.921 0 CA-C-O 122.007 0.908 . . . . 0.0 108.654 175.664 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 34' ' ' LYS . . . . . 0.404 ' HA ' ' HA3' ' B' ' 70' ' ' GLY . 22.5 pttp -64.91 86.58 0.05 Allowed 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 114.202 -1.363 . . . . 0.0 109.452 176.735 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 35' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' B' ' 33' ' ' GLU . 74.9 mt -107.93 158.49 17.31 Favored 'General case' 0 N--CA 1.431 -1.399 0 CA-C-N 113.759 -1.564 . . . . 0.0 109.522 -175.679 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -107.75 98.27 1.24 Allowed Glycine 0 N--CA 1.404 -3.437 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 176.443 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.458 HG22 ' HB ' ' B' ' 21' ' ' ILE . 27.9 mm -87.35 87.78 2.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 177.058 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -85.69 166.54 16.06 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.399 -1.273 . . . . 0.0 108.705 -176.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 57.4 t -77.9 136.47 24.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 175.107 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -96.04 -42.07 8.44 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -178.309 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 41' ' ' THR . . . . . 0.463 ' HA ' HG23 ' B' ' 56' ' ' VAL . 3.5 t -157.05 168.8 26.41 Favored 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 21.3 t -130.47 97.35 3.19 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 178.265 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 40.5 m -73.89 124.64 26.54 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 124.281 1.033 . . . . 0.0 111.709 -176.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 44' ' ' GLU . . . . . 0.579 ' HA ' ' HB3' ' B' ' 49' ' ' HIS . 1.7 pm0 -65.53 -22.41 66.71 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 124.44 1.096 . . . . 0.0 113.904 -178.042 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.54 -23.87 72.23 Favored Glycine 0 N--CA 1.439 -1.128 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.243 176.214 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -104.4 173.15 21.01 Favored Glycine 0 N--CA 1.424 -2.163 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.837 -177.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 47' ' ' ALA . . . . . 0.404 ' HB2' ' OD2' ' B' ' 13' ' ' ASP . . . -58.54 -41.34 85.34 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 125.205 1.402 . . . . 0.0 114.265 -175.647 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 48' ' ' ALA . . . . . 0.626 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -57.19 -37.52 72.28 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -173.39 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 49' ' ' HIS . . . . . 0.579 ' HB3' ' HA ' ' B' ' 44' ' ' GLU . 8.4 t60 -74.97 -35.4 62.07 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -178.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 68.9 mtt180 -68.43 -47.74 66.41 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 -178.452 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -60.41 -61.39 2.63 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 114.456 -1.247 . . . . 0.0 110.722 176.476 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 91.02 6.14 67.23 Favored Glycine 0 N--CA 1.433 -1.528 0 N-CA-C 114.824 0.69 . . . . 0.0 114.824 175.144 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.497 ' HD2' ' O ' ' B' ' 9' ' ' GLU . 65.4 mtt180 -83.3 -33.64 25.9 Favored 'General case' 0 N--CA 1.441 -0.892 0 CA-C-N 118.392 1.096 . . . . 0.0 111.316 179.107 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.445 HD11 ' CE2' ' B' ' 89' ' ' PHE . 28.8 mt -83.29 117.03 28.4 Favored 'Isoleucine or valine' 0 C--O 1.248 0.984 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 174.116 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 22.7 mt-30 -91.45 163.96 13.99 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 121.356 0.598 . . . . 0.0 110.47 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.463 HG23 ' HA ' ' B' ' 41' ' ' THR . 13.2 p -75.51 -2.11 3.79 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.854 0 CA-C-O 122.488 1.137 . . . . 0.0 109.976 178.361 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -114.02 0.06 14.21 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.058 -175.597 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -82.29 174.34 11.23 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 112.926 0.713 . . . . 0.0 112.926 -174.076 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 25.8 tp -141.6 131.15 23.91 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.54 -0.755 . . . . 0.0 110.521 -175.539 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -81.71 95.63 7.29 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.688 0.756 . . . . 0.0 110.22 178.227 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.569 ' HB ' ' O ' ' B' ' 90' ' ' MET . 27.8 t -86.95 -40.73 14.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.695 177.03 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.536 ' HG3' ' HA ' ' B' ' 67' ' ' SER . 32.4 tt0 -156.2 148.75 23.72 Favored 'General case' 0 C--N 1.273 -2.727 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.48 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.513 ' O ' ' HG2' ' B' ' 62' ' ' GLU . 9.9 p -102.39 -168.45 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 104.912 -2.255 . . . . 0.0 104.912 176.419 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.425 ' H ' HG22 ' B' ' 63' ' ' VAL . 12.2 t70 -50.19 -54.21 22.47 Favored 'General case' 0 N--CA 1.479 1.004 0 CA-C-N 119.189 0.904 . . . . 0.0 112.27 178.369 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -106.16 -53.78 0.73 Allowed Glycine 0 C--N 1.308 -0.989 0 C-N-CA 119.538 -1.315 . . . . 0.0 114.088 -178.3 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 6.1 m -72.37 120.81 18.51 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 123.101 0.56 . . . . 0.0 112.492 -174.732 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 67' ' ' SER . . . . . 0.536 ' HA ' ' HG3' ' B' ' 62' ' ' GLU . 64.9 m -86.12 121.15 28.31 Favored 'General case' 0 N--CA 1.435 -1.204 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 174.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.471 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 28.9 mt -83.3 100.23 10.51 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-O 121.087 0.47 . . . . 0.0 110.226 -179.308 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 29.0 m -89.48 12.5 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-O 121.759 0.79 . . . . 0.0 109.463 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 70' ' ' GLY . . . . . 0.404 ' HA3' ' HA ' ' B' ' 34' ' ' LYS . . . 111.71 90.23 1.94 Allowed Glycine 0 N--CA 1.402 -3.615 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -174.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 26.4 m -117.15 174.4 3.73 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.28 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 20.7 p -76.87 159.86 29.7 Favored 'General case' 0 N--CA 1.413 -2.281 0 CA-C-O 120.957 0.408 . . . . 0.0 110.051 177.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 60.6 tt0 -58.66 -35.28 72.29 Favored 'General case' 0 C--N 1.311 -1.096 0 C-N-CA 123.788 0.835 . . . . 0.0 109.824 178.768 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 19.7 m -70.96 -39.14 72.73 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.576 179.559 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -62.56 -48.9 77.45 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.068 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.516 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -57.81 -45.42 86.11 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.258 179.304 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.01 -39.19 91.42 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.641 0.734 . . . . 0.0 110.792 178.553 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 50.6 m -71.83 -27.5 62.95 Favored 'General case' 0 N--CA 1.433 -1.32 0 CA-C-N 115.377 -0.829 . . . . 0.0 112.511 -177.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.516 HG12 ' O ' ' B' ' 76' ' ' ALA . 5.0 p -77.25 -30.4 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 C-N-CA 119.546 -0.862 . . . . 0.0 108.852 -177.164 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 80' ' ' LEU . . . . . 0.491 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 77.1 mt -67.46 -35.85 80.01 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.306 176.08 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 79.4 mtp180 -78.05 -32.74 51.01 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.275 178.317 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -72.3 -36.71 69.0 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 123.234 0.614 . . . . 0.0 111.478 -179.081 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.667 ' HB ' HG11 ' B' ' 87' ' ' VAL . 8.5 p -67.82 159.81 29.57 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 113.693 0.997 . . . . 0.0 113.693 -177.117 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -66.56 -166.07 0.04 OUTLIER 'General case' 0 C--O 1.255 1.371 0 C-N-CA 125.729 1.612 . . . . 0.0 114.806 -174.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 85' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' B' ' 12' ' ' LYS . . . -70.86 -17.12 75.03 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 114.631 -1.168 . . . . 0.0 113.3 -177.514 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 86' ' ' ARG . . . . . 0.522 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 57.1 ttp180 -157.49 118.3 3.54 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 121.165 0.507 . . . . 0.0 111.016 174.465 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.667 HG11 ' HB ' ' B' ' 83' ' ' THR . 14.8 m -132.1 145.72 34.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.237 179.351 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -98.05 128.89 44.85 Favored 'General case' 0 CA--C 1.482 -1.654 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.518 178.402 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.536 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 4.8 m-85 -105.38 157.36 17.39 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 106.965 -1.495 . . . . 0.0 106.965 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.569 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 63.0 mtt -109.87 117.51 34.02 Favored 'General case' 0 C--N 1.282 -2.352 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 172.134 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 1.4 mp -105.96 122.38 59.5 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 -179.157 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.37 103.76 2.51 Favored Glycine 0 CA--C 1.464 -3.11 0 N-CA-C 109.169 -1.573 . . . . 0.0 109.169 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 9.3 tpp180 -141.81 121.41 13.36 Favored 'General case' 0 C--N 1.265 -3.073 0 CA-C-N 114.214 -0.993 . . . . 0.0 110.572 -175.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -83.97 86.79 7.13 Favored 'General case' 0 N--CA 1.429 -1.519 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 168.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 45.6 ttt180 -65.96 -61.63 5.32 Favored Pre-proline 0 C--N 1.302 -1.488 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.612 179.099 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -74.69 136.47 21.13 Favored 'Trans proline' 0 N--CA 1.444 -1.438 0 C-N-CA 121.888 1.725 . . . . 0.0 114.379 -178.183 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -143.13 -94.85 0.2 Allowed Glycine 0 C--N 1.286 -2.246 0 N-CA-C 107.343 -2.303 . . . . 0.0 107.343 174.741 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -103.53 77.45 1.5 Allowed 'General case' 0 N--CA 1.421 -1.9 0 CA-C-O 122.659 1.218 . . . . 0.0 109.881 173.501 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -129.72 -66.69 0.78 Allowed 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 12.3 m -94.65 169.64 10.03 Favored 'General case' 0 N--CA 1.425 -1.682 0 N-CA-C 105.651 -1.981 . . . . 0.0 105.651 169.225 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 6.1 tm-20 70.28 8.76 6.77 Favored 'General case' 0 N--CA 1.479 0.986 0 CA-C-O 121.686 0.755 . . . . 0.0 111.457 176.769 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 15.8 m -65.3 113.78 2.32 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-O 121.965 0.888 . . . . 0.0 112.077 -178.344 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -118.44 -33.01 4.45 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.797 -1.092 . . . . 0.0 109.984 -177.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 59.9 tp60 -78.63 93.27 4.84 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 175.127 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 82.0 mt -119.03 120.99 38.83 Favored 'General case' 0 C--N 1.297 -1.715 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.024 -173.068 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 1.7 mp -91.08 -56.37 5.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 174.124 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 13.1 mm100 -96.03 100.03 11.73 Favored 'General case' 0 N--CA 1.438 -1.066 0 CA-C-N 115.325 -0.852 . . . . 0.0 108.771 175.383 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 52.7 mt-30 -84.04 34.8 0.51 Allowed 'General case' 0 C--N 1.31 -1.113 0 C-N-CA 123.153 0.581 . . . . 0.0 111.752 -177.225 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 9.7 t -63.77 -25.41 68.17 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 122.979 0.512 . . . . 0.0 112.163 -177.037 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -81.22 -7.61 59.6 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -100.2 129.1 46.18 Favored 'General case' 0 N--CA 1.44 -0.961 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 175.568 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 45.2 mt-30 -82.85 148.26 27.84 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-O 120.935 0.397 . . . . 0.0 111.223 -174.026 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 . . . . . 0 C--N 1.302 -1.478 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.771 -177.949 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.205 0 CA-C-O 119.715 -0.492 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 15.0 t-80 -71.33 -69.92 0.35 Allowed 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 122.989 0.516 . . . . 0.0 109.835 -176.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 92.8 mmm -104.09 106.11 16.5 Favored 'General case' 0 CA--C 1.469 -2.171 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 177.126 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 4' ' ' GLU . . . . . 0.491 ' OE2' ' HD2' ' B' ' 93' ' ' ARG . 12.0 mt-10 -98.62 96.4 7.92 Favored 'General case' 0 C--N 1.275 -2.643 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.013 -175.614 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -84.38 97.51 9.52 Favored 'General case' 0 N--CA 1.427 -1.606 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 177.201 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -130.85 147.48 66.39 Favored Pre-proline 0 C--N 1.279 -2.495 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.481 177.534 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 7' ' ' PRO . . . . . 0.442 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 49.7 Cg_endo -75.84 136.89 19.28 Favored 'Trans proline' 0 N--CA 1.44 -1.65 0 C-N-CA 121.868 1.712 . . . . 0.0 111.625 175.831 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 91.4 t -121.56 148.54 24.93 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.071 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.091 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -126.98 143.65 51.23 Favored 'General case' 0 C--N 1.279 -2.469 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -177.451 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.55 HD11 ' HB2' ' B' ' 48' ' ' ALA . 0.8 OUTLIER -141.04 157.18 45.67 Favored 'General case' 0 CA--C 1.478 -1.789 0 CA-C-O 121.05 0.452 . . . . 0.0 109.908 174.431 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -127.15 112.59 15.32 Favored 'General case' 0 C--N 1.275 -2.632 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 177.491 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 5.4 ptpp? -77.14 150.77 35.55 Favored 'General case' 0 C--N 1.283 -2.317 0 CA-C-N 115.143 -0.935 . . . . 0.0 113.357 -172.017 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -93.78 -172.93 3.01 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 177.698 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 12.3 t -71.25 -25.65 62.57 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.954 -1.499 . . . . 0.0 106.954 173.09 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 11.9 tp10 -67.27 -20.87 65.71 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.444 172.411 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.07 -116.06 4.83 Favored Glycine 0 N--CA 1.416 -2.657 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -177.188 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -101.2 -175.06 2.76 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -178.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 18' ' ' GLY . . . . . 0.432 ' CA ' ' HA3' ' B' ' 46' ' ' GLY . . . -150.45 67.99 0.34 Allowed Glycine 0 CA--C 1.477 -2.325 0 N-CA-C 110.931 -0.868 . . . . 0.0 110.931 -179.754 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.466 ' HA ' ' H ' ' B' ' 43' ' ' THR . 4.3 pt -162.59 169.98 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 C-N-CA 125.277 1.431 . . . . 0.0 107.867 -176.527 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.4 m -131.76 141.99 49.65 Favored 'General case' 0 C--N 1.253 -3.611 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 174.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.502 ' HB ' HG22 ' B' ' 37' ' ' ILE . 8.6 pt -115.23 149.37 17.47 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.012 0 O-C-N 123.45 0.469 . . . . 0.0 109.81 -178.188 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.1 tp -119.22 134.88 61.42 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -177.465 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.74 94.58 1.55 Allowed Glycine 0 N--CA 1.43 -1.707 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.688 -177.271 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 88.9 mmm -84.05 113.23 20.87 Favored 'General case' 0 C--O 1.253 1.268 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -83.22 68.17 3.61 Favored Glycine 0 CA--C 1.481 -2.052 0 CA-C-O 122.268 0.926 . . . . 0.0 113.163 -175.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -163.72 -45.95 0.03 OUTLIER 'General case' 0 C--N 1.251 -3.692 0 CA-C-N 112.528 -1.836 . . . . 0.0 108.383 178.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 49.59 -119.58 6.7 Favored Glycine 0 C--N 1.27 -3.123 0 CA-C-N 111.358 -2.656 . . . . 0.0 113.206 178.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -121.79 89.09 3.05 Favored 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.538 ' HA ' ' HA ' ' B' ' 33' ' ' GLU . 17.6 t70 -69.0 -41.28 78.02 Favored 'General case' 0 CA--C 1.492 -1.284 0 N-CA-C 112.851 0.686 . . . . 0.0 112.851 -176.022 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 23.0 ptp -91.74 45.75 1.24 Allowed 'General case' 0 C--N 1.274 -2.675 0 CA-C-O 122.75 1.262 . . . . 0.0 108.899 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -161.01 -63.96 0.02 OUTLIER Glycine 0 N--CA 1.42 -2.376 0 CA-C-N 113.221 -1.809 . . . . 0.0 112.12 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -129.07 -3.97 5.05 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -174.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 33' ' ' GLU . . . . . 0.538 ' HA ' ' HA ' ' B' ' 29' ' ' ASP . 8.6 pt-20 49.01 22.04 0.54 Allowed 'General case' 0 N--CA 1.503 2.206 0 C-N-CA 126.439 1.895 . . . . 0.0 114.553 -175.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -130.85 175.46 9.03 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 112.115 0.413 . . . . 0.0 112.115 -177.112 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 78.6 mt -52.61 140.74 22.37 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 125.403 1.481 . . . . 0.0 113.955 -175.17 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -111.18 103.64 1.61 Allowed Glycine 0 N--CA 1.423 -2.212 0 N-CA-C 108.614 -1.794 . . . . 0.0 108.614 175.789 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.502 HG22 ' HB ' ' B' ' 21' ' ' ILE . 26.3 mm -94.15 90.38 2.8 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-O 121.674 0.749 . . . . 0.0 109.403 -177.759 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -88.79 167.07 13.59 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.207 -178.128 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 64.7 t -80.77 130.3 36.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 CA-C-O 121.28 0.562 . . . . 0.0 109.641 175.387 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -94.42 -41.11 9.56 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.218 -176.681 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -156.57 164.0 38.7 Favored 'General case' 0 N--CA 1.437 -1.082 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.412 ' HA ' HG22 ' B' ' 19' ' ' ILE . 21.3 t -112.05 102.52 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.031 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 174.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.466 ' H ' ' HA ' ' B' ' 19' ' ' ILE . 31.2 m -69.73 122.04 18.38 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 124.112 0.965 . . . . 0.0 111.825 -174.357 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 44' ' ' GLU . . . . . 0.473 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 32.8 mt-10 -58.23 -41.45 84.15 Favored 'General case' 0 CA--C 1.507 -0.695 0 C-N-CA 124.662 1.185 . . . . 0.0 111.736 -175.568 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -67.22 -12.24 60.37 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 115.197 -0.911 . . . . 0.0 114.237 -177.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.432 ' HA3' ' CA ' ' B' ' 18' ' ' GLY . . . -112.23 170.0 13.35 Favored Glycine 0 N--CA 1.41 -3.078 0 C-N-CA 120.124 -1.036 . . . . 0.0 113.797 -175.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -57.64 -35.07 70.02 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 115.045 1.498 . . . . 0.0 115.045 -171.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 48' ' ' ALA . . . . . 0.55 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -67.53 -35.46 79.12 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 119.952 -0.699 . . . . 0.0 112.695 -174.396 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 49' ' ' HIS . . . . . 0.473 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 5.4 t60 -78.53 -39.62 37.38 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 64.4 mtp180 -67.13 -39.48 86.6 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.683 -177.68 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -79.56 -48.63 13.51 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 177.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 94.15 51.22 2.1 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -178.452 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 13.1 mmt180 -109.75 -79.44 0.58 Allowed 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 111.85 0.315 . . . . 0.0 111.85 -175.673 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.488 HD11 ' CE2' ' B' ' 89' ' ' PHE . 62.7 mt -71.16 132.7 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.977 -179.203 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 -103.58 173.51 6.27 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.234 0.54 . . . . 0.0 110.996 -177.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.1 p -79.27 2.43 2.17 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.145 0 CA-C-O 121.949 0.88 . . . . 0.0 111.638 -174.662 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -121.46 11.36 10.65 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 122.218 1.009 . . . . 0.0 108.683 -175.316 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 19.2 m-20 -89.07 168.49 12.29 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.929 -175.858 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.511 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 23.5 tp -144.69 131.47 20.14 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 124.008 0.923 . . . . 0.0 108.83 -177.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 76.6 mt -85.08 94.23 8.8 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.506 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.2 t -80.09 -39.96 19.89 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 CA-C-O 121.739 0.78 . . . . 0.0 110.147 177.864 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -160.0 156.73 27.53 Favored 'General case' 0 C--N 1.28 -2.451 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.41 173.046 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.426 HG22 ' H ' ' B' ' 64' ' ' ASP . 5.7 p -102.01 -173.74 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 N-CA-C 105.455 -2.054 . . . . 0.0 105.455 177.635 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.436 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 18.0 t70 -53.79 -48.75 69.49 Favored 'General case' 0 C--N 1.311 -1.093 0 C-N-CA 122.992 0.517 . . . . 0.0 112.387 -179.471 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -101.87 -60.21 0.77 Allowed Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 120.22 -0.991 . . . . 0.0 114.187 -179.278 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 9.1 m -77.57 129.66 35.93 Favored 'General case' 0 CA--C 1.557 1.248 0 CA-C-O 121.164 0.507 . . . . 0.0 112.201 -176.119 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 49.4 m -94.44 121.84 36.39 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.058 178.358 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.506 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 32.0 mt -88.9 111.89 22.64 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.105 0.478 . . . . 0.0 111.838 -175.352 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 43.6 t -85.57 -23.67 7.06 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 174.597 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 147.63 68.6 0.01 OUTLIER Glycine 0 CA--C 1.475 -2.42 0 N-CA-C 109.396 -1.481 . . . . 0.0 109.396 -177.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 28.2 m -85.22 172.08 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 CA-C-N 114.467 -0.867 . . . . 0.0 109.383 -177.094 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 24.6 p -71.7 157.2 38.36 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 120.93 0.395 . . . . 0.0 110.138 177.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -57.43 -39.4 76.13 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 123.345 0.658 . . . . 0.0 110.458 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 40.0 t -68.17 -37.8 81.38 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.01 179.742 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -66.44 -45.45 79.79 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -179.124 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.591 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.2 -44.02 97.95 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.505 178.426 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.98 -34.12 75.58 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 121.756 0.788 . . . . 0.0 110.599 177.756 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 39.3 m -79.31 -27.68 42.16 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 115.489 -0.778 . . . . 0.0 112.094 -178.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.591 HG12 ' O ' ' B' ' 76' ' ' ALA . 4.5 p -71.53 -31.97 44.43 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-O 121.906 0.86 . . . . 0.0 109.07 -175.711 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 53.9 mt -66.03 -29.44 69.8 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 114.528 -1.214 . . . . 0.0 110.553 176.425 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 71.4 mtt180 -90.74 -16.85 27.71 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.373 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -90.38 -14.65 32.58 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.038 0.447 . . . . 0.0 111.268 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.722 ' HB ' HG11 ' B' ' 87' ' ' VAL . 6.7 p -90.63 171.76 9.16 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 77.1 mttt -60.37 -178.7 0.09 Allowed 'General case' 0 C--O 1.245 0.817 0 C-N-CA 124.612 1.165 . . . . 0.0 114.077 -179.06 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.38 -52.06 46.98 Favored Glycine 0 N--CA 1.44 -1.049 0 CA-C-N 114.208 -1.36 . . . . 0.0 111.117 177.367 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 14.5 ttp180 -114.82 117.64 31.31 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 177.068 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.722 HG11 ' HB ' ' B' ' 83' ' ' THR . 14.0 m -132.13 157.57 43.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.353 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 15.9 mtm180 -108.5 152.64 24.45 Favored 'General case' 0 N--CA 1.422 -1.833 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 179.435 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.488 ' CE2' HD11 ' B' ' 54' ' ' ILE . 1.7 m-85 -133.5 164.99 25.91 Favored 'General case' 0 C--N 1.267 -3.004 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 179.555 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.457 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 84.3 mtp -112.82 117.43 32.14 Favored 'General case' 0 C--N 1.286 -2.195 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 170.571 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.511 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.5 mp -102.88 133.18 47.36 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.395 -177.11 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -113.6 93.86 0.68 Allowed Glycine 0 CA--C 1.463 -3.208 0 N-CA-C 108.18 -1.968 . . . . 0.0 108.18 172.401 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 93' ' ' ARG . . . . . 0.491 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 36.8 ttm180 -71.34 126.71 30.34 Favored 'General case' 0 C--N 1.273 -2.754 0 CA-C-N 114.244 -0.978 . . . . 0.0 111.152 -175.846 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -87.7 74.26 9.19 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 172.205 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 10.9 ttm180 -56.07 -59.36 11.97 Favored Pre-proline 0 C--O 1.239 0.532 0 CA-C-N 115.002 -0.999 . . . . 0.0 112.779 -178.798 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -60.21 111.95 1.16 Allowed 'Trans proline' 0 N--CA 1.424 -2.608 0 C-N-CA 121.4 1.4 . . . . 0.0 112.514 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -177.97 -59.35 0.07 OUTLIER Glycine 0 C--N 1.263 -3.506 1 N-CA-C 102.862 -4.095 . . . . 0.0 102.862 -176.48 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -94.15 85.9 4.81 Favored 'General case' 0 N--CA 1.428 -1.565 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 166.144 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 -157.16 -51.13 0.07 Allowed 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 102.678 -3.082 . . . . 0.0 102.678 -179.365 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 19.9 m -86.16 -179.09 6.66 Favored 'General case' 0 N--CA 1.427 -1.617 0 N-CA-C 103.847 -2.649 . . . . 0.0 103.847 161.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 54.4 73.45 0.4 Allowed 'General case' 0 N--CA 1.441 -0.92 0 CA-C-N 118.741 0.7 . . . . 0.0 109.649 -173.51 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 9.0 p -137.97 171.36 15.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 -175.096 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . 71.86 86.84 0.11 Allowed 'General case' 0 N--CA 1.442 -0.857 0 C-N-CA 125.298 1.439 . . . . 0.0 113.041 177.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 55.71 88.51 0.04 OUTLIER 'General case' 0 C--O 1.246 0.878 0 C-N-CA 124.851 1.26 . . . . 0.0 111.573 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . 0.273 36.0 mt -75.72 75.59 2.7 Favored 'General case' 0 CA--C 1.508 -0.656 0 N-CA-C 115.176 1.547 . . . . 0.0 115.176 -173.605 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 15.5 mm -150.81 -57.71 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.283 -2.318 0 N-CA-C 102.386 -3.19 . . . . 0.0 102.386 170.314 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 52.1 tt0 49.92 65.92 1.28 Allowed 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 113.13 -1.85 . . . . 0.0 112.252 175.215 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -92.53 -21.55 20.06 Favored 'General case' 0 C--N 1.312 -1.043 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 174.203 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 12.5 t -90.25 163.14 14.89 Favored 'General case' 0 N--CA 1.411 -2.403 0 N-CA-C 105.605 -1.998 . . . . 0.0 105.605 172.393 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 92.2 mt 68.12 -79.7 0.04 OUTLIER 'General case' 0 C--N 1.309 -1.193 0 C-N-CA 123.979 0.912 . . . . 0.0 111.591 -178.204 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 65.34 -49.34 0.37 Allowed 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 126.242 1.817 . . . . 0.0 111.858 -175.282 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 27.1 tp60 -123.59 101.03 7.09 Favored 'General case' 0 N--CA 1.418 -2.05 0 N-CA-C 108.309 -0.996 . . . . 0.0 108.309 176.411 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 . . . . . 0 C--N 1.292 -1.93 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 175.273 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.49 -1.484 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 25.6 t-80 -63.57 -44.6 93.61 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 174.46 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 20.2 ptp -102.07 142.04 33.96 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 172.237 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 4' ' ' GLU . . . . . 0.489 ' OE2' ' HG2' ' B' ' 93' ' ' ARG . 2.6 mt-10 -116.35 101.56 8.77 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -93.1 91.04 7.13 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 -179.125 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -117.67 146.52 38.9 Favored Pre-proline 0 C--N 1.29 -1.998 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.307 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -81.1 144.25 14.72 Favored 'Trans proline' 0 N--CA 1.449 -1.089 0 C-N-CA 122.5 2.133 . . . . 0.0 112.811 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.588 HG13 ' HB3' ' B' ' 53' ' ' ARG . 73.6 t -127.94 133.87 66.39 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.032 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.73 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -121.24 125.49 47.24 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 118.477 0.58 . . . . 0.0 110.173 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.449 ' CD1' ' H ' ' B' ' 54' ' ' ILE . 0.9 OUTLIER -148.82 175.95 10.81 Favored 'General case' 0 N--CA 1.438 -1.037 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -178.188 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -147.03 178.02 8.69 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.086 -178.622 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -93.02 153.85 18.48 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.248 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 13' ' ' ASP . . . . . 0.559 ' HB2' ' N ' ' B' ' 47' ' ' ALA . 10.8 t70 -103.17 -164.37 1.07 Allowed 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 22.8 p -55.43 -44.28 76.14 Favored 'General case' 0 C--O 1.243 0.756 0 C-N-CA 124.558 1.143 . . . . 0.0 111.57 -179.053 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -78.3 -48.72 15.06 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 177.78 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.08 -120.54 1.64 Allowed Glycine 0 N--CA 1.426 -2.006 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.831 178.171 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -89.23 101.4 14.06 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 121.397 0.618 . . . . 0.0 111.293 -178.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -92.12 59.84 2.7 Favored Glycine 0 C--O 1.21 -1.369 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 177.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.499 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.0 pt -155.46 178.92 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 C-N-CA 125.406 1.482 . . . . 0.0 107.128 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 20' ' ' SER . . . . . 0.472 ' HB2' HG22 ' B' ' 41' ' ' THR . 51.0 m -158.19 155.81 29.71 Favored 'General case' 0 C--N 1.27 -2.88 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 176.55 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.457 ' HB ' HG22 ' B' ' 37' ' ' ILE . 18.6 pt -115.71 161.12 14.69 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 O-C-N 123.445 0.466 . . . . 0.0 110.343 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 22' ' ' ILE . . . . . 0.429 ' HA ' ' NE2' ' B' ' 73' ' ' GLN . 8.1 tp -140.5 135.51 35.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.24 112.11 3.85 Favored Glycine 0 N--CA 1.428 -1.846 0 C-N-CA 120.494 -0.86 . . . . 0.0 111.982 -178.237 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 93.9 mmm -111.8 141.89 44.85 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 176.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.18 134.66 12.91 Favored Glycine 0 N--CA 1.423 -2.228 0 C-N-CA 119.599 -1.286 . . . . 0.0 111.624 -179.138 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -132.44 128.13 36.8 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 176.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -123.32 32.92 4.17 Favored Glycine 0 N--CA 1.427 -1.96 0 C-N-CA 119.338 -1.41 . . . . 0.0 113.955 -172.641 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.623 ' HB3' ' HB2' ' B' ' 33' ' ' GLU . . . -84.58 69.6 10.63 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 122.688 1.232 . . . . 0.0 108.546 177.457 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -74.63 -24.45 58.85 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 113.443 -1.708 . . . . 0.0 110.735 -174.18 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 23.2 ptp -63.62 -23.6 67.45 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 114.436 -1.256 . . . . 0.0 110.203 178.477 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -105.02 -73.45 0.91 Allowed Glycine 0 N--CA 1.416 -2.667 0 N-CA-C 110.106 -1.198 . . . . 0.0 110.106 177.29 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 32' ' ' LEU . . . . . 0.518 ' O ' ' HG ' ' B' ' 32' ' ' LEU . 18.7 tp 167.4 18.11 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 123.471 0.709 . . . . 0.0 110.647 -176.717 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 33' ' ' GLU . . . . . 0.623 ' HB2' ' HB3' ' B' ' 28' ' ' ALA . 16.4 mm-40 -100.98 82.98 2.45 Favored 'General case' 0 C--N 1.295 -1.764 0 O-C-N 120.84 -1.162 . . . . 0.0 108.328 -172.255 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? -82.15 -171.35 3.36 Favored 'General case' 0 C--N 1.278 -2.512 0 CA-C-N 112.991 -1.913 . . . . 0.0 110.235 175.854 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 35' ' ' LEU . . . . . 0.547 HD22 ' H ' ' B' ' 35' ' ' LEU . 3.0 mm? -35.7 119.37 0.54 Allowed 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 124.882 1.273 . . . . 0.0 113.164 -178.149 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -99.0 103.82 2.8 Favored Glycine 0 N--CA 1.414 -2.805 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.854 -176.326 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.457 HG22 ' HB ' ' B' ' 21' ' ' ILE . 30.2 mm -88.45 89.2 3.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.876 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.566 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.477 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 89.6 m-85 -82.3 173.45 12.06 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 114.674 -1.148 . . . . 0.0 109.981 -176.639 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.41 HG11 ' O ' ' B' ' 55' ' ' GLN . 59.3 t -83.42 137.09 21.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 175.873 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 32.2 ttmt -93.77 -48.87 6.11 Favored 'General case' 0 N--CA 1.433 -1.289 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.784 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 41' ' ' THR . . . . . 0.495 ' HA ' HG23 ' B' ' 56' ' ' VAL . 5.2 t -150.03 170.79 18.05 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.499 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.7 p -156.42 113.25 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 C-N-CA 124.587 1.155 . . . . 0.0 108.005 -177.774 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.415 HG22 ' H ' ' B' ' 45' ' ' GLY . 32.1 m -112.14 144.81 40.91 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 114.856 -1.066 . . . . 0.0 110.061 -171.199 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 44' ' ' GLU . . . . . 0.478 ' HA ' ' HB3' ' B' ' 49' ' ' HIS . 9.0 pt-20 -71.75 4.46 3.23 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -178.651 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 45' ' ' GLY . . . . . 0.415 ' H ' HG22 ' B' ' 43' ' ' THR . . . -74.79 -19.5 79.89 Favored Glycine 0 N--CA 1.436 -1.329 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 172.753 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -113.03 169.49 12.97 Favored Glycine 0 N--CA 1.413 -2.86 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 175.532 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 47' ' ' ALA . . . . . 0.559 ' N ' ' HB2' ' B' ' 13' ' ' ASP . . . -75.18 -23.94 57.78 Favored 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 115.096 -0.552 . . . . 0.0 111.274 -175.251 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 48' ' ' ALA . . . . . 0.446 ' HA ' ' CD1' ' B' ' 10' ' ' LEU . . . -56.46 -44.56 80.67 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -176.111 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 49' ' ' HIS . . . . . 0.479 ' HB2' HG22 ' B' ' 42' ' ' VAL . 10.3 t60 -73.49 -41.27 63.32 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.381 -179.059 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 81.5 mtp180 -72.42 -34.88 68.15 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.43 0.633 . . . . 0.0 110.945 -174.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 51' ' ' ASP . . . . . 0.502 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 30.4 t70 -72.42 -49.99 29.55 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.889 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.7 27.49 9.64 Favored Glycine 0 CA--C 1.494 -1.259 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.486 172.132 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.588 ' HB3' HG13 ' B' ' 8' ' ' VAL . 5.4 mpt_? -101.39 -60.17 1.57 Allowed 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 112.008 0.373 . . . . 0.0 112.008 -179.276 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.567 HD11 ' CE2' ' B' ' 89' ' ' PHE . 58.7 mt -72.79 134.82 29.04 Favored 'Isoleucine or valine' 0 C--O 1.251 1.157 0 N-CA-C 107.1 -1.445 . . . . 0.0 107.1 169.61 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 55' ' ' GLN . . . . . 0.41 ' O ' HG11 ' B' ' 39' ' ' VAL . 15.3 mm100 -110.19 -170.74 1.7 Allowed 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -174.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.495 HG23 ' HA ' ' B' ' 41' ' ' THR . 8.0 p -100.39 4.87 10.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 CA-C-O 121.567 0.698 . . . . 0.0 110.083 174.877 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 19.9 t-20 -133.28 10.98 4.16 Favored 'General case' 0 C--N 1.311 -1.104 0 O-C-N 121.623 -0.673 . . . . 0.0 111.965 -174.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -94.86 -173.64 3.04 Favored 'General case' 0 C--N 1.318 -0.804 0 O-C-N 121.308 -0.87 . . . . 0.0 111.381 179.127 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.477 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 25.8 tp -144.92 125.4 13.98 Favored 'General case' 0 C--N 1.318 -0.769 0 C-N-CA 123.194 0.598 . . . . 0.0 111.116 -172.568 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 60' ' ' LEU . . . . . 0.438 ' O ' HD12 ' B' ' 68' ' ' LEU . 68.9 mt -83.69 96.49 8.72 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.399 0.618 . . . . 0.0 109.369 178.799 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.571 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 9.2 t -79.28 -37.32 18.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-O 121.685 0.755 . . . . 0.0 111.133 178.826 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.401 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 10.4 pt-20 -157.02 153.51 28.09 Favored 'General case' 0 C--N 1.276 -2.608 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.506 176.032 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.464 HG22 ' H ' ' B' ' 64' ' ' ASP . 5.2 p -100.52 -174.63 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.42 -1.975 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 178.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.464 ' H ' HG22 ' B' ' 63' ' ' VAL . 28.1 t70 -53.18 -42.46 66.23 Favored 'General case' 0 C--N 1.311 -1.078 0 C-N-CA 124.138 0.975 . . . . 0.0 112.475 -178.214 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -106.91 -66.24 0.63 Allowed Glycine 0 N--CA 1.439 -1.161 0 C-N-CA 120.813 -0.708 . . . . 0.0 113.627 179.199 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 7.2 m -74.1 135.7 42.96 Favored 'General case' 0 CA--C 1.554 1.099 0 C-N-CA 122.882 0.473 . . . . 0.0 112.266 -175.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 15.9 m -96.31 126.49 41.55 Favored 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 177.116 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.571 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 28.9 mt -83.28 -69.86 0.6 Allowed 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 112.241 0.459 . . . . 0.0 112.241 -177.131 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 86.8 t 73.28 -27.2 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 124.189 0.995 . . . . 0.0 111.246 -175.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 70' ' ' GLY . . . . . 0.514 ' HA2' ' O ' ' B' ' 35' ' ' LEU . . . 153.16 81.39 0.03 OUTLIER Glycine 0 N--CA 1.42 -2.404 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -178.211 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.1 m -106.76 -179.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.71 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 39.9 p -78.63 156.51 29.03 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 175.213 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 73' ' ' GLN . . . . . 0.429 ' NE2' ' HA ' ' B' ' 22' ' ' ILE . 61.9 tt0 -58.4 -39.4 79.6 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.23 0.538 . . . . 0.0 110.637 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 14.9 m -66.82 -35.47 80.12 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.73 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -65.33 -49.36 69.71 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 179.049 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.553 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -59.51 -40.73 88.03 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.069 178.586 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.34 -32.65 73.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.331 0.586 . . . . 0.0 110.468 177.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.6 m -79.25 -28.44 42.43 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.454 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.553 HG12 ' O ' ' B' ' 76' ' ' ALA . 5.7 p -72.6 -36.31 53.23 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.889 0 C-N-CA 119.574 -0.851 . . . . 0.0 109.172 -176.559 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 26.3 mt -70.44 -7.14 40.97 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.848 178.225 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 68.5 mtp180 -108.66 -1.51 19.44 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 121.617 0.723 . . . . 0.0 110.102 177.438 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 32.2 m-80 -115.06 6.41 15.2 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.067 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.53 HG23 ' O ' ' B' ' 79' ' ' VAL . 7.7 p -87.2 175.81 7.87 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.323 -178.825 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 28.8 mmtm -75.64 -169.18 0.99 Allowed 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.472 0.709 . . . . 0.0 109.733 174.357 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.17 -38.97 45.93 Favored Glycine 0 N--CA 1.444 -0.827 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 177.784 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -124.31 131.56 53.52 Favored 'General case' 0 N--CA 1.431 -1.397 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.51 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.516 HG11 ' HB ' ' B' ' 83' ' ' THR . 11.2 m -142.08 153.01 18.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 CA-C-O 121.53 0.681 . . . . 0.0 111.445 -179.584 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 -96.05 164.07 12.86 Favored 'General case' 0 C--N 1.291 -1.975 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 174.05 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.567 ' CE2' HD11 ' B' ' 54' ' ' ILE . 8.9 m-85 -145.28 157.33 44.08 Favored 'General case' 0 C--N 1.284 -2.261 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 177.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.505 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 81.0 mtp -112.38 120.15 40.69 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 169.694 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.464 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -98.58 119.04 46.06 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.164 0 CA-C-N 114.246 -1.343 . . . . 0.0 109.485 -175.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -96.93 93.3 1.45 Allowed Glycine 0 CA--C 1.457 -3.57 0 N-CA-C 106.96 -2.456 . . . . 0.0 106.96 172.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 93' ' ' ARG . . . . . 0.489 ' HG2' ' OE2' ' B' ' 4' ' ' GLU . 5.9 tpt180 -62.81 107.84 1.06 Allowed 'General case' 0 C--N 1.257 -3.429 0 CA-C-N 112.932 -1.634 . . . . 0.0 113.129 -174.278 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -79.41 94.34 5.52 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 104.642 -2.355 . . . . 0.0 104.642 165.75 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 95' ' ' ARG . . . . . 0.577 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 49.4 ttt180 -88.85 -55.87 0.3 Allowed Pre-proline 0 N--CA 1.398 -3.074 0 CA-C-N 113.098 -1.865 . . . . 0.0 108.827 173.227 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 96' ' ' PRO . . . . . 0.577 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 84.9 Cg_endo -88.81 108.56 0.49 Allowed 'Trans proline' 0 N--CA 1.426 -2.49 0 CA-C-O 123.448 1.353 . . . . 0.0 114.927 174.256 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -113.44 -11.46 13.24 Favored Glycine 1 C--N 1.251 -4.163 0 CA-C-N 112.467 -2.152 . . . . 0.0 108.255 174.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -89.45 11.03 20.5 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.482 -1.359 . . . . 0.0 109.466 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 52.3 mt-30 -126.82 135.21 50.71 Favored 'General case' 0 N--CA 1.402 -2.847 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 175.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 11.0 m -79.57 175.51 10.55 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 123.869 0.731 . . . . 0.0 111.995 -175.443 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -85.39 69.6 10.72 Favored 'General case' 0 N--CA 1.442 -0.862 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 -178.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -134.99 133.03 53.67 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.196 0 CA-C-N 114.185 -1.371 . . . . 0.0 112.461 179.076 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -141.92 -65.83 0.41 Allowed 'General case' 0 C--N 1.294 -1.836 0 CA-C-N 114.47 -1.241 . . . . 0.0 108.038 175.15 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 61.6 tp60 -162.82 120.73 2.03 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.601 175.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -109.35 138.15 46.13 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 116.326 -0.397 . . . . 0.0 109.959 -179.165 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 31.5 mm -78.47 -56.39 7.55 Favored 'Isoleucine or valine' 0 C--O 1.246 0.875 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 176.283 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -67.11 109.34 2.99 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 170.288 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 15.7 tp60 167.5 -23.27 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 127.605 2.362 . . . . 0.0 105.091 -165.588 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 109' ' ' THR . . . . . 0.473 HG23 ' HG2' ' B' ' 111' ' ' GLU . 8.9 t -69.55 -12.43 61.64 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 113.043 -1.89 . . . . 0.0 111.531 178.428 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 49.6 mt 73.7 33.07 1.07 Allowed 'General case' 0 C--N 1.342 0.242 0 C-N-CA 123.926 0.89 . . . . 0.0 112.33 173.337 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 111' ' ' GLU . . . . . 0.473 ' HG2' HG23 ' B' ' 109' ' ' THR . 5.6 mm-40 -80.41 -12.2 59.6 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 121.99 0.9 . . . . 0.0 108.975 174.435 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 9.9 pt20 -176.85 -35.86 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 127.19 2.196 . . . . 0.0 105.504 178.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 . . . . . 0 N--CA 1.407 -2.591 0 N-CA-C 105.636 -1.986 . . . . 0.0 105.636 175.289 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.84 0 N-CA-C 111.671 -0.571 . . . . 0.0 111.671 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 84.2 m-70 -154.19 -162.84 1.49 Allowed 'General case' 0 C--O 1.243 0.721 0 N-CA-C 105.871 -1.9 . . . . 0.0 105.871 -178.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -68.15 129.5 40.12 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 104.704 -2.332 . . . . 0.0 104.704 164.818 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 4' ' ' GLU . . . . . 0.57 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 18.4 mt-10 -87.72 101.08 13.33 Favored 'General case' 0 C--N 1.293 -1.871 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.263 -171.128 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -85.62 85.73 7.4 Favored 'General case' 0 N--CA 1.428 -1.531 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 176.101 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -109.43 142.43 25.66 Favored Pre-proline 0 C--N 1.295 -1.801 0 C-N-CA 120.461 -0.496 . . . . 0.0 112.229 -178.026 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 7' ' ' PRO . . . . . 0.422 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 42.0 Cg_endo -80.34 126.4 6.17 Favored 'Trans proline' 0 N--CA 1.428 -2.371 0 C-N-CA 121.943 1.762 . . . . 0.0 112.541 177.105 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 95.2 t -107.08 151.94 8.78 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.82 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 175.685 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 9' ' ' GLU . . . . . 0.464 ' O ' ' HG2' ' B' ' 53' ' ' ARG . 45.0 tt0 -138.12 136.16 36.46 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 119.005 0.82 . . . . 0.0 109.696 -176.085 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.523 HD21 ' HA ' ' B' ' 48' ' ' ALA . 4.5 mt -139.34 165.31 27.54 Favored 'General case' 0 CA--C 1.475 -1.906 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 179.625 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -151.12 146.68 26.31 Favored 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 104.503 -2.406 . . . . 0.0 104.503 177.348 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.5 ptpt -88.41 171.33 10.2 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.883 0.849 . . . . 0.0 112.177 -174.184 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 13' ' ' ASP . . . . . 0.412 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 19.5 t70 -99.92 176.61 5.37 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.804 -1.089 . . . . 0.0 108.214 176.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 7.0 m -59.66 -33.12 71.14 Favored 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 123.939 0.895 . . . . 0.0 109.261 175.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -77.15 -45.63 26.11 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 174.694 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.25 -138.36 7.65 Favored Glycine 0 N--CA 1.435 -1.406 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.273 179.255 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 91.8 mt -82.03 -176.24 6.04 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 123.033 0.533 . . . . 0.0 110.99 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 18' ' ' GLY . . . . . 0.418 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -158.13 66.06 0.29 Allowed Glycine 0 CA--C 1.487 -1.665 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.614 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 pt -166.73 175.91 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.49 -1.361 0 C-N-CA 124.815 1.246 . . . . 0.0 108.408 -177.55 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 20' ' ' SER . . . . . 0.406 ' HB2' HG22 ' B' ' 41' ' ' THR . 29.2 m -148.53 144.17 27.14 Favored 'General case' 0 C--N 1.27 -2.859 0 N-CA-C 105.784 -1.932 . . . . 0.0 105.784 174.011 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.497 ' HB ' HG22 ' B' ' 37' ' ' ILE . 11.0 pt -115.09 158.13 15.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 CA-C-N 117.866 0.303 . . . . 0.0 110.395 -177.764 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 10.3 tp -139.32 140.75 37.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-O 120.636 0.255 . . . . 0.0 110.415 -176.658 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -91.24 109.53 3.72 Favored Glycine 0 N--CA 1.435 -1.398 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.687 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 66.2 mtt -122.7 114.92 21.22 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 177.084 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 162.15 -157.38 29.21 Favored Glycine 0 C--N 1.284 -2.359 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 -177.194 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -144.48 107.7 4.56 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 177.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.73 53.44 4.71 Favored Glycine 0 CA--C 1.488 -1.63 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.569 -177.533 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -160.57 86.71 0.74 Allowed 'General case' 0 N--CA 1.408 -2.537 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 177.563 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -129.0 21.5 5.81 Favored 'General case' 0 C--N 1.277 -2.573 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -177.162 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . 0.318 20.7 ptm 42.53 58.88 2.94 Favored 'General case' 0 CA--C 1.506 -0.735 0 CA-C-N 112.982 -1.917 . . . . 0.0 113.241 -174.156 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 146.91 -66.6 0.41 Allowed Glycine 0 N--CA 1.431 -1.656 0 CA-C-N 114.024 -1.444 . . . . 0.0 111.906 177.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 86.9 mt -71.17 -34.31 70.82 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 111.871 0.323 . . . . 0.0 111.871 -177.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 46.93 53.41 10.5 Favored 'General case' 0 C--N 1.349 0.578 0 C-N-CA 124.669 1.188 . . . . 0.0 108.661 -176.145 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 14.1 ptmm? -77.75 105.7 9.09 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 115.515 1.672 . . . . 0.0 115.515 -166.723 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 70.1 mt -108.78 129.34 55.38 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 114.504 -1.225 . . . . 0.0 108.583 172.179 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -96.85 109.97 3.95 Favored Glycine 0 N--CA 1.419 -2.46 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.296 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.497 HG22 ' HB ' ' B' ' 21' ' ' ILE . 28.4 mm -89.09 92.04 3.85 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -85.68 169.01 13.87 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.106 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.436 HG21 HG23 ' B' ' 54' ' ' ILE . 59.5 t -82.77 136.57 22.6 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.496 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 174.685 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 31.1 ttpt -96.57 -35.9 10.92 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.085 0.469 . . . . 0.0 110.088 -176.459 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 41' ' ' THR . . . . . 0.406 HG22 ' HB2' ' B' ' 20' ' ' SER . 2.8 t -161.27 165.28 29.44 Favored 'General case' 0 C--O 1.251 1.182 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.871 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 20.4 t -126.8 93.24 2.21 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.025 0 N-CA-C 106.843 -1.539 . . . . 0.0 106.843 177.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 20.8 m -60.91 123.32 17.24 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 115.207 -0.906 . . . . 0.0 111.282 -177.257 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 44' ' ' GLU . . . . . 0.435 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 12.7 pt-20 -70.43 -23.77 62.79 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-N 115.804 -0.634 . . . . 0.0 112.478 -174.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.32 -11.77 82.11 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 121.075 -0.584 . . . . 0.0 112.729 179.379 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.418 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -110.29 172.82 15.89 Favored Glycine 0 N--CA 1.413 -2.847 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.007 -178.36 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 47' ' ' ALA . . . . . 0.412 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -61.34 -35.7 78.15 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 114.998 1.481 . . . . 0.0 114.998 -172.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 48' ' ' ALA . . . . . 0.523 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -61.37 -42.17 98.27 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -172.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 49' ' ' HIS . . . . . 0.435 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 5.0 t60 -71.22 -40.85 70.87 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 122.143 0.973 . . . . 0.0 108.864 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 71.1 mtp180 -69.05 -29.65 67.83 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.34 -177.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 51' ' ' ASP . . . . . 0.64 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 11.9 t70 -82.0 -45.44 15.32 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.61 35.28 6.57 Favored Glycine 0 CA--C 1.494 -1.263 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.637 173.529 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.64 ' HD3' ' OD2' ' B' ' 51' ' ' ASP . 5.3 mpt_? -107.82 -74.77 0.65 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.288 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.436 HG23 HG21 ' B' ' 39' ' ' VAL . 27.9 mt -68.52 118.43 12.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 C-N-CA 120.051 -0.659 . . . . 0.0 110.033 177.187 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 80.0 mm-40 -104.25 -179.48 3.96 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.1 p -80.82 2.02 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.173 0 CA-C-O 122.253 1.025 . . . . 0.0 111.099 -175.541 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 25.3 t-20 -110.76 1.29 17.72 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 122.138 0.971 . . . . 0.0 109.496 -177.426 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -78.93 155.01 29.2 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.233 -177.694 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 26.7 tp -139.3 126.68 21.51 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.735 -176.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 68.6 mt -79.3 91.47 5.03 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.258 0.551 . . . . 0.0 109.836 179.186 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.616 ' HB ' ' O ' ' B' ' 90' ' ' MET . 24.1 t -82.64 -39.28 15.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.997 0 CA-C-O 122.001 0.905 . . . . 0.0 110.053 177.272 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.426 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 10.9 pt-20 -162.2 157.27 22.83 Favored 'General case' 0 C--N 1.28 -2.42 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.411 172.532 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.621 HG12 ' HB ' ' B' ' 66' ' ' THR . 3.7 p -94.11 -177.86 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 N-CA-C 105.638 -1.986 . . . . 0.0 105.638 178.104 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.584 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.2 t70 -44.54 -48.64 10.24 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 124.721 1.208 . . . . 0.0 112.975 -177.532 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -140.56 45.5 0.98 Allowed Glycine 0 CA--C 1.525 0.702 0 C-N-CA 119.991 -1.099 . . . . 0.0 113.847 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 66' ' ' THR . . . . . 0.621 ' HB ' HG12 ' B' ' 63' ' ' VAL . 45.5 m -158.42 119.51 3.42 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 177.375 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 67' ' ' SER . . . . . 0.419 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 45.8 m -85.48 133.18 34.1 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -175.788 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.521 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 23.9 mt -99.67 138.44 36.75 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.665 174.751 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -116.92 -26.77 2.63 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 CA-C-O 122.132 0.968 . . . . 0.0 109.146 173.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 160.45 87.75 0.06 OUTLIER Glycine 0 N--CA 1.399 -3.83 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 -176.629 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 m -111.58 173.17 2.54 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.667 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 41.7 p -75.21 160.2 30.68 Favored 'General case' 0 C--N 1.289 -2.039 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -59.57 -35.27 73.94 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 177.326 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 12.6 m -69.73 -41.03 75.82 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.632 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -63.54 -45.67 89.51 Favored 'General case' 0 CA--C 1.514 -0.429 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.139 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.538 ' O ' ' HG ' ' B' ' 80' ' ' LEU . . . -58.46 -46.26 86.95 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.487 178.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.39 -34.93 74.62 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.593 0.711 . . . . 0.0 110.736 178.067 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 45.5 m -80.37 -21.47 42.32 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 113.043 0.756 . . . . 0.0 113.043 -177.452 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.52 HG12 ' O ' ' B' ' 76' ' ' ALA . 8.4 p -78.52 -31.58 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.484 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 80' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 63.4 mt -69.39 -13.54 62.42 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.656 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -107.88 -0.64 21.37 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.503 0.668 . . . . 0.0 110.898 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -99.0 -23.74 15.18 Favored 'General case' 0 C--O 1.248 0.981 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.021 178.621 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.646 ' HB ' HG11 ' B' ' 87' ' ' VAL . 2.1 p -68.47 169.42 10.88 Favored 'General case' 0 N--CA 1.422 -1.841 0 CA-C-N 114.517 -1.22 . . . . 0.0 114.01 -176.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 41.0 mmtm -70.58 -170.78 0.43 Allowed 'General case' 0 N--CA 1.437 -1.099 0 CA-C-N 115.132 -0.94 . . . . 0.0 112.488 178.554 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.38 -35.33 90.83 Favored Glycine 0 C--O 1.217 -0.946 0 CA-C-N 114.776 -1.102 . . . . 0.0 114.275 -176.008 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 34.3 ttp180 -143.0 125.04 15.26 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.619 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.646 HG11 ' HB ' ' B' ' 83' ' ' THR . 14.0 m -133.11 154.71 39.98 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.746 0 CA-C-O 121.804 0.812 . . . . 0.0 112.559 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 87.4 mtm180 -94.5 170.6 9.36 Favored 'General case' 0 N--CA 1.41 -2.429 0 CA-C-N 113.681 -1.6 . . . . 0.0 108.489 173.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.459 ' HB2' ' CD1' ' B' ' 91' ' ' ILE . 6.2 m-85 -145.55 149.11 34.0 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 175.486 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.616 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 1.1 mpt? -103.68 108.58 19.93 Favored 'General case' 0 C--N 1.276 -2.626 0 CA-C-O 121.604 0.716 . . . . 0.0 109.567 176.112 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.459 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.4 mp -98.84 110.92 27.18 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 114.329 -1.305 . . . . 0.0 107.95 -179.086 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 92' ' ' GLY . . . . . 0.57 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -104.15 103.71 2.33 Favored Glycine 0 CA--C 1.458 -3.514 0 N-CA-C 107.987 -2.045 . . . . 0.0 107.987 173.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 93' ' ' ARG . . . . . 0.416 ' HD2' ' OE1' ' B' ' 4' ' ' GLU . 1.9 ptp180 -84.39 150.02 25.62 Favored 'General case' 0 C--N 1.281 -2.37 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.232 -175.7 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -82.29 73.57 9.32 Favored 'General case' 0 N--CA 1.411 -2.408 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 175.397 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 95' ' ' ARG . . . . . 0.491 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 27.2 ttt180 -65.91 -57.52 13.49 Favored Pre-proline 0 N--CA 1.426 -1.63 0 CA-C-N 114.283 -1.326 . . . . 0.0 109.141 174.121 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 96' ' ' PRO . . . . . 0.491 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 69.6 Cg_endo -89.3 148.63 5.39 Favored 'Trans proline' 0 N--CA 1.441 -1.616 0 C-N-CA 121.513 1.475 . . . . 0.0 111.199 172.195 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 163.72 -31.63 0.27 Allowed Glycine 0 C--N 1.294 -1.76 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.265 -179.477 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -95.43 3.2 54.52 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.158 0.504 . . . . 0.0 109.761 179.347 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 7.3 tp60 64.97 115.17 0.03 OUTLIER 'General case' 0 N--CA 1.444 -0.744 0 C-N-CA 126.238 1.815 . . . . 0.0 113.678 179.075 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 22.6 m -127.41 -162.85 1.2 Allowed 'General case' 0 C--N 1.281 -2.412 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 177.155 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -74.32 -15.24 60.96 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.865 0.841 . . . . 0.0 111.482 178.308 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 15.0 m -77.27 78.99 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.29 -2.008 0 CA-C-O 123.052 1.406 . . . . 0.0 111.034 174.476 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -127.62 -53.83 1.34 Allowed 'General case' 0 C--N 1.29 -2.015 0 CA-C-N 112.947 -1.933 . . . . 0.0 106.912 178.327 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 52.1 tt0 -88.9 97.72 11.34 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 172.03 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 68.5 mt -84.64 113.89 21.61 Favored 'General case' 0 C--N 1.295 -1.789 0 CA-C-N 115.131 -0.941 . . . . 0.0 111.435 -172.019 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 44.7 mm -66.06 -68.86 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 174.537 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 56.9 tp60 66.71 -28.61 0.13 Allowed 'General case' 0 CA--C 1.551 1.019 0 N-CA-C 115.743 1.757 . . . . 0.0 115.743 170.274 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 84.1 mm-40 73.96 75.42 0.12 Allowed 'General case' 0 CA--C 1.493 -1.225 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 -170.6 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 12.9 t -77.62 65.65 3.17 Favored 'General case' 0 N--CA 1.436 -1.14 0 CA-C-O 123.509 1.623 . . . . 0.0 110.298 -174.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 58.5 mt -111.64 -39.63 4.55 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 114.131 -1.395 . . . . 0.0 108.999 -177.529 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 52.31 73.59 0.33 Allowed 'General case' 0 C--O 1.24 0.596 0 O-C-N 124.355 1.035 . . . . 0.0 110.769 179.561 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -91.04 -24.39 20.07 Favored 'General case' 0 C--N 1.298 -1.671 0 CA-C-N 114.631 -1.168 . . . . 0.0 108.845 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 . . . . . 0 N--CA 1.424 -1.729 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 179.649 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.489 -1.571 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 17.5 t-80 -78.42 -60.69 2.27 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 178.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -103.3 115.67 31.0 Favored 'General case' 0 C--N 1.281 -2.412 0 N-CA-C 105.5 -2.037 . . . . 0.0 105.5 168.109 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -91.34 92.86 8.78 Favored 'General case' 0 C--N 1.281 -2.4 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -174.907 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -88.56 86.04 6.94 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -107.49 140.93 22.01 Favored Pre-proline 0 C--N 1.297 -1.714 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.531 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -80.51 134.84 10.17 Favored 'Trans proline' 0 N--CA 1.432 -2.146 0 C-N-CA 122.086 1.857 . . . . 0.0 112.672 178.828 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.668 HG13 ' HB3' ' B' ' 53' ' ' ARG . 25.5 t -115.67 114.93 47.71 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.283 0 CA-C-N 114.374 -1.284 . . . . 0.0 108.554 176.121 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -105.59 105.84 16.06 Favored 'General case' 0 C--N 1.276 -2.611 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -178.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.514 HD23 ' H ' ' B' ' 11' ' ' GLU . 0.9 OUTLIER -123.72 153.85 40.3 Favored 'General case' 0 N--CA 1.418 -2.073 0 CA-C-O 121.685 0.755 . . . . 0.0 111.692 178.995 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.514 ' H ' HD23 ' B' ' 10' ' ' LEU . 40.7 tt0 -122.23 143.16 49.76 Favored 'General case' 0 C--N 1.276 -2.588 0 CA-C-N 114.245 -1.343 . . . . 0.0 108.083 -173.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 12' ' ' LYS . . . . . 0.421 ' HG2' HD21 ' B' ' 17' ' ' LEU . 45.5 mtmt -75.98 158.63 31.73 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 122.002 0.906 . . . . 0.0 112.276 -176.739 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 13' ' ' ASP . . . . . 0.568 ' HB2' ' H ' ' B' ' 16' ' ' GLY . 11.1 m-20 -83.52 177.13 8.57 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 113.717 -1.583 . . . . 0.0 107.963 173.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.9 m -73.46 -25.37 60.46 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 171.542 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -82.06 -30.85 31.13 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.7 -1.136 . . . . 0.0 109.779 177.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.568 ' H ' ' HB2' ' B' ' 13' ' ' ASP . . . 134.34 -108.44 0.72 Allowed Glycine 0 N--CA 1.432 -1.6 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.122 179.117 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.421 HD21 ' HG2' ' B' ' 12' ' ' LYS . 84.7 mt -132.8 115.72 15.65 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 121.073 0.464 . . . . 0.0 111.481 -175.276 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 18' ' ' GLY . . . . . 0.537 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -86.96 60.99 4.39 Favored Glycine 0 C--O 1.213 -1.168 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 178.567 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.534 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 5.7 pt -151.73 174.04 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 C-N-CA 125.137 1.375 . . . . 0.0 109.021 179.169 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 20' ' ' SER . . . . . 0.407 ' HB2' HG22 ' B' ' 41' ' ' THR . 62.8 m -151.92 156.96 41.13 Favored 'General case' 0 C--N 1.271 -2.817 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 175.496 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.429 ' HB ' HG22 ' B' ' 37' ' ' ILE . 12.0 pt -124.33 161.24 27.71 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.129 0 O-C-N 123.437 0.461 . . . . 0.0 110.737 -177.761 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -143.11 133.55 22.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.6 119.0 6.36 Favored Glycine 0 N--CA 1.435 -1.388 0 C-N-CA 120.629 -0.796 . . . . 0.0 113.162 -177.595 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 68.9 mtm -134.05 156.72 47.73 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 177.424 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 132.08 -148.99 19.3 Favored Glycine 0 C--N 1.306 -1.13 0 C-N-CA 120.244 -0.979 . . . . 0.0 111.222 -178.203 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -128.02 99.96 5.7 Favored 'General case' 0 C--O 1.245 0.817 0 CA-C-O 121.242 0.544 . . . . 0.0 110.458 178.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.04 57.64 5.03 Favored Glycine 0 N--CA 1.45 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 112.15 -177.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.16 107.47 17.89 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 179.556 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -72.45 -6.29 42.64 Favored 'General case' 0 N--CA 1.48 1.056 0 C-N-CA 124.584 1.153 . . . . 0.0 112.127 -172.538 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 27.0 ptm -73.57 30.59 0.07 Allowed 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 125.42 1.488 . . . . 0.0 112.006 -178.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.66 18.22 49.07 Favored Glycine 0 C--N 1.294 -1.771 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.673 177.158 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 83.4 mt -108.3 -67.92 0.94 Allowed 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 49.61 34.56 7.27 Favored 'General case' 0 C--O 1.216 -0.683 0 C-N-CA 125.131 1.372 . . . . 0.0 113.216 176.263 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -88.54 78.2 7.87 Favored 'General case' 0 N--CA 1.426 -1.668 0 CA-C-O 122.815 1.293 . . . . 0.0 110.792 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 18.8 tp -107.59 172.67 6.7 Favored 'General case' 0 C--N 1.286 -2.194 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 178.124 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -142.44 117.72 1.18 Allowed Glycine 0 C--N 1.27 -3.128 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.351 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.429 HG22 ' HB ' ' B' ' 21' ' ' ILE . 28.9 mm -96.72 88.76 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 178.015 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.415 ' HA ' ' HA ' ' B' ' 59' ' ' LEU . 94.5 m-85 -81.83 168.76 17.64 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 114.386 -1.279 . . . . 0.0 109.225 -176.584 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.8 t -79.31 139.52 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.376 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.551 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 22.8 ttpp -101.12 -44.44 5.7 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.083 0.468 . . . . 0.0 109.829 -178.086 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 41' ' ' THR . . . . . 0.407 HG22 ' HB2' ' B' ' 20' ' ' SER . 0.6 OUTLIER -154.62 162.13 41.27 Favored 'General case' 0 N--CA 1.432 -1.351 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 -176.781 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.534 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.2 p -144.06 97.79 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 CA-C-O 122.408 1.099 . . . . 0.0 109.356 176.63 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 23.9 m -62.65 126.59 27.84 Favored 'General case' 0 N--CA 1.431 -1.417 0 CA-C-N 113.262 -1.79 . . . . 0.0 112.256 -174.713 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 44' ' ' GLU . . . . . 0.572 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 1.8 mp0 -55.57 -36.91 67.37 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.693 1.597 . . . . 0.0 110.775 -178.052 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.97 -0.48 56.12 Favored Glycine 0 N--CA 1.438 -1.173 0 CA-C-N 115.437 -0.802 . . . . 0.0 113.877 -179.191 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.537 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -112.56 162.01 12.52 Favored Glycine 0 N--CA 1.417 -2.605 0 C-N-CA 120.121 -1.037 . . . . 0.0 113.093 179.211 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 47' ' ' ALA . . . . . 0.406 ' H ' ' CG ' ' B' ' 13' ' ' ASP . . . -57.45 -36.36 71.3 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 125.688 1.595 . . . . 0.0 112.06 -175.026 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -63.01 -34.54 77.77 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 49' ' ' HIS . . . . . 0.572 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 6.4 t60 -82.14 -39.12 23.73 Favored 'General case' 0 C--O 1.24 0.575 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.473 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 59.5 mtp180 -61.94 -39.56 92.49 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.137 179.277 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -74.68 -69.65 0.45 Allowed 'General case' 0 C--N 1.309 -1.174 0 C-N-CA 124.11 0.964 . . . . 0.0 109.382 175.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 110.99 -2.08 28.57 Favored Glycine 0 N--CA 1.436 -1.346 0 C-N-CA 120.21 -0.995 . . . . 0.0 114.565 177.363 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.668 ' HB3' HG13 ' B' ' 8' ' ' VAL . 39.5 mmt180 -72.24 -50.9 23.77 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 118.503 1.151 . . . . 0.0 113.054 177.293 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.509 HD11 ' CE2' ' B' ' 89' ' ' PHE . 54.6 mt -72.97 123.02 26.92 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 C-N-CA 119.034 -1.066 . . . . 0.0 108.891 173.141 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -116.47 146.96 42.18 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -178.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 13.2 p -56.54 -23.45 17.01 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.067 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -168.605 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -109.3 -3.53 17.1 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 120.875 -1.141 . . . . 0.0 111.469 -174.785 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -87.49 179.15 6.61 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 113.693 0.998 . . . . 0.0 113.693 -174.649 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.439 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 24.6 tp -124.46 126.08 45.31 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.372 -172.239 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 82.0 mt -83.7 104.31 13.71 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 106.063 -1.829 . . . . 0.0 106.063 173.569 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.735 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 0.5 OUTLIER -91.09 -27.65 4.92 Favored 'Isoleucine or valine' 0 C--O 1.198 -1.627 0 C-N-CA 119.667 -0.813 . . . . 0.0 110.117 -174.625 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.585 ' HB2' ' HA ' ' B' ' 67' ' ' SER . 13.2 pt-20 -158.35 166.11 33.08 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-N 114.725 -1.125 . . . . 0.0 111.389 176.122 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.515 HG22 ' H ' ' B' ' 64' ' ' ASP . 6.4 p -105.57 -174.39 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.023 0 N-CA-C 106.549 -1.649 . . . . 0.0 106.549 178.239 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.515 ' H ' HG22 ' B' ' 63' ' ' VAL . 18.9 t70 -56.55 -39.44 73.44 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 123.272 0.629 . . . . 0.0 112.479 -177.037 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -107.55 -65.29 0.6 Allowed Glycine 0 C--N 1.309 -0.945 0 C-N-CA 120.581 -0.818 . . . . 0.0 113.511 179.444 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 7.0 m -69.5 115.44 8.76 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 122.882 0.473 . . . . 0.0 112.059 -177.036 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 67' ' ' SER . . . . . 0.585 ' HA ' ' HB2' ' B' ' 62' ' ' GLU . 48.6 m -87.36 114.93 24.42 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 174.749 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.735 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 75.5 mt -85.46 140.48 30.67 Favored 'General case' 0 N--CA 1.435 -1.176 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.402 -177.606 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 p -100.09 -18.72 6.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 144.63 70.84 0.02 OUTLIER Glycine 0 N--CA 1.426 -1.985 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 -176.345 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.419 HG11 HD22 ' B' ' 68' ' ' LEU . 35.3 m -83.76 173.66 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 CA-C-N 114.478 -0.861 . . . . 0.0 110.021 -178.254 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 37.7 p -71.93 160.29 32.79 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 177.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.5 tt0 -61.14 -37.1 81.65 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.35 0.595 . . . . 0.0 110.437 -178.024 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.7 m -73.18 -30.27 63.43 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.664 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 51.1 t80 -71.6 -41.79 68.49 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.507 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.601 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -64.46 -40.98 96.75 Favored 'General case' 0 N--CA 1.435 -1.182 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.828 177.768 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.01 -41.91 93.18 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.049 0.452 . . . . 0.0 110.829 177.803 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.1 p -76.75 -23.24 52.98 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 112.957 0.725 . . . . 0.0 112.957 -178.109 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.601 HG12 ' O ' ' B' ' 76' ' ' ALA . 6.7 p -72.47 -35.12 50.49 Favored 'Isoleucine or valine' 0 C--N 1.345 0.4 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -177.595 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 80' ' ' LEU . . . . . 0.493 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 51.2 mt -68.35 -18.39 64.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 114.551 -1.204 . . . . 0.0 110.349 178.186 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -97.14 -9.95 26.89 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.534 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -96.35 -21.29 17.89 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-O 121.248 0.547 . . . . 0.0 110.203 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.537 ' HB ' HG11 ' B' ' 87' ' ' VAL . 17.9 p -80.67 174.27 11.78 Favored 'General case' 0 N--CA 1.425 -1.686 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.915 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 38.1 mttp -70.27 -168.03 0.2 Allowed 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.799 0.809 . . . . 0.0 112.393 178.706 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -72.62 -30.62 63.87 Favored Glycine 0 N--CA 1.437 -1.293 0 CA-C-N 114.932 -1.031 . . . . 0.0 111.989 178.661 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 50.4 ttp180 -135.16 123.37 23.0 Favored 'General case' 0 C--N 1.31 -1.129 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.537 HG11 ' HB ' ' B' ' 83' ' ' THR . 3.3 m -137.44 160.01 35.1 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.131 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 88' ' ' ARG . . . . . 0.446 ' H ' ' HB2' ' B' ' 64' ' ' ASP . 81.3 mtm180 -107.82 110.99 22.91 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.635 -179.323 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.509 ' CE2' HD11 ' B' ' 54' ' ' ILE . 3.4 m-85 -92.29 156.18 17.44 Favored 'General case' 0 C--N 1.275 -2.664 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 179.802 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.436 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 57.1 mtt -108.46 121.73 45.57 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.435 172.304 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.461 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.4 mp -99.64 117.5 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.405 -2.682 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 179.507 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -105.45 104.04 2.25 Favored Glycine 0 CA--C 1.458 -3.505 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 178.828 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 13.8 tpp180 -96.62 99.06 10.7 Favored 'General case' 0 C--N 1.268 -2.977 0 CA-C-N 114.142 -1.029 . . . . 0.0 109.071 178.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -81.91 84.3 6.96 Favored 'General case' 0 C--N 1.287 -2.121 0 N-CA-C 104.842 -2.281 . . . . 0.0 104.842 171.662 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 95' ' ' ARG . . . . . 0.438 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 14.0 ttm180 -54.08 -60.98 6.08 Favored Pre-proline 0 N--CA 1.442 -0.851 0 CA-C-N 114.032 -1.44 . . . . 0.0 111.536 -175.127 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 96' ' ' PRO . . . . . 0.438 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 71.9 Cg_endo -80.29 149.04 19.18 Favored 'Trans proline' 0 N--CA 1.443 -1.483 0 C-N-CA 121.236 1.291 . . . . 0.0 110.092 172.051 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -136.58 59.83 0.63 Allowed Glycine 0 C--N 1.297 -1.624 0 C-N-CA 119.624 -1.274 . . . . 0.0 113.339 -174.616 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 39.2 61.04 1.38 Allowed 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 125.237 1.415 . . . . 0.0 113.374 -178.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -138.39 30.07 2.41 Favored 'General case' 0 N--CA 1.425 -1.698 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 -176.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 57.9 p -101.08 166.74 10.65 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 114.478 -1.237 . . . . 0.0 110.38 -179.273 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -107.84 2.31 23.41 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.916 0.865 . . . . 0.0 109.937 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 31.1 m -85.77 93.84 3.91 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-O 122.35 1.071 . . . . 0.0 111.725 -178.361 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -154.45 127.46 8.28 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 176.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 98.3 mt-30 59.43 84.47 0.11 Allowed 'General case' 0 C--O 1.239 0.514 0 O-C-N 124.318 1.011 . . . . 0.0 111.401 -178.038 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 75.0 mt -139.66 179.78 6.37 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 -177.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 35.7 mm -88.2 -72.81 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 173.353 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 6.9 tt0 50.17 -87.82 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 126.045 1.738 . . . . 0.0 112.41 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 52.7 mt-30 55.8 89.11 0.04 OUTLIER 'General case' 0 C--O 1.24 0.602 0 C-N-CA 124.193 0.997 . . . . 0.0 110.309 -176.054 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 14.3 t -124.79 -174.43 3.03 Favored 'General case' 0 N--CA 1.404 -2.772 0 CA-C-N 114.652 -1.158 . . . . 0.0 108.684 -172.7 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 110' ' ' LEU . . . . . 0.439 ' O ' HD12 ' B' ' 110' ' ' LEU . 0.6 OUTLIER -101.27 104.69 15.72 Favored 'General case' 0 C--N 1.269 -2.916 0 CA-C-N 114.832 -1.076 . . . . 0.0 109.937 179.449 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 65.97 99.22 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 114.375 -1.284 . . . . 0.0 111.63 178.326 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 7.3 tp60 -108.05 -44.19 4.24 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 -178.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 113' ' ' GLU . . . . . 0.448 ' H ' ' CD ' ' B' ' 113' ' ' GLU . 1.1 pm0 . . . . . 0 N--CA 1.42 -1.949 0 CA-C-N 114.306 -1.316 . . . . 0.0 110.791 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.505 -0.554 0 N-CA-C 112.121 -0.392 . . . . 0.0 112.121 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 36.1 m80 -69.7 -42.77 73.64 Favored 'General case' 0 CA--C 1.503 -0.837 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 174.315 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 47.8 mtm -112.42 129.9 56.16 Favored 'General case' 0 N--CA 1.418 -2.063 0 N-CA-C 103.635 -2.728 . . . . 0.0 103.635 168.333 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 4' ' ' GLU . . . . . 0.444 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 16.2 mt-10 -88.4 97.29 10.97 Favored 'General case' 0 C--N 1.284 -2.276 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.263 -176.422 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -86.37 89.55 7.91 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 172.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 23.6 p90 -108.81 144.78 30.29 Favored Pre-proline 0 C--N 1.297 -1.7 0 CA-C-N 115.52 -0.764 . . . . 0.0 112.092 -177.783 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 7' ' ' PRO . . . . . 0.414 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 53.6 Cg_endo -73.85 138.59 26.3 Favored 'Trans proline' 0 N--CA 1.447 -1.255 0 C-N-CA 122.303 2.002 . . . . 0.0 113.314 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.458 ' HB ' HD13 ' B' ' 91' ' ' ILE . 74.8 t -129.49 126.55 63.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.824 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 175.219 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -108.39 135.75 49.17 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.668 -177.338 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.575 HD11 ' HB2' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -139.75 162.21 35.68 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.614 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.44 ' H ' HD23 ' B' ' 10' ' ' LEU . 11.9 pt-20 -134.13 159.36 41.1 Favored 'General case' 0 C--N 1.285 -2.208 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.31 177.019 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -77.22 134.87 38.49 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.579 -178.13 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 13' ' ' ASP . . . . . 0.55 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 15.6 t70 -87.61 -179.74 6.37 Favored 'General case' 0 C--N 1.292 -1.917 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 175.55 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.3 m -64.65 -29.8 70.8 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 176.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -91.66 -8.96 45.63 Favored 'General case' 0 CA--C 1.548 0.891 0 CA-C-O 121.661 0.743 . . . . 0.0 109.975 177.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 106.51 -100.07 1.57 Allowed Glycine 0 N--CA 1.44 -1.038 0 C-N-CA 121.068 -0.586 . . . . 0.0 113.02 177.594 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.55 ' HG ' ' H ' ' B' ' 18' ' ' GLY . 17.7 tp -98.85 -173.28 2.48 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -177.255 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 18' ' ' GLY . . . . . 0.55 ' H ' ' HG ' ' B' ' 17' ' ' LEU . . . -164.91 58.18 0.26 Allowed Glycine 0 N--CA 1.435 -1.371 0 C-N-CA 120.262 -0.971 . . . . 0.0 112.688 177.677 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.504 HG23 ' HB3' ' B' ' 48' ' ' ALA . 5.7 pt -162.93 177.46 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.487 -1.473 0 C-N-CA 124.662 1.185 . . . . 0.0 108.228 -179.134 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.2 m -138.83 147.25 42.25 Favored 'General case' 0 C--N 1.262 -3.21 0 N-CA-C 105.522 -2.029 . . . . 0.0 105.522 174.065 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 9.3 pt -114.85 167.17 7.72 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.827 0 O-C-N 123.36 0.412 . . . . 0.0 109.931 -178.647 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 10.1 tp -142.82 135.81 26.06 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.455 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -90.12 110.31 3.75 Favored Glycine 0 N--CA 1.435 -1.392 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.615 -178.205 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 89.1 mtp -130.05 -178.85 4.91 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 177.252 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 118.84 145.73 7.78 Favored Glycine 0 C--N 1.302 -1.338 0 C-N-CA 120.318 -0.944 . . . . 0.0 113.003 176.268 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -166.98 166.17 15.49 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 176.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 143.28 -138.4 8.19 Favored Glycine 0 N--CA 1.438 -1.207 0 C-N-CA 120.803 -0.713 . . . . 0.0 111.542 177.237 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.35 89.28 2.09 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 177.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.475 ' O ' ' HB3' ' B' ' 33' ' ' GLU . 30.6 t70 -71.56 -39.23 70.77 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 121.521 0.676 . . . . 0.0 112.342 -175.823 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 23.5 ptp -85.58 -8.4 58.3 Favored 'General case' 0 C--N 1.272 -2.793 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.345 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -104.8 -51.46 0.9 Allowed Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 120.801 -0.714 . . . . 0.0 113.395 -179.386 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 77.9 mt -119.25 -35.49 3.59 Favored 'General case' 0 C--O 1.211 -0.958 0 O-C-N 122.62 -0.341 . . . . 0.0 111.416 -174.461 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 33' ' ' GLU . . . . . 0.475 ' HB3' ' O ' ' B' ' 29' ' ' ASP . 11.3 pt-20 50.98 30.12 5.05 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 126.138 1.775 . . . . 0.0 112.254 -178.492 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 34' ' ' LYS . . . . . 0.401 ' HA ' ' O ' ' B' ' 69' ' ' VAL . 0.1 OUTLIER -70.83 103.03 2.49 Favored 'General case' 0 N--CA 1.425 -1.685 0 CA-C-O 122.614 1.197 . . . . 0.0 110.734 -177.426 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 91.8 mt -97.48 151.8 19.63 Favored 'General case' 0 C--N 1.284 -2.24 0 CA-C-N 114.655 -1.157 . . . . 0.0 108.583 176.703 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -112.12 95.17 0.78 Allowed Glycine 0 N--CA 1.398 -3.843 0 C-N-CA 120.63 -0.795 . . . . 0.0 111.467 -176.087 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 30.8 mm -86.99 86.01 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.824 0 N-CA-C 106.428 -1.693 . . . . 0.0 106.428 172.58 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -84.1 166.85 17.31 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 114.335 -1.302 . . . . 0.0 108.727 -175.374 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.1 t -79.67 133.05 30.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 175.084 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -95.41 -41.76 8.83 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 120.932 0.396 . . . . 0.0 110.008 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -156.88 163.03 39.63 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -179.603 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.451 ' HA ' HG22 ' B' ' 19' ' ' ILE . 21.9 t -118.62 108.69 24.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 177.255 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' B' ' 49' ' ' HIS . 24.3 m -64.92 123.68 20.05 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 123.422 0.689 . . . . 0.0 111.088 -176.188 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 44' ' ' GLU . . . . . 0.446 ' HG2' ' CE1' ' B' ' 49' ' ' HIS . 32.8 mt-10 -67.72 -33.7 75.4 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 124.588 1.155 . . . . 0.0 109.839 -175.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.46 16.82 47.36 Favored Glycine 0 N--CA 1.431 -1.633 0 CA-C-N 114.761 -1.108 . . . . 0.0 112.114 178.212 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -127.07 174.75 18.23 Favored Glycine 0 N--CA 1.405 -3.422 0 C-N-CA 120.81 -0.71 . . . . 0.0 113.464 -178.648 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 47' ' ' ALA . . . . . 0.55 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -56.84 -54.84 41.79 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -173.612 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 48' ' ' ALA . . . . . 0.575 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -61.13 -27.14 68.18 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 114.017 1.117 . . . . 0.0 114.017 -171.105 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 49' ' ' HIS . . . . . 0.446 ' CE1' ' HG2' ' B' ' 44' ' ' GLU . 2.4 t60 -78.98 -38.7 36.19 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -179.197 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 92.1 mtt180 -73.5 -38.82 65.23 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.373 -178.418 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -66.85 -67.1 0.48 Allowed 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.088 173.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.84 3.49 52.17 Favored Glycine 0 N--CA 1.439 -1.104 0 N-CA-C 114.722 0.649 . . . . 0.0 114.722 175.478 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -81.2 -45.94 15.59 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 118.489 1.144 . . . . 0.0 112.061 -179.543 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.516 HD11 ' CE2' ' B' ' 89' ' ' PHE . 19.7 mt -78.56 127.89 38.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.142 174.746 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 50.7 mt-30 -110.92 167.07 10.52 Favored 'General case' 0 N--CA 1.436 -1.165 0 CA-C-O 121.07 0.462 . . . . 0.0 110.396 176.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.6 p -70.71 -2.1 2.42 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.704 0 N-CA-C 114.191 1.182 . . . . 0.0 114.191 -171.423 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -119.85 15.01 12.57 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.723 -1.236 . . . . 0.0 110.546 179.565 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -90.47 168.76 11.6 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.783 -178.2 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.512 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 22.8 tp -133.23 132.59 41.66 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.716 -176.637 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 78.2 mt -86.06 99.54 11.55 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 177.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.53 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.3 t -83.52 -42.42 17.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 CA-C-O 121.461 0.648 . . . . 0.0 110.647 177.546 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.536 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 15.9 pt-20 -159.67 158.53 31.63 Favored 'General case' 0 C--N 1.282 -2.332 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.546 175.364 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.507 HG12 ' HB ' ' B' ' 66' ' ' THR . 4.0 p -100.74 -173.58 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.228 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.458 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 22.8 t70 -51.49 -47.73 63.13 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 113.126 0.787 . . . . 0.0 113.126 -178.431 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -137.4 44.56 1.13 Allowed Glycine 0 C--N 1.314 -0.678 0 C-N-CA 119.362 -1.399 . . . . 0.0 114.207 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 66' ' ' THR . . . . . 0.507 ' HB ' HG12 ' B' ' 63' ' ' VAL . 94.9 m -161.31 119.43 2.38 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.027 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 67' ' ' SER . . . . . 0.536 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 21.2 m -97.92 132.48 43.46 Favored 'General case' 0 N--CA 1.431 -1.394 0 CA-C-O 121.075 0.464 . . . . 0.0 111.853 -176.486 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.53 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 42.4 mt -96.06 115.42 27.4 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.108 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 69' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' B' ' 34' ' ' LYS . 40.1 t -81.85 -23.51 9.78 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 174.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 145.75 75.76 0.02 OUTLIER Glycine 0 N--CA 1.424 -2.124 0 N-CA-C 108.871 -1.692 . . . . 0.0 108.871 -177.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 m -93.53 -178.32 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-N 115.554 -0.323 . . . . 0.0 110.557 -175.577 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 41.3 p -82.6 165.32 20.17 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 176.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.0 tt0 -63.15 -33.91 76.48 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.23 0.538 . . . . 0.0 109.596 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.3 m -66.28 -44.93 82.19 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.991 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -60.19 -48.2 82.75 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.496 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -59.08 -44.2 91.87 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.122 178.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.4 -37.27 80.3 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-O 121.204 0.526 . . . . 0.0 110.324 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 36.0 m -66.84 -35.96 81.24 Favored 'General case' 0 N--CA 1.435 -1.182 0 CA-C-N 115.366 -0.834 . . . . 0.0 111.344 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.496 HG12 ' O ' ' B' ' 76' ' ' ALA . 4.2 p -75.66 -34.17 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 C-N-CA 119.558 -0.857 . . . . 0.0 109.81 -174.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 25.0 mt -64.82 -42.29 95.09 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.261 -0.882 . . . . 0.0 111.167 176.616 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 39.1 mtp180 -77.64 -30.16 52.03 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.819 0.342 . . . . 0.0 111.922 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 6.5 t30 -74.8 -27.09 60.16 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.412 ' HB ' HG11 ' B' ' 87' ' ' VAL . 16.3 p -71.88 158.69 35.59 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 -178.114 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -66.74 -168.04 0.06 Allowed 'General case' 0 C--O 1.251 1.163 0 C-N-CA 124.708 1.203 . . . . 0.0 112.933 -178.56 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.12 -49.95 64.7 Favored Glycine 0 N--CA 1.431 -1.689 0 CA-C-N 114.644 -1.162 . . . . 0.0 112.828 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 23.0 ttp180 -135.04 121.65 20.7 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.981 -0.688 . . . . 0.0 111.961 -177.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.458 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 15.8 m -138.24 149.56 24.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 114.879 -1.055 . . . . 0.0 109.383 -179.361 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -94.6 155.95 16.66 Favored 'General case' 0 C--N 1.295 -1.796 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.755 174.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.516 ' CE2' HD11 ' B' ' 54' ' ' ILE . 9.1 m-85 -126.99 162.33 26.25 Favored 'General case' 0 C--N 1.276 -2.63 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 176.689 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.505 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 24.5 mmt -111.58 113.1 25.28 Favored 'General case' 0 C--N 1.28 -2.448 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.597 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.512 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -97.21 129.23 47.58 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -179.331 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 92' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -109.45 116.28 4.5 Favored Glycine 0 CA--C 1.468 -2.858 0 C-N-CA 120.19 -1.005 . . . . 0.0 112.079 -178.792 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 8.7 tpp180 -83.86 118.25 23.84 Favored 'General case' 0 C--N 1.284 -2.257 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 176.023 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -105.15 79.61 1.51 Allowed 'General case' 0 N--CA 1.407 -2.605 0 C-N-CA 119.002 -1.079 . . . . 0.0 108.17 171.595 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 30.0 ttt180 -62.78 -58.1 18.44 Favored Pre-proline 0 CA--C 1.562 1.41 0 CA-C-N 114.602 -1.181 . . . . 0.0 110.164 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -77.05 145.59 24.85 Favored 'Trans proline' 0 C--N 1.387 2.602 0 C-N-CA 122.169 1.912 . . . . 0.0 112.898 178.504 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 154.11 43.86 0.02 OUTLIER Glycine 0 C--N 1.288 -2.136 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 -178.406 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 55.0 mm-40 54.53 23.5 4.64 Favored 'General case' 0 N--CA 1.436 -1.151 0 N-CA-C 115.385 1.624 . . . . 0.0 115.385 -173.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 10.1 tt0 -74.35 -43.71 55.42 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 104.988 -2.227 . . . . 0.0 104.988 170.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 43.7 p 56.49 156.97 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 127.202 2.201 . . . . 0.0 116.448 175.171 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -90.64 21.88 3.79 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.98 -177.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 21.6 t -83.28 137.06 21.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -106.52 -73.42 0.69 Allowed 'General case' 0 C--N 1.311 -1.107 0 CA-C-O 120.813 0.34 . . . . 0.0 110.855 178.049 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 95.8 mt-30 -123.68 74.83 1.29 Allowed 'General case' 0 C--N 1.309 -1.171 0 N-CA-C 112.906 0.706 . . . . 0.0 112.906 -178.501 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -140.67 170.07 16.45 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 174.656 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 1.7 mp -77.88 -57.86 5.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 174.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 107' ' ' GLN . . . . . 0.435 ' HA ' ' OE1' ' B' ' 107' ' ' GLN . 4.3 tp60 -166.39 143.68 5.15 Favored 'General case' 0 N--CA 1.421 -1.909 0 CA-C-N 114.233 -1.349 . . . . 0.0 107.834 173.726 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -108.53 68.32 0.69 Allowed 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 122.536 1.16 . . . . 0.0 108.915 176.474 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 13.4 t -83.66 -26.78 29.58 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 114.547 -1.206 . . . . 0.0 109.245 -177.007 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 92.3 mt -86.89 30.76 0.73 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.28 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -59.04 -42.59 90.6 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.376 178.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 58.25 33.27 22.99 Favored 'General case' 0 C--N 1.354 0.765 0 CA-C-O 122.118 0.961 . . . . 0.0 111.744 176.478 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 20.6 mm-40 . . . . . 0 N--CA 1.435 -1.192 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.653 177.131 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.499 -0.957 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 28.6 t-80 -83.21 -44.31 15.15 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 3' ' ' MET . . . . . 0.439 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 65.6 mtt -110.11 109.28 19.76 Favored 'General case' 0 N--CA 1.424 -1.752 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 172.393 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -77.47 103.98 7.73 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -176.374 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -78.05 91.39 4.27 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 124.106 0.878 . . . . 0.0 108.822 176.628 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -113.22 142.99 28.37 Favored Pre-proline 0 C--N 1.281 -2.371 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.646 176.593 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 7' ' ' PRO . . . . . 0.517 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 34.2 Cg_endo -75.01 128.84 11.79 Favored 'Trans proline' 0 N--CA 1.438 -1.791 0 C-N-CA 121.943 1.762 . . . . 0.0 112.843 179.327 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.461 ' HB ' HD13 ' B' ' 91' ' ' ILE . 72.0 t -113.41 122.78 68.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.266 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 9' ' ' GLU . . . . . 0.532 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 36.5 tt0 -106.86 132.15 53.15 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -174.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.522 HD11 ' HB2' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -127.4 158.27 37.75 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 177.548 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.417 ' H ' HD23 ' B' ' 10' ' ' LEU . 45.7 tt0 -134.41 138.51 44.88 Favored 'General case' 0 C--N 1.279 -2.481 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 176.001 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 34.7 mmtp -68.54 152.97 44.63 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 114.876 1.435 . . . . 0.0 114.876 -174.33 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 13' ' ' ASP . . . . . 0.455 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 15.2 t70 -92.76 177.33 6.13 Favored 'General case' 0 C--O 1.247 0.922 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 173.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 13.2 p -69.62 -28.76 66.19 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 118.327 0.512 . . . . 0.0 110.356 178.715 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -80.24 -53.04 7.03 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 173.131 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 147.92 -96.98 0.18 Allowed Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.34 179.091 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 96.3 mt -128.36 175.48 8.46 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 122.928 0.491 . . . . 0.0 109.996 -178.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 18' ' ' GLY . . . . . 0.492 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -156.38 69.05 0.28 Allowed Glycine 0 CA--C 1.482 -1.977 0 N-CA-C 108.254 -1.938 . . . . 0.0 108.254 179.166 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.514 HG22 ' HB ' ' B' ' 42' ' ' VAL . 12.7 pt -145.22 -179.09 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.281 -2.393 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 -177.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 20' ' ' SER . . . . . 0.475 ' HB2' HG22 ' B' ' 41' ' ' THR . 28.5 m -154.88 155.46 34.38 Favored 'General case' 0 C--N 1.253 -3.627 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 174.829 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.473 ' HB ' HG22 ' B' ' 37' ' ' ILE . 7.9 pt -127.58 154.5 38.07 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.892 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -129.26 132.13 67.08 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -179.347 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.78 103.18 2.28 Favored Glycine 0 N--CA 1.423 -2.231 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.192 -176.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 72.6 mtm -127.57 140.32 52.19 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-O 121.085 0.469 . . . . 0.0 110.672 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.95 -178.64 43.3 Favored Glycine 0 N--CA 1.425 -2.052 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 -178.533 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -125.15 24.82 7.37 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.992 0.901 . . . . 0.0 109.075 179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 86.6 -72.91 2.56 Favored Glycine 0 N--CA 1.436 -1.345 0 CA-C-N 114.572 -1.194 . . . . 0.0 111.442 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . 50.43 59.23 4.72 Favored 'General case' 0 C--O 1.244 0.773 0 CA-C-O 122.274 1.035 . . . . 0.0 110.739 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.523 ' HA ' ' HA ' ' B' ' 33' ' ' GLU . 6.0 p-10 -63.09 -26.3 68.77 Favored 'General case' 0 N--CA 1.422 -1.856 0 CA-C-N 113.937 -1.483 . . . . 0.0 112.922 -174.136 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 26.6 ptm -66.08 -26.57 67.55 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.817 -178.729 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 31' ' ' GLY . . . . . 0.482 ' HA3' ' HE3' ' B' ' 34' ' ' LYS . . . -106.81 53.43 0.62 Allowed Glycine 0 N--CA 1.425 -2.076 0 C-N-CA 120.509 -0.853 . . . . 0.0 111.156 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 28.8 mt 67.86 29.74 6.52 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 124.284 1.034 . . . . 0.0 110.89 176.254 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 33' ' ' GLU . . . . . 0.523 ' HA ' ' HA ' ' B' ' 29' ' ' ASP 0.271 13.6 pt-20 46.11 64.93 1.3 Allowed 'General case' 0 N--CA 1.475 0.792 0 CA-C-O 122.791 1.281 . . . . 0.0 111.656 -174.698 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 34' ' ' LYS . . . . . 0.482 ' HE3' ' HA3' ' B' ' 31' ' ' GLY . 19.0 ptpt -78.99 110.31 14.09 Favored 'General case' 0 N--CA 1.427 -1.605 0 CA-C-N 113.171 -1.831 . . . . 0.0 111.806 -173.103 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 83.6 mt -115.07 130.12 56.86 Favored 'General case' 0 C--N 1.297 -1.686 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 176.205 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -87.64 91.67 1.75 Allowed Glycine 0 N--CA 1.41 -3.063 0 C-N-CA 120.365 -0.921 . . . . 0.0 111.982 -177.146 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.473 HG22 ' HB ' ' B' ' 21' ' ' ILE . 20.1 mm -87.38 84.91 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.549 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 173.467 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -84.71 165.01 18.22 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 114.636 -1.165 . . . . 0.0 108.695 -178.031 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 56.9 t -75.8 133.12 31.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 176.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -92.71 -46.4 7.59 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.622 -177.535 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 41' ' ' THR . . . . . 0.525 ' HA ' HG23 ' B' ' 56' ' ' VAL . 6.3 t -155.14 174.58 15.0 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.84 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.514 ' HB ' HG22 ' B' ' 19' ' ' ILE . 2.4 p -158.81 98.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 C-N-CA 124.793 1.237 . . . . 0.0 109.201 -177.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.424 HG22 ' H ' ' B' ' 45' ' ' GLY . 26.5 m -87.76 143.27 27.24 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 113.915 -1.493 . . . . 0.0 110.32 -174.597 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -56.78 -19.89 19.48 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 124.593 1.157 . . . . 0.0 112.744 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 45' ' ' GLY . . . . . 0.424 ' H ' HG22 ' B' ' 43' ' ' THR . . . -72.98 -12.44 79.14 Favored Glycine 0 N--CA 1.439 -1.102 0 CA-C-N 116.11 -0.496 . . . . 0.0 113.363 -178.721 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.492 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -116.5 169.0 12.87 Favored Glycine 0 N--CA 1.422 -2.3 0 C-N-CA 119.438 -1.363 . . . . 0.0 113.328 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 47' ' ' ALA . . . . . 0.455 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -56.77 -41.25 77.31 Favored 'General case' 0 C--O 1.19 -2.066 0 CA-C-N 113.977 -1.111 . . . . 0.0 113.568 -175.078 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 48' ' ' ALA . . . . . 0.522 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -59.87 -35.94 75.84 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -173.516 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 4.9 t60 -81.45 -38.76 25.91 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -179.574 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -69.29 -46.17 67.82 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.07 -178.411 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -70.89 -36.01 72.58 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.81 47.68 7.05 Favored Glycine 0 CA--C 1.494 -1.276 0 CA-C-N 114.102 -1.408 . . . . 0.0 112.463 173.431 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.532 ' HG3' ' O ' ' B' ' 9' ' ' GLU . 35.2 mmt180 -116.14 -60.78 1.82 Allowed 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -177.244 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.463 HD11 ' CE2' ' B' ' 89' ' ' PHE . 43.9 mt -77.28 125.73 37.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 C-N-CA 120.255 -0.578 . . . . 0.0 109.735 178.695 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 65.4 mt-30 -99.74 159.04 15.35 Favored 'General case' 0 C--N 1.287 -2.144 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.525 HG23 ' HA ' ' B' ' 41' ' ' THR . 11.8 p -70.03 -4.83 4.43 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.699 0 CA-C-O 121.804 0.812 . . . . 0.0 112.027 -177.45 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -113.15 10.14 18.6 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.451 -0.78 . . . . 0.0 110.824 -177.015 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 87.9 m-20 -85.01 175.31 9.12 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.293 0.568 . . . . 0.0 112.379 -177.573 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.401 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 26.6 tp -143.05 130.97 21.61 Favored 'General case' 0 C--N 1.315 -0.908 0 C-N-CA 123.894 0.878 . . . . 0.0 109.752 -177.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 71.7 mt -87.49 98.12 11.21 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 178.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.575 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 36.6 t -81.97 -41.41 18.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 CA-C-O 121.941 0.877 . . . . 0.0 110.477 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.46 ' HG2' ' HB2' ' B' ' 90' ' ' MET . 9.7 pt-20 -157.26 158.95 37.08 Favored 'General case' 0 C--N 1.275 -2.633 0 CA-C-N 114.858 -1.065 . . . . 0.0 109.763 173.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.453 HG12 ' O ' ' B' ' 66' ' ' THR . 3.3 p -101.57 -173.89 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 105.825 -1.917 . . . . 0.0 105.825 178.61 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.511 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.2 t70 -55.34 -58.68 6.74 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 113.092 0.775 . . . . 0.0 113.092 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -119.23 33.43 4.7 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 119.818 -1.182 . . . . 0.0 114.535 -176.74 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 66' ' ' THR . . . . . 0.453 ' O ' HG12 ' B' ' 63' ' ' VAL . 18.8 m -160.71 128.53 4.43 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 179.002 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 67' ' ' SER . . . . . 0.405 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 39.0 m -93.91 136.77 33.85 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.899 -0.501 . . . . 0.0 111.092 -179.249 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.575 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 17.2 mt -93.34 -77.39 0.45 Allowed 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.373 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 61.4 t 70.49 -29.4 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 125.34 1.456 . . . . 0.0 111.181 -175.206 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 70' ' ' GLY . . . . . 0.467 ' H ' ' C ' ' B' ' 68' ' ' LEU . . . 164.59 89.29 0.07 OUTLIER Glycine 1 N--CA 1.395 -4.085 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -177.226 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.415 HG21 HD22 ' B' ' 68' ' ' LEU . 33.6 m -118.42 -178.74 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.282 -2.356 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 175.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 36.7 p -79.92 161.8 25.33 Favored 'General case' 0 C--N 1.292 -1.931 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 177.226 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -60.42 -35.03 74.84 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 121.287 0.565 . . . . 0.0 110.129 -177.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 50.0 m -74.22 -36.44 63.94 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.831 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -63.25 -46.22 87.91 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.533 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -63.01 -38.92 93.11 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.279 179.534 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.67 -38.33 88.98 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.489 0.661 . . . . 0.0 110.122 178.222 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 34.7 t -64.49 -39.28 93.5 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.956 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.533 HG12 ' O ' ' B' ' 76' ' ' ALA . 2.6 p -70.31 -27.94 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 121.947 0.879 . . . . 0.0 110.374 -172.047 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 80' ' ' LEU . . . . . 0.501 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 55.8 mt -72.51 -6.6 44.99 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.376 178.672 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 67.6 mtt180 -116.88 -17.48 10.42 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-O 120.852 0.358 . . . . 0.0 111.948 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.9 m-20 -87.76 -8.36 56.11 Favored 'General case' 0 C--O 1.241 0.645 0 C-N-CA 123.308 0.643 . . . . 0.0 111.378 179.644 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.612 ' HB ' HG11 ' B' ' 87' ' ' VAL . 1.4 p -87.25 -175.16 5.18 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 113.873 1.064 . . . . 0.0 113.873 -178.844 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -77.34 -171.5 2.12 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.879 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -75.97 -38.27 36.1 Favored Glycine 0 N--CA 1.44 -1.067 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.927 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 86' ' ' ARG . . . . . 0.427 ' HA ' ' O ' ' B' ' 10' ' ' LEU . 13.0 ttp180 -127.69 118.49 23.92 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.397 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.612 HG11 ' HB ' ' B' ' 83' ' ' THR . 15.6 m -135.5 154.82 35.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -175.165 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 88' ' ' ARG . . . . . 0.42 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 99.7 mtt180 -109.66 126.19 53.4 Favored 'General case' 0 CA--C 1.49 -1.345 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.115 179.307 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.517 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 3.1 m-85 -105.58 155.05 19.58 Favored 'General case' 0 C--N 1.28 -2.45 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 178.023 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.46 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 19.6 mmt -98.74 109.69 22.4 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 173.871 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.484 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.5 mp -98.06 119.92 46.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.943 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.53 111.89 4.07 Favored Glycine 0 CA--C 1.466 -3.007 0 N-CA-C 108.726 -1.75 . . . . 0.0 108.726 175.26 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 93' ' ' ARG . . . . . 0.439 ' O ' ' HA ' ' B' ' 3' ' ' MET . 8.3 tpp180 -68.63 114.43 7.0 Favored 'General case' 0 C--N 1.285 -2.224 0 CA-C-N 114.637 -0.781 . . . . 0.0 111.679 -178.906 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -79.74 82.04 5.9 Favored 'General case' 0 N--CA 1.413 -2.316 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 170.008 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 24.2 ttm180 -59.27 -57.95 23.16 Favored Pre-proline 0 CA--C 1.562 1.436 0 CA-C-N 115.193 -0.912 . . . . 0.0 112.208 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -74.54 166.62 28.99 Favored 'Trans proline' 0 C--N 1.358 1.046 0 C-N-CA 122.056 1.837 . . . . 0.0 112.097 177.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -132.58 19.99 4.43 Favored Glycine 0 C--N 1.295 -1.716 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.13 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -87.08 -27.68 23.0 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 52.6 tp60 -84.89 -51.62 6.6 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-N 114.784 -1.098 . . . . 0.0 112.503 -170.282 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 73.2 m 58.77 -179.27 0.08 Allowed 'General case' 0 CA--C 1.558 1.277 0 C-N-CA 124.19 0.996 . . . . 0.0 112.217 -174.419 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 101' ' ' GLU . . . . . 0.457 ' H ' ' CD ' ' B' ' 101' ' ' GLU . 0.7 OUTLIER -75.98 -45.93 32.21 Favored 'General case' 0 CA--C 1.495 -1.146 0 CA-C-O 122.895 1.331 . . . . 0.0 109.0 -178.939 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 102' ' ' VAL . . . . . 0.528 HG23 ' HG ' ' B' ' 105' ' ' LEU . 3.9 p -77.25 140.9 16.35 Favored 'Isoleucine or valine' 0 C--N 1.261 -3.243 0 CA-C-N 111.936 -2.393 . . . . 0.0 111.523 -175.631 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -98.52 -62.16 1.28 Allowed 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.612 177.225 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 7.0 tp-100 -162.74 117.77 1.79 Allowed 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 179.47 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 105' ' ' LEU . . . . . 0.528 ' HG ' HG23 ' B' ' 102' ' ' VAL . 83.2 mt -114.35 110.68 20.28 Favored 'General case' 0 C--N 1.309 -1.158 0 C-N-CA 120.578 -0.449 . . . . 0.0 111.4 179.579 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 46.8 mm -81.84 -65.05 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 171.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 53.7 mt-30 -98.97 133.21 43.56 Favored 'General case' 0 N--CA 1.431 -1.412 0 N-CA-C 104.231 -2.507 . . . . 0.0 104.231 166.406 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -76.83 -77.94 0.13 Allowed 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 114.22 1.192 . . . . 0.0 114.22 -174.016 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 109' ' ' THR . . . . . 0.464 HG23 ' H ' ' B' ' 111' ' ' GLU . 15.1 t -81.96 -14.61 55.8 Favored 'General case' 0 C--N 1.282 -2.352 0 CA-C-N 115.235 -0.893 . . . . 0.0 111.553 -173.729 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 38.8 mt 69.82 16.3 7.82 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.812 0.845 . . . . 0.0 111.333 175.535 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 111' ' ' GLU . . . . . 0.464 ' H ' HG23 ' B' ' 109' ' ' THR . 9.3 tp10 -101.3 49.86 0.87 Allowed 'General case' 0 N--CA 1.433 -1.275 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -177.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 12.3 mm100 60.44 -102.09 0.13 Allowed 'General case' 0 C--O 1.246 0.883 0 CA-C-N 114.207 -1.36 . . . . 0.0 111.175 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 . . . . . 0 N--CA 1.423 -1.786 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 177.02 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.496 -1.145 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 56.5 t60 -68.43 -51.8 39.73 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 176.082 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 20.6 ptp -94.44 135.05 36.3 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 173.259 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 4' ' ' GLU . . . . . 0.522 ' OE2' ' HD2' ' B' ' 93' ' ' ARG . 17.1 mt-10 -89.85 100.09 12.97 Favored 'General case' 0 C--N 1.289 -2.037 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -177.647 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -91.4 89.94 7.47 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 175.021 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -119.14 143.88 34.97 Favored Pre-proline 0 C--N 1.29 -1.997 0 C-N-CA 120.736 -0.386 . . . . 0.0 111.946 178.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 7' ' ' PRO . . . . . 0.489 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 56.7 Cg_endo -75.15 139.49 23.97 Favored 'Trans proline' 0 N--CA 1.439 -1.716 0 C-N-CA 122.076 1.851 . . . . 0.0 111.73 176.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.45 ' HB ' HD13 ' B' ' 91' ' ' ILE . 90.5 t -128.33 123.34 59.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -179.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 9' ' ' GLU . . . . . 0.5 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 38.9 tt0 -103.24 129.6 50.24 Favored 'General case' 0 C--N 1.285 -2.196 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.196 -178.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.446 HD12 HG13 ' B' ' 54' ' ' ILE . 2.0 mt -142.81 165.37 27.55 Favored 'General case' 0 CA--C 1.478 -1.812 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.812 175.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -135.58 164.67 27.3 Favored 'General case' 0 C--N 1.283 -2.324 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.726 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -82.38 163.14 21.89 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 121.616 0.722 . . . . 0.0 112.156 -179.821 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -111.44 -159.54 0.68 Allowed 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 104.12 -2.548 . . . . 0.0 104.12 173.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 22.8 t -75.17 -25.45 58.32 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 169.473 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -86.73 -60.83 1.88 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.977 176.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 122.84 75.45 0.32 Allowed Glycine 0 N--CA 1.439 -1.108 0 C-N-CA 120.223 -0.989 . . . . 0.0 112.143 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp 77.12 172.04 0.22 Allowed 'General case' 0 CA--C 1.507 -0.678 0 C-N-CA 124.576 1.15 . . . . 0.0 112.402 178.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -141.83 74.44 0.35 Allowed Glycine 0 CA--C 1.471 -2.675 0 N-CA-C 109.097 -1.601 . . . . 0.0 109.097 -178.818 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.443 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 14.2 pt -157.51 -177.53 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 -178.673 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 24.0 t -149.08 142.31 25.05 Favored 'General case' 0 C--N 1.272 -2.793 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 176.006 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 20.6 pt -109.17 152.87 11.11 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -129.76 136.14 59.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.65 97.85 2.15 Favored Glycine 0 N--CA 1.434 -1.472 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.025 179.477 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 26.5 ptm -110.69 130.62 55.52 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 120.894 0.378 . . . . 0.0 110.025 -179.044 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -164.35 -133.41 1.49 Allowed Glycine 0 N--CA 1.431 -1.672 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.012 -178.147 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . 62.46 26.76 15.94 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.587 1.155 . . . . 0.0 111.021 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -117.04 -75.49 0.55 Allowed Glycine 0 N--CA 1.43 -1.752 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 179.652 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -109.9 90.21 3.24 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 121.474 0.654 . . . . 0.0 111.6 -178.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 19.5 p-10 -86.89 -35.25 19.09 Favored 'General case' 0 CA--C 1.491 -1.319 0 CA-C-O 122.249 1.023 . . . . 0.0 109.795 177.13 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 25.3 ptm -76.01 2.17 13.43 Favored 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 113.406 -1.725 . . . . 0.0 110.361 178.379 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -98.13 38.63 3.02 Favored Glycine 0 N--CA 1.421 -2.363 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 176.026 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 8.5 mp 73.01 27.53 2.05 Favored 'General case' 0 CA--C 1.502 -0.903 0 C-N-CA 123.732 0.813 . . . . 0.0 110.282 175.045 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 33' ' ' GLU . . . . . 0.703 ' O ' ' HA3' ' B' ' 70' ' ' GLY . 32.0 mt-10 56.25 32.25 19.98 Favored 'General case' 0 CA--C 1.504 -0.817 0 CA-C-N 115.22 -0.9 . . . . 0.0 113.377 -177.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 34' ' ' LYS . . . . . 0.426 ' HD3' ' O ' ' B' ' 69' ' ' VAL . 70.1 mmtt -67.86 88.55 0.26 Allowed 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 122.324 1.059 . . . . 0.0 110.18 176.255 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 20.2 tp -87.47 159.11 18.78 Favored 'General case' 0 N--CA 1.413 -2.286 0 CA-C-N 113.808 -1.542 . . . . 0.0 107.674 -178.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -110.49 89.5 0.55 Allowed Glycine 0 N--CA 1.398 -3.849 0 C-N-CA 119.99 -1.1 . . . . 0.0 111.982 -176.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 29.6 mm -90.21 78.4 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.212 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 171.574 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -86.05 167.63 14.83 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-N 113.911 -1.495 . . . . 0.0 109.137 -176.57 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.414 HG21 ' CG2' ' B' ' 54' ' ' ILE . 51.1 t -81.07 131.34 34.14 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 176.2 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 36.4 ttpt -91.9 -40.97 10.86 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.771 -175.778 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -156.63 162.73 39.84 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 -177.012 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 21.8 t -127.53 92.11 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 178.29 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 10.5 m -72.31 132.55 44.16 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 123.541 0.736 . . . . 0.0 111.672 -176.698 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 44' ' ' GLU . . . . . 0.45 ' HA ' ' HB3' ' B' ' 49' ' ' HIS . 11.3 pt-20 -67.83 -3.52 9.83 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 123.886 0.874 . . . . 0.0 113.208 -179.163 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.1 3.23 85.72 Favored Glycine 0 N--CA 1.44 -1.098 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.133 -177.793 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -139.36 170.94 23.94 Favored Glycine 0 N--CA 1.407 -3.273 0 C-N-CA 119.862 -1.161 . . . . 0.0 113.556 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.94 -35.05 44.54 Favored 'General case' 0 C--O 1.195 -1.812 0 C-N-CA 126.235 1.814 . . . . 0.0 114.726 -174.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -64.63 -45.28 87.53 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 120.284 -0.566 . . . . 0.0 112.348 -174.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 49' ' ' HIS . . . . . 0.45 ' HB3' ' HA ' ' B' ' 44' ' ' GLU . 5.1 t60 -73.44 -41.09 63.65 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 108.679 -0.859 . . . . 0.0 108.679 177.155 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -59.81 -42.76 94.2 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.71 -178.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 51' ' ' ASP . . . . . 0.601 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 9.7 t70 -78.19 -51.85 9.58 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.279 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.95 42.71 3.23 Favored Glycine 0 N--CA 1.434 -1.463 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.615 ' NE ' ' HA ' ' B' ' 53' ' ' ARG . 4.9 mmp_? -104.97 -82.77 0.51 Allowed 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -178.828 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.474 HD11 ' CE2' ' B' ' 89' ' ' PHE . 49.9 mt -61.28 122.94 13.1 Favored 'Isoleucine or valine' 0 C--O 1.244 0.785 0 C-N-CA 120.165 -0.614 . . . . 0.0 110.435 176.574 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 55' ' ' GLN . . . . . 0.419 ' HB2' ' OD1' ' B' ' 58' ' ' ASP . 48.0 mt-30 -100.81 173.45 6.5 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.845 0.355 . . . . 0.0 111.039 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.8 p -77.83 -1.97 4.36 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 CA-C-O 121.374 0.607 . . . . 0.0 112.388 -174.022 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -124.07 24.55 8.16 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-O 122.053 0.93 . . . . 0.0 109.584 -178.461 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 58' ' ' ASP . . . . . 0.419 ' OD1' ' HB2' ' B' ' 55' ' ' GLN . 11.1 m-20 -98.21 166.36 11.44 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 114.345 -1.298 . . . . 0.0 110.421 -177.411 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.577 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 24.8 tp -140.39 133.35 29.27 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 123.423 0.689 . . . . 0.0 109.851 -177.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 71.1 mt -82.72 99.75 9.83 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 177.401 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.472 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.1 t -85.02 -40.81 15.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 122.0 0.905 . . . . 0.0 110.676 178.51 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.481 ' HG2' ' HB2' ' B' ' 90' ' ' MET . 10.2 pt-20 -155.51 154.25 31.51 Favored 'General case' 0 C--N 1.27 -2.883 0 CA-C-N 115.17 -0.923 . . . . 0.0 109.633 173.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.538 HG12 ' HB ' ' B' ' 66' ' ' THR . 6.6 p -100.4 -171.86 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 N-CA-C 105.825 -1.917 . . . . 0.0 105.825 178.65 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.562 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 8.6 t70 -44.14 -55.21 4.95 Favored 'General case' 0 N--CA 1.482 1.125 0 C-N-CA 124.117 0.967 . . . . 0.0 112.959 177.719 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -136.21 43.39 1.24 Allowed Glycine 0 C--N 1.304 -1.234 0 C-N-CA 119.07 -1.538 . . . . 0.0 114.98 -179.214 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 66' ' ' THR . . . . . 0.538 ' HB ' HG12 ' B' ' 63' ' ' VAL . 88.5 m -155.09 123.5 5.98 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 117.558 0.679 . . . . 0.0 109.326 177.293 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 5.7 m -87.58 125.02 34.11 Favored 'General case' 0 N--CA 1.441 -0.909 0 C-N-CA 123.091 0.557 . . . . 0.0 109.782 -177.796 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.472 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 25.1 mt -90.38 99.54 12.55 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 122.21 1.005 . . . . 0.0 110.856 179.327 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 69' ' ' VAL . . . . . 0.426 ' O ' ' HD3' ' B' ' 34' ' ' LYS . 58.1 t -69.22 -33.07 56.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-N 114.759 -1.109 . . . . 0.0 108.046 175.189 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 70' ' ' GLY . . . . . 0.703 ' HA3' ' O ' ' B' ' 33' ' ' GLU . . . 149.35 66.46 0.01 OUTLIER Glycine 0 CA--C 1.468 -2.845 0 N-CA-C 108.901 -1.68 . . . . 0.0 108.901 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 29.8 m -83.06 171.97 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.878 0 CA-C-N 113.694 -1.253 . . . . 0.0 109.188 -177.379 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 25.4 p -77.91 163.79 25.7 Favored 'General case' 0 N--CA 1.412 -2.339 0 C-N-CA 121.042 -0.263 . . . . 0.0 110.465 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -59.74 -37.53 79.22 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.314 0.578 . . . . 0.0 109.899 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 32.9 t -65.23 -41.36 94.48 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.776 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -64.57 -48.1 76.25 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.596 ' O ' ' HG ' ' B' ' 80' ' ' LEU . . . -55.78 -43.29 76.63 Favored 'General case' 0 C--O 1.217 -0.642 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.772 178.794 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.62 -39.1 91.12 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.28 0.562 . . . . 0.0 111.033 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.1 t -72.17 -29.41 63.99 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.9 -177.099 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.446 HG12 ' O ' ' B' ' 76' ' ' ALA . 9.8 p -75.69 -33.85 27.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 -176.173 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 80' ' ' LEU . . . . . 0.596 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 70.2 mt -68.19 -12.02 60.24 Favored 'General case' 0 C--O 1.214 -0.794 0 CA-C-N 114.517 -1.22 . . . . 0.0 110.789 176.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 96.6 mtt180 -106.16 -5.78 19.05 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.467 0.651 . . . . 0.0 111.036 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 13.0 m-80 -96.95 -24.04 16.02 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.546 177.074 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.791 ' HB ' HG11 ' B' ' 87' ' ' VAL . 3.9 p -68.44 179.74 1.57 Allowed 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -178.132 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 66.3 mmtt -72.03 -170.33 0.58 Allowed 'General case' 0 C--O 1.239 0.514 0 C-N-CA 123.462 0.705 . . . . 0.0 110.921 176.045 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.95 -36.09 47.99 Favored Glycine 0 N--CA 1.445 -0.759 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.648 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 26.3 ttm180 -127.52 122.48 33.45 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.496 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.791 HG11 ' HB ' ' B' ' 83' ' ' THR . 13.6 m -133.75 150.14 31.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.085 0 CA-C-O 121.085 0.469 . . . . 0.0 111.051 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 69.6 mtp85 -108.36 118.63 37.28 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.459 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.489 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 1.3 m-85 -98.73 170.74 8.56 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -177.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.481 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 48.5 mtt -113.54 116.88 30.24 Favored 'General case' 0 CA--C 1.473 -1.992 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 167.535 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.577 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.3 mp -94.49 121.72 45.34 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 177.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 92' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -112.67 96.45 0.83 Allowed Glycine 0 CA--C 1.461 -3.321 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 177.557 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 93' ' ' ARG . . . . . 0.522 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 36.6 ttm180 -96.51 120.36 36.67 Favored 'General case' 0 C--N 1.257 -3.435 0 CA-C-N 114.761 -0.719 . . . . 0.0 110.512 -176.077 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -85.6 79.03 9.51 Favored 'General case' 0 N--CA 1.423 -1.808 0 N-CA-C 106.529 -1.656 . . . . 0.0 106.529 170.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 12.5 ttm180 -57.89 -62.31 5.69 Favored Pre-proline 0 CA--C 1.551 1.003 0 CA-C-N 113.572 -1.649 . . . . 0.0 112.535 -179.166 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -61.14 144.91 99.29 Favored 'Trans proline' 0 C--N 1.371 1.715 0 C-N-CA 121.613 1.542 . . . . 0.0 111.331 179.321 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 129.36 -50.43 0.89 Allowed Glycine 0 N--CA 1.419 -2.491 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -176.026 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -75.69 -35.51 60.31 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.689 0.28 . . . . 0.0 111.142 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 18.7 tt0 -78.65 106.76 10.84 Favored 'General case' 0 N--CA 1.436 -1.139 0 CA-C-O 121.127 0.489 . . . . 0.0 111.339 -174.013 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 29.2 m -78.37 -178.07 5.55 Favored 'General case' 0 N--CA 1.426 -1.664 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 172.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 69.4 mm-40 -81.08 55.0 2.36 Favored 'General case' 0 C--N 1.306 -1.307 0 CA-C-O 121.963 0.887 . . . . 0.0 111.601 -178.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 25.3 m -95.24 112.34 27.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 CA-C-N 114.887 -1.051 . . . . 0.0 109.031 176.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -121.86 33.91 5.35 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 114.941 -1.027 . . . . 0.0 108.685 -176.418 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 104' ' ' GLN . . . . . 0.455 ' HA ' ' OE1' ' B' ' 104' ' ' GLN . 5.6 tp60 79.49 117.34 0.06 Allowed 'General case' 0 CA--C 1.508 -0.669 0 C-N-CA 125.606 1.562 . . . . 0.0 110.403 -175.319 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 6.3 mp -87.17 -179.66 6.48 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.386 -175.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 1.7 mp -74.46 -56.26 9.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.284 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -138.3 125.05 20.98 Favored 'General case' 0 N--CA 1.429 -1.487 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 176.517 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 3.7 tp-100 -87.0 92.9 9.2 Favored 'General case' 0 N--CA 1.434 -1.239 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 178.335 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 12.4 t -64.5 -17.67 64.08 Favored 'General case' 0 CA--C 1.551 0.982 0 N-CA-C 114.53 1.307 . . . . 0.0 114.53 -171.055 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 94.0 mt -108.56 14.06 24.85 Favored 'General case' 0 C--N 1.317 -0.844 0 O-C-N 121.923 -0.485 . . . . 0.0 110.895 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 63.1 -87.56 0.02 OUTLIER 'General case' 0 C--O 1.21 -0.974 0 C-N-CA 124.588 1.155 . . . . 0.0 110.592 -177.686 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 77.6 mt-30 -162.51 155.26 19.54 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 178.098 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 . . . . . 0 C--N 1.294 -1.826 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 178.406 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.488 -1.627 0 N-CA-C 110.465 -1.054 . . . . 0.0 110.465 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 63.6 m80 66.45 -163.86 0.23 Allowed 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.145 0.978 . . . . 0.0 110.483 178.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 3' ' ' MET . . . . . 0.522 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 66.8 mtt -77.09 95.41 4.22 Favored 'General case' 0 CA--C 1.505 -0.765 0 CA-C-O 120.901 0.381 . . . . 0.0 110.734 178.777 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 4' ' ' GLU . . . . . 0.408 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 19.7 mt-10 -84.85 105.6 15.75 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -85.34 93.59 8.75 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 174.517 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -117.02 141.5 28.47 Favored Pre-proline 0 C--N 1.288 -2.068 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.196 179.398 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 7' ' ' PRO . . . . . 0.51 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 61.0 Cg_endo -79.32 137.79 13.57 Favored 'Trans proline' 0 N--CA 1.444 -1.411 0 C-N-CA 122.379 2.052 . . . . 0.0 112.984 178.413 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 79.0 t -125.61 142.19 43.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 N-CA-C 106.855 -1.535 . . . . 0.0 106.855 177.659 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -127.97 123.2 34.24 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 118.659 0.663 . . . . 0.0 110.708 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.453 ' O ' ' HD3' ' B' ' 86' ' ' ARG . 1.2 mt -113.7 163.94 14.35 Favored 'General case' 0 CA--C 1.486 -1.503 0 CA-C-O 121.589 0.709 . . . . 0.0 111.478 178.812 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -124.88 145.89 49.58 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 174.309 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -91.02 164.14 14.07 Favored 'General case' 0 N--CA 1.418 -2.026 0 CA-C-O 121.874 0.845 . . . . 0.0 110.36 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 13' ' ' ASP . . . . . 0.567 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 25.3 t70 -111.44 -179.41 3.71 Favored 'General case' 0 C--N 1.274 -2.683 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 178.073 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 16.1 m -69.54 -25.92 64.25 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 176.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 8.3 tp10 -85.89 1.71 48.85 Favored 'General case' 0 CA--C 1.548 0.876 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.443 178.651 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.45 -138.75 14.6 Favored Glycine 0 N--CA 1.437 -1.285 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.573 179.751 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 93.9 mt -95.54 -177.94 4.25 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 177.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -138.42 58.04 0.63 Allowed Glycine 0 CA--C 1.478 -2.23 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.453 -178.356 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.561 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 7.0 pt -150.4 179.13 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 C-N-CA 123.52 0.728 . . . . 0.0 109.396 -177.819 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 20' ' ' SER . . . . . 0.426 ' HB2' HG22 ' B' ' 41' ' ' THR . 70.0 m -150.97 160.92 43.61 Favored 'General case' 0 C--N 1.269 -2.93 0 N-CA-C 105.14 -2.171 . . . . 0.0 105.14 175.673 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.475 ' HB ' HG22 ' B' ' 37' ' ' ILE . 10.3 pt -130.73 159.96 42.32 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.621 0 CA-C-N 117.877 0.308 . . . . 0.0 110.226 -177.607 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.2 tp -136.5 135.86 48.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-O 120.985 0.421 . . . . 0.0 110.348 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 23' ' ' GLY . . . . . 0.412 ' HA2' ' CD1' ' B' ' 37' ' ' ILE . . . -83.63 99.16 2.16 Favored Glycine 0 N--CA 1.437 -1.24 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.591 -178.082 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 3.8 mmt -113.83 175.59 5.4 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.473 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.03 170.54 47.54 Favored Glycine 0 N--CA 1.435 -1.418 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 174.167 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 26' ' ' ALA . . . . . 0.455 ' HB3' ' HG3' ' B' ' 34' ' ' LYS . . . -123.96 164.96 18.26 Favored 'General case' 0 C--N 1.295 -1.775 0 CA-C-N 117.394 0.597 . . . . 0.0 109.879 179.759 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.79 -28.74 41.26 Favored Glycine 0 N--CA 1.439 -1.153 0 C-N-CA 120.93 -0.652 . . . . 0.0 113.428 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.14 54.88 0.19 Allowed 'General case' 0 N--CA 1.484 1.248 0 N-CA-C 114.311 1.226 . . . . 0.0 114.311 -175.4 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' B' ' 33' ' ' GLU . 16.6 t70 -73.97 -33.26 63.81 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.659 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 13.0 ptp -60.6 -34.41 74.17 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 114.451 -1.25 . . . . 0.0 111.18 -177.543 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -105.88 -49.81 0.93 Allowed Glycine 0 N--CA 1.421 -2.327 0 C-N-CA 120.232 -0.985 . . . . 0.0 114.078 -175.199 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 93.9 mt -119.02 -10.56 9.81 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 114.323 1.231 . . . . 0.0 114.323 -171.785 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 33' ' ' GLU . . . . . 0.465 ' HA ' ' HA ' ' B' ' 29' ' ' ASP . 48.0 mt-10 52.13 41.69 30.19 Favored 'General case' 0 N--CA 1.481 1.099 0 CA-C-O 122.494 1.14 . . . . 0.0 108.436 -176.397 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 34' ' ' LYS . . . . . 0.455 ' HG3' ' HB3' ' B' ' 26' ' ' ALA . 21.8 ptmt -90.23 172.45 8.78 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-N 114.147 -1.388 . . . . 0.0 114.464 -167.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 94.7 mt -106.93 161.81 14.38 Favored 'General case' 0 N--CA 1.427 -1.588 0 CA-C-N 113.504 -1.68 . . . . 0.0 107.627 176.094 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -124.69 102.8 0.71 Allowed Glycine 0 N--CA 1.414 -2.803 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 -178.301 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.475 HG22 ' HB ' ' B' ' 21' ' ' ILE . 23.7 mm -88.18 88.84 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 178.297 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -83.9 163.46 20.03 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.689 -1.141 . . . . 0.0 109.342 -178.548 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 65.8 t -71.49 130.99 35.09 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 174.871 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -90.31 -48.73 6.96 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.42 -177.263 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 41' ' ' THR . . . . . 0.426 HG22 ' HB2' ' B' ' 20' ' ' SER . 0.6 OUTLIER -150.05 163.86 37.04 Favored 'General case' 0 N--CA 1.428 -1.529 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -177.875 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.0 p -139.01 93.7 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 CA-C-O 122.693 1.235 . . . . 0.0 109.29 178.63 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.429 HG22 ' H ' ' B' ' 45' ' ' GLY . 10.3 m -75.6 130.91 39.55 Favored 'General case' 0 N--CA 1.44 -0.974 0 CA-C-N 113.443 -1.708 . . . . 0.0 112.72 -172.44 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -57.93 -24.12 56.45 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 124.22 1.008 . . . . 0.0 112.901 179.831 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 45' ' ' GLY . . . . . 0.429 ' H ' HG22 ' B' ' 43' ' ' THR . . . -78.47 -1.26 81.67 Favored Glycine 0 N--CA 1.436 -1.313 0 CA-C-N 115.97 -0.559 . . . . 0.0 113.465 -178.129 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -122.28 170.23 15.08 Favored Glycine 0 N--CA 1.421 -2.354 0 C-N-CA 120.229 -0.986 . . . . 0.0 112.733 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 47' ' ' ALA . . . . . 0.567 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -59.94 -39.41 85.45 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 114.261 1.208 . . . . 0.0 114.261 -173.877 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 48' ' ' ALA . . . . . 0.4 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -64.34 -39.82 94.65 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -173.003 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -72.36 -44.53 62.44 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.509 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 17.2 mtp180 -62.24 -45.49 93.1 Favored 'General case' 0 CA--C 1.511 -0.536 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.188 -177.047 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 51' ' ' ASP . . . . . 0.484 ' OD2' ' HD2' ' B' ' 53' ' ' ARG . 19.1 t70 -65.54 -51.4 60.2 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 176.692 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 95.04 39.48 4.56 Favored Glycine 0 CA--C 1.478 -2.278 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.553 ' NE ' ' HA ' ' B' ' 53' ' ' ARG . 0.0 OUTLIER -99.66 -73.18 0.64 Allowed 'General case' 0 N--CA 1.419 -2.023 0 CA-C-N 114.221 -0.989 . . . . 0.0 110.483 -170.965 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.555 HD11 ' CE2' ' B' ' 89' ' ' PHE . 47.1 mt -82.78 125.1 39.95 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 175.725 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 55' ' ' GLN . . . . . 0.512 ' HG2' ' OD2' ' B' ' 58' ' ' ASP . 24.2 pt20 -100.42 169.52 9.04 Favored 'General case' 0 C--N 1.309 -1.196 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -178.26 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.1 p -66.82 -2.28 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.507 0 C-N-CA 123.964 0.906 . . . . 0.0 113.361 -174.182 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -127.27 19.39 6.93 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.044 -1.035 . . . . 0.0 110.769 -178.349 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 58' ' ' ASP . . . . . 0.512 ' OD2' ' HG2' ' B' ' 55' ' ' GLN . 80.8 m-20 -84.66 168.24 15.46 Favored 'General case' 0 C--N 1.312 -1.038 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.595 176.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 28.6 tp -136.06 127.45 28.48 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.393 -176.303 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 82.5 mt -81.73 90.91 6.39 Favored 'General case' 0 N--CA 1.434 -1.236 0 CA-C-O 121.534 0.683 . . . . 0.0 109.875 178.401 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.643 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 10.9 t -74.25 -39.6 49.56 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.126 175.869 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.486 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 11.9 pt-20 -164.56 159.66 19.42 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.862 171.009 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.566 HG12 ' HB ' ' B' ' 66' ' ' THR . 3.0 p -96.95 178.19 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.606 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 19.9 t70 -42.59 -54.34 4.01 Favored 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 125.409 1.484 . . . . 0.0 113.762 -176.185 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -132.56 43.85 1.25 Allowed Glycine 0 C--N 1.304 -1.232 0 C-N-CA 119.581 -1.295 . . . . 0.0 113.682 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 66' ' ' THR . . . . . 0.566 ' HB ' HG12 ' B' ' 63' ' ' VAL . 51.6 m -157.43 114.34 2.99 Favored 'General case' 0 C--O 1.247 0.923 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 175.867 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 67' ' ' SER . . . . . 0.486 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 44.6 m -81.99 111.65 18.36 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 112.476 0.547 . . . . 0.0 112.476 -177.177 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.643 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 44.2 mt -79.52 110.48 14.88 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.887 176.496 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 14.7 p -75.84 -24.98 16.98 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 177.677 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 142.54 64.04 0.03 OUTLIER Glycine 0 CA--C 1.484 -1.87 0 N-CA-C 108.928 -1.669 . . . . 0.0 108.928 -177.172 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.9 m -82.26 -178.59 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 114.366 -0.917 . . . . 0.0 110.406 -176.216 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 40.4 p -82.89 166.29 19.04 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 120.926 0.393 . . . . 0.0 110.93 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.7 tt0 -59.55 -42.89 93.4 Favored 'General case' 0 C--N 1.324 -0.539 0 C-N-CA 123.237 0.615 . . . . 0.0 110.168 -179.064 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 23.2 t -66.49 -38.96 88.41 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.247 -178.632 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -63.13 -50.22 71.33 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.554 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.3 -37.59 83.75 Favored 'General case' 0 CA--C 1.539 0.526 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.261 178.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.34 -30.54 71.24 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.657 0.741 . . . . 0.0 110.502 177.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.4 m -82.36 -27.48 32.12 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.521 -178.129 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.554 HG12 ' O ' ' B' ' 76' ' ' ALA . 3.9 p -72.03 -31.34 39.88 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.453 0 CA-C-O 121.396 0.617 . . . . 0.0 109.56 -176.126 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 19.4 mt -67.12 -17.35 64.82 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.918 -1.037 . . . . 0.0 111.322 176.519 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 22.1 mtm180 -100.72 -7.9 23.34 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-O 121.292 0.568 . . . . 0.0 110.31 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -89.99 -15.01 32.78 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 121.744 0.783 . . . . 0.0 109.655 176.255 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.655 ' HB ' HG11 ' B' ' 87' ' ' VAL . 9.3 p -92.06 167.2 12.24 Favored 'General case' 0 N--CA 1.412 -2.351 0 CA-C-N 115.261 -0.881 . . . . 0.0 111.855 179.191 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -76.88 -167.49 0.86 Allowed 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.277 -0.874 . . . . 0.0 112.876 177.242 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.26 -13.33 79.09 Favored Glycine 0 C--O 1.207 -1.555 0 CA-C-N 114.738 -1.119 . . . . 0.0 112.732 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 86' ' ' ARG . . . . . 0.453 ' HD3' ' O ' ' B' ' 10' ' ' LEU . 4.4 tpp180 -137.74 116.3 12.08 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 175.909 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.655 HG11 ' HB ' ' B' ' 83' ' ' THR . 6.3 m -149.12 157.59 6.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 122.969 0.508 . . . . 0.0 110.534 -179.06 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 77.0 mtm180 -96.18 170.18 9.44 Favored 'General case' 0 C--N 1.287 -2.145 0 CA-C-N 114.545 -1.207 . . . . 0.0 108.246 176.644 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.555 ' CE2' HD11 ' B' ' 54' ' ' ILE . 3.4 m-85 -150.9 162.16 41.32 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 105.163 -2.162 . . . . 0.0 105.163 175.397 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.543 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 66.4 mtm -115.54 114.45 24.99 Favored 'General case' 0 C--N 1.286 -2.195 0 CA-C-O 121.721 0.772 . . . . 0.0 110.139 170.548 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.45 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -97.38 127.33 49.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.73 0 CA-C-N 113.819 -1.537 . . . . 0.0 108.024 -176.566 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 92' ' ' GLY . . . . . 0.408 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -106.83 118.05 5.51 Favored Glycine 0 CA--C 1.466 -3.014 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 176.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 93' ' ' ARG . . . . . 0.522 ' O ' ' HA ' ' B' ' 3' ' ' MET . 9.9 tpp180 -72.94 91.23 1.53 Allowed 'General case' 0 C--N 1.288 -2.084 0 CA-C-N 115.067 -0.567 . . . . 0.0 110.416 178.648 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -85.2 73.53 10.59 Favored 'General case' 0 N--CA 1.424 -1.762 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 172.063 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 95' ' ' ARG . . . . . 0.522 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 36.6 ttt180 -81.09 -57.26 0.57 Allowed Pre-proline 0 N--CA 1.424 -1.762 0 CA-C-N 113.585 -1.643 . . . . 0.0 110.533 179.295 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 96' ' ' PRO . . . . . 0.522 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 60.5 Cg_endo -87.78 163.55 7.65 Favored 'Trans proline' 0 C--N 1.364 1.378 0 C-N-CA 122.289 1.993 . . . . 0.0 113.591 178.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -137.21 -75.75 0.07 OUTLIER Glycine 0 N--CA 1.423 -2.208 0 N-CA-C 108.457 -1.857 . . . . 0.0 108.457 174.675 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -82.35 68.8 8.93 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-O 122.479 1.133 . . . . 0.0 111.207 175.725 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 21.4 mm-40 -141.49 -160.36 1.07 Allowed 'General case' 0 N--CA 1.417 -2.085 0 C-N-CA 126.754 2.022 . . . . 0.0 106.473 176.472 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 7.4 m -62.32 158.5 17.21 Favored 'General case' 0 C--O 1.248 0.993 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 176.776 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 62.54 76.07 0.38 Allowed 'General case' 0 CA--C 1.506 -0.724 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 -170.616 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 15.8 m -71.9 86.86 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 114.44 -1.255 . . . . 0.0 112.871 -173.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -116.25 109.66 17.71 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.96 -176.832 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 60.9 tp60 55.85 86.03 0.06 Allowed 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 124.404 1.082 . . . . 0.0 112.737 177.846 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -103.91 153.73 20.45 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 176.495 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 48.9 mm -81.02 -75.9 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 120.739 -0.384 . . . . 0.0 111.022 -177.726 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 56.87 101.24 0.02 OUTLIER 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.151 0.981 . . . . 0.0 111.537 -175.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 46.5 tt0 -96.61 1.87 51.66 Favored 'General case' 0 C--N 1.288 -2.096 0 CA-C-O 121.787 0.803 . . . . 0.0 109.554 -177.853 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 6.3 t -114.18 173.23 6.55 Favored 'General case' 0 C--N 1.305 -1.331 0 O-C-N 121.912 -0.492 . . . . 0.0 110.981 -176.769 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 95.5 mt 60.19 -94.78 0.05 OUTLIER 'General case' 0 N--CA 1.469 0.516 0 C-N-CA 125.14 1.376 . . . . 0.0 111.991 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -84.35 78.95 9.71 Favored 'General case' 0 N--CA 1.426 -1.658 0 CA-C-O 122.468 1.128 . . . . 0.0 108.969 175.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 23.3 pt20 -105.95 22.57 15.4 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 114.234 -1.348 . . . . 0.0 110.653 -175.7 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 . . . . . 0 N--CA 1.432 -1.336 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 175.817 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.491 -1.461 0 N-CA-C 110.851 -0.899 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 76.52 156.27 0.17 Allowed 'General case' 0 C--O 1.246 0.918 0 C-N-CA 124.834 1.254 . . . . 0.0 111.777 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 68.5 mtm -73.86 129.71 38.44 Favored 'General case' 0 N--CA 1.424 -1.752 0 CA-C-N 115.236 -0.893 . . . . 0.0 109.161 178.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -76.03 102.12 5.53 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.507 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 0.6 OUTLIER -85.93 84.64 7.48 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.056 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -113.49 142.93 28.42 Favored Pre-proline 0 C--N 1.301 -1.522 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.906 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 7' ' ' PRO . . . . . 0.454 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 59.0 Cg_endo -80.0 131.59 9.03 Favored 'Trans proline' 0 N--CA 1.444 -1.391 0 C-N-CA 122.115 1.877 . . . . 0.0 113.396 179.238 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.469 HG13 ' HB3' ' B' ' 53' ' ' ARG . 75.9 t -119.08 141.23 39.97 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.998 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.502 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -129.82 139.67 51.18 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.496 HD12 HG13 ' B' ' 54' ' ' ILE . 1.0 OUTLIER -144.09 157.68 44.17 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.001 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.606 ' OE2' ' HD3' ' B' ' 86' ' ' ARG . 68.4 mm-40 -95.11 133.14 39.26 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 114.061 -1.427 . . . . 0.0 107.71 177.138 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 12' ' ' LYS . . . . . 0.429 ' HA ' HD13 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -80.73 135.3 35.97 Favored 'General case' 0 N--CA 1.426 -1.664 0 C-N-CA 118.928 -1.109 . . . . 0.0 108.491 173.815 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 13' ' ' ASP . . . . . 0.435 ' HB3' ' HB2' ' B' ' 47' ' ' ALA . 2.6 p30 -85.76 -178.12 6.54 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -174.059 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 18.9 m -68.93 -26.39 65.05 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.394 -175.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -81.91 -46.61 13.83 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 176.492 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 168.25 -85.07 0.09 OUTLIER Glycine 0 N--CA 1.423 -2.225 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 177.569 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.429 HD13 ' HA ' ' B' ' 12' ' ' LYS . 27.2 tp -164.15 108.28 0.97 Allowed 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 175.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 18' ' ' GLY . . . . . 0.479 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -67.7 59.22 0.33 Allowed Glycine 0 C--O 1.215 -1.077 0 C-N-CA 124.704 1.145 . . . . 0.0 115.581 -173.858 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.478 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.8 pt -144.8 -178.42 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.267 -3.006 0 C-N-CA 125.565 1.546 . . . . 0.0 107.365 173.265 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.4 m -156.69 161.68 39.84 Favored 'General case' 0 C--N 1.272 -2.804 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.141 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.443 ' HB ' HG22 ' B' ' 37' ' ' ILE . 26.3 pt -124.43 153.52 31.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-N 117.99 0.359 . . . . 0.0 110.278 -179.513 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.2 tp -137.64 135.15 46.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.676 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.87 103.63 2.93 Favored Glycine 0 N--CA 1.421 -2.311 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.179 -178.616 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 25.9 mmt -106.45 116.46 31.96 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 176.49 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 135.85 151.9 6.26 Favored Glycine 0 N--CA 1.414 -2.827 0 C-N-CA 120.22 -0.991 . . . . 0.0 112.14 179.087 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -143.86 106.67 4.47 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 175.095 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -171.92 32.4 0.13 Allowed Glycine 0 N--CA 1.436 -1.333 0 C-N-CA 119.729 -1.224 . . . . 0.0 113.55 -177.489 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.54 75.19 10.19 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 176.774 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -106.24 13.95 28.17 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 114.468 -1.242 . . . . 0.0 109.671 -174.613 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 89.2 mtp 64.19 9.16 4.56 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.118 0.967 . . . . 0.0 112.959 -178.726 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -157.13 29.61 0.53 Allowed Glycine 0 C--O 1.217 -0.922 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 75.1 mt -146.24 -69.37 0.26 Allowed 'General case' 0 CA--C 1.486 -1.506 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 179.617 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . 0.288 6.2 pt-20 40.43 70.79 0.22 Allowed 'General case' 0 C--N 1.352 0.699 0 O-C-N 124.862 1.351 . . . . 0.0 114.421 175.124 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -132.74 85.66 2.24 Favored 'General case' 0 N--CA 1.431 -1.403 0 CA-C-N 113.857 -1.519 . . . . 0.0 107.089 176.698 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -111.52 129.24 56.12 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-N 114.883 -1.053 . . . . 0.0 108.78 -179.051 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -94.68 87.64 1.1 Allowed Glycine 0 N--CA 1.4 -3.764 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.443 HG22 ' HB ' ' B' ' 21' ' ' ILE . 20.7 mm -82.99 78.38 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.362 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 173.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -81.56 169.77 16.67 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 114.193 -1.367 . . . . 0.0 109.371 -172.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 79.4 t -75.69 128.98 37.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-O 121.372 0.606 . . . . 0.0 109.814 176.231 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 9.2 tmtm? -84.5 -54.42 4.76 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.11 -177.823 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 7.9 t -145.7 175.2 10.56 Favored 'General case' 0 N--CA 1.429 -1.508 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 179.182 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.478 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.5 p -154.88 96.4 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 -179.378 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.425 HG22 ' H ' ' B' ' 45' ' ' GLY . 6.0 m -78.25 134.96 37.48 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 113.59 -1.641 . . . . 0.0 111.514 -170.621 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -61.87 -12.8 19.46 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.004 0.922 . . . . 0.0 113.238 178.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 45' ' ' GLY . . . . . 0.425 ' H ' HG22 ' B' ' 43' ' ' THR . . . -86.18 -2.05 85.98 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 116.528 -0.306 . . . . 0.0 112.455 177.688 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.479 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -115.88 169.97 13.15 Favored Glycine 0 N--CA 1.418 -2.544 0 C-N-CA 120.291 -0.957 . . . . 0.0 111.823 179.169 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 47' ' ' ALA . . . . . 0.435 ' HB2' ' HB3' ' B' ' 13' ' ' ASP . . . -69.28 -36.26 76.88 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 114.882 -0.659 . . . . 0.0 111.745 -175.088 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -57.03 -40.52 76.9 Favored 'General case' 0 CA--C 1.542 0.657 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -175.417 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -71.34 -42.46 68.51 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.213 0.53 . . . . 0.0 110.209 -179.081 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -75.09 -28.52 60.32 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.952 -175.345 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -80.75 -41.79 22.92 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.723 -177.582 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 83.78 43.24 7.33 Favored Glycine 0 C--N 1.309 -0.924 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.576 176.447 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.533 ' HE ' ' HA ' ' B' ' 53' ' ' ARG . 1.4 mmp_? -115.22 -69.72 0.84 Allowed 'General case' 0 C--N 1.301 -1.537 0 CA-C-O 119.091 -0.48 . . . . 0.0 110.848 178.847 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.601 HD11 ' CE2' ' B' ' 89' ' ' PHE . 77.7 mt -73.55 136.97 24.25 Favored 'Isoleucine or valine' 0 C--O 1.253 1.241 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 171.755 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 19.6 mt-30 -118.21 162.51 18.12 Favored 'General case' 0 C--N 1.289 -2.04 0 C-N-CA 123.909 0.884 . . . . 0.0 109.639 -174.718 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.478 ' HB ' HG12 ' B' ' 42' ' ' VAL . 9.7 p -73.6 -4.34 5.29 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-O 121.695 0.76 . . . . 0.0 111.075 -178.384 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -116.55 -5.49 11.68 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -176.144 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -91.39 -175.39 4.22 Favored 'General case' 0 C--O 1.247 0.958 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 -175.225 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.528 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 35.6 tp -139.35 128.07 23.29 Favored 'General case' 0 N--CA 1.435 -1.212 0 CA-C-N 114.775 -1.102 . . . . 0.0 109.883 -174.043 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 57.0 mt -87.09 95.38 9.93 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.455 -0.942 . . . . 0.0 108.455 178.141 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.441 ' HB ' ' O ' ' B' ' 90' ' ' MET . 36.3 t -75.65 -43.07 41.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 CA-C-O 121.843 0.83 . . . . 0.0 111.301 -178.445 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.419 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 12.2 pt-20 -146.63 160.95 41.53 Favored 'General case' 0 C--N 1.267 -2.997 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 173.511 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.554 HG21 HG21 ' B' ' 83' ' ' THR . 4.8 p -113.18 -177.44 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.728 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.505 ' H ' HG22 ' B' ' 63' ' ' VAL . 31.2 t70 -49.53 -45.73 47.75 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -176.369 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -132.29 31.33 3.03 Favored Glycine 0 CA--C 1.522 0.525 0 C-N-CA 119.687 -1.244 . . . . 0.0 114.607 -177.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 66' ' ' THR . . . . . 0.411 ' HB ' HG12 ' B' ' 63' ' ' VAL . 36.1 m -159.73 135.47 8.51 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 67' ' ' SER . . . . . 0.419 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 30.5 m -108.64 146.83 32.78 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.43 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 43.6 mt -104.31 115.05 29.7 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-O 120.938 0.399 . . . . 0.0 110.66 176.49 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 12.3 p -81.38 -20.39 10.95 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 N-CA-C 108.544 -0.909 . . . . 0.0 108.544 174.529 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 140.79 71.27 0.04 OUTLIER Glycine 0 CA--C 1.487 -1.672 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 -177.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.9 m -92.79 179.33 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 114.856 -0.672 . . . . 0.0 110.681 -175.051 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 43.5 p -82.86 165.28 19.93 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 177.192 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -59.45 -42.11 91.2 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.949 0.404 . . . . 0.0 110.108 179.37 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 48.5 m -66.5 -35.92 81.46 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.473 -179.413 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -66.61 -46.67 75.09 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.386 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.401 ' O ' ' HB ' ' B' ' 79' ' ' VAL . . . -60.52 -41.56 94.65 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.132 178.149 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.25 -34.96 75.99 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.072 178.268 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 24.5 m -76.9 -20.92 55.66 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.984 -179.018 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.401 ' HB ' ' O ' ' B' ' 76' ' ' ALA . 24.3 t -71.37 -57.11 8.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 16.6 mt -57.79 -18.59 22.74 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 125.325 1.45 . . . . 0.0 112.964 178.205 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 69.9 mtp180 -88.94 -18.09 28.2 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-O 121.279 0.561 . . . . 0.0 110.813 176.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -99.71 -6.19 27.54 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.729 0.776 . . . . 0.0 110.749 -176.747 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.554 HG21 HG21 ' B' ' 63' ' ' VAL . 18.9 p -82.41 165.96 19.81 Favored 'General case' 0 C--O 1.249 1.07 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 -178.482 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 57.7 mmtt -73.1 -167.58 0.41 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 124.594 1.158 . . . . 0.0 112.012 179.052 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.05 -34.23 55.87 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-N 115.509 -0.769 . . . . 0.0 112.516 -179.307 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 86' ' ' ARG . . . . . 0.606 ' HD3' ' OE2' ' B' ' 11' ' ' GLU . 45.5 ttp180 -134.69 124.69 25.68 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 175.621 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.539 HG11 ' HB ' ' B' ' 83' ' ' THR . 13.7 m -137.13 160.32 36.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.915 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -102.15 163.11 12.42 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 176.609 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.601 ' CE2' HD11 ' B' ' 54' ' ' ILE . 4.9 m-85 -140.44 155.99 46.52 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 179.072 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.441 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 9.5 ttt -110.22 115.07 29.05 Favored 'General case' 0 C--N 1.275 -2.631 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 174.082 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.528 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -92.29 138.45 19.92 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.342 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -177.679 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.26 112.99 1.29 Allowed Glycine 0 CA--C 1.486 -1.742 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 175.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 18.1 tpp180 -148.87 125.92 11.34 Favored 'General case' 0 C--N 1.286 -2.156 0 CA-C-N 115.099 -0.55 . . . . 0.0 109.757 -179.126 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -92.36 78.03 5.09 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 173.484 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 95' ' ' ARG . . . . . 0.469 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 32.7 ttm180 -77.92 -59.96 0.73 Allowed Pre-proline 0 N--CA 1.421 -1.876 0 CA-C-N 114.331 -1.304 . . . . 0.0 110.056 178.078 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 96' ' ' PRO . . . . . 0.469 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 91.7 Cg_endo -84.46 169.53 10.94 Favored 'Trans proline' 0 C--N 1.363 1.338 0 C-N-CA 122.166 1.911 . . . . 0.0 111.285 177.567 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 99.14 18.57 24.0 Favored Glycine 0 N--CA 1.428 -1.855 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.476 -177.686 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -77.27 -58.57 3.2 Favored 'General case' 0 N--CA 1.442 -0.841 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 178.37 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 63.44 -71.71 0.06 Allowed 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.952 1.301 . . . . 0.0 112.597 178.322 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 100' ' ' SER . . . . . 0.439 ' C ' ' H ' ' B' ' 102' ' ' VAL . 23.1 t -98.32 -155.06 0.48 Allowed 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -80.89 20.76 0.74 Allowed 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 123.626 0.77 . . . . 0.0 109.798 177.302 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 102' ' ' VAL . . . . . 0.439 ' H ' ' C ' ' B' ' 100' ' ' SER . 58.8 t -111.47 146.14 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 124.611 1.164 . . . . 0.0 108.374 -174.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -142.94 -77.17 0.25 Allowed 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 173.609 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -107.0 134.3 50.35 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 177.219 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 83.8 mt -115.24 109.78 18.47 Favored 'General case' 0 C--N 1.296 -1.731 0 CA-C-O 120.984 0.421 . . . . 0.0 111.259 179.344 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 1.7 mp -88.72 -62.24 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.073 178.14 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 5.5 pm0 -99.86 127.6 46.02 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 176.399 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 48.1 mt-30 -127.17 111.85 14.46 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 -178.745 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 11.5 t -104.93 -32.57 8.71 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 120.386 -0.525 . . . . 0.0 111.21 -178.65 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 96.2 mt -138.24 88.67 2.33 Favored 'General case' 0 C--O 1.242 0.684 0 CA-C-O 121.064 0.459 . . . . 0.0 112.064 -177.551 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 8.3 tp10 -92.36 -29.77 16.15 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 168.105 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 4.6 pp0? -158.33 158.83 35.08 Favored 'General case' 0 N--CA 1.43 -1.432 0 CA-C-N 113.839 -1.528 . . . . 0.0 107.163 174.685 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 . . . . . 0 C--N 1.294 -1.845 0 CA-C-O 118.786 -0.626 . . . . 0.0 110.618 -173.911 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.514 0 CA-C-O 120.007 -0.33 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 56.8 m80 -70.75 -42.14 70.86 Favored 'General case' 0 CA--C 1.507 -0.695 0 N-CA-C 107.409 -1.33 . . . . 0.0 107.409 175.705 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 64.4 mtm -125.85 133.08 52.07 Favored 'General case' 0 N--CA 1.423 -1.779 0 N-CA-C 104.466 -2.42 . . . . 0.0 104.466 171.272 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 4' ' ' GLU . . . . . 0.533 ' HB2' ' HB3' ' B' ' 93' ' ' ARG . 12.0 mt-10 -94.3 93.36 7.68 Favored 'General case' 0 C--N 1.289 -2.036 0 C-N-CA 118.46 -1.296 . . . . 0.0 110.4 -175.581 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -82.52 95.85 7.85 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 177.443 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 7.1 p90 -119.46 144.33 36.41 Favored Pre-proline 0 C--N 1.279 -2.48 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.128 176.575 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 7' ' ' PRO . . . . . 0.596 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 30.4 Cg_endo -72.87 129.46 14.39 Favored 'Trans proline' 0 N--CA 1.432 -2.099 0 C-N-CA 122.005 1.803 . . . . 0.0 112.242 176.719 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.492 ' HB ' HD13 ' B' ' 91' ' ' ILE . 70.5 t -115.02 122.02 68.28 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.046 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 177.527 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 9' ' ' GLU . . . . . 0.485 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 31.8 tt0 -105.58 132.22 52.0 Favored 'General case' 0 C--N 1.269 -2.895 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -176.574 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.601 HD11 ' HB2' ' B' ' 48' ' ' ALA . 0.6 OUTLIER -124.09 159.77 29.21 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 175.264 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.411 ' H ' HD23 ' B' ' 10' ' ' LEU . 4.5 pt-20 -132.12 125.81 32.2 Favored 'General case' 0 C--N 1.26 -3.322 0 CA-C-N 113.919 -1.491 . . . . 0.0 107.187 178.187 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt -66.14 151.88 45.98 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 121.938 0.875 . . . . 0.0 112.608 -178.206 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -102.66 178.34 4.6 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 14.7 m -67.79 -26.5 66.12 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 121.7 0.762 . . . . 0.0 109.035 175.885 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -72.74 -21.28 61.05 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-N 114.62 -1.173 . . . . 0.0 109.607 173.763 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.62 -105.12 2.7 Favored Glycine 0 N--CA 1.422 -2.236 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -176.863 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 94.8 mt -109.79 -176.87 3.12 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.1 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 18' ' ' GLY . . . . . 0.409 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -156.19 61.62 0.35 Allowed Glycine 0 CA--C 1.476 -2.383 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.22 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.586 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 3.1 pt -161.46 175.78 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.481 -1.693 0 C-N-CA 124.557 1.143 . . . . 0.0 108.157 -176.654 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 20' ' ' SER . . . . . 0.443 ' HB2' HG22 ' B' ' 41' ' ' THR . 54.9 m -148.59 151.7 35.49 Favored 'General case' 0 C--N 1.262 -3.2 0 N-CA-C 105.854 -1.906 . . . . 0.0 105.854 174.813 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.494 ' HB ' HG22 ' B' ' 37' ' ' ILE . 16.6 pt -116.94 162.06 15.2 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.537 0 O-C-N 123.421 0.45 . . . . 0.0 110.613 -176.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.5 tp -146.84 137.61 17.92 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.19 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.98 111.41 3.73 Favored Glycine 0 N--CA 1.431 -1.668 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.482 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 85.9 mtp -105.74 138.62 41.63 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 176.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 152.39 155.02 6.88 Favored Glycine 0 C--N 1.297 -1.619 0 C-N-CA 119.74 -1.219 . . . . 0.0 112.305 179.252 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -165.34 98.62 0.71 Allowed 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 124.62 1.168 . . . . 0.0 108.666 179.179 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.08 161.06 20.71 Favored Glycine 0 CA--C 1.487 -1.699 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -176.837 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.602 ' HA ' ' O ' ' B' ' 33' ' ' GLU . . . -136.38 107.95 6.97 Favored 'General case' 0 N--CA 1.422 -1.869 0 CA-C-O 121.758 0.79 . . . . 0.0 112.628 179.304 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.629 ' HB3' ' HB2' ' B' ' 33' ' ' GLU . 22.4 t70 -92.38 -10.07 39.44 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 114.33 -1.304 . . . . 0.0 108.18 173.062 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . 0.337 21.5 ptm 59.27 -6.54 0.06 Allowed 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 128.083 2.553 . . . . 0.0 114.404 -173.175 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 31' ' ' GLY . . . . . 0.421 ' H ' ' C ' ' B' ' 29' ' ' ASP . . . -105.52 69.09 0.24 Allowed Glycine 0 N--CA 1.434 -1.483 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 174.263 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . 0.275 4.4 mm? 77.95 -8.76 1.62 Allowed 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 114.68 1.363 . . . . 0.0 114.68 179.473 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 33' ' ' GLU . . . . . 0.629 ' HB2' ' HB3' ' B' ' 29' ' ' ASP . 29.9 mm-40 -103.21 74.27 1.28 Allowed 'General case' 0 N--CA 1.413 -2.31 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 177.517 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 12.6 mtmt -144.95 -171.65 3.68 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.146 -2.168 . . . . 0.0 105.146 176.15 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 35' ' ' LEU . . . . . 0.594 ' O ' ' HA2' ' B' ' 70' ' ' GLY . 85.9 mt -63.75 115.94 5.26 Favored 'General case' 0 C--N 1.291 -1.95 0 CA-C-O 121.881 0.848 . . . . 0.0 111.764 177.265 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -101.7 115.48 5.27 Favored Glycine 0 N--CA 1.4 -3.722 0 N-CA-C 106.903 -2.479 . . . . 0.0 106.903 176.11 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.494 HG22 ' HB ' ' B' ' 21' ' ' ILE . 29.1 mm -89.03 88.17 2.9 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 -177.888 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.478 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 73.5 m-85 -83.32 171.72 13.26 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 114.716 -1.129 . . . . 0.0 109.419 -177.664 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 58.9 t -78.19 136.22 24.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.67 0.748 . . . . 0.0 110.053 176.448 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -92.68 -48.13 6.74 Favored 'General case' 0 N--CA 1.426 -1.672 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.131 177.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 41' ' ' THR . . . . . 0.443 HG22 ' HB2' ' B' ' 20' ' ' SER . 1.0 OUTLIER -154.13 167.27 30.43 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -178.44 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.586 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.4 p -133.92 96.66 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.065 0 CA-C-O 122.389 1.09 . . . . 0.0 109.821 176.697 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 27.9 m -59.87 125.57 24.17 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 113.257 -1.792 . . . . 0.0 112.2 -175.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 44' ' ' GLU . . . . . 0.47 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 45.4 mt-10 -61.27 -35.07 76.31 Favored 'General case' 0 CA--C 1.516 -0.35 0 C-N-CA 124.21 1.004 . . . . 0.0 111.889 -176.122 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.79 -10.13 84.95 Favored Glycine 0 N--CA 1.441 -1.015 0 CA-C-N 115.861 -0.609 . . . . 0.0 113.415 -179.295 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.478 ' O ' ' HG3' ' B' ' 50' ' ' ARG . . . -106.23 171.2 17.38 Favored Glycine 0 N--CA 1.417 -2.629 0 C-N-CA 119.828 -1.177 . . . . 0.0 113.85 -175.452 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.26 -50.59 38.21 Favored 'General case' 0 C--O 1.208 -1.131 0 C-N-CA 125.213 1.405 . . . . 0.0 114.788 -173.52 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 48' ' ' ALA . . . . . 0.601 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -63.96 -32.44 73.97 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 113.88 1.067 . . . . 0.0 113.88 -172.018 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 49' ' ' HIS . . . . . 0.47 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 2.7 t60 -83.75 -38.8 20.89 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.128 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 50' ' ' ARG . . . . . 0.478 ' HG3' ' O ' ' B' ' 46' ' ' GLY . 74.9 mtp180 -70.32 -42.52 71.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.072 -178.683 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -74.09 -43.08 58.97 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 89.98 51.49 2.8 Favored Glycine 0 CA--C 1.504 -0.608 0 CA-C-N 115.113 -0.949 . . . . 0.0 112.406 175.729 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 34.0 mmt180 -112.94 -82.84 0.59 Allowed 'General case' 0 N--CA 1.442 -0.868 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.053 -177.356 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.463 HD11 ' CE2' ' B' ' 89' ' ' PHE . 70.7 mt -65.52 134.87 29.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 O-C-N 123.774 0.671 . . . . 0.0 109.396 179.648 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 24.4 mm-40 -111.95 164.77 12.74 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.416 HG23 ' HA ' ' B' ' 41' ' ' THR . 14.9 p -65.0 -8.34 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.578 2.028 0 N-CA-C 113.093 0.775 . . . . 0.0 113.093 -175.853 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -115.3 -6.09 12.37 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 -172.603 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -94.25 179.2 5.38 Favored 'General case' 0 N--CA 1.432 -1.373 0 N-CA-C 114.998 1.481 . . . . 0.0 114.998 -178.513 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.478 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 25.8 tp -135.25 136.69 41.89 Favored 'General case' 0 C--O 1.247 0.933 0 CA-C-N 114.958 -1.019 . . . . 0.0 110.954 -172.269 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 52.6 mt -83.82 96.84 8.89 Favored 'General case' 0 N--CA 1.425 -1.69 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 176.556 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.501 ' HB ' ' O ' ' B' ' 90' ' ' MET . 35.0 t -69.74 -42.75 80.28 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-O 122.159 0.98 . . . . 0.0 109.752 179.314 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -156.94 158.87 37.43 Favored 'General case' 0 C--N 1.277 -2.572 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.821 173.056 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.449 HG23 ' CD1' ' B' ' 89' ' ' PHE . 5.0 p -106.36 -175.9 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.099 0 N-CA-C 104.796 -2.298 . . . . 0.0 104.796 178.297 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.524 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 8.9 t70 -52.44 -54.47 31.77 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 112.792 0.664 . . . . 0.0 112.792 178.459 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -122.29 35.73 3.4 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 119.81 -1.186 . . . . 0.0 115.277 -177.072 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 66' ' ' THR . . . . . 0.448 ' HB ' HG12 ' B' ' 63' ' ' VAL . 19.2 m -160.9 141.64 11.5 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 177.45 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 47.3 t -107.02 151.37 25.42 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 -178.628 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.456 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.6 mm? -116.27 106.28 13.5 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 120.98 0.419 . . . . 0.0 110.434 178.609 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 42.6 t -103.51 -8.09 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-O 122.221 1.01 . . . . 0.0 109.096 176.234 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 70' ' ' GLY . . . . . 0.594 ' HA2' ' O ' ' B' ' 35' ' ' LEU . . . 131.52 78.02 0.16 Allowed Glycine 0 CA--C 1.484 -1.898 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -177.47 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.431 HG22 HD12 ' B' ' 68' ' ' LEU . 26.4 m -106.13 -175.08 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.098 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -175.836 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 72' ' ' THR . . . . . 0.41 ' O ' HG23 ' B' ' 71' ' ' VAL . 45.7 p -83.86 159.8 21.28 Favored 'General case' 0 N--CA 1.426 -1.655 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 175.061 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.0 tt0 -63.26 -31.37 72.51 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-O 121.519 0.676 . . . . 0.0 109.567 178.564 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 9.7 m -64.89 -43.18 93.75 Favored 'General case' 0 C--O 1.247 0.948 0 CA-C-N 115.052 -0.977 . . . . 0.0 110.051 177.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -62.27 -51.89 65.9 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 115.212 -0.904 . . . . 0.0 108.782 177.46 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.673 ' O ' ' HB ' ' B' ' 79' ' ' VAL . . . -57.61 -37.55 73.45 Favored 'General case' 0 C--O 1.214 -0.814 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.434 -178.131 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.84 -32.64 73.31 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.174 0.512 . . . . 0.0 111.037 178.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 19.0 m -79.36 -19.65 49.71 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.767 179.535 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.673 ' HB ' ' O ' ' B' ' 76' ' ' ALA . 3.9 t -57.15 -57.46 9.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.447 1.099 . . . . 0.0 111.843 177.072 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 80' ' ' LEU . . . . . 0.511 ' H ' HD22 ' B' ' 80' ' ' LEU . 2.6 mm? -58.62 -30.15 67.04 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 122.822 0.449 . . . . 0.0 111.781 178.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 31.6 mtp85 -80.76 -16.76 52.99 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.785 -179.158 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -81.97 -27.91 32.97 Favored 'General case' 0 N--CA 1.44 -0.973 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.659 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.611 ' HB ' HG11 ' B' ' 87' ' ' VAL . 12.5 p -88.99 159.86 17.4 Favored 'General case' 0 N--CA 1.417 -2.088 0 CA-C-N 114.882 -1.054 . . . . 0.0 112.887 179.05 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 72.5 mttt -64.6 -174.91 0.15 Allowed 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 124.914 1.286 . . . . 0.0 113.682 -177.114 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.94 -42.53 94.78 Favored Glycine 0 N--CA 1.445 -0.762 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.985 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 56.9 ttm-85 -123.13 118.46 27.73 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 176.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.611 HG11 ' HB ' ' B' ' 83' ' ' THR . 6.2 m -146.41 156.3 11.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.786 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.256 -178.037 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 88' ' ' ARG . . . . . 0.485 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 95.5 mtt180 -105.71 125.54 51.11 Favored 'General case' 0 N--CA 1.423 -1.799 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.47 177.452 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.596 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 1.8 m-85 -100.32 166.79 10.79 Favored 'General case' 0 C--N 1.27 -2.856 0 N-CA-C 106.026 -1.842 . . . . 0.0 106.026 176.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.501 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 64.3 mtt -113.3 112.92 24.52 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 171.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.492 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.4 mp -97.25 128.77 48.18 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -101.39 100.89 2.15 Favored Glycine 0 CA--C 1.46 -3.356 0 N-CA-C 108.522 -1.831 . . . . 0.0 108.522 176.338 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 93' ' ' ARG . . . . . 0.533 ' HB3' ' HB2' ' B' ' 4' ' ' GLU . 21.2 tpp180 -69.39 118.79 12.72 Favored 'General case' 0 C--N 1.277 -2.547 0 CA-C-N 114.398 -0.901 . . . . 0.0 109.991 -177.218 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -87.06 79.99 8.51 Favored 'General case' 0 N--CA 1.409 -2.521 0 N-CA-C 104.826 -2.287 . . . . 0.0 104.826 172.035 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 95' ' ' ARG . . . . . 0.413 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 16.4 ttm180 -57.46 -59.48 12.75 Favored Pre-proline 0 CA--C 1.549 0.939 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.865 -179.206 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 96' ' ' PRO . . . . . 0.413 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 90.9 Cg_endo -82.92 -177.65 3.46 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.163 1.909 . . . . 0.0 111.625 175.167 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -121.99 -38.21 0.62 Allowed Glycine 0 C--N 1.297 -1.589 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 175.553 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 19.0 mt-10 -82.43 -14.51 55.01 Favored 'General case' 0 C--N 1.315 -0.892 0 C-N-CA 123.656 0.782 . . . . 0.0 108.974 178.841 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 58.9 tp60 63.32 -95.4 0.05 OUTLIER 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 125.384 1.473 . . . . 0.0 109.452 -173.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 72.5 m -170.46 166.18 8.46 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 126.084 1.754 . . . . 0.0 106.271 176.567 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -117.19 3.69 12.65 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 121.537 0.684 . . . . 0.0 110.857 177.487 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 21.1 m -120.14 144.72 27.97 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-N 115.038 -0.983 . . . . 0.0 109.506 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -152.96 -80.45 0.1 Allowed 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 177.162 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 5.9 tp-100 -130.61 115.1 16.26 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 107.213 -1.402 . . . . 0.0 107.213 -179.736 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 5.8 mp -96.76 69.74 2.48 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.527 0.68 . . . . 0.0 111.202 -175.665 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 31.9 mm -111.1 -59.99 3.03 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.796 178.103 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -72.2 -16.87 61.96 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.658 0.742 . . . . 0.0 109.355 177.528 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 54.9 mt-30 -73.76 79.88 1.57 Allowed 'General case' 0 N--CA 1.433 -1.306 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.168 178.778 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 15.3 t -129.71 -4.06 4.69 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 107.286 -1.375 . . . . 0.0 107.286 170.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 95.1 mt -134.37 83.24 2.02 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 114.546 -1.206 . . . . 0.0 107.924 177.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.27 149.58 33.64 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 -179.83 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 23.6 tt0 -90.85 87.45 6.66 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 179.405 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 . . . . . 0 C--N 1.296 -1.747 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.792 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.272 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 2' ' ' HIS . . . . . 0.493 ' O ' ' HB2' ' B' ' 94' ' ' GLU . 22.9 p-80 -138.89 165.97 25.69 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 -177.443 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 1.7 mpt? -88.95 121.72 31.59 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 176.656 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -75.97 98.55 4.3 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 177.435 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -81.28 88.97 6.04 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 175.77 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -109.92 145.31 31.78 Favored Pre-proline 0 C--N 1.288 -2.077 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.672 178.781 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -75.91 129.92 11.94 Favored 'Trans proline' 0 N--CA 1.44 -1.66 0 C-N-CA 122.19 1.926 . . . . 0.0 111.97 177.65 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.521 HG13 ' HB3' ' B' ' 53' ' ' ARG . 84.9 t -116.61 126.2 73.96 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.401 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.331 -179.071 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 9' ' ' GLU . . . . . 0.477 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 41.4 tt0 -120.81 128.78 53.18 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -178.675 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.557 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -115.41 -162.59 0.84 Allowed 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.796 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.518 ' H ' HD22 ' B' ' 10' ' ' LEU . 2.3 mm-40 -156.67 167.69 29.69 Favored 'General case' 0 C--N 1.29 -1.998 0 C-N-CA 126.251 1.82 . . . . 0.0 106.145 176.353 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -92.81 -173.15 3.23 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 121.297 0.57 . . . . 0.0 111.35 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 13' ' ' ASP . . . . . 0.47 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 21.9 t70 -128.52 172.05 11.53 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 22.8 t -61.75 -30.98 71.14 Favored 'General case' 0 C--N 1.307 -1.251 0 O-C-N 123.789 0.681 . . . . 0.0 109.199 178.298 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -91.59 -51.95 5.0 Favored 'General case' 0 N--CA 1.446 -0.662 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 173.377 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.461 ' H ' ' HB3' ' B' ' 13' ' ' ASP . . . 126.47 133.27 3.83 Favored Glycine 0 N--CA 1.428 -1.848 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.977 178.043 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mm? 63.66 -168.66 0.2 Allowed 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 176.648 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.19 54.29 0.05 OUTLIER Glycine 0 C--O 1.209 -1.43 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 179.035 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.599 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 4.9 pt -166.91 177.62 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.493 -1.246 0 C-N-CA 125.068 1.347 . . . . 0.0 108.657 -173.707 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 20' ' ' SER . . . . . 0.421 ' HB2' HG22 ' B' ' 41' ' ' THR . 39.1 m -151.95 144.92 24.47 Favored 'General case' 0 C--N 1.27 -2.853 0 N-CA-C 105.461 -2.051 . . . . 0.0 105.461 174.146 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.464 ' HB ' HG22 ' B' ' 37' ' ' ILE . 12.3 pt -111.1 160.76 10.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.054 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 -178.361 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.8 tp -138.75 138.17 42.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-O 120.939 0.399 . . . . 0.0 110.177 -178.375 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.72 98.7 2.3 Favored Glycine 0 N--CA 1.423 -2.221 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 177.453 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 86.4 mtp -91.97 157.24 16.91 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 178.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.3 173.36 14.68 Favored Glycine 1 N--CA 1.388 -4.555 0 N-CA-C 107.359 -2.296 . . . . 0.0 107.359 179.665 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . 64.94 73.12 0.42 Allowed 'General case' 0 C--N 1.287 -2.148 0 CA-C-O 122.192 0.996 . . . . 0.0 111.319 -177.678 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -128.16 60.98 0.66 Allowed Glycine 0 N--CA 1.428 -1.859 0 CA-C-N 114.923 -1.035 . . . . 0.0 111.014 -178.425 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.16 75.14 8.14 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 121.868 0.842 . . . . 0.0 109.626 178.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 11.7 p-10 -89.61 -9.66 48.88 Favored 'General case' 0 N--CA 1.42 -1.957 0 C-N-CA 125.049 1.34 . . . . 0.0 110.034 -176.66 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 61.1 mtt 67.56 73.78 0.32 Allowed 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 114.266 -1.334 . . . . 0.0 109.743 -172.63 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 31' ' ' GLY . . . . . 0.489 ' H ' ' HG3' ' B' ' 33' ' ' GLU . . . 168.51 -59.74 0.2 Allowed Glycine 0 N--CA 1.437 -1.256 0 CA-C-N 113.673 -1.603 . . . . 0.0 109.511 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 32' ' ' LEU . . . . . 0.448 ' HG ' ' HA ' ' B' ' 69' ' ' VAL . 9.3 mp -88.92 -53.31 4.66 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 176.527 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 33' ' ' GLU . . . . . 0.489 ' HG3' ' H ' ' B' ' 31' ' ' GLY . 47.5 mt-10 54.29 29.45 10.79 Favored 'General case' 0 C--N 1.349 0.555 0 C-N-CA 124.733 1.213 . . . . 0.0 112.241 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 37.2 mtmm -147.0 -168.79 3.14 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.15 -175.883 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 77.6 mt -47.54 129.92 13.69 Favored 'General case' 0 C--O 1.248 0.996 0 O-C-N 124.926 1.391 . . . . 0.0 111.483 177.303 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -113.59 123.42 6.13 Favored Glycine 0 N--CA 1.412 -2.935 0 N-CA-C 108.892 -1.683 . . . . 0.0 108.892 177.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.464 HG22 ' HB ' ' B' ' 21' ' ' ILE . 20.7 mm -93.81 89.21 2.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.375 -0.93 . . . . 0.0 108.91 -179.46 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.457 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 90.5 m-85 -89.69 169.6 11.17 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.598 -178.376 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 58.0 t -75.32 134.83 28.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 CA-C-O 121.29 0.567 . . . . 0.0 109.723 175.364 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -93.04 -45.71 7.79 Favored 'General case' 0 N--CA 1.435 -1.186 0 CA-C-N 115.337 -0.847 . . . . 0.0 108.835 -179.09 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 41' ' ' THR . . . . . 0.433 ' HA ' HG23 ' B' ' 56' ' ' VAL . 2.5 t -155.21 169.2 24.72 Favored 'General case' 0 N--CA 1.419 -2.003 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.455 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.599 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.3 p -140.47 99.67 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.279 -2.496 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 -179.709 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 9.8 m -61.13 124.46 20.6 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 113.804 -1.543 . . . . 0.0 111.549 -175.095 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -69.92 -20.93 63.33 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.256 0.551 . . . . 0.0 111.863 -177.725 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.95 4.76 85.54 Favored Glycine 0 N--CA 1.437 -1.292 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.673 175.245 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -113.29 172.09 14.24 Favored Glycine 0 N--CA 1.425 -2.044 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.92 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 47' ' ' ALA . . . . . 0.47 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -64.86 -42.05 95.19 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -173.581 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 48' ' ' ALA . . . . . 0.557 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -58.85 -38.09 77.96 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 113.649 0.981 . . . . 0.0 113.649 -173.601 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -75.79 -41.07 53.95 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.244 0.545 . . . . 0.0 109.581 -177.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 64.4 mtp180 -68.18 -44.04 76.81 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.717 -178.264 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -63.21 -59.4 4.79 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.909 176.595 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 110.83 -15.53 28.78 Favored Glycine 0 N--CA 1.437 -1.233 0 C-N-CA 120.286 -0.959 . . . . 0.0 114.279 176.171 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.521 ' HB3' HG13 ' B' ' 8' ' ' VAL . 30.4 mmt180 -62.85 -52.33 63.55 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 114.131 1.16 . . . . 0.0 114.131 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.522 HD11 ' CE2' ' B' ' 89' ' ' PHE . 39.0 mt -95.7 119.01 43.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 C-N-CA 119.634 -0.826 . . . . 0.0 109.901 178.57 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 85.0 mm-40 -107.69 -179.92 4.05 Favored 'General case' 0 N--CA 1.433 -1.317 0 CA-C-O 121.269 0.557 . . . . 0.0 109.881 177.22 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.433 HG23 ' HA ' ' B' ' 41' ' ' THR . 12.7 p -71.02 -5.46 5.75 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.329 0 N-CA-C 113.087 0.773 . . . . 0.0 113.087 -174.681 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -117.12 4.24 12.7 Favored 'General case' 0 C--N 1.313 -0.996 0 O-C-N 121.06 -1.025 . . . . 0.0 111.354 -175.214 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -79.09 164.22 24.47 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.504 -175.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.457 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 23.2 tp -136.69 128.34 28.81 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 123.078 0.551 . . . . 0.0 110.349 -176.587 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 70.3 mt -79.78 92.36 5.43 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.749 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.529 ' HB ' ' O ' ' B' ' 90' ' ' MET . 40.8 t -76.31 -42.24 36.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-O 122.066 0.936 . . . . 0.0 109.749 178.394 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.415 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 8.6 pt-20 -154.23 147.49 24.84 Favored 'General case' 0 C--N 1.274 -2.697 0 CA-C-N 114.843 -1.072 . . . . 0.0 109.348 174.809 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.41 HG12 ' O ' ' B' ' 66' ' ' THR . 5.3 p -97.61 -174.98 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 104.349 -2.463 . . . . 0.0 104.349 174.524 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.55 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 28.8 t70 -56.37 -44.11 79.83 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 118.643 0.656 . . . . 0.0 112.563 -179.259 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -103.88 -66.57 0.72 Allowed Glycine 0 CA--C 1.528 0.85 0 C-N-CA 120.391 -0.909 . . . . 0.0 113.277 178.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 66' ' ' THR . . . . . 0.41 ' O ' HG12 ' B' ' 63' ' ' VAL . 14.2 m -66.87 129.86 41.27 Favored 'General case' 0 CA--C 1.547 0.849 0 CA-C-O 121.135 0.493 . . . . 0.0 112.124 -177.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 4.4 m -95.15 139.48 31.43 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 177.157 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.512 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.3 mm? -101.44 125.97 48.15 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.696 0.76 . . . . 0.0 111.39 -179.009 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 69' ' ' VAL . . . . . 0.448 ' HA ' ' HG ' ' B' ' 32' ' ' LEU . 8.8 p -125.13 9.57 4.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 115.163 -0.926 . . . . 0.0 109.104 178.79 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 120.09 87.89 1.05 Allowed Glycine 0 CA--C 1.499 -0.942 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -177.356 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.0 m -121.94 -179.11 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -177.776 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 32.3 p -83.88 164.16 19.62 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 175.543 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.3 tt0 -60.89 -41.23 95.63 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.278 0.561 . . . . 0.0 110.246 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 12.9 t -66.74 -36.41 82.38 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.282 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 75' ' ' PHE . . . . . 0.416 ' O ' HG13 ' B' ' 79' ' ' VAL . 38.0 t80 -62.29 -52.29 64.26 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -179.65 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.698 ' O ' HG22 ' B' ' 79' ' ' VAL . . . -65.93 -31.32 72.18 Favored 'General case' 0 C--O 1.218 -0.574 0 CA-C-O 120.978 0.418 . . . . 0.0 110.383 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.4 -34.54 77.96 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.757 0.789 . . . . 0.0 109.603 175.811 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.4 m -84.18 -17.14 40.94 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 115.194 -0.912 . . . . 0.0 112.112 -177.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.698 HG22 ' O ' ' B' ' 76' ' ' ALA . 23.5 m -68.81 -38.87 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 CA-C-O 121.53 0.681 . . . . 0.0 109.588 -178.439 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 23.5 mt -65.56 -21.31 66.59 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 125.193 1.397 . . . . 0.0 110.884 176.728 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 80.7 mtt180 -92.94 -14.36 27.65 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.491 -177.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -94.79 -22.28 18.17 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.669 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.705 ' HB ' HG11 ' B' ' 87' ' ' VAL . 6.6 p -80.77 -177.37 6.3 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.707 177.854 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -67.8 -171.48 0.21 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 123.484 0.714 . . . . 0.0 111.217 178.21 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -73.15 -42.05 44.94 Favored Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.134 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 86' ' ' ARG . . . . . 0.483 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 16.0 ttp180 -121.99 124.13 43.29 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 175.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.705 HG11 ' HB ' ' B' ' 83' ' ' THR . 5.2 m -137.86 165.58 25.93 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 CA-C-O 121.055 0.455 . . . . 0.0 110.858 178.084 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 51.8 mtp85 -106.52 147.91 28.84 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.405 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.522 ' CE2' HD11 ' B' ' 54' ' ' ILE . 0.7 OUTLIER -129.83 170.38 13.97 Favored 'General case' 0 C--N 1.277 -2.578 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 -179.224 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.529 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 59.8 mtt -121.16 122.93 41.06 Favored 'General case' 0 C--N 1.292 -1.923 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 168.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 1.3 mp -105.7 133.31 50.4 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 CA-C-N 114.194 -1.366 . . . . 0.0 107.446 -178.307 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -117.69 101.14 0.9 Allowed Glycine 0 CA--C 1.48 -2.113 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 177.819 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 19.2 tpp180 -147.98 128.21 13.83 Favored 'General case' 0 C--N 1.274 -2.685 0 CA-C-N 114.435 -0.883 . . . . 0.0 110.099 -176.18 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 94' ' ' GLU . . . . . 0.493 ' HB2' ' O ' ' B' ' 2' ' ' HIS . 45.1 tt0 -101.29 84.57 2.65 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 172.28 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 95' ' ' ARG . . . . . 0.409 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 46.4 ttt180 -80.28 -57.15 0.66 Allowed Pre-proline 0 C--N 1.295 -1.765 0 CA-C-N 114.722 -1.127 . . . . 0.0 110.995 178.63 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 96' ' ' PRO . . . . . 0.409 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 65.8 Cg_endo -86.54 -178.48 2.7 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 122.2 1.933 . . . . 0.0 110.888 176.284 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -105.67 -33.97 3.43 Favored Glycine 0 C--N 1.295 -1.702 0 C-N-CA 120.441 -0.885 . . . . 0.0 110.956 176.018 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -144.1 -28.88 0.5 Allowed 'General case' 0 N--CA 1.425 -1.695 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -178.591 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 -84.86 79.83 9.49 Favored 'General case' 0 N--CA 1.426 -1.648 0 CA-C-O 122.012 0.911 . . . . 0.0 112.413 -178.606 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 19.5 m -105.94 170.64 7.79 Favored 'General case' 0 C--N 1.288 -2.069 0 CA-C-N 114.28 -1.327 . . . . 0.0 108.178 177.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -98.12 -39.16 9.03 Favored 'General case' 0 CA--C 1.485 -1.527 0 C-N-CA 119.219 -0.993 . . . . 0.0 110.074 175.473 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 20.5 t -94.46 78.38 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.262 -3.204 0 CA-C-N 114.255 -1.339 . . . . 0.0 108.069 -179.64 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -102.75 -68.91 0.81 Allowed 'General case' 0 C--N 1.264 -3.115 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.036 178.25 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 76.1 mm-40 -106.69 19.79 19.96 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.19 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -91.45 21.35 4.61 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.295 0.569 . . . . 0.0 111.184 -179.136 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 36.5 mm -78.41 -60.24 2.43 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 178.234 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 25.1 mm-40 35.86 91.24 0.01 OUTLIER 'General case' 0 C--O 1.235 0.329 0 C-N-CA 127.314 2.246 . . . . 0.0 114.264 173.241 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 108' ' ' GLN . . . . . 0.431 HE21 ' HB2' ' B' ' 112' ' ' GLN . 49.8 tp60 -141.85 97.73 3.2 Favored 'General case' 0 C--N 1.311 -1.093 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.457 -179.25 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 5.7 t -153.04 161.12 42.9 Favored 'General case' 0 N--CA 1.427 -1.591 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 176.328 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 96.0 mt 63.09 30.23 16.18 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 123.835 0.854 . . . . 0.0 111.121 174.642 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -158.34 -50.77 0.06 Allowed 'General case' 0 C--N 1.313 -0.978 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -176.823 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 112' ' ' GLN . . . . . 0.431 ' HB2' HE21 ' B' ' 108' ' ' GLN . 32.7 tt0 -94.82 -59.36 1.93 Allowed 'General case' 0 C--N 1.308 -1.204 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 176.068 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 11.2 tp10 . . . . . 0 N--CA 1.414 -2.257 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 175.363 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.488 -1.609 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 60.9 m80 58.5 -89.23 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.406 1.082 . . . . 0.0 109.669 -175.1 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 3' ' ' MET . . . . . 0.46 ' O ' HD22 ' B' ' 5' ' ' LEU . 25.5 mmt -95.03 97.6 10.07 Favored 'General case' 0 N--CA 1.432 -1.34 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 169.824 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -83.38 92.3 7.52 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 -175.45 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.46 HD22 ' O ' ' B' ' 3' ' ' MET . 0.7 OUTLIER -88.49 93.99 9.72 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 176.585 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -111.77 142.89 27.54 Favored Pre-proline 0 C--N 1.281 -2.395 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.539 179.562 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 7' ' ' PRO . . . . . 0.498 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 57.8 Cg_endo -78.64 132.82 11.17 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 122.319 2.013 . . . . 0.0 113.316 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.503 HG13 ' HB3' ' B' ' 53' ' ' ARG . 71.6 t -117.69 122.59 70.16 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -106.77 132.25 52.96 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.192 -175.21 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.434 HD21 ' HA ' ' B' ' 48' ' ' ALA . 1.0 OUTLIER -135.51 158.57 44.04 Favored 'General case' 0 N--CA 1.427 -1.607 0 CA-C-O 121.293 0.568 . . . . 0.0 110.743 176.606 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -145.37 161.37 39.82 Favored 'General case' 0 C--N 1.278 -2.515 0 CA-C-N 114.105 -1.407 . . . . 0.0 107.228 175.198 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 60.6 mttp -86.71 156.64 19.88 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-O 122.029 0.919 . . . . 0.0 113.259 -172.852 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -71.55 -69.95 0.35 Allowed 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 113.69 -1.595 . . . . 0.0 110.744 178.62 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 47.0 t -176.55 -39.62 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 105.398 -2.075 . . . . 0.0 105.398 -175.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -78.3 -57.02 4.0 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 172.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 161.61 -142.54 8.1 Favored Glycine 0 N--CA 1.428 -1.887 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 179.354 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -91.59 -174.47 3.88 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.392 0.615 . . . . 0.0 110.003 176.31 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -133.98 -113.78 1.42 Allowed Glycine 0 N--CA 1.419 -2.475 0 N-CA-C 108.411 -1.876 . . . . 0.0 108.411 176.443 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.56 HG22 ' HA ' ' B' ' 42' ' ' VAL . 24.0 pt 45.04 -177.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 C-N-CA 125.573 1.549 . . . . 0.0 114.993 178.22 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 43.8 m -157.87 146.39 19.13 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 104.823 -2.288 . . . . 0.0 104.823 173.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.525 ' HB ' HG22 ' B' ' 37' ' ' ILE . 12.5 pt -119.58 161.02 19.27 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.364 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 22' ' ' ILE . . . . . 0.415 ' HB ' ' CG ' ' B' ' 40' ' ' LYS . 8.7 tp -136.75 135.32 48.61 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 CA-C-O 120.964 0.412 . . . . 0.0 110.446 -176.363 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.33 103.24 3.02 Favored Glycine 0 N--CA 1.426 -2.011 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.025 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 68.6 mtm -129.3 107.48 9.56 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.266 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -163.15 154.09 24.88 Favored Glycine 0 N--CA 1.42 -2.397 0 C-N-CA 120.34 -0.933 . . . . 0.0 111.568 -177.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -136.15 94.2 3.01 Favored 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 176.637 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -176.42 33.85 0.09 OUTLIER Glycine 0 N--CA 1.43 -1.732 0 C-N-CA 120.633 -0.794 . . . . 0.0 113.222 -177.845 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -76.96 117.63 18.75 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 174.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -143.12 30.59 1.41 Allowed 'General case' 0 C--N 1.288 -2.081 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -173.375 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 15.6 ptt? 45.48 44.31 9.6 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 125.021 1.328 . . . . 0.0 112.973 -179.175 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.09 -51.3 0.26 Allowed Glycine 0 N--CA 1.443 -0.865 0 CA-C-N 114.98 -1.009 . . . . 0.0 112.126 -179.12 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 91.1 mt -66.57 -48.55 69.26 Favored 'General case' 0 CA--C 1.512 -0.512 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 178.001 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 33' ' ' GLU . . . . . 0.63 ' O ' ' HA3' ' B' ' 70' ' ' GLY . 5.0 mm-40 46.49 40.88 8.78 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 126.185 1.794 . . . . 0.0 113.472 177.81 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 56.9 pttt -76.71 82.07 3.34 Favored 'General case' 0 N--CA 1.438 -1.069 0 CA-C-O 122.195 0.998 . . . . 0.0 113.21 -175.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 97.6 mt -108.15 142.59 38.14 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 114.065 -1.425 . . . . 0.0 108.142 176.528 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -108.54 114.15 4.01 Favored Glycine 0 N--CA 1.422 -2.269 0 C-N-CA 120.235 -0.984 . . . . 0.0 111.571 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.525 HG22 ' HB ' ' B' ' 21' ' ' ILE . 20.7 mm -95.32 88.19 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.521 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 175.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.411 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 96.1 m-85 -82.07 172.1 13.6 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 114.901 -1.045 . . . . 0.0 108.686 -178.192 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 45.5 t -79.17 142.58 13.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 175.645 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 40' ' ' LYS . . . . . 0.415 ' CG ' ' HB ' ' B' ' 22' ' ' ILE . 0.1 OUTLIER -103.08 -42.63 5.72 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 -178.363 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 41' ' ' THR . . . . . 0.452 ' HA ' HG23 ' B' ' 56' ' ' VAL . 1.5 t -155.78 164.8 38.08 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 179.108 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.56 ' HA ' HG22 ' B' ' 19' ' ' ILE . 16.9 t -124.63 94.73 2.91 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.512 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 6.3 m -54.61 124.9 17.71 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 123.34 0.656 . . . . 0.0 111.517 179.752 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -62.09 -30.6 71.11 Favored 'General case' 0 C--O 1.222 -0.345 0 O-C-N 124.415 1.072 . . . . 0.0 112.26 -177.298 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.46 -23.46 77.05 Favored Glycine 0 N--CA 1.438 -1.172 0 C-N-CA 121.221 -0.514 . . . . 0.0 112.464 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.08 159.79 30.36 Favored Glycine 0 N--CA 1.416 -2.669 0 C-N-CA 119.692 -1.242 . . . . 0.0 113.158 -175.284 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -56.01 -38.31 70.34 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.27 -1.465 . . . . 0.0 112.458 -176.475 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 48' ' ' ALA . . . . . 0.434 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -59.03 -35.32 73.09 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -175.645 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 4.2 t60 -78.17 -40.69 36.99 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.491 0.663 . . . . 0.0 109.38 -179.223 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 65.6 mtp180 -73.86 -39.46 63.95 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 114.508 -1.223 . . . . 0.0 110.072 -174.484 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 51' ' ' ASP . . . . . 0.462 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 9.9 t70 -68.06 -60.08 2.76 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 173.174 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 97.69 11.38 50.82 Favored Glycine 0 N--CA 1.427 -1.919 0 CA-C-O 119.073 -0.849 . . . . 0.0 114.964 175.101 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.567 ' NE ' ' HA ' ' B' ' 53' ' ' ARG . 3.6 mmp_? -76.09 -50.25 15.21 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 118.655 1.227 . . . . 0.0 112.492 174.551 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.487 HD11 ' CE2' ' B' ' 89' ' ' PHE . 33.4 mt -77.36 141.02 16.14 Favored 'Isoleucine or valine' 0 C--O 1.249 1.072 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 175.538 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 72.5 mm-40 -114.54 -177.17 3.06 Favored 'General case' 0 N--CA 1.433 -1.315 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 -178.159 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.452 HG23 ' HA ' ' B' ' 41' ' ' THR . 8.4 p -90.45 3.55 6.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 CA-C-O 121.436 0.636 . . . . 0.0 111.416 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -119.38 -16.4 8.98 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 -174.693 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -76.39 178.65 6.39 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 114.491 1.293 . . . . 0.0 114.491 -173.43 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.47 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 27.8 tp -133.79 121.9 22.51 Favored 'General case' 0 N--CA 1.437 -1.113 0 CA-C-N 114.933 -1.03 . . . . 0.0 110.911 -172.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 74.6 mt -80.67 91.66 5.89 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.458 179.128 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.583 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 10.8 t -72.5 -37.43 57.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 123.189 0.596 . . . . 0.0 111.078 179.076 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.558 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 12.8 pt-20 -160.43 157.64 28.08 Favored 'General case' 0 C--N 1.28 -2.413 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.001 171.806 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.461 HG12 ' HB ' ' B' ' 66' ' ' THR . 5.6 p -101.82 -178.35 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 105.484 -2.043 . . . . 0.0 105.484 178.434 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.415 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 9.4 t70 -55.94 -53.64 54.39 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -178.556 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -112.17 22.14 18.71 Favored Glycine 0 C--N 1.318 -0.425 0 C-N-CA 120.151 -1.023 . . . . 0.0 114.703 -175.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 66' ' ' THR . . . . . 0.461 ' HB ' HG12 ' B' ' 63' ' ' VAL . 32.3 m -153.89 115.19 4.13 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 117.859 0.83 . . . . 0.0 109.709 178.778 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 67' ' ' SER . . . . . 0.558 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 45.6 m -87.09 138.05 31.82 Favored 'General case' 0 N--CA 1.433 -1.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.751 178.322 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.583 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 52.5 mt -107.71 101.54 10.84 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-O 120.918 0.39 . . . . 0.0 111.695 -178.294 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 12.2 p -71.39 -26.63 26.97 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 172.675 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 70' ' ' GLY . . . . . 0.63 ' HA3' ' O ' ' B' ' 33' ' ' GLU . . . 151.62 85.77 0.05 OUTLIER Glycine 0 N--CA 1.424 -2.165 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -178.406 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 33.0 m -105.72 -177.56 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 CA-C-N 115.141 -0.53 . . . . 0.0 109.82 -177.056 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 71.6 p -81.37 166.68 20.21 Favored 'General case' 0 N--CA 1.428 -1.559 0 CA-C-O 121.236 0.541 . . . . 0.0 110.112 177.148 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -62.18 -39.85 94.09 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.584 -0.735 . . . . 0.0 109.935 178.788 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 20.3 t -69.77 -39.02 76.9 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.092 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 75' ' ' PHE . . . . . 0.437 ' O ' HG13 ' B' ' 79' ' ' VAL . 17.8 t80 -60.4 -51.57 68.91 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 -179.611 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.631 ' O ' HG22 ' B' ' 79' ' ' VAL . . . -64.38 -33.56 76.13 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.113 179.426 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.46 -37.44 87.3 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.622 0.725 . . . . 0.0 109.709 176.832 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.6 p -79.1 -18.06 54.0 Favored 'General case' 0 N--CA 1.427 -1.592 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 178.756 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.631 HG22 ' O ' ' B' ' 76' ' ' ALA . 32.9 m -73.67 -36.17 46.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 121.976 0.894 . . . . 0.0 109.703 -178.797 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 51.9 mt -66.1 -26.69 67.58 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 114.245 -1.343 . . . . 0.0 110.914 177.151 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 23.0 mtp180 -96.1 -8.0 34.53 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -176.523 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 25.7 m-80 -102.28 -13.77 17.24 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 120.852 0.358 . . . . 0.0 111.634 178.072 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.604 ' HB ' HG11 ' B' ' 87' ' ' VAL . 2.6 p -81.79 173.29 12.42 Favored 'General case' 0 N--CA 1.426 -1.665 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.108 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 66.5 mmtt -65.06 -172.36 0.09 Allowed 'General case' 0 C--O 1.242 0.679 0 C-N-CA 124.151 0.98 . . . . 0.0 113.347 -176.767 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.06 -49.12 63.88 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.635 179.691 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 -125.51 121.27 33.21 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -178.208 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.604 HG11 ' HB ' ' B' ' 83' ' ' THR . 12.5 m -138.78 154.55 26.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 123.945 0.778 . . . . 0.0 111.396 -175.521 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 89.5 mtt180 -110.48 124.37 51.66 Favored 'General case' 0 N--CA 1.429 -1.521 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.917 178.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.498 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 4.8 m-85 -97.27 160.66 14.2 Favored 'General case' 0 C--N 1.28 -2.423 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 179.446 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.487 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 63.1 mtt -110.5 117.35 33.31 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 171.64 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.47 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -100.77 129.92 50.9 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.128 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -114.97 119.15 4.54 Favored Glycine 0 CA--C 1.473 -2.574 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.376 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 -107.72 114.57 28.63 Favored 'General case' 0 C--N 1.278 -2.526 0 CA-C-N 114.728 -0.736 . . . . 0.0 110.551 177.827 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -82.21 86.35 6.66 Favored 'General case' 0 N--CA 1.424 -1.744 0 N-CA-C 105.996 -1.853 . . . . 0.0 105.996 168.005 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 95' ' ' ARG . . . . . 0.419 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 59.1 ttt180 -70.14 -59.34 4.32 Favored Pre-proline 0 C--N 1.294 -1.84 0 CA-C-N 114.094 -1.412 . . . . 0.0 111.183 -178.794 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 96' ' ' PRO . . . . . 0.56 ' HB2' ' O ' ' B' ' 99' ' ' GLN . 98.3 Cg_endo -79.95 -169.37 0.78 Allowed 'Trans proline' 0 N--CA 1.437 -1.825 0 C-N-CA 121.88 1.72 . . . . 0.0 112.218 175.556 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 153.03 -58.4 0.41 Allowed Glycine 0 C--N 1.288 -2.135 0 N-CA-C 108.181 -1.968 . . . . 0.0 108.181 -175.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -74.19 -27.05 60.63 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 171.809 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 99' ' ' GLN . . . . . 0.56 ' O ' ' HB2' ' B' ' 96' ' ' PRO . 52.9 tt0 -94.73 111.9 23.66 Favored 'General case' 0 N--CA 1.422 -1.851 0 N-CA-C 105.734 -1.95 . . . . 0.0 105.734 170.065 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 100' ' ' SER . . . . . 0.464 ' OG ' HG12 ' B' ' 102' ' ' VAL . 12.1 p -92.48 -162.98 0.98 Allowed 'General case' 0 C--N 1.292 -1.934 0 CA-C-O 120.596 0.236 . . . . 0.0 111.258 -176.304 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -87.74 5.25 40.86 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 121.087 0.47 . . . . 0.0 111.325 -177.268 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 102' ' ' VAL . . . . . 0.464 HG12 ' OG ' ' B' ' 100' ' ' SER . 7.1 p -82.25 110.57 17.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 CA-C-O 122.755 1.264 . . . . 0.0 111.513 -178.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -154.63 37.79 0.42 Allowed 'General case' 0 C--N 1.283 -2.289 0 CA-C-N 113.08 -1.873 . . . . 0.0 107.316 -177.893 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 36.4 tt0 69.36 93.74 0.08 Allowed 'General case' 0 C--O 1.243 0.726 0 CA-C-N 114.194 -1.366 . . . . 0.0 109.698 -171.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 6.0 mp -77.72 146.17 36.12 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 115.025 -0.988 . . . . 0.0 109.683 -178.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 35.3 mm -84.32 -62.24 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 176.252 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 107' ' ' GLN . . . . . 0.539 ' HG2' HG22 ' B' ' 109' ' ' THR . 23.8 tt0 51.87 94.66 0.02 OUTLIER 'General case' 0 C--O 1.242 0.678 0 C-N-CA 125.579 1.551 . . . . 0.0 111.553 176.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 28.9 pt20 -66.47 -13.55 60.99 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -173.57 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 109' ' ' THR . . . . . 0.539 HG22 ' HG2' ' B' ' 107' ' ' GLN . 11.7 t -83.19 -13.41 55.48 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 120.3 -0.56 . . . . 0.0 110.644 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 41.6 mt 61.54 29.78 18.45 Favored 'General case' 0 N--CA 1.477 0.884 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 172.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 49.7 mt-10 -89.47 -9.18 51.04 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 112.449 0.537 . . . . 0.0 112.449 -177.197 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 25.4 pt20 -76.32 144.39 40.22 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.167 178.685 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 56.7 mm-40 . . . . . 0 C--N 1.302 -1.463 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 175.52 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.636 0 N-CA-C 112.32 -0.312 . . . . 0.0 112.32 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 11.6 p80 -143.8 -172.54 3.76 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -178.47 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 3' ' ' MET . . . . . 0.474 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 25.4 ptp -65.05 117.31 7.49 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 121.421 0.629 . . . . 0.0 110.092 175.675 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -106.07 104.7 14.46 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -88.55 89.58 8.05 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 178.692 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -118.51 144.47 35.34 Favored Pre-proline 0 C--N 1.297 -1.699 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -178.518 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 7' ' ' PRO . . . . . 0.414 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 28.7 Cg_endo -80.95 127.8 6.3 Favored 'Trans proline' 0 N--CA 1.445 -1.38 0 C-N-CA 122.337 2.024 . . . . 0.0 112.629 177.531 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.561 HG13 ' HB3' ' B' ' 53' ' ' ARG . 76.0 t -112.49 134.73 54.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.032 0 CA-C-N 114.913 -1.039 . . . . 0.0 108.214 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 9' ' ' GLU . . . . . 0.46 ' OE2' ' HD3' ' B' ' 86' ' ' ARG . 34.9 tt0 -121.75 130.79 53.68 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -178.087 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.56 HD23 ' H ' ' B' ' 11' ' ' GLU . 0.5 OUTLIER -143.78 162.66 35.45 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.116 0.484 . . . . 0.0 111.075 -179.606 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.56 ' H ' HD23 ' B' ' 10' ' ' LEU . 6.7 mm-40 -86.97 156.75 19.66 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 125.172 1.389 . . . . 0.0 107.414 179.585 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 15.8 ptpt -79.28 -167.59 1.23 Allowed 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 122.11 0.957 . . . . 0.0 109.961 172.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 13' ' ' ASP . . . . . 0.433 ' HB3' ' N ' ' B' ' 17' ' ' LEU . 6.9 t70 -126.18 162.65 24.91 Favored 'General case' 0 C--N 1.285 -2.206 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 -179.036 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 31.0 t -61.54 -33.7 74.27 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 124.057 0.848 . . . . 0.0 110.658 -176.54 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -88.78 -51.86 5.43 Favored 'General case' 0 N--CA 1.437 -1.082 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 176.47 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.79 94.48 0.16 Allowed Glycine 0 N--CA 1.43 -1.7 0 CA-C-N 115.266 -0.879 . . . . 0.0 111.417 179.743 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.433 ' N ' ' HB3' ' B' ' 13' ' ' ASP . 3.8 mm? 59.64 98.02 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 124.605 1.162 . . . . 0.0 113.941 178.203 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -83.15 59.9 4.94 Favored Glycine 0 C--O 1.219 -0.843 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.576 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 6.7 pt -148.79 -175.51 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 C-N-CA 126.416 1.887 . . . . 0.0 107.072 179.024 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 66.7 m -151.27 146.99 26.43 Favored 'General case' 0 C--N 1.261 -3.271 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 176.293 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.44 ' HB ' HG22 ' B' ' 37' ' ' ILE . 13.9 pt -113.49 157.86 14.04 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 O-C-N 123.405 0.44 . . . . 0.0 110.072 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 22' ' ' ILE . . . . . 0.444 ' HB ' ' HB2' ' B' ' 40' ' ' LYS . 8.5 tp -131.94 130.24 61.22 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.84 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.67 89.85 1.62 Allowed Glycine 0 N--CA 1.408 -3.186 0 C-N-CA 120.926 -0.654 . . . . 0.0 111.819 -177.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 25.4 mmt -72.86 108.41 5.79 Favored 'General case' 0 N--CA 1.434 -1.262 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 176.146 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.02 67.56 3.37 Favored Glycine 0 CA--C 1.465 -3.063 0 CA-C-O 122.291 0.94 . . . . 0.0 112.928 -174.726 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -111.68 75.75 0.94 Allowed 'General case' 1 C--N 1.239 -4.22 0 CA-C-N 112.628 -1.786 . . . . 0.0 106.242 174.447 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.73 104.2 1.34 Allowed Glycine 0 N--CA 1.426 -2.032 0 CA-C-N 114.382 -1.281 . . . . 0.0 111.748 -175.329 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.61 105.56 3.17 Favored 'General case' 0 C--O 1.256 1.403 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 177.722 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -82.8 67.44 8.87 Favored 'General case' 0 N--CA 1.434 -1.267 0 CA-C-O 122.988 1.375 . . . . 0.0 110.555 -176.849 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 24.4 ptm -112.83 26.59 10.37 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 112.916 -1.947 . . . . 0.0 109.28 178.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.06 10.34 59.86 Favored Glycine 0 CA--C 1.495 -1.204 0 CA-C-N 114.901 -1.045 . . . . 0.0 111.595 179.271 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 88.9 mt -132.19 -19.19 2.53 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 119.336 -0.364 . . . . 0.0 111.867 -177.261 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 42.11 36.93 0.75 Allowed 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 125.036 1.334 . . . . 0.0 111.355 -172.05 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -62.91 122.18 15.35 Favored 'General case' 0 N--CA 1.437 -1.094 0 CA-C-N 114.226 -1.352 . . . . 0.0 112.687 -174.225 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 88.3 mt -85.58 160.54 19.61 Favored 'General case' 0 C--N 1.3 -1.567 0 CA-C-N 114.404 -1.271 . . . . 0.0 108.147 175.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -112.44 95.01 0.76 Allowed Glycine 0 N--CA 1.429 -1.815 0 C-N-CA 120.021 -1.085 . . . . 0.0 110.882 179.409 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.44 HG22 ' HB ' ' B' ' 21' ' ' ILE . 16.4 mm -87.84 85.33 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 CA-C-O 121.905 0.86 . . . . 0.0 109.237 179.65 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -84.71 175.47 9.17 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.898 -178.544 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 48.5 t -79.92 142.35 14.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 175.344 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 40' ' ' LYS . . . . . 0.444 ' HB2' ' HB ' ' B' ' 22' ' ' ILE . 87.5 tttt -100.82 -51.84 3.46 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.654 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -149.53 162.88 39.29 Favored 'General case' 0 N--CA 1.417 -2.102 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -175.537 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.576 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.4 p -140.84 105.48 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.04 0 CA-C-O 121.836 0.826 . . . . 0.0 109.839 178.271 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 16.5 m -62.95 125.97 25.77 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-N 114.355 -1.293 . . . . 0.0 111.566 -175.414 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 44' ' ' GLU . . . . . 0.449 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 11.1 pt-20 -65.47 -23.2 66.85 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.395 -178.063 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -83.65 3.96 83.57 Favored Glycine 0 N--CA 1.441 -0.992 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.23 177.033 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -108.07 164.49 12.82 Favored Glycine 0 N--CA 1.424 -2.156 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.208 179.261 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -65.57 -36.33 83.46 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-N 114.279 -0.96 . . . . 0.0 112.357 -176.501 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.72 -38.44 90.49 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -175.046 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 49' ' ' HIS . . . . . 0.449 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 7.9 t60 -69.91 -41.9 74.08 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 121.499 0.666 . . . . 0.0 109.713 -178.398 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 23.9 mtp180 -75.49 -35.76 60.74 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.697 -174.74 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 51' ' ' ASP . . . . . 0.439 ' CB ' HD21 ' B' ' 10' ' ' LEU . 16.8 t70 -64.4 -63.64 1.08 Allowed 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.088 175.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 117.88 -20.25 10.86 Favored Glycine 0 N--CA 1.428 -1.9 0 C-N-CA 119.871 -1.157 . . . . 0.0 114.027 178.185 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.561 ' HB3' HG13 ' B' ' 8' ' ' VAL . 12.9 mmt180 -62.11 -62.83 1.5 Allowed 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 113.718 1.006 . . . . 0.0 113.718 179.588 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.644 HD11 ' CE2' ' B' ' 89' ' ' PHE . 62.9 mt -77.36 109.0 11.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 C-N-CA 119.374 -0.93 . . . . 0.0 109.137 174.43 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 79.6 mm-40 -102.01 173.89 6.18 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 121.163 0.506 . . . . 0.0 110.549 175.012 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.5 p -63.88 -12.97 12.6 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 114.165 1.172 . . . . 0.0 114.165 -173.381 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -125.62 16.89 8.15 Favored 'General case' 0 C--N 1.311 -1.091 0 O-C-N 120.976 -1.078 . . . . 0.0 111.145 -176.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 25.7 m-20 -83.22 172.6 12.44 Favored 'General case' 0 C--N 1.317 -0.812 0 O-C-N 121.362 -0.836 . . . . 0.0 111.084 179.098 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.494 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 29.7 tp -128.51 116.06 19.11 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 120.563 0.221 . . . . 0.0 110.808 -175.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 32.8 mt -93.17 95.29 9.31 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 179.126 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.709 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 96.3 t -73.19 -65.3 0.68 Allowed 'Isoleucine or valine' 0 C--O 1.175 -2.845 0 C-N-CA 120.607 -0.437 . . . . 0.0 109.83 178.647 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.461 ' O ' ' HA ' ' B' ' 89' ' ' PHE . 8.6 pt-20 -129.05 157.26 42.22 Favored 'General case' 0 C--N 1.272 -2.787 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -177.019 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.559 HG21 HG21 ' B' ' 83' ' ' THR . 5.0 p -103.51 -176.19 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.554 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 -178.358 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.516 ' H ' HG22 ' B' ' 63' ' ' VAL . 27.5 t70 -51.25 -54.9 21.44 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 114.174 1.176 . . . . 0.0 114.174 -177.082 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -121.53 27.67 6.22 Favored Glycine 0 C--N 1.315 -0.591 0 C-N-CA 120.252 -0.975 . . . . 0.0 114.486 -175.251 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 51.4 m -152.57 120.67 6.22 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 176.791 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 19.7 m -94.21 111.38 23.11 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.168 -175.61 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.709 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 51.3 mt -89.57 121.36 31.7 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 176.957 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 14.8 p -83.74 -22.18 8.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.372 0.605 . . . . 0.0 109.565 177.451 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 145.88 69.16 0.01 OUTLIER Glycine 0 CA--C 1.487 -1.706 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 -177.318 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 34.9 m -90.6 -178.66 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 CA-C-N 114.563 -0.819 . . . . 0.0 109.742 -177.125 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 32.3 p -78.19 164.66 24.75 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 120.825 0.345 . . . . 0.0 111.066 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.3 tt0 -58.9 -40.43 84.45 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 123.429 0.692 . . . . 0.0 110.15 179.646 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 30.3 t -66.83 -36.48 82.45 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.323 -179.386 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -68.37 -47.84 66.35 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -179.649 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.539 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -62.6 -39.31 93.35 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.929 178.814 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.33 -39.77 91.76 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-O 121.178 0.513 . . . . 0.0 111.153 178.826 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 13.3 p -82.1 -10.76 59.09 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -177.504 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.539 HG12 ' O ' ' B' ' 76' ' ' ALA . 5.3 p -86.18 -34.65 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.383 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 58.9 mt -69.87 -20.22 63.4 Favored 'General case' 0 C--O 1.213 -0.848 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.437 176.745 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 77.0 mtp180 -94.57 4.11 54.26 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.588 0.709 . . . . 0.0 110.244 177.429 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.2 t30 -113.6 0.86 14.76 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.734 0.778 . . . . 0.0 110.424 -176.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.559 HG21 HG21 ' B' ' 63' ' ' VAL . 23.1 p -91.78 170.76 9.63 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.001 1.112 . . . . 0.0 114.001 -174.117 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.7 mmtt -73.88 -167.38 0.47 Allowed 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 124.795 1.238 . . . . 0.0 111.82 176.733 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.09 -33.93 84.95 Favored Glycine 0 C--O 1.225 -0.434 0 CA-C-N 115.628 -0.714 . . . . 0.0 113.274 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 86' ' ' ARG . . . . . 0.46 ' HD3' ' OE2' ' B' ' 9' ' ' GLU . 16.6 ttm180 -140.99 133.48 28.47 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 178.173 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.468 HG11 ' HB ' ' B' ' 83' ' ' THR . 11.9 m -139.02 164.51 25.27 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.031 0 CA-C-O 121.167 0.508 . . . . 0.0 111.591 178.886 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 88' ' ' ARG . . . . . 0.473 ' H ' ' HB2' ' B' ' 64' ' ' ASP . 54.3 mtm180 -100.01 159.03 15.4 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-N 114.649 -1.159 . . . . 0.0 108.221 176.448 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.644 ' CE2' HD11 ' B' ' 54' ' ' ILE . 4.9 m-85 -141.82 152.92 44.13 Favored 'General case' 0 C--N 1.283 -2.306 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 175.551 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.402 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 87.3 mmm -98.41 112.89 24.75 Favored 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 120.101 -0.64 . . . . 0.0 109.913 173.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.555 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.5 mp -101.8 117.2 46.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -179.159 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.89 101.28 2.07 Favored Glycine 0 CA--C 1.458 -3.498 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 174.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 93' ' ' ARG . . . . . 0.474 ' O ' ' HA ' ' B' ' 3' ' ' MET . 19.9 tpp180 -76.09 93.74 3.36 Favored 'General case' 0 C--N 1.276 -2.59 0 CA-C-N 114.478 -0.861 . . . . 0.0 109.884 178.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 94' ' ' GLU . . . . . 0.422 ' HG3' ' O ' ' B' ' 96' ' ' PRO . 7.8 tp10 -83.71 80.67 9.05 Favored 'General case' 0 N--CA 1.403 -2.783 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 173.774 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 95' ' ' ARG . . . . . 0.429 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 31.7 ttm180 -62.91 -58.24 17.5 Favored Pre-proline 0 C--N 1.304 -1.401 0 CA-C-N 114.086 -1.415 . . . . 0.0 110.796 176.135 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 96' ' ' PRO . . . . . 0.429 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 83.5 Cg_endo -82.35 -159.01 0.1 OUTLIER 'Trans proline' 0 C--N 1.357 0.993 0 C-N-CA 122.252 1.968 . . . . 0.0 111.254 173.425 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 121.36 35.85 0.78 Allowed Glycine 0 C--N 1.29 -2.014 0 C-N-CA 120.781 -0.724 . . . . 0.0 111.853 176.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 54.55 15.21 0.98 Allowed 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 115.834 1.791 . . . . 0.0 115.834 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 51.7 tp60 -77.72 -29.86 51.43 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 173.205 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 23.9 m -128.27 158.87 36.96 Favored 'General case' 0 N--CA 1.414 -2.253 0 N-CA-C 105.289 -2.115 . . . . 0.0 105.289 174.09 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -108.9 75.34 0.95 Allowed 'General case' 0 C--N 1.291 -1.954 0 CA-C-O 122.091 0.948 . . . . 0.0 110.799 -173.541 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 20.7 t -90.82 119.25 37.64 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.539 0 N-CA-C 104.706 -2.331 . . . . 0.0 104.706 170.876 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -139.18 102.77 4.59 Favored 'General case' 0 C--N 1.283 -2.316 0 O-C-N 123.238 0.336 . . . . 0.0 111.839 -172.647 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 7.1 tp60 59.49 97.61 0.03 OUTLIER 'General case' 0 C--O 1.249 1.034 0 C-N-CA 125.025 1.33 . . . . 0.0 112.874 178.196 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 89.7 mt -85.64 119.05 25.56 Favored 'General case' 0 C--N 1.278 -2.543 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 176.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 40.1 mm -61.81 -60.56 2.51 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.697 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 60.3 tt0 60.26 95.54 0.03 OUTLIER 'General case' 0 N--CA 1.435 -1.194 0 O-C-N 125.029 1.456 . . . . 0.0 112.422 174.677 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 108' ' ' GLN . . . . . 0.483 ' HB3' ' HA ' ' B' ' 111' ' ' GLU . 98.2 mt-30 -66.71 103.64 1.14 Allowed 'General case' 0 N--CA 1.437 -1.121 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 174.223 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 12.7 t -70.07 -27.99 65.06 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.018 -172.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 58.3 mt -98.11 -27.35 14.23 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 176.083 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 111' ' ' GLU . . . . . 0.483 ' HA ' ' HB3' ' B' ' 108' ' ' GLN . 29.1 tt0 64.24 78.95 0.27 Allowed 'General case' 0 C--O 1.251 1.137 0 CA-C-N 113.78 -1.555 . . . . 0.0 110.988 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 66.0 mt-30 65.78 -177.31 0.19 Allowed 'General case' 0 C--O 1.242 0.703 0 CA-C-N 113.827 -1.533 . . . . 0.0 110.736 -179.589 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 15.4 mm-40 . . . . . 0 C--N 1.303 -1.433 0 CA-C-O 118.765 -0.636 . . . . 0.0 109.403 179.718 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.201 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -79.13 -50.17 11.44 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 178.406 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 3' ' ' MET . . . . . 0.491 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 66.2 mtt -125.58 125.98 44.05 Favored 'General case' 0 N--CA 1.427 -1.605 0 CA-C-N 114.235 -1.348 . . . . 0.0 110.045 178.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -94.54 101.55 13.45 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.276 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.46 90.71 8.47 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.33 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -119.29 144.59 36.66 Favored Pre-proline 0 C--N 1.29 -1.985 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.109 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 7' ' ' PRO . . . . . 0.433 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 56.4 Cg_endo -75.49 139.23 22.83 Favored 'Trans proline' 0 N--CA 1.446 -1.297 0 C-N-CA 122.271 1.981 . . . . 0.0 111.767 177.36 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.463 ' HB ' HD13 ' B' ' 91' ' ' ILE . 87.5 t -129.73 128.99 66.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -179.298 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 9' ' ' GLU . . . . . 0.52 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 38.6 tt0 -114.99 123.26 48.65 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.48 HD21 ' HA ' ' B' ' 48' ' ' ALA . 1.1 mt -132.93 164.05 27.79 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 178.143 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -123.56 137.49 54.75 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 174.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 12' ' ' LYS . . . . . 0.415 ' HB2' ' O ' ' B' ' 16' ' ' GLY . 18.3 ptmt -74.96 162.48 28.56 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.189 179.143 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -134.78 -166.13 1.77 Allowed 'General case' 0 C--N 1.291 -1.965 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.811 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.5 m -66.49 -22.31 66.19 Favored 'General case' 0 C--N 1.313 -1.003 0 C-N-CA 123.666 0.786 . . . . 0.0 111.598 -178.279 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -86.06 2.34 46.89 Favored 'General case' 0 CA--C 1.55 0.952 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 177.543 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.415 ' O ' ' HB2' ' B' ' 12' ' ' LYS . . . 85.06 -91.57 1.7 Allowed Glycine 0 N--CA 1.417 -2.58 0 N-CA-C 107.34 -2.304 . . . . 0.0 107.34 -175.077 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.405 ' HB3' HG12 ' B' ' 19' ' ' ILE . 3.5 mm? -124.75 134.14 52.91 Favored 'General case' 0 C--N 1.281 -2.396 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 174.719 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -83.45 53.3 4.84 Favored Glycine 0 C--O 1.216 -1.005 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.531 HG22 ' HA ' ' B' ' 42' ' ' VAL . 8.0 pt -161.87 176.56 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 C-N-CA 126.126 1.77 . . . . 0.0 107.491 -177.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 20' ' ' SER . . . . . 0.402 ' HB2' HG22 ' B' ' 41' ' ' THR . 27.3 m -143.41 146.21 33.28 Favored 'General case' 0 C--N 1.268 -2.951 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 173.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.475 ' HB ' HG22 ' B' ' 37' ' ' ILE . 10.1 pt -114.31 162.56 12.33 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -179.164 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 22' ' ' ILE . . . . . 0.43 ' HB ' ' HB2' ' B' ' 40' ' ' LYS . 10.8 tp -137.89 138.37 44.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-O 121.041 0.448 . . . . 0.0 110.362 -177.714 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.54 108.58 3.45 Favored Glycine 0 N--CA 1.427 -1.94 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.662 178.304 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 22.7 mmt -124.33 149.36 46.67 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 177.65 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 135.1 168.4 11.62 Favored Glycine 0 N--CA 1.426 -1.979 0 C-N-CA 120.205 -0.998 . . . . 0.0 111.612 178.4 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -171.77 161.51 5.96 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 179.685 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 144.51 -149.11 21.17 Favored Glycine 0 N--CA 1.426 -2.031 0 C-N-CA 120.297 -0.954 . . . . 0.0 111.984 178.7 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.38 101.17 2.33 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-O 121.204 0.526 . . . . 0.0 111.133 179.65 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.437 ' HA ' ' HA ' ' B' ' 33' ' ' GLU . 18.8 t70 -100.43 -7.58 24.16 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-O 121.962 0.886 . . . . 0.0 109.186 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 24.0 ptm -60.09 -33.97 72.82 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 114.255 -1.339 . . . . 0.0 112.949 -178.552 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -171.22 56.25 0.18 Allowed Glycine 0 N--CA 1.445 -0.737 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 177.57 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 65.5 tp -171.01 -51.45 0.02 OUTLIER 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 -178.19 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 33' ' ' GLU . . . . . 0.437 ' HA ' ' HA ' ' B' ' 29' ' ' ASP 0.356 10.0 pt-20 51.8 68.66 0.77 Allowed 'General case' 0 CA--C 1.504 -0.804 0 O-C-N 125.22 1.575 . . . . 0.0 113.387 -178.813 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.11 101.91 8.15 Favored 'General case' 0 N--CA 1.42 -1.937 0 CA-C-N 113.341 -1.754 . . . . 0.0 110.271 179.037 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 35' ' ' LEU . . . . . 0.434 HD23 ' O ' ' B' ' 71' ' ' VAL . 14.5 tp -135.35 165.42 25.49 Favored 'General case' 0 C--N 1.282 -2.34 0 N-CA-C 104.797 -2.297 . . . . 0.0 104.797 179.348 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -138.94 120.36 1.9 Allowed Glycine 0 C--N 1.273 -2.929 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.051 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.475 HG22 ' HB ' ' B' ' 21' ' ' ILE . 32.0 mm -96.84 89.22 2.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 179.23 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -84.31 170.88 13.2 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.55 -1.204 . . . . 0.0 108.192 -179.176 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 49.8 t -75.86 145.22 10.92 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 174.151 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 40' ' ' LYS . . . . . 0.43 ' HB2' ' HB ' ' B' ' 22' ' ' ILE . 2.0 tmmm? -105.08 -41.26 5.63 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 -179.522 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 41' ' ' THR . . . . . 0.424 ' HA ' HG23 ' B' ' 56' ' ' VAL . 1.0 OUTLIER -158.39 164.15 36.58 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 -179.533 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.531 ' HA ' HG22 ' B' ' 19' ' ' ILE . 15.3 t -119.0 95.15 3.46 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 175.634 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.45 ' H ' ' HA ' ' B' ' 19' ' ' ILE . 7.0 m -64.09 121.03 13.21 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 123.976 0.91 . . . . 0.0 112.159 -175.67 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -69.59 -18.18 63.6 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.18 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.45 -11.77 84.09 Favored Glycine 0 N--CA 1.436 -1.313 0 C-N-CA 120.978 -0.629 . . . . 0.0 112.354 178.094 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -115.69 172.43 14.21 Favored Glycine 0 N--CA 1.426 -1.982 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.303 -178.591 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -67.53 -27.03 66.63 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 114.698 1.37 . . . . 0.0 114.698 -172.171 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 48' ' ' ALA . . . . . 0.48 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -63.72 -41.89 98.0 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 112.486 0.551 . . . . 0.0 112.486 -175.829 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -70.83 -38.01 73.23 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 121.807 0.813 . . . . 0.0 109.276 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 -72.7 -34.08 66.89 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 114.197 -1.365 . . . . 0.0 110.626 -174.843 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 51' ' ' ASP . . . . . 0.542 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 15.5 t0 -75.81 -52.87 9.44 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 175.742 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.82 29.62 8.03 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.546 -177.436 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.542 ' HG2' ' OD1' ' B' ' 51' ' ' ASP . 32.6 mmt180 -90.0 -81.74 0.28 Allowed 'General case' 0 CA--C 1.513 -0.478 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.455 HD11 ' CE2' ' B' ' 89' ' ' PHE . 81.3 mt -67.01 125.41 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 O-C-N 123.293 0.37 . . . . 0.0 110.197 176.48 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 55' ' ' GLN . . . . . 0.445 ' HB2' ' OD2' ' B' ' 58' ' ' ASP . 8.5 mt-30 -104.39 161.61 13.93 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.635 -176.677 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.424 HG23 ' HA ' ' B' ' 41' ' ' THR . 7.3 p -62.43 -21.32 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 N-CA-C 115.771 1.767 . . . . 0.0 115.771 -168.22 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.508 ' OD1' ' HA ' ' B' ' 98' ' ' GLU . 0.2 OUTLIER -122.57 22.63 9.85 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.936 -1.106 . . . . 0.0 109.066 -176.974 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 58' ' ' ASP . . . . . 0.445 ' OD2' ' HB2' ' B' ' 55' ' ' GLN . 78.5 m-20 -87.96 170.9 10.74 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.976 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 28.2 tp -132.12 131.22 42.12 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.626 -178.157 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 78.9 mt -83.2 95.03 8.0 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 176.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.478 ' HB ' ' O ' ' B' ' 90' ' ' MET . 21.4 t -74.0 -40.96 52.7 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.886 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.448 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 11.3 pt-20 -160.56 149.66 17.07 Favored 'General case' 0 C--N 1.283 -2.307 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.482 176.22 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.407 HG12 ' O ' ' B' ' 66' ' ' THR . 4.8 p -98.27 -179.27 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 105.037 -2.209 . . . . 0.0 105.037 176.67 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.57 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 16.6 t70 -53.52 -53.33 53.04 Favored 'General case' 0 C--N 1.311 -1.076 0 N-CA-C 114.081 1.141 . . . . 0.0 114.081 -177.567 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -105.23 -1.77 41.4 Favored Glycine 0 C--N 1.312 -0.768 0 C-N-CA 119.408 -1.377 . . . . 0.0 115.509 -175.632 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 66' ' ' THR . . . . . 0.407 ' O ' HG12 ' B' ' 63' ' ' VAL . 13.8 m -142.89 133.29 24.82 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 118.163 0.982 . . . . 0.0 110.011 -175.344 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 67' ' ' SER . . . . . 0.448 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 13.0 t -94.15 157.15 16.21 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.72 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.45 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.3 mm? -118.25 115.21 24.27 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.956 0.408 . . . . 0.0 111.062 -179.075 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 13.8 p -97.52 -20.28 5.7 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-O 121.918 0.866 . . . . 0.0 109.497 175.437 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 143.52 86.15 0.08 OUTLIER Glycine 0 CA--C 1.485 -1.791 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -178.812 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.434 ' O ' HD23 ' B' ' 35' ' ' LEU . 33.5 m -109.46 -179.04 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.301 0 CA-C-N 115.032 -0.584 . . . . 0.0 109.515 -175.665 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 71.2 p -75.24 159.56 31.41 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 109.173 -0.676 . . . . 0.0 109.173 176.651 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.6 tt0 -62.17 -33.38 74.41 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.469 0.652 . . . . 0.0 110.046 -179.116 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 22.3 m -73.24 -37.37 66.38 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.004 178.159 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -62.41 -46.1 90.12 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.334 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.477 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -62.6 -42.42 99.57 Favored 'General case' 0 C--O 1.209 -1.075 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.747 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.0 -31.02 71.35 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 121.719 0.771 . . . . 0.0 111.057 178.788 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 33.4 t -90.47 -4.85 56.68 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.893 -179.201 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.477 HG12 ' O ' ' B' ' 76' ' ' ALA . 1.2 p -76.27 -31.98 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 C-N-CA 119.776 -0.77 . . . . 0.0 109.494 -177.916 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -67.86 -30.81 70.27 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.574 174.388 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -82.09 -7.59 59.62 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.648 -178.278 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -92.17 -23.11 19.49 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.989 178.259 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.516 ' HB ' HG11 ' B' ' 87' ' ' VAL . 11.6 p -97.46 -178.76 4.25 Favored 'General case' 0 N--CA 1.428 -1.535 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.241 177.479 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 65.3 mmtt -70.93 -171.56 0.56 Allowed 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 123.245 0.618 . . . . 0.0 111.387 177.169 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -78.39 -35.71 32.5 Favored Glycine 0 N--CA 1.442 -0.932 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.716 -178.835 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 29.5 ttt180 -123.13 117.33 25.15 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 176.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.57 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 7.8 m -148.5 160.02 6.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 123.878 0.736 . . . . 0.0 110.009 -177.371 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 88' ' ' ARG . . . . . 0.52 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 96.3 mtt180 -103.49 134.12 47.38 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.708 177.761 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.455 ' CE2' HD11 ' B' ' 54' ' ' ILE . 0.7 OUTLIER -112.93 166.37 11.46 Favored 'General case' 0 C--N 1.281 -2.407 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 178.879 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.478 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 85.0 mtp -111.66 114.55 27.65 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 171.381 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.463 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.4 mp -97.76 130.0 47.11 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.188 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -118.65 95.23 0.61 Allowed Glycine 0 CA--C 1.45 -3.97 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 177.003 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 93' ' ' ARG . . . . . 0.491 ' O ' ' HA ' ' B' ' 3' ' ' MET . 24.4 ttp180 -84.93 125.93 33.08 Favored 'General case' 0 C--N 1.268 -2.953 0 CA-C-N 114.322 -0.939 . . . . 0.0 111.716 -178.256 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -87.04 89.86 8.15 Favored 'General case' 0 N--CA 1.406 -2.655 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 170.177 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 24.0 ttt180 -39.17 -58.46 1.82 Allowed Pre-proline 0 CA--C 1.554 1.116 0 C-N-CA 126.282 1.833 . . . . 0.0 112.956 -177.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -70.39 139.05 37.19 Favored 'Trans proline' 0 N--CA 1.449 -1.093 0 C-N-CA 122.005 1.803 . . . . 0.0 110.888 174.324 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 97' ' ' GLY . . . . . 0.428 ' HA2' ' OG ' ' B' ' 100' ' ' SER . . . 118.73 7.29 10.75 Favored Glycine 0 C--N 1.286 -2.211 0 C-N-CA 120.059 -1.067 . . . . 0.0 112.299 -177.846 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 98' ' ' GLU . . . . . 0.508 ' HA ' ' OD1' ' B' ' 57' ' ' ASN . 5.4 pt-20 -82.22 -41.86 19.71 Favored 'General case' 0 N--CA 1.438 -1.042 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.381 176.766 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 99' ' ' GLN . . . . . 0.433 ' HG2' ' HG3' ' B' ' 98' ' ' GLU . 81.5 mm-40 -92.04 -60.91 1.74 Allowed 'General case' 0 N--CA 1.421 -1.897 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 100' ' ' SER . . . . . 0.428 ' OG ' ' HA2' ' B' ' 97' ' ' GLY . 73.5 m 53.12 -175.64 0.03 OUTLIER 'General case' 0 C--O 1.246 0.888 0 C-N-CA 125.117 1.367 . . . . 0.0 113.821 -179.567 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -121.31 72.12 0.98 Allowed 'General case' 0 N--CA 1.423 -1.796 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 175.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 102' ' ' VAL . . . . . 0.537 ' HB ' HD11 ' B' ' 105' ' ' LEU . 14.2 m -126.53 97.72 4.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.686 -178.575 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -113.42 -54.22 2.63 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.943 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 98.0 mt-30 -122.7 95.01 4.46 Favored 'General case' 0 C--N 1.29 -1.989 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 178.543 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 105' ' ' LEU . . . . . 0.537 HD11 ' HB ' ' B' ' 102' ' ' VAL . 5.7 mp -78.93 76.87 5.41 Favored 'General case' 0 C--N 1.31 -1.12 0 CA-C-O 121.261 0.553 . . . . 0.0 110.895 -177.683 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 45.9 mm -101.66 -71.67 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 175.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -159.82 115.07 2.39 Favored 'General case' 0 N--CA 1.438 -1.046 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 176.631 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 80.2 mt-30 -87.0 102.09 14.07 Favored 'General case' 0 N--CA 1.425 -1.708 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 177.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 7.4 t -82.59 -22.81 34.67 Favored 'General case' 0 N--CA 1.431 -1.386 0 CA-C-N 114.661 -1.154 . . . . 0.0 108.093 -177.49 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 92.3 mt -96.68 91.35 5.67 Favored 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 174.687 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -69.48 115.28 8.56 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 176.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 29.2 tt0 -111.82 -57.18 2.29 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.136 -174.196 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 55.9 mm-40 . . . . . 0 N--CA 1.432 -1.367 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.541 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.503 -0.696 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 2' ' ' HIS . . . . . 0.437 ' O ' ' HD2' ' B' ' 96' ' ' PRO . 67.3 t60 -72.18 -46.83 54.71 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 176.452 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 22.3 ptt? -103.31 115.99 31.61 Favored 'General case' 0 N--CA 1.421 -1.884 0 CA-C-N 114.601 -1.181 . . . . 0.0 107.813 172.865 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 4' ' ' GLU . . . . . 0.502 ' OE2' ' HD2' ' B' ' 93' ' ' ARG . 15.4 mt-10 -87.07 101.3 13.33 Favored 'General case' 0 C--N 1.294 -1.831 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.038 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -90.34 88.49 7.22 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 174.09 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -110.82 145.15 31.78 Favored Pre-proline 0 C--N 1.29 -1.985 0 CA-C-N 116.119 -0.491 . . . . 0.0 112.027 -177.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 7' ' ' PRO . . . . . 0.53 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 60.1 Cg_endo -81.89 134.65 8.45 Favored 'Trans proline' 0 N--CA 1.439 -1.707 0 C-N-CA 122.142 1.894 . . . . 0.0 113.526 178.09 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 65.4 t -121.97 130.76 74.31 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 176.447 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -115.22 132.95 56.45 Favored 'General case' 0 C--N 1.294 -1.84 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.165 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.424 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -121.15 161.21 22.21 Favored 'General case' 0 CA--C 1.493 -1.231 0 CA-C-O 121.403 0.62 . . . . 0.0 111.251 179.562 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -132.94 132.99 42.61 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 107.41 -1.329 . . . . 0.0 107.41 174.835 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 12' ' ' LYS . . . . . 0.502 ' HA ' ' CB ' ' B' ' 47' ' ' ALA . 36.0 mtmm -97.43 160.31 14.4 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 121.467 0.651 . . . . 0.0 112.468 -171.869 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 m-20 -113.27 -168.27 1.31 Allowed 'General case' 0 C--N 1.308 -1.2 0 CA-C-N 114.882 -1.054 . . . . 0.0 109.652 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.1 m -60.27 -35.93 76.67 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 113.618 0.969 . . . . 0.0 113.618 -174.624 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -79.6 -22.08 44.15 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-O 121.641 0.734 . . . . 0.0 109.364 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.06 -132.02 10.78 Favored Glycine 0 N--CA 1.423 -2.205 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.139 178.623 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.423 ' HG ' HG12 ' B' ' 19' ' ' ILE . 24.0 tp -82.83 169.71 15.81 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -178.804 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 18' ' ' GLY . . . . . 0.514 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -149.54 66.24 0.38 Allowed Glycine 0 CA--C 1.48 -2.122 0 C-N-CA 119.805 -1.188 . . . . 0.0 112.442 -177.647 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.468 HG22 ' HA ' ' B' ' 42' ' ' VAL . 8.4 pt -160.14 172.17 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.486 -1.482 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 179.488 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 20' ' ' SER . . . . . 0.424 ' HB2' HG22 ' B' ' 41' ' ' THR . 56.7 m -133.39 151.57 51.84 Favored 'General case' 0 C--N 1.257 -3.444 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 174.578 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.519 ' HB ' HG22 ' B' ' 37' ' ' ILE . 13.2 pt -121.59 148.2 25.15 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.681 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 -178.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.6 tp -119.02 132.49 68.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -179.374 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -96.56 97.97 2.11 Favored Glycine 0 N--CA 1.427 -1.951 0 C-N-CA 120.231 -0.985 . . . . 0.0 113.689 -174.408 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 82.3 mtp -95.89 112.94 24.54 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.083 -1.081 . . . . 0.0 108.083 175.672 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.524 ' HA3' ' HG ' ' B' ' 35' ' ' LEU . . . 149.95 173.26 20.15 Favored Glycine 0 N--CA 1.414 -2.809 0 C-N-CA 120.367 -0.921 . . . . 0.0 111.935 -178.374 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -152.76 -168.79 3.15 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 -178.562 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.36 113.55 5.42 Favored Glycine 0 N--CA 1.437 -1.234 0 O-C-N 123.673 0.608 . . . . 0.0 112.924 -178.25 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -132.85 45.0 2.79 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 105.748 -1.945 . . . . 0.0 105.748 176.783 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -79.63 2.5 22.27 Favored 'General case' 0 C--N 1.301 -1.529 0 CA-C-N 112.433 -2.167 . . . . 0.0 111.777 -171.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 26.5 ptm -75.45 11.71 1.18 Allowed 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.476 177.607 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 111.22 27.06 4.36 Favored Glycine 0 N--CA 1.435 -1.375 0 C-N-CA 121.369 -0.443 . . . . 0.0 112.818 177.602 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 95.3 mt -124.89 -69.99 0.77 Allowed 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 116.936 0.368 . . . . 0.0 110.536 -178.644 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . 0.295 10.4 pt-20 43.02 62.74 1.71 Allowed 'General case' 0 C--O 1.213 -0.821 0 C-N-CA 125.086 1.354 . . . . 0.0 114.285 -176.504 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 9.3 mtpm? -107.06 89.13 2.9 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 175.753 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 35' ' ' LEU . . . . . 0.524 ' HG ' ' HA3' ' B' ' 25' ' ' GLY . 9.4 mp -113.75 155.22 26.02 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.748 -175.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -116.18 97.77 0.79 Allowed Glycine 0 N--CA 1.413 -2.858 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.917 -177.095 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.519 HG22 ' HB ' ' B' ' 21' ' ' ILE . 23.3 mm -92.98 87.69 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 174.771 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -85.17 164.44 18.11 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.614 -175.238 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 94.2 t -77.65 128.31 38.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 174.765 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -93.45 -37.45 11.95 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.123 0.487 . . . . 0.0 110.556 -176.003 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 41' ' ' THR . . . . . 0.424 HG22 ' HB2' ' B' ' 20' ' ' SER . 0.6 OUTLIER -158.4 163.46 37.22 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 -178.51 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.468 ' HA ' HG22 ' B' ' 19' ' ' ILE . 19.4 t -120.54 96.22 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.71 0 N-CA-C 106.468 -1.679 . . . . 0.0 106.468 176.441 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 17.1 m -59.99 124.31 19.8 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 124.186 0.995 . . . . 0.0 112.183 -175.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 44' ' ' GLU . . . . . 0.576 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 36.0 mt-10 -55.14 -33.83 63.25 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 124.767 1.227 . . . . 0.0 112.628 -176.709 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.67 -18.79 78.87 Favored Glycine 0 N--CA 1.438 -1.214 0 CA-C-N 115.674 -0.694 . . . . 0.0 114.521 -177.016 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.514 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -106.03 170.37 16.74 Favored Glycine 0 N--CA 1.423 -2.228 0 C-N-CA 118.497 -1.811 . . . . 0.0 114.719 -173.602 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 47' ' ' ALA . . . . . 0.502 ' CB ' ' HA ' ' B' ' 12' ' ' LYS . . . -59.53 -33.64 71.65 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 113.605 -1.298 . . . . 0.0 114.401 -174.14 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 48' ' ' ALA . . . . . 0.424 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -65.69 -33.0 74.86 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.243 -176.596 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 49' ' ' HIS . . . . . 0.576 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 12.2 t60 -77.31 -40.6 43.75 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.532 178.147 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 40.0 mtp-105 -66.97 -39.61 87.25 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.602 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 51' ' ' ASP . . . . . 0.528 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 12.0 t70 -78.0 -58.22 3.38 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.136 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.71 -4.87 36.9 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.628 -0.796 . . . . 0.0 113.662 179.146 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.528 ' HG2' ' OD1' ' B' ' 51' ' ' ASP . 0.4 OUTLIER -54.16 -62.13 1.86 Allowed 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 179.183 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.55 HD11 ' CE2' ' B' ' 89' ' ' PHE . 35.1 mt -81.31 126.46 39.8 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.227 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -103.29 168.51 9.12 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.162 177.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.1 p -73.53 4.46 0.84 Allowed 'Isoleucine or valine' 0 CA--C 1.57 1.725 0 CA-C-O 121.981 0.896 . . . . 0.0 111.533 -177.109 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -117.85 5.58 12.21 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.281 1.039 . . . . 0.0 109.529 -177.749 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -87.34 161.68 17.79 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.701 -177.536 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.626 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 25.5 tp -138.31 127.21 23.88 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 123.494 0.717 . . . . 0.0 109.742 -175.471 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 66.0 mt -88.01 97.48 10.98 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.619 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 0.8 OUTLIER -92.9 -21.42 6.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-O 122.219 1.009 . . . . 0.0 109.5 -177.277 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.561 ' HG2' ' O ' ' B' ' 63' ' ' VAL . 30.9 tt0 -164.64 150.99 10.65 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 113.133 -1.848 . . . . 0.0 108.701 175.013 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.561 ' O ' ' HG2' ' B' ' 62' ' ' GLU . 6.2 p -93.18 -162.6 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.202 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 176.367 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.587 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 11.7 t70 -56.59 -54.31 47.41 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 123.277 0.631 . . . . 0.0 111.687 -178.749 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -113.64 -54.18 0.44 Allowed Glycine 0 N--CA 1.439 -1.162 0 C-N-CA 120.478 -0.868 . . . . 0.0 113.213 -178.643 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 25.6 m -62.87 115.25 4.2 Favored 'General case' 0 C--O 1.246 0.909 0 CA-C-O 121.744 0.783 . . . . 0.0 112.731 -175.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 67' ' ' SER . . . . . 0.506 ' HA ' ' HG3' ' B' ' 62' ' ' GLU . 25.1 m -77.72 109.87 12.09 Favored 'General case' 0 N--CA 1.424 -1.75 0 C-N-CA 124.992 1.317 . . . . 0.0 113.397 -176.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.619 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 54.8 mt -90.88 -164.74 1.22 Allowed 'General case' 0 N--CA 1.421 -1.911 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 174.003 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 p 175.73 -30.86 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 106.236 -1.765 . . . . 0.0 106.236 178.368 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 70' ' ' GLY . . . . . 0.498 ' HA3' ' H ' ' B' ' 35' ' ' LEU . . . 169.02 77.06 0.04 OUTLIER Glycine 1 N--CA 1.39 -4.373 0 CA-C-N 114.48 -1.236 . . . . 0.0 111.227 -179.279 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 27.0 m -99.74 178.1 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.277 -2.581 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 34.6 p -76.84 161.74 28.19 Favored 'General case' 0 C--N 1.291 -1.95 0 C-N-CA 120.415 -0.514 . . . . 0.0 109.892 175.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -57.99 -40.77 81.55 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 123.829 0.851 . . . . 0.0 109.614 178.675 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 22.3 m -68.46 -38.57 81.22 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.077 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -62.93 -47.92 81.13 Favored 'General case' 0 C--O 1.24 0.566 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 178.747 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.572 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -58.75 -45.37 89.86 Favored 'General case' 0 C--O 1.208 -1.105 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.845 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.91 -36.82 77.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.982 0.42 . . . . 0.0 111.749 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 15.4 p -77.88 -14.83 59.43 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 112.967 0.729 . . . . 0.0 112.967 -179.5 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.572 HG12 ' O ' ' B' ' 76' ' ' ALA . 2.8 p -73.31 -37.3 51.36 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.952 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.071 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -59.64 -18.81 44.76 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.97 0.908 . . . . 0.0 112.433 176.541 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 6.6 mtp180 -100.21 -6.66 25.73 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 121.213 0.53 . . . . 0.0 111.918 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -114.95 10.69 16.37 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.41 0.624 . . . . 0.0 111.245 179.153 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.724 ' HB ' HG11 ' B' ' 87' ' ' VAL . 7.9 p -92.46 -173.42 3.38 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 115.491 -0.777 . . . . 0.0 112.298 178.513 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 44.9 mttm -76.67 -169.0 1.12 Allowed 'General case' 0 N--CA 1.437 -1.111 0 C-N-CA 123.506 0.722 . . . . 0.0 111.113 175.163 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -73.37 -49.69 14.52 Favored Glycine 0 N--CA 1.437 -1.274 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.056 176.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 16.2 ttm180 -118.38 121.44 40.37 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 176.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.724 HG11 ' HB ' ' B' ' 83' ' ' THR . 8.8 m -130.13 151.98 36.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 71.7 mtm180 -94.96 169.66 9.97 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 113.788 -1.551 . . . . 0.0 108.006 173.499 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.55 ' CE2' HD11 ' B' ' 54' ' ' ILE . 4.7 m-85 -144.14 151.1 39.1 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 176.053 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 90' ' ' MET . . . . . . . . . . . . . 48.0 mtm -100.43 115.12 29.3 Favored 'General case' 0 N--CA 1.425 -1.698 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 173.443 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.626 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.5 mp -96.93 127.84 48.72 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.002 -179.142 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -108.36 120.87 6.1 Favored Glycine 0 N--CA 1.427 -1.962 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 177.312 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 93' ' ' ARG . . . . . 0.502 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 35.5 ttm180 -120.85 123.25 42.1 Favored 'General case' 0 C--N 1.281 -2.377 0 CA-C-N 115.207 -0.497 . . . . 0.0 109.731 178.218 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -87.88 81.72 7.47 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 171.445 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 13.8 ttm-85 -63.05 -64.38 3.08 Favored Pre-proline 0 CA--C 1.556 1.192 0 CA-C-N 115.136 -0.938 . . . . 0.0 113.387 -178.795 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 96' ' ' PRO . . . . . 0.437 ' HD2' ' O ' ' B' ' 2' ' ' HIS . 30.9 Cg_endo -67.13 159.92 49.86 Favored 'Trans proline' 0 C--N 1.364 1.368 0 C-N-CA 122.015 1.81 . . . . 0.0 113.952 -176.313 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 155.33 -47.21 0.51 Allowed Glycine 0 N--CA 1.436 -1.366 0 CA-C-N 114.716 -1.129 . . . . 0.0 110.34 -178.882 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -68.58 -32.49 72.44 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.308 -0.446 . . . . 0.0 111.056 178.427 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 64.3 tp60 52.32 74.56 0.27 Allowed 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 124.856 1.262 . . . . 0.0 110.838 -177.463 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 71.0 m -93.45 158.43 15.72 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.524 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -87.68 -21.48 25.22 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-O 122.708 1.242 . . . . 0.0 109.798 -176.544 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 12.9 m -114.68 71.01 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.269 -2.918 0 CA-C-N 113.946 -1.479 . . . . 0.0 112.721 178.477 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -139.99 13.3 2.45 Favored 'General case' 0 C--N 1.282 -2.333 0 CA-C-N 113.342 -1.754 . . . . 0.0 108.078 175.825 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 55.2 tp60 -161.48 93.64 0.94 Allowed 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 -179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 3.8 mp -121.63 93.8 4.12 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 120.957 0.408 . . . . 0.0 110.269 -176.139 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 32.7 mm -96.94 -61.87 2.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 175.454 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 29.8 tt0 68.54 -33.39 0.24 Allowed 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 125.828 1.651 . . . . 0.0 114.486 174.64 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 108' ' ' GLN . . . . . 0.426 ' HA ' ' OE1' ' B' ' 108' ' ' GLN . 12.5 mm-40 64.34 78.08 0.3 Allowed 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 124.075 0.95 . . . . 0.0 110.614 -179.562 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 5.2 t -81.17 -48.85 11.55 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.061 -177.365 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 89.7 mt -91.19 -14.31 31.27 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-O 121.277 0.561 . . . . 0.0 110.467 -178.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -96.78 102.6 14.41 Favored 'General case' 0 N--CA 1.418 -2.052 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.435 179.444 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 3.5 pm0 -122.22 103.59 8.87 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 174.703 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 . . . . . 0 N--CA 1.42 -1.972 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -177.336 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.505 -0.552 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 14.9 p-80 -103.84 160.6 14.66 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 116.809 0.305 . . . . 0.0 110.841 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 66.8 mtt -81.82 137.0 35.35 Favored 'General case' 0 N--CA 1.431 -1.377 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 172.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 14.0 mt-10 -90.81 97.77 11.38 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 120.43 -0.508 . . . . 0.0 109.931 -173.044 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -86.87 93.56 9.34 Favored 'General case' 0 N--CA 1.439 -0.977 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 177.339 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -114.59 143.56 30.18 Favored Pre-proline 0 C--N 1.283 -2.286 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.851 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -74.21 132.89 17.11 Favored 'Trans proline' 0 N--CA 1.45 -1.054 0 C-N-CA 122.331 2.02 . . . . 0.0 113.493 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.517 ' HB ' HD13 ' B' ' 91' ' ' ILE . 77.6 t -124.66 123.82 66.79 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 CA-C-N 114.783 -1.099 . . . . 0.0 108.316 178.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -111.3 123.62 50.58 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -176.192 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.468 HD11 ' HB2' ' B' ' 48' ' ' ALA . 1.6 mt -117.46 177.01 4.9 Favored 'General case' 0 CA--C 1.489 -1.389 0 CA-C-O 121.233 0.539 . . . . 0.0 111.218 177.22 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -155.18 166.55 33.21 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 12' ' ' LYS . . . . . 0.435 ' HG2' ' CD1' ' B' ' 17' ' ' LEU . 10.1 mtmp? -116.11 160.72 19.96 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 118.407 0.549 . . . . 0.0 112.264 -176.157 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -97.79 -160.22 0.79 Allowed 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 169.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 17.6 m -69.6 -27.06 64.76 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 120.993 0.425 . . . . 0.0 110.221 177.808 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -75.9 -64.42 1.09 Allowed 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.96 75.63 0.68 Allowed Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.209 -0.996 . . . . 0.0 112.628 179.683 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.435 ' CD1' ' HG2' ' B' ' 12' ' ' LYS . 10.7 mp 71.92 172.82 0.31 Allowed 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 124.309 1.044 . . . . 0.0 112.916 179.289 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 18' ' ' GLY . . . . . 0.486 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -172.59 88.88 0.08 OUTLIER Glycine 0 CA--C 1.488 -1.612 0 N-CA-C 107.806 -2.118 . . . . 0.0 107.806 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.549 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.8 pt -157.62 -173.65 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 -176.421 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 20' ' ' SER . . . . . 0.493 ' HB2' HG22 ' B' ' 41' ' ' THR . 40.5 m -152.72 144.61 23.67 Favored 'General case' 0 C--N 1.257 -3.452 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 173.656 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.511 ' HB ' HG22 ' B' ' 37' ' ' ILE . 16.3 pt -116.74 162.93 14.34 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.584 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 179.282 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.1 tp -140.81 136.77 35.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 CA-C-O 120.98 0.419 . . . . 0.0 110.665 -178.806 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 23' ' ' GLY . . . . . 0.464 ' HA2' ' CD1' ' B' ' 37' ' ' ILE . . . -67.13 101.92 0.73 Allowed Glycine 0 N--CA 1.435 -1.372 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.1 178.862 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 91.7 mtp -145.93 159.37 43.34 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 -178.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 167.68 -148.51 13.0 Favored Glycine 0 N--CA 1.42 -2.421 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 -177.68 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -142.97 168.68 19.15 Favored 'General case' 0 C--N 1.289 -2.059 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.436 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.38 69.75 2.73 Favored Glycine 0 N--CA 1.442 -0.922 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 174.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.81 81.05 6.13 Favored 'General case' 0 N--CA 1.42 -1.934 0 N-CA-C 113.129 0.788 . . . . 0.0 113.129 -173.39 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -72.5 -24.64 61.19 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 123.059 1.409 . . . . 0.0 107.32 173.742 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 25.6 ptt? -80.8 4.3 19.56 Favored 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 112.318 -2.219 . . . . 0.0 110.057 176.233 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -153.68 40.93 0.67 Allowed Glycine 0 C--O 1.206 -1.603 0 C-N-CA 119.973 -1.108 . . . . 0.0 113.839 -177.485 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 2.8 mm? 62.6 26.09 15.49 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 112.727 0.64 . . . . 0.0 112.727 171.602 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 61.84 26.58 16.13 Favored 'General case' 0 C--O 1.243 0.733 0 C-N-CA 124.622 1.169 . . . . 0.0 111.529 -179.071 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -71.0 126.46 29.64 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 114.788 1.403 . . . . 0.0 114.788 -172.214 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 91.1 mt -100.0 129.2 46.03 Favored 'General case' 0 N--CA 1.417 -2.083 0 N-CA-C 104.174 -2.528 . . . . 0.0 104.174 167.052 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 36' ' ' GLY . . . . . 0.462 ' HA3' HD11 ' B' ' 59' ' ' LEU . . . -99.67 -13.78 36.72 Favored Glycine 0 C--N 1.291 -1.968 0 C-N-CA 118.881 -1.628 . . . . 0.0 111.048 -175.223 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.511 HG22 ' HB ' ' B' ' 21' ' ' ILE . 31.2 mm 64.64 98.02 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.557 1.241 0 C-N-CA 124.396 1.078 . . . . 0.0 111.08 -179.145 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 62.4 m-85 -76.36 164.91 25.56 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.823 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 47.8 t -76.61 142.54 14.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 177.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 31.9 ttmt -98.36 -46.34 5.82 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.331 -179.614 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 41' ' ' THR . . . . . 0.536 ' HA ' HG23 ' B' ' 56' ' ' VAL . 1.1 t -161.15 166.79 27.36 Favored 'General case' 0 N--CA 1.428 -1.55 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -178.355 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.549 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.8 p -137.71 97.26 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.282 -2.342 0 CA-C-O 122.102 0.953 . . . . 0.0 109.381 177.694 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 12.8 m -54.61 129.67 37.31 Favored 'General case' 0 N--CA 1.435 -1.2 0 CA-C-N 113.453 -1.703 . . . . 0.0 111.1 -176.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 44' ' ' GLU . . . . . 0.461 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 38.7 mt-10 -60.55 -27.17 67.45 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 123.537 0.735 . . . . 0.0 111.407 -177.13 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.63 -7.85 88.13 Favored Glycine 0 N--CA 1.434 -1.434 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.843 178.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.486 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -93.02 161.08 25.37 Favored Glycine 0 CA--C 1.485 -1.788 0 C-N-CA 120.326 -0.94 . . . . 0.0 114.243 -175.516 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -62.57 -34.6 77.3 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 113.614 -1.293 . . . . 0.0 111.642 -178.103 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 48' ' ' ALA . . . . . 0.468 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -66.15 -31.89 73.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.762 -0.199 . . . . 0.0 111.36 -177.881 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 49' ' ' HIS . . . . . 0.461 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 4.6 t60 -80.46 -42.6 22.32 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.568 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 50' ' ' ARG . . . . . 0.414 ' HG3' ' O ' ' B' ' 46' ' ' GLY . 82.5 mtp180 -64.59 -42.63 95.48 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.836 -179.632 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -76.52 -43.42 39.46 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 88.24 52.48 2.88 Favored Glycine 0 CA--C 1.503 -0.657 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.787 178.702 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.463 ' HB3' ' CG1' ' B' ' 8' ' ' VAL . 30.8 mmt180 -118.76 -74.29 0.61 Allowed 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -175.4 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.406 HD11 ' CE2' ' B' ' 89' ' ' PHE . 60.9 mt -72.24 107.81 3.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 176.586 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -97.25 153.52 17.97 Favored 'General case' 0 N--CA 1.425 -1.709 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.703 -175.707 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.536 HG23 ' HA ' ' B' ' 41' ' ' THR . 10.0 p -55.05 -24.07 14.0 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.56 0 N-CA-C 115.747 1.758 . . . . 0.0 115.747 -171.236 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -114.43 9.31 16.77 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 120.966 -1.084 . . . . 0.0 111.54 -172.304 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 58' ' ' ASP . . . . . 0.41 ' HB3' ' CG2' ' B' ' 91' ' ' ILE . 5.9 m-20 -99.49 -177.74 3.68 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 119.804 -0.759 . . . . 0.0 112.559 -176.85 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.482 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 29.3 tp -133.67 139.26 46.34 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 112.445 0.535 . . . . 0.0 112.445 -170.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 60' ' ' LEU . . . . . 0.407 ' O ' HD12 ' B' ' 68' ' ' LEU . 67.1 mt -89.27 101.76 14.43 Favored 'General case' 0 C--O 1.208 -1.104 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 176.781 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.552 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 24.8 t -83.46 -42.91 17.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-O 121.84 0.828 . . . . 0.0 111.509 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.494 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 11.8 pt-20 -154.98 150.12 27.01 Favored 'General case' 0 C--N 1.272 -2.8 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.559 176.653 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.438 HG22 ' H ' ' B' ' 64' ' ' ASP . 5.0 p -96.1 -178.51 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.07 0 N-CA-C 105.909 -1.885 . . . . 0.0 105.909 178.623 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.47 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.8 t70 -49.47 -54.89 15.34 Favored 'General case' 0 C--N 1.315 -0.919 0 C-N-CA 124.16 0.984 . . . . 0.0 113.344 -176.381 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -121.12 24.2 7.46 Favored Glycine 0 C--N 1.32 -0.354 0 C-N-CA 119.372 -1.394 . . . . 0.0 114.254 -177.754 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 66' ' ' THR . . . . . 0.431 ' HB ' HG12 ' B' ' 63' ' ' VAL . 25.8 m -152.61 126.54 9.02 Favored 'General case' 0 C--N 1.316 -0.889 0 O-C-N 121.732 -0.864 . . . . 0.0 109.693 179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 67' ' ' SER . . . . . 0.42 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 23.4 m -91.82 132.19 36.62 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 120.889 0.376 . . . . 0.0 110.757 -179.531 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.552 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 26.9 mt -81.69 95.66 7.29 Favored 'General case' 0 N--CA 1.431 -1.4 0 CA-C-O 121.374 0.607 . . . . 0.0 110.509 177.326 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 10.3 p -92.56 16.73 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 CA-C-O 122.317 1.056 . . . . 0.0 108.943 178.581 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 117.54 87.46 1.24 Allowed Glycine 0 CA--C 1.474 -2.493 0 C-N-CA 120.328 -0.939 . . . . 0.0 111.543 178.599 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 15.5 m -120.44 174.2 5.57 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -178.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 62.9 p -85.51 164.62 17.71 Favored 'General case' 0 N--CA 1.42 -1.928 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 176.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -60.97 -38.28 85.4 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 177.12 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.1 m -64.15 -41.28 97.23 Favored 'General case' 0 N--CA 1.433 -1.324 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.951 178.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -65.62 -46.72 78.18 Favored 'General case' 0 CA--C 1.521 -0.138 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.529 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.515 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -56.82 -43.43 81.03 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-O 120.999 0.428 . . . . 0.0 110.773 179.121 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.18 -24.54 66.65 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.605 0.716 . . . . 0.0 111.056 178.173 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 32.6 m -85.79 -26.43 25.78 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.821 -178.678 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.515 HG12 ' O ' ' B' ' 76' ' ' ALA . 9.0 p -73.69 -32.54 35.54 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.679 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 80' ' ' LEU . . . . . 0.428 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 64.5 mt -65.78 -23.12 66.64 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.485 177.04 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 59.7 mtm180 -99.53 -0.4 40.65 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.834 179.457 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -100.78 -29.38 12.29 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.203 177.497 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.727 ' HB ' HG11 ' B' ' 87' ' ' VAL . 7.8 p -74.38 164.03 27.08 Favored 'General case' 0 N--CA 1.425 -1.699 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.87 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 68.5 mmtt -68.83 -166.78 0.08 Allowed 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.102 1.361 . . . . 0.0 112.771 -179.092 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.93 -39.18 93.27 Favored Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.562 -0.744 . . . . 0.0 113.186 -179.161 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 86' ' ' ARG . . . . . 0.426 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 41.7 ttm180 -128.19 124.56 37.06 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 -179.614 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.727 HG11 ' HB ' ' B' ' 83' ' ' THR . 13.6 m -135.2 147.68 29.06 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 CA-C-O 121.138 0.494 . . . . 0.0 111.448 178.075 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 36.2 mtp85 -108.87 120.37 42.31 Favored 'General case' 0 N--CA 1.428 -1.536 0 CA-C-N 114.925 -1.034 . . . . 0.0 109.086 -179.08 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.443 ' HB2' ' CD1' ' B' ' 91' ' ' ILE . 2.9 m-85 -103.82 159.36 15.7 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 -177.124 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.494 ' HB2' ' CG ' ' B' ' 62' ' ' GLU . 0.5 OUTLIER -104.34 109.35 21.16 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 168.939 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.517 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.3 mp -89.79 129.92 39.92 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.158 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 178.757 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 92' ' ' GLY . . . . . 0.466 ' O ' ' HB3' ' B' ' 59' ' ' LEU . . . -112.38 104.31 1.59 Allowed Glycine 0 CA--C 1.458 -3.483 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 178.512 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 -73.87 118.43 16.82 Favored 'General case' 0 C--N 1.27 -2.849 0 CA-C-N 114.913 -0.644 . . . . 0.0 109.664 178.566 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -76.46 75.74 3.2 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 173.582 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 31.5 ttt180 -71.05 -56.42 5.63 Favored Pre-proline 0 C--N 1.294 -1.814 0 CA-C-N 113.312 -1.767 . . . . 0.0 111.354 177.837 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.95 167.31 27.53 Favored 'Trans proline' 0 C--N 1.364 1.358 0 C-N-CA 121.855 1.704 . . . . 0.0 112.038 177.429 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -146.89 66.88 0.4 Allowed Glycine 0 N--CA 1.435 -1.385 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.348 -178.592 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 49.33 25.15 1.19 Allowed 'General case' 0 CA--C 1.539 0.522 0 N-CA-C 115.287 1.588 . . . . 0.0 115.287 177.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 23.9 tp60 -95.7 -17.8 20.98 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 178.471 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 28.5 m -77.68 157.98 29.9 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.952 -178.556 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 52.94 81.78 0.08 Allowed 'General case' 0 C--O 1.251 1.144 0 C-N-CA 125.584 1.554 . . . . 0.0 112.46 178.059 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 4.0 p -114.79 132.48 63.85 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.044 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.194 176.025 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -101.21 -74.5 0.61 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.495 -179.084 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -154.69 99.0 2.12 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-O 121.691 0.758 . . . . 0.0 110.92 -177.04 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 78.0 mt -100.84 -13.82 18.23 Favored 'General case' 0 CA--C 1.502 -0.885 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.871 -177.106 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 38.3 mm -88.17 -60.43 2.28 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.017 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.272 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 28.1 tt0 -102.14 105.17 15.83 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.943 177.454 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -105.26 112.38 25.47 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.394 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 9.2 t -80.28 -41.55 24.75 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 120.59 -0.444 . . . . 0.0 111.397 -176.071 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 96.5 mt -133.53 -24.32 1.79 Allowed 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.121 -179.544 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 68.91 123.16 0.03 OUTLIER 'General case' 0 C--O 1.235 0.325 0 C-N-CA 124.914 1.285 . . . . 0.0 112.073 -177.83 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 89.4 mt-30 -115.66 -76.34 0.58 Allowed 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 105.842 -1.91 . . . . 0.0 105.842 175.818 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 . . . . . 0 N--CA 1.434 -1.245 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 169.017 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.241 0.583 0 N-CA-C 111.489 -0.645 . . . . 0.0 111.489 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 57.9 m80 -90.57 -56.76 3.07 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 179.104 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 67.8 mtm -127.31 151.98 48.05 Favored 'General case' 0 N--CA 1.432 -1.347 0 CA-C-N 115.254 -0.884 . . . . 0.0 109.0 178.194 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 4' ' ' GLU . . . . . 0.463 ' HG3' ' HA ' ' B' ' 94' ' ' GLU . 18.7 mt-10 -85.26 108.34 17.72 Favored 'General case' 0 N--CA 1.426 -1.652 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 179.136 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.522 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 1.1 mm? -85.35 89.46 7.68 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 174.219 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -111.7 142.6 26.93 Favored Pre-proline 0 C--N 1.288 -2.094 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.295 -179.37 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -75.8 132.88 14.83 Favored 'Trans proline' 0 N--CA 1.44 -1.632 0 C-N-CA 122.223 1.949 . . . . 0.0 111.878 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.498 HG13 ' HB3' ' B' ' 53' ' ' ARG . 76.4 t -120.83 120.77 63.39 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.389 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.178 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 9' ' ' GLU . . . . . 0.414 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 38.4 tt0 -115.29 120.18 38.8 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.704 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.554 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -108.34 -173.58 2.31 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 178.832 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -158.83 155.85 28.59 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 105.046 -2.205 . . . . 0.0 105.046 176.528 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 10.6 ptpp? -84.96 163.38 18.95 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-O 121.743 0.782 . . . . 0.0 112.991 -173.346 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 13' ' ' ASP . . . . . 0.515 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 14.0 t70 -111.34 -176.35 2.93 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 104.697 -2.334 . . . . 0.0 104.697 170.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 34.3 m -63.8 -30.33 71.44 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 119.278 0.944 . . . . 0.0 111.575 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -88.91 -13.0 40.12 Favored 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 121.711 0.767 . . . . 0.0 109.64 178.12 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.01 -108.11 2.43 Favored Glycine 0 N--CA 1.433 -1.505 0 C-N-CA 120.862 -0.685 . . . . 0.0 111.78 179.55 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -95.63 172.63 7.93 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 120.954 0.407 . . . . 0.0 110.105 -178.285 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -137.12 53.86 0.73 Allowed Glycine 0 CA--C 1.486 -1.744 0 N-CA-C 109.944 -1.263 . . . . 0.0 109.944 -179.519 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.518 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 6.9 pt -157.95 -178.64 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.489 -1.369 0 C-N-CA 124.84 1.256 . . . . 0.0 108.282 -174.204 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 20' ' ' SER . . . . . 0.433 ' HB2' ' HB3' ' B' ' 40' ' ' LYS . 46.8 m -152.58 156.21 38.87 Favored 'General case' 0 C--N 1.27 -2.853 0 N-CA-C 105.106 -2.183 . . . . 0.0 105.106 174.361 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 21' ' ' ILE . . . . . 0.419 ' HB ' HG22 ' B' ' 37' ' ' ILE . 29.5 pt -117.3 158.96 17.71 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 CA-C-N 118.181 0.446 . . . . 0.0 110.287 -177.045 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -148.48 136.26 14.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 CA-C-O 121.422 0.629 . . . . 0.0 110.181 178.694 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -75.19 122.15 6.78 Favored Glycine 0 N--CA 1.423 -2.232 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.044 178.751 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 24' ' ' MET . . . . . 0.67 ' HB2' ' CD1' ' B' ' 38' ' ' PHE . 64.6 mtt -126.34 144.75 50.7 Favored 'General case' 0 CA--C 1.491 -1.298 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 174.908 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 145.08 -170.37 26.53 Favored Glycine 0 N--CA 1.42 -2.389 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 -177.741 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -138.98 169.41 17.84 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.98 69.41 1.88 Allowed Glycine 0 N--CA 1.449 -0.467 0 O-C-N 123.412 0.445 . . . . 0.0 113.669 -176.556 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -99.34 54.1 0.96 Allowed 'General case' 0 C--N 1.298 -1.663 0 CA-C-O 122.193 0.997 . . . . 0.0 109.142 177.53 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.411 ' HA ' ' HG3' ' B' ' 33' ' ' GLU . 6.2 p-10 -84.05 19.94 1.67 Allowed 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 113.97 -1.468 . . . . 0.0 111.618 -175.706 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 23.5 ptp -88.75 23.72 2.23 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 123.428 0.691 . . . . 0.0 110.597 -178.149 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.04 36.27 3.71 Favored Glycine 0 N--CA 1.437 -1.247 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 -178.66 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 48.6 tp -140.63 -77.11 0.31 Allowed 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.061 -177.566 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 33' ' ' GLU . . . . . 0.627 ' O ' ' HA3' ' B' ' 70' ' ' GLY . 45.7 mt-10 47.66 42.41 15.19 Favored 'General case' 0 C--O 1.215 -0.726 0 C-N-CA 124.922 1.289 . . . . 0.0 114.472 -179.355 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 34' ' ' LYS . . . . . 0.442 ' HA ' ' O ' ' B' ' 69' ' ' VAL . 65.2 mttm -73.46 87.16 1.57 Allowed 'General case' 0 CA--C 1.512 -0.492 0 CA-C-O 122.366 1.079 . . . . 0.0 112.847 178.684 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 10.8 mp -125.84 -171.47 2.39 Favored 'General case' 0 C--N 1.296 -1.749 0 CA-C-N 113.181 -1.827 . . . . 0.0 106.662 178.581 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -170.99 1.63 0.03 OUTLIER Glycine 0 C--N 1.292 -1.892 0 C-N-CA 119.817 -1.183 . . . . 0.0 111.067 174.409 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 37' ' ' ILE . . . . . 0.419 HG22 ' HB ' ' B' ' 21' ' ' ILE . 40.9 mm 65.39 114.64 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 CA-C-O 122.495 1.141 . . . . 0.0 110.543 -173.649 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.67 ' CD1' ' HB2' ' B' ' 24' ' ' MET . 29.0 m-85 -88.55 176.19 7.25 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.103 -0.953 . . . . 0.0 108.881 -175.205 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 64.6 t -83.93 142.9 12.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-O 121.654 0.74 . . . . 0.0 110.759 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 40' ' ' LYS . . . . . 0.433 ' HB3' ' HB2' ' B' ' 20' ' ' SER . 16.3 ttmm -94.34 -47.03 6.78 Favored 'General case' 0 N--CA 1.434 -1.261 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.769 -179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 3.1 t -162.32 171.76 16.73 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 -178.64 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.518 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.2 p -147.9 91.51 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.861 0 CA-C-O 122.35 1.071 . . . . 0.0 109.193 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 8.2 m -59.3 128.94 39.61 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 113.557 -1.656 . . . . 0.0 111.528 -176.518 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 44' ' ' GLU . . . . . 0.576 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 8.1 pt-20 -68.01 -17.2 64.35 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 112.558 0.577 . . . . 0.0 112.558 -177.901 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.26 -0.04 85.27 Favored Glycine 0 N--CA 1.436 -1.351 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.486 177.532 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -111.14 169.59 13.36 Favored Glycine 0 N--CA 1.418 -2.503 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.923 -177.492 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 47' ' ' ALA . . . . . 0.515 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -55.08 -54.67 40.11 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 113.911 -1.144 . . . . 0.0 113.651 -174.198 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 48' ' ' ALA . . . . . 0.554 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -56.24 -35.37 67.29 Favored 'General case' 0 C--O 1.243 0.75 0 N-CA-C 114.051 1.13 . . . . 0.0 114.051 -172.246 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 49' ' ' HIS . . . . . 0.576 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 6.6 t60 -75.39 -46.8 30.71 Favored 'General case' 0 C--N 1.312 -1.037 0 O-C-N 123.656 0.597 . . . . 0.0 109.953 -177.003 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 65.7 mtp180 -73.49 -34.98 65.57 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.422 -175.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -66.01 -51.36 59.06 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.419 178.549 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 95.13 52.77 1.7 Allowed Glycine 0 N--CA 1.432 -1.571 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 53' ' ' ARG . . . . . 0.498 ' HB3' HG13 ' B' ' 8' ' ' VAL . 21.6 mmt180 -129.78 -72.78 0.57 Allowed 'General case' 0 N--CA 1.432 -1.328 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -178.629 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.596 HD11 ' CE2' ' B' ' 89' ' ' PHE . 45.4 mt -80.06 129.15 38.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 C-N-CA 119.288 -0.965 . . . . 0.0 108.925 178.278 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 55' ' ' GLN . . . . . 0.741 ' HB2' ' OD1' ' B' ' 58' ' ' ASP . 53.3 mt-30 -116.78 164.15 15.09 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 -176.624 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.8 p -59.14 -33.95 52.01 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.276 0 N-CA-C 115.949 1.833 . . . . 0.0 115.949 -171.511 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -105.52 5.46 31.47 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.112 -0.993 . . . . 0.0 112.421 -172.721 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 58' ' ' ASP . . . . . 0.741 ' OD1' ' HB2' ' B' ' 55' ' ' GLN . 5.2 m-20 -82.01 171.09 14.8 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-O 121.318 0.58 . . . . 0.0 111.984 -175.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 59' ' ' LEU . . . . . 0.473 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 23.1 tp -131.54 133.11 44.72 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.312 -174.318 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 66.0 mt -87.25 96.36 10.31 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 178.095 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 61' ' ' VAL . . . . . 0.621 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 16.1 t -73.94 -38.46 49.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 CA-C-O 121.589 0.709 . . . . 0.0 110.928 179.092 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.565 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 10.0 pt-20 -159.95 156.67 27.56 Favored 'General case' 0 C--N 1.282 -2.357 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.653 174.662 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 63' ' ' VAL . . . . . 0.468 HG22 ' H ' ' B' ' 64' ' ' ASP . 6.2 p -100.53 177.35 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 177.479 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 64' ' ' ASP . . . . . 0.468 ' H ' HG22 ' B' ' 63' ' ' VAL . 27.3 t70 -46.65 -56.67 5.74 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 114.156 1.169 . . . . 0.0 114.156 -173.808 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -117.98 27.44 7.44 Favored Glycine 0 C--N 1.31 -0.877 0 C-N-CA 119.392 -1.385 . . . . 0.0 114.072 -177.504 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 66' ' ' THR . . . . . 0.43 ' HB ' HG12 ' B' ' 63' ' ' VAL . 29.6 m -154.11 123.86 6.71 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 117.754 0.777 . . . . 0.0 109.788 179.193 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 67' ' ' SER . . . . . 0.565 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 11.1 t -96.46 129.19 43.87 Favored 'General case' 0 N--CA 1.426 -1.671 0 CA-C-O 121.078 0.466 . . . . 0.0 110.607 -177.25 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.621 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 62.7 mt -92.03 124.2 35.95 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.081 179.212 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 69' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' B' ' 34' ' ' LYS . 14.4 p -93.05 -25.39 4.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 174.164 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 70' ' ' GLY . . . . . 0.627 ' HA3' ' O ' ' B' ' 33' ' ' GLU . . . 149.26 75.13 0.02 OUTLIER Glycine 0 N--CA 1.423 -2.176 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 -176.648 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 31.3 m -93.15 178.45 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 CA-C-N 114.912 -0.644 . . . . 0.0 110.691 -175.368 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 36.6 p -80.88 160.98 24.6 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 175.482 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -62.59 -35.42 79.47 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 120.944 0.402 . . . . 0.0 110.307 -178.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 19.2 m -66.41 -40.18 89.42 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.279 178.122 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -64.31 -46.35 83.95 Favored 'General case' 0 C--N 1.338 0.101 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 76' ' ' ALA . . . . . 0.413 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -57.89 -46.91 84.2 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.382 178.293 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.49 -42.01 86.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.005 0.431 . . . . 0.0 110.687 178.345 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 22.8 t -68.73 -32.68 72.64 Favored 'General case' 0 N--CA 1.431 -1.377 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.736 -178.565 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 79' ' ' VAL . . . . . 0.413 HG12 ' O ' ' B' ' 76' ' ' ALA . 9.8 p -78.09 -39.13 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 119.582 -0.847 . . . . 0.0 109.921 -174.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 45.6 mt -63.93 -34.02 77.02 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.822 177.647 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -87.66 -5.02 58.9 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.344 179.446 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -89.07 -37.04 15.41 Favored 'General case' 0 N--CA 1.431 -1.387 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 175.609 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 83' ' ' THR . . . . . 0.68 ' HB ' HG11 ' B' ' 87' ' ' VAL . 12.8 p -77.11 172.24 13.54 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.463 177.058 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt -69.11 -173.74 0.55 Allowed 'General case' 0 N--CA 1.444 -0.748 0 CA-C-O 121.738 0.78 . . . . 0.0 111.725 177.607 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -81.4 -28.66 43.16 Favored Glycine 0 N--CA 1.431 -1.661 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 175.634 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 86' ' ' ARG . . . . . 0.459 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 21.9 ttm-85 -106.76 111.3 23.76 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 121.406 0.622 . . . . 0.0 110.162 175.804 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 87' ' ' VAL . . . . . 0.68 HG11 ' HB ' ' B' ' 83' ' ' THR . 2.6 m -147.63 151.68 13.44 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-N 114.58 -1.191 . . . . 0.0 109.679 178.348 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 88' ' ' ARG . . . . . 0.431 ' HA ' ' O ' ' B' ' 8' ' ' VAL . 10.3 mtm-85 -101.28 110.31 22.3 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 123.992 0.808 . . . . 0.0 109.726 -179.718 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 89' ' ' PHE . . . . . 0.596 ' CE2' HD11 ' B' ' 54' ' ' ILE . 3.0 m-85 -95.23 158.97 15.23 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 179.426 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 90' ' ' MET . . . . . 0.479 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 86.3 mtp -107.8 114.04 27.71 Favored 'General case' 0 C--N 1.29 -1.993 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 170.273 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.522 ' O ' ' HA ' ' B' ' 5' ' ' LEU . 1.4 mp -95.45 136.78 25.39 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 -179.006 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.93 100.9 0.73 Allowed Glycine 0 CA--C 1.474 -2.506 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 175.283 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 16.4 tpp180 -163.61 132.78 3.96 Favored 'General case' 0 C--N 1.275 -2.652 0 CA-C-N 113.824 -1.188 . . . . 0.0 108.726 -178.73 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 94' ' ' GLU . . . . . 0.469 ' HG2' ' O ' ' B' ' 96' ' ' PRO . 41.6 tt0 -99.39 91.14 4.8 Favored 'General case' 0 N--CA 1.415 -2.19 0 N-CA-C 106.352 -1.721 . . . . 0.0 106.352 170.066 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 45.0 ttt180 -58.13 -59.15 14.24 Favored Pre-proline 0 CA--C 1.554 1.12 0 CA-C-N 114.209 -1.36 . . . . 0.0 111.881 -177.633 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 96' ' ' PRO . . . . . 0.469 ' O ' ' HG2' ' B' ' 94' ' ' GLU . 41.6 Cg_endo -87.96 -172.38 0.8 Allowed 'Trans proline' 0 N--CA 1.448 -1.181 0 C-N-CA 122.005 1.804 . . . . 0.0 109.993 174.755 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -106.34 -85.45 1.8 Allowed Glycine 0 C--N 1.28 -2.537 0 N-CA-C 107.436 -2.266 . . . . 0.0 107.436 171.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 30.0 mt-10 -115.06 80.64 1.45 Allowed 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 174.065 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 35.0 tt0 -72.06 148.84 45.41 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.942 -178.022 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 64.5 m 62.79 152.66 0.03 OUTLIER 'General case' 0 N--CA 1.437 -1.087 0 C-N-CA 126.514 1.925 . . . . 0.0 114.948 179.441 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -124.87 20.6 8.38 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-N 114.976 -1.011 . . . . 0.0 109.584 -174.549 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 66.7 t -120.5 124.97 73.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 CA-C-O 122.075 0.941 . . . . 0.0 112.805 -171.725 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -94.02 -76.33 0.48 Allowed 'General case' 0 C--N 1.277 -2.583 0 CA-C-N 114.639 -1.164 . . . . 0.0 108.346 173.215 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 20.9 mm-40 -127.08 24.52 6.36 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.093 176.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -82.4 61.26 5.49 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 177.443 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 106' ' ' ILE . . . . . 0.414 ' HB ' ' OE1' ' B' ' 107' ' ' GLN . 38.2 mm -126.48 -60.44 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 N-CA-C 106.345 -1.724 . . . . 0.0 106.345 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 107' ' ' GLN . . . . . 0.414 ' OE1' ' HB ' ' B' ' 106' ' ' ILE . 0.3 OUTLIER -74.0 159.13 33.15 Favored 'General case' 0 N--CA 1.44 -0.953 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 172.879 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -140.73 138.34 34.11 Favored 'General case' 0 C--N 1.274 -2.711 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 176.192 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 10.2 t -74.73 124.18 26.31 Favored 'General case' 0 N--CA 1.417 -2.106 0 CA-C-O 121.711 0.767 . . . . 0.0 109.707 179.23 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 31.3 mt -105.35 5.48 31.88 Favored 'General case' 0 C--N 1.281 -2.39 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 179.558 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -102.21 66.93 1.03 Allowed 'General case' 0 N--CA 1.417 -2.112 0 N-CA-C 105.649 -1.982 . . . . 0.0 105.649 174.32 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -144.8 93.2 2.37 Favored 'General case' 0 N--CA 1.427 -1.619 0 CA-C-N 114.376 -1.283 . . . . 0.0 107.726 -178.126 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 . . . . . 0 C--N 1.286 -2.158 0 CA-C-N 114.519 -1.219 . . . . 0.0 108.553 -176.217 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 56.9 mtt . . . . . 0 N--CA 1.433 -1.292 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . 0.548 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 27.0 mt-10 -79.95 98.82 7.32 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.423 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 1.0 OUTLIER -82.67 89.84 6.78 Favored 'General case' 0 C--N 1.311 -1.105 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 174.602 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 13.5 p90 -110.59 142.11 25.42 Favored Pre-proline 0 C--N 1.286 -2.158 0 CA-C-N 116.038 -0.528 . . . . 0.0 112.128 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -68.78 129.46 18.7 Favored 'Trans proline' 0 N--CA 1.451 -1.024 0 C-N-CA 122.67 2.247 . . . . 0.0 112.482 178.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.703 HG13 ' HG3' ' B' ' 53' ' ' ARG . 79.1 t -120.88 122.91 69.01 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.515 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.725 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . 0.468 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 31.3 tt0 -123.11 113.84 19.53 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 mt -104.26 160.4 14.91 Favored 'General case' 0 C--N 1.283 -2.309 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.342 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.464 ' HB3' ' NH2' ' B' ' 86' ' ' ARG . 8.5 pt-20 -123.55 113.68 19.04 Favored 'General case' 0 C--N 1.271 -2.821 0 CA-C-N 114.271 -1.331 . . . . 0.0 108.421 173.019 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.4 ptpt -79.82 156.93 27.16 Favored 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.421 -0.808 . . . . 0.0 110.496 -175.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -89.18 -173.13 3.92 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.163 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 35.8 t -68.99 -21.15 64.17 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 173.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -69.7 -46.82 65.14 Favored 'General case' 0 N--CA 1.44 -0.929 0 CA-C-N 114.318 -1.31 . . . . 0.0 108.48 173.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.3 -132.73 8.66 Favored Glycine 0 N--CA 1.419 -2.496 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -176.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 90.7 mt -95.65 179.0 5.28 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . 0.531 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -151.3 66.59 0.35 Allowed Glycine 0 CA--C 1.481 -2.07 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.524 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 3.5 pt -151.71 -177.6 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.104 0 C-N-CA 124.608 1.163 . . . . 0.0 108.246 -177.226 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . 0.457 ' HB2' HG22 ' B' ' 41' ' ' THR . 49.3 m -153.73 162.7 41.01 Favored 'General case' 0 C--N 1.261 -3.243 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.236 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.419 ' HB ' HG22 ' B' ' 37' ' ' ILE . 19.0 pt -127.92 164.4 29.43 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 -178.403 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -144.0 138.57 24.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 178.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . 0.419 ' HA2' ' CD1' ' B' ' 37' ' ' ILE . . . -83.61 96.03 1.92 Allowed Glycine 0 N--CA 1.426 -2.028 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.936 178.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 24.8 mmt . . . . . 0 C--N 1.307 -1.281 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 177.341 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 96.6 mt . . . . . 0 CA--C 1.495 -1.165 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -136.9 109.58 0.73 Allowed Glycine 0 N--CA 1.411 -3.02 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.627 -178.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.419 ' CD1' ' HA2' ' B' ' 23' ' ' GLY . 33.8 mm -89.62 84.55 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.89 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 175.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.487 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 90.4 m-85 -82.91 164.97 20.13 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.192 -1.367 . . . . 0.0 109.235 -176.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 52.1 t -73.21 126.47 33.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 176.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -86.87 -36.7 18.28 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.052 -176.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . 0.457 HG22 ' HB2' ' B' ' 20' ' ' SER . 1.3 t -160.88 165.87 29.41 Favored 'General case' 0 N--CA 1.423 -1.791 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.208 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.524 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.3 p -139.1 94.22 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-O 122.562 1.173 . . . . 0.0 109.077 177.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.417 HG22 ' H ' ' B' ' 45' ' ' GLY . 45.6 m -65.74 126.79 29.54 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-N 113.064 -1.88 . . . . 0.0 113.038 -173.238 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . 0.453 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 9.2 pt-20 -53.13 -31.4 42.15 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 125.218 1.407 . . . . 0.0 113.254 -179.089 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . 0.417 ' H ' HG22 ' B' ' 43' ' ' THR . . . -64.65 -29.69 75.9 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 121.427 -0.416 . . . . 0.0 112.908 -179.503 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.531 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -95.98 165.79 24.43 Favored Glycine 0 N--CA 1.422 -2.298 0 C-N-CA 119.884 -1.15 . . . . 0.0 113.527 -176.031 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -58.45 -33.66 69.98 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 113.358 -1.421 . . . . 0.0 113.48 -175.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -59.51 -38.87 82.08 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -175.565 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . 0.453 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 7.9 t60 -75.06 -38.49 61.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.11 0.481 . . . . 0.0 110.145 -178.784 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 22.5 mtm-85 -77.89 -29.55 50.28 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.682 -175.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . 0.547 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 23.9 t70 -80.0 -53.78 6.41 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 176.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.39 39.66 4.16 Favored Glycine 0 CA--C 1.497 -1.077 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 179.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.703 ' HG3' HG13 ' B' ' 8' ' ' VAL . 0.5 OUTLIER -103.07 -69.41 0.79 Allowed 'General case' 0 N--CA 1.425 -1.717 0 CA-C-N 114.618 -0.791 . . . . 0.0 109.532 -174.26 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.609 HD11 ' CE2' ' B' ' 89' ' ' PHE . 52.1 mt -85.61 108.34 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 174.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 32.5 mt-30 -101.9 167.7 9.89 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -176.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 9.5 p -70.73 -4.54 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.568 1.641 0 CA-C-O 121.79 0.805 . . . . 0.0 112.3 -173.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -114.16 7.05 16.51 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.889 0.852 . . . . 0.0 109.232 -175.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -95.21 165.01 12.61 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.809 -176.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.515 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 23.8 tp -136.5 133.98 37.1 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.668 -176.773 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 69.3 mt -80.48 96.51 6.78 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 176.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.505 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 38.8 t -78.4 -45.67 25.99 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-O 121.66 0.743 . . . . 0.0 109.917 178.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -154.11 151.69 29.57 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 114.968 -1.015 . . . . 0.0 109.931 174.167 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.53 HG12 ' HB ' ' B' ' 66' ' ' THR . 4.3 p -95.28 -173.49 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 178.224 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.513 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 13.0 t70 -47.26 -49.62 23.09 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -139.6 43.06 1.18 Allowed Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 119.29 -1.433 . . . . 0.0 113.964 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . 0.53 ' HB ' HG12 ' B' ' 63' ' ' VAL . 31.8 m -160.64 115.66 2.21 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 178.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 43.4 m -76.75 133.76 39.36 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-O 121.133 0.492 . . . . 0.0 110.891 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.515 HD12 ' CG2' ' B' ' 71' ' ' VAL . 4.1 mm? -87.42 -68.06 0.78 Allowed 'General case' 0 N--CA 1.434 -1.228 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.995 177.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 59.9 t 70.05 -40.46 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 124.456 1.102 . . . . 0.0 111.52 -177.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 157.44 85.22 0.05 OUTLIER Glycine 0 N--CA 1.417 -2.628 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.515 ' CG2' HD12 ' B' ' 68' ' ' LEU . 35.5 m -105.58 -172.73 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 123.543 0.737 . . . . 0.0 109.49 -178.311 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . 0.437 ' O ' HG23 ' B' ' 71' ' ' VAL . 19.8 p -81.64 157.03 24.81 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 172.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -61.49 -35.59 78.11 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.194 0.521 . . . . 0.0 110.735 -176.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 25.4 m -62.65 -38.02 88.66 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.915 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -63.83 -49.13 74.04 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.527 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.64 -42.95 99.62 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.793 -178.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.04 -32.51 73.02 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.278 0.561 . . . . 0.0 110.696 178.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 8.1 t -82.38 -28.45 31.47 Favored 'General case' 0 N--CA 1.428 -1.56 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.059 -177.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.527 HG12 ' O ' ' B' ' 76' ' ' ALA . 7.2 p -71.44 -33.01 48.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 O-C-N 121.412 -0.805 . . . . 0.0 109.714 -174.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 29.1 mt -69.81 -16.88 63.35 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.573 -1.194 . . . . 0.0 111.02 176.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -96.14 -24.22 16.39 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.049 0.452 . . . . 0.0 110.787 178.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 29.2 m-80 -82.68 -21.5 34.89 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 121.373 0.606 . . . . 0.0 111.351 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.524 ' HB ' HG11 ' B' ' 87' ' ' VAL . 7.4 p -85.32 167.75 15.31 Favored 'General case' 0 N--CA 1.425 -1.683 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.928 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 37.4 mmtm -67.89 -173.76 0.39 Allowed 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 123.425 0.69 . . . . 0.0 112.422 179.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -75.16 -30.61 58.67 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.17 -0.923 . . . . 0.0 112.064 -178.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . 0.464 ' NH2' ' HB3' ' B' ' 11' ' ' GLU . 21.4 ttm-85 -130.62 116.09 17.62 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.062 0.458 . . . . 0.0 110.003 175.067 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.524 HG11 ' HB ' ' B' ' 83' ' ' THR . 5.8 m -136.71 144.64 31.93 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.737 179.172 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . 0.468 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 99.7 mtt180 -91.8 129.12 37.82 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 175.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.609 ' CE2' HD11 ' B' ' 54' ' ' ILE . 2.0 m-85 -105.93 161.0 14.84 Favored 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 178.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.486 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 62.1 mtt -109.14 106.64 16.62 Favored 'General case' 0 C--N 1.286 -2.167 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 169.449 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.515 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.3 mp -87.57 135.48 25.28 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 CA-C-N 114.459 -1.246 . . . . 0.0 107.648 178.492 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . 0.548 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -127.0 104.06 0.69 Allowed Glycine 0 CA--C 1.465 -3.088 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 177.186 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 11.2 ptp180 . . . . . 0 C--N 1.271 -2.809 0 N-CA-C 108.963 -0.754 . . . . 0.0 108.963 -179.892 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 24.7 mmt . . . . . 0 N--CA 1.434 -1.23 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . 0.464 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 19.0 mt-10 -89.85 100.25 13.1 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -95.46 93.93 7.5 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 177.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -118.53 141.48 29.87 Favored Pre-proline 0 C--N 1.283 -2.323 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.067 178.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . 0.413 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 79.2 Cg_endo -79.51 143.51 17.15 Favored 'Trans proline' 0 N--CA 1.446 -1.268 0 C-N-CA 122.151 1.901 . . . . 0.0 112.306 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.449 HG13 ' HB3' ' B' ' 53' ' ' ARG . 53.8 t -131.49 127.7 59.99 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.981 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 176.599 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . 0.488 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 32.0 tt0 -110.4 121.61 45.72 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -177.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.523 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -114.61 165.6 12.6 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 121.515 0.674 . . . . 0.0 110.707 178.685 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -115.52 126.63 54.52 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 105.728 -1.953 . . . . 0.0 105.728 175.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . 0.412 ' HG2' ' HA2' ' B' ' 85' ' ' GLY . 21.1 ptmt -79.85 160.45 26.08 Favored 'General case' 0 N--CA 1.417 -2.092 0 C-N-CA 117.627 -1.629 . . . . 0.0 107.022 170.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . 0.407 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 22.2 t70 -115.75 178.31 4.36 Favored 'General case' 0 C--N 1.258 -3.391 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 -178.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 13.1 t -67.32 -20.54 65.62 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 179.398 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -92.61 7.24 44.22 Favored 'General case' 0 CA--C 1.555 1.168 0 CA-C-O 121.869 0.843 . . . . 0.0 109.42 176.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.57 -115.93 4.63 Favored Glycine 0 N--CA 1.435 -1.421 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.493 178.506 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -103.05 -173.19 2.25 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 121.42 0.629 . . . . 0.0 110.483 -177.282 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . 0.462 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -149.44 53.75 0.51 Allowed Glycine 0 CA--C 1.491 -1.433 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 178.291 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 2.6 pt -154.3 -179.99 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-O 121.961 0.886 . . . . 0.0 111.407 -175.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 51.0 m -152.49 131.45 12.56 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 175.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.505 ' HB ' HG22 ' B' ' 37' ' ' ILE . 15.6 pt -108.66 162.53 6.51 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 C-N-CA 122.713 0.405 . . . . 0.0 109.946 -178.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . 0.479 ' HB ' ' HB2' ' B' ' 40' ' ' LYS . 9.5 tp -136.22 136.69 49.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 CA-C-O 121.134 0.493 . . . . 0.0 110.673 -178.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -82.58 105.63 2.64 Favored Glycine 0 N--CA 1.426 -2.022 0 CA-C-N 115.663 -0.699 . . . . 0.0 112.527 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . 0.531 ' O ' ' HG ' ' B' ' 35' ' ' LEU . 26.3 mmt . . . . . 0 C--N 1.306 -1.322 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 176.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' B' ' 24' ' ' MET . 15.4 tp . . . . . 0 N--CA 1.429 -1.491 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . 0.475 ' H ' ' HG ' ' B' ' 35' ' ' LEU . . . -137.06 87.72 0.22 Allowed Glycine 0 N--CA 1.422 -2.296 0 C-N-CA 119.882 -1.151 . . . . 0.0 111.724 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.505 HG22 ' HB ' ' B' ' 21' ' ' ILE . 34.5 mm -84.62 80.32 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 176.233 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.413 ' CD1' ' HB2' ' B' ' 59' ' ' LEU . 96.9 m-85 -77.17 169.93 17.45 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.172 -176.38 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 49.1 t -80.36 135.46 25.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . 0.479 ' HB2' ' HB ' ' B' ' 22' ' ' ILE . 2.4 ttpm? -95.84 -41.47 8.81 Favored 'General case' 0 CA--C 1.482 -1.652 0 CA-C-O 121.187 0.517 . . . . 0.0 109.899 -178.125 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 1.1 m -154.83 146.98 23.72 Favored 'General case' 1 N--CA 1.369 -4.483 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -174.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 39.5 t -114.76 105.69 19.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 175.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 7.2 m -64.41 122.68 17.3 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.215 -174.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . 0.505 ' HG2' ' CE1' ' B' ' 49' ' ' HIS . 36.1 mt-10 -66.8 -28.36 68.31 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.457 -175.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.3 -1.11 85.4 Favored Glycine 0 N--CA 1.435 -1.401 0 CA-C-N 115.042 -0.981 . . . . 0.0 113.396 -179.266 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.462 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -117.07 170.29 13.38 Favored Glycine 0 N--CA 1.411 -2.972 0 C-N-CA 119.933 -1.127 . . . . 0.0 112.818 -178.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . 0.407 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -60.72 -35.79 77.23 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 114.088 1.144 . . . . 0.0 114.088 -174.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . 0.523 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -63.28 -38.74 92.35 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 113.199 0.815 . . . . 0.0 113.199 -174.277 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . 0.505 ' CE1' ' HG2' ' B' ' 44' ' ' GLU . 4.1 t60 -74.15 -39.34 63.33 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.659 0.742 . . . . 0.0 109.342 -179.199 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 -76.63 -26.2 54.65 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 114.862 -1.063 . . . . 0.0 111.785 -175.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . 0.523 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 12.6 t70 -77.92 -46.18 22.0 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 176.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 97.08 16.34 35.76 Favored Glycine 0 CA--C 1.498 -1.03 0 CA-C-N 115.515 -0.766 . . . . 0.0 112.624 172.399 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.523 ' HD3' ' OD2' ' B' ' 51' ' ' ASP . 1.5 mpt_? -91.96 -63.46 1.24 Allowed 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 113.335 0.865 . . . . 0.0 113.335 -177.124 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.5 HD11 ' CE2' ' B' ' 89' ' ' PHE . 39.4 mt -69.3 133.09 32.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 C-N-CA 119.805 -0.758 . . . . 0.0 110.53 176.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 30.7 mm-40 -113.37 153.66 28.19 Favored 'General case' 0 CA--C 1.511 -0.543 0 C-N-CA 122.408 0.283 . . . . 0.0 110.634 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.3 p -73.6 -7.48 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.86 0 CA-C-O 121.709 0.766 . . . . 0.0 111.986 -176.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -114.35 9.83 16.97 Favored 'General case' 0 C--N 1.293 -1.879 0 O-C-N 121.581 -0.699 . . . . 0.0 111.95 -175.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -112.42 177.78 4.52 Favored 'General case' 0 C--O 1.244 0.784 0 CA-C-O 120.979 0.418 . . . . 0.0 111.767 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.413 ' HB2' ' CD1' ' B' ' 38' ' ' PHE . 24.9 tp -126.91 128.22 46.12 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.739 -176.638 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 31.7 mt -90.15 107.68 19.28 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 105.569 -2.011 . . . . 0.0 105.569 175.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.534 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 41.4 t -79.2 -74.36 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.19 -2.03 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.45 ' HA ' HD23 ' B' ' 68' ' ' LEU . 10.9 pt-20 -118.6 165.2 14.24 Favored 'General case' 0 C--N 1.269 -2.903 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.032 -173.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.485 HG22 ' H ' ' B' ' 64' ' ' ASP . 4.6 p -113.34 -175.19 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -174.705 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.491 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 12.6 t70 -40.18 -63.35 0.62 Allowed 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 125.76 1.624 . . . . 0.0 113.918 -178.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -134.68 41.01 1.5 Allowed Glycine 0 CA--C 1.496 -1.133 0 C-N-CA 119.333 -1.413 . . . . 0.0 113.401 -178.097 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 37.7 m -150.35 126.24 10.44 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 178.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 2.3 p -84.18 133.18 34.61 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 115.457 -0.792 . . . . 0.0 112.047 -177.09 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.534 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 4.2 mm? -118.69 141.91 48.16 Favored 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 175.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 44.6 t -123.47 -42.59 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 175.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 175.49 81.0 0.05 OUTLIER Glycine 0 N--CA 1.409 -3.164 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.552 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 27.1 m -100.91 -177.39 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.217 0 CA-C-N 114.197 -1.002 . . . . 0.0 109.532 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 72.0 p -76.1 163.4 27.15 Favored 'General case' 0 N--CA 1.432 -1.359 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 177.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -61.93 -31.85 72.2 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.651 0.739 . . . . 0.0 109.412 177.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 28.1 t -72.69 -42.6 64.05 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.872 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 19.4 t80 -62.46 -47.81 82.4 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.586 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.72 -40.32 94.64 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.577 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.73 -28.84 69.35 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.499 0.666 . . . . 0.0 110.959 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.8 m -85.16 -16.94 38.75 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.171 -177.4 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.586 HG12 ' O ' ' B' ' 76' ' ' ALA . 4.2 p -72.91 -28.25 26.5 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.518 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 -179.236 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 55.2 mt -71.81 -7.14 46.48 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 114.09 -1.414 . . . . 0.0 110.815 177.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 88.3 mtt180 -103.65 -14.7 16.03 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 121.37 0.605 . . . . 0.0 109.707 178.192 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 -86.59 -29.03 22.91 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.471 176.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.674 ' HB ' HG11 ' B' ' 87' ' ' VAL . 9.3 p -69.49 170.08 11.27 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 115.402 1.63 . . . . 0.0 115.402 -173.392 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 35.1 mttp -73.56 -162.4 0.13 Allowed 'General case' 0 C--O 1.241 0.622 0 CA-C-N 114.845 -1.07 . . . . 0.0 110.253 173.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . 0.412 ' HA2' ' HG2' ' B' ' 12' ' ' LYS . . . -80.0 -38.5 19.06 Favored Glycine 0 N--CA 1.437 -1.291 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.871 178.277 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 41.0 ttm180 -120.96 123.52 42.65 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.674 HG11 ' HB ' ' B' ' 83' ' ' THR . 26.7 m -139.71 142.76 31.88 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 CA-C-O 120.867 0.365 . . . . 0.0 111.543 -177.767 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . 0.488 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 52.2 mtt180 -99.4 116.68 32.13 Favored 'General case' 0 CA--C 1.485 -1.556 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.164 176.528 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.5 ' CE2' HD11 ' B' ' 54' ' ' ILE . 6.8 m-85 -92.91 152.44 19.37 Favored 'General case' 0 C--N 1.285 -2.234 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.507 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . . . . . . . . . 86.0 mtp -102.1 106.98 17.93 Favored 'General case' 0 C--N 1.286 -2.177 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 171.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.454 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.4 mp -84.77 120.86 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.942 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -117.27 109.95 1.97 Allowed Glycine 1 CA--C 1.445 -4.283 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 179.219 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 7.3 tpp180 . . . . . 0 C--N 1.279 -2.475 0 CA-C-N 114.6 -0.8 . . . . 0.0 109.431 177.122 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 19.7 ptp . . . . . 0 N--CA 1.425 -1.709 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -84.99 104.93 15.37 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 -177.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -79.55 83.73 5.5 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 173.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -102.58 143.02 25.76 Favored Pre-proline 0 C--N 1.294 -1.845 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.396 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . 0.536 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 51.1 Cg_endo -79.28 134.61 11.53 Favored 'Trans proline' 0 N--CA 1.429 -2.267 0 C-N-CA 121.634 1.556 . . . . 0.0 112.291 177.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 73.4 t -115.22 127.54 72.75 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 175.272 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . 0.497 ' O ' ' HD2' ' B' ' 53' ' ' ARG . 43.3 tt0 -119.59 116.12 25.38 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 -176.291 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.626 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -102.41 153.27 20.19 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.766 0.793 . . . . 0.0 110.761 -177.949 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.443 ' H ' HD23 ' B' ' 10' ' ' LEU . 80.4 mm-40 -99.68 103.36 15.03 Favored 'General case' 0 C--N 1.276 -2.607 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 174.718 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . 0.438 ' HE2' ' HB3' ' B' ' 12' ' ' LYS . 6.5 mmmm -81.61 157.02 24.86 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 114.301 1.223 . . . . 0.0 114.301 -171.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . 0.498 ' H ' ' HA3' ' B' ' 16' ' ' GLY . 22.1 m-20 -128.47 178.82 6.02 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 171.184 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 14.7 m -74.61 -19.56 60.26 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.652 0.739 . . . . 0.0 110.033 177.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 9.2 tp10 -128.56 31.49 4.98 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 105.762 -1.94 . . . . 0.0 105.762 176.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.498 ' HA3' ' H ' ' B' ' 13' ' ' ASP . . . -71.21 -5.03 58.16 Favored Glycine 0 CA--C 1.494 -1.263 0 CA-C-N 113.662 -1.608 . . . . 0.0 116.481 -169.181 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -75.16 86.45 2.41 Favored 'General case' 0 N--CA 1.429 -1.488 0 C-N-CA 119.302 -0.959 . . . . 0.0 111.096 177.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -96.78 55.45 1.37 Allowed Glycine 0 CA--C 1.484 -1.85 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 6.6 pt -161.67 -177.49 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 C-N-CA 124.7 1.2 . . . . 0.0 107.92 -175.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . 0.434 ' HB2' HG22 ' B' ' 41' ' ' THR . 43.2 m -149.65 145.61 26.83 Favored 'General case' 0 C--N 1.27 -2.865 0 N-CA-C 105.425 -2.065 . . . . 0.0 105.425 172.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.458 ' HB ' HG22 ' B' ' 37' ' ' ILE . 16.0 pt -115.95 154.1 17.48 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.297 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.3 tp -127.08 136.79 59.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 CA-C-O 120.884 0.374 . . . . 0.0 110.764 -176.044 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.58 98.08 2.38 Favored Glycine 0 N--CA 1.434 -1.438 0 C-N-CA 121.058 -0.591 . . . . 0.0 111.791 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 95.4 mmm . . . . . 0 C--N 1.302 -1.492 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 178.408 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 74.9 mt . . . . . 0 N--CA 1.431 -1.399 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -107.75 98.27 1.24 Allowed Glycine 0 N--CA 1.404 -3.437 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 176.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.458 HG22 ' HB ' ' B' ' 21' ' ' ILE . 27.9 mm -87.35 87.78 2.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 177.058 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -85.69 166.54 16.06 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.399 -1.273 . . . . 0.0 108.705 -176.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 57.4 t -77.9 136.47 24.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 175.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -96.04 -42.07 8.44 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -178.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . 0.463 ' HA ' HG23 ' B' ' 56' ' ' VAL . 3.5 t -157.05 168.8 26.41 Favored 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 21.3 t -130.47 97.35 3.19 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 178.265 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 40.5 m -73.89 124.64 26.54 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 124.281 1.033 . . . . 0.0 111.709 -176.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . 0.579 ' HA ' ' HB3' ' B' ' 49' ' ' HIS . 1.7 pm0 -65.53 -22.41 66.71 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 124.44 1.096 . . . . 0.0 113.904 -178.042 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.54 -23.87 72.23 Favored Glycine 0 N--CA 1.439 -1.128 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.243 176.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -104.4 173.15 21.01 Favored Glycine 0 N--CA 1.424 -2.163 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.837 -177.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . 0.404 ' HB2' ' OD2' ' B' ' 13' ' ' ASP . . . -58.54 -41.34 85.34 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 125.205 1.402 . . . . 0.0 114.265 -175.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . 0.626 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -57.19 -37.52 72.28 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -173.39 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . 0.579 ' HB3' ' HA ' ' B' ' 44' ' ' GLU . 8.4 t60 -74.97 -35.4 62.07 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -178.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 68.9 mtt180 -68.43 -47.74 66.41 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 -178.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -60.41 -61.39 2.63 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 114.456 -1.247 . . . . 0.0 110.722 176.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 91.02 6.14 67.23 Favored Glycine 0 N--CA 1.433 -1.528 0 N-CA-C 114.824 0.69 . . . . 0.0 114.824 175.144 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.497 ' HD2' ' O ' ' B' ' 9' ' ' GLU . 65.4 mtt180 -83.3 -33.64 25.9 Favored 'General case' 0 N--CA 1.441 -0.892 0 CA-C-N 118.392 1.096 . . . . 0.0 111.316 179.107 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.445 HD11 ' CE2' ' B' ' 89' ' ' PHE . 28.8 mt -83.29 117.03 28.4 Favored 'Isoleucine or valine' 0 C--O 1.248 0.984 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 174.116 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 22.7 mt-30 -91.45 163.96 13.99 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 121.356 0.598 . . . . 0.0 110.47 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.463 HG23 ' HA ' ' B' ' 41' ' ' THR . 13.2 p -75.51 -2.11 3.79 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.854 0 CA-C-O 122.488 1.137 . . . . 0.0 109.976 178.361 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -114.02 0.06 14.21 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.058 -175.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -82.29 174.34 11.23 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 112.926 0.713 . . . . 0.0 112.926 -174.076 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 25.8 tp -141.6 131.15 23.91 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.54 -0.755 . . . . 0.0 110.521 -175.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -81.71 95.63 7.29 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.688 0.756 . . . . 0.0 110.22 178.227 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.569 ' HB ' ' O ' ' B' ' 90' ' ' MET . 27.8 t -86.95 -40.73 14.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.695 177.03 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.536 ' HG3' ' HA ' ' B' ' 67' ' ' SER . 32.4 tt0 -156.2 148.75 23.72 Favored 'General case' 0 C--N 1.273 -2.727 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.48 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.513 ' O ' ' HG2' ' B' ' 62' ' ' GLU . 9.9 p -102.39 -168.45 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 104.912 -2.255 . . . . 0.0 104.912 176.419 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.425 ' H ' HG22 ' B' ' 63' ' ' VAL . 12.2 t70 -50.19 -54.21 22.47 Favored 'General case' 0 N--CA 1.479 1.004 0 CA-C-N 119.189 0.904 . . . . 0.0 112.27 178.369 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -106.16 -53.78 0.73 Allowed Glycine 0 C--N 1.308 -0.989 0 C-N-CA 119.538 -1.315 . . . . 0.0 114.088 -178.3 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 6.1 m -72.37 120.81 18.51 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 123.101 0.56 . . . . 0.0 112.492 -174.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . 0.536 ' HA ' ' HG3' ' B' ' 62' ' ' GLU . 64.9 m -86.12 121.15 28.31 Favored 'General case' 0 N--CA 1.435 -1.204 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 174.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.471 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 28.9 mt -83.3 100.23 10.51 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-O 121.087 0.47 . . . . 0.0 110.226 -179.308 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 29.0 m -89.48 12.5 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-O 121.759 0.79 . . . . 0.0 109.463 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 111.71 90.23 1.94 Allowed Glycine 0 N--CA 1.402 -3.615 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -174.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 26.4 m -117.15 174.4 3.73 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.28 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 20.7 p -76.87 159.86 29.7 Favored 'General case' 0 N--CA 1.413 -2.281 0 CA-C-O 120.957 0.408 . . . . 0.0 110.051 177.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 60.6 tt0 -58.66 -35.28 72.29 Favored 'General case' 0 C--N 1.311 -1.096 0 C-N-CA 123.788 0.835 . . . . 0.0 109.824 178.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 19.7 m -70.96 -39.14 72.73 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.576 179.559 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -62.56 -48.9 77.45 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.068 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.516 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -57.81 -45.42 86.11 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.258 179.304 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.01 -39.19 91.42 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.641 0.734 . . . . 0.0 110.792 178.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 50.6 m -71.83 -27.5 62.95 Favored 'General case' 0 N--CA 1.433 -1.32 0 CA-C-N 115.377 -0.829 . . . . 0.0 112.511 -177.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.516 HG12 ' O ' ' B' ' 76' ' ' ALA . 5.0 p -77.25 -30.4 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 C-N-CA 119.546 -0.862 . . . . 0.0 108.852 -177.164 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . 0.491 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 77.1 mt -67.46 -35.85 80.01 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.306 176.08 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 79.4 mtp180 -78.05 -32.74 51.01 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.275 178.317 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -72.3 -36.71 69.0 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 123.234 0.614 . . . . 0.0 111.478 -179.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.667 ' HB ' HG11 ' B' ' 87' ' ' VAL . 8.5 p -67.82 159.81 29.57 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 113.693 0.997 . . . . 0.0 113.693 -177.117 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -66.56 -166.07 0.04 OUTLIER 'General case' 0 C--O 1.255 1.371 0 C-N-CA 125.729 1.612 . . . . 0.0 114.806 -174.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' B' ' 12' ' ' LYS . . . -70.86 -17.12 75.03 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 114.631 -1.168 . . . . 0.0 113.3 -177.514 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . 0.522 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 57.1 ttp180 -157.49 118.3 3.54 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 121.165 0.507 . . . . 0.0 111.016 174.465 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.667 HG11 ' HB ' ' B' ' 83' ' ' THR . 14.8 m -132.1 145.72 34.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.237 179.351 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -98.05 128.89 44.85 Favored 'General case' 0 CA--C 1.482 -1.654 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.518 178.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.536 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 4.8 m-85 -105.38 157.36 17.39 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 106.965 -1.495 . . . . 0.0 106.965 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.569 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 63.0 mtt -109.87 117.51 34.02 Favored 'General case' 0 C--N 1.282 -2.352 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 172.134 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 1.4 mp -105.96 122.38 59.5 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 -179.157 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.37 103.76 2.51 Favored Glycine 0 CA--C 1.464 -3.11 0 N-CA-C 109.169 -1.573 . . . . 0.0 109.169 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 9.3 tpp180 . . . . . 0 C--N 1.265 -3.073 0 CA-C-N 114.214 -0.993 . . . . 0.0 110.572 -175.749 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 92.8 mmm . . . . . 0 CA--C 1.469 -2.171 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . 0.491 ' OE2' ' HD2' ' B' ' 93' ' ' ARG . 12.0 mt-10 -98.62 96.4 7.92 Favored 'General case' 0 C--N 1.275 -2.643 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.013 -175.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -84.38 97.51 9.52 Favored 'General case' 0 N--CA 1.427 -1.606 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 177.201 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -130.85 147.48 66.39 Favored Pre-proline 0 C--N 1.279 -2.495 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.481 177.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . 0.442 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 49.7 Cg_endo -75.84 136.89 19.28 Favored 'Trans proline' 0 N--CA 1.44 -1.65 0 C-N-CA 121.868 1.712 . . . . 0.0 111.625 175.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 91.4 t -121.56 148.54 24.93 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.071 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.091 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -126.98 143.65 51.23 Favored 'General case' 0 C--N 1.279 -2.469 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -177.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.55 HD11 ' HB2' ' B' ' 48' ' ' ALA . 0.8 OUTLIER -141.04 157.18 45.67 Favored 'General case' 0 CA--C 1.478 -1.789 0 CA-C-O 121.05 0.452 . . . . 0.0 109.908 174.431 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -127.15 112.59 15.32 Favored 'General case' 0 C--N 1.275 -2.632 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 177.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 5.4 ptpp? -77.14 150.77 35.55 Favored 'General case' 0 C--N 1.283 -2.317 0 CA-C-N 115.143 -0.935 . . . . 0.0 113.357 -172.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -93.78 -172.93 3.01 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 177.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 12.3 t -71.25 -25.65 62.57 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.954 -1.499 . . . . 0.0 106.954 173.09 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 11.9 tp10 -67.27 -20.87 65.71 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.444 172.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.07 -116.06 4.83 Favored Glycine 0 N--CA 1.416 -2.657 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -177.188 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -101.2 -175.06 2.76 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -178.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . 0.432 ' CA ' ' HA3' ' B' ' 46' ' ' GLY . . . -150.45 67.99 0.34 Allowed Glycine 0 CA--C 1.477 -2.325 0 N-CA-C 110.931 -0.868 . . . . 0.0 110.931 -179.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.466 ' HA ' ' H ' ' B' ' 43' ' ' THR . 4.3 pt -162.59 169.98 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 C-N-CA 125.277 1.431 . . . . 0.0 107.867 -176.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.4 m -131.76 141.99 49.65 Favored 'General case' 0 C--N 1.253 -3.611 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 174.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.502 ' HB ' HG22 ' B' ' 37' ' ' ILE . 8.6 pt -115.23 149.37 17.47 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.012 0 O-C-N 123.45 0.469 . . . . 0.0 109.81 -178.188 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.1 tp -119.22 134.88 61.42 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -177.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.74 94.58 1.55 Allowed Glycine 0 N--CA 1.43 -1.707 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.688 -177.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 88.9 mmm . . . . . 0 C--O 1.253 1.268 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.934 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 78.6 mt . . . . . 0 C--O 1.235 0.331 0 N-CA-C 113.955 1.094 . . . . 0.0 113.955 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -111.18 103.64 1.61 Allowed Glycine 0 N--CA 1.423 -2.212 0 N-CA-C 108.614 -1.794 . . . . 0.0 108.614 175.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.502 HG22 ' HB ' ' B' ' 21' ' ' ILE . 26.3 mm -94.15 90.38 2.8 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-O 121.674 0.749 . . . . 0.0 109.403 -177.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -88.79 167.07 13.59 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.207 -178.128 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 64.7 t -80.77 130.3 36.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 CA-C-O 121.28 0.562 . . . . 0.0 109.641 175.387 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -94.42 -41.11 9.56 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.218 -176.681 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -156.57 164.0 38.7 Favored 'General case' 0 N--CA 1.437 -1.082 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.412 ' HA ' HG22 ' B' ' 19' ' ' ILE . 21.3 t -112.05 102.52 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.031 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 174.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.466 ' H ' ' HA ' ' B' ' 19' ' ' ILE . 31.2 m -69.73 122.04 18.38 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 124.112 0.965 . . . . 0.0 111.825 -174.357 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . 0.473 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 32.8 mt-10 -58.23 -41.45 84.15 Favored 'General case' 0 CA--C 1.507 -0.695 0 C-N-CA 124.662 1.185 . . . . 0.0 111.736 -175.568 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -67.22 -12.24 60.37 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 115.197 -0.911 . . . . 0.0 114.237 -177.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.432 ' HA3' ' CA ' ' B' ' 18' ' ' GLY . . . -112.23 170.0 13.35 Favored Glycine 0 N--CA 1.41 -3.078 0 C-N-CA 120.124 -1.036 . . . . 0.0 113.797 -175.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -57.64 -35.07 70.02 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 115.045 1.498 . . . . 0.0 115.045 -171.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . 0.55 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -67.53 -35.46 79.12 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 119.952 -0.699 . . . . 0.0 112.695 -174.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . 0.473 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 5.4 t60 -78.53 -39.62 37.38 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 64.4 mtp180 -67.13 -39.48 86.6 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.683 -177.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -79.56 -48.63 13.51 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 177.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 94.15 51.22 2.1 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -178.452 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 13.1 mmt180 -109.75 -79.44 0.58 Allowed 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 111.85 0.315 . . . . 0.0 111.85 -175.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.488 HD11 ' CE2' ' B' ' 89' ' ' PHE . 62.7 mt -71.16 132.7 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.977 -179.203 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 -103.58 173.51 6.27 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.234 0.54 . . . . 0.0 110.996 -177.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.1 p -79.27 2.43 2.17 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.145 0 CA-C-O 121.949 0.88 . . . . 0.0 111.638 -174.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -121.46 11.36 10.65 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 122.218 1.009 . . . . 0.0 108.683 -175.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 19.2 m-20 -89.07 168.49 12.29 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.929 -175.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.511 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 23.5 tp -144.69 131.47 20.14 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 124.008 0.923 . . . . 0.0 108.83 -177.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 76.6 mt -85.08 94.23 8.8 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.506 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.2 t -80.09 -39.96 19.89 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 CA-C-O 121.739 0.78 . . . . 0.0 110.147 177.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -160.0 156.73 27.53 Favored 'General case' 0 C--N 1.28 -2.451 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.41 173.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.426 HG22 ' H ' ' B' ' 64' ' ' ASP . 5.7 p -102.01 -173.74 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 N-CA-C 105.455 -2.054 . . . . 0.0 105.455 177.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.436 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 18.0 t70 -53.79 -48.75 69.49 Favored 'General case' 0 C--N 1.311 -1.093 0 C-N-CA 122.992 0.517 . . . . 0.0 112.387 -179.471 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -101.87 -60.21 0.77 Allowed Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 120.22 -0.991 . . . . 0.0 114.187 -179.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 9.1 m -77.57 129.66 35.93 Favored 'General case' 0 CA--C 1.557 1.248 0 CA-C-O 121.164 0.507 . . . . 0.0 112.201 -176.119 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 49.4 m -94.44 121.84 36.39 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.058 178.358 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.506 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 32.0 mt -88.9 111.89 22.64 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.105 0.478 . . . . 0.0 111.838 -175.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 43.6 t -85.57 -23.67 7.06 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 174.597 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 147.63 68.6 0.01 OUTLIER Glycine 0 CA--C 1.475 -2.42 0 N-CA-C 109.396 -1.481 . . . . 0.0 109.396 -177.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 28.2 m -85.22 172.08 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 CA-C-N 114.467 -0.867 . . . . 0.0 109.383 -177.094 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 24.6 p -71.7 157.2 38.36 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 120.93 0.395 . . . . 0.0 110.138 177.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -57.43 -39.4 76.13 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 123.345 0.658 . . . . 0.0 110.458 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 40.0 t -68.17 -37.8 81.38 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.01 179.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -66.44 -45.45 79.79 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -179.124 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.591 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.2 -44.02 97.95 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.505 178.426 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.98 -34.12 75.58 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 121.756 0.788 . . . . 0.0 110.599 177.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 39.3 m -79.31 -27.68 42.16 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 115.489 -0.778 . . . . 0.0 112.094 -178.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.591 HG12 ' O ' ' B' ' 76' ' ' ALA . 4.5 p -71.53 -31.97 44.43 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-O 121.906 0.86 . . . . 0.0 109.07 -175.711 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 53.9 mt -66.03 -29.44 69.8 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 114.528 -1.214 . . . . 0.0 110.553 176.425 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 71.4 mtt180 -90.74 -16.85 27.71 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.373 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -90.38 -14.65 32.58 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.038 0.447 . . . . 0.0 111.268 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.722 ' HB ' HG11 ' B' ' 87' ' ' VAL . 6.7 p -90.63 171.76 9.16 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 77.1 mttt -60.37 -178.7 0.09 Allowed 'General case' 0 C--O 1.245 0.817 0 C-N-CA 124.612 1.165 . . . . 0.0 114.077 -179.06 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.38 -52.06 46.98 Favored Glycine 0 N--CA 1.44 -1.049 0 CA-C-N 114.208 -1.36 . . . . 0.0 111.117 177.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 14.5 ttp180 -114.82 117.64 31.31 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 177.068 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.722 HG11 ' HB ' ' B' ' 83' ' ' THR . 14.0 m -132.13 157.57 43.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.353 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 15.9 mtm180 -108.5 152.64 24.45 Favored 'General case' 0 N--CA 1.422 -1.833 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 179.435 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.488 ' CE2' HD11 ' B' ' 54' ' ' ILE . 1.7 m-85 -133.5 164.99 25.91 Favored 'General case' 0 C--N 1.267 -3.004 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 179.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.457 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 84.3 mtp -112.82 117.43 32.14 Favored 'General case' 0 C--N 1.286 -2.195 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 170.571 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.511 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.5 mp -102.88 133.18 47.36 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.395 -177.11 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -113.6 93.86 0.68 Allowed Glycine 0 CA--C 1.463 -3.208 0 N-CA-C 108.18 -1.968 . . . . 0.0 108.18 172.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . 0.491 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 36.8 ttm180 . . . . . 0 C--N 1.273 -2.754 0 CA-C-N 114.244 -0.978 . . . . 0.0 111.152 -175.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 20.2 ptp . . . . . 0 N--CA 1.437 -1.086 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . 0.489 ' OE2' ' HG2' ' B' ' 93' ' ' ARG . 2.6 mt-10 -116.35 101.56 8.77 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -93.1 91.04 7.13 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 -179.125 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -117.67 146.52 38.9 Favored Pre-proline 0 C--N 1.29 -1.998 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.307 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -81.1 144.25 14.72 Favored 'Trans proline' 0 N--CA 1.449 -1.089 0 C-N-CA 122.5 2.133 . . . . 0.0 112.811 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.588 HG13 ' HB3' ' B' ' 53' ' ' ARG . 73.6 t -127.94 133.87 66.39 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.032 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -121.24 125.49 47.24 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 118.477 0.58 . . . . 0.0 110.173 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.449 ' CD1' ' H ' ' B' ' 54' ' ' ILE . 0.9 OUTLIER -148.82 175.95 10.81 Favored 'General case' 0 N--CA 1.438 -1.037 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -178.188 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -147.03 178.02 8.69 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.086 -178.622 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -93.02 153.85 18.48 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.248 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . 0.559 ' HB2' ' N ' ' B' ' 47' ' ' ALA . 10.8 t70 -103.17 -164.37 1.07 Allowed 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 22.8 p -55.43 -44.28 76.14 Favored 'General case' 0 C--O 1.243 0.756 0 C-N-CA 124.558 1.143 . . . . 0.0 111.57 -179.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -78.3 -48.72 15.06 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 177.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.08 -120.54 1.64 Allowed Glycine 0 N--CA 1.426 -2.006 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.831 178.171 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -89.23 101.4 14.06 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 121.397 0.618 . . . . 0.0 111.293 -178.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -92.12 59.84 2.7 Favored Glycine 0 C--O 1.21 -1.369 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 177.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.499 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.0 pt -155.46 178.92 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 C-N-CA 125.406 1.482 . . . . 0.0 107.128 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . 0.472 ' HB2' HG22 ' B' ' 41' ' ' THR . 51.0 m -158.19 155.81 29.71 Favored 'General case' 0 C--N 1.27 -2.88 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 176.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.457 ' HB ' HG22 ' B' ' 37' ' ' ILE . 18.6 pt -115.71 161.12 14.69 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 O-C-N 123.445 0.466 . . . . 0.0 110.343 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . 0.429 ' HA ' ' NE2' ' B' ' 73' ' ' GLN . 8.1 tp -140.5 135.51 35.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.24 112.11 3.85 Favored Glycine 0 N--CA 1.428 -1.846 0 C-N-CA 120.494 -0.86 . . . . 0.0 111.982 -178.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 93.9 mmm . . . . . 0 C--N 1.302 -1.476 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 176.964 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . 0.514 ' O ' ' HA2' ' B' ' 70' ' ' GLY . 3.0 mm? . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 113.164 0.802 . . . . 0.0 113.164 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -99.0 103.82 2.8 Favored Glycine 0 N--CA 1.414 -2.805 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.854 -176.326 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.457 HG22 ' HB ' ' B' ' 21' ' ' ILE . 30.2 mm -88.45 89.2 3.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.876 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.566 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.477 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 89.6 m-85 -82.3 173.45 12.06 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 114.674 -1.148 . . . . 0.0 109.981 -176.639 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.41 HG11 ' O ' ' B' ' 55' ' ' GLN . 59.3 t -83.42 137.09 21.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 175.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 32.2 ttmt -93.77 -48.87 6.11 Favored 'General case' 0 N--CA 1.433 -1.289 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.784 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . 0.495 ' HA ' HG23 ' B' ' 56' ' ' VAL . 5.2 t -150.03 170.79 18.05 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.499 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.7 p -156.42 113.25 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 C-N-CA 124.587 1.155 . . . . 0.0 108.005 -177.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.415 HG22 ' H ' ' B' ' 45' ' ' GLY . 32.1 m -112.14 144.81 40.91 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 114.856 -1.066 . . . . 0.0 110.061 -171.199 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . 0.478 ' HA ' ' HB3' ' B' ' 49' ' ' HIS . 9.0 pt-20 -71.75 4.46 3.23 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -178.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . 0.415 ' H ' HG22 ' B' ' 43' ' ' THR . . . -74.79 -19.5 79.89 Favored Glycine 0 N--CA 1.436 -1.329 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 172.753 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -113.03 169.49 12.97 Favored Glycine 0 N--CA 1.413 -2.86 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 175.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . 0.559 ' N ' ' HB2' ' B' ' 13' ' ' ASP . . . -75.18 -23.94 57.78 Favored 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 115.096 -0.552 . . . . 0.0 111.274 -175.251 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . 0.446 ' HA ' ' CD1' ' B' ' 10' ' ' LEU . . . -56.46 -44.56 80.67 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -176.111 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . 0.479 ' HB2' HG22 ' B' ' 42' ' ' VAL . 10.3 t60 -73.49 -41.27 63.32 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.381 -179.059 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 81.5 mtp180 -72.42 -34.88 68.15 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.43 0.633 . . . . 0.0 110.945 -174.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . 0.502 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 30.4 t70 -72.42 -49.99 29.55 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.889 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.7 27.49 9.64 Favored Glycine 0 CA--C 1.494 -1.259 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.486 172.132 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.588 ' HB3' HG13 ' B' ' 8' ' ' VAL . 5.4 mpt_? -101.39 -60.17 1.57 Allowed 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 112.008 0.373 . . . . 0.0 112.008 -179.276 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.567 HD11 ' CE2' ' B' ' 89' ' ' PHE . 58.7 mt -72.79 134.82 29.04 Favored 'Isoleucine or valine' 0 C--O 1.251 1.157 0 N-CA-C 107.1 -1.445 . . . . 0.0 107.1 169.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . 0.41 ' O ' HG11 ' B' ' 39' ' ' VAL . 15.3 mm100 -110.19 -170.74 1.7 Allowed 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -174.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.495 HG23 ' HA ' ' B' ' 41' ' ' THR . 8.0 p -100.39 4.87 10.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 CA-C-O 121.567 0.698 . . . . 0.0 110.083 174.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 19.9 t-20 -133.28 10.98 4.16 Favored 'General case' 0 C--N 1.311 -1.104 0 O-C-N 121.623 -0.673 . . . . 0.0 111.965 -174.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -94.86 -173.64 3.04 Favored 'General case' 0 C--N 1.318 -0.804 0 O-C-N 121.308 -0.87 . . . . 0.0 111.381 179.127 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.477 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 25.8 tp -144.92 125.4 13.98 Favored 'General case' 0 C--N 1.318 -0.769 0 C-N-CA 123.194 0.598 . . . . 0.0 111.116 -172.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . 0.438 ' O ' HD12 ' B' ' 68' ' ' LEU . 68.9 mt -83.69 96.49 8.72 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.399 0.618 . . . . 0.0 109.369 178.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.571 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 9.2 t -79.28 -37.32 18.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-O 121.685 0.755 . . . . 0.0 111.133 178.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.401 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 10.4 pt-20 -157.02 153.51 28.09 Favored 'General case' 0 C--N 1.276 -2.608 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.506 176.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.464 HG22 ' H ' ' B' ' 64' ' ' ASP . 5.2 p -100.52 -174.63 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.42 -1.975 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 178.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.464 ' H ' HG22 ' B' ' 63' ' ' VAL . 28.1 t70 -53.18 -42.46 66.23 Favored 'General case' 0 C--N 1.311 -1.078 0 C-N-CA 124.138 0.975 . . . . 0.0 112.475 -178.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -106.91 -66.24 0.63 Allowed Glycine 0 N--CA 1.439 -1.161 0 C-N-CA 120.813 -0.708 . . . . 0.0 113.627 179.199 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 7.2 m -74.1 135.7 42.96 Favored 'General case' 0 CA--C 1.554 1.099 0 C-N-CA 122.882 0.473 . . . . 0.0 112.266 -175.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 15.9 m -96.31 126.49 41.55 Favored 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 177.116 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.571 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 28.9 mt -83.28 -69.86 0.6 Allowed 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 112.241 0.459 . . . . 0.0 112.241 -177.131 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 86.8 t 73.28 -27.2 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 124.189 0.995 . . . . 0.0 111.246 -175.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . 0.514 ' HA2' ' O ' ' B' ' 35' ' ' LEU . . . 153.16 81.39 0.03 OUTLIER Glycine 0 N--CA 1.42 -2.404 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -178.211 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.1 m -106.76 -179.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 39.9 p -78.63 156.51 29.03 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 175.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . 0.429 ' NE2' ' HA ' ' B' ' 22' ' ' ILE . 61.9 tt0 -58.4 -39.4 79.6 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.23 0.538 . . . . 0.0 110.637 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 14.9 m -66.82 -35.47 80.12 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.73 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -65.33 -49.36 69.71 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 179.049 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.553 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -59.51 -40.73 88.03 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.069 178.586 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.34 -32.65 73.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.331 0.586 . . . . 0.0 110.468 177.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.6 m -79.25 -28.44 42.43 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.454 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.553 HG12 ' O ' ' B' ' 76' ' ' ALA . 5.7 p -72.6 -36.31 53.23 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.889 0 C-N-CA 119.574 -0.851 . . . . 0.0 109.172 -176.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 26.3 mt -70.44 -7.14 40.97 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.848 178.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 68.5 mtp180 -108.66 -1.51 19.44 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 121.617 0.723 . . . . 0.0 110.102 177.438 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 32.2 m-80 -115.06 6.41 15.2 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.067 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.53 HG23 ' O ' ' B' ' 79' ' ' VAL . 7.7 p -87.2 175.81 7.87 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.323 -178.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 28.8 mmtm -75.64 -169.18 0.99 Allowed 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.472 0.709 . . . . 0.0 109.733 174.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.17 -38.97 45.93 Favored Glycine 0 N--CA 1.444 -0.827 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 177.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -124.31 131.56 53.52 Favored 'General case' 0 N--CA 1.431 -1.397 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.516 HG11 ' HB ' ' B' ' 83' ' ' THR . 11.2 m -142.08 153.01 18.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 CA-C-O 121.53 0.681 . . . . 0.0 111.445 -179.584 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 -96.05 164.07 12.86 Favored 'General case' 0 C--N 1.291 -1.975 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 174.05 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.567 ' CE2' HD11 ' B' ' 54' ' ' ILE . 8.9 m-85 -145.28 157.33 44.08 Favored 'General case' 0 C--N 1.284 -2.261 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 177.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.505 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 81.0 mtp -112.38 120.15 40.69 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 169.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.464 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -98.58 119.04 46.06 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.164 0 CA-C-N 114.246 -1.343 . . . . 0.0 109.485 -175.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -96.93 93.3 1.45 Allowed Glycine 0 CA--C 1.457 -3.57 0 N-CA-C 106.96 -2.456 . . . . 0.0 106.96 172.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . 0.489 ' HG2' ' OE2' ' B' ' 4' ' ' GLU . 5.9 tpt180 . . . . . 0 C--N 1.257 -3.429 0 CA-C-N 112.932 -1.634 . . . . 0.0 113.129 -174.278 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.438 -1.033 0 N-CA-C 104.704 -2.332 . . . . 0.0 104.704 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . 0.57 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 18.4 mt-10 -87.72 101.08 13.33 Favored 'General case' 0 C--N 1.293 -1.871 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.263 -171.128 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -85.62 85.73 7.4 Favored 'General case' 0 N--CA 1.428 -1.531 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 176.101 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -109.43 142.43 25.66 Favored Pre-proline 0 C--N 1.295 -1.801 0 C-N-CA 120.461 -0.496 . . . . 0.0 112.229 -178.026 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . 0.422 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 42.0 Cg_endo -80.34 126.4 6.17 Favored 'Trans proline' 0 N--CA 1.428 -2.371 0 C-N-CA 121.943 1.762 . . . . 0.0 112.541 177.105 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 95.2 t -107.08 151.94 8.78 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.82 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 175.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . 0.464 ' O ' ' HG2' ' B' ' 53' ' ' ARG . 45.0 tt0 -138.12 136.16 36.46 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 119.005 0.82 . . . . 0.0 109.696 -176.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.523 HD21 ' HA ' ' B' ' 48' ' ' ALA . 4.5 mt -139.34 165.31 27.54 Favored 'General case' 0 CA--C 1.475 -1.906 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 179.625 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -151.12 146.68 26.31 Favored 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 104.503 -2.406 . . . . 0.0 104.503 177.348 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.5 ptpt -88.41 171.33 10.2 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.883 0.849 . . . . 0.0 112.177 -174.184 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . 0.412 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 19.5 t70 -99.92 176.61 5.37 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.804 -1.089 . . . . 0.0 108.214 176.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 7.0 m -59.66 -33.12 71.14 Favored 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 123.939 0.895 . . . . 0.0 109.261 175.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -77.15 -45.63 26.11 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 174.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.25 -138.36 7.65 Favored Glycine 0 N--CA 1.435 -1.406 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.273 179.255 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 91.8 mt -82.03 -176.24 6.04 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 123.033 0.533 . . . . 0.0 110.99 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . 0.418 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -158.13 66.06 0.29 Allowed Glycine 0 CA--C 1.487 -1.665 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.614 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 pt -166.73 175.91 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.49 -1.361 0 C-N-CA 124.815 1.246 . . . . 0.0 108.408 -177.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . 0.406 ' HB2' HG22 ' B' ' 41' ' ' THR . 29.2 m -148.53 144.17 27.14 Favored 'General case' 0 C--N 1.27 -2.859 0 N-CA-C 105.784 -1.932 . . . . 0.0 105.784 174.011 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.497 ' HB ' HG22 ' B' ' 37' ' ' ILE . 11.0 pt -115.09 158.13 15.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 CA-C-N 117.866 0.303 . . . . 0.0 110.395 -177.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 10.3 tp -139.32 140.75 37.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-O 120.636 0.255 . . . . 0.0 110.415 -176.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -91.24 109.53 3.72 Favored Glycine 0 N--CA 1.435 -1.398 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.687 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 66.2 mtt . . . . . 0 C--N 1.308 -1.226 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 177.084 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 70.1 mt . . . . . 0 N--CA 1.433 -1.286 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -96.85 109.97 3.95 Favored Glycine 0 N--CA 1.419 -2.46 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.497 HG22 ' HB ' ' B' ' 21' ' ' ILE . 28.4 mm -89.09 92.04 3.85 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -85.68 169.01 13.87 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.106 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.436 HG21 HG23 ' B' ' 54' ' ' ILE . 59.5 t -82.77 136.57 22.6 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.496 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 174.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 31.1 ttpt -96.57 -35.9 10.92 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.085 0.469 . . . . 0.0 110.088 -176.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . 0.406 HG22 ' HB2' ' B' ' 20' ' ' SER . 2.8 t -161.27 165.28 29.44 Favored 'General case' 0 C--O 1.251 1.182 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 20.4 t -126.8 93.24 2.21 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.025 0 N-CA-C 106.843 -1.539 . . . . 0.0 106.843 177.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 20.8 m -60.91 123.32 17.24 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 115.207 -0.906 . . . . 0.0 111.282 -177.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . 0.435 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 12.7 pt-20 -70.43 -23.77 62.79 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-N 115.804 -0.634 . . . . 0.0 112.478 -174.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.32 -11.77 82.11 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 121.075 -0.584 . . . . 0.0 112.729 179.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.418 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -110.29 172.82 15.89 Favored Glycine 0 N--CA 1.413 -2.847 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.007 -178.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . 0.412 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -61.34 -35.7 78.15 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 114.998 1.481 . . . . 0.0 114.998 -172.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . 0.523 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -61.37 -42.17 98.27 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -172.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . 0.435 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 5.0 t60 -71.22 -40.85 70.87 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 122.143 0.973 . . . . 0.0 108.864 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 71.1 mtp180 -69.05 -29.65 67.83 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.34 -177.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . 0.64 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 11.9 t70 -82.0 -45.44 15.32 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.61 35.28 6.57 Favored Glycine 0 CA--C 1.494 -1.263 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.637 173.529 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.64 ' HD3' ' OD2' ' B' ' 51' ' ' ASP . 5.3 mpt_? -107.82 -74.77 0.65 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.288 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.436 HG23 HG21 ' B' ' 39' ' ' VAL . 27.9 mt -68.52 118.43 12.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 C-N-CA 120.051 -0.659 . . . . 0.0 110.033 177.187 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 14.8 mm100 -104.25 -179.48 3.96 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.1 p -80.82 2.02 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.173 0 CA-C-O 122.253 1.025 . . . . 0.0 111.099 -175.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 25.3 t-20 -110.76 1.29 17.72 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 122.138 0.971 . . . . 0.0 109.496 -177.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -78.93 155.01 29.2 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.233 -177.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 26.7 tp -139.3 126.68 21.51 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.735 -176.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 68.6 mt -79.3 91.47 5.03 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.258 0.551 . . . . 0.0 109.836 179.186 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.616 ' HB ' ' O ' ' B' ' 90' ' ' MET . 24.1 t -82.64 -39.28 15.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.997 0 CA-C-O 122.001 0.905 . . . . 0.0 110.053 177.272 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.426 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 10.9 pt-20 -162.2 157.27 22.83 Favored 'General case' 0 C--N 1.28 -2.42 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.411 172.532 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.621 HG12 ' HB ' ' B' ' 66' ' ' THR . 3.7 p -94.11 -177.86 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 N-CA-C 105.638 -1.986 . . . . 0.0 105.638 178.104 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.584 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.2 t70 -44.54 -48.64 10.24 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 124.721 1.208 . . . . 0.0 112.975 -177.532 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -140.56 45.5 0.98 Allowed Glycine 0 CA--C 1.525 0.702 0 C-N-CA 119.991 -1.099 . . . . 0.0 113.847 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . 0.621 ' HB ' HG12 ' B' ' 63' ' ' VAL . 45.5 m -158.42 119.51 3.42 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 177.375 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . 0.419 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 45.8 m -85.48 133.18 34.1 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -175.788 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.521 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 23.9 mt -99.67 138.44 36.75 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.665 174.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -116.92 -26.77 2.63 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 CA-C-O 122.132 0.968 . . . . 0.0 109.146 173.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 160.45 87.75 0.06 OUTLIER Glycine 0 N--CA 1.399 -3.83 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 -176.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 m -111.58 173.17 2.54 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.667 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 41.7 p -75.21 160.2 30.68 Favored 'General case' 0 C--N 1.289 -2.039 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -59.57 -35.27 73.94 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 177.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 12.6 m -69.73 -41.03 75.82 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.632 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -63.54 -45.67 89.51 Favored 'General case' 0 CA--C 1.514 -0.429 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.538 ' O ' ' HG ' ' B' ' 80' ' ' LEU . . . -58.46 -46.26 86.95 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.487 178.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.39 -34.93 74.62 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.593 0.711 . . . . 0.0 110.736 178.067 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 45.5 m -80.37 -21.47 42.32 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 113.043 0.756 . . . . 0.0 113.043 -177.452 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.52 HG12 ' O ' ' B' ' 76' ' ' ALA . 8.4 p -78.52 -31.58 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.484 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 63.4 mt -69.39 -13.54 62.42 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.656 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -107.88 -0.64 21.37 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.503 0.668 . . . . 0.0 110.898 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -99.0 -23.74 15.18 Favored 'General case' 0 C--O 1.248 0.981 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.021 178.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.646 ' HB ' HG11 ' B' ' 87' ' ' VAL . 2.1 p -68.47 169.42 10.88 Favored 'General case' 0 N--CA 1.422 -1.841 0 CA-C-N 114.517 -1.22 . . . . 0.0 114.01 -176.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 41.0 mmtm -70.58 -170.78 0.43 Allowed 'General case' 0 N--CA 1.437 -1.099 0 CA-C-N 115.132 -0.94 . . . . 0.0 112.488 178.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.38 -35.33 90.83 Favored Glycine 0 C--O 1.217 -0.946 0 CA-C-N 114.776 -1.102 . . . . 0.0 114.275 -176.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 34.3 ttp180 -143.0 125.04 15.26 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.646 HG11 ' HB ' ' B' ' 83' ' ' THR . 14.0 m -133.11 154.71 39.98 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.746 0 CA-C-O 121.804 0.812 . . . . 0.0 112.559 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 87.4 mtm180 -94.5 170.6 9.36 Favored 'General case' 0 N--CA 1.41 -2.429 0 CA-C-N 113.681 -1.6 . . . . 0.0 108.489 173.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.459 ' HB2' ' CD1' ' B' ' 91' ' ' ILE . 6.2 m-85 -145.55 149.11 34.0 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 175.486 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.616 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 1.1 mpt? -103.68 108.58 19.93 Favored 'General case' 0 C--N 1.276 -2.626 0 CA-C-O 121.604 0.716 . . . . 0.0 109.567 176.112 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.459 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.4 mp -98.84 110.92 27.18 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 114.329 -1.305 . . . . 0.0 107.95 -179.086 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . 0.57 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -104.15 103.71 2.33 Favored Glycine 0 CA--C 1.458 -3.514 0 N-CA-C 107.987 -2.045 . . . . 0.0 107.987 173.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . 0.416 ' HD2' ' OE1' ' B' ' 4' ' ' GLU . 1.9 ptp180 . . . . . 0 C--N 1.281 -2.37 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.232 -175.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.415 -2.217 0 N-CA-C 105.5 -2.037 . . . . 0.0 105.5 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -91.34 92.86 8.78 Favored 'General case' 0 C--N 1.281 -2.4 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -174.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -88.56 86.04 6.94 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -107.49 140.93 22.01 Favored Pre-proline 0 C--N 1.297 -1.714 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.531 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -80.51 134.84 10.17 Favored 'Trans proline' 0 N--CA 1.432 -2.146 0 C-N-CA 122.086 1.857 . . . . 0.0 112.672 178.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.668 HG13 ' HB3' ' B' ' 53' ' ' ARG . 25.5 t -115.67 114.93 47.71 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.283 0 CA-C-N 114.374 -1.284 . . . . 0.0 108.554 176.121 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -105.59 105.84 16.06 Favored 'General case' 0 C--N 1.276 -2.611 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -178.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.514 HD23 ' H ' ' B' ' 11' ' ' GLU . 0.9 OUTLIER -123.72 153.85 40.3 Favored 'General case' 0 N--CA 1.418 -2.073 0 CA-C-O 121.685 0.755 . . . . 0.0 111.692 178.995 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.514 ' H ' HD23 ' B' ' 10' ' ' LEU . 40.7 tt0 -122.23 143.16 49.76 Favored 'General case' 0 C--N 1.276 -2.588 0 CA-C-N 114.245 -1.343 . . . . 0.0 108.083 -173.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . 0.421 ' HG2' HD21 ' B' ' 17' ' ' LEU . 45.5 mtmt -75.98 158.63 31.73 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 122.002 0.906 . . . . 0.0 112.276 -176.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . 0.568 ' HB2' ' H ' ' B' ' 16' ' ' GLY . 11.1 m-20 -83.52 177.13 8.57 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 113.717 -1.583 . . . . 0.0 107.963 173.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.9 m -73.46 -25.37 60.46 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 171.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -82.06 -30.85 31.13 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.7 -1.136 . . . . 0.0 109.779 177.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.568 ' H ' ' HB2' ' B' ' 13' ' ' ASP . . . 134.34 -108.44 0.72 Allowed Glycine 0 N--CA 1.432 -1.6 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.122 179.117 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.421 HD21 ' HG2' ' B' ' 12' ' ' LYS . 84.7 mt -132.8 115.72 15.65 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 121.073 0.464 . . . . 0.0 111.481 -175.276 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . 0.537 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -86.96 60.99 4.39 Favored Glycine 0 C--O 1.213 -1.168 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 178.567 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.534 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 5.7 pt -151.73 174.04 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 C-N-CA 125.137 1.375 . . . . 0.0 109.021 179.169 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . 0.407 ' HB2' HG22 ' B' ' 41' ' ' THR . 62.8 m -151.92 156.96 41.13 Favored 'General case' 0 C--N 1.271 -2.817 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 175.496 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.429 ' HB ' HG22 ' B' ' 37' ' ' ILE . 12.0 pt -124.33 161.24 27.71 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.129 0 O-C-N 123.437 0.461 . . . . 0.0 110.737 -177.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -143.11 133.55 22.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.6 119.0 6.36 Favored Glycine 0 N--CA 1.435 -1.388 0 C-N-CA 120.629 -0.796 . . . . 0.0 113.162 -177.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 68.9 mtm . . . . . 0 C--N 1.31 -1.144 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 177.424 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 18.8 tp . . . . . 0 N--CA 1.418 -2.069 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -142.44 117.72 1.18 Allowed Glycine 0 C--N 1.27 -3.128 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.351 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.429 HG22 ' HB ' ' B' ' 21' ' ' ILE . 28.9 mm -96.72 88.76 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 178.015 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.415 ' HA ' ' HA ' ' B' ' 59' ' ' LEU . 94.5 m-85 -81.83 168.76 17.64 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 114.386 -1.279 . . . . 0.0 109.225 -176.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.8 t -79.31 139.52 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.376 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 22.8 ttpp -101.12 -44.44 5.7 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.083 0.468 . . . . 0.0 109.829 -178.086 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . 0.407 HG22 ' HB2' ' B' ' 20' ' ' SER . 0.6 OUTLIER -154.62 162.13 41.27 Favored 'General case' 0 N--CA 1.432 -1.351 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 -176.781 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.534 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.2 p -144.06 97.79 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 CA-C-O 122.408 1.099 . . . . 0.0 109.356 176.63 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 23.9 m -62.65 126.59 27.84 Favored 'General case' 0 N--CA 1.431 -1.417 0 CA-C-N 113.262 -1.79 . . . . 0.0 112.256 -174.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . 0.572 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 1.8 mp0 -55.57 -36.91 67.37 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.693 1.597 . . . . 0.0 110.775 -178.052 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.97 -0.48 56.12 Favored Glycine 0 N--CA 1.438 -1.173 0 CA-C-N 115.437 -0.802 . . . . 0.0 113.877 -179.191 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.537 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -112.56 162.01 12.52 Favored Glycine 0 N--CA 1.417 -2.605 0 C-N-CA 120.121 -1.037 . . . . 0.0 113.093 179.211 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . 0.406 ' H ' ' CG ' ' B' ' 13' ' ' ASP . . . -57.45 -36.36 71.3 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 125.688 1.595 . . . . 0.0 112.06 -175.026 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -63.01 -34.54 77.77 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . 0.572 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 6.4 t60 -82.14 -39.12 23.73 Favored 'General case' 0 C--O 1.24 0.575 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 59.5 mtp180 -61.94 -39.56 92.49 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.137 179.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -74.68 -69.65 0.45 Allowed 'General case' 0 C--N 1.309 -1.174 0 C-N-CA 124.11 0.964 . . . . 0.0 109.382 175.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 110.99 -2.08 28.57 Favored Glycine 0 N--CA 1.436 -1.346 0 C-N-CA 120.21 -0.995 . . . . 0.0 114.565 177.363 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.668 ' HB3' HG13 ' B' ' 8' ' ' VAL . 39.5 mmt180 -72.24 -50.9 23.77 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 118.503 1.151 . . . . 0.0 113.054 177.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.509 HD11 ' CE2' ' B' ' 89' ' ' PHE . 54.6 mt -72.97 123.02 26.92 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 C-N-CA 119.034 -1.066 . . . . 0.0 108.891 173.141 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -116.47 146.96 42.18 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -178.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 13.2 p -56.54 -23.45 17.01 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.067 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -168.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -109.3 -3.53 17.1 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 120.875 -1.141 . . . . 0.0 111.469 -174.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -87.49 179.15 6.61 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 113.693 0.998 . . . . 0.0 113.693 -174.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.439 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 24.6 tp -124.46 126.08 45.31 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.372 -172.239 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 82.0 mt -83.7 104.31 13.71 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 106.063 -1.829 . . . . 0.0 106.063 173.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.735 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 0.5 OUTLIER -91.09 -27.65 4.92 Favored 'Isoleucine or valine' 0 C--O 1.198 -1.627 0 C-N-CA 119.667 -0.813 . . . . 0.0 110.117 -174.625 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.585 ' HB2' ' HA ' ' B' ' 67' ' ' SER . 13.2 pt-20 -158.35 166.11 33.08 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-N 114.725 -1.125 . . . . 0.0 111.389 176.122 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.515 HG22 ' H ' ' B' ' 64' ' ' ASP . 6.4 p -105.57 -174.39 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.023 0 N-CA-C 106.549 -1.649 . . . . 0.0 106.549 178.239 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.515 ' H ' HG22 ' B' ' 63' ' ' VAL . 18.9 t70 -56.55 -39.44 73.44 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 123.272 0.629 . . . . 0.0 112.479 -177.037 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -107.55 -65.29 0.6 Allowed Glycine 0 C--N 1.309 -0.945 0 C-N-CA 120.581 -0.818 . . . . 0.0 113.511 179.444 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 7.0 m -69.5 115.44 8.76 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 122.882 0.473 . . . . 0.0 112.059 -177.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . 0.585 ' HA ' ' HB2' ' B' ' 62' ' ' GLU . 48.6 m -87.36 114.93 24.42 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 174.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.735 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 75.5 mt -85.46 140.48 30.67 Favored 'General case' 0 N--CA 1.435 -1.176 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.402 -177.606 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 p -100.09 -18.72 6.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 144.63 70.84 0.02 OUTLIER Glycine 0 N--CA 1.426 -1.985 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 -176.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.419 HG11 HD22 ' B' ' 68' ' ' LEU . 35.3 m -83.76 173.66 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 CA-C-N 114.478 -0.861 . . . . 0.0 110.021 -178.254 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 37.7 p -71.93 160.29 32.79 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 177.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.5 tt0 -61.14 -37.1 81.65 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.35 0.595 . . . . 0.0 110.437 -178.024 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.7 m -73.18 -30.27 63.43 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.664 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 51.1 t80 -71.6 -41.79 68.49 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.601 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -64.46 -40.98 96.75 Favored 'General case' 0 N--CA 1.435 -1.182 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.828 177.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.01 -41.91 93.18 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.049 0.452 . . . . 0.0 110.829 177.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.1 p -76.75 -23.24 52.98 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 112.957 0.725 . . . . 0.0 112.957 -178.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.601 HG12 ' O ' ' B' ' 76' ' ' ALA . 6.7 p -72.47 -35.12 50.49 Favored 'Isoleucine or valine' 0 C--N 1.345 0.4 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -177.595 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . 0.493 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 51.2 mt -68.35 -18.39 64.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 114.551 -1.204 . . . . 0.0 110.349 178.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -97.14 -9.95 26.89 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.534 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -96.35 -21.29 17.89 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-O 121.248 0.547 . . . . 0.0 110.203 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.537 ' HB ' HG11 ' B' ' 87' ' ' VAL . 17.9 p -80.67 174.27 11.78 Favored 'General case' 0 N--CA 1.425 -1.686 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.915 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 38.1 mttp -70.27 -168.03 0.2 Allowed 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.799 0.809 . . . . 0.0 112.393 178.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -72.62 -30.62 63.87 Favored Glycine 0 N--CA 1.437 -1.293 0 CA-C-N 114.932 -1.031 . . . . 0.0 111.989 178.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 50.4 ttp180 -135.16 123.37 23.0 Favored 'General case' 0 C--N 1.31 -1.129 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.537 HG11 ' HB ' ' B' ' 83' ' ' THR . 3.3 m -137.44 160.01 35.1 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.131 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . 0.446 ' H ' ' HB2' ' B' ' 64' ' ' ASP . 81.3 mtm180 -107.82 110.99 22.91 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.635 -179.323 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.509 ' CE2' HD11 ' B' ' 54' ' ' ILE . 3.4 m-85 -92.29 156.18 17.44 Favored 'General case' 0 C--N 1.275 -2.664 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 179.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.436 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 57.1 mtt -108.46 121.73 45.57 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.435 172.304 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.461 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.4 mp -99.64 117.5 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.405 -2.682 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 179.507 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -105.45 104.04 2.25 Favored Glycine 0 CA--C 1.458 -3.505 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 178.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 13.8 tpp180 . . . . . 0 C--N 1.268 -2.977 0 CA-C-N 114.142 -1.029 . . . . 0.0 109.071 178.824 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 47.8 mtm . . . . . 0 N--CA 1.418 -2.063 0 N-CA-C 103.635 -2.728 . . . . 0.0 103.635 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . 0.444 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 16.2 mt-10 -88.4 97.29 10.97 Favored 'General case' 0 C--N 1.284 -2.276 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.263 -176.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -86.37 89.55 7.91 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 172.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 23.6 p90 -108.81 144.78 30.29 Favored Pre-proline 0 C--N 1.297 -1.7 0 CA-C-N 115.52 -0.764 . . . . 0.0 112.092 -177.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . 0.414 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 53.6 Cg_endo -73.85 138.59 26.3 Favored 'Trans proline' 0 N--CA 1.447 -1.255 0 C-N-CA 122.303 2.002 . . . . 0.0 113.314 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.458 ' HB ' HD13 ' B' ' 91' ' ' ILE . 74.8 t -129.49 126.55 63.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.824 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 175.219 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -108.39 135.75 49.17 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.668 -177.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.575 HD11 ' HB2' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -139.75 162.21 35.68 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.614 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.44 ' H ' HD23 ' B' ' 10' ' ' LEU . 11.9 pt-20 -134.13 159.36 41.1 Favored 'General case' 0 C--N 1.285 -2.208 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.31 177.019 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -77.22 134.87 38.49 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.579 -178.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . 0.55 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 15.6 t70 -87.61 -179.74 6.37 Favored 'General case' 0 C--N 1.292 -1.917 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 175.55 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.3 m -64.65 -29.8 70.8 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 176.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -91.66 -8.96 45.63 Favored 'General case' 0 CA--C 1.548 0.891 0 CA-C-O 121.661 0.743 . . . . 0.0 109.975 177.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 106.51 -100.07 1.57 Allowed Glycine 0 N--CA 1.44 -1.038 0 C-N-CA 121.068 -0.586 . . . . 0.0 113.02 177.594 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.55 ' HG ' ' H ' ' B' ' 18' ' ' GLY . 17.7 tp -98.85 -173.28 2.48 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -177.255 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . 0.55 ' H ' ' HG ' ' B' ' 17' ' ' LEU . . . -164.91 58.18 0.26 Allowed Glycine 0 N--CA 1.435 -1.371 0 C-N-CA 120.262 -0.971 . . . . 0.0 112.688 177.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.504 HG23 ' HB3' ' B' ' 48' ' ' ALA . 5.7 pt -162.93 177.46 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.487 -1.473 0 C-N-CA 124.662 1.185 . . . . 0.0 108.228 -179.134 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.2 m -138.83 147.25 42.25 Favored 'General case' 0 C--N 1.262 -3.21 0 N-CA-C 105.522 -2.029 . . . . 0.0 105.522 174.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 9.3 pt -114.85 167.17 7.72 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.827 0 O-C-N 123.36 0.412 . . . . 0.0 109.931 -178.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 10.1 tp -142.82 135.81 26.06 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -90.12 110.31 3.75 Favored Glycine 0 N--CA 1.435 -1.392 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.615 -178.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 89.1 mtp . . . . . 0 C--N 1.303 -1.429 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 177.252 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 91.8 mt . . . . . 0 N--CA 1.425 -1.709 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -112.12 95.17 0.78 Allowed Glycine 0 N--CA 1.398 -3.843 0 C-N-CA 120.63 -0.795 . . . . 0.0 111.467 -176.087 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 30.8 mm -86.99 86.01 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.824 0 N-CA-C 106.428 -1.693 . . . . 0.0 106.428 172.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -84.1 166.85 17.31 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 114.335 -1.302 . . . . 0.0 108.727 -175.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.1 t -79.67 133.05 30.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 175.084 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -95.41 -41.76 8.83 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 120.932 0.396 . . . . 0.0 110.008 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -156.88 163.03 39.63 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -179.603 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.451 ' HA ' HG22 ' B' ' 19' ' ' ILE . 21.9 t -118.62 108.69 24.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 177.255 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' B' ' 49' ' ' HIS . 24.3 m -64.92 123.68 20.05 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 123.422 0.689 . . . . 0.0 111.088 -176.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . 0.446 ' HG2' ' CE1' ' B' ' 49' ' ' HIS . 32.8 mt-10 -67.72 -33.7 75.4 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 124.588 1.155 . . . . 0.0 109.839 -175.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.46 16.82 47.36 Favored Glycine 0 N--CA 1.431 -1.633 0 CA-C-N 114.761 -1.108 . . . . 0.0 112.114 178.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -127.07 174.75 18.23 Favored Glycine 0 N--CA 1.405 -3.422 0 C-N-CA 120.81 -0.71 . . . . 0.0 113.464 -178.648 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . 0.55 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -56.84 -54.84 41.79 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -173.612 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . 0.575 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -61.13 -27.14 68.18 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 114.017 1.117 . . . . 0.0 114.017 -171.105 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . 0.446 ' CE1' ' HG2' ' B' ' 44' ' ' GLU . 2.4 t60 -78.98 -38.7 36.19 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -179.197 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 92.1 mtt180 -73.5 -38.82 65.23 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.373 -178.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -66.85 -67.1 0.48 Allowed 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.088 173.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.84 3.49 52.17 Favored Glycine 0 N--CA 1.439 -1.104 0 N-CA-C 114.722 0.649 . . . . 0.0 114.722 175.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -81.2 -45.94 15.59 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 118.489 1.144 . . . . 0.0 112.061 -179.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.516 HD11 ' CE2' ' B' ' 89' ' ' PHE . 19.7 mt -78.56 127.89 38.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.142 174.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 50.7 mt-30 -110.92 167.07 10.52 Favored 'General case' 0 N--CA 1.436 -1.165 0 CA-C-O 121.07 0.462 . . . . 0.0 110.396 176.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.6 p -70.71 -2.1 2.42 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.704 0 N-CA-C 114.191 1.182 . . . . 0.0 114.191 -171.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -119.85 15.01 12.57 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.723 -1.236 . . . . 0.0 110.546 179.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -90.47 168.76 11.6 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.783 -178.2 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.512 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 22.8 tp -133.23 132.59 41.66 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.716 -176.637 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 78.2 mt -86.06 99.54 11.55 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 177.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.53 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.3 t -83.52 -42.42 17.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 CA-C-O 121.461 0.648 . . . . 0.0 110.647 177.546 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.536 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 15.9 pt-20 -159.67 158.53 31.63 Favored 'General case' 0 C--N 1.282 -2.332 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.546 175.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.507 HG12 ' HB ' ' B' ' 66' ' ' THR . 4.0 p -100.74 -173.58 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.228 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.458 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 22.8 t70 -51.49 -47.73 63.13 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 113.126 0.787 . . . . 0.0 113.126 -178.431 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -137.4 44.56 1.13 Allowed Glycine 0 C--N 1.314 -0.678 0 C-N-CA 119.362 -1.399 . . . . 0.0 114.207 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . 0.507 ' HB ' HG12 ' B' ' 63' ' ' VAL . 94.9 m -161.31 119.43 2.38 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.027 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . 0.536 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 21.2 m -97.92 132.48 43.46 Favored 'General case' 0 N--CA 1.431 -1.394 0 CA-C-O 121.075 0.464 . . . . 0.0 111.853 -176.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.53 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 42.4 mt -96.06 115.42 27.4 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.108 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 40.1 t -81.85 -23.51 9.78 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 174.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 145.75 75.76 0.02 OUTLIER Glycine 0 N--CA 1.424 -2.124 0 N-CA-C 108.871 -1.692 . . . . 0.0 108.871 -177.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 m -93.53 -178.32 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-N 115.554 -0.323 . . . . 0.0 110.557 -175.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 41.3 p -82.6 165.32 20.17 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 176.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.0 tt0 -63.15 -33.91 76.48 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.23 0.538 . . . . 0.0 109.596 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.3 m -66.28 -44.93 82.19 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.991 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -60.19 -48.2 82.75 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.496 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -59.08 -44.2 91.87 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.122 178.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.4 -37.27 80.3 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-O 121.204 0.526 . . . . 0.0 110.324 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 36.0 m -66.84 -35.96 81.24 Favored 'General case' 0 N--CA 1.435 -1.182 0 CA-C-N 115.366 -0.834 . . . . 0.0 111.344 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.496 HG12 ' O ' ' B' ' 76' ' ' ALA . 4.2 p -75.66 -34.17 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 C-N-CA 119.558 -0.857 . . . . 0.0 109.81 -174.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 25.0 mt -64.82 -42.29 95.09 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.261 -0.882 . . . . 0.0 111.167 176.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 39.1 mtp180 -77.64 -30.16 52.03 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.819 0.342 . . . . 0.0 111.922 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 6.5 t30 -74.8 -27.09 60.16 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.412 ' HB ' HG11 ' B' ' 87' ' ' VAL . 16.3 p -71.88 158.69 35.59 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 -178.114 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -66.74 -168.04 0.06 Allowed 'General case' 0 C--O 1.251 1.163 0 C-N-CA 124.708 1.203 . . . . 0.0 112.933 -178.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.12 -49.95 64.7 Favored Glycine 0 N--CA 1.431 -1.689 0 CA-C-N 114.644 -1.162 . . . . 0.0 112.828 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 23.0 ttp180 -135.04 121.65 20.7 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.981 -0.688 . . . . 0.0 111.961 -177.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.458 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 15.8 m -138.24 149.56 24.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 114.879 -1.055 . . . . 0.0 109.383 -179.361 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -94.6 155.95 16.66 Favored 'General case' 0 C--N 1.295 -1.796 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.755 174.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.516 ' CE2' HD11 ' B' ' 54' ' ' ILE . 9.1 m-85 -126.99 162.33 26.25 Favored 'General case' 0 C--N 1.276 -2.63 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 176.689 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.505 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 24.5 mmt -111.58 113.1 25.28 Favored 'General case' 0 C--N 1.28 -2.448 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.597 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.512 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -97.21 129.23 47.58 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -179.331 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -109.45 116.28 4.5 Favored Glycine 0 CA--C 1.468 -2.858 0 C-N-CA 120.19 -1.005 . . . . 0.0 112.079 -178.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 8.7 tpp180 . . . . . 0 C--N 1.284 -2.257 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 176.023 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . 0.439 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 65.6 mtt . . . . . 0 N--CA 1.424 -1.752 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -77.47 103.98 7.73 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -176.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -78.05 91.39 4.27 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 124.106 0.878 . . . . 0.0 108.822 176.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -113.22 142.99 28.37 Favored Pre-proline 0 C--N 1.281 -2.371 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.646 176.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . 0.517 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 34.2 Cg_endo -75.01 128.84 11.79 Favored 'Trans proline' 0 N--CA 1.438 -1.791 0 C-N-CA 121.943 1.762 . . . . 0.0 112.843 179.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.461 ' HB ' HD13 ' B' ' 91' ' ' ILE . 72.0 t -113.41 122.78 68.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.266 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . 0.532 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 36.5 tt0 -106.86 132.15 53.15 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -174.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.522 HD11 ' HB2' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -127.4 158.27 37.75 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 177.548 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.417 ' H ' HD23 ' B' ' 10' ' ' LEU . 45.7 tt0 -134.41 138.51 44.88 Favored 'General case' 0 C--N 1.279 -2.481 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 176.001 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 34.7 mmtp -68.54 152.97 44.63 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 114.876 1.435 . . . . 0.0 114.876 -174.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . 0.455 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 15.2 t70 -92.76 177.33 6.13 Favored 'General case' 0 C--O 1.247 0.922 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 173.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 13.2 p -69.62 -28.76 66.19 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 118.327 0.512 . . . . 0.0 110.356 178.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -80.24 -53.04 7.03 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 173.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 147.92 -96.98 0.18 Allowed Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.34 179.091 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 96.3 mt -128.36 175.48 8.46 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 122.928 0.491 . . . . 0.0 109.996 -178.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . 0.492 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -156.38 69.05 0.28 Allowed Glycine 0 CA--C 1.482 -1.977 0 N-CA-C 108.254 -1.938 . . . . 0.0 108.254 179.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.514 HG22 ' HB ' ' B' ' 42' ' ' VAL . 12.7 pt -145.22 -179.09 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.281 -2.393 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 -177.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . 0.475 ' HB2' HG22 ' B' ' 41' ' ' THR . 28.5 m -154.88 155.46 34.38 Favored 'General case' 0 C--N 1.253 -3.627 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 174.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.473 ' HB ' HG22 ' B' ' 37' ' ' ILE . 7.9 pt -127.58 154.5 38.07 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.892 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -129.26 132.13 67.08 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -179.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.78 103.18 2.28 Favored Glycine 0 N--CA 1.423 -2.231 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.192 -176.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 72.6 mtm . . . . . 0 C--N 1.303 -1.438 0 CA-C-O 121.085 0.469 . . . . 0.0 110.672 -179.829 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 83.6 mt . . . . . 0 CA--C 1.493 -1.218 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -87.64 91.67 1.75 Allowed Glycine 0 N--CA 1.41 -3.063 0 C-N-CA 120.365 -0.921 . . . . 0.0 111.982 -177.146 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.473 HG22 ' HB ' ' B' ' 21' ' ' ILE . 20.1 mm -87.38 84.91 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.549 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 173.467 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -84.71 165.01 18.22 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 114.636 -1.165 . . . . 0.0 108.695 -178.031 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 56.9 t -75.8 133.12 31.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 176.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -92.71 -46.4 7.59 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.622 -177.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . 0.525 ' HA ' HG23 ' B' ' 56' ' ' VAL . 6.3 t -155.14 174.58 15.0 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.514 ' HB ' HG22 ' B' ' 19' ' ' ILE . 2.4 p -158.81 98.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 C-N-CA 124.793 1.237 . . . . 0.0 109.201 -177.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.424 HG22 ' H ' ' B' ' 45' ' ' GLY . 26.5 m -87.76 143.27 27.24 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 113.915 -1.493 . . . . 0.0 110.32 -174.597 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -56.78 -19.89 19.48 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 124.593 1.157 . . . . 0.0 112.744 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . 0.424 ' H ' HG22 ' B' ' 43' ' ' THR . . . -72.98 -12.44 79.14 Favored Glycine 0 N--CA 1.439 -1.102 0 CA-C-N 116.11 -0.496 . . . . 0.0 113.363 -178.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.492 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -116.5 169.0 12.87 Favored Glycine 0 N--CA 1.422 -2.3 0 C-N-CA 119.438 -1.363 . . . . 0.0 113.328 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . 0.455 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -56.77 -41.25 77.31 Favored 'General case' 0 C--O 1.19 -2.066 0 CA-C-N 113.977 -1.111 . . . . 0.0 113.568 -175.078 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . 0.522 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -59.87 -35.94 75.84 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -173.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 4.9 t60 -81.45 -38.76 25.91 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -179.574 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -69.29 -46.17 67.82 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.07 -178.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -70.89 -36.01 72.58 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.81 47.68 7.05 Favored Glycine 0 CA--C 1.494 -1.276 0 CA-C-N 114.102 -1.408 . . . . 0.0 112.463 173.431 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.532 ' HG3' ' O ' ' B' ' 9' ' ' GLU . 35.2 mmt180 -116.14 -60.78 1.82 Allowed 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -177.244 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.463 HD11 ' CE2' ' B' ' 89' ' ' PHE . 43.9 mt -77.28 125.73 37.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 C-N-CA 120.255 -0.578 . . . . 0.0 109.735 178.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 65.4 mt-30 -99.74 159.04 15.35 Favored 'General case' 0 C--N 1.287 -2.144 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.525 HG23 ' HA ' ' B' ' 41' ' ' THR . 11.8 p -70.03 -4.83 4.43 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.699 0 CA-C-O 121.804 0.812 . . . . 0.0 112.027 -177.45 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -113.15 10.14 18.6 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.451 -0.78 . . . . 0.0 110.824 -177.015 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 87.9 m-20 -85.01 175.31 9.12 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.293 0.568 . . . . 0.0 112.379 -177.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.401 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 26.6 tp -143.05 130.97 21.61 Favored 'General case' 0 C--N 1.315 -0.908 0 C-N-CA 123.894 0.878 . . . . 0.0 109.752 -177.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 71.7 mt -87.49 98.12 11.21 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 178.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.575 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 36.6 t -81.97 -41.41 18.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 CA-C-O 121.941 0.877 . . . . 0.0 110.477 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.46 ' HG2' ' HB2' ' B' ' 90' ' ' MET . 9.7 pt-20 -157.26 158.95 37.08 Favored 'General case' 0 C--N 1.275 -2.633 0 CA-C-N 114.858 -1.065 . . . . 0.0 109.763 173.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.453 HG12 ' O ' ' B' ' 66' ' ' THR . 3.3 p -101.57 -173.89 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 105.825 -1.917 . . . . 0.0 105.825 178.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.511 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.2 t70 -55.34 -58.68 6.74 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 113.092 0.775 . . . . 0.0 113.092 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -119.23 33.43 4.7 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 119.818 -1.182 . . . . 0.0 114.535 -176.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . 0.453 ' O ' HG12 ' B' ' 63' ' ' VAL . 18.8 m -160.71 128.53 4.43 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 179.002 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . 0.405 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 39.0 m -93.91 136.77 33.85 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.899 -0.501 . . . . 0.0 111.092 -179.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.575 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 17.2 mt -93.34 -77.39 0.45 Allowed 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.373 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 61.4 t 70.49 -29.4 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 125.34 1.456 . . . . 0.0 111.181 -175.206 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . 0.467 ' H ' ' C ' ' B' ' 68' ' ' LEU . . . 164.59 89.29 0.07 OUTLIER Glycine 1 N--CA 1.395 -4.085 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -177.226 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.415 HG21 HD22 ' B' ' 68' ' ' LEU . 33.6 m -118.42 -178.74 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.282 -2.356 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 175.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 36.7 p -79.92 161.8 25.33 Favored 'General case' 0 C--N 1.292 -1.931 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 177.226 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -60.42 -35.03 74.84 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 121.287 0.565 . . . . 0.0 110.129 -177.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 50.0 m -74.22 -36.44 63.94 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.831 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -63.25 -46.22 87.91 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.533 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -63.01 -38.92 93.11 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.279 179.534 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.67 -38.33 88.98 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.489 0.661 . . . . 0.0 110.122 178.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 34.7 t -64.49 -39.28 93.5 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.956 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.533 HG12 ' O ' ' B' ' 76' ' ' ALA . 2.6 p -70.31 -27.94 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 121.947 0.879 . . . . 0.0 110.374 -172.047 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . 0.501 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 55.8 mt -72.51 -6.6 44.99 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.376 178.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 67.6 mtt180 -116.88 -17.48 10.42 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-O 120.852 0.358 . . . . 0.0 111.948 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.9 m-20 -87.76 -8.36 56.11 Favored 'General case' 0 C--O 1.241 0.645 0 C-N-CA 123.308 0.643 . . . . 0.0 111.378 179.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.612 ' HB ' HG11 ' B' ' 87' ' ' VAL . 1.4 p -87.25 -175.16 5.18 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 113.873 1.064 . . . . 0.0 113.873 -178.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -77.34 -171.5 2.12 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.879 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -75.97 -38.27 36.1 Favored Glycine 0 N--CA 1.44 -1.067 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.927 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . 0.427 ' HA ' ' O ' ' B' ' 10' ' ' LEU . 13.0 ttp180 -127.69 118.49 23.92 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.612 HG11 ' HB ' ' B' ' 83' ' ' THR . 15.6 m -135.5 154.82 35.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -175.165 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . 0.42 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 99.7 mtt180 -109.66 126.19 53.4 Favored 'General case' 0 CA--C 1.49 -1.345 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.115 179.307 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.517 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 3.1 m-85 -105.58 155.05 19.58 Favored 'General case' 0 C--N 1.28 -2.45 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 178.023 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.46 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 19.6 mmt -98.74 109.69 22.4 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 173.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.484 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.5 mp -98.06 119.92 46.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.943 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.53 111.89 4.07 Favored Glycine 0 CA--C 1.466 -3.007 0 N-CA-C 108.726 -1.75 . . . . 0.0 108.726 175.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . 0.439 ' O ' ' HA ' ' B' ' 3' ' ' MET . 8.3 tpp180 . . . . . 0 C--N 1.285 -2.224 0 CA-C-N 114.637 -0.781 . . . . 0.0 111.679 -178.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 20.6 ptp . . . . . 0 N--CA 1.429 -1.482 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . 0.522 ' OE2' ' HD2' ' B' ' 93' ' ' ARG . 17.1 mt-10 -89.85 100.09 12.97 Favored 'General case' 0 C--N 1.289 -2.037 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -177.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -91.4 89.94 7.47 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 175.021 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -119.14 143.88 34.97 Favored Pre-proline 0 C--N 1.29 -1.997 0 C-N-CA 120.736 -0.386 . . . . 0.0 111.946 178.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . 0.489 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 56.7 Cg_endo -75.15 139.49 23.97 Favored 'Trans proline' 0 N--CA 1.439 -1.716 0 C-N-CA 122.076 1.851 . . . . 0.0 111.73 176.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.45 ' HB ' HD13 ' B' ' 91' ' ' ILE . 90.5 t -128.33 123.34 59.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -179.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . 0.5 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 38.9 tt0 -103.24 129.6 50.24 Favored 'General case' 0 C--N 1.285 -2.196 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.196 -178.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.446 HD12 HG13 ' B' ' 54' ' ' ILE . 2.0 mt -142.81 165.37 27.55 Favored 'General case' 0 CA--C 1.478 -1.812 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.812 175.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -135.58 164.67 27.3 Favored 'General case' 0 C--N 1.283 -2.324 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.726 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -82.38 163.14 21.89 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 121.616 0.722 . . . . 0.0 112.156 -179.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -111.44 -159.54 0.68 Allowed 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 104.12 -2.548 . . . . 0.0 104.12 173.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 22.8 t -75.17 -25.45 58.32 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 169.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -86.73 -60.83 1.88 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.977 176.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 122.84 75.45 0.32 Allowed Glycine 0 N--CA 1.439 -1.108 0 C-N-CA 120.223 -0.989 . . . . 0.0 112.143 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp 77.12 172.04 0.22 Allowed 'General case' 0 CA--C 1.507 -0.678 0 C-N-CA 124.576 1.15 . . . . 0.0 112.402 178.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -141.83 74.44 0.35 Allowed Glycine 0 CA--C 1.471 -2.675 0 N-CA-C 109.097 -1.601 . . . . 0.0 109.097 -178.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.443 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 14.2 pt -157.51 -177.53 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 -178.673 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 24.0 t -149.08 142.31 25.05 Favored 'General case' 0 C--N 1.272 -2.793 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 176.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 20.6 pt -109.17 152.87 11.11 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -129.76 136.14 59.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.65 97.85 2.15 Favored Glycine 0 N--CA 1.434 -1.472 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.025 179.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 26.5 ptm . . . . . 0 C--N 1.308 -1.216 0 CA-C-O 120.894 0.378 . . . . 0.0 110.025 -179.044 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 20.2 tp . . . . . 0 N--CA 1.413 -2.286 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -110.49 89.5 0.55 Allowed Glycine 0 N--CA 1.398 -3.849 0 C-N-CA 119.99 -1.1 . . . . 0.0 111.982 -176.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 29.6 mm -90.21 78.4 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.212 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 171.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -86.05 167.63 14.83 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-N 113.911 -1.495 . . . . 0.0 109.137 -176.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.414 HG21 ' CG2' ' B' ' 54' ' ' ILE . 51.1 t -81.07 131.34 34.14 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 176.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 36.4 ttpt -91.9 -40.97 10.86 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.771 -175.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -156.63 162.73 39.84 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 -177.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 21.8 t -127.53 92.11 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 178.29 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 10.5 m -72.31 132.55 44.16 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 123.541 0.736 . . . . 0.0 111.672 -176.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . 0.45 ' HA ' ' HB3' ' B' ' 49' ' ' HIS . 11.3 pt-20 -67.83 -3.52 9.83 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 123.886 0.874 . . . . 0.0 113.208 -179.163 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.1 3.23 85.72 Favored Glycine 0 N--CA 1.44 -1.098 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.133 -177.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -139.36 170.94 23.94 Favored Glycine 0 N--CA 1.407 -3.273 0 C-N-CA 119.862 -1.161 . . . . 0.0 113.556 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.94 -35.05 44.54 Favored 'General case' 0 C--O 1.195 -1.812 0 C-N-CA 126.235 1.814 . . . . 0.0 114.726 -174.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -64.63 -45.28 87.53 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 120.284 -0.566 . . . . 0.0 112.348 -174.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . 0.45 ' HB3' ' HA ' ' B' ' 44' ' ' GLU . 5.1 t60 -73.44 -41.09 63.65 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 108.679 -0.859 . . . . 0.0 108.679 177.155 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -59.81 -42.76 94.2 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.71 -178.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . 0.601 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 9.7 t70 -78.19 -51.85 9.58 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.279 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.95 42.71 3.23 Favored Glycine 0 N--CA 1.434 -1.463 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.615 ' HA ' ' NE ' ' B' ' 53' ' ' ARG . 4.9 mmp_? -104.97 -82.77 0.51 Allowed 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -178.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.474 HD11 ' CE2' ' B' ' 89' ' ' PHE . 49.9 mt -61.28 122.94 13.1 Favored 'Isoleucine or valine' 0 C--O 1.244 0.785 0 C-N-CA 120.165 -0.614 . . . . 0.0 110.435 176.574 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . 0.419 ' HB2' ' OD1' ' B' ' 58' ' ' ASP . 48.0 mt-30 -100.81 173.45 6.5 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.845 0.355 . . . . 0.0 111.039 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.8 p -77.83 -1.97 4.36 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 CA-C-O 121.374 0.607 . . . . 0.0 112.388 -174.022 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -124.07 24.55 8.16 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-O 122.053 0.93 . . . . 0.0 109.584 -178.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . 0.419 ' OD1' ' HB2' ' B' ' 55' ' ' GLN . 11.1 m-20 -98.21 166.36 11.44 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 114.345 -1.298 . . . . 0.0 110.421 -177.411 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.577 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 24.8 tp -140.39 133.35 29.27 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 123.423 0.689 . . . . 0.0 109.851 -177.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 71.1 mt -82.72 99.75 9.83 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 177.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.472 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.1 t -85.02 -40.81 15.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 122.0 0.905 . . . . 0.0 110.676 178.51 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.481 ' HG2' ' HB2' ' B' ' 90' ' ' MET . 10.2 pt-20 -155.51 154.25 31.51 Favored 'General case' 0 C--N 1.27 -2.883 0 CA-C-N 115.17 -0.923 . . . . 0.0 109.633 173.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.538 HG12 ' HB ' ' B' ' 66' ' ' THR . 6.6 p -100.4 -171.86 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 N-CA-C 105.825 -1.917 . . . . 0.0 105.825 178.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.562 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 8.6 t70 -44.14 -55.21 4.95 Favored 'General case' 0 N--CA 1.482 1.125 0 C-N-CA 124.117 0.967 . . . . 0.0 112.959 177.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -136.21 43.39 1.24 Allowed Glycine 0 C--N 1.304 -1.234 0 C-N-CA 119.07 -1.538 . . . . 0.0 114.98 -179.214 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . 0.538 ' HB ' HG12 ' B' ' 63' ' ' VAL . 88.5 m -155.09 123.5 5.98 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 117.558 0.679 . . . . 0.0 109.326 177.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 5.7 m -87.58 125.02 34.11 Favored 'General case' 0 N--CA 1.441 -0.909 0 C-N-CA 123.091 0.557 . . . . 0.0 109.782 -177.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.472 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 25.1 mt -90.38 99.54 12.55 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 122.21 1.005 . . . . 0.0 110.856 179.327 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 58.1 t -69.22 -33.07 56.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-N 114.759 -1.109 . . . . 0.0 108.046 175.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 149.35 66.46 0.01 OUTLIER Glycine 0 CA--C 1.468 -2.845 0 N-CA-C 108.901 -1.68 . . . . 0.0 108.901 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 29.8 m -83.06 171.97 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.878 0 CA-C-N 113.694 -1.253 . . . . 0.0 109.188 -177.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 25.4 p -77.91 163.79 25.7 Favored 'General case' 0 N--CA 1.412 -2.339 0 C-N-CA 121.042 -0.263 . . . . 0.0 110.465 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -59.74 -37.53 79.22 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.314 0.578 . . . . 0.0 109.899 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 32.9 t -65.23 -41.36 94.48 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.776 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -64.57 -48.1 76.25 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.596 ' O ' ' HG ' ' B' ' 80' ' ' LEU . . . -55.78 -43.29 76.63 Favored 'General case' 0 C--O 1.217 -0.642 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.772 178.794 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.62 -39.1 91.12 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.28 0.562 . . . . 0.0 111.033 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.1 t -72.17 -29.41 63.99 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.9 -177.099 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.446 HG12 ' O ' ' B' ' 76' ' ' ALA . 9.8 p -75.69 -33.85 27.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 -176.173 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . 0.596 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 70.2 mt -68.19 -12.02 60.24 Favored 'General case' 0 C--O 1.214 -0.794 0 CA-C-N 114.517 -1.22 . . . . 0.0 110.789 176.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 96.6 mtt180 -106.16 -5.78 19.05 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.467 0.651 . . . . 0.0 111.036 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 13.0 m-80 -96.95 -24.04 16.02 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.546 177.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.791 ' HB ' HG11 ' B' ' 87' ' ' VAL . 3.9 p -68.44 179.74 1.57 Allowed 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -178.132 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 66.3 mmtt -72.03 -170.33 0.58 Allowed 'General case' 0 C--O 1.239 0.514 0 C-N-CA 123.462 0.705 . . . . 0.0 110.921 176.045 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.95 -36.09 47.99 Favored Glycine 0 N--CA 1.445 -0.759 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.648 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 26.3 ttm180 -127.52 122.48 33.45 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.791 HG11 ' HB ' ' B' ' 83' ' ' THR . 13.6 m -133.75 150.14 31.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.085 0 CA-C-O 121.085 0.469 . . . . 0.0 111.051 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 69.6 mtp85 -108.36 118.63 37.28 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.459 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.489 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 1.3 m-85 -98.73 170.74 8.56 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -177.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.481 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 48.5 mtt -113.54 116.88 30.24 Favored 'General case' 0 CA--C 1.473 -1.992 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 167.535 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.577 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.3 mp -94.49 121.72 45.34 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 177.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -112.67 96.45 0.83 Allowed Glycine 0 CA--C 1.461 -3.321 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 177.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . 0.522 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 36.6 ttm180 . . . . . 0 C--N 1.257 -3.435 0 CA-C-N 114.761 -0.719 . . . . 0.0 110.512 -176.077 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . 0.522 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 66.8 mtt . . . . . 0 CA--C 1.505 -0.765 0 CA-C-O 120.901 0.381 . . . . 0.0 110.734 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . 0.408 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 19.7 mt-10 -84.85 105.6 15.75 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -85.34 93.59 8.75 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 174.517 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -117.02 141.5 28.47 Favored Pre-proline 0 C--N 1.288 -2.068 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.196 179.398 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . 0.51 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 61.0 Cg_endo -79.32 137.79 13.57 Favored 'Trans proline' 0 N--CA 1.444 -1.411 0 C-N-CA 122.379 2.052 . . . . 0.0 112.984 178.413 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 79.0 t -125.61 142.19 43.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 N-CA-C 106.855 -1.535 . . . . 0.0 106.855 177.659 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -127.97 123.2 34.24 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 118.659 0.663 . . . . 0.0 110.708 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.453 ' O ' ' HD3' ' B' ' 86' ' ' ARG . 1.2 mt -113.7 163.94 14.35 Favored 'General case' 0 CA--C 1.486 -1.503 0 CA-C-O 121.589 0.709 . . . . 0.0 111.478 178.812 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -124.88 145.89 49.58 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 174.309 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -91.02 164.14 14.07 Favored 'General case' 0 N--CA 1.418 -2.026 0 CA-C-O 121.874 0.845 . . . . 0.0 110.36 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . 0.567 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 25.3 t70 -111.44 -179.41 3.71 Favored 'General case' 0 C--N 1.274 -2.683 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 178.073 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 16.1 m -69.54 -25.92 64.25 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 176.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 8.3 tp10 -85.89 1.71 48.85 Favored 'General case' 0 CA--C 1.548 0.876 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.443 178.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.45 -138.75 14.6 Favored Glycine 0 N--CA 1.437 -1.285 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.573 179.751 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 93.9 mt -95.54 -177.94 4.25 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 177.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -138.42 58.04 0.63 Allowed Glycine 0 CA--C 1.478 -2.23 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.453 -178.356 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.561 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 7.0 pt -150.4 179.13 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 C-N-CA 123.52 0.728 . . . . 0.0 109.396 -177.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . 0.426 ' HB2' HG22 ' B' ' 41' ' ' THR . 70.0 m -150.97 160.92 43.61 Favored 'General case' 0 C--N 1.269 -2.93 0 N-CA-C 105.14 -2.171 . . . . 0.0 105.14 175.673 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.475 ' HB ' HG22 ' B' ' 37' ' ' ILE . 10.3 pt -130.73 159.96 42.32 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.621 0 CA-C-N 117.877 0.308 . . . . 0.0 110.226 -177.607 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.2 tp -136.5 135.86 48.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-O 120.985 0.421 . . . . 0.0 110.348 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . 0.412 ' HA2' ' CD1' ' B' ' 37' ' ' ILE . . . -83.63 99.16 2.16 Favored Glycine 0 N--CA 1.437 -1.24 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.591 -178.082 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 3.8 mmt . . . . . 0 C--N 1.3 -1.583 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.473 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 94.7 mt . . . . . 0 N--CA 1.427 -1.588 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -124.69 102.8 0.71 Allowed Glycine 0 N--CA 1.414 -2.803 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 -178.301 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.475 HG22 ' HB ' ' B' ' 21' ' ' ILE . 23.7 mm -88.18 88.84 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 178.297 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -83.9 163.46 20.03 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.689 -1.141 . . . . 0.0 109.342 -178.548 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 65.8 t -71.49 130.99 35.09 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 174.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -90.31 -48.73 6.96 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.42 -177.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . 0.426 HG22 ' HB2' ' B' ' 20' ' ' SER . 0.6 OUTLIER -150.05 163.86 37.04 Favored 'General case' 0 N--CA 1.428 -1.529 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -177.875 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.0 p -139.01 93.7 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 CA-C-O 122.693 1.235 . . . . 0.0 109.29 178.63 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.429 HG22 ' H ' ' B' ' 45' ' ' GLY . 10.3 m -75.6 130.91 39.55 Favored 'General case' 0 N--CA 1.44 -0.974 0 CA-C-N 113.443 -1.708 . . . . 0.0 112.72 -172.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -57.93 -24.12 56.45 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 124.22 1.008 . . . . 0.0 112.901 179.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . 0.429 ' H ' HG22 ' B' ' 43' ' ' THR . . . -78.47 -1.26 81.67 Favored Glycine 0 N--CA 1.436 -1.313 0 CA-C-N 115.97 -0.559 . . . . 0.0 113.465 -178.129 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -122.28 170.23 15.08 Favored Glycine 0 N--CA 1.421 -2.354 0 C-N-CA 120.229 -0.986 . . . . 0.0 112.733 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . 0.567 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -59.94 -39.41 85.45 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 114.261 1.208 . . . . 0.0 114.261 -173.877 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . 0.4 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -64.34 -39.82 94.65 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -173.003 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -72.36 -44.53 62.44 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.509 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 17.2 mtp180 -62.24 -45.49 93.1 Favored 'General case' 0 CA--C 1.511 -0.536 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.188 -177.047 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . 0.484 ' OD2' ' HD2' ' B' ' 53' ' ' ARG . 19.1 t70 -65.54 -51.4 60.2 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 176.692 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 95.04 39.48 4.56 Favored Glycine 0 CA--C 1.478 -2.278 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.553 ' HA ' ' NE ' ' B' ' 53' ' ' ARG . 0.0 OUTLIER -99.66 -73.18 0.64 Allowed 'General case' 0 N--CA 1.419 -2.023 0 CA-C-N 114.221 -0.989 . . . . 0.0 110.483 -170.965 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.555 HD11 ' CE2' ' B' ' 89' ' ' PHE . 47.1 mt -82.78 125.1 39.95 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 175.725 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . 0.512 ' HG2' ' OD2' ' B' ' 58' ' ' ASP . 24.2 pt20 -100.42 169.52 9.04 Favored 'General case' 0 C--N 1.309 -1.196 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -178.26 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.1 p -66.82 -2.28 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.507 0 C-N-CA 123.964 0.906 . . . . 0.0 113.361 -174.182 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -127.27 19.39 6.93 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.044 -1.035 . . . . 0.0 110.769 -178.349 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . 0.512 ' OD2' ' HG2' ' B' ' 55' ' ' GLN . 80.8 m-20 -84.66 168.24 15.46 Favored 'General case' 0 C--N 1.312 -1.038 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.595 176.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 28.6 tp -136.06 127.45 28.48 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.393 -176.303 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 82.5 mt -81.73 90.91 6.39 Favored 'General case' 0 N--CA 1.434 -1.236 0 CA-C-O 121.534 0.683 . . . . 0.0 109.875 178.401 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.643 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 10.9 t -74.25 -39.6 49.56 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.126 175.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.486 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 11.9 pt-20 -164.56 159.66 19.42 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.862 171.009 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.566 HG12 ' HB ' ' B' ' 66' ' ' THR . 3.0 p -96.95 178.19 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.606 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 19.9 t70 -42.59 -54.34 4.01 Favored 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 125.409 1.484 . . . . 0.0 113.762 -176.185 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -132.56 43.85 1.25 Allowed Glycine 0 C--N 1.304 -1.232 0 C-N-CA 119.581 -1.295 . . . . 0.0 113.682 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . 0.566 ' HB ' HG12 ' B' ' 63' ' ' VAL . 51.6 m -157.43 114.34 2.99 Favored 'General case' 0 C--O 1.247 0.923 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 175.867 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . 0.486 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 44.6 m -81.99 111.65 18.36 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 112.476 0.547 . . . . 0.0 112.476 -177.177 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.643 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 44.2 mt -79.52 110.48 14.88 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.887 176.496 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 14.7 p -75.84 -24.98 16.98 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 177.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 142.54 64.04 0.03 OUTLIER Glycine 0 CA--C 1.484 -1.87 0 N-CA-C 108.928 -1.669 . . . . 0.0 108.928 -177.172 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.9 m -82.26 -178.59 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 114.366 -0.917 . . . . 0.0 110.406 -176.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 40.4 p -82.89 166.29 19.04 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 120.926 0.393 . . . . 0.0 110.93 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.7 tt0 -59.55 -42.89 93.4 Favored 'General case' 0 C--N 1.324 -0.539 0 C-N-CA 123.237 0.615 . . . . 0.0 110.168 -179.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 23.2 t -66.49 -38.96 88.41 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.247 -178.632 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -63.13 -50.22 71.33 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.554 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.3 -37.59 83.75 Favored 'General case' 0 CA--C 1.539 0.526 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.261 178.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.34 -30.54 71.24 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.657 0.741 . . . . 0.0 110.502 177.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.4 m -82.36 -27.48 32.12 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.521 -178.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.554 HG12 ' O ' ' B' ' 76' ' ' ALA . 3.9 p -72.03 -31.34 39.88 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.453 0 CA-C-O 121.396 0.617 . . . . 0.0 109.56 -176.126 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 19.4 mt -67.12 -17.35 64.82 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.918 -1.037 . . . . 0.0 111.322 176.519 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 22.1 mtm180 -100.72 -7.9 23.34 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-O 121.292 0.568 . . . . 0.0 110.31 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -89.99 -15.01 32.78 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 121.744 0.783 . . . . 0.0 109.655 176.255 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.655 ' HB ' HG11 ' B' ' 87' ' ' VAL . 9.3 p -92.06 167.2 12.24 Favored 'General case' 0 N--CA 1.412 -2.351 0 CA-C-N 115.261 -0.881 . . . . 0.0 111.855 179.191 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -76.88 -167.49 0.86 Allowed 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.277 -0.874 . . . . 0.0 112.876 177.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.26 -13.33 79.09 Favored Glycine 0 C--O 1.207 -1.555 0 CA-C-N 114.738 -1.119 . . . . 0.0 112.732 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . 0.453 ' HD3' ' O ' ' B' ' 10' ' ' LEU . 4.4 tpp180 -137.74 116.3 12.08 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 175.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.655 HG11 ' HB ' ' B' ' 83' ' ' THR . 6.3 m -149.12 157.59 6.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 122.969 0.508 . . . . 0.0 110.534 -179.06 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 77.0 mtm180 -96.18 170.18 9.44 Favored 'General case' 0 C--N 1.287 -2.145 0 CA-C-N 114.545 -1.207 . . . . 0.0 108.246 176.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.555 ' CE2' HD11 ' B' ' 54' ' ' ILE . 3.4 m-85 -150.9 162.16 41.32 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 105.163 -2.162 . . . . 0.0 105.163 175.397 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.543 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 66.4 mtm -115.54 114.45 24.99 Favored 'General case' 0 C--N 1.286 -2.195 0 CA-C-O 121.721 0.772 . . . . 0.0 110.139 170.548 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.45 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -97.38 127.33 49.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.73 0 CA-C-N 113.819 -1.537 . . . . 0.0 108.024 -176.566 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . 0.408 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -106.83 118.05 5.51 Favored Glycine 0 CA--C 1.466 -3.014 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 176.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . 0.522 ' O ' ' HA ' ' B' ' 3' ' ' MET . 9.9 tpp180 . . . . . 0 C--N 1.288 -2.084 0 CA-C-N 115.067 -0.567 . . . . 0.0 110.416 178.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 68.5 mtm . . . . . 0 N--CA 1.424 -1.752 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -76.03 102.12 5.53 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.507 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 0.6 OUTLIER -85.93 84.64 7.48 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.056 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -113.49 142.93 28.42 Favored Pre-proline 0 C--N 1.301 -1.522 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.906 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . 0.454 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 59.0 Cg_endo -80.0 131.59 9.03 Favored 'Trans proline' 0 N--CA 1.444 -1.391 0 C-N-CA 122.115 1.877 . . . . 0.0 113.396 179.238 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.469 HG13 ' HB3' ' B' ' 53' ' ' ARG . 75.9 t -119.08 141.23 39.97 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.998 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.502 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -129.82 139.67 51.18 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.496 HD12 HG13 ' B' ' 54' ' ' ILE . 1.0 OUTLIER -144.09 157.68 44.17 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.001 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.606 ' OE2' ' HD3' ' B' ' 86' ' ' ARG . 68.4 mm-40 -95.11 133.14 39.26 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 114.061 -1.427 . . . . 0.0 107.71 177.138 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . 0.429 ' HA ' HD13 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -80.73 135.3 35.97 Favored 'General case' 0 N--CA 1.426 -1.664 0 C-N-CA 118.928 -1.109 . . . . 0.0 108.491 173.815 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . 0.435 ' HB3' ' HB2' ' B' ' 47' ' ' ALA . 2.6 p30 -85.76 -178.12 6.54 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -174.059 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 18.9 m -68.93 -26.39 65.05 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.394 -175.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -81.91 -46.61 13.83 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 176.492 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 168.25 -85.07 0.09 OUTLIER Glycine 0 N--CA 1.423 -2.225 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 177.569 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.429 HD13 ' HA ' ' B' ' 12' ' ' LYS . 27.2 tp -164.15 108.28 0.97 Allowed 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 175.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . 0.479 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -67.7 59.22 0.33 Allowed Glycine 0 C--O 1.215 -1.077 0 C-N-CA 124.704 1.145 . . . . 0.0 115.581 -173.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.478 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.8 pt -144.8 -178.42 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.267 -3.006 0 C-N-CA 125.565 1.546 . . . . 0.0 107.365 173.265 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.4 m -156.69 161.68 39.84 Favored 'General case' 0 C--N 1.272 -2.804 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.141 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.443 ' HB ' HG22 ' B' ' 37' ' ' ILE . 26.3 pt -124.43 153.52 31.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-N 117.99 0.359 . . . . 0.0 110.278 -179.513 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.2 tp -137.64 135.15 46.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.676 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.87 103.63 2.93 Favored Glycine 0 N--CA 1.421 -2.311 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.179 -178.616 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 25.9 mmt . . . . . 0 C--N 1.298 -1.657 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 176.49 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 2.9 mm? . . . . . 0 CA--C 1.48 -1.74 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -94.68 87.64 1.1 Allowed Glycine 0 N--CA 1.4 -3.764 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.443 HG22 ' HB ' ' B' ' 21' ' ' ILE . 20.7 mm -82.99 78.38 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.362 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 173.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -81.56 169.77 16.67 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 114.193 -1.367 . . . . 0.0 109.371 -172.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 79.4 t -75.69 128.98 37.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-O 121.372 0.606 . . . . 0.0 109.814 176.231 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 9.2 tmtm? -84.5 -54.42 4.76 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.11 -177.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 7.9 t -145.7 175.2 10.56 Favored 'General case' 0 N--CA 1.429 -1.508 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 179.182 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.478 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.5 p -154.88 96.4 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 -179.378 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.425 HG22 ' H ' ' B' ' 45' ' ' GLY . 6.0 m -78.25 134.96 37.48 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 113.59 -1.641 . . . . 0.0 111.514 -170.621 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -61.87 -12.8 19.46 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.004 0.922 . . . . 0.0 113.238 178.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . 0.425 ' H ' HG22 ' B' ' 43' ' ' THR . . . -86.18 -2.05 85.98 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 116.528 -0.306 . . . . 0.0 112.455 177.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.479 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -115.88 169.97 13.15 Favored Glycine 0 N--CA 1.418 -2.544 0 C-N-CA 120.291 -0.957 . . . . 0.0 111.823 179.169 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . 0.435 ' HB2' ' HB3' ' B' ' 13' ' ' ASP . . . -69.28 -36.26 76.88 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 114.882 -0.659 . . . . 0.0 111.745 -175.088 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -57.03 -40.52 76.9 Favored 'General case' 0 CA--C 1.542 0.657 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -175.417 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -71.34 -42.46 68.51 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.213 0.53 . . . . 0.0 110.209 -179.081 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -75.09 -28.52 60.32 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.952 -175.345 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -80.75 -41.79 22.92 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.723 -177.582 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 83.78 43.24 7.33 Favored Glycine 0 C--N 1.309 -0.924 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.576 176.447 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.533 ' HA ' ' HE ' ' B' ' 53' ' ' ARG . 1.4 mmp_? -115.22 -69.72 0.84 Allowed 'General case' 0 C--N 1.301 -1.537 0 CA-C-O 119.091 -0.48 . . . . 0.0 110.848 178.847 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.601 HD11 ' CE2' ' B' ' 89' ' ' PHE . 77.7 mt -73.55 136.97 24.25 Favored 'Isoleucine or valine' 0 C--O 1.253 1.241 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 171.755 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 19.6 mt-30 -118.21 162.51 18.12 Favored 'General case' 0 C--N 1.289 -2.04 0 C-N-CA 123.909 0.884 . . . . 0.0 109.639 -174.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.478 ' HB ' HG12 ' B' ' 42' ' ' VAL . 9.7 p -73.6 -4.34 5.29 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-O 121.695 0.76 . . . . 0.0 111.075 -178.384 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -116.55 -5.49 11.68 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -176.144 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -91.39 -175.39 4.22 Favored 'General case' 0 C--O 1.247 0.958 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 -175.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.528 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 35.6 tp -139.35 128.07 23.29 Favored 'General case' 0 N--CA 1.435 -1.212 0 CA-C-N 114.775 -1.102 . . . . 0.0 109.883 -174.043 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 57.0 mt -87.09 95.38 9.93 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.455 -0.942 . . . . 0.0 108.455 178.141 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.441 ' HB ' ' O ' ' B' ' 90' ' ' MET . 36.3 t -75.65 -43.07 41.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 CA-C-O 121.843 0.83 . . . . 0.0 111.301 -178.445 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.419 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 12.2 pt-20 -146.63 160.95 41.53 Favored 'General case' 0 C--N 1.267 -2.997 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 173.511 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.554 HG21 HG21 ' B' ' 83' ' ' THR . 4.8 p -113.18 -177.44 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.505 ' H ' HG22 ' B' ' 63' ' ' VAL . 31.2 t70 -49.53 -45.73 47.75 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -176.369 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -132.29 31.33 3.03 Favored Glycine 0 CA--C 1.522 0.525 0 C-N-CA 119.687 -1.244 . . . . 0.0 114.607 -177.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . 0.411 ' HB ' HG12 ' B' ' 63' ' ' VAL . 36.1 m -159.73 135.47 8.51 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . 0.419 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 30.5 m -108.64 146.83 32.78 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.43 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 43.6 mt -104.31 115.05 29.7 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-O 120.938 0.399 . . . . 0.0 110.66 176.49 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 12.3 p -81.38 -20.39 10.95 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 N-CA-C 108.544 -0.909 . . . . 0.0 108.544 174.529 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 140.79 71.27 0.04 OUTLIER Glycine 0 CA--C 1.487 -1.672 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 -177.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.9 m -92.79 179.33 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 114.856 -0.672 . . . . 0.0 110.681 -175.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 43.5 p -82.86 165.28 19.93 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 177.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -59.45 -42.11 91.2 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.949 0.404 . . . . 0.0 110.108 179.37 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 48.5 m -66.5 -35.92 81.46 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.473 -179.413 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -66.61 -46.67 75.09 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.401 ' O ' ' HB ' ' B' ' 79' ' ' VAL . . . -60.52 -41.56 94.65 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.132 178.149 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.25 -34.96 75.99 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.072 178.268 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 24.5 m -76.9 -20.92 55.66 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.984 -179.018 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.401 ' HB ' ' O ' ' B' ' 76' ' ' ALA . 24.3 t -71.37 -57.11 8.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 16.6 mt -57.79 -18.59 22.74 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 125.325 1.45 . . . . 0.0 112.964 178.205 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 69.9 mtp180 -88.94 -18.09 28.2 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-O 121.279 0.561 . . . . 0.0 110.813 176.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -99.71 -6.19 27.54 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.729 0.776 . . . . 0.0 110.749 -176.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.554 HG21 HG21 ' B' ' 63' ' ' VAL . 18.9 p -82.41 165.96 19.81 Favored 'General case' 0 C--O 1.249 1.07 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 -178.482 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 57.7 mmtt -73.1 -167.58 0.41 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 124.594 1.158 . . . . 0.0 112.012 179.052 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.05 -34.23 55.87 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-N 115.509 -0.769 . . . . 0.0 112.516 -179.307 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . 0.606 ' HD3' ' OE2' ' B' ' 11' ' ' GLU . 45.5 ttp180 -134.69 124.69 25.68 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 175.621 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.539 HG11 ' HB ' ' B' ' 83' ' ' THR . 13.7 m -137.13 160.32 36.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.915 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -102.15 163.11 12.42 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 176.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.601 ' CE2' HD11 ' B' ' 54' ' ' ILE . 4.9 m-85 -140.44 155.99 46.52 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 179.072 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.441 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 9.5 ttt -110.22 115.07 29.05 Favored 'General case' 0 C--N 1.275 -2.631 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 174.082 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.528 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -92.29 138.45 19.92 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.342 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -177.679 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.26 112.99 1.29 Allowed Glycine 0 CA--C 1.486 -1.742 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 175.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 18.1 tpp180 . . . . . 0 C--N 1.286 -2.156 0 CA-C-N 115.099 -0.55 . . . . 0.0 109.757 -179.126 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 64.4 mtm . . . . . 0 N--CA 1.423 -1.779 0 N-CA-C 104.466 -2.42 . . . . 0.0 104.466 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . 0.533 ' HB2' ' HB3' ' B' ' 93' ' ' ARG . 12.0 mt-10 -94.3 93.36 7.68 Favored 'General case' 0 C--N 1.289 -2.036 0 C-N-CA 118.46 -1.296 . . . . 0.0 110.4 -175.581 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -82.52 95.85 7.85 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 177.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 7.1 p90 -119.46 144.33 36.41 Favored Pre-proline 0 C--N 1.279 -2.48 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.128 176.575 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . 0.596 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 30.4 Cg_endo -72.87 129.46 14.39 Favored 'Trans proline' 0 N--CA 1.432 -2.099 0 C-N-CA 122.005 1.803 . . . . 0.0 112.242 176.719 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.492 ' HB ' HD13 ' B' ' 91' ' ' ILE . 70.5 t -115.02 122.02 68.28 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.046 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 177.527 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . 0.485 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 31.8 tt0 -105.58 132.22 52.0 Favored 'General case' 0 C--N 1.269 -2.895 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -176.574 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.601 HD11 ' HB2' ' B' ' 48' ' ' ALA . 0.6 OUTLIER -124.09 159.77 29.21 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 175.264 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.411 ' H ' HD23 ' B' ' 10' ' ' LEU . 4.5 pt-20 -132.12 125.81 32.2 Favored 'General case' 0 C--N 1.26 -3.322 0 CA-C-N 113.919 -1.491 . . . . 0.0 107.187 178.187 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt -66.14 151.88 45.98 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 121.938 0.875 . . . . 0.0 112.608 -178.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -102.66 178.34 4.6 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 14.7 m -67.79 -26.5 66.12 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 121.7 0.762 . . . . 0.0 109.035 175.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -72.74 -21.28 61.05 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-N 114.62 -1.173 . . . . 0.0 109.607 173.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.62 -105.12 2.7 Favored Glycine 0 N--CA 1.422 -2.236 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -176.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 94.8 mt -109.79 -176.87 3.12 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.1 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . 0.409 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -156.19 61.62 0.35 Allowed Glycine 0 CA--C 1.476 -2.383 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.22 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.586 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 3.1 pt -161.46 175.78 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.481 -1.693 0 C-N-CA 124.557 1.143 . . . . 0.0 108.157 -176.654 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . 0.443 ' HB2' HG22 ' B' ' 41' ' ' THR . 54.9 m -148.59 151.7 35.49 Favored 'General case' 0 C--N 1.262 -3.2 0 N-CA-C 105.854 -1.906 . . . . 0.0 105.854 174.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.494 ' HB ' HG22 ' B' ' 37' ' ' ILE . 16.6 pt -116.94 162.06 15.2 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.537 0 O-C-N 123.421 0.45 . . . . 0.0 110.613 -176.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.5 tp -146.84 137.61 17.92 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.19 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.98 111.41 3.73 Favored Glycine 0 N--CA 1.431 -1.668 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.482 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 85.9 mtp . . . . . 0 C--N 1.305 -1.341 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 176.993 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . 0.594 ' O ' ' HA2' ' B' ' 70' ' ' GLY . 85.9 mt . . . . . 0 N--CA 1.442 -0.844 0 CA-C-O 121.881 0.848 . . . . 0.0 111.764 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -101.7 115.48 5.27 Favored Glycine 0 N--CA 1.4 -3.722 0 N-CA-C 106.903 -2.479 . . . . 0.0 106.903 176.11 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.494 HG22 ' HB ' ' B' ' 21' ' ' ILE . 29.1 mm -89.03 88.17 2.9 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 -177.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.478 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 73.5 m-85 -83.32 171.72 13.26 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 114.716 -1.129 . . . . 0.0 109.419 -177.664 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 58.9 t -78.19 136.22 24.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.67 0.748 . . . . 0.0 110.053 176.448 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -92.68 -48.13 6.74 Favored 'General case' 0 N--CA 1.426 -1.672 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.131 177.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . 0.443 HG22 ' HB2' ' B' ' 20' ' ' SER . 1.0 OUTLIER -154.13 167.27 30.43 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -178.44 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.586 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.4 p -133.92 96.66 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.065 0 CA-C-O 122.389 1.09 . . . . 0.0 109.821 176.697 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 27.9 m -59.87 125.57 24.17 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 113.257 -1.792 . . . . 0.0 112.2 -175.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . 0.47 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 45.4 mt-10 -61.27 -35.07 76.31 Favored 'General case' 0 CA--C 1.516 -0.35 0 C-N-CA 124.21 1.004 . . . . 0.0 111.889 -176.122 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.79 -10.13 84.95 Favored Glycine 0 N--CA 1.441 -1.015 0 CA-C-N 115.861 -0.609 . . . . 0.0 113.415 -179.295 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.478 ' O ' ' HG3' ' B' ' 50' ' ' ARG . . . -106.23 171.2 17.38 Favored Glycine 0 N--CA 1.417 -2.629 0 C-N-CA 119.828 -1.177 . . . . 0.0 113.85 -175.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.26 -50.59 38.21 Favored 'General case' 0 C--O 1.208 -1.131 0 C-N-CA 125.213 1.405 . . . . 0.0 114.788 -173.52 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . 0.601 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -63.96 -32.44 73.97 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 113.88 1.067 . . . . 0.0 113.88 -172.018 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . 0.47 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 2.7 t60 -83.75 -38.8 20.89 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.128 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . 0.478 ' HG3' ' O ' ' B' ' 46' ' ' GLY . 74.9 mtp180 -70.32 -42.52 71.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.072 -178.683 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -74.09 -43.08 58.97 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 89.98 51.49 2.8 Favored Glycine 0 CA--C 1.504 -0.608 0 CA-C-N 115.113 -0.949 . . . . 0.0 112.406 175.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 34.0 mmt180 -112.94 -82.84 0.59 Allowed 'General case' 0 N--CA 1.442 -0.868 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.053 -177.356 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.463 HD11 ' CE2' ' B' ' 89' ' ' PHE . 70.7 mt -65.52 134.87 29.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 O-C-N 123.774 0.671 . . . . 0.0 109.396 179.648 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 24.4 mm-40 -111.95 164.77 12.74 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.416 HG23 ' HA ' ' B' ' 41' ' ' THR . 14.9 p -65.0 -8.34 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.578 2.028 0 N-CA-C 113.093 0.775 . . . . 0.0 113.093 -175.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -115.3 -6.09 12.37 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 -172.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -94.25 179.2 5.38 Favored 'General case' 0 N--CA 1.432 -1.373 0 N-CA-C 114.998 1.481 . . . . 0.0 114.998 -178.513 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.478 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 25.8 tp -135.25 136.69 41.89 Favored 'General case' 0 C--O 1.247 0.933 0 CA-C-N 114.958 -1.019 . . . . 0.0 110.954 -172.269 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 52.6 mt -83.82 96.84 8.89 Favored 'General case' 0 N--CA 1.425 -1.69 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 176.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.501 ' HB ' ' O ' ' B' ' 90' ' ' MET . 35.0 t -69.74 -42.75 80.28 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-O 122.159 0.98 . . . . 0.0 109.752 179.314 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -156.94 158.87 37.43 Favored 'General case' 0 C--N 1.277 -2.572 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.821 173.056 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.449 HG23 ' CD1' ' B' ' 89' ' ' PHE . 5.0 p -106.36 -175.9 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.099 0 N-CA-C 104.796 -2.298 . . . . 0.0 104.796 178.297 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.524 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 8.9 t70 -52.44 -54.47 31.77 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 112.792 0.664 . . . . 0.0 112.792 178.459 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -122.29 35.73 3.4 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 119.81 -1.186 . . . . 0.0 115.277 -177.072 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . 0.448 ' HB ' HG12 ' B' ' 63' ' ' VAL . 19.2 m -160.9 141.64 11.5 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 177.45 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 47.3 t -107.02 151.37 25.42 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 -178.628 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.456 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.6 mm? -116.27 106.28 13.5 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 120.98 0.419 . . . . 0.0 110.434 178.609 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 42.6 t -103.51 -8.09 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-O 122.221 1.01 . . . . 0.0 109.096 176.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . 0.594 ' HA2' ' O ' ' B' ' 35' ' ' LEU . . . 131.52 78.02 0.16 Allowed Glycine 0 CA--C 1.484 -1.898 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -177.47 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.431 HG22 HD12 ' B' ' 68' ' ' LEU . 26.4 m -106.13 -175.08 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.098 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -175.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . 0.41 ' O ' HG23 ' B' ' 71' ' ' VAL . 45.7 p -83.86 159.8 21.28 Favored 'General case' 0 N--CA 1.426 -1.655 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 175.061 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.0 tt0 -63.26 -31.37 72.51 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-O 121.519 0.676 . . . . 0.0 109.567 178.564 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 9.7 m -64.89 -43.18 93.75 Favored 'General case' 0 C--O 1.247 0.948 0 CA-C-N 115.052 -0.977 . . . . 0.0 110.051 177.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -62.27 -51.89 65.9 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 115.212 -0.904 . . . . 0.0 108.782 177.46 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.673 ' O ' ' HB ' ' B' ' 79' ' ' VAL . . . -57.61 -37.55 73.45 Favored 'General case' 0 C--O 1.214 -0.814 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.434 -178.131 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.84 -32.64 73.31 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.174 0.512 . . . . 0.0 111.037 178.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 19.0 m -79.36 -19.65 49.71 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.767 179.535 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.673 ' HB ' ' O ' ' B' ' 76' ' ' ALA . 3.9 t -57.15 -57.46 9.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.447 1.099 . . . . 0.0 111.843 177.072 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . 0.511 HD22 ' H ' ' B' ' 80' ' ' LEU . 2.6 mm? -58.62 -30.15 67.04 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 122.822 0.449 . . . . 0.0 111.781 178.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 31.6 mtp85 -80.76 -16.76 52.99 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.785 -179.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -81.97 -27.91 32.97 Favored 'General case' 0 N--CA 1.44 -0.973 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.611 ' HB ' HG11 ' B' ' 87' ' ' VAL . 12.5 p -88.99 159.86 17.4 Favored 'General case' 0 N--CA 1.417 -2.088 0 CA-C-N 114.882 -1.054 . . . . 0.0 112.887 179.05 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 72.5 mttt -64.6 -174.91 0.15 Allowed 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 124.914 1.286 . . . . 0.0 113.682 -177.114 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.94 -42.53 94.78 Favored Glycine 0 N--CA 1.445 -0.762 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.985 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 56.9 ttm-85 -123.13 118.46 27.73 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 176.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.611 HG11 ' HB ' ' B' ' 83' ' ' THR . 6.2 m -146.41 156.3 11.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.786 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.256 -178.037 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . 0.485 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 95.5 mtt180 -105.71 125.54 51.11 Favored 'General case' 0 N--CA 1.423 -1.799 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.47 177.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.596 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 1.8 m-85 -100.32 166.79 10.79 Favored 'General case' 0 C--N 1.27 -2.856 0 N-CA-C 106.026 -1.842 . . . . 0.0 106.026 176.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.501 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 64.3 mtt -113.3 112.92 24.52 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 171.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.492 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.4 mp -97.25 128.77 48.18 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -101.39 100.89 2.15 Favored Glycine 0 CA--C 1.46 -3.356 0 N-CA-C 108.522 -1.831 . . . . 0.0 108.522 176.338 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . 0.533 ' HB3' ' HB2' ' B' ' 4' ' ' GLU . 21.2 tpp180 . . . . . 0 C--N 1.277 -2.547 0 CA-C-N 114.398 -0.901 . . . . 0.0 109.991 -177.218 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 1.7 mpt? . . . . . 0 N--CA 1.432 -1.352 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -75.97 98.55 4.3 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 177.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -81.28 88.97 6.04 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 175.77 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -109.92 145.31 31.78 Favored Pre-proline 0 C--N 1.288 -2.077 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.672 178.781 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -75.91 129.92 11.94 Favored 'Trans proline' 0 N--CA 1.44 -1.66 0 C-N-CA 122.19 1.926 . . . . 0.0 111.97 177.65 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.521 HG13 ' HB3' ' B' ' 53' ' ' ARG . 84.9 t -116.61 126.2 73.96 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.401 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.331 -179.071 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . 0.477 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 41.4 tt0 -120.81 128.78 53.18 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -178.675 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.557 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -115.41 -162.59 0.84 Allowed 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.796 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.518 ' H ' HD22 ' B' ' 10' ' ' LEU . 2.3 mm-40 -156.67 167.69 29.69 Favored 'General case' 0 C--N 1.29 -1.998 0 C-N-CA 126.251 1.82 . . . . 0.0 106.145 176.353 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -92.81 -173.15 3.23 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 121.297 0.57 . . . . 0.0 111.35 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . 0.47 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 21.9 t70 -128.52 172.05 11.53 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 22.8 t -61.75 -30.98 71.14 Favored 'General case' 0 C--N 1.307 -1.251 0 O-C-N 123.789 0.681 . . . . 0.0 109.199 178.298 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -91.59 -51.95 5.0 Favored 'General case' 0 N--CA 1.446 -0.662 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 173.377 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.461 ' H ' ' HB3' ' B' ' 13' ' ' ASP . . . 126.47 133.27 3.83 Favored Glycine 0 N--CA 1.428 -1.848 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.977 178.043 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mm? 63.66 -168.66 0.2 Allowed 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 176.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.19 54.29 0.05 OUTLIER Glycine 0 C--O 1.209 -1.43 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 179.035 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.599 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 4.9 pt -166.91 177.62 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.493 -1.246 0 C-N-CA 125.068 1.347 . . . . 0.0 108.657 -173.707 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . 0.421 ' HB2' HG22 ' B' ' 41' ' ' THR . 39.1 m -151.95 144.92 24.47 Favored 'General case' 0 C--N 1.27 -2.853 0 N-CA-C 105.461 -2.051 . . . . 0.0 105.461 174.146 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.464 ' HB ' HG22 ' B' ' 37' ' ' ILE . 12.3 pt -111.1 160.76 10.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.054 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 -178.361 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.8 tp -138.75 138.17 42.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-O 120.939 0.399 . . . . 0.0 110.177 -178.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.72 98.7 2.3 Favored Glycine 0 N--CA 1.423 -2.221 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 177.453 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 86.4 mtp . . . . . 0 C--N 1.306 -1.29 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 178.922 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 77.6 mt . . . . . 0 C--O 1.248 0.996 0 CA-C-O 121.091 0.472 . . . . 0.0 111.483 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -113.59 123.42 6.13 Favored Glycine 0 N--CA 1.412 -2.935 0 N-CA-C 108.892 -1.683 . . . . 0.0 108.892 177.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.464 HG22 ' HB ' ' B' ' 21' ' ' ILE . 20.7 mm -93.81 89.21 2.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.375 -0.93 . . . . 0.0 108.91 -179.46 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.457 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 90.5 m-85 -89.69 169.6 11.17 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.598 -178.376 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 58.0 t -75.32 134.83 28.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 CA-C-O 121.29 0.567 . . . . 0.0 109.723 175.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -93.04 -45.71 7.79 Favored 'General case' 0 N--CA 1.435 -1.186 0 CA-C-N 115.337 -0.847 . . . . 0.0 108.835 -179.09 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . 0.433 ' HA ' HG23 ' B' ' 56' ' ' VAL . 2.5 t -155.21 169.2 24.72 Favored 'General case' 0 N--CA 1.419 -2.003 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.455 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.599 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.3 p -140.47 99.67 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.279 -2.496 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 -179.709 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 9.8 m -61.13 124.46 20.6 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 113.804 -1.543 . . . . 0.0 111.549 -175.095 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -69.92 -20.93 63.33 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.256 0.551 . . . . 0.0 111.863 -177.725 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.95 4.76 85.54 Favored Glycine 0 N--CA 1.437 -1.292 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.673 175.245 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -113.29 172.09 14.24 Favored Glycine 0 N--CA 1.425 -2.044 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.92 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . 0.47 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -64.86 -42.05 95.19 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -173.581 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . 0.557 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -58.85 -38.09 77.96 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 113.649 0.981 . . . . 0.0 113.649 -173.601 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -75.79 -41.07 53.95 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.244 0.545 . . . . 0.0 109.581 -177.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 64.4 mtp180 -68.18 -44.04 76.81 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.717 -178.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -63.21 -59.4 4.79 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.909 176.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 110.83 -15.53 28.78 Favored Glycine 0 N--CA 1.437 -1.233 0 C-N-CA 120.286 -0.959 . . . . 0.0 114.279 176.171 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.521 ' HB3' HG13 ' B' ' 8' ' ' VAL . 30.4 mmt180 -62.85 -52.33 63.55 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 114.131 1.16 . . . . 0.0 114.131 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.522 HD11 ' CE2' ' B' ' 89' ' ' PHE . 39.0 mt -95.7 119.01 43.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 C-N-CA 119.634 -0.826 . . . . 0.0 109.901 178.57 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 85.0 mm-40 -107.69 -179.92 4.05 Favored 'General case' 0 N--CA 1.433 -1.317 0 CA-C-O 121.269 0.557 . . . . 0.0 109.881 177.22 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.433 HG23 ' HA ' ' B' ' 41' ' ' THR . 12.7 p -71.02 -5.46 5.75 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.329 0 N-CA-C 113.087 0.773 . . . . 0.0 113.087 -174.681 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -117.12 4.24 12.7 Favored 'General case' 0 C--N 1.313 -0.996 0 O-C-N 121.06 -1.025 . . . . 0.0 111.354 -175.214 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -79.09 164.22 24.47 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.504 -175.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.457 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 23.2 tp -136.69 128.34 28.81 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 123.078 0.551 . . . . 0.0 110.349 -176.587 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 70.3 mt -79.78 92.36 5.43 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.749 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.529 ' HB ' ' O ' ' B' ' 90' ' ' MET . 40.8 t -76.31 -42.24 36.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-O 122.066 0.936 . . . . 0.0 109.749 178.394 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.415 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 8.6 pt-20 -154.23 147.49 24.84 Favored 'General case' 0 C--N 1.274 -2.697 0 CA-C-N 114.843 -1.072 . . . . 0.0 109.348 174.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.41 HG12 ' O ' ' B' ' 66' ' ' THR . 5.3 p -97.61 -174.98 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 104.349 -2.463 . . . . 0.0 104.349 174.524 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.55 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 28.8 t70 -56.37 -44.11 79.83 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 118.643 0.656 . . . . 0.0 112.563 -179.259 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -103.88 -66.57 0.72 Allowed Glycine 0 CA--C 1.528 0.85 0 C-N-CA 120.391 -0.909 . . . . 0.0 113.277 178.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . 0.41 ' O ' HG12 ' B' ' 63' ' ' VAL . 14.2 m -66.87 129.86 41.27 Favored 'General case' 0 CA--C 1.547 0.849 0 CA-C-O 121.135 0.493 . . . . 0.0 112.124 -177.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 4.4 m -95.15 139.48 31.43 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 177.157 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.512 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.3 mm? -101.44 125.97 48.15 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.696 0.76 . . . . 0.0 111.39 -179.009 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 8.8 p -125.13 9.57 4.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 115.163 -0.926 . . . . 0.0 109.104 178.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 120.09 87.89 1.05 Allowed Glycine 0 CA--C 1.499 -0.942 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -177.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.0 m -121.94 -179.11 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -177.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 32.3 p -83.88 164.16 19.62 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 175.543 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.3 tt0 -60.89 -41.23 95.63 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.278 0.561 . . . . 0.0 110.246 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 12.9 t -66.74 -36.41 82.38 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.282 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . 0.416 ' O ' HG13 ' B' ' 79' ' ' VAL . 38.0 t80 -62.29 -52.29 64.26 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -179.65 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.698 ' O ' HG22 ' B' ' 79' ' ' VAL . . . -65.93 -31.32 72.18 Favored 'General case' 0 C--O 1.218 -0.574 0 CA-C-O 120.978 0.418 . . . . 0.0 110.383 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.4 -34.54 77.96 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.757 0.789 . . . . 0.0 109.603 175.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.4 m -84.18 -17.14 40.94 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 115.194 -0.912 . . . . 0.0 112.112 -177.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.698 HG22 ' O ' ' B' ' 76' ' ' ALA . 23.5 m -68.81 -38.87 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 CA-C-O 121.53 0.681 . . . . 0.0 109.588 -178.439 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 23.5 mt -65.56 -21.31 66.59 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 125.193 1.397 . . . . 0.0 110.884 176.728 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 80.7 mtt180 -92.94 -14.36 27.65 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.491 -177.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -94.79 -22.28 18.17 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.669 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.705 ' HB ' HG11 ' B' ' 87' ' ' VAL . 6.6 p -80.77 -177.37 6.3 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.707 177.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -67.8 -171.48 0.21 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 123.484 0.714 . . . . 0.0 111.217 178.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -73.15 -42.05 44.94 Favored Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.134 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . 0.483 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 16.0 ttp180 -121.99 124.13 43.29 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 175.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.705 HG11 ' HB ' ' B' ' 83' ' ' THR . 5.2 m -137.86 165.58 25.93 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 CA-C-O 121.055 0.455 . . . . 0.0 110.858 178.084 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 51.8 mtp85 -106.52 147.91 28.84 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.405 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.522 ' CE2' HD11 ' B' ' 54' ' ' ILE . 0.7 OUTLIER -129.83 170.38 13.97 Favored 'General case' 0 C--N 1.277 -2.578 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 -179.224 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.529 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 59.8 mtt -121.16 122.93 41.06 Favored 'General case' 0 C--N 1.292 -1.923 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 168.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 1.3 mp -105.7 133.31 50.4 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 CA-C-N 114.194 -1.366 . . . . 0.0 107.446 -178.307 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -117.69 101.14 0.9 Allowed Glycine 0 CA--C 1.48 -2.113 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 177.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 19.2 tpp180 . . . . . 0 C--N 1.274 -2.685 0 CA-C-N 114.435 -0.883 . . . . 0.0 110.099 -176.18 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . 0.46 ' O ' HD22 ' B' ' 5' ' ' LEU . 25.5 mmt . . . . . 0 N--CA 1.432 -1.34 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -83.38 92.3 7.52 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 -175.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.46 HD22 ' O ' ' B' ' 3' ' ' MET . 0.7 OUTLIER -88.49 93.99 9.72 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 176.585 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -111.77 142.89 27.54 Favored Pre-proline 0 C--N 1.281 -2.395 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.539 179.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . 0.498 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 57.8 Cg_endo -78.64 132.82 11.17 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 122.319 2.013 . . . . 0.0 113.316 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.503 HG13 ' HB3' ' B' ' 53' ' ' ARG . 71.6 t -117.69 122.59 70.16 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -106.77 132.25 52.96 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.192 -175.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.434 HD21 ' HA ' ' B' ' 48' ' ' ALA . 1.0 OUTLIER -135.51 158.57 44.04 Favored 'General case' 0 N--CA 1.427 -1.607 0 CA-C-O 121.293 0.568 . . . . 0.0 110.743 176.606 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -145.37 161.37 39.82 Favored 'General case' 0 C--N 1.278 -2.515 0 CA-C-N 114.105 -1.407 . . . . 0.0 107.228 175.198 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 60.6 mttp -86.71 156.64 19.88 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-O 122.029 0.919 . . . . 0.0 113.259 -172.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -71.55 -69.95 0.35 Allowed 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 113.69 -1.595 . . . . 0.0 110.744 178.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 47.0 t -176.55 -39.62 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 105.398 -2.075 . . . . 0.0 105.398 -175.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -78.3 -57.02 4.0 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 172.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 161.61 -142.54 8.1 Favored Glycine 0 N--CA 1.428 -1.887 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 179.354 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -91.59 -174.47 3.88 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.392 0.615 . . . . 0.0 110.003 176.31 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -133.98 -113.78 1.42 Allowed Glycine 0 N--CA 1.419 -2.475 0 N-CA-C 108.411 -1.876 . . . . 0.0 108.411 176.443 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.56 HG22 ' HA ' ' B' ' 42' ' ' VAL . 24.0 pt 45.04 -177.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 C-N-CA 125.573 1.549 . . . . 0.0 114.993 178.22 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 43.8 m -157.87 146.39 19.13 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 104.823 -2.288 . . . . 0.0 104.823 173.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.525 ' HB ' HG22 ' B' ' 37' ' ' ILE . 12.5 pt -119.58 161.02 19.27 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.364 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . 0.415 ' HB ' ' CG ' ' B' ' 40' ' ' LYS . 8.7 tp -136.75 135.32 48.61 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 CA-C-O 120.964 0.412 . . . . 0.0 110.446 -176.363 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.33 103.24 3.02 Favored Glycine 0 N--CA 1.426 -2.011 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.025 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 68.6 mtm . . . . . 0 C--N 1.311 -1.067 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.266 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 97.6 mt . . . . . 0 N--CA 1.438 -1.042 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -108.54 114.15 4.01 Favored Glycine 0 N--CA 1.422 -2.269 0 C-N-CA 120.235 -0.984 . . . . 0.0 111.571 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.525 HG22 ' HB ' ' B' ' 21' ' ' ILE . 20.7 mm -95.32 88.19 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.521 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 175.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.411 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 96.1 m-85 -82.07 172.1 13.6 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 114.901 -1.045 . . . . 0.0 108.686 -178.192 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 45.5 t -79.17 142.58 13.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 175.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . 0.415 ' CG ' ' HB ' ' B' ' 22' ' ' ILE . 0.1 OUTLIER -103.08 -42.63 5.72 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 -178.363 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . 0.452 ' HA ' HG23 ' B' ' 56' ' ' VAL . 1.5 t -155.78 164.8 38.08 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 179.108 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.56 ' HA ' HG22 ' B' ' 19' ' ' ILE . 16.9 t -124.63 94.73 2.91 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.512 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 6.3 m -54.61 124.9 17.71 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 123.34 0.656 . . . . 0.0 111.517 179.752 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -62.09 -30.6 71.11 Favored 'General case' 0 C--O 1.222 -0.345 0 O-C-N 124.415 1.072 . . . . 0.0 112.26 -177.298 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.46 -23.46 77.05 Favored Glycine 0 N--CA 1.438 -1.172 0 C-N-CA 121.221 -0.514 . . . . 0.0 112.464 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.08 159.79 30.36 Favored Glycine 0 N--CA 1.416 -2.669 0 C-N-CA 119.692 -1.242 . . . . 0.0 113.158 -175.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -56.01 -38.31 70.34 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.27 -1.465 . . . . 0.0 112.458 -176.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . 0.434 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -59.03 -35.32 73.09 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -175.645 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 4.2 t60 -78.17 -40.69 36.99 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.491 0.663 . . . . 0.0 109.38 -179.223 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 65.6 mtp180 -73.86 -39.46 63.95 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 114.508 -1.223 . . . . 0.0 110.072 -174.484 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . 0.462 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 9.9 t70 -68.06 -60.08 2.76 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 173.174 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 97.69 11.38 50.82 Favored Glycine 0 N--CA 1.427 -1.919 0 CA-C-O 119.073 -0.849 . . . . 0.0 114.964 175.101 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.567 ' HA ' ' NE ' ' B' ' 53' ' ' ARG . 3.6 mmp_? -76.09 -50.25 15.21 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 118.655 1.227 . . . . 0.0 112.492 174.551 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.487 HD11 ' CE2' ' B' ' 89' ' ' PHE . 33.4 mt -77.36 141.02 16.14 Favored 'Isoleucine or valine' 0 C--O 1.249 1.072 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 175.538 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 72.5 mm-40 -114.54 -177.17 3.06 Favored 'General case' 0 N--CA 1.433 -1.315 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 -178.159 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.452 HG23 ' HA ' ' B' ' 41' ' ' THR . 8.4 p -90.45 3.55 6.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 CA-C-O 121.436 0.636 . . . . 0.0 111.416 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -119.38 -16.4 8.98 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 -174.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -76.39 178.65 6.39 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 114.491 1.293 . . . . 0.0 114.491 -173.43 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.47 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 27.8 tp -133.79 121.9 22.51 Favored 'General case' 0 N--CA 1.437 -1.113 0 CA-C-N 114.933 -1.03 . . . . 0.0 110.911 -172.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 74.6 mt -80.67 91.66 5.89 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.458 179.128 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.583 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 10.8 t -72.5 -37.43 57.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 123.189 0.596 . . . . 0.0 111.078 179.076 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.558 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 12.8 pt-20 -160.43 157.64 28.08 Favored 'General case' 0 C--N 1.28 -2.413 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.001 171.806 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.461 HG12 ' HB ' ' B' ' 66' ' ' THR . 5.6 p -101.82 -178.35 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 105.484 -2.043 . . . . 0.0 105.484 178.434 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.415 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 9.4 t70 -55.94 -53.64 54.39 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -178.556 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -112.17 22.14 18.71 Favored Glycine 0 C--N 1.318 -0.425 0 C-N-CA 120.151 -1.023 . . . . 0.0 114.703 -175.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . 0.461 ' HB ' HG12 ' B' ' 63' ' ' VAL . 32.3 m -153.89 115.19 4.13 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 117.859 0.83 . . . . 0.0 109.709 178.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . 0.558 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 45.6 m -87.09 138.05 31.82 Favored 'General case' 0 N--CA 1.433 -1.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.751 178.322 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.583 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 52.5 mt -107.71 101.54 10.84 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-O 120.918 0.39 . . . . 0.0 111.695 -178.294 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 12.2 p -71.39 -26.63 26.97 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 172.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 151.62 85.77 0.05 OUTLIER Glycine 0 N--CA 1.424 -2.165 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -178.406 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 33.0 m -105.72 -177.56 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 CA-C-N 115.141 -0.53 . . . . 0.0 109.82 -177.056 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 71.6 p -81.37 166.68 20.21 Favored 'General case' 0 N--CA 1.428 -1.559 0 CA-C-O 121.236 0.541 . . . . 0.0 110.112 177.148 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -62.18 -39.85 94.09 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.584 -0.735 . . . . 0.0 109.935 178.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 20.3 t -69.77 -39.02 76.9 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.092 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . 0.437 ' O ' HG13 ' B' ' 79' ' ' VAL . 17.8 t80 -60.4 -51.57 68.91 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 -179.611 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.631 ' O ' HG22 ' B' ' 79' ' ' VAL . . . -64.38 -33.56 76.13 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.113 179.426 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.46 -37.44 87.3 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.622 0.725 . . . . 0.0 109.709 176.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.6 p -79.1 -18.06 54.0 Favored 'General case' 0 N--CA 1.427 -1.592 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 178.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.631 HG22 ' O ' ' B' ' 76' ' ' ALA . 32.9 m -73.67 -36.17 46.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 121.976 0.894 . . . . 0.0 109.703 -178.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 51.9 mt -66.1 -26.69 67.58 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 114.245 -1.343 . . . . 0.0 110.914 177.151 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 23.0 mtp180 -96.1 -8.0 34.53 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -176.523 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 25.7 m-80 -102.28 -13.77 17.24 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 120.852 0.358 . . . . 0.0 111.634 178.072 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.604 ' HB ' HG11 ' B' ' 87' ' ' VAL . 2.6 p -81.79 173.29 12.42 Favored 'General case' 0 N--CA 1.426 -1.665 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.108 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 66.5 mmtt -65.06 -172.36 0.09 Allowed 'General case' 0 C--O 1.242 0.679 0 C-N-CA 124.151 0.98 . . . . 0.0 113.347 -176.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.06 -49.12 63.88 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.635 179.691 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 -125.51 121.27 33.21 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -178.208 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.604 HG11 ' HB ' ' B' ' 83' ' ' THR . 12.5 m -138.78 154.55 26.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 123.945 0.778 . . . . 0.0 111.396 -175.521 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 89.5 mtt180 -110.48 124.37 51.66 Favored 'General case' 0 N--CA 1.429 -1.521 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.917 178.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.498 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 4.8 m-85 -97.27 160.66 14.2 Favored 'General case' 0 C--N 1.28 -2.423 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 179.446 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.487 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 63.1 mtt -110.5 117.35 33.31 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 171.64 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.47 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -100.77 129.92 50.9 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.128 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -114.97 119.15 4.54 Favored Glycine 0 CA--C 1.473 -2.574 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.376 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 . . . . . 0 C--N 1.278 -2.526 0 CA-C-N 114.728 -0.736 . . . . 0.0 110.551 177.827 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . 0.474 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 25.4 ptp . . . . . 0 C--O 1.239 0.539 0 CA-C-O 121.421 0.629 . . . . 0.0 110.092 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -106.07 104.7 14.46 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -88.55 89.58 8.05 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 178.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -118.51 144.47 35.34 Favored Pre-proline 0 C--N 1.297 -1.699 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -178.518 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . 0.414 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 28.7 Cg_endo -80.95 127.8 6.3 Favored 'Trans proline' 0 N--CA 1.445 -1.38 0 C-N-CA 122.337 2.024 . . . . 0.0 112.629 177.531 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.561 HG13 ' HB3' ' B' ' 53' ' ' ARG . 76.0 t -112.49 134.73 54.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.032 0 CA-C-N 114.913 -1.039 . . . . 0.0 108.214 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . 0.46 ' OE2' ' HD3' ' B' ' 86' ' ' ARG . 34.9 tt0 -121.75 130.79 53.68 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -178.087 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.56 HD23 ' H ' ' B' ' 11' ' ' GLU . 0.5 OUTLIER -143.78 162.66 35.45 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.116 0.484 . . . . 0.0 111.075 -179.606 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.56 ' H ' HD23 ' B' ' 10' ' ' LEU . 6.7 mm-40 -86.97 156.75 19.66 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 125.172 1.389 . . . . 0.0 107.414 179.585 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 15.8 ptpt -79.28 -167.59 1.23 Allowed 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 122.11 0.957 . . . . 0.0 109.961 172.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . 0.433 ' HB3' ' N ' ' B' ' 17' ' ' LEU . 6.9 t70 -126.18 162.65 24.91 Favored 'General case' 0 C--N 1.285 -2.206 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 -179.036 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 31.0 t -61.54 -33.7 74.27 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 124.057 0.848 . . . . 0.0 110.658 -176.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -88.78 -51.86 5.43 Favored 'General case' 0 N--CA 1.437 -1.082 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 176.47 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.79 94.48 0.16 Allowed Glycine 0 N--CA 1.43 -1.7 0 CA-C-N 115.266 -0.879 . . . . 0.0 111.417 179.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.433 ' N ' ' HB3' ' B' ' 13' ' ' ASP . 3.8 mm? 59.64 98.02 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 124.605 1.162 . . . . 0.0 113.941 178.203 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -83.15 59.9 4.94 Favored Glycine 0 C--O 1.219 -0.843 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.576 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 6.7 pt -148.79 -175.51 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 C-N-CA 126.416 1.887 . . . . 0.0 107.072 179.024 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 66.7 m -151.27 146.99 26.43 Favored 'General case' 0 C--N 1.261 -3.271 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 176.293 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.44 ' HB ' HG22 ' B' ' 37' ' ' ILE . 13.9 pt -113.49 157.86 14.04 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 O-C-N 123.405 0.44 . . . . 0.0 110.072 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . 0.444 ' HB ' ' HB2' ' B' ' 40' ' ' LYS . 8.5 tp -131.94 130.24 61.22 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.84 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.67 89.85 1.62 Allowed Glycine 0 N--CA 1.408 -3.186 0 C-N-CA 120.926 -0.654 . . . . 0.0 111.819 -177.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 25.4 mmt . . . . . 0 N--CA 1.434 -1.262 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 176.146 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 88.3 mt . . . . . 0 N--CA 1.437 -1.111 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -112.44 95.01 0.76 Allowed Glycine 0 N--CA 1.429 -1.815 0 C-N-CA 120.021 -1.085 . . . . 0.0 110.882 179.409 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.44 HG22 ' HB ' ' B' ' 21' ' ' ILE . 16.4 mm -87.84 85.33 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 CA-C-O 121.905 0.86 . . . . 0.0 109.237 179.65 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -84.71 175.47 9.17 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.898 -178.544 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 48.5 t -79.92 142.35 14.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 175.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . 0.444 ' HB2' ' HB ' ' B' ' 22' ' ' ILE . 87.5 tttt -100.82 -51.84 3.46 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.654 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -149.53 162.88 39.29 Favored 'General case' 0 N--CA 1.417 -2.102 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -175.537 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.576 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.4 p -140.84 105.48 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.04 0 CA-C-O 121.836 0.826 . . . . 0.0 109.839 178.271 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 16.5 m -62.95 125.97 25.77 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-N 114.355 -1.293 . . . . 0.0 111.566 -175.414 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . 0.449 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 11.1 pt-20 -65.47 -23.2 66.85 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.395 -178.063 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -83.65 3.96 83.57 Favored Glycine 0 N--CA 1.441 -0.992 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.23 177.033 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -108.07 164.49 12.82 Favored Glycine 0 N--CA 1.424 -2.156 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.208 179.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -65.57 -36.33 83.46 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-N 114.279 -0.96 . . . . 0.0 112.357 -176.501 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.72 -38.44 90.49 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -175.046 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . 0.449 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 7.9 t60 -69.91 -41.9 74.08 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 121.499 0.666 . . . . 0.0 109.713 -178.398 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 23.9 mtp180 -75.49 -35.76 60.74 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.697 -174.74 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . 0.439 ' CB ' HD21 ' B' ' 10' ' ' LEU . 16.8 t70 -64.4 -63.64 1.08 Allowed 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.088 175.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 117.88 -20.25 10.86 Favored Glycine 0 N--CA 1.428 -1.9 0 C-N-CA 119.871 -1.157 . . . . 0.0 114.027 178.185 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.561 ' HB3' HG13 ' B' ' 8' ' ' VAL . 12.9 mmt180 -62.11 -62.83 1.5 Allowed 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 113.718 1.006 . . . . 0.0 113.718 179.588 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.644 HD11 ' CE2' ' B' ' 89' ' ' PHE . 62.9 mt -77.36 109.0 11.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 C-N-CA 119.374 -0.93 . . . . 0.0 109.137 174.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 79.6 mm-40 -102.01 173.89 6.18 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 121.163 0.506 . . . . 0.0 110.549 175.012 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.5 p -63.88 -12.97 12.6 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 114.165 1.172 . . . . 0.0 114.165 -173.381 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -125.62 16.89 8.15 Favored 'General case' 0 C--N 1.311 -1.091 0 O-C-N 120.976 -1.078 . . . . 0.0 111.145 -176.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 25.7 m-20 -83.22 172.6 12.44 Favored 'General case' 0 C--N 1.317 -0.812 0 O-C-N 121.362 -0.836 . . . . 0.0 111.084 179.098 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.494 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 29.7 tp -128.51 116.06 19.11 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 120.563 0.221 . . . . 0.0 110.808 -175.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 32.8 mt -93.17 95.29 9.31 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 179.126 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.709 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 96.3 t -73.19 -65.3 0.68 Allowed 'Isoleucine or valine' 0 C--O 1.175 -2.845 0 C-N-CA 120.607 -0.437 . . . . 0.0 109.83 178.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.461 ' O ' ' HA ' ' B' ' 89' ' ' PHE . 8.6 pt-20 -129.05 157.26 42.22 Favored 'General case' 0 C--N 1.272 -2.787 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -177.019 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.559 HG21 HG21 ' B' ' 83' ' ' THR . 5.0 p -103.51 -176.19 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.554 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 -178.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.516 ' H ' HG22 ' B' ' 63' ' ' VAL . 27.5 t70 -51.25 -54.9 21.44 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 114.174 1.176 . . . . 0.0 114.174 -177.082 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -121.53 27.67 6.22 Favored Glycine 0 C--N 1.315 -0.591 0 C-N-CA 120.252 -0.975 . . . . 0.0 114.486 -175.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 51.4 m -152.57 120.67 6.22 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 176.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 19.7 m -94.21 111.38 23.11 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.168 -175.61 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.709 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 51.3 mt -89.57 121.36 31.7 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 176.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 14.8 p -83.74 -22.18 8.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.372 0.605 . . . . 0.0 109.565 177.451 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 145.88 69.16 0.01 OUTLIER Glycine 0 CA--C 1.487 -1.706 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 -177.318 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 34.9 m -90.6 -178.66 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 CA-C-N 114.563 -0.819 . . . . 0.0 109.742 -177.125 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 32.3 p -78.19 164.66 24.75 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 120.825 0.345 . . . . 0.0 111.066 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.3 tt0 -58.9 -40.43 84.45 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 123.429 0.692 . . . . 0.0 110.15 179.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 30.3 t -66.83 -36.48 82.45 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.323 -179.386 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -68.37 -47.84 66.35 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -179.649 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.539 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -62.6 -39.31 93.35 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.929 178.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.33 -39.77 91.76 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-O 121.178 0.513 . . . . 0.0 111.153 178.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 13.3 p -82.1 -10.76 59.09 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -177.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.539 HG12 ' O ' ' B' ' 76' ' ' ALA . 5.3 p -86.18 -34.65 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.383 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 58.9 mt -69.87 -20.22 63.4 Favored 'General case' 0 C--O 1.213 -0.848 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.437 176.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 77.0 mtp180 -94.57 4.11 54.26 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.588 0.709 . . . . 0.0 110.244 177.429 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.2 t30 -113.6 0.86 14.76 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.734 0.778 . . . . 0.0 110.424 -176.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.559 HG21 HG21 ' B' ' 63' ' ' VAL . 23.1 p -91.78 170.76 9.63 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.001 1.112 . . . . 0.0 114.001 -174.117 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.7 mmtt -73.88 -167.38 0.47 Allowed 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 124.795 1.238 . . . . 0.0 111.82 176.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.09 -33.93 84.95 Favored Glycine 0 C--O 1.225 -0.434 0 CA-C-N 115.628 -0.714 . . . . 0.0 113.274 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . 0.46 ' HD3' ' OE2' ' B' ' 9' ' ' GLU . 16.6 ttm180 -140.99 133.48 28.47 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 178.173 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.468 HG11 ' HB ' ' B' ' 83' ' ' THR . 11.9 m -139.02 164.51 25.27 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.031 0 CA-C-O 121.167 0.508 . . . . 0.0 111.591 178.886 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . 0.473 ' H ' ' HB2' ' B' ' 64' ' ' ASP . 54.3 mtm180 -100.01 159.03 15.4 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-N 114.649 -1.159 . . . . 0.0 108.221 176.448 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.644 ' CE2' HD11 ' B' ' 54' ' ' ILE . 4.9 m-85 -141.82 152.92 44.13 Favored 'General case' 0 C--N 1.283 -2.306 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 175.551 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.402 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 87.3 mmm -98.41 112.89 24.75 Favored 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 120.101 -0.64 . . . . 0.0 109.913 173.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.555 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.5 mp -101.8 117.2 46.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -179.159 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.89 101.28 2.07 Favored Glycine 0 CA--C 1.458 -3.498 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 174.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . 0.474 ' O ' ' HA ' ' B' ' 3' ' ' MET . 19.9 tpp180 . . . . . 0 C--N 1.276 -2.59 0 CA-C-N 114.478 -0.861 . . . . 0.0 109.884 178.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . 0.491 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 66.2 mtt . . . . . 0 N--CA 1.427 -1.605 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -94.54 101.55 13.45 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.276 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.46 90.71 8.47 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.33 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -119.29 144.59 36.66 Favored Pre-proline 0 C--N 1.29 -1.985 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.109 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . 0.433 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 56.4 Cg_endo -75.49 139.23 22.83 Favored 'Trans proline' 0 N--CA 1.446 -1.297 0 C-N-CA 122.271 1.981 . . . . 0.0 111.767 177.36 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.463 ' HB ' HD13 ' B' ' 91' ' ' ILE . 87.5 t -129.73 128.99 66.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -179.298 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . 0.52 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 38.6 tt0 -114.99 123.26 48.65 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.48 HD21 ' HA ' ' B' ' 48' ' ' ALA . 1.1 mt -132.93 164.05 27.79 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 178.143 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -123.56 137.49 54.75 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 174.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . 0.415 ' HB2' ' O ' ' B' ' 16' ' ' GLY . 18.3 ptmt -74.96 162.48 28.56 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.189 179.143 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -134.78 -166.13 1.77 Allowed 'General case' 0 C--N 1.291 -1.965 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.5 m -66.49 -22.31 66.19 Favored 'General case' 0 C--N 1.313 -1.003 0 C-N-CA 123.666 0.786 . . . . 0.0 111.598 -178.279 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -86.06 2.34 46.89 Favored 'General case' 0 CA--C 1.55 0.952 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 177.543 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.415 ' O ' ' HB2' ' B' ' 12' ' ' LYS . . . 85.06 -91.57 1.7 Allowed Glycine 0 N--CA 1.417 -2.58 0 N-CA-C 107.34 -2.304 . . . . 0.0 107.34 -175.077 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.405 ' HB3' HG12 ' B' ' 19' ' ' ILE . 3.5 mm? -124.75 134.14 52.91 Favored 'General case' 0 C--N 1.281 -2.396 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 174.719 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -83.45 53.3 4.84 Favored Glycine 0 C--O 1.216 -1.005 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.531 HG22 ' HA ' ' B' ' 42' ' ' VAL . 8.0 pt -161.87 176.56 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 C-N-CA 126.126 1.77 . . . . 0.0 107.491 -177.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . 0.402 ' HB2' HG22 ' B' ' 41' ' ' THR . 27.3 m -143.41 146.21 33.28 Favored 'General case' 0 C--N 1.268 -2.951 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 173.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.475 ' HB ' HG22 ' B' ' 37' ' ' ILE . 10.1 pt -114.31 162.56 12.33 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -179.164 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . 0.43 ' HB ' ' HB2' ' B' ' 40' ' ' LYS . 10.8 tp -137.89 138.37 44.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-O 121.041 0.448 . . . . 0.0 110.362 -177.714 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.54 108.58 3.45 Favored Glycine 0 N--CA 1.427 -1.94 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.662 178.304 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 22.7 mmt . . . . . 0 C--N 1.304 -1.371 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 177.65 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . 0.434 HD23 ' O ' ' B' ' 71' ' ' VAL . 14.5 tp . . . . . 0 N--CA 1.419 -2.017 0 N-CA-C 104.797 -2.297 . . . . 0.0 104.797 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -138.94 120.36 1.9 Allowed Glycine 0 C--N 1.273 -2.929 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.051 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.475 HG22 ' HB ' ' B' ' 21' ' ' ILE . 32.0 mm -96.84 89.22 2.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 179.23 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -84.31 170.88 13.2 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.55 -1.204 . . . . 0.0 108.192 -179.176 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 49.8 t -75.86 145.22 10.92 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 174.151 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . 0.43 ' HB2' ' HB ' ' B' ' 22' ' ' ILE . 2.0 tmmm? -105.08 -41.26 5.63 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 -179.522 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . 0.424 ' HA ' HG23 ' B' ' 56' ' ' VAL . 1.0 OUTLIER -158.39 164.15 36.58 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 -179.533 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.531 ' HA ' HG22 ' B' ' 19' ' ' ILE . 15.3 t -119.0 95.15 3.46 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 175.634 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.45 ' H ' ' HA ' ' B' ' 19' ' ' ILE . 7.0 m -64.09 121.03 13.21 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 123.976 0.91 . . . . 0.0 112.159 -175.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -69.59 -18.18 63.6 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.18 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.45 -11.77 84.09 Favored Glycine 0 N--CA 1.436 -1.313 0 C-N-CA 120.978 -0.629 . . . . 0.0 112.354 178.094 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -115.69 172.43 14.21 Favored Glycine 0 N--CA 1.426 -1.982 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.303 -178.591 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -67.53 -27.03 66.63 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 114.698 1.37 . . . . 0.0 114.698 -172.171 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . 0.48 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -63.72 -41.89 98.0 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 112.486 0.551 . . . . 0.0 112.486 -175.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -70.83 -38.01 73.23 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 121.807 0.813 . . . . 0.0 109.276 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 -72.7 -34.08 66.89 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 114.197 -1.365 . . . . 0.0 110.626 -174.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . 0.542 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 15.5 t0 -75.81 -52.87 9.44 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 175.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.82 29.62 8.03 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.546 -177.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.542 ' HG2' ' OD1' ' B' ' 51' ' ' ASP . 32.6 mmt180 -90.0 -81.74 0.28 Allowed 'General case' 0 CA--C 1.513 -0.478 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.455 HD11 ' CE2' ' B' ' 89' ' ' PHE . 81.3 mt -67.01 125.41 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 O-C-N 123.293 0.37 . . . . 0.0 110.197 176.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . 0.495 ' NE2' HH12 ' B' ' 93' ' ' ARG . 0.9 OUTLIER -104.39 161.61 13.93 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.635 -176.677 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.424 HG23 ' HA ' ' B' ' 41' ' ' THR . 7.3 p -62.43 -21.32 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 N-CA-C 115.771 1.767 . . . . 0.0 115.771 -168.22 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 -122.57 22.63 9.85 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.936 -1.106 . . . . 0.0 109.066 -176.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . 0.445 ' OD2' ' HB2' ' B' ' 55' ' ' GLN . 78.5 m-20 -87.96 170.9 10.74 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.976 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 28.2 tp -132.12 131.22 42.12 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.626 -178.157 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 78.9 mt -83.2 95.03 8.0 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 176.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.478 ' HB ' ' O ' ' B' ' 90' ' ' MET . 21.4 t -74.0 -40.96 52.7 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.886 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.448 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 11.3 pt-20 -160.56 149.66 17.07 Favored 'General case' 0 C--N 1.283 -2.307 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.482 176.22 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.407 HG12 ' O ' ' B' ' 66' ' ' THR . 4.8 p -98.27 -179.27 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 105.037 -2.209 . . . . 0.0 105.037 176.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.57 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 16.6 t70 -53.52 -53.33 53.04 Favored 'General case' 0 C--N 1.311 -1.076 0 N-CA-C 114.081 1.141 . . . . 0.0 114.081 -177.567 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -105.23 -1.77 41.4 Favored Glycine 0 C--N 1.312 -0.768 0 C-N-CA 119.408 -1.377 . . . . 0.0 115.509 -175.632 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . 0.407 ' O ' HG12 ' B' ' 63' ' ' VAL . 13.8 m -142.89 133.29 24.82 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 118.163 0.982 . . . . 0.0 110.011 -175.344 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . 0.448 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 13.0 t -94.15 157.15 16.21 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.72 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.45 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.3 mm? -118.25 115.21 24.27 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.956 0.408 . . . . 0.0 111.062 -179.075 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 13.8 p -97.52 -20.28 5.7 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-O 121.918 0.866 . . . . 0.0 109.497 175.437 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 143.52 86.15 0.08 OUTLIER Glycine 0 CA--C 1.485 -1.791 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -178.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.434 ' O ' HD23 ' B' ' 35' ' ' LEU . 33.5 m -109.46 -179.04 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.301 0 CA-C-N 115.032 -0.584 . . . . 0.0 109.515 -175.665 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 71.2 p -75.24 159.56 31.41 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 109.173 -0.676 . . . . 0.0 109.173 176.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.6 tt0 -62.17 -33.38 74.41 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.469 0.652 . . . . 0.0 110.046 -179.116 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 22.3 m -73.24 -37.37 66.38 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.004 178.159 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -62.41 -46.1 90.12 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.334 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.477 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -62.6 -42.42 99.57 Favored 'General case' 0 C--O 1.209 -1.075 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.747 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.0 -31.02 71.35 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 121.719 0.771 . . . . 0.0 111.057 178.788 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 33.4 t -90.47 -4.85 56.68 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.893 -179.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.477 HG12 ' O ' ' B' ' 76' ' ' ALA . 1.2 p -76.27 -31.98 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 C-N-CA 119.776 -0.77 . . . . 0.0 109.494 -177.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -67.86 -30.81 70.27 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.574 174.388 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -82.09 -7.59 59.62 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.648 -178.278 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -92.17 -23.11 19.49 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.989 178.259 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.516 ' HB ' HG11 ' B' ' 87' ' ' VAL . 11.6 p -97.46 -178.76 4.25 Favored 'General case' 0 N--CA 1.428 -1.535 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.241 177.479 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 65.3 mmtt -70.93 -171.56 0.56 Allowed 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 123.245 0.618 . . . . 0.0 111.387 177.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -78.39 -35.71 32.5 Favored Glycine 0 N--CA 1.442 -0.932 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.716 -178.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 29.5 ttt180 -123.13 117.33 25.15 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 176.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.57 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 7.8 m -148.5 160.02 6.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 123.878 0.736 . . . . 0.0 110.009 -177.371 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . 0.52 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 96.3 mtt180 -103.49 134.12 47.38 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.708 177.761 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.455 ' CE2' HD11 ' B' ' 54' ' ' ILE . 0.7 OUTLIER -112.93 166.37 11.46 Favored 'General case' 0 C--N 1.281 -2.407 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 178.879 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.478 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 85.0 mtp -111.66 114.55 27.65 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 171.381 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.463 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.4 mp -97.76 130.0 47.11 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.188 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -118.65 95.23 0.61 Allowed Glycine 0 CA--C 1.45 -3.97 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 177.003 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . 0.495 HH12 ' NE2' ' B' ' 55' ' ' GLN . 24.4 ttp180 . . . . . 0 C--N 1.268 -2.953 0 CA-C-N 114.322 -0.939 . . . . 0.0 111.716 -178.256 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 22.3 ptt? . . . . . 0 N--CA 1.421 -1.884 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . 0.502 ' OE2' ' HD2' ' B' ' 93' ' ' ARG . 15.4 mt-10 -87.07 101.3 13.33 Favored 'General case' 0 C--N 1.294 -1.831 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.038 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -90.34 88.49 7.22 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 174.09 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -110.82 145.15 31.78 Favored Pre-proline 0 C--N 1.29 -1.985 0 CA-C-N 116.119 -0.491 . . . . 0.0 112.027 -177.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . 0.53 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 60.1 Cg_endo -81.89 134.65 8.45 Favored 'Trans proline' 0 N--CA 1.439 -1.707 0 C-N-CA 122.142 1.894 . . . . 0.0 113.526 178.09 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 65.4 t -121.97 130.76 74.31 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 176.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -115.22 132.95 56.45 Favored 'General case' 0 C--N 1.294 -1.84 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.165 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.424 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -121.15 161.21 22.21 Favored 'General case' 0 CA--C 1.493 -1.231 0 CA-C-O 121.403 0.62 . . . . 0.0 111.251 179.562 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -132.94 132.99 42.61 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 107.41 -1.329 . . . . 0.0 107.41 174.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . 0.502 ' HA ' ' CB ' ' B' ' 47' ' ' ALA . 36.0 mtmm -97.43 160.31 14.4 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 121.467 0.651 . . . . 0.0 112.468 -171.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 m-20 -113.27 -168.27 1.31 Allowed 'General case' 0 C--N 1.308 -1.2 0 CA-C-N 114.882 -1.054 . . . . 0.0 109.652 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.1 m -60.27 -35.93 76.67 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 113.618 0.969 . . . . 0.0 113.618 -174.624 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -79.6 -22.08 44.15 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-O 121.641 0.734 . . . . 0.0 109.364 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.06 -132.02 10.78 Favored Glycine 0 N--CA 1.423 -2.205 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.139 178.623 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.423 ' HG ' HG12 ' B' ' 19' ' ' ILE . 24.0 tp -82.83 169.71 15.81 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -178.804 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . 0.514 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -149.54 66.24 0.38 Allowed Glycine 0 CA--C 1.48 -2.122 0 C-N-CA 119.805 -1.188 . . . . 0.0 112.442 -177.647 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.468 HG22 ' HA ' ' B' ' 42' ' ' VAL . 8.4 pt -160.14 172.17 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.486 -1.482 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 179.488 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . 0.424 ' HB2' HG22 ' B' ' 41' ' ' THR . 56.7 m -133.39 151.57 51.84 Favored 'General case' 0 C--N 1.257 -3.444 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 174.578 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.519 ' HB ' HG22 ' B' ' 37' ' ' ILE . 13.2 pt -121.59 148.2 25.15 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.681 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 -178.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.6 tp -119.02 132.49 68.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -179.374 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -96.56 97.97 2.11 Favored Glycine 0 N--CA 1.427 -1.951 0 C-N-CA 120.231 -0.985 . . . . 0.0 113.689 -174.408 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 82.3 mtp . . . . . 0 C--N 1.301 -1.537 0 N-CA-C 108.083 -1.081 . . . . 0.0 108.083 175.672 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 9.4 mp . . . . . 0 CA--C 1.488 -1.423 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -116.18 97.77 0.79 Allowed Glycine 0 N--CA 1.413 -2.858 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.917 -177.095 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.519 HG22 ' HB ' ' B' ' 21' ' ' ILE . 23.3 mm -92.98 87.69 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 174.771 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -85.17 164.44 18.11 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.614 -175.238 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 94.2 t -77.65 128.31 38.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 174.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -93.45 -37.45 11.95 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.123 0.487 . . . . 0.0 110.556 -176.003 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . 0.424 HG22 ' HB2' ' B' ' 20' ' ' SER . 0.6 OUTLIER -158.4 163.46 37.22 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 -178.51 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.468 ' HA ' HG22 ' B' ' 19' ' ' ILE . 19.4 t -120.54 96.22 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.71 0 N-CA-C 106.468 -1.679 . . . . 0.0 106.468 176.441 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 17.1 m -59.99 124.31 19.8 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 124.186 0.995 . . . . 0.0 112.183 -175.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . 0.576 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 36.0 mt-10 -55.14 -33.83 63.25 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 124.767 1.227 . . . . 0.0 112.628 -176.709 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.67 -18.79 78.87 Favored Glycine 0 N--CA 1.438 -1.214 0 CA-C-N 115.674 -0.694 . . . . 0.0 114.521 -177.016 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.514 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -106.03 170.37 16.74 Favored Glycine 0 N--CA 1.423 -2.228 0 C-N-CA 118.497 -1.811 . . . . 0.0 114.719 -173.602 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . 0.502 ' CB ' ' HA ' ' B' ' 12' ' ' LYS . . . -59.53 -33.64 71.65 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 113.605 -1.298 . . . . 0.0 114.401 -174.14 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . 0.424 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -65.69 -33.0 74.86 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.243 -176.596 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . 0.576 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 12.2 t60 -77.31 -40.6 43.75 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.532 178.147 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 40.0 mtp-105 -66.97 -39.61 87.25 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.602 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . 0.528 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 12.0 t70 -78.0 -58.22 3.38 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.136 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.71 -4.87 36.9 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.628 -0.796 . . . . 0.0 113.662 179.146 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.528 ' HG2' ' OD1' ' B' ' 51' ' ' ASP . 0.4 OUTLIER -54.16 -62.13 1.86 Allowed 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 179.183 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.55 HD11 ' CE2' ' B' ' 89' ' ' PHE . 35.1 mt -81.31 126.46 39.8 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.227 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -103.29 168.51 9.12 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.162 177.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.1 p -73.53 4.46 0.84 Allowed 'Isoleucine or valine' 0 CA--C 1.57 1.725 0 CA-C-O 121.981 0.896 . . . . 0.0 111.533 -177.109 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -117.85 5.58 12.21 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.281 1.039 . . . . 0.0 109.529 -177.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -87.34 161.68 17.79 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.701 -177.536 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.626 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 25.5 tp -138.31 127.21 23.88 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 123.494 0.717 . . . . 0.0 109.742 -175.471 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 66.0 mt -88.01 97.48 10.98 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.619 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 0.8 OUTLIER -92.9 -21.42 6.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-O 122.219 1.009 . . . . 0.0 109.5 -177.277 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.561 ' HG2' ' O ' ' B' ' 63' ' ' VAL . 30.9 tt0 -164.64 150.99 10.65 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 113.133 -1.848 . . . . 0.0 108.701 175.013 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.561 ' O ' ' HG2' ' B' ' 62' ' ' GLU . 6.2 p -93.18 -162.6 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.202 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 176.367 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.587 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 11.7 t70 -56.59 -54.31 47.41 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 123.277 0.631 . . . . 0.0 111.687 -178.749 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -113.64 -54.18 0.44 Allowed Glycine 0 N--CA 1.439 -1.162 0 C-N-CA 120.478 -0.868 . . . . 0.0 113.213 -178.643 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 25.6 m -62.87 115.25 4.2 Favored 'General case' 0 C--O 1.246 0.909 0 CA-C-O 121.744 0.783 . . . . 0.0 112.731 -175.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . 0.506 ' HA ' ' HG3' ' B' ' 62' ' ' GLU . 25.1 m -77.72 109.87 12.09 Favored 'General case' 0 N--CA 1.424 -1.75 0 C-N-CA 124.992 1.317 . . . . 0.0 113.397 -176.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.619 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 54.8 mt -90.88 -164.74 1.22 Allowed 'General case' 0 N--CA 1.421 -1.911 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 174.003 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 p 175.73 -30.86 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 106.236 -1.765 . . . . 0.0 106.236 178.368 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 169.02 77.06 0.04 OUTLIER Glycine 1 N--CA 1.39 -4.373 0 CA-C-N 114.48 -1.236 . . . . 0.0 111.227 -179.279 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 27.0 m -99.74 178.1 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.277 -2.581 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 34.6 p -76.84 161.74 28.19 Favored 'General case' 0 C--N 1.291 -1.95 0 C-N-CA 120.415 -0.514 . . . . 0.0 109.892 175.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -57.99 -40.77 81.55 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 123.829 0.851 . . . . 0.0 109.614 178.675 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 22.3 m -68.46 -38.57 81.22 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.077 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -62.93 -47.92 81.13 Favored 'General case' 0 C--O 1.24 0.566 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 178.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.572 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -58.75 -45.37 89.86 Favored 'General case' 0 C--O 1.208 -1.105 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.845 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.91 -36.82 77.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.982 0.42 . . . . 0.0 111.749 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 15.4 p -77.88 -14.83 59.43 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 112.967 0.729 . . . . 0.0 112.967 -179.5 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.572 HG12 ' O ' ' B' ' 76' ' ' ALA . 2.8 p -73.31 -37.3 51.36 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.952 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.071 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -59.64 -18.81 44.76 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.97 0.908 . . . . 0.0 112.433 176.541 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 6.6 mtp180 -100.21 -6.66 25.73 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 121.213 0.53 . . . . 0.0 111.918 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -114.95 10.69 16.37 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.41 0.624 . . . . 0.0 111.245 179.153 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.724 ' HB ' HG11 ' B' ' 87' ' ' VAL . 7.9 p -92.46 -173.42 3.38 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 115.491 -0.777 . . . . 0.0 112.298 178.513 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 44.9 mttm -76.67 -169.0 1.12 Allowed 'General case' 0 N--CA 1.437 -1.111 0 C-N-CA 123.506 0.722 . . . . 0.0 111.113 175.163 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -73.37 -49.69 14.52 Favored Glycine 0 N--CA 1.437 -1.274 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.056 176.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 16.2 ttm180 -118.38 121.44 40.37 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 176.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.724 HG11 ' HB ' ' B' ' 83' ' ' THR . 8.8 m -130.13 151.98 36.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 71.7 mtm180 -94.96 169.66 9.97 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 113.788 -1.551 . . . . 0.0 108.006 173.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.55 ' CE2' HD11 ' B' ' 54' ' ' ILE . 4.7 m-85 -144.14 151.1 39.1 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 176.053 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . . . . . . . . . 48.0 mtm -100.43 115.12 29.3 Favored 'General case' 0 N--CA 1.425 -1.698 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 173.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.626 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.5 mp -96.93 127.84 48.72 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.002 -179.142 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -108.36 120.87 6.1 Favored Glycine 0 N--CA 1.427 -1.962 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 177.312 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . 0.502 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 35.5 ttm180 . . . . . 0 C--N 1.281 -2.377 0 CA-C-N 115.207 -0.497 . . . . 0.0 109.731 178.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 66.8 mtt . . . . . 0 N--CA 1.431 -1.377 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 14.0 mt-10 -90.81 97.77 11.38 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 120.43 -0.508 . . . . 0.0 109.931 -173.044 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -86.87 93.56 9.34 Favored 'General case' 0 N--CA 1.439 -0.977 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 177.339 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -114.59 143.56 30.18 Favored Pre-proline 0 C--N 1.283 -2.286 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.851 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -74.21 132.89 17.11 Favored 'Trans proline' 0 N--CA 1.45 -1.054 0 C-N-CA 122.331 2.02 . . . . 0.0 113.493 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.517 ' HB ' HD13 ' B' ' 91' ' ' ILE . 77.6 t -124.66 123.82 66.79 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 CA-C-N 114.783 -1.099 . . . . 0.0 108.316 178.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -111.3 123.62 50.58 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -176.192 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.468 HD11 ' HB2' ' B' ' 48' ' ' ALA . 1.6 mt -117.46 177.01 4.9 Favored 'General case' 0 CA--C 1.489 -1.389 0 CA-C-O 121.233 0.539 . . . . 0.0 111.218 177.22 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -155.18 166.55 33.21 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . 0.435 ' HG2' ' CD1' ' B' ' 17' ' ' LEU . 10.1 mtmp? -116.11 160.72 19.96 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 118.407 0.549 . . . . 0.0 112.264 -176.157 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -97.79 -160.22 0.79 Allowed 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 169.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 17.6 m -69.6 -27.06 64.76 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 120.993 0.425 . . . . 0.0 110.221 177.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -75.9 -64.42 1.09 Allowed 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.96 75.63 0.68 Allowed Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.209 -0.996 . . . . 0.0 112.628 179.683 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.435 ' CD1' ' HG2' ' B' ' 12' ' ' LYS . 10.7 mp 71.92 172.82 0.31 Allowed 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 124.309 1.044 . . . . 0.0 112.916 179.289 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . 0.486 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -172.59 88.88 0.08 OUTLIER Glycine 0 CA--C 1.488 -1.612 0 N-CA-C 107.806 -2.118 . . . . 0.0 107.806 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.549 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.8 pt -157.62 -173.65 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 -176.421 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . 0.493 ' HB2' HG22 ' B' ' 41' ' ' THR . 40.5 m -152.72 144.61 23.67 Favored 'General case' 0 C--N 1.257 -3.452 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 173.656 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.511 ' HB ' HG22 ' B' ' 37' ' ' ILE . 16.3 pt -116.74 162.93 14.34 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.584 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 179.282 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.1 tp -140.81 136.77 35.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 CA-C-O 120.98 0.419 . . . . 0.0 110.665 -178.806 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . 0.464 ' HA2' ' CD1' ' B' ' 37' ' ' ILE . . . -67.13 101.92 0.73 Allowed Glycine 0 N--CA 1.435 -1.372 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.1 178.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 91.7 mtp . . . . . 0 N--CA 1.431 -1.411 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 -178.95 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 91.1 mt . . . . . 0 N--CA 1.417 -2.083 0 N-CA-C 104.174 -2.528 . . . . 0.0 104.174 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . 0.462 ' HA3' HD11 ' B' ' 59' ' ' LEU . . . -99.67 -13.78 36.72 Favored Glycine 0 C--N 1.291 -1.968 0 C-N-CA 118.881 -1.628 . . . . 0.0 111.048 -175.223 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.511 HG22 ' HB ' ' B' ' 21' ' ' ILE . 31.2 mm 64.64 98.02 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.557 1.241 0 C-N-CA 124.396 1.078 . . . . 0.0 111.08 -179.145 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 62.4 m-85 -76.36 164.91 25.56 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.823 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 47.8 t -76.61 142.54 14.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 177.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 31.9 ttmt -98.36 -46.34 5.82 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.331 -179.614 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . 0.536 ' HA ' HG23 ' B' ' 56' ' ' VAL . 1.1 t -161.15 166.79 27.36 Favored 'General case' 0 N--CA 1.428 -1.55 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -178.355 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.549 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.8 p -137.71 97.26 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.282 -2.342 0 CA-C-O 122.102 0.953 . . . . 0.0 109.381 177.694 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 12.8 m -54.61 129.67 37.31 Favored 'General case' 0 N--CA 1.435 -1.2 0 CA-C-N 113.453 -1.703 . . . . 0.0 111.1 -176.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . 0.461 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 38.7 mt-10 -60.55 -27.17 67.45 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 123.537 0.735 . . . . 0.0 111.407 -177.13 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.63 -7.85 88.13 Favored Glycine 0 N--CA 1.434 -1.434 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.843 178.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.486 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -93.02 161.08 25.37 Favored Glycine 0 CA--C 1.485 -1.788 0 C-N-CA 120.326 -0.94 . . . . 0.0 114.243 -175.516 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -62.57 -34.6 77.3 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 113.614 -1.293 . . . . 0.0 111.642 -178.103 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . 0.468 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -66.15 -31.89 73.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.762 -0.199 . . . . 0.0 111.36 -177.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . 0.461 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 4.6 t60 -80.46 -42.6 22.32 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.568 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . 0.414 ' HG3' ' O ' ' B' ' 46' ' ' GLY . 82.5 mtp180 -64.59 -42.63 95.48 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.836 -179.632 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -76.52 -43.42 39.46 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 88.24 52.48 2.88 Favored Glycine 0 CA--C 1.503 -0.657 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.787 178.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.463 ' HB3' ' CG1' ' B' ' 8' ' ' VAL . 30.8 mmt180 -118.76 -74.29 0.61 Allowed 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -175.4 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.406 HD11 ' CE2' ' B' ' 89' ' ' PHE . 60.9 mt -72.24 107.81 3.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 176.586 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -97.25 153.52 17.97 Favored 'General case' 0 N--CA 1.425 -1.709 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.703 -175.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.536 HG23 ' HA ' ' B' ' 41' ' ' THR . 10.0 p -55.05 -24.07 14.0 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.56 0 N-CA-C 115.747 1.758 . . . . 0.0 115.747 -171.236 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -114.43 9.31 16.77 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 120.966 -1.084 . . . . 0.0 111.54 -172.304 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . 0.41 ' HB3' ' CG2' ' B' ' 91' ' ' ILE . 5.9 m-20 -99.49 -177.74 3.68 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 119.804 -0.759 . . . . 0.0 112.559 -176.85 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.482 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 29.3 tp -133.67 139.26 46.34 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 112.445 0.535 . . . . 0.0 112.445 -170.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . 0.407 ' O ' HD12 ' B' ' 68' ' ' LEU . 67.1 mt -89.27 101.76 14.43 Favored 'General case' 0 C--O 1.208 -1.104 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 176.781 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.552 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 24.8 t -83.46 -42.91 17.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-O 121.84 0.828 . . . . 0.0 111.509 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.494 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 11.8 pt-20 -154.98 150.12 27.01 Favored 'General case' 0 C--N 1.272 -2.8 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.559 176.653 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.438 HG22 ' H ' ' B' ' 64' ' ' ASP . 5.0 p -96.1 -178.51 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.07 0 N-CA-C 105.909 -1.885 . . . . 0.0 105.909 178.623 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.47 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.8 t70 -49.47 -54.89 15.34 Favored 'General case' 0 C--N 1.315 -0.919 0 C-N-CA 124.16 0.984 . . . . 0.0 113.344 -176.381 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -121.12 24.2 7.46 Favored Glycine 0 C--N 1.32 -0.354 0 C-N-CA 119.372 -1.394 . . . . 0.0 114.254 -177.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . 0.431 ' HB ' HG12 ' B' ' 63' ' ' VAL . 25.8 m -152.61 126.54 9.02 Favored 'General case' 0 C--N 1.316 -0.889 0 O-C-N 121.732 -0.864 . . . . 0.0 109.693 179.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . 0.42 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 23.4 m -91.82 132.19 36.62 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 120.889 0.376 . . . . 0.0 110.757 -179.531 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.552 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 26.9 mt -81.69 95.66 7.29 Favored 'General case' 0 N--CA 1.431 -1.4 0 CA-C-O 121.374 0.607 . . . . 0.0 110.509 177.326 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 10.3 p -92.56 16.73 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 CA-C-O 122.317 1.056 . . . . 0.0 108.943 178.581 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 117.54 87.46 1.24 Allowed Glycine 0 CA--C 1.474 -2.493 0 C-N-CA 120.328 -0.939 . . . . 0.0 111.543 178.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 15.5 m -120.44 174.2 5.57 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -178.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 62.9 p -85.51 164.62 17.71 Favored 'General case' 0 N--CA 1.42 -1.928 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 176.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -60.97 -38.28 85.4 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 177.12 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.1 m -64.15 -41.28 97.23 Favored 'General case' 0 N--CA 1.433 -1.324 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.951 178.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -65.62 -46.72 78.18 Favored 'General case' 0 CA--C 1.521 -0.138 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.529 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.515 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -56.82 -43.43 81.03 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-O 120.999 0.428 . . . . 0.0 110.773 179.121 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.18 -24.54 66.65 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.605 0.716 . . . . 0.0 111.056 178.173 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 32.6 m -85.79 -26.43 25.78 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.821 -178.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.515 HG12 ' O ' ' B' ' 76' ' ' ALA . 9.0 p -73.69 -32.54 35.54 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.679 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . 0.428 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 64.5 mt -65.78 -23.12 66.64 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.485 177.04 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 59.7 mtm180 -99.53 -0.4 40.65 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.834 179.457 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -100.78 -29.38 12.29 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.203 177.497 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.727 ' HB ' HG11 ' B' ' 87' ' ' VAL . 7.8 p -74.38 164.03 27.08 Favored 'General case' 0 N--CA 1.425 -1.699 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.87 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 68.5 mmtt -68.83 -166.78 0.08 Allowed 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.102 1.361 . . . . 0.0 112.771 -179.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.93 -39.18 93.27 Favored Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.562 -0.744 . . . . 0.0 113.186 -179.161 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . 0.426 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 41.7 ttm180 -128.19 124.56 37.06 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 -179.614 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.727 HG11 ' HB ' ' B' ' 83' ' ' THR . 13.6 m -135.2 147.68 29.06 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 CA-C-O 121.138 0.494 . . . . 0.0 111.448 178.075 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 36.2 mtp85 -108.87 120.37 42.31 Favored 'General case' 0 N--CA 1.428 -1.536 0 CA-C-N 114.925 -1.034 . . . . 0.0 109.086 -179.08 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.443 ' HB2' ' CD1' ' B' ' 91' ' ' ILE . 2.9 m-85 -103.82 159.36 15.7 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 -177.124 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.494 ' HB2' ' CG ' ' B' ' 62' ' ' GLU . 0.5 OUTLIER -104.34 109.35 21.16 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 168.939 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.517 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.3 mp -89.79 129.92 39.92 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.158 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 178.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . 0.466 ' O ' ' HB3' ' B' ' 59' ' ' LEU . . . -112.38 104.31 1.59 Allowed Glycine 0 CA--C 1.458 -3.483 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 178.512 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 . . . . . 0 C--N 1.27 -2.849 0 CA-C-N 114.913 -0.644 . . . . 0.0 109.664 178.566 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 67.8 mtm . . . . . 0 N--CA 1.432 -1.347 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -85.26 108.34 17.72 Favored 'General case' 0 N--CA 1.426 -1.652 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 179.136 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.522 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 1.1 mm? -85.35 89.46 7.68 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 174.219 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -111.7 142.6 26.93 Favored Pre-proline 0 C--N 1.288 -2.094 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.295 -179.37 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -75.8 132.88 14.83 Favored 'Trans proline' 0 N--CA 1.44 -1.632 0 C-N-CA 122.223 1.949 . . . . 0.0 111.878 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.498 HG13 ' HB3' ' B' ' 53' ' ' ARG . 76.4 t -120.83 120.77 63.39 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.389 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.178 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 9' ' ' GLU . . . . . 0.414 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 38.4 tt0 -115.29 120.18 38.8 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.704 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.554 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -108.34 -173.58 2.31 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 178.832 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -158.83 155.85 28.59 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 105.046 -2.205 . . . . 0.0 105.046 176.528 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 10.6 ptpp? -84.96 163.38 18.95 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-O 121.743 0.782 . . . . 0.0 112.991 -173.346 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 13' ' ' ASP . . . . . 0.515 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 14.0 t70 -111.34 -176.35 2.93 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 104.697 -2.334 . . . . 0.0 104.697 170.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 34.3 m -63.8 -30.33 71.44 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 119.278 0.944 . . . . 0.0 111.575 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -88.91 -13.0 40.12 Favored 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 121.711 0.767 . . . . 0.0 109.64 178.12 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.01 -108.11 2.43 Favored Glycine 0 N--CA 1.433 -1.505 0 C-N-CA 120.862 -0.685 . . . . 0.0 111.78 179.55 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -95.63 172.63 7.93 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 120.954 0.407 . . . . 0.0 110.105 -178.285 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -137.12 53.86 0.73 Allowed Glycine 0 CA--C 1.486 -1.744 0 N-CA-C 109.944 -1.263 . . . . 0.0 109.944 -179.519 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.518 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 6.9 pt -157.95 -178.64 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.489 -1.369 0 C-N-CA 124.84 1.256 . . . . 0.0 108.282 -174.204 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 20' ' ' SER . . . . . 0.433 ' HB2' ' HB3' ' B' ' 40' ' ' LYS . 46.8 m -152.58 156.21 38.87 Favored 'General case' 0 C--N 1.27 -2.853 0 N-CA-C 105.106 -2.183 . . . . 0.0 105.106 174.361 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 21' ' ' ILE . . . . . 0.419 ' HB ' HG22 ' B' ' 37' ' ' ILE . 29.5 pt -117.3 158.96 17.71 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 CA-C-N 118.181 0.446 . . . . 0.0 110.287 -177.045 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -148.48 136.26 14.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 CA-C-O 121.422 0.629 . . . . 0.0 110.181 178.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -75.19 122.15 6.78 Favored Glycine 0 N--CA 1.423 -2.232 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.044 178.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 24' ' ' MET . . . . . 0.67 ' HB2' ' CD1' ' B' ' 38' ' ' PHE . 64.6 mtt . . . . . 0 CA--C 1.491 -1.298 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 174.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 10.8 mp . . . . . 0 N--CA 1.429 -1.486 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -170.99 1.63 0.03 OUTLIER Glycine 0 C--N 1.292 -1.892 0 C-N-CA 119.817 -1.183 . . . . 0.0 111.067 174.409 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 37' ' ' ILE . . . . . 0.419 HG22 ' HB ' ' B' ' 21' ' ' ILE . 40.9 mm 65.39 114.64 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 CA-C-O 122.495 1.141 . . . . 0.0 110.543 -173.649 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.67 ' CD1' ' HB2' ' B' ' 24' ' ' MET . 29.0 m-85 -88.55 176.19 7.25 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.103 -0.953 . . . . 0.0 108.881 -175.205 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 64.6 t -83.93 142.9 12.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-O 121.654 0.74 . . . . 0.0 110.759 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 40' ' ' LYS . . . . . 0.433 ' HB3' ' HB2' ' B' ' 20' ' ' SER . 16.3 ttmm -94.34 -47.03 6.78 Favored 'General case' 0 N--CA 1.434 -1.261 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.769 -179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 3.1 t -162.32 171.76 16.73 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 -178.64 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.518 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.2 p -147.9 91.51 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.861 0 CA-C-O 122.35 1.071 . . . . 0.0 109.193 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 8.2 m -59.3 128.94 39.61 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 113.557 -1.656 . . . . 0.0 111.528 -176.518 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 44' ' ' GLU . . . . . 0.576 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 8.1 pt-20 -68.01 -17.2 64.35 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 112.558 0.577 . . . . 0.0 112.558 -177.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.26 -0.04 85.27 Favored Glycine 0 N--CA 1.436 -1.351 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.486 177.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -111.14 169.59 13.36 Favored Glycine 0 N--CA 1.418 -2.503 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.923 -177.492 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . 0.515 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -55.08 -54.67 40.11 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 113.911 -1.144 . . . . 0.0 113.651 -174.198 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 48' ' ' ALA . . . . . 0.554 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -56.24 -35.37 67.29 Favored 'General case' 0 C--O 1.243 0.75 0 N-CA-C 114.051 1.13 . . . . 0.0 114.051 -172.246 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 49' ' ' HIS . . . . . 0.576 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 6.6 t60 -75.39 -46.8 30.71 Favored 'General case' 0 C--N 1.312 -1.037 0 O-C-N 123.656 0.597 . . . . 0.0 109.953 -177.003 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 65.7 mtp180 -73.49 -34.98 65.57 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.422 -175.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -66.01 -51.36 59.06 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.419 178.549 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 95.13 52.77 1.7 Allowed Glycine 0 N--CA 1.432 -1.571 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 53' ' ' ARG . . . . . 0.498 ' HB3' HG13 ' B' ' 8' ' ' VAL . 21.6 mmt180 -129.78 -72.78 0.57 Allowed 'General case' 0 N--CA 1.432 -1.328 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -178.629 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.596 HD11 ' CE2' ' B' ' 89' ' ' PHE . 45.4 mt -80.06 129.15 38.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 C-N-CA 119.288 -0.965 . . . . 0.0 108.925 178.278 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 55' ' ' GLN . . . . . 0.741 ' HB2' ' OD1' ' B' ' 58' ' ' ASP . 6.9 mt-30 -116.78 164.15 15.09 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 -176.624 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.8 p -59.14 -33.95 52.01 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.276 0 N-CA-C 115.949 1.833 . . . . 0.0 115.949 -171.511 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -105.52 5.46 31.47 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.112 -0.993 . . . . 0.0 112.421 -172.721 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 58' ' ' ASP . . . . . 0.741 ' OD1' ' HB2' ' B' ' 55' ' ' GLN . 5.2 m-20 -82.01 171.09 14.8 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-O 121.318 0.58 . . . . 0.0 111.984 -175.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 59' ' ' LEU . . . . . 0.473 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 23.1 tp -131.54 133.11 44.72 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.312 -174.318 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 66.0 mt -87.25 96.36 10.31 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 178.095 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 61' ' ' VAL . . . . . 0.621 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 16.1 t -73.94 -38.46 49.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 CA-C-O 121.589 0.709 . . . . 0.0 110.928 179.092 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.565 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 10.0 pt-20 -159.95 156.67 27.56 Favored 'General case' 0 C--N 1.282 -2.357 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.653 174.662 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 63' ' ' VAL . . . . . 0.468 HG22 ' H ' ' B' ' 64' ' ' ASP . 6.2 p -100.53 177.35 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 177.479 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 64' ' ' ASP . . . . . 0.468 ' H ' HG22 ' B' ' 63' ' ' VAL . 27.3 t70 -46.65 -56.67 5.74 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 114.156 1.169 . . . . 0.0 114.156 -173.808 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -117.98 27.44 7.44 Favored Glycine 0 C--N 1.31 -0.877 0 C-N-CA 119.392 -1.385 . . . . 0.0 114.072 -177.504 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 66' ' ' THR . . . . . 0.43 ' HB ' HG12 ' B' ' 63' ' ' VAL . 29.6 m -154.11 123.86 6.71 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 117.754 0.777 . . . . 0.0 109.788 179.193 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 67' ' ' SER . . . . . 0.565 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 11.1 t -96.46 129.19 43.87 Favored 'General case' 0 N--CA 1.426 -1.671 0 CA-C-O 121.078 0.466 . . . . 0.0 110.607 -177.25 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.621 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 62.7 mt -92.03 124.2 35.95 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.081 179.212 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 14.4 p -93.05 -25.39 4.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 174.164 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 149.26 75.13 0.02 OUTLIER Glycine 0 N--CA 1.423 -2.176 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 -176.648 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 31.3 m -93.15 178.45 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 CA-C-N 114.912 -0.644 . . . . 0.0 110.691 -175.368 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 36.6 p -80.88 160.98 24.6 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 175.482 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -62.59 -35.42 79.47 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 120.944 0.402 . . . . 0.0 110.307 -178.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 19.2 m -66.41 -40.18 89.42 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.279 178.122 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -64.31 -46.35 83.95 Favored 'General case' 0 C--N 1.338 0.101 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 76' ' ' ALA . . . . . 0.413 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -57.89 -46.91 84.2 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.382 178.293 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.49 -42.01 86.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.005 0.431 . . . . 0.0 110.687 178.345 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 22.8 t -68.73 -32.68 72.64 Favored 'General case' 0 N--CA 1.431 -1.377 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.736 -178.565 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 79' ' ' VAL . . . . . 0.413 HG12 ' O ' ' B' ' 76' ' ' ALA . 9.8 p -78.09 -39.13 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 119.582 -0.847 . . . . 0.0 109.921 -174.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 45.6 mt -63.93 -34.02 77.02 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.822 177.647 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -87.66 -5.02 58.9 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.344 179.446 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -89.07 -37.04 15.41 Favored 'General case' 0 N--CA 1.431 -1.387 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 175.609 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 83' ' ' THR . . . . . 0.68 ' HB ' HG11 ' B' ' 87' ' ' VAL . 12.8 p -77.11 172.24 13.54 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.463 177.058 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt -69.11 -173.74 0.55 Allowed 'General case' 0 N--CA 1.444 -0.748 0 CA-C-O 121.738 0.78 . . . . 0.0 111.725 177.607 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -81.4 -28.66 43.16 Favored Glycine 0 N--CA 1.431 -1.661 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 175.634 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . 0.459 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 21.9 ttm-85 -106.76 111.3 23.76 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 121.406 0.622 . . . . 0.0 110.162 175.804 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 87' ' ' VAL . . . . . 0.68 HG11 ' HB ' ' B' ' 83' ' ' THR . 2.6 m -147.63 151.68 13.44 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-N 114.58 -1.191 . . . . 0.0 109.679 178.348 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . 0.431 ' HA ' ' O ' ' B' ' 8' ' ' VAL . 10.3 mtm-85 -101.28 110.31 22.3 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 123.992 0.808 . . . . 0.0 109.726 -179.718 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 89' ' ' PHE . . . . . 0.596 ' CE2' HD11 ' B' ' 54' ' ' ILE . 3.0 m-85 -95.23 158.97 15.23 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 179.426 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 90' ' ' MET . . . . . 0.479 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 86.3 mtp -107.8 114.04 27.71 Favored 'General case' 0 C--N 1.29 -1.993 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 170.273 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.522 ' O ' ' HA ' ' B' ' 5' ' ' LEU . 1.4 mp -95.45 136.78 25.39 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 -179.006 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.93 100.9 0.73 Allowed Glycine 0 CA--C 1.474 -2.506 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 175.283 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 16.4 tpp180 . . . . . 0 C--N 1.275 -2.652 0 CA-C-N 113.824 -1.188 . . . . 0.0 108.726 -178.73 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.298 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 45.2 p-80 -167.56 166.28 14.2 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 117.876 0.838 . . . . 0.0 109.095 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 56.9 mtt -95.09 128.57 42.02 Favored 'General case' 0 N--CA 1.433 -1.292 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 171.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . 0.548 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 27.0 mt-10 -79.95 98.82 7.32 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.423 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 1.0 OUTLIER -82.67 89.84 6.78 Favored 'General case' 0 C--N 1.311 -1.105 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 174.602 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 13.5 p90 -110.59 142.11 25.42 Favored Pre-proline 0 C--N 1.286 -2.158 0 CA-C-N 116.038 -0.528 . . . . 0.0 112.128 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -68.78 129.46 18.7 Favored 'Trans proline' 0 N--CA 1.451 -1.024 0 C-N-CA 122.67 2.247 . . . . 0.0 112.482 178.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.703 HG13 ' HG3' ' B' ' 53' ' ' ARG . 79.1 t -120.88 122.91 69.01 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.515 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.725 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . 0.468 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 31.3 tt0 -123.11 113.84 19.53 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 mt -104.26 160.4 14.91 Favored 'General case' 0 C--N 1.283 -2.309 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.342 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.464 ' HB3' ' NH2' ' B' ' 86' ' ' ARG . 8.5 pt-20 -123.55 113.68 19.04 Favored 'General case' 0 C--N 1.271 -2.821 0 CA-C-N 114.271 -1.331 . . . . 0.0 108.421 173.019 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.4 ptpt -79.82 156.93 27.16 Favored 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.421 -0.808 . . . . 0.0 110.496 -175.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 65.4 m-20 -89.18 -173.13 3.92 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.163 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 35.8 t -68.99 -21.15 64.17 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 173.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -69.7 -46.82 65.14 Favored 'General case' 0 N--CA 1.44 -0.929 0 CA-C-N 114.318 -1.31 . . . . 0.0 108.48 173.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.3 -132.73 8.66 Favored Glycine 0 N--CA 1.419 -2.496 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -176.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 90.7 mt -95.65 179.0 5.28 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . 0.531 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -151.3 66.59 0.35 Allowed Glycine 0 CA--C 1.481 -2.07 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.524 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 3.5 pt -151.71 -177.6 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.104 0 C-N-CA 124.608 1.163 . . . . 0.0 108.246 -177.226 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . 0.457 ' HB2' HG22 ' B' ' 41' ' ' THR . 49.3 m -153.73 162.7 41.01 Favored 'General case' 0 C--N 1.261 -3.243 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.236 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.419 ' HB ' HG22 ' B' ' 37' ' ' ILE . 19.0 pt -127.92 164.4 29.43 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 -178.403 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -144.0 138.57 24.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 178.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . 0.419 ' HA2' ' CD1' ' B' ' 37' ' ' ILE . . . -83.61 96.03 1.92 Allowed Glycine 0 N--CA 1.426 -2.028 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.936 178.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 24.8 mmt -113.05 175.83 5.27 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 177.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 105.93 164.92 23.19 Favored Glycine 0 N--CA 1.428 -1.881 0 C-N-CA 120.156 -1.021 . . . . 0.0 110.645 -179.072 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.59 138.25 23.31 Favored 'General case' 0 C--N 1.284 -2.262 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 177.565 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.438 ' O ' ' HA ' ' B' ' 33' ' ' GLU . . . 125.65 62.36 0.17 Allowed Glycine 0 N--CA 1.421 -2.339 0 C-N-CA 120.197 -1.001 . . . . 0.0 112.35 178.373 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.15 82.91 6.12 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 175.289 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.44 ' HB3' ' HB3' ' B' ' 32' ' ' LEU . 18.5 t70 -79.17 -7.04 57.9 Favored 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 113.522 -1.672 . . . . 0.0 113.383 -170.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 63.5 mtt 61.89 77.85 0.31 Allowed 'General case' 0 CA--C 1.496 -1.113 0 CA-C-O 121.85 0.833 . . . . 0.0 111.38 -176.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.66 45.89 1.47 Allowed Glycine 0 C--N 1.294 -1.772 0 CA-C-N 114.931 -1.032 . . . . 0.0 112.346 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . 0.44 ' HB3' ' HB3' ' B' ' 29' ' ' ASP . 3.3 tm? 178.44 -64.24 0.01 OUTLIER 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 104.802 -2.296 . . . . 0.0 104.802 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' B' ' 27' ' ' GLY . 16.5 mt-10 45.86 86.86 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 125.352 1.461 . . . . 0.0 114.876 172.403 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 8.6 ptmm? -80.92 76.83 7.84 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.436 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 96.6 mt -115.39 162.2 17.47 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 114.399 -1.273 . . . . 0.0 108.787 179.272 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -136.9 109.58 0.73 Allowed Glycine 0 N--CA 1.411 -3.02 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.627 -178.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.419 ' CD1' ' HA2' ' B' ' 23' ' ' GLY . 33.8 mm -89.62 84.55 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.89 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 175.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.487 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 90.4 m-85 -82.91 164.97 20.13 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.192 -1.367 . . . . 0.0 109.235 -176.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 52.1 t -73.21 126.47 33.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 176.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -86.87 -36.7 18.28 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.052 -176.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . 0.457 HG22 ' HB2' ' B' ' 20' ' ' SER . 1.3 t -160.88 165.87 29.41 Favored 'General case' 0 N--CA 1.423 -1.791 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.208 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.524 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.3 p -139.1 94.22 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-O 122.562 1.173 . . . . 0.0 109.077 177.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.417 HG22 ' H ' ' B' ' 45' ' ' GLY . 45.6 m -65.74 126.79 29.54 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-N 113.064 -1.88 . . . . 0.0 113.038 -173.238 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . 0.453 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 9.2 pt-20 -53.13 -31.4 42.15 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 125.218 1.407 . . . . 0.0 113.254 -179.089 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . 0.417 ' H ' HG22 ' B' ' 43' ' ' THR . . . -64.65 -29.69 75.9 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 121.427 -0.416 . . . . 0.0 112.908 -179.503 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.531 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -95.98 165.79 24.43 Favored Glycine 0 N--CA 1.422 -2.298 0 C-N-CA 119.884 -1.15 . . . . 0.0 113.527 -176.031 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -58.45 -33.66 69.98 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 113.358 -1.421 . . . . 0.0 113.48 -175.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -59.51 -38.87 82.08 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -175.565 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . 0.453 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 7.9 t60 -75.06 -38.49 61.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.11 0.481 . . . . 0.0 110.145 -178.784 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 22.5 mtm-85 -77.89 -29.55 50.28 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.682 -175.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . 0.547 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 23.9 t70 -80.0 -53.78 6.41 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 176.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.39 39.66 4.16 Favored Glycine 0 CA--C 1.497 -1.077 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 179.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.703 ' HG3' HG13 ' B' ' 8' ' ' VAL . 0.5 OUTLIER -103.07 -69.41 0.79 Allowed 'General case' 0 N--CA 1.425 -1.717 0 CA-C-N 114.618 -0.791 . . . . 0.0 109.532 -174.26 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.609 HD11 ' CE2' ' B' ' 89' ' ' PHE . 52.1 mt -85.61 108.34 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 174.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 32.5 mt-30 -101.9 167.7 9.89 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -176.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 9.5 p -70.73 -4.54 4.46 Favored 'Isoleucine or valine' 0 CA--C 1.568 1.641 0 CA-C-O 121.79 0.805 . . . . 0.0 112.3 -173.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -114.16 7.05 16.51 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.889 0.852 . . . . 0.0 109.232 -175.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -95.21 165.01 12.61 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.809 -176.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.515 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 23.8 tp -136.5 133.98 37.1 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.668 -176.773 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 69.3 mt -80.48 96.51 6.78 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 176.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.505 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 38.8 t -78.4 -45.67 25.99 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-O 121.66 0.743 . . . . 0.0 109.917 178.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -154.11 151.69 29.57 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 114.968 -1.015 . . . . 0.0 109.931 174.167 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.53 HG12 ' HB ' ' B' ' 66' ' ' THR . 4.3 p -95.28 -173.49 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 178.224 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.513 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 13.0 t70 -47.26 -49.62 23.09 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -139.6 43.06 1.18 Allowed Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 119.29 -1.433 . . . . 0.0 113.964 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . 0.53 ' HB ' HG12 ' B' ' 63' ' ' VAL . 31.8 m -160.64 115.66 2.21 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 178.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 43.4 m -76.75 133.76 39.36 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-O 121.133 0.492 . . . . 0.0 110.891 179.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.515 HD12 ' CG2' ' B' ' 71' ' ' VAL . 4.1 mm? -87.42 -68.06 0.78 Allowed 'General case' 0 N--CA 1.434 -1.228 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.995 177.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 59.9 t 70.05 -40.46 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 124.456 1.102 . . . . 0.0 111.52 -177.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 157.44 85.22 0.05 OUTLIER Glycine 0 N--CA 1.417 -2.628 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.515 ' CG2' HD12 ' B' ' 68' ' ' LEU . 35.5 m -105.58 -172.73 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 123.543 0.737 . . . . 0.0 109.49 -178.311 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . 0.437 ' O ' HG23 ' B' ' 71' ' ' VAL . 19.8 p -81.64 157.03 24.81 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 172.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -61.49 -35.59 78.11 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.194 0.521 . . . . 0.0 110.735 -176.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 25.4 m -62.65 -38.02 88.66 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.915 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -63.83 -49.13 74.04 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.527 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.64 -42.95 99.62 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.793 -178.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.04 -32.51 73.02 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.278 0.561 . . . . 0.0 110.696 178.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 8.1 t -82.38 -28.45 31.47 Favored 'General case' 0 N--CA 1.428 -1.56 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.059 -177.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.527 HG12 ' O ' ' B' ' 76' ' ' ALA . 7.2 p -71.44 -33.01 48.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 O-C-N 121.412 -0.805 . . . . 0.0 109.714 -174.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 29.1 mt -69.81 -16.88 63.35 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.573 -1.194 . . . . 0.0 111.02 176.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -96.14 -24.22 16.39 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.049 0.452 . . . . 0.0 110.787 178.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 29.2 m-80 -82.68 -21.5 34.89 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 121.373 0.606 . . . . 0.0 111.351 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.524 ' HB ' HG11 ' B' ' 87' ' ' VAL . 7.4 p -85.32 167.75 15.31 Favored 'General case' 0 N--CA 1.425 -1.683 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.928 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 37.4 mmtm -67.89 -173.76 0.39 Allowed 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 123.425 0.69 . . . . 0.0 112.422 179.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -75.16 -30.61 58.67 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.17 -0.923 . . . . 0.0 112.064 -178.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . 0.464 ' NH2' ' HB3' ' B' ' 11' ' ' GLU . 21.4 ttm-85 -130.62 116.09 17.62 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.062 0.458 . . . . 0.0 110.003 175.067 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.524 HG11 ' HB ' ' B' ' 83' ' ' THR . 5.8 m -136.71 144.64 31.93 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.737 179.172 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . 0.468 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 99.7 mtt180 -91.8 129.12 37.82 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 175.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.609 ' CE2' HD11 ' B' ' 54' ' ' ILE . 2.0 m-85 -105.93 161.0 14.84 Favored 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 178.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.486 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 62.1 mtt -109.14 106.64 16.62 Favored 'General case' 0 C--N 1.286 -2.167 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 169.449 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.515 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.3 mp -87.57 135.48 25.28 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 CA-C-N 114.459 -1.246 . . . . 0.0 107.648 178.492 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . 0.548 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -127.0 104.06 0.69 Allowed Glycine 0 CA--C 1.465 -3.088 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 177.186 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 11.2 ptp180 -104.88 148.96 26.1 Favored 'General case' 0 C--N 1.271 -2.809 0 N-CA-C 108.963 -0.754 . . . . 0.0 108.963 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -94.95 77.49 3.58 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 174.288 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 45.4 ttt180 -64.0 -59.36 11.48 Favored Pre-proline 0 C--N 1.3 -1.568 0 CA-C-N 113.69 -1.596 . . . . 0.0 112.623 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -73.5 161.61 41.95 Favored 'Trans proline' 0 C--N 1.37 1.661 0 C-N-CA 121.298 1.332 . . . . 0.0 112.92 -179.056 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 153.63 -46.55 0.55 Allowed Glycine 0 CA--C 1.492 -1.387 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 176.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -79.29 23.27 0.39 Allowed 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 123.088 0.555 . . . . 0.0 111.017 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -66.2 -54.64 22.71 Favored 'General case' 0 N--CA 1.436 -1.136 0 C-N-CA 124.073 0.949 . . . . 0.0 111.076 -175.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 19.6 m -156.05 175.77 13.52 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 -177.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 67.59 17.83 9.94 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 124.058 0.943 . . . . 0.0 111.583 175.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 30.0 m -90.84 144.76 8.47 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.166 -0.959 . . . . 0.0 110.798 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . 67.5 -65.68 0.23 Allowed 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 125.579 1.552 . . . . 0.0 114.089 178.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 35.0 tt0 -85.02 -23.26 28.7 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.298 -178.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 11.1 mp 60.47 -172.26 0.13 Allowed 'General case' 0 C--O 1.242 0.701 0 C-N-CA 123.869 0.868 . . . . 0.0 110.657 -173.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 38.6 mm -76.39 -64.38 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 176.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 28.1 tp60 55.94 94.61 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.483 0 O-C-N 124.665 1.228 . . . . 0.0 113.001 173.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -76.72 77.99 3.35 Favored 'General case' 0 CA--C 1.515 -0.382 0 C-N-CA 119.916 -0.714 . . . . 0.0 109.351 177.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 8.1 t -89.51 -29.61 18.83 Favored 'General case' 0 N--CA 1.423 -1.791 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.589 -177.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 90.0 mt -83.63 12.87 5.17 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.57 0.7 . . . . 0.0 111.485 -176.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -135.87 98.85 4.0 Favored 'General case' 0 N--CA 1.426 -1.644 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 175.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.39 16.25 6.57 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.087 0.47 . . . . 0.0 111.742 177.25 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 16.2 mp0 . . . . . 0 CA--C 1.513 -0.445 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 172.833 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.171 0 N-CA-C 110.121 -1.192 . . . . 0.0 110.121 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 32.8 p-80 -144.06 145.26 32.06 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 118.047 0.924 . . . . 0.0 111.408 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . 0.526 ' SD ' ' HA ' ' B' ' 94' ' ' GLU . 24.7 mmt -105.93 118.69 37.25 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 175.602 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . 0.464 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 19.0 mt-10 -89.85 100.25 13.1 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -95.46 93.93 7.5 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 177.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -118.53 141.48 29.87 Favored Pre-proline 0 C--N 1.283 -2.323 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.067 178.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . 0.413 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 79.2 Cg_endo -79.51 143.51 17.15 Favored 'Trans proline' 0 N--CA 1.446 -1.268 0 C-N-CA 122.151 1.901 . . . . 0.0 112.306 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.449 HG13 ' HB3' ' B' ' 53' ' ' ARG . 53.8 t -131.49 127.7 59.99 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.981 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 176.599 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . 0.488 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 32.0 tt0 -110.4 121.61 45.72 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -177.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.523 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -114.61 165.6 12.6 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 121.515 0.674 . . . . 0.0 110.707 178.685 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -115.52 126.63 54.52 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 105.728 -1.953 . . . . 0.0 105.728 175.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . 0.412 ' HG2' ' HA2' ' B' ' 85' ' ' GLY . 21.1 ptmt -79.85 160.45 26.08 Favored 'General case' 0 N--CA 1.417 -2.092 0 C-N-CA 117.627 -1.629 . . . . 0.0 107.022 170.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . 0.407 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 22.2 t70 -115.75 178.31 4.36 Favored 'General case' 0 C--N 1.258 -3.391 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 -178.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 13.1 t -67.32 -20.54 65.62 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 179.398 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -92.61 7.24 44.22 Favored 'General case' 0 CA--C 1.555 1.168 0 CA-C-O 121.869 0.843 . . . . 0.0 109.42 176.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 89.57 -115.93 4.63 Favored Glycine 0 N--CA 1.435 -1.421 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.493 178.506 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -103.05 -173.19 2.25 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 121.42 0.629 . . . . 0.0 110.483 -177.282 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . 0.462 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -149.44 53.75 0.51 Allowed Glycine 0 CA--C 1.491 -1.433 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 178.291 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 2.6 pt -154.3 -179.99 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-O 121.961 0.886 . . . . 0.0 111.407 -175.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 51.0 m -152.49 131.45 12.56 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 175.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.505 ' HB ' HG22 ' B' ' 37' ' ' ILE . 15.6 pt -108.66 162.53 6.51 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 C-N-CA 122.713 0.405 . . . . 0.0 109.946 -178.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . 0.479 ' HB ' ' HB2' ' B' ' 40' ' ' LYS . 9.5 tp -136.22 136.69 49.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 CA-C-O 121.134 0.493 . . . . 0.0 110.673 -178.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -82.58 105.63 2.64 Favored Glycine 0 N--CA 1.426 -2.022 0 CA-C-N 115.663 -0.699 . . . . 0.0 112.527 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . 0.531 ' O ' ' HG ' ' B' ' 35' ' ' LEU . 26.3 mmt -131.07 178.22 6.85 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 176.196 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 121.14 -162.52 14.85 Favored Glycine 0 C--N 1.289 -2.033 0 C-N-CA 120.465 -0.874 . . . . 0.0 111.206 179.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -135.46 137.8 42.56 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 176.464 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.98 83.75 0.71 Allowed Glycine 0 N--CA 1.443 -0.856 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 179.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.91 79.26 0.31 Allowed 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.587 0.708 . . . . 0.0 112.065 -178.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -76.29 2.95 11.91 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-O 122.876 1.322 . . . . 0.0 110.687 -175.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . 0.429 ' HG3' HD23 ' B' ' 32' ' ' LEU . 24.5 ptm -73.12 19.72 0.09 Allowed 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.207 -1.36 . . . . 0.0 111.801 175.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.0 17.55 32.05 Favored Glycine 0 N--CA 1.442 -0.935 0 C-N-CA 121.442 -0.408 . . . . 0.0 112.768 177.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . 0.429 HD23 ' HG3' ' B' ' 30' ' ' MET . 4.4 mm? -121.55 -53.62 1.99 Allowed 'General case' 0 C--N 1.312 -1.033 0 C-N-CA 119.87 -0.732 . . . . 0.0 112.288 -177.676 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . 0.482 ' O ' ' HA3' ' B' ' 70' ' ' GLY . 40.9 mt-10 59.66 24.81 13.68 Favored 'General case' 0 CA--C 1.502 -0.876 0 C-N-CA 125.381 1.472 . . . . 0.0 111.649 -173.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . 0.442 ' HA ' ' O ' ' B' ' 69' ' ' VAL . 14.1 ptmm? -72.21 124.29 24.73 Favored 'General case' 0 N--CA 1.423 -1.784 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 179.08 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' B' ' 24' ' ' MET . 15.4 tp -123.37 -172.44 2.51 Favored 'General case' 0 C--N 1.28 -2.447 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 -174.124 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . 0.475 ' H ' ' HG ' ' B' ' 35' ' ' LEU . . . -137.06 87.72 0.22 Allowed Glycine 0 N--CA 1.422 -2.296 0 C-N-CA 119.882 -1.151 . . . . 0.0 111.724 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.505 HG22 ' HB ' ' B' ' 21' ' ' ILE . 34.5 mm -84.62 80.32 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 176.233 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.413 ' CD1' ' HB2' ' B' ' 59' ' ' LEU . 96.9 m-85 -77.17 169.93 17.45 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.172 -176.38 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 49.1 t -80.36 135.46 25.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . 0.479 ' HB2' ' HB ' ' B' ' 22' ' ' ILE . 2.4 ttpm? -95.84 -41.47 8.81 Favored 'General case' 0 CA--C 1.482 -1.652 0 CA-C-O 121.187 0.517 . . . . 0.0 109.899 -178.125 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 1.1 m -154.83 146.98 23.72 Favored 'General case' 1 N--CA 1.369 -4.483 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -174.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 39.5 t -114.76 105.69 19.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 175.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 7.2 m -64.41 122.68 17.3 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.215 -174.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . 0.505 ' HG2' ' CE1' ' B' ' 49' ' ' HIS . 36.1 mt-10 -66.8 -28.36 68.31 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.457 -175.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.3 -1.11 85.4 Favored Glycine 0 N--CA 1.435 -1.401 0 CA-C-N 115.042 -0.981 . . . . 0.0 113.396 -179.266 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.462 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -117.07 170.29 13.38 Favored Glycine 0 N--CA 1.411 -2.972 0 C-N-CA 119.933 -1.127 . . . . 0.0 112.818 -178.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . 0.407 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -60.72 -35.79 77.23 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 114.088 1.144 . . . . 0.0 114.088 -174.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . 0.523 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -63.28 -38.74 92.35 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 113.199 0.815 . . . . 0.0 113.199 -174.277 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . 0.505 ' CE1' ' HG2' ' B' ' 44' ' ' GLU . 4.1 t60 -74.15 -39.34 63.33 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.659 0.742 . . . . 0.0 109.342 -179.199 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 -76.63 -26.2 54.65 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 114.862 -1.063 . . . . 0.0 111.785 -175.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . 0.523 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 12.6 t70 -77.92 -46.18 22.0 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 176.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 97.08 16.34 35.76 Favored Glycine 0 CA--C 1.498 -1.03 0 CA-C-N 115.515 -0.766 . . . . 0.0 112.624 172.399 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.523 ' HD3' ' OD2' ' B' ' 51' ' ' ASP . 1.5 mpt_? -91.96 -63.46 1.24 Allowed 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 113.335 0.865 . . . . 0.0 113.335 -177.124 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.5 HD11 ' CE2' ' B' ' 89' ' ' PHE . 39.4 mt -69.3 133.09 32.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 C-N-CA 119.805 -0.758 . . . . 0.0 110.53 176.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 30.7 mm-40 -113.37 153.66 28.19 Favored 'General case' 0 CA--C 1.511 -0.543 0 C-N-CA 122.408 0.283 . . . . 0.0 110.634 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.3 p -73.6 -7.48 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.86 0 CA-C-O 121.709 0.766 . . . . 0.0 111.986 -176.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -114.35 9.83 16.97 Favored 'General case' 0 C--N 1.293 -1.879 0 O-C-N 121.581 -0.699 . . . . 0.0 111.95 -175.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -112.42 177.78 4.52 Favored 'General case' 0 C--O 1.244 0.784 0 CA-C-O 120.979 0.418 . . . . 0.0 111.767 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.413 ' HB2' ' CD1' ' B' ' 38' ' ' PHE . 24.9 tp -126.91 128.22 46.12 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.739 -176.638 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 31.7 mt -90.15 107.68 19.28 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 105.569 -2.011 . . . . 0.0 105.569 175.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.534 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 41.4 t -79.2 -74.36 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.19 -2.03 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.45 ' HA ' HD23 ' B' ' 68' ' ' LEU . 10.9 pt-20 -118.6 165.2 14.24 Favored 'General case' 0 C--N 1.269 -2.903 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.032 -173.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.485 HG22 ' H ' ' B' ' 64' ' ' ASP . 4.6 p -113.34 -175.19 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -174.705 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.491 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 12.6 t70 -40.18 -63.35 0.62 Allowed 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 125.76 1.624 . . . . 0.0 113.918 -178.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -134.68 41.01 1.5 Allowed Glycine 0 CA--C 1.496 -1.133 0 C-N-CA 119.333 -1.413 . . . . 0.0 113.401 -178.097 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 37.7 m -150.35 126.24 10.44 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 178.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 2.3 p -84.18 133.18 34.61 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 115.457 -0.792 . . . . 0.0 112.047 -177.09 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.534 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 4.2 mm? -118.69 141.91 48.16 Favored 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 175.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' B' ' 34' ' ' LYS . 44.6 t -123.47 -42.59 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 175.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . 0.482 ' HA3' ' O ' ' B' ' 33' ' ' GLU . . . 175.49 81.0 0.05 OUTLIER Glycine 0 N--CA 1.409 -3.164 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.552 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 27.1 m -100.91 -177.39 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.217 0 CA-C-N 114.197 -1.002 . . . . 0.0 109.532 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 72.0 p -76.1 163.4 27.15 Favored 'General case' 0 N--CA 1.432 -1.359 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 177.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -61.93 -31.85 72.2 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.651 0.739 . . . . 0.0 109.412 177.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 28.1 t -72.69 -42.6 64.05 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.872 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 19.4 t80 -62.46 -47.81 82.4 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.586 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.72 -40.32 94.64 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.577 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.73 -28.84 69.35 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.499 0.666 . . . . 0.0 110.959 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.8 m -85.16 -16.94 38.75 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.171 -177.4 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.586 HG12 ' O ' ' B' ' 76' ' ' ALA . 4.2 p -72.91 -28.25 26.5 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.518 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 -179.236 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 55.2 mt -71.81 -7.14 46.48 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-N 114.09 -1.414 . . . . 0.0 110.815 177.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 88.3 mtt180 -103.65 -14.7 16.03 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 121.37 0.605 . . . . 0.0 109.707 178.192 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 -86.59 -29.03 22.91 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.471 176.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.674 ' HB ' HG11 ' B' ' 87' ' ' VAL . 9.3 p -69.49 170.08 11.27 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 115.402 1.63 . . . . 0.0 115.402 -173.392 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 35.1 mttp -73.56 -162.4 0.13 Allowed 'General case' 0 C--O 1.241 0.622 0 CA-C-N 114.845 -1.07 . . . . 0.0 110.253 173.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . 0.412 ' HA2' ' HG2' ' B' ' 12' ' ' LYS . . . -80.0 -38.5 19.06 Favored Glycine 0 N--CA 1.437 -1.291 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.871 178.277 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 41.0 ttm180 -120.96 123.52 42.65 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.674 HG11 ' HB ' ' B' ' 83' ' ' THR . 26.7 m -139.71 142.76 31.88 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 CA-C-O 120.867 0.365 . . . . 0.0 111.543 -177.767 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . 0.488 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 52.2 mtt180 -99.4 116.68 32.13 Favored 'General case' 0 CA--C 1.485 -1.556 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.164 176.528 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.5 ' CE2' HD11 ' B' ' 54' ' ' ILE . 6.8 m-85 -92.91 152.44 19.37 Favored 'General case' 0 C--N 1.285 -2.234 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.507 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . . . . . . . . . 86.0 mtp -102.1 106.98 17.93 Favored 'General case' 0 C--N 1.286 -2.177 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 171.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.454 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.4 mp -84.77 120.86 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.942 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -117.27 109.95 1.97 Allowed Glycine 1 CA--C 1.445 -4.283 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 179.219 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 7.3 tpp180 -69.72 94.57 0.81 Allowed 'General case' 0 C--N 1.279 -2.475 0 CA-C-N 114.6 -0.8 . . . . 0.0 109.431 177.122 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . 0.526 ' HA ' ' SD ' ' B' ' 3' ' ' MET . 31.8 tt0 -81.88 77.79 8.66 Favored 'General case' 0 N--CA 1.408 -2.549 0 CA-C-O 122.783 1.278 . . . . 0.0 107.762 173.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 28.3 ttm105 -78.71 -58.09 0.77 Allowed Pre-proline 0 N--CA 1.408 -2.55 0 CA-C-N 112.774 -2.012 . . . . 0.0 109.309 176.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -72.89 117.27 5.05 Favored 'Trans proline' 0 N--CA 1.424 -2.578 0 C-N-CA 121.376 1.384 . . . . 0.0 112.853 178.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -149.1 -37.16 0.04 OUTLIER Glycine 0 C--N 1.267 -3.277 0 CA-C-N 113.045 -1.888 . . . . 0.0 108.843 -179.453 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -80.59 22.5 0.57 Allowed 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 124.123 0.969 . . . . 0.0 110.904 176.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 84.1 mm-40 -85.48 114.25 22.37 Favored 'General case' 0 N--CA 1.407 -2.584 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.664 179.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 24.4 m -114.57 170.56 8.23 Favored 'General case' 0 C--N 1.279 -2.458 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 177.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 66.29 31.21 8.62 Favored 'General case' 0 CA--C 1.555 1.157 0 CA-C-O 122.565 1.174 . . . . 0.0 109.8 177.197 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 35.2 m -99.36 172.9 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 114.744 -1.116 . . . . 0.0 110.605 -177.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -118.93 -91.73 0.55 Allowed 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 114.122 1.156 . . . . 0.0 114.122 -176.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 10.2 pt20 -82.04 25.51 0.57 Allowed 'General case' 0 N--CA 1.476 0.855 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 -173.318 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 73.8 mt -83.7 -3.3 57.65 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-O 122.25 1.024 . . . . 0.0 108.349 174.749 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 46.5 mm -79.79 -65.68 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 CA-C-N 113.875 -1.511 . . . . 0.0 107.967 174.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -118.68 115.89 25.45 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.265 175.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -91.36 89.61 7.34 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 177.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 7.9 t -106.44 150.81 25.69 Favored 'General case' 0 N--CA 1.412 -2.344 0 CA-C-N 115.087 -0.961 . . . . 0.0 109.455 -178.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 28.4 mt -96.13 -5.39 40.85 Favored 'General case' 0 C--N 1.285 -2.204 0 CA-C-N 115.244 -0.889 . . . . 0.0 108.962 -178.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -135.3 79.05 1.76 Allowed 'General case' 0 N--CA 1.432 -1.346 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.417 178.12 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 59.9 tt0 -100.05 99.31 10.02 Favored 'General case' 0 C--N 1.306 -1.315 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 174.007 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 . . . . . 0 C--N 1.285 -2.228 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -173.288 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.502 -0.777 0 N-CA-C 110.226 -1.15 . . . . 0.0 110.226 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 60.5 m-70 -83.47 -45.14 13.97 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 171.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 19.7 ptp -96.44 149.68 21.45 Favored 'General case' 0 N--CA 1.425 -1.709 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 173.08 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -84.99 104.93 15.37 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 -177.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -79.55 83.73 5.5 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 173.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -102.58 143.02 25.76 Favored Pre-proline 0 C--N 1.294 -1.845 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.396 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . 0.536 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 51.1 Cg_endo -79.28 134.61 11.53 Favored 'Trans proline' 0 N--CA 1.429 -2.267 0 C-N-CA 121.634 1.556 . . . . 0.0 112.291 177.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 73.4 t -115.22 127.54 72.75 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 175.272 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . 0.497 ' O ' ' HD2' ' B' ' 53' ' ' ARG . 43.3 tt0 -119.59 116.12 25.38 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 -176.291 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.626 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -102.41 153.27 20.19 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.766 0.793 . . . . 0.0 110.761 -177.949 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.443 ' H ' HD23 ' B' ' 10' ' ' LEU . 80.4 mm-40 -99.68 103.36 15.03 Favored 'General case' 0 C--N 1.276 -2.607 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 174.718 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . 0.438 ' HE2' ' HB3' ' B' ' 12' ' ' LYS . 6.5 mmmm -81.61 157.02 24.86 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 114.301 1.223 . . . . 0.0 114.301 -171.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . 0.498 ' H ' ' HA3' ' B' ' 16' ' ' GLY . 22.1 m-20 -128.47 178.82 6.02 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 171.184 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 14.7 m -74.61 -19.56 60.26 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.652 0.739 . . . . 0.0 110.033 177.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 9.2 tp10 -128.56 31.49 4.98 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 105.762 -1.94 . . . . 0.0 105.762 176.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.498 ' HA3' ' H ' ' B' ' 13' ' ' ASP . . . -71.21 -5.03 58.16 Favored Glycine 0 CA--C 1.494 -1.263 0 CA-C-N 113.662 -1.608 . . . . 0.0 116.481 -169.181 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -75.16 86.45 2.41 Favored 'General case' 0 N--CA 1.429 -1.488 0 C-N-CA 119.302 -0.959 . . . . 0.0 111.096 177.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -96.78 55.45 1.37 Allowed Glycine 0 CA--C 1.484 -1.85 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 178.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 6.6 pt -161.67 -177.49 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 C-N-CA 124.7 1.2 . . . . 0.0 107.92 -175.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . 0.434 ' HB2' HG22 ' B' ' 41' ' ' THR . 43.2 m -149.65 145.61 26.83 Favored 'General case' 0 C--N 1.27 -2.865 0 N-CA-C 105.425 -2.065 . . . . 0.0 105.425 172.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.458 ' HB ' HG22 ' B' ' 37' ' ' ILE . 16.0 pt -115.95 154.1 17.48 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.297 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.3 tp -127.08 136.79 59.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 CA-C-O 120.884 0.374 . . . . 0.0 110.764 -176.044 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.58 98.08 2.38 Favored Glycine 0 N--CA 1.434 -1.438 0 C-N-CA 121.058 -0.591 . . . . 0.0 111.791 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 95.4 mmm -102.95 118.9 37.85 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 178.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 144.92 177.83 20.05 Favored Glycine 0 N--CA 1.425 -2.043 0 C-N-CA 119.959 -1.115 . . . . 0.0 113.099 177.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -159.29 154.49 25.31 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 177.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 164.82 -162.06 35.24 Favored Glycine 0 N--CA 1.434 -1.433 0 C-N-CA 120.072 -1.061 . . . . 0.0 112.542 178.651 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.69 98.45 10.7 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-O 120.835 0.35 . . . . 0.0 111.118 -179.11 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.422 ' HA ' ' HB3' ' B' ' 33' ' ' GLU . 9.7 p-10 -75.24 49.89 0.48 Allowed 'General case' 0 N--CA 1.445 -0.68 0 C-N-CA 125.056 1.342 . . . . 0.0 112.345 -177.811 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 25.9 ptt? -128.31 26.32 5.72 Favored 'General case' 0 C--N 1.29 -2.012 0 CA-C-N 115.067 -0.97 . . . . 0.0 109.423 -178.29 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.37 16.68 12.68 Favored Glycine 0 N--CA 1.444 -0.778 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.755 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 26.3 mt -150.5 26.91 0.75 Allowed 'General case' 0 C--O 1.25 1.12 0 C-N-CA 123.253 0.621 . . . . 0.0 111.134 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . 0.485 ' O ' ' HG ' ' B' ' 35' ' ' LEU . 2.4 pm0 -79.94 71.62 6.65 Favored 'General case' 0 N--CA 1.421 -1.921 0 CA-C-O 122.007 0.908 . . . . 0.0 108.654 175.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . 0.404 ' HA ' ' HA3' ' B' ' 70' ' ' GLY . 22.5 pttp -64.91 86.58 0.05 Allowed 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 114.202 -1.363 . . . . 0.0 109.452 176.735 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' B' ' 33' ' ' GLU . 74.9 mt -107.93 158.49 17.31 Favored 'General case' 0 N--CA 1.431 -1.399 0 CA-C-N 113.759 -1.564 . . . . 0.0 109.522 -175.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -107.75 98.27 1.24 Allowed Glycine 0 N--CA 1.404 -3.437 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 176.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.458 HG22 ' HB ' ' B' ' 21' ' ' ILE . 27.9 mm -87.35 87.78 2.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 177.058 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -85.69 166.54 16.06 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.399 -1.273 . . . . 0.0 108.705 -176.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 57.4 t -77.9 136.47 24.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 175.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -96.04 -42.07 8.44 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -178.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . 0.463 ' HA ' HG23 ' B' ' 56' ' ' VAL . 3.5 t -157.05 168.8 26.41 Favored 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 21.3 t -130.47 97.35 3.19 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 178.265 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 40.5 m -73.89 124.64 26.54 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 124.281 1.033 . . . . 0.0 111.709 -176.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . 0.579 ' HA ' ' HB3' ' B' ' 49' ' ' HIS . 1.7 pm0 -65.53 -22.41 66.71 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 124.44 1.096 . . . . 0.0 113.904 -178.042 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.54 -23.87 72.23 Favored Glycine 0 N--CA 1.439 -1.128 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.243 176.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -104.4 173.15 21.01 Favored Glycine 0 N--CA 1.424 -2.163 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.837 -177.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . 0.404 ' HB2' ' OD2' ' B' ' 13' ' ' ASP . . . -58.54 -41.34 85.34 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 125.205 1.402 . . . . 0.0 114.265 -175.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . 0.626 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -57.19 -37.52 72.28 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 114.227 1.195 . . . . 0.0 114.227 -173.39 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . 0.579 ' HB3' ' HA ' ' B' ' 44' ' ' GLU . 8.4 t60 -74.97 -35.4 62.07 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -178.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 68.9 mtt180 -68.43 -47.74 66.41 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 -178.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -60.41 -61.39 2.63 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 114.456 -1.247 . . . . 0.0 110.722 176.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 91.02 6.14 67.23 Favored Glycine 0 N--CA 1.433 -1.528 0 N-CA-C 114.824 0.69 . . . . 0.0 114.824 175.144 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.497 ' HD2' ' O ' ' B' ' 9' ' ' GLU . 65.4 mtt180 -83.3 -33.64 25.9 Favored 'General case' 0 N--CA 1.441 -0.892 0 CA-C-N 118.392 1.096 . . . . 0.0 111.316 179.107 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.445 HD11 ' CE2' ' B' ' 89' ' ' PHE . 28.8 mt -83.29 117.03 28.4 Favored 'Isoleucine or valine' 0 C--O 1.248 0.984 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 174.116 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 22.7 mt-30 -91.45 163.96 13.99 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 121.356 0.598 . . . . 0.0 110.47 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.463 HG23 ' HA ' ' B' ' 41' ' ' THR . 13.2 p -75.51 -2.11 3.79 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.854 0 CA-C-O 122.488 1.137 . . . . 0.0 109.976 178.361 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -114.02 0.06 14.21 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.058 -175.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -82.29 174.34 11.23 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 112.926 0.713 . . . . 0.0 112.926 -174.076 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 25.8 tp -141.6 131.15 23.91 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.54 -0.755 . . . . 0.0 110.521 -175.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -81.71 95.63 7.29 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.688 0.756 . . . . 0.0 110.22 178.227 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.569 ' HB ' ' O ' ' B' ' 90' ' ' MET . 27.8 t -86.95 -40.73 14.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.695 177.03 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.536 ' HG3' ' HA ' ' B' ' 67' ' ' SER . 32.4 tt0 -156.2 148.75 23.72 Favored 'General case' 0 C--N 1.273 -2.727 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.48 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.513 ' O ' ' HG2' ' B' ' 62' ' ' GLU . 9.9 p -102.39 -168.45 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 104.912 -2.255 . . . . 0.0 104.912 176.419 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.425 ' H ' HG22 ' B' ' 63' ' ' VAL . 12.2 t70 -50.19 -54.21 22.47 Favored 'General case' 0 N--CA 1.479 1.004 0 CA-C-N 119.189 0.904 . . . . 0.0 112.27 178.369 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -106.16 -53.78 0.73 Allowed Glycine 0 C--N 1.308 -0.989 0 C-N-CA 119.538 -1.315 . . . . 0.0 114.088 -178.3 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 6.1 m -72.37 120.81 18.51 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 123.101 0.56 . . . . 0.0 112.492 -174.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . 0.536 ' HA ' ' HG3' ' B' ' 62' ' ' GLU . 64.9 m -86.12 121.15 28.31 Favored 'General case' 0 N--CA 1.435 -1.204 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 174.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.471 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 28.9 mt -83.3 100.23 10.51 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-O 121.087 0.47 . . . . 0.0 110.226 -179.308 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 29.0 m -89.48 12.5 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-O 121.759 0.79 . . . . 0.0 109.463 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . 0.404 ' HA3' ' HA ' ' B' ' 34' ' ' LYS . . . 111.71 90.23 1.94 Allowed Glycine 0 N--CA 1.402 -3.615 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -174.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 26.4 m -117.15 174.4 3.73 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.28 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 20.7 p -76.87 159.86 29.7 Favored 'General case' 0 N--CA 1.413 -2.281 0 CA-C-O 120.957 0.408 . . . . 0.0 110.051 177.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 60.6 tt0 -58.66 -35.28 72.29 Favored 'General case' 0 C--N 1.311 -1.096 0 C-N-CA 123.788 0.835 . . . . 0.0 109.824 178.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 19.7 m -70.96 -39.14 72.73 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.576 179.559 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -62.56 -48.9 77.45 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.068 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.516 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -57.81 -45.42 86.11 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.258 179.304 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.01 -39.19 91.42 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.641 0.734 . . . . 0.0 110.792 178.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 50.6 m -71.83 -27.5 62.95 Favored 'General case' 0 N--CA 1.433 -1.32 0 CA-C-N 115.377 -0.829 . . . . 0.0 112.511 -177.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.516 HG12 ' O ' ' B' ' 76' ' ' ALA . 5.0 p -77.25 -30.4 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 C-N-CA 119.546 -0.862 . . . . 0.0 108.852 -177.164 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . 0.491 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 77.1 mt -67.46 -35.85 80.01 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.306 176.08 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 79.4 mtp180 -78.05 -32.74 51.01 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.275 178.317 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -72.3 -36.71 69.0 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 123.234 0.614 . . . . 0.0 111.478 -179.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.667 ' HB ' HG11 ' B' ' 87' ' ' VAL . 8.5 p -67.82 159.81 29.57 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 113.693 0.997 . . . . 0.0 113.693 -177.117 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -66.56 -166.07 0.04 OUTLIER 'General case' 0 C--O 1.255 1.371 0 C-N-CA 125.729 1.612 . . . . 0.0 114.806 -174.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' B' ' 12' ' ' LYS . . . -70.86 -17.12 75.03 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 114.631 -1.168 . . . . 0.0 113.3 -177.514 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . 0.522 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 57.1 ttp180 -157.49 118.3 3.54 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 121.165 0.507 . . . . 0.0 111.016 174.465 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.667 HG11 ' HB ' ' B' ' 83' ' ' THR . 14.8 m -132.1 145.72 34.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.237 179.351 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -98.05 128.89 44.85 Favored 'General case' 0 CA--C 1.482 -1.654 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.518 178.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.536 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 4.8 m-85 -105.38 157.36 17.39 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 106.965 -1.495 . . . . 0.0 106.965 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.569 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 63.0 mtt -109.87 117.51 34.02 Favored 'General case' 0 C--N 1.282 -2.352 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 172.134 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 1.4 mp -105.96 122.38 59.5 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 -179.157 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.37 103.76 2.51 Favored Glycine 0 CA--C 1.464 -3.11 0 N-CA-C 109.169 -1.573 . . . . 0.0 109.169 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 9.3 tpp180 -141.81 121.41 13.36 Favored 'General case' 0 C--N 1.265 -3.073 0 CA-C-N 114.214 -0.993 . . . . 0.0 110.572 -175.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -83.97 86.79 7.13 Favored 'General case' 0 N--CA 1.429 -1.519 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 168.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 45.6 ttt180 -65.96 -61.63 5.32 Favored Pre-proline 0 C--N 1.302 -1.488 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.612 179.099 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -74.69 136.47 21.13 Favored 'Trans proline' 0 N--CA 1.444 -1.438 0 C-N-CA 121.888 1.725 . . . . 0.0 114.379 -178.183 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -143.13 -94.85 0.2 Allowed Glycine 0 C--N 1.286 -2.246 0 N-CA-C 107.343 -2.303 . . . . 0.0 107.343 174.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -103.53 77.45 1.5 Allowed 'General case' 0 N--CA 1.421 -1.9 0 CA-C-O 122.659 1.218 . . . . 0.0 109.881 173.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -129.72 -66.69 0.78 Allowed 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 12.3 m -94.65 169.64 10.03 Favored 'General case' 0 N--CA 1.425 -1.682 0 N-CA-C 105.651 -1.981 . . . . 0.0 105.651 169.225 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 6.1 tm-20 70.28 8.76 6.77 Favored 'General case' 0 N--CA 1.479 0.986 0 CA-C-O 121.686 0.755 . . . . 0.0 111.457 176.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 15.8 m -65.3 113.78 2.32 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-O 121.965 0.888 . . . . 0.0 112.077 -178.344 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -118.44 -33.01 4.45 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.797 -1.092 . . . . 0.0 109.984 -177.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -78.63 93.27 4.84 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 175.127 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 82.0 mt -119.03 120.99 38.83 Favored 'General case' 0 C--N 1.297 -1.715 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.024 -173.068 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 1.7 mp -91.08 -56.37 5.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 174.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 13.1 mm100 -96.03 100.03 11.73 Favored 'General case' 0 N--CA 1.438 -1.066 0 CA-C-N 115.325 -0.852 . . . . 0.0 108.771 175.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 52.7 mt-30 -84.04 34.8 0.51 Allowed 'General case' 0 C--N 1.31 -1.113 0 C-N-CA 123.153 0.581 . . . . 0.0 111.752 -177.225 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 9.7 t -63.77 -25.41 68.17 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 122.979 0.512 . . . . 0.0 112.163 -177.037 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -81.22 -7.61 59.6 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -100.2 129.1 46.18 Favored 'General case' 0 N--CA 1.44 -0.961 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 175.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 45.2 mt-30 -82.85 148.26 27.84 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-O 120.935 0.397 . . . . 0.0 111.223 -174.026 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 . . . . . 0 C--N 1.302 -1.478 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.771 -177.949 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.205 0 CA-C-O 119.715 -0.492 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 15.0 t-80 -71.33 -69.92 0.35 Allowed 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 122.989 0.516 . . . . 0.0 109.835 -176.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 92.8 mmm -104.09 106.11 16.5 Favored 'General case' 0 CA--C 1.469 -2.171 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 177.126 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . 0.491 ' OE2' ' HD2' ' B' ' 93' ' ' ARG . 12.0 mt-10 -98.62 96.4 7.92 Favored 'General case' 0 C--N 1.275 -2.643 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.013 -175.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -84.38 97.51 9.52 Favored 'General case' 0 N--CA 1.427 -1.606 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 177.201 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -130.85 147.48 66.39 Favored Pre-proline 0 C--N 1.279 -2.495 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.481 177.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . 0.442 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 49.7 Cg_endo -75.84 136.89 19.28 Favored 'Trans proline' 0 N--CA 1.44 -1.65 0 C-N-CA 121.868 1.712 . . . . 0.0 111.625 175.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 91.4 t -121.56 148.54 24.93 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.071 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.091 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -126.98 143.65 51.23 Favored 'General case' 0 C--N 1.279 -2.469 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -177.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.55 HD11 ' HB2' ' B' ' 48' ' ' ALA . 0.8 OUTLIER -141.04 157.18 45.67 Favored 'General case' 0 CA--C 1.478 -1.789 0 CA-C-O 121.05 0.452 . . . . 0.0 109.908 174.431 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -127.15 112.59 15.32 Favored 'General case' 0 C--N 1.275 -2.632 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 177.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 5.4 ptpp? -77.14 150.77 35.55 Favored 'General case' 0 C--N 1.283 -2.317 0 CA-C-N 115.143 -0.935 . . . . 0.0 113.357 -172.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -93.78 -172.93 3.01 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 177.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 12.3 t -71.25 -25.65 62.57 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.954 -1.499 . . . . 0.0 106.954 173.09 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 11.9 tp10 -67.27 -20.87 65.71 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 114.663 -1.153 . . . . 0.0 109.444 172.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.07 -116.06 4.83 Favored Glycine 0 N--CA 1.416 -2.657 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -177.188 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -101.2 -175.06 2.76 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -178.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . 0.432 ' CA ' ' HA3' ' B' ' 46' ' ' GLY . . . -150.45 67.99 0.34 Allowed Glycine 0 CA--C 1.477 -2.325 0 N-CA-C 110.931 -0.868 . . . . 0.0 110.931 -179.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.466 ' HA ' ' H ' ' B' ' 43' ' ' THR . 4.3 pt -162.59 169.98 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.905 0 C-N-CA 125.277 1.431 . . . . 0.0 107.867 -176.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.4 m -131.76 141.99 49.65 Favored 'General case' 0 C--N 1.253 -3.611 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 174.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.502 ' HB ' HG22 ' B' ' 37' ' ' ILE . 8.6 pt -115.23 149.37 17.47 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.012 0 O-C-N 123.45 0.469 . . . . 0.0 109.81 -178.188 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.1 tp -119.22 134.88 61.42 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -177.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -97.74 94.58 1.55 Allowed Glycine 0 N--CA 1.43 -1.707 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.688 -177.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 88.9 mmm -84.05 113.23 20.87 Favored 'General case' 0 C--O 1.253 1.268 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -83.22 68.17 3.61 Favored Glycine 0 CA--C 1.481 -2.052 0 CA-C-O 122.268 0.926 . . . . 0.0 113.163 -175.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -163.72 -45.95 0.03 OUTLIER 'General case' 0 C--N 1.251 -3.692 0 CA-C-N 112.528 -1.836 . . . . 0.0 108.383 178.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 49.59 -119.58 6.7 Favored Glycine 0 C--N 1.27 -3.123 0 CA-C-N 111.358 -2.656 . . . . 0.0 113.206 178.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -121.79 89.09 3.05 Favored 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.538 ' HA ' ' HA ' ' B' ' 33' ' ' GLU . 17.6 t70 -69.0 -41.28 78.02 Favored 'General case' 0 CA--C 1.492 -1.284 0 N-CA-C 112.851 0.686 . . . . 0.0 112.851 -176.022 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 23.0 ptp -91.74 45.75 1.24 Allowed 'General case' 0 C--N 1.274 -2.675 0 CA-C-O 122.75 1.262 . . . . 0.0 108.899 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -161.01 -63.96 0.02 OUTLIER Glycine 0 N--CA 1.42 -2.376 0 CA-C-N 113.221 -1.809 . . . . 0.0 112.12 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -129.07 -3.97 5.05 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -174.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . 0.538 ' HA ' ' HA ' ' B' ' 29' ' ' ASP . 8.6 pt-20 49.01 22.04 0.54 Allowed 'General case' 0 N--CA 1.503 2.206 0 C-N-CA 126.439 1.895 . . . . 0.0 114.553 -175.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -130.85 175.46 9.03 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 112.115 0.413 . . . . 0.0 112.115 -177.112 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 78.6 mt -52.61 140.74 22.37 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 125.403 1.481 . . . . 0.0 113.955 -175.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -111.18 103.64 1.61 Allowed Glycine 0 N--CA 1.423 -2.212 0 N-CA-C 108.614 -1.794 . . . . 0.0 108.614 175.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.502 HG22 ' HB ' ' B' ' 21' ' ' ILE . 26.3 mm -94.15 90.38 2.8 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-O 121.674 0.749 . . . . 0.0 109.403 -177.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -88.79 167.07 13.59 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.207 -178.128 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 64.7 t -80.77 130.3 36.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 CA-C-O 121.28 0.562 . . . . 0.0 109.641 175.387 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -94.42 -41.11 9.56 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.218 -176.681 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -156.57 164.0 38.7 Favored 'General case' 0 N--CA 1.437 -1.082 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.412 ' HA ' HG22 ' B' ' 19' ' ' ILE . 21.3 t -112.05 102.52 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.031 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 174.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.466 ' H ' ' HA ' ' B' ' 19' ' ' ILE . 31.2 m -69.73 122.04 18.38 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 124.112 0.965 . . . . 0.0 111.825 -174.357 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . 0.473 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 32.8 mt-10 -58.23 -41.45 84.15 Favored 'General case' 0 CA--C 1.507 -0.695 0 C-N-CA 124.662 1.185 . . . . 0.0 111.736 -175.568 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -67.22 -12.24 60.37 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 115.197 -0.911 . . . . 0.0 114.237 -177.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.432 ' HA3' ' CA ' ' B' ' 18' ' ' GLY . . . -112.23 170.0 13.35 Favored Glycine 0 N--CA 1.41 -3.078 0 C-N-CA 120.124 -1.036 . . . . 0.0 113.797 -175.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -57.64 -35.07 70.02 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 115.045 1.498 . . . . 0.0 115.045 -171.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . 0.55 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -67.53 -35.46 79.12 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 119.952 -0.699 . . . . 0.0 112.695 -174.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . 0.473 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 5.4 t60 -78.53 -39.62 37.38 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 178.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 64.4 mtp180 -67.13 -39.48 86.6 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.683 -177.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -79.56 -48.63 13.51 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 177.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 94.15 51.22 2.1 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -178.452 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 13.1 mmt180 -109.75 -79.44 0.58 Allowed 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 111.85 0.315 . . . . 0.0 111.85 -175.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.488 HD11 ' CE2' ' B' ' 89' ' ' PHE . 62.7 mt -71.16 132.7 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.977 -179.203 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 -103.58 173.51 6.27 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.234 0.54 . . . . 0.0 110.996 -177.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.1 p -79.27 2.43 2.17 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.145 0 CA-C-O 121.949 0.88 . . . . 0.0 111.638 -174.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -121.46 11.36 10.65 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 122.218 1.009 . . . . 0.0 108.683 -175.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 19.2 m-20 -89.07 168.49 12.29 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.929 -175.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.511 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 23.5 tp -144.69 131.47 20.14 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 124.008 0.923 . . . . 0.0 108.83 -177.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 76.6 mt -85.08 94.23 8.8 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.506 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.2 t -80.09 -39.96 19.89 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 CA-C-O 121.739 0.78 . . . . 0.0 110.147 177.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -160.0 156.73 27.53 Favored 'General case' 0 C--N 1.28 -2.451 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.41 173.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.426 HG22 ' H ' ' B' ' 64' ' ' ASP . 5.7 p -102.01 -173.74 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 N-CA-C 105.455 -2.054 . . . . 0.0 105.455 177.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.436 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 18.0 t70 -53.79 -48.75 69.49 Favored 'General case' 0 C--N 1.311 -1.093 0 C-N-CA 122.992 0.517 . . . . 0.0 112.387 -179.471 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -101.87 -60.21 0.77 Allowed Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 120.22 -0.991 . . . . 0.0 114.187 -179.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 9.1 m -77.57 129.66 35.93 Favored 'General case' 0 CA--C 1.557 1.248 0 CA-C-O 121.164 0.507 . . . . 0.0 112.201 -176.119 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 49.4 m -94.44 121.84 36.39 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.058 178.358 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.506 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 32.0 mt -88.9 111.89 22.64 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.105 0.478 . . . . 0.0 111.838 -175.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 43.6 t -85.57 -23.67 7.06 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 174.597 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 147.63 68.6 0.01 OUTLIER Glycine 0 CA--C 1.475 -2.42 0 N-CA-C 109.396 -1.481 . . . . 0.0 109.396 -177.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 28.2 m -85.22 172.08 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 CA-C-N 114.467 -0.867 . . . . 0.0 109.383 -177.094 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 24.6 p -71.7 157.2 38.36 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 120.93 0.395 . . . . 0.0 110.138 177.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -57.43 -39.4 76.13 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 123.345 0.658 . . . . 0.0 110.458 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 40.0 t -68.17 -37.8 81.38 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.01 179.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -66.44 -45.45 79.79 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -179.124 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.591 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.2 -44.02 97.95 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.505 178.426 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.98 -34.12 75.58 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 121.756 0.788 . . . . 0.0 110.599 177.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 39.3 m -79.31 -27.68 42.16 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 115.489 -0.778 . . . . 0.0 112.094 -178.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.591 HG12 ' O ' ' B' ' 76' ' ' ALA . 4.5 p -71.53 -31.97 44.43 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 CA-C-O 121.906 0.86 . . . . 0.0 109.07 -175.711 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 53.9 mt -66.03 -29.44 69.8 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 114.528 -1.214 . . . . 0.0 110.553 176.425 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 71.4 mtt180 -90.74 -16.85 27.71 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.373 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -90.38 -14.65 32.58 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.038 0.447 . . . . 0.0 111.268 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.722 ' HB ' HG11 ' B' ' 87' ' ' VAL . 6.7 p -90.63 171.76 9.16 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 77.1 mttt -60.37 -178.7 0.09 Allowed 'General case' 0 C--O 1.245 0.817 0 C-N-CA 124.612 1.165 . . . . 0.0 114.077 -179.06 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.38 -52.06 46.98 Favored Glycine 0 N--CA 1.44 -1.049 0 CA-C-N 114.208 -1.36 . . . . 0.0 111.117 177.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 14.5 ttp180 -114.82 117.64 31.31 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 177.068 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.722 HG11 ' HB ' ' B' ' 83' ' ' THR . 14.0 m -132.13 157.57 43.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.353 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 15.9 mtm180 -108.5 152.64 24.45 Favored 'General case' 0 N--CA 1.422 -1.833 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 179.435 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.488 ' CE2' HD11 ' B' ' 54' ' ' ILE . 1.7 m-85 -133.5 164.99 25.91 Favored 'General case' 0 C--N 1.267 -3.004 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 179.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.457 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 84.3 mtp -112.82 117.43 32.14 Favored 'General case' 0 C--N 1.286 -2.195 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 170.571 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.511 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.5 mp -102.88 133.18 47.36 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.395 -177.11 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -113.6 93.86 0.68 Allowed Glycine 0 CA--C 1.463 -3.208 0 N-CA-C 108.18 -1.968 . . . . 0.0 108.18 172.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . 0.491 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 36.8 ttm180 -71.34 126.71 30.34 Favored 'General case' 0 C--N 1.273 -2.754 0 CA-C-N 114.244 -0.978 . . . . 0.0 111.152 -175.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -87.7 74.26 9.19 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 172.205 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 10.9 ttm180 -56.07 -59.36 11.97 Favored Pre-proline 0 C--O 1.239 0.532 0 CA-C-N 115.002 -0.999 . . . . 0.0 112.779 -178.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -60.21 111.95 1.16 Allowed 'Trans proline' 0 N--CA 1.424 -2.608 0 C-N-CA 121.4 1.4 . . . . 0.0 112.514 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -177.97 -59.35 0.07 OUTLIER Glycine 0 C--N 1.263 -3.506 1 N-CA-C 102.862 -4.095 . . . . 0.0 102.862 -176.48 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -94.15 85.9 4.81 Favored 'General case' 0 N--CA 1.428 -1.565 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 166.144 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . 0.557 HE21 ' HA ' ' B' ' 99' ' ' GLN . 0.0 OUTLIER -157.16 -51.13 0.07 Allowed 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 102.678 -3.082 . . . . 0.0 102.678 -179.365 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 19.9 m -86.16 -179.09 6.66 Favored 'General case' 0 N--CA 1.427 -1.617 0 N-CA-C 103.847 -2.649 . . . . 0.0 103.847 161.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 54.4 73.45 0.4 Allowed 'General case' 0 N--CA 1.441 -0.92 0 CA-C-N 118.741 0.7 . . . . 0.0 109.649 -173.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 9.0 p -137.97 171.36 15.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 -175.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . 71.86 86.84 0.11 Allowed 'General case' 0 N--CA 1.442 -0.857 0 C-N-CA 125.298 1.439 . . . . 0.0 113.041 177.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 55.71 88.51 0.04 OUTLIER 'General case' 0 C--O 1.246 0.878 0 C-N-CA 124.851 1.26 . . . . 0.0 111.573 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . 0.273 36.0 mt -75.72 75.59 2.7 Favored 'General case' 0 CA--C 1.508 -0.656 0 N-CA-C 115.176 1.547 . . . . 0.0 115.176 -173.605 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 15.5 mm -150.81 -57.71 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.283 -2.318 0 N-CA-C 102.386 -3.19 . . . . 0.0 102.386 170.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 9.3 tt0 49.92 65.92 1.28 Allowed 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 113.13 -1.85 . . . . 0.0 112.252 175.215 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -92.53 -21.55 20.06 Favored 'General case' 0 C--N 1.312 -1.043 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 174.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 12.5 t -90.25 163.14 14.89 Favored 'General case' 0 N--CA 1.411 -2.403 0 N-CA-C 105.605 -1.998 . . . . 0.0 105.605 172.393 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 92.2 mt 68.12 -79.7 0.04 OUTLIER 'General case' 0 C--N 1.309 -1.193 0 C-N-CA 123.979 0.912 . . . . 0.0 111.591 -178.204 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 65.34 -49.34 0.37 Allowed 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 126.242 1.817 . . . . 0.0 111.858 -175.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 27.1 tp60 -123.59 101.03 7.09 Favored 'General case' 0 N--CA 1.418 -2.05 0 N-CA-C 108.309 -0.996 . . . . 0.0 108.309 176.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 . . . . . 0 C--N 1.292 -1.93 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 175.273 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.49 -1.484 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 25.6 t-80 -63.57 -44.6 93.61 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 174.46 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 20.2 ptp -102.07 142.04 33.96 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 172.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . 0.489 ' OE2' ' HG2' ' B' ' 93' ' ' ARG . 2.6 mt-10 -116.35 101.56 8.77 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -93.1 91.04 7.13 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 -179.125 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -117.67 146.52 38.9 Favored Pre-proline 0 C--N 1.29 -1.998 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.307 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -81.1 144.25 14.72 Favored 'Trans proline' 0 N--CA 1.449 -1.089 0 C-N-CA 122.5 2.133 . . . . 0.0 112.811 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.588 HG13 ' HB3' ' B' ' 53' ' ' ARG . 73.6 t -127.94 133.87 66.39 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.032 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -121.24 125.49 47.24 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 118.477 0.58 . . . . 0.0 110.173 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.449 ' CD1' ' H ' ' B' ' 54' ' ' ILE . 0.9 OUTLIER -148.82 175.95 10.81 Favored 'General case' 0 N--CA 1.438 -1.037 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -178.188 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -147.03 178.02 8.69 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.086 -178.622 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -93.02 153.85 18.48 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.248 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . 0.559 ' HB2' ' N ' ' B' ' 47' ' ' ALA . 10.8 t70 -103.17 -164.37 1.07 Allowed 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 22.8 p -55.43 -44.28 76.14 Favored 'General case' 0 C--O 1.243 0.756 0 C-N-CA 124.558 1.143 . . . . 0.0 111.57 -179.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -78.3 -48.72 15.06 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 177.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 142.08 -120.54 1.64 Allowed Glycine 0 N--CA 1.426 -2.006 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.831 178.171 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -89.23 101.4 14.06 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 121.397 0.618 . . . . 0.0 111.293 -178.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -92.12 59.84 2.7 Favored Glycine 0 C--O 1.21 -1.369 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 177.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.499 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.0 pt -155.46 178.92 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 C-N-CA 125.406 1.482 . . . . 0.0 107.128 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . 0.472 ' HB2' HG22 ' B' ' 41' ' ' THR . 51.0 m -158.19 155.81 29.71 Favored 'General case' 0 C--N 1.27 -2.88 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 176.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.457 ' HB ' HG22 ' B' ' 37' ' ' ILE . 18.6 pt -115.71 161.12 14.69 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 O-C-N 123.445 0.466 . . . . 0.0 110.343 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . 0.429 ' HA ' ' NE2' ' B' ' 73' ' ' GLN . 8.1 tp -140.5 135.51 35.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.24 112.11 3.85 Favored Glycine 0 N--CA 1.428 -1.846 0 C-N-CA 120.494 -0.86 . . . . 0.0 111.982 -178.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 93.9 mmm -111.8 141.89 44.85 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 176.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.18 134.66 12.91 Favored Glycine 0 N--CA 1.423 -2.228 0 C-N-CA 119.599 -1.286 . . . . 0.0 111.624 -179.138 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -132.44 128.13 36.8 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 176.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -123.32 32.92 4.17 Favored Glycine 0 N--CA 1.427 -1.96 0 C-N-CA 119.338 -1.41 . . . . 0.0 113.955 -172.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.623 ' HB3' ' HB2' ' B' ' 33' ' ' GLU . . . -84.58 69.6 10.63 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 122.688 1.232 . . . . 0.0 108.546 177.457 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -74.63 -24.45 58.85 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 113.443 -1.708 . . . . 0.0 110.735 -174.18 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 23.2 ptp -63.62 -23.6 67.45 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 114.436 -1.256 . . . . 0.0 110.203 178.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -105.02 -73.45 0.91 Allowed Glycine 0 N--CA 1.416 -2.667 0 N-CA-C 110.106 -1.198 . . . . 0.0 110.106 177.29 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . 0.518 ' HG ' ' O ' ' B' ' 32' ' ' LEU . 18.7 tp 167.4 18.11 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 123.471 0.709 . . . . 0.0 110.647 -176.717 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . 0.623 ' HB2' ' HB3' ' B' ' 28' ' ' ALA . 16.4 mm-40 -100.98 82.98 2.45 Favored 'General case' 0 C--N 1.295 -1.764 0 O-C-N 120.84 -1.162 . . . . 0.0 108.328 -172.255 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? -82.15 -171.35 3.36 Favored 'General case' 0 C--N 1.278 -2.512 0 CA-C-N 112.991 -1.913 . . . . 0.0 110.235 175.854 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . 0.547 HD22 ' H ' ' B' ' 35' ' ' LEU . 3.0 mm? -35.7 119.37 0.54 Allowed 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 124.882 1.273 . . . . 0.0 113.164 -178.149 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -99.0 103.82 2.8 Favored Glycine 0 N--CA 1.414 -2.805 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.854 -176.326 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.457 HG22 ' HB ' ' B' ' 21' ' ' ILE . 30.2 mm -88.45 89.2 3.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.876 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.566 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.477 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 89.6 m-85 -82.3 173.45 12.06 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 114.674 -1.148 . . . . 0.0 109.981 -176.639 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.41 HG11 ' O ' ' B' ' 55' ' ' GLN . 59.3 t -83.42 137.09 21.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 175.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 32.2 ttmt -93.77 -48.87 6.11 Favored 'General case' 0 N--CA 1.433 -1.289 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.784 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . 0.495 ' HA ' HG23 ' B' ' 56' ' ' VAL . 5.2 t -150.03 170.79 18.05 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.499 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.7 p -156.42 113.25 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 C-N-CA 124.587 1.155 . . . . 0.0 108.005 -177.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.415 HG22 ' H ' ' B' ' 45' ' ' GLY . 32.1 m -112.14 144.81 40.91 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 114.856 -1.066 . . . . 0.0 110.061 -171.199 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . 0.478 ' HA ' ' HB3' ' B' ' 49' ' ' HIS . 9.0 pt-20 -71.75 4.46 3.23 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -178.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . 0.415 ' H ' HG22 ' B' ' 43' ' ' THR . . . -74.79 -19.5 79.89 Favored Glycine 0 N--CA 1.436 -1.329 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 172.753 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -113.03 169.49 12.97 Favored Glycine 0 N--CA 1.413 -2.86 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 175.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . 0.559 ' N ' ' HB2' ' B' ' 13' ' ' ASP . . . -75.18 -23.94 57.78 Favored 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 115.096 -0.552 . . . . 0.0 111.274 -175.251 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . 0.446 ' HA ' ' CD1' ' B' ' 10' ' ' LEU . . . -56.46 -44.56 80.67 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -176.111 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . 0.479 ' HB2' HG22 ' B' ' 42' ' ' VAL . 10.3 t60 -73.49 -41.27 63.32 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.381 -179.059 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 81.5 mtp180 -72.42 -34.88 68.15 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.43 0.633 . . . . 0.0 110.945 -174.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . 0.502 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 30.4 t70 -72.42 -49.99 29.55 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.889 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.7 27.49 9.64 Favored Glycine 0 CA--C 1.494 -1.259 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.486 172.132 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.588 ' HB3' HG13 ' B' ' 8' ' ' VAL . 5.4 mpt_? -101.39 -60.17 1.57 Allowed 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 112.008 0.373 . . . . 0.0 112.008 -179.276 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.567 HD11 ' CE2' ' B' ' 89' ' ' PHE . 58.7 mt -72.79 134.82 29.04 Favored 'Isoleucine or valine' 0 C--O 1.251 1.157 0 N-CA-C 107.1 -1.445 . . . . 0.0 107.1 169.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . 0.41 ' O ' HG11 ' B' ' 39' ' ' VAL . 15.3 mm100 -110.19 -170.74 1.7 Allowed 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -174.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.495 HG23 ' HA ' ' B' ' 41' ' ' THR . 8.0 p -100.39 4.87 10.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 CA-C-O 121.567 0.698 . . . . 0.0 110.083 174.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 19.9 t-20 -133.28 10.98 4.16 Favored 'General case' 0 C--N 1.311 -1.104 0 O-C-N 121.623 -0.673 . . . . 0.0 111.965 -174.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -94.86 -173.64 3.04 Favored 'General case' 0 C--N 1.318 -0.804 0 O-C-N 121.308 -0.87 . . . . 0.0 111.381 179.127 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.477 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 25.8 tp -144.92 125.4 13.98 Favored 'General case' 0 C--N 1.318 -0.769 0 C-N-CA 123.194 0.598 . . . . 0.0 111.116 -172.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . 0.438 ' O ' HD12 ' B' ' 68' ' ' LEU . 68.9 mt -83.69 96.49 8.72 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.399 0.618 . . . . 0.0 109.369 178.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.571 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 9.2 t -79.28 -37.32 18.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 CA-C-O 121.685 0.755 . . . . 0.0 111.133 178.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.401 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 10.4 pt-20 -157.02 153.51 28.09 Favored 'General case' 0 C--N 1.276 -2.608 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.506 176.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.464 HG22 ' H ' ' B' ' 64' ' ' ASP . 5.2 p -100.52 -174.63 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.42 -1.975 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 178.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.464 ' H ' HG22 ' B' ' 63' ' ' VAL . 28.1 t70 -53.18 -42.46 66.23 Favored 'General case' 0 C--N 1.311 -1.078 0 C-N-CA 124.138 0.975 . . . . 0.0 112.475 -178.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -106.91 -66.24 0.63 Allowed Glycine 0 N--CA 1.439 -1.161 0 C-N-CA 120.813 -0.708 . . . . 0.0 113.627 179.199 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 7.2 m -74.1 135.7 42.96 Favored 'General case' 0 CA--C 1.554 1.099 0 C-N-CA 122.882 0.473 . . . . 0.0 112.266 -175.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 15.9 m -96.31 126.49 41.55 Favored 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 177.116 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.571 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 28.9 mt -83.28 -69.86 0.6 Allowed 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 112.241 0.459 . . . . 0.0 112.241 -177.131 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 86.8 t 73.28 -27.2 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 124.189 0.995 . . . . 0.0 111.246 -175.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . 0.514 ' HA2' ' O ' ' B' ' 35' ' ' LEU . . . 153.16 81.39 0.03 OUTLIER Glycine 0 N--CA 1.42 -2.404 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -178.211 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.1 m -106.76 -179.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 39.9 p -78.63 156.51 29.03 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 175.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . 0.429 ' NE2' ' HA ' ' B' ' 22' ' ' ILE . 61.9 tt0 -58.4 -39.4 79.6 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.23 0.538 . . . . 0.0 110.637 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 14.9 m -66.82 -35.47 80.12 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.73 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -65.33 -49.36 69.71 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 179.049 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.553 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -59.51 -40.73 88.03 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.069 178.586 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.34 -32.65 73.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.331 0.586 . . . . 0.0 110.468 177.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.6 m -79.25 -28.44 42.43 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.454 -178.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.553 HG12 ' O ' ' B' ' 76' ' ' ALA . 5.7 p -72.6 -36.31 53.23 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.889 0 C-N-CA 119.574 -0.851 . . . . 0.0 109.172 -176.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 26.3 mt -70.44 -7.14 40.97 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.848 178.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 68.5 mtp180 -108.66 -1.51 19.44 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 121.617 0.723 . . . . 0.0 110.102 177.438 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 32.2 m-80 -115.06 6.41 15.2 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.067 176.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.53 HG23 ' O ' ' B' ' 79' ' ' VAL . 7.7 p -87.2 175.81 7.87 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.323 -178.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 28.8 mmtm -75.64 -169.18 0.99 Allowed 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.472 0.709 . . . . 0.0 109.733 174.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.17 -38.97 45.93 Favored Glycine 0 N--CA 1.444 -0.827 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 177.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -124.31 131.56 53.52 Favored 'General case' 0 N--CA 1.431 -1.397 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.516 HG11 ' HB ' ' B' ' 83' ' ' THR . 11.2 m -142.08 153.01 18.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 CA-C-O 121.53 0.681 . . . . 0.0 111.445 -179.584 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 -96.05 164.07 12.86 Favored 'General case' 0 C--N 1.291 -1.975 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 174.05 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.567 ' CE2' HD11 ' B' ' 54' ' ' ILE . 8.9 m-85 -145.28 157.33 44.08 Favored 'General case' 0 C--N 1.284 -2.261 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 177.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.505 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 81.0 mtp -112.38 120.15 40.69 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 169.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.464 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -98.58 119.04 46.06 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.164 0 CA-C-N 114.246 -1.343 . . . . 0.0 109.485 -175.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -96.93 93.3 1.45 Allowed Glycine 0 CA--C 1.457 -3.57 0 N-CA-C 106.96 -2.456 . . . . 0.0 106.96 172.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . 0.489 ' HG2' ' OE2' ' B' ' 4' ' ' GLU . 5.9 tpt180 -62.81 107.84 1.06 Allowed 'General case' 0 C--N 1.257 -3.429 0 CA-C-N 112.932 -1.634 . . . . 0.0 113.129 -174.278 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -79.41 94.34 5.52 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 104.642 -2.355 . . . . 0.0 104.642 165.75 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . 0.577 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 49.4 ttt180 -88.85 -55.87 0.3 Allowed Pre-proline 0 N--CA 1.398 -3.074 0 CA-C-N 113.098 -1.865 . . . . 0.0 108.827 173.227 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . 0.577 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 84.9 Cg_endo -88.81 108.56 0.49 Allowed 'Trans proline' 0 N--CA 1.426 -2.49 0 CA-C-O 123.448 1.353 . . . . 0.0 114.927 174.256 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -113.44 -11.46 13.24 Favored Glycine 1 C--N 1.251 -4.163 0 CA-C-N 112.467 -2.152 . . . . 0.0 108.255 174.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -89.45 11.03 20.5 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.482 -1.359 . . . . 0.0 109.466 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 52.3 mt-30 -126.82 135.21 50.71 Favored 'General case' 0 N--CA 1.402 -2.847 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 175.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 11.0 m -79.57 175.51 10.55 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 123.869 0.731 . . . . 0.0 111.995 -175.443 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -85.39 69.6 10.72 Favored 'General case' 0 N--CA 1.442 -0.862 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 -178.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -134.99 133.03 53.67 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.196 0 CA-C-N 114.185 -1.371 . . . . 0.0 112.461 179.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -141.92 -65.83 0.41 Allowed 'General case' 0 C--N 1.294 -1.836 0 CA-C-N 114.47 -1.241 . . . . 0.0 108.038 175.15 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -162.82 120.73 2.03 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.601 175.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -109.35 138.15 46.13 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 116.326 -0.397 . . . . 0.0 109.959 -179.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 31.5 mm -78.47 -56.39 7.55 Favored 'Isoleucine or valine' 0 C--O 1.246 0.875 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 176.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -67.11 109.34 2.99 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 170.288 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 15.7 tp60 167.5 -23.27 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 127.605 2.362 . . . . 0.0 105.091 -165.588 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . 0.473 HG23 ' HG2' ' B' ' 111' ' ' GLU . 8.9 t -69.55 -12.43 61.64 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 113.043 -1.89 . . . . 0.0 111.531 178.428 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 49.6 mt 73.7 33.07 1.07 Allowed 'General case' 0 C--N 1.342 0.242 0 C-N-CA 123.926 0.89 . . . . 0.0 112.33 173.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . 0.473 ' HG2' HG23 ' B' ' 109' ' ' THR . 5.6 mm-40 -80.41 -12.2 59.6 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 121.99 0.9 . . . . 0.0 108.975 174.435 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 9.9 pt20 -176.85 -35.86 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 127.19 2.196 . . . . 0.0 105.504 178.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 . . . . . 0 N--CA 1.407 -2.591 0 N-CA-C 105.636 -1.986 . . . . 0.0 105.636 175.289 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.84 0 N-CA-C 111.671 -0.571 . . . . 0.0 111.671 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 84.2 m-70 -154.19 -162.84 1.49 Allowed 'General case' 0 C--O 1.243 0.721 0 N-CA-C 105.871 -1.9 . . . . 0.0 105.871 -178.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -68.15 129.5 40.12 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 104.704 -2.332 . . . . 0.0 104.704 164.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . 0.57 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 18.4 mt-10 -87.72 101.08 13.33 Favored 'General case' 0 C--N 1.293 -1.871 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.263 -171.128 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -85.62 85.73 7.4 Favored 'General case' 0 N--CA 1.428 -1.531 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 176.101 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -109.43 142.43 25.66 Favored Pre-proline 0 C--N 1.295 -1.801 0 C-N-CA 120.461 -0.496 . . . . 0.0 112.229 -178.026 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . 0.422 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 42.0 Cg_endo -80.34 126.4 6.17 Favored 'Trans proline' 0 N--CA 1.428 -2.371 0 C-N-CA 121.943 1.762 . . . . 0.0 112.541 177.105 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 95.2 t -107.08 151.94 8.78 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.82 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 175.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . 0.464 ' O ' ' HG2' ' B' ' 53' ' ' ARG . 45.0 tt0 -138.12 136.16 36.46 Favored 'General case' 0 C--N 1.293 -1.852 0 CA-C-N 119.005 0.82 . . . . 0.0 109.696 -176.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.523 HD21 ' HA ' ' B' ' 48' ' ' ALA . 4.5 mt -139.34 165.31 27.54 Favored 'General case' 0 CA--C 1.475 -1.906 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 179.625 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -151.12 146.68 26.31 Favored 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 104.503 -2.406 . . . . 0.0 104.503 177.348 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.5 ptpt -88.41 171.33 10.2 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.883 0.849 . . . . 0.0 112.177 -174.184 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . 0.412 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 19.5 t70 -99.92 176.61 5.37 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.804 -1.089 . . . . 0.0 108.214 176.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 7.0 m -59.66 -33.12 71.14 Favored 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 123.939 0.895 . . . . 0.0 109.261 175.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -77.15 -45.63 26.11 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 174.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.25 -138.36 7.65 Favored Glycine 0 N--CA 1.435 -1.406 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.273 179.255 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 91.8 mt -82.03 -176.24 6.04 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 123.033 0.533 . . . . 0.0 110.99 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . 0.418 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -158.13 66.06 0.29 Allowed Glycine 0 CA--C 1.487 -1.665 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.614 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 pt -166.73 175.91 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.49 -1.361 0 C-N-CA 124.815 1.246 . . . . 0.0 108.408 -177.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . 0.406 ' HB2' HG22 ' B' ' 41' ' ' THR . 29.2 m -148.53 144.17 27.14 Favored 'General case' 0 C--N 1.27 -2.859 0 N-CA-C 105.784 -1.932 . . . . 0.0 105.784 174.011 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.497 ' HB ' HG22 ' B' ' 37' ' ' ILE . 11.0 pt -115.09 158.13 15.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 CA-C-N 117.866 0.303 . . . . 0.0 110.395 -177.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 10.3 tp -139.32 140.75 37.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-O 120.636 0.255 . . . . 0.0 110.415 -176.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -91.24 109.53 3.72 Favored Glycine 0 N--CA 1.435 -1.398 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.687 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 66.2 mtt -122.7 114.92 21.22 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 177.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 162.15 -157.38 29.21 Favored Glycine 0 C--N 1.284 -2.359 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 -177.194 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -144.48 107.7 4.56 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 177.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.73 53.44 4.71 Favored Glycine 0 CA--C 1.488 -1.63 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.569 -177.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -160.57 86.71 0.74 Allowed 'General case' 0 N--CA 1.408 -2.537 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 177.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -129.0 21.5 5.81 Favored 'General case' 0 C--N 1.277 -2.573 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -177.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . 0.318 20.7 ptm 42.53 58.88 2.94 Favored 'General case' 0 CA--C 1.506 -0.735 0 CA-C-N 112.982 -1.917 . . . . 0.0 113.241 -174.156 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 146.91 -66.6 0.41 Allowed Glycine 0 N--CA 1.431 -1.656 0 CA-C-N 114.024 -1.444 . . . . 0.0 111.906 177.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 86.9 mt -71.17 -34.31 70.82 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 111.871 0.323 . . . . 0.0 111.871 -177.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 46.93 53.41 10.5 Favored 'General case' 0 C--N 1.349 0.578 0 C-N-CA 124.669 1.188 . . . . 0.0 108.661 -176.145 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 14.1 ptmm? -77.75 105.7 9.09 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 115.515 1.672 . . . . 0.0 115.515 -166.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 70.1 mt -108.78 129.34 55.38 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 114.504 -1.225 . . . . 0.0 108.583 172.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -96.85 109.97 3.95 Favored Glycine 0 N--CA 1.419 -2.46 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.497 HG22 ' HB ' ' B' ' 21' ' ' ILE . 28.4 mm -89.09 92.04 3.85 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -85.68 169.01 13.87 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.106 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.436 HG21 HG23 ' B' ' 54' ' ' ILE . 59.5 t -82.77 136.57 22.6 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.496 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 174.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 31.1 ttpt -96.57 -35.9 10.92 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.085 0.469 . . . . 0.0 110.088 -176.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . 0.406 HG22 ' HB2' ' B' ' 20' ' ' SER . 2.8 t -161.27 165.28 29.44 Favored 'General case' 0 C--O 1.251 1.182 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . . . . . . . . . 20.4 t -126.8 93.24 2.21 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.025 0 N-CA-C 106.843 -1.539 . . . . 0.0 106.843 177.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 20.8 m -60.91 123.32 17.24 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 115.207 -0.906 . . . . 0.0 111.282 -177.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . 0.435 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 12.7 pt-20 -70.43 -23.77 62.79 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-N 115.804 -0.634 . . . . 0.0 112.478 -174.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.32 -11.77 82.11 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 121.075 -0.584 . . . . 0.0 112.729 179.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.418 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -110.29 172.82 15.89 Favored Glycine 0 N--CA 1.413 -2.847 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.007 -178.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . 0.412 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -61.34 -35.7 78.15 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 114.998 1.481 . . . . 0.0 114.998 -172.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . 0.523 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -61.37 -42.17 98.27 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -172.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . 0.435 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 5.0 t60 -71.22 -40.85 70.87 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 122.143 0.973 . . . . 0.0 108.864 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 71.1 mtp180 -69.05 -29.65 67.83 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.34 -177.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . 0.64 ' OD2' ' HD3' ' B' ' 53' ' ' ARG . 11.9 t70 -82.0 -45.44 15.32 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.61 35.28 6.57 Favored Glycine 0 CA--C 1.494 -1.263 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.637 173.529 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.64 ' HD3' ' OD2' ' B' ' 51' ' ' ASP . 5.3 mpt_? -107.82 -74.77 0.65 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.288 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.436 HG23 HG21 ' B' ' 39' ' ' VAL . 27.9 mt -68.52 118.43 12.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 C-N-CA 120.051 -0.659 . . . . 0.0 110.033 177.187 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 14.8 mm100 -104.25 -179.48 3.96 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 8.1 p -80.82 2.02 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.173 0 CA-C-O 122.253 1.025 . . . . 0.0 111.099 -175.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 25.3 t-20 -110.76 1.29 17.72 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 122.138 0.971 . . . . 0.0 109.496 -177.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -78.93 155.01 29.2 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.233 -177.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 26.7 tp -139.3 126.68 21.51 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.735 -176.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 68.6 mt -79.3 91.47 5.03 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.258 0.551 . . . . 0.0 109.836 179.186 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.616 ' HB ' ' O ' ' B' ' 90' ' ' MET . 24.1 t -82.64 -39.28 15.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.997 0 CA-C-O 122.001 0.905 . . . . 0.0 110.053 177.272 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.426 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 10.9 pt-20 -162.2 157.27 22.83 Favored 'General case' 0 C--N 1.28 -2.42 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.411 172.532 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.621 HG12 ' HB ' ' B' ' 66' ' ' THR . 3.7 p -94.11 -177.86 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 N-CA-C 105.638 -1.986 . . . . 0.0 105.638 178.104 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.584 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.2 t70 -44.54 -48.64 10.24 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 124.721 1.208 . . . . 0.0 112.975 -177.532 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -140.56 45.5 0.98 Allowed Glycine 0 CA--C 1.525 0.702 0 C-N-CA 119.991 -1.099 . . . . 0.0 113.847 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . 0.621 ' HB ' HG12 ' B' ' 63' ' ' VAL . 45.5 m -158.42 119.51 3.42 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 177.375 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . 0.419 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 45.8 m -85.48 133.18 34.1 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -175.788 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.521 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 23.9 mt -99.67 138.44 36.75 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.665 174.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -116.92 -26.77 2.63 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 CA-C-O 122.132 0.968 . . . . 0.0 109.146 173.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 160.45 87.75 0.06 OUTLIER Glycine 0 N--CA 1.399 -3.83 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 -176.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 m -111.58 173.17 2.54 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.667 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 41.7 p -75.21 160.2 30.68 Favored 'General case' 0 C--N 1.289 -2.039 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 176.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -59.57 -35.27 73.94 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 177.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 12.6 m -69.73 -41.03 75.82 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.632 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -63.54 -45.67 89.51 Favored 'General case' 0 CA--C 1.514 -0.429 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.538 ' O ' ' HG ' ' B' ' 80' ' ' LEU . . . -58.46 -46.26 86.95 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.487 178.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.39 -34.93 74.62 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.593 0.711 . . . . 0.0 110.736 178.067 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 45.5 m -80.37 -21.47 42.32 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 113.043 0.756 . . . . 0.0 113.043 -177.452 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.52 HG12 ' O ' ' B' ' 76' ' ' ALA . 8.4 p -78.52 -31.58 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.484 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 63.4 mt -69.39 -13.54 62.42 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.656 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -107.88 -0.64 21.37 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.503 0.668 . . . . 0.0 110.898 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -99.0 -23.74 15.18 Favored 'General case' 0 C--O 1.248 0.981 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.021 178.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.646 ' HB ' HG11 ' B' ' 87' ' ' VAL . 2.1 p -68.47 169.42 10.88 Favored 'General case' 0 N--CA 1.422 -1.841 0 CA-C-N 114.517 -1.22 . . . . 0.0 114.01 -176.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 41.0 mmtm -70.58 -170.78 0.43 Allowed 'General case' 0 N--CA 1.437 -1.099 0 CA-C-N 115.132 -0.94 . . . . 0.0 112.488 178.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.38 -35.33 90.83 Favored Glycine 0 C--O 1.217 -0.946 0 CA-C-N 114.776 -1.102 . . . . 0.0 114.275 -176.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 34.3 ttp180 -143.0 125.04 15.26 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.646 HG11 ' HB ' ' B' ' 83' ' ' THR . 14.0 m -133.11 154.71 39.98 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.746 0 CA-C-O 121.804 0.812 . . . . 0.0 112.559 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 87.4 mtm180 -94.5 170.6 9.36 Favored 'General case' 0 N--CA 1.41 -2.429 0 CA-C-N 113.681 -1.6 . . . . 0.0 108.489 173.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.459 ' HB2' ' CD1' ' B' ' 91' ' ' ILE . 6.2 m-85 -145.55 149.11 34.0 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 175.486 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.616 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 1.1 mpt? -103.68 108.58 19.93 Favored 'General case' 0 C--N 1.276 -2.626 0 CA-C-O 121.604 0.716 . . . . 0.0 109.567 176.112 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.459 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.4 mp -98.84 110.92 27.18 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 114.329 -1.305 . . . . 0.0 107.95 -179.086 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . 0.57 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -104.15 103.71 2.33 Favored Glycine 0 CA--C 1.458 -3.514 0 N-CA-C 107.987 -2.045 . . . . 0.0 107.987 173.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . 0.416 ' HD2' ' OE1' ' B' ' 4' ' ' GLU . 1.9 ptp180 -84.39 150.02 25.62 Favored 'General case' 0 C--N 1.281 -2.37 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.232 -175.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -82.29 73.57 9.32 Favored 'General case' 0 N--CA 1.411 -2.408 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 175.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . 0.491 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 27.2 ttt180 -65.91 -57.52 13.49 Favored Pre-proline 0 N--CA 1.426 -1.63 0 CA-C-N 114.283 -1.326 . . . . 0.0 109.141 174.121 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . 0.491 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 69.6 Cg_endo -89.3 148.63 5.39 Favored 'Trans proline' 0 N--CA 1.441 -1.616 0 C-N-CA 121.513 1.475 . . . . 0.0 111.199 172.195 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 163.72 -31.63 0.27 Allowed Glycine 0 C--N 1.294 -1.76 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.265 -179.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -95.43 3.2 54.52 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.158 0.504 . . . . 0.0 109.761 179.347 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 7.3 tp60 64.97 115.17 0.03 OUTLIER 'General case' 0 N--CA 1.444 -0.744 0 C-N-CA 126.238 1.815 . . . . 0.0 113.678 179.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 22.6 m -127.41 -162.85 1.2 Allowed 'General case' 0 C--N 1.281 -2.412 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 177.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -74.32 -15.24 60.96 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.865 0.841 . . . . 0.0 111.482 178.308 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 15.0 m -77.27 78.99 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.29 -2.008 0 CA-C-O 123.052 1.406 . . . . 0.0 111.034 174.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -127.62 -53.83 1.34 Allowed 'General case' 0 C--N 1.29 -2.015 0 CA-C-N 112.947 -1.933 . . . . 0.0 106.912 178.327 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -88.9 97.72 11.34 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 172.03 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 68.5 mt -84.64 113.89 21.61 Favored 'General case' 0 C--N 1.295 -1.789 0 CA-C-N 115.131 -0.941 . . . . 0.0 111.435 -172.019 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 44.7 mm -66.06 -68.86 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 174.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 56.9 tp60 66.71 -28.61 0.13 Allowed 'General case' 0 CA--C 1.551 1.019 0 N-CA-C 115.743 1.757 . . . . 0.0 115.743 170.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 84.1 mm-40 73.96 75.42 0.12 Allowed 'General case' 0 CA--C 1.493 -1.225 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 -170.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 12.9 t -77.62 65.65 3.17 Favored 'General case' 0 N--CA 1.436 -1.14 0 CA-C-O 123.509 1.623 . . . . 0.0 110.298 -174.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 58.5 mt -111.64 -39.63 4.55 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 114.131 -1.395 . . . . 0.0 108.999 -177.529 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 52.31 73.59 0.33 Allowed 'General case' 0 C--O 1.24 0.596 0 O-C-N 124.355 1.035 . . . . 0.0 110.769 179.561 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 9.5 tt0 -91.04 -24.39 20.07 Favored 'General case' 0 C--N 1.298 -1.671 0 CA-C-N 114.631 -1.168 . . . . 0.0 108.845 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 . . . . . 0 N--CA 1.424 -1.729 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 179.649 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.489 -1.571 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 17.5 t-80 -78.42 -60.69 2.27 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 178.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -103.3 115.67 31.0 Favored 'General case' 0 C--N 1.281 -2.412 0 N-CA-C 105.5 -2.037 . . . . 0.0 105.5 168.109 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -91.34 92.86 8.78 Favored 'General case' 0 C--N 1.281 -2.4 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -174.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -88.56 86.04 6.94 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -107.49 140.93 22.01 Favored Pre-proline 0 C--N 1.297 -1.714 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.531 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -80.51 134.84 10.17 Favored 'Trans proline' 0 N--CA 1.432 -2.146 0 C-N-CA 122.086 1.857 . . . . 0.0 112.672 178.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.668 HG13 ' HB3' ' B' ' 53' ' ' ARG . 25.5 t -115.67 114.93 47.71 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.283 0 CA-C-N 114.374 -1.284 . . . . 0.0 108.554 176.121 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -105.59 105.84 16.06 Favored 'General case' 0 C--N 1.276 -2.611 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -178.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.514 HD23 ' H ' ' B' ' 11' ' ' GLU . 0.9 OUTLIER -123.72 153.85 40.3 Favored 'General case' 0 N--CA 1.418 -2.073 0 CA-C-O 121.685 0.755 . . . . 0.0 111.692 178.995 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.514 ' H ' HD23 ' B' ' 10' ' ' LEU . 40.7 tt0 -122.23 143.16 49.76 Favored 'General case' 0 C--N 1.276 -2.588 0 CA-C-N 114.245 -1.343 . . . . 0.0 108.083 -173.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . 0.421 ' HG2' HD21 ' B' ' 17' ' ' LEU . 45.5 mtmt -75.98 158.63 31.73 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 122.002 0.906 . . . . 0.0 112.276 -176.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . 0.568 ' HB2' ' H ' ' B' ' 16' ' ' GLY . 11.1 m-20 -83.52 177.13 8.57 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 113.717 -1.583 . . . . 0.0 107.963 173.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.9 m -73.46 -25.37 60.46 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 171.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -82.06 -30.85 31.13 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.7 -1.136 . . . . 0.0 109.779 177.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.568 ' H ' ' HB2' ' B' ' 13' ' ' ASP . . . 134.34 -108.44 0.72 Allowed Glycine 0 N--CA 1.432 -1.6 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.122 179.117 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.421 HD21 ' HG2' ' B' ' 12' ' ' LYS . 84.7 mt -132.8 115.72 15.65 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 121.073 0.464 . . . . 0.0 111.481 -175.276 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . 0.537 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -86.96 60.99 4.39 Favored Glycine 0 C--O 1.213 -1.168 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 178.567 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.534 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 5.7 pt -151.73 174.04 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 C-N-CA 125.137 1.375 . . . . 0.0 109.021 179.169 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . 0.407 ' HB2' HG22 ' B' ' 41' ' ' THR . 62.8 m -151.92 156.96 41.13 Favored 'General case' 0 C--N 1.271 -2.817 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 175.496 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.429 ' HB ' HG22 ' B' ' 37' ' ' ILE . 12.0 pt -124.33 161.24 27.71 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.129 0 O-C-N 123.437 0.461 . . . . 0.0 110.737 -177.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -143.11 133.55 22.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.6 119.0 6.36 Favored Glycine 0 N--CA 1.435 -1.388 0 C-N-CA 120.629 -0.796 . . . . 0.0 113.162 -177.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 68.9 mtm -134.05 156.72 47.73 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 177.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 132.08 -148.99 19.3 Favored Glycine 0 C--N 1.306 -1.13 0 C-N-CA 120.244 -0.979 . . . . 0.0 111.222 -178.203 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -128.02 99.96 5.7 Favored 'General case' 0 C--O 1.245 0.817 0 CA-C-O 121.242 0.544 . . . . 0.0 110.458 178.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.04 57.64 5.03 Favored Glycine 0 N--CA 1.45 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 112.15 -177.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.16 107.47 17.89 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 179.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -72.45 -6.29 42.64 Favored 'General case' 0 N--CA 1.48 1.056 0 C-N-CA 124.584 1.153 . . . . 0.0 112.127 -172.538 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 27.0 ptm -73.57 30.59 0.07 Allowed 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 125.42 1.488 . . . . 0.0 112.006 -178.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.66 18.22 49.07 Favored Glycine 0 C--N 1.294 -1.771 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.673 177.158 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 83.4 mt -108.3 -67.92 0.94 Allowed 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 49.61 34.56 7.27 Favored 'General case' 0 C--O 1.216 -0.683 0 C-N-CA 125.131 1.372 . . . . 0.0 113.216 176.263 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -88.54 78.2 7.87 Favored 'General case' 0 N--CA 1.426 -1.668 0 CA-C-O 122.815 1.293 . . . . 0.0 110.792 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 18.8 tp -107.59 172.67 6.7 Favored 'General case' 0 C--N 1.286 -2.194 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 178.124 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -142.44 117.72 1.18 Allowed Glycine 0 C--N 1.27 -3.128 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.351 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.429 HG22 ' HB ' ' B' ' 21' ' ' ILE . 28.9 mm -96.72 88.76 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 178.015 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.415 ' HA ' ' HA ' ' B' ' 59' ' ' LEU . 94.5 m-85 -81.83 168.76 17.64 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 114.386 -1.279 . . . . 0.0 109.225 -176.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.8 t -79.31 139.52 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.376 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 22.8 ttpp -101.12 -44.44 5.7 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.083 0.468 . . . . 0.0 109.829 -178.086 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . 0.407 HG22 ' HB2' ' B' ' 20' ' ' SER . 0.6 OUTLIER -154.62 162.13 41.27 Favored 'General case' 0 N--CA 1.432 -1.351 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 -176.781 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.534 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.2 p -144.06 97.79 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 CA-C-O 122.408 1.099 . . . . 0.0 109.356 176.63 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 23.9 m -62.65 126.59 27.84 Favored 'General case' 0 N--CA 1.431 -1.417 0 CA-C-N 113.262 -1.79 . . . . 0.0 112.256 -174.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . 0.572 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 1.8 mp0 -55.57 -36.91 67.37 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.693 1.597 . . . . 0.0 110.775 -178.052 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.97 -0.48 56.12 Favored Glycine 0 N--CA 1.438 -1.173 0 CA-C-N 115.437 -0.802 . . . . 0.0 113.877 -179.191 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.537 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -112.56 162.01 12.52 Favored Glycine 0 N--CA 1.417 -2.605 0 C-N-CA 120.121 -1.037 . . . . 0.0 113.093 179.211 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . 0.406 ' H ' ' CG ' ' B' ' 13' ' ' ASP . . . -57.45 -36.36 71.3 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 125.688 1.595 . . . . 0.0 112.06 -175.026 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -63.01 -34.54 77.77 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . 0.572 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 6.4 t60 -82.14 -39.12 23.73 Favored 'General case' 0 C--O 1.24 0.575 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 59.5 mtp180 -61.94 -39.56 92.49 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.137 179.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -74.68 -69.65 0.45 Allowed 'General case' 0 C--N 1.309 -1.174 0 C-N-CA 124.11 0.964 . . . . 0.0 109.382 175.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 110.99 -2.08 28.57 Favored Glycine 0 N--CA 1.436 -1.346 0 C-N-CA 120.21 -0.995 . . . . 0.0 114.565 177.363 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.668 ' HB3' HG13 ' B' ' 8' ' ' VAL . 39.5 mmt180 -72.24 -50.9 23.77 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 118.503 1.151 . . . . 0.0 113.054 177.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.509 HD11 ' CE2' ' B' ' 89' ' ' PHE . 54.6 mt -72.97 123.02 26.92 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 C-N-CA 119.034 -1.066 . . . . 0.0 108.891 173.141 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -116.47 146.96 42.18 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -178.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 13.2 p -56.54 -23.45 17.01 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.067 0 N-CA-C 115.892 1.812 . . . . 0.0 115.892 -168.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -109.3 -3.53 17.1 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 120.875 -1.141 . . . . 0.0 111.469 -174.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -87.49 179.15 6.61 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 113.693 0.998 . . . . 0.0 113.693 -174.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.439 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 24.6 tp -124.46 126.08 45.31 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.372 -172.239 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 82.0 mt -83.7 104.31 13.71 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 106.063 -1.829 . . . . 0.0 106.063 173.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.735 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 0.5 OUTLIER -91.09 -27.65 4.92 Favored 'Isoleucine or valine' 0 C--O 1.198 -1.627 0 C-N-CA 119.667 -0.813 . . . . 0.0 110.117 -174.625 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.585 ' HB2' ' HA ' ' B' ' 67' ' ' SER . 13.2 pt-20 -158.35 166.11 33.08 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-N 114.725 -1.125 . . . . 0.0 111.389 176.122 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.515 HG22 ' H ' ' B' ' 64' ' ' ASP . 6.4 p -105.57 -174.39 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.023 0 N-CA-C 106.549 -1.649 . . . . 0.0 106.549 178.239 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.515 ' H ' HG22 ' B' ' 63' ' ' VAL . 18.9 t70 -56.55 -39.44 73.44 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 123.272 0.629 . . . . 0.0 112.479 -177.037 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -107.55 -65.29 0.6 Allowed Glycine 0 C--N 1.309 -0.945 0 C-N-CA 120.581 -0.818 . . . . 0.0 113.511 179.444 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 7.0 m -69.5 115.44 8.76 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 122.882 0.473 . . . . 0.0 112.059 -177.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . 0.585 ' HA ' ' HB2' ' B' ' 62' ' ' GLU . 48.6 m -87.36 114.93 24.42 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 174.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.735 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 75.5 mt -85.46 140.48 30.67 Favored 'General case' 0 N--CA 1.435 -1.176 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.402 -177.606 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 p -100.09 -18.72 6.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 144.63 70.84 0.02 OUTLIER Glycine 0 N--CA 1.426 -1.985 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 -176.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.419 HG11 HD22 ' B' ' 68' ' ' LEU . 35.3 m -83.76 173.66 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 CA-C-N 114.478 -0.861 . . . . 0.0 110.021 -178.254 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 37.7 p -71.93 160.29 32.79 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 177.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.5 tt0 -61.14 -37.1 81.65 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.35 0.595 . . . . 0.0 110.437 -178.024 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.7 m -73.18 -30.27 63.43 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.664 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 51.1 t80 -71.6 -41.79 68.49 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.601 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -64.46 -40.98 96.75 Favored 'General case' 0 N--CA 1.435 -1.182 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.828 177.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.01 -41.91 93.18 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.049 0.452 . . . . 0.0 110.829 177.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.1 p -76.75 -23.24 52.98 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 112.957 0.725 . . . . 0.0 112.957 -178.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.601 HG12 ' O ' ' B' ' 76' ' ' ALA . 6.7 p -72.47 -35.12 50.49 Favored 'Isoleucine or valine' 0 C--N 1.345 0.4 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -177.595 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . 0.493 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 51.2 mt -68.35 -18.39 64.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 114.551 -1.204 . . . . 0.0 110.349 178.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -97.14 -9.95 26.89 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.534 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -96.35 -21.29 17.89 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-O 121.248 0.547 . . . . 0.0 110.203 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.537 ' HB ' HG11 ' B' ' 87' ' ' VAL . 17.9 p -80.67 174.27 11.78 Favored 'General case' 0 N--CA 1.425 -1.686 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.915 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 38.1 mttp -70.27 -168.03 0.2 Allowed 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.799 0.809 . . . . 0.0 112.393 178.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -72.62 -30.62 63.87 Favored Glycine 0 N--CA 1.437 -1.293 0 CA-C-N 114.932 -1.031 . . . . 0.0 111.989 178.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 50.4 ttp180 -135.16 123.37 23.0 Favored 'General case' 0 C--N 1.31 -1.129 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.537 HG11 ' HB ' ' B' ' 83' ' ' THR . 3.3 m -137.44 160.01 35.1 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.131 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . 0.446 ' H ' ' HB2' ' B' ' 64' ' ' ASP . 81.3 mtm180 -107.82 110.99 22.91 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.635 -179.323 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.509 ' CE2' HD11 ' B' ' 54' ' ' ILE . 3.4 m-85 -92.29 156.18 17.44 Favored 'General case' 0 C--N 1.275 -2.664 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 179.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.436 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 57.1 mtt -108.46 121.73 45.57 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.435 172.304 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.461 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.4 mp -99.64 117.5 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.405 -2.682 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 179.507 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -105.45 104.04 2.25 Favored Glycine 0 CA--C 1.458 -3.505 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 178.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 13.8 tpp180 -96.62 99.06 10.7 Favored 'General case' 0 C--N 1.268 -2.977 0 CA-C-N 114.142 -1.029 . . . . 0.0 109.071 178.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -81.91 84.3 6.96 Favored 'General case' 0 C--N 1.287 -2.121 0 N-CA-C 104.842 -2.281 . . . . 0.0 104.842 171.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . 0.438 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 14.0 ttm180 -54.08 -60.98 6.08 Favored Pre-proline 0 N--CA 1.442 -0.851 0 CA-C-N 114.032 -1.44 . . . . 0.0 111.536 -175.127 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . 0.438 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 71.9 Cg_endo -80.29 149.04 19.18 Favored 'Trans proline' 0 N--CA 1.443 -1.483 0 C-N-CA 121.236 1.291 . . . . 0.0 110.092 172.051 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -136.58 59.83 0.63 Allowed Glycine 0 C--N 1.297 -1.624 0 C-N-CA 119.624 -1.274 . . . . 0.0 113.339 -174.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 39.2 61.04 1.38 Allowed 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 125.237 1.415 . . . . 0.0 113.374 -178.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -138.39 30.07 2.41 Favored 'General case' 0 N--CA 1.425 -1.698 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 -176.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 57.9 p -101.08 166.74 10.65 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 114.478 -1.237 . . . . 0.0 110.38 -179.273 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -107.84 2.31 23.41 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.916 0.865 . . . . 0.0 109.937 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 31.1 m -85.77 93.84 3.91 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-O 122.35 1.071 . . . . 0.0 111.725 -178.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -154.45 127.46 8.28 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 176.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 98.3 mt-30 59.43 84.47 0.11 Allowed 'General case' 0 C--O 1.239 0.514 0 O-C-N 124.318 1.011 . . . . 0.0 111.401 -178.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 75.0 mt -139.66 179.78 6.37 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 -177.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 35.7 mm -88.2 -72.81 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 173.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 43.5 tt0 50.17 -87.82 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 126.045 1.738 . . . . 0.0 112.41 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 52.7 mt-30 55.8 89.11 0.04 OUTLIER 'General case' 0 C--O 1.24 0.602 0 C-N-CA 124.193 0.997 . . . . 0.0 110.309 -176.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 14.3 t -124.79 -174.43 3.03 Favored 'General case' 0 N--CA 1.404 -2.772 0 CA-C-N 114.652 -1.158 . . . . 0.0 108.684 -172.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . 0.439 ' O ' HD12 ' B' ' 110' ' ' LEU . 0.6 OUTLIER -101.27 104.69 15.72 Favored 'General case' 0 C--N 1.269 -2.916 0 CA-C-N 114.832 -1.076 . . . . 0.0 109.937 179.449 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 65.97 99.22 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 114.375 -1.284 . . . . 0.0 111.63 178.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 7.3 tp60 -108.05 -44.19 4.24 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 -178.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . 0.448 ' H ' ' CD ' ' B' ' 113' ' ' GLU . 1.1 pm0 . . . . . 0 N--CA 1.42 -1.949 0 CA-C-N 114.306 -1.316 . . . . 0.0 110.791 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.505 -0.554 0 N-CA-C 112.121 -0.392 . . . . 0.0 112.121 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 36.1 m80 -69.7 -42.77 73.64 Favored 'General case' 0 CA--C 1.503 -0.837 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 174.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 47.8 mtm -112.42 129.9 56.16 Favored 'General case' 0 N--CA 1.418 -2.063 0 N-CA-C 103.635 -2.728 . . . . 0.0 103.635 168.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . 0.444 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 16.2 mt-10 -88.4 97.29 10.97 Favored 'General case' 0 C--N 1.284 -2.276 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.263 -176.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -86.37 89.55 7.91 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 172.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 23.6 p90 -108.81 144.78 30.29 Favored Pre-proline 0 C--N 1.297 -1.7 0 CA-C-N 115.52 -0.764 . . . . 0.0 112.092 -177.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . 0.414 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 53.6 Cg_endo -73.85 138.59 26.3 Favored 'Trans proline' 0 N--CA 1.447 -1.255 0 C-N-CA 122.303 2.002 . . . . 0.0 113.314 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.458 ' HB ' HD13 ' B' ' 91' ' ' ILE . 74.8 t -129.49 126.55 63.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.824 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 175.219 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -108.39 135.75 49.17 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.668 -177.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.575 HD11 ' HB2' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -139.75 162.21 35.68 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.614 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.44 ' H ' HD23 ' B' ' 10' ' ' LEU . 11.9 pt-20 -134.13 159.36 41.1 Favored 'General case' 0 C--N 1.285 -2.208 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.31 177.019 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -77.22 134.87 38.49 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.579 -178.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . 0.55 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 15.6 t70 -87.61 -179.74 6.37 Favored 'General case' 0 C--N 1.292 -1.917 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 175.55 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.3 m -64.65 -29.8 70.8 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 176.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -91.66 -8.96 45.63 Favored 'General case' 0 CA--C 1.548 0.891 0 CA-C-O 121.661 0.743 . . . . 0.0 109.975 177.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 106.51 -100.07 1.57 Allowed Glycine 0 N--CA 1.44 -1.038 0 C-N-CA 121.068 -0.586 . . . . 0.0 113.02 177.594 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.55 ' HG ' ' H ' ' B' ' 18' ' ' GLY . 17.7 tp -98.85 -173.28 2.48 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -177.255 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . 0.55 ' H ' ' HG ' ' B' ' 17' ' ' LEU . . . -164.91 58.18 0.26 Allowed Glycine 0 N--CA 1.435 -1.371 0 C-N-CA 120.262 -0.971 . . . . 0.0 112.688 177.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.504 HG23 ' HB3' ' B' ' 48' ' ' ALA . 5.7 pt -162.93 177.46 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.487 -1.473 0 C-N-CA 124.662 1.185 . . . . 0.0 108.228 -179.134 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.2 m -138.83 147.25 42.25 Favored 'General case' 0 C--N 1.262 -3.21 0 N-CA-C 105.522 -2.029 . . . . 0.0 105.522 174.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 9.3 pt -114.85 167.17 7.72 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.827 0 O-C-N 123.36 0.412 . . . . 0.0 109.931 -178.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 10.1 tp -142.82 135.81 26.06 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -90.12 110.31 3.75 Favored Glycine 0 N--CA 1.435 -1.392 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.615 -178.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 89.1 mtp -130.05 -178.85 4.91 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 177.252 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 118.84 145.73 7.78 Favored Glycine 0 C--N 1.302 -1.338 0 C-N-CA 120.318 -0.944 . . . . 0.0 113.003 176.268 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -166.98 166.17 15.49 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 176.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 143.28 -138.4 8.19 Favored Glycine 0 N--CA 1.438 -1.207 0 C-N-CA 120.803 -0.713 . . . . 0.0 111.542 177.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.35 89.28 2.09 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 177.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.475 ' O ' ' HB3' ' B' ' 33' ' ' GLU . 30.6 t70 -71.56 -39.23 70.77 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 121.521 0.676 . . . . 0.0 112.342 -175.823 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 23.5 ptp -85.58 -8.4 58.3 Favored 'General case' 0 C--N 1.272 -2.793 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.345 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -104.8 -51.46 0.9 Allowed Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 120.801 -0.714 . . . . 0.0 113.395 -179.386 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 77.9 mt -119.25 -35.49 3.59 Favored 'General case' 0 C--O 1.211 -0.958 0 O-C-N 122.62 -0.341 . . . . 0.0 111.416 -174.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . 0.475 ' HB3' ' O ' ' B' ' 29' ' ' ASP . 11.3 pt-20 50.98 30.12 5.05 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 126.138 1.775 . . . . 0.0 112.254 -178.492 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . 0.401 ' HA ' ' O ' ' B' ' 69' ' ' VAL . 0.1 OUTLIER -70.83 103.03 2.49 Favored 'General case' 0 N--CA 1.425 -1.685 0 CA-C-O 122.614 1.197 . . . . 0.0 110.734 -177.426 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 91.8 mt -97.48 151.8 19.63 Favored 'General case' 0 C--N 1.284 -2.24 0 CA-C-N 114.655 -1.157 . . . . 0.0 108.583 176.703 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -112.12 95.17 0.78 Allowed Glycine 0 N--CA 1.398 -3.843 0 C-N-CA 120.63 -0.795 . . . . 0.0 111.467 -176.087 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 30.8 mm -86.99 86.01 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.824 0 N-CA-C 106.428 -1.693 . . . . 0.0 106.428 172.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -84.1 166.85 17.31 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 114.335 -1.302 . . . . 0.0 108.727 -175.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.1 t -79.67 133.05 30.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 175.084 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -95.41 -41.76 8.83 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 120.932 0.396 . . . . 0.0 110.008 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -156.88 163.03 39.63 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -179.603 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.451 ' HA ' HG22 ' B' ' 19' ' ' ILE . 21.9 t -118.62 108.69 24.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 177.255 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' B' ' 49' ' ' HIS . 24.3 m -64.92 123.68 20.05 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 123.422 0.689 . . . . 0.0 111.088 -176.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . 0.446 ' HG2' ' CE1' ' B' ' 49' ' ' HIS . 32.8 mt-10 -67.72 -33.7 75.4 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 124.588 1.155 . . . . 0.0 109.839 -175.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.46 16.82 47.36 Favored Glycine 0 N--CA 1.431 -1.633 0 CA-C-N 114.761 -1.108 . . . . 0.0 112.114 178.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -127.07 174.75 18.23 Favored Glycine 0 N--CA 1.405 -3.422 0 C-N-CA 120.81 -0.71 . . . . 0.0 113.464 -178.648 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . 0.55 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -56.84 -54.84 41.79 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -173.612 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . 0.575 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -61.13 -27.14 68.18 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 114.017 1.117 . . . . 0.0 114.017 -171.105 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . 0.446 ' CE1' ' HG2' ' B' ' 44' ' ' GLU . 2.4 t60 -78.98 -38.7 36.19 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -179.197 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 92.1 mtt180 -73.5 -38.82 65.23 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.373 -178.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -66.85 -67.1 0.48 Allowed 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.088 173.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 101.84 3.49 52.17 Favored Glycine 0 N--CA 1.439 -1.104 0 N-CA-C 114.722 0.649 . . . . 0.0 114.722 175.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -81.2 -45.94 15.59 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-N 118.489 1.144 . . . . 0.0 112.061 -179.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.516 HD11 ' CE2' ' B' ' 89' ' ' PHE . 19.7 mt -78.56 127.89 38.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.142 174.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 50.7 mt-30 -110.92 167.07 10.52 Favored 'General case' 0 N--CA 1.436 -1.165 0 CA-C-O 121.07 0.462 . . . . 0.0 110.396 176.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.6 p -70.71 -2.1 2.42 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.704 0 N-CA-C 114.191 1.182 . . . . 0.0 114.191 -171.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -119.85 15.01 12.57 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.723 -1.236 . . . . 0.0 110.546 179.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -90.47 168.76 11.6 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.783 -178.2 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.512 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 22.8 tp -133.23 132.59 41.66 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.716 -176.637 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 78.2 mt -86.06 99.54 11.55 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 177.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.53 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.3 t -83.52 -42.42 17.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 CA-C-O 121.461 0.648 . . . . 0.0 110.647 177.546 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.536 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 15.9 pt-20 -159.67 158.53 31.63 Favored 'General case' 0 C--N 1.282 -2.332 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.546 175.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.507 HG12 ' HB ' ' B' ' 66' ' ' THR . 4.0 p -100.74 -173.58 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.228 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.458 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 22.8 t70 -51.49 -47.73 63.13 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 113.126 0.787 . . . . 0.0 113.126 -178.431 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -137.4 44.56 1.13 Allowed Glycine 0 C--N 1.314 -0.678 0 C-N-CA 119.362 -1.399 . . . . 0.0 114.207 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . 0.507 ' HB ' HG12 ' B' ' 63' ' ' VAL . 94.9 m -161.31 119.43 2.38 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.027 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . 0.536 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 21.2 m -97.92 132.48 43.46 Favored 'General case' 0 N--CA 1.431 -1.394 0 CA-C-O 121.075 0.464 . . . . 0.0 111.853 -176.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.53 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 42.4 mt -96.06 115.42 27.4 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.108 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' B' ' 34' ' ' LYS . 40.1 t -81.85 -23.51 9.78 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 174.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 145.75 75.76 0.02 OUTLIER Glycine 0 N--CA 1.424 -2.124 0 N-CA-C 108.871 -1.692 . . . . 0.0 108.871 -177.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 m -93.53 -178.32 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-N 115.554 -0.323 . . . . 0.0 110.557 -175.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 41.3 p -82.6 165.32 20.17 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 176.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.0 tt0 -63.15 -33.91 76.48 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.23 0.538 . . . . 0.0 109.596 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.3 m -66.28 -44.93 82.19 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.991 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -60.19 -48.2 82.75 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.496 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -59.08 -44.2 91.87 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.122 178.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -60.4 -37.27 80.3 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-O 121.204 0.526 . . . . 0.0 110.324 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 36.0 m -66.84 -35.96 81.24 Favored 'General case' 0 N--CA 1.435 -1.182 0 CA-C-N 115.366 -0.834 . . . . 0.0 111.344 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.496 HG12 ' O ' ' B' ' 76' ' ' ALA . 4.2 p -75.66 -34.17 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 C-N-CA 119.558 -0.857 . . . . 0.0 109.81 -174.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 25.0 mt -64.82 -42.29 95.09 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.261 -0.882 . . . . 0.0 111.167 176.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 39.1 mtp180 -77.64 -30.16 52.03 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.819 0.342 . . . . 0.0 111.922 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 6.5 t30 -74.8 -27.09 60.16 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.412 ' HB ' HG11 ' B' ' 87' ' ' VAL . 16.3 p -71.88 158.69 35.59 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 -178.114 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -66.74 -168.04 0.06 Allowed 'General case' 0 C--O 1.251 1.163 0 C-N-CA 124.708 1.203 . . . . 0.0 112.933 -178.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.12 -49.95 64.7 Favored Glycine 0 N--CA 1.431 -1.689 0 CA-C-N 114.644 -1.162 . . . . 0.0 112.828 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 23.0 ttp180 -135.04 121.65 20.7 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.981 -0.688 . . . . 0.0 111.961 -177.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.458 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 15.8 m -138.24 149.56 24.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-N 114.879 -1.055 . . . . 0.0 109.383 -179.361 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -94.6 155.95 16.66 Favored 'General case' 0 C--N 1.295 -1.796 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.755 174.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.516 ' CE2' HD11 ' B' ' 54' ' ' ILE . 9.1 m-85 -126.99 162.33 26.25 Favored 'General case' 0 C--N 1.276 -2.63 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 176.689 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.505 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 24.5 mmt -111.58 113.1 25.28 Favored 'General case' 0 C--N 1.28 -2.448 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.597 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.512 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -97.21 129.23 47.58 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -179.331 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -109.45 116.28 4.5 Favored Glycine 0 CA--C 1.468 -2.858 0 C-N-CA 120.19 -1.005 . . . . 0.0 112.079 -178.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 8.7 tpp180 -83.86 118.25 23.84 Favored 'General case' 0 C--N 1.284 -2.257 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 176.023 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -105.15 79.61 1.51 Allowed 'General case' 0 N--CA 1.407 -2.605 0 C-N-CA 119.002 -1.079 . . . . 0.0 108.17 171.595 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 30.0 ttt180 -62.78 -58.1 18.44 Favored Pre-proline 0 CA--C 1.562 1.41 0 CA-C-N 114.602 -1.181 . . . . 0.0 110.164 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -77.05 145.59 24.85 Favored 'Trans proline' 0 C--N 1.387 2.602 0 C-N-CA 122.169 1.912 . . . . 0.0 112.898 178.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 154.11 43.86 0.02 OUTLIER Glycine 0 C--N 1.288 -2.136 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 -178.406 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 55.0 mm-40 54.53 23.5 4.64 Favored 'General case' 0 N--CA 1.436 -1.151 0 N-CA-C 115.385 1.624 . . . . 0.0 115.385 -173.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 10.1 tt0 -74.35 -43.71 55.42 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 104.988 -2.227 . . . . 0.0 104.988 170.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 43.7 p 56.49 156.97 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 127.202 2.201 . . . . 0.0 116.448 175.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -90.64 21.88 3.79 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.98 -177.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 21.6 t -83.28 137.06 21.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -106.52 -73.42 0.69 Allowed 'General case' 0 C--N 1.311 -1.107 0 CA-C-O 120.813 0.34 . . . . 0.0 110.855 178.049 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 95.8 mt-30 -123.68 74.83 1.29 Allowed 'General case' 0 C--N 1.309 -1.171 0 N-CA-C 112.906 0.706 . . . . 0.0 112.906 -178.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -140.67 170.07 16.45 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 174.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 1.7 mp -77.88 -57.86 5.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 174.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . 0.435 ' HA ' ' OE1' ' B' ' 107' ' ' GLN . 4.3 tp60 -166.39 143.68 5.15 Favored 'General case' 0 N--CA 1.421 -1.909 0 CA-C-N 114.233 -1.349 . . . . 0.0 107.834 173.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -108.53 68.32 0.69 Allowed 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 122.536 1.16 . . . . 0.0 108.915 176.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 13.4 t -83.66 -26.78 29.58 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 114.547 -1.206 . . . . 0.0 109.245 -177.007 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 92.3 mt -86.89 30.76 0.73 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.28 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -59.04 -42.59 90.6 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.376 178.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 58.25 33.27 22.99 Favored 'General case' 0 C--N 1.354 0.765 0 CA-C-O 122.118 0.961 . . . . 0.0 111.744 176.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 20.6 mm-40 . . . . . 0 N--CA 1.435 -1.192 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.653 177.131 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.499 -0.957 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 28.6 t-80 -83.21 -44.31 15.15 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . 0.439 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 65.6 mtt -110.11 109.28 19.76 Favored 'General case' 0 N--CA 1.424 -1.752 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 172.393 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -77.47 103.98 7.73 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -176.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -78.05 91.39 4.27 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 124.106 0.878 . . . . 0.0 108.822 176.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -113.22 142.99 28.37 Favored Pre-proline 0 C--N 1.281 -2.371 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.646 176.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . 0.517 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 34.2 Cg_endo -75.01 128.84 11.79 Favored 'Trans proline' 0 N--CA 1.438 -1.791 0 C-N-CA 121.943 1.762 . . . . 0.0 112.843 179.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.461 ' HB ' HD13 ' B' ' 91' ' ' ILE . 72.0 t -113.41 122.78 68.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.266 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . 0.532 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 36.5 tt0 -106.86 132.15 53.15 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -174.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.522 HD11 ' HB2' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -127.4 158.27 37.75 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 177.548 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.417 ' H ' HD23 ' B' ' 10' ' ' LEU . 45.7 tt0 -134.41 138.51 44.88 Favored 'General case' 0 C--N 1.279 -2.481 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 176.001 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 34.7 mmtp -68.54 152.97 44.63 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 114.876 1.435 . . . . 0.0 114.876 -174.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . 0.455 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 15.2 t70 -92.76 177.33 6.13 Favored 'General case' 0 C--O 1.247 0.922 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 173.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 13.2 p -69.62 -28.76 66.19 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 118.327 0.512 . . . . 0.0 110.356 178.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -80.24 -53.04 7.03 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 173.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 147.92 -96.98 0.18 Allowed Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.34 179.091 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 96.3 mt -128.36 175.48 8.46 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 122.928 0.491 . . . . 0.0 109.996 -178.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . 0.492 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -156.38 69.05 0.28 Allowed Glycine 0 CA--C 1.482 -1.977 0 N-CA-C 108.254 -1.938 . . . . 0.0 108.254 179.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.514 HG22 ' HB ' ' B' ' 42' ' ' VAL . 12.7 pt -145.22 -179.09 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.281 -2.393 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 -177.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . 0.475 ' HB2' HG22 ' B' ' 41' ' ' THR . 28.5 m -154.88 155.46 34.38 Favored 'General case' 0 C--N 1.253 -3.627 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 174.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.473 ' HB ' HG22 ' B' ' 37' ' ' ILE . 7.9 pt -127.58 154.5 38.07 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.892 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -129.26 132.13 67.08 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -179.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.78 103.18 2.28 Favored Glycine 0 N--CA 1.423 -2.231 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.192 -176.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 72.6 mtm -127.57 140.32 52.19 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-O 121.085 0.469 . . . . 0.0 110.672 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.95 -178.64 43.3 Favored Glycine 0 N--CA 1.425 -2.052 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 -178.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -125.15 24.82 7.37 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.992 0.901 . . . . 0.0 109.075 179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 86.6 -72.91 2.56 Favored Glycine 0 N--CA 1.436 -1.345 0 CA-C-N 114.572 -1.194 . . . . 0.0 111.442 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . 50.43 59.23 4.72 Favored 'General case' 0 C--O 1.244 0.773 0 CA-C-O 122.274 1.035 . . . . 0.0 110.739 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.523 ' HA ' ' HA ' ' B' ' 33' ' ' GLU . 6.0 p-10 -63.09 -26.3 68.77 Favored 'General case' 0 N--CA 1.422 -1.856 0 CA-C-N 113.937 -1.483 . . . . 0.0 112.922 -174.136 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 26.6 ptm -66.08 -26.57 67.55 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.817 -178.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . 0.482 ' HA3' ' HE3' ' B' ' 34' ' ' LYS . . . -106.81 53.43 0.62 Allowed Glycine 0 N--CA 1.425 -2.076 0 C-N-CA 120.509 -0.853 . . . . 0.0 111.156 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 28.8 mt 67.86 29.74 6.52 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 124.284 1.034 . . . . 0.0 110.89 176.254 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . 0.523 ' HA ' ' HA ' ' B' ' 29' ' ' ASP 0.271 13.6 pt-20 46.11 64.93 1.3 Allowed 'General case' 0 N--CA 1.475 0.792 0 CA-C-O 122.791 1.281 . . . . 0.0 111.656 -174.698 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . 0.482 ' HE3' ' HA3' ' B' ' 31' ' ' GLY . 19.0 ptpt -78.99 110.31 14.09 Favored 'General case' 0 N--CA 1.427 -1.605 0 CA-C-N 113.171 -1.831 . . . . 0.0 111.806 -173.103 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 83.6 mt -115.07 130.12 56.86 Favored 'General case' 0 C--N 1.297 -1.686 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 176.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -87.64 91.67 1.75 Allowed Glycine 0 N--CA 1.41 -3.063 0 C-N-CA 120.365 -0.921 . . . . 0.0 111.982 -177.146 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.473 HG22 ' HB ' ' B' ' 21' ' ' ILE . 20.1 mm -87.38 84.91 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.549 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 173.467 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -84.71 165.01 18.22 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 114.636 -1.165 . . . . 0.0 108.695 -178.031 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 56.9 t -75.8 133.12 31.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 176.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -92.71 -46.4 7.59 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.622 -177.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . 0.525 ' HA ' HG23 ' B' ' 56' ' ' VAL . 6.3 t -155.14 174.58 15.0 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.514 ' HB ' HG22 ' B' ' 19' ' ' ILE . 2.4 p -158.81 98.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 C-N-CA 124.793 1.237 . . . . 0.0 109.201 -177.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.424 HG22 ' H ' ' B' ' 45' ' ' GLY . 26.5 m -87.76 143.27 27.24 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 113.915 -1.493 . . . . 0.0 110.32 -174.597 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -56.78 -19.89 19.48 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 124.593 1.157 . . . . 0.0 112.744 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . 0.424 ' H ' HG22 ' B' ' 43' ' ' THR . . . -72.98 -12.44 79.14 Favored Glycine 0 N--CA 1.439 -1.102 0 CA-C-N 116.11 -0.496 . . . . 0.0 113.363 -178.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.492 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -116.5 169.0 12.87 Favored Glycine 0 N--CA 1.422 -2.3 0 C-N-CA 119.438 -1.363 . . . . 0.0 113.328 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . 0.455 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -56.77 -41.25 77.31 Favored 'General case' 0 C--O 1.19 -2.066 0 CA-C-N 113.977 -1.111 . . . . 0.0 113.568 -175.078 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . 0.522 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -59.87 -35.94 75.84 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -173.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 4.9 t60 -81.45 -38.76 25.91 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -179.574 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -69.29 -46.17 67.82 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.07 -178.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -70.89 -36.01 72.58 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.81 47.68 7.05 Favored Glycine 0 CA--C 1.494 -1.276 0 CA-C-N 114.102 -1.408 . . . . 0.0 112.463 173.431 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.532 ' HG3' ' O ' ' B' ' 9' ' ' GLU . 35.2 mmt180 -116.14 -60.78 1.82 Allowed 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -177.244 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.463 HD11 ' CE2' ' B' ' 89' ' ' PHE . 43.9 mt -77.28 125.73 37.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 C-N-CA 120.255 -0.578 . . . . 0.0 109.735 178.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 65.4 mt-30 -99.74 159.04 15.35 Favored 'General case' 0 C--N 1.287 -2.144 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.525 HG23 ' HA ' ' B' ' 41' ' ' THR . 11.8 p -70.03 -4.83 4.43 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.699 0 CA-C-O 121.804 0.812 . . . . 0.0 112.027 -177.45 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -113.15 10.14 18.6 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.451 -0.78 . . . . 0.0 110.824 -177.015 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 87.9 m-20 -85.01 175.31 9.12 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.293 0.568 . . . . 0.0 112.379 -177.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.401 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 26.6 tp -143.05 130.97 21.61 Favored 'General case' 0 C--N 1.315 -0.908 0 C-N-CA 123.894 0.878 . . . . 0.0 109.752 -177.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 71.7 mt -87.49 98.12 11.21 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 178.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.575 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 36.6 t -81.97 -41.41 18.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 CA-C-O 121.941 0.877 . . . . 0.0 110.477 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.46 ' HG2' ' HB2' ' B' ' 90' ' ' MET . 9.7 pt-20 -157.26 158.95 37.08 Favored 'General case' 0 C--N 1.275 -2.633 0 CA-C-N 114.858 -1.065 . . . . 0.0 109.763 173.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.453 HG12 ' O ' ' B' ' 66' ' ' THR . 3.3 p -101.57 -173.89 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 105.825 -1.917 . . . . 0.0 105.825 178.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.511 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.2 t70 -55.34 -58.68 6.74 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 113.092 0.775 . . . . 0.0 113.092 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -119.23 33.43 4.7 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 119.818 -1.182 . . . . 0.0 114.535 -176.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . 0.453 ' O ' HG12 ' B' ' 63' ' ' VAL . 18.8 m -160.71 128.53 4.43 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 179.002 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . 0.405 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 39.0 m -93.91 136.77 33.85 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.899 -0.501 . . . . 0.0 111.092 -179.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.575 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 17.2 mt -93.34 -77.39 0.45 Allowed 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.373 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 61.4 t 70.49 -29.4 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 125.34 1.456 . . . . 0.0 111.181 -175.206 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . 0.467 ' H ' ' C ' ' B' ' 68' ' ' LEU . . . 164.59 89.29 0.07 OUTLIER Glycine 1 N--CA 1.395 -4.085 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -177.226 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.415 HG21 HD22 ' B' ' 68' ' ' LEU . 33.6 m -118.42 -178.74 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.282 -2.356 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 175.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 36.7 p -79.92 161.8 25.33 Favored 'General case' 0 C--N 1.292 -1.931 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 177.226 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -60.42 -35.03 74.84 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 121.287 0.565 . . . . 0.0 110.129 -177.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 50.0 m -74.22 -36.44 63.94 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.831 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -63.25 -46.22 87.91 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.533 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -63.01 -38.92 93.11 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.279 179.534 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.67 -38.33 88.98 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.489 0.661 . . . . 0.0 110.122 178.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 34.7 t -64.49 -39.28 93.5 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.956 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.533 HG12 ' O ' ' B' ' 76' ' ' ALA . 2.6 p -70.31 -27.94 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 121.947 0.879 . . . . 0.0 110.374 -172.047 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . 0.501 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 55.8 mt -72.51 -6.6 44.99 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.376 178.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 67.6 mtt180 -116.88 -17.48 10.42 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-O 120.852 0.358 . . . . 0.0 111.948 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.9 m-20 -87.76 -8.36 56.11 Favored 'General case' 0 C--O 1.241 0.645 0 C-N-CA 123.308 0.643 . . . . 0.0 111.378 179.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.612 ' HB ' HG11 ' B' ' 87' ' ' VAL . 1.4 p -87.25 -175.16 5.18 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 113.873 1.064 . . . . 0.0 113.873 -178.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -77.34 -171.5 2.12 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.879 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -75.97 -38.27 36.1 Favored Glycine 0 N--CA 1.44 -1.067 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.927 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . 0.427 ' HA ' ' O ' ' B' ' 10' ' ' LEU . 13.0 ttp180 -127.69 118.49 23.92 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.612 HG11 ' HB ' ' B' ' 83' ' ' THR . 15.6 m -135.5 154.82 35.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -175.165 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . 0.42 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 99.7 mtt180 -109.66 126.19 53.4 Favored 'General case' 0 CA--C 1.49 -1.345 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.115 179.307 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.517 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 3.1 m-85 -105.58 155.05 19.58 Favored 'General case' 0 C--N 1.28 -2.45 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 178.023 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.46 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 19.6 mmt -98.74 109.69 22.4 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 173.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.484 ' CD1' ' HB2' ' B' ' 89' ' ' PHE . 1.5 mp -98.06 119.92 46.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.943 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.53 111.89 4.07 Favored Glycine 0 CA--C 1.466 -3.007 0 N-CA-C 108.726 -1.75 . . . . 0.0 108.726 175.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . 0.439 ' O ' ' HA ' ' B' ' 3' ' ' MET . 8.3 tpp180 -68.63 114.43 7.0 Favored 'General case' 0 C--N 1.285 -2.224 0 CA-C-N 114.637 -0.781 . . . . 0.0 111.679 -178.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -79.74 82.04 5.9 Favored 'General case' 0 N--CA 1.413 -2.316 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 170.008 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 24.2 ttm180 -59.27 -57.95 23.16 Favored Pre-proline 0 CA--C 1.562 1.436 0 CA-C-N 115.193 -0.912 . . . . 0.0 112.208 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -74.54 166.62 28.99 Favored 'Trans proline' 0 C--N 1.358 1.046 0 C-N-CA 122.056 1.837 . . . . 0.0 112.097 177.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -132.58 19.99 4.43 Favored Glycine 0 C--N 1.295 -1.716 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.13 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -87.08 -27.68 23.0 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 52.6 tp60 -84.89 -51.62 6.6 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-N 114.784 -1.098 . . . . 0.0 112.503 -170.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 73.2 m 58.77 -179.27 0.08 Allowed 'General case' 0 CA--C 1.558 1.277 0 C-N-CA 124.19 0.996 . . . . 0.0 112.217 -174.419 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . 0.457 ' H ' ' CD ' ' B' ' 101' ' ' GLU . 0.7 OUTLIER -75.98 -45.93 32.21 Favored 'General case' 0 CA--C 1.495 -1.146 0 CA-C-O 122.895 1.331 . . . . 0.0 109.0 -178.939 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . 0.528 HG23 ' HG ' ' B' ' 105' ' ' LEU . 3.9 p -77.25 140.9 16.35 Favored 'Isoleucine or valine' 0 C--N 1.261 -3.243 0 CA-C-N 111.936 -2.393 . . . . 0.0 111.523 -175.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -98.52 -62.16 1.28 Allowed 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.612 177.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 21.5 tp60 -162.74 117.77 1.79 Allowed 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 179.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . 0.528 ' HG ' HG23 ' B' ' 102' ' ' VAL . 83.2 mt -114.35 110.68 20.28 Favored 'General case' 0 C--N 1.309 -1.158 0 C-N-CA 120.578 -0.449 . . . . 0.0 111.4 179.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 46.8 mm -81.84 -65.05 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 171.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 53.7 mt-30 -98.97 133.21 43.56 Favored 'General case' 0 N--CA 1.431 -1.412 0 N-CA-C 104.231 -2.507 . . . . 0.0 104.231 166.406 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -76.83 -77.94 0.13 Allowed 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 114.22 1.192 . . . . 0.0 114.22 -174.016 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . 0.464 HG23 ' H ' ' B' ' 111' ' ' GLU . 15.1 t -81.96 -14.61 55.8 Favored 'General case' 0 C--N 1.282 -2.352 0 CA-C-N 115.235 -0.893 . . . . 0.0 111.553 -173.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 38.8 mt 69.82 16.3 7.82 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.812 0.845 . . . . 0.0 111.333 175.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . 0.464 ' H ' HG23 ' B' ' 109' ' ' THR . 9.3 tp10 -101.3 49.86 0.87 Allowed 'General case' 0 N--CA 1.433 -1.275 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -177.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 12.3 mm100 60.44 -102.09 0.13 Allowed 'General case' 0 C--O 1.246 0.883 0 CA-C-N 114.207 -1.36 . . . . 0.0 111.175 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 . . . . . 0 N--CA 1.423 -1.786 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 177.02 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.496 -1.145 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 56.5 t60 -68.43 -51.8 39.73 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 176.082 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 20.6 ptp -94.44 135.05 36.3 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 173.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . 0.522 ' OE2' ' HD2' ' B' ' 93' ' ' ARG . 17.1 mt-10 -89.85 100.09 12.97 Favored 'General case' 0 C--N 1.289 -2.037 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -177.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -91.4 89.94 7.47 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 175.021 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -119.14 143.88 34.97 Favored Pre-proline 0 C--N 1.29 -1.997 0 C-N-CA 120.736 -0.386 . . . . 0.0 111.946 178.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . 0.489 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 56.7 Cg_endo -75.15 139.49 23.97 Favored 'Trans proline' 0 N--CA 1.439 -1.716 0 C-N-CA 122.076 1.851 . . . . 0.0 111.73 176.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.45 ' HB ' HD13 ' B' ' 91' ' ' ILE . 90.5 t -128.33 123.34 59.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -179.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . 0.5 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 38.9 tt0 -103.24 129.6 50.24 Favored 'General case' 0 C--N 1.285 -2.196 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.196 -178.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.446 HD12 HG13 ' B' ' 54' ' ' ILE . 2.0 mt -142.81 165.37 27.55 Favored 'General case' 0 CA--C 1.478 -1.812 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.812 175.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -135.58 164.67 27.3 Favored 'General case' 0 C--N 1.283 -2.324 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.726 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -82.38 163.14 21.89 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 121.616 0.722 . . . . 0.0 112.156 -179.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -111.44 -159.54 0.68 Allowed 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 104.12 -2.548 . . . . 0.0 104.12 173.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 22.8 t -75.17 -25.45 58.32 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 169.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -86.73 -60.83 1.88 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.977 176.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 122.84 75.45 0.32 Allowed Glycine 0 N--CA 1.439 -1.108 0 C-N-CA 120.223 -0.989 . . . . 0.0 112.143 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp 77.12 172.04 0.22 Allowed 'General case' 0 CA--C 1.507 -0.678 0 C-N-CA 124.576 1.15 . . . . 0.0 112.402 178.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -141.83 74.44 0.35 Allowed Glycine 0 CA--C 1.471 -2.675 0 N-CA-C 109.097 -1.601 . . . . 0.0 109.097 -178.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.443 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 14.2 pt -157.51 -177.53 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 -178.673 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 24.0 t -149.08 142.31 25.05 Favored 'General case' 0 C--N 1.272 -2.793 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 176.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . . . . . . . . . 20.6 pt -109.17 152.87 11.11 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -129.76 136.14 59.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.65 97.85 2.15 Favored Glycine 0 N--CA 1.434 -1.472 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.025 179.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 26.5 ptm -110.69 130.62 55.52 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 120.894 0.378 . . . . 0.0 110.025 -179.044 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -164.35 -133.41 1.49 Allowed Glycine 0 N--CA 1.431 -1.672 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.012 -178.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . 62.46 26.76 15.94 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.587 1.155 . . . . 0.0 111.021 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -117.04 -75.49 0.55 Allowed Glycine 0 N--CA 1.43 -1.752 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 179.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -109.9 90.21 3.24 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 121.474 0.654 . . . . 0.0 111.6 -178.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 19.5 p-10 -86.89 -35.25 19.09 Favored 'General case' 0 CA--C 1.491 -1.319 0 CA-C-O 122.249 1.023 . . . . 0.0 109.795 177.13 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 25.3 ptm -76.01 2.17 13.43 Favored 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 113.406 -1.725 . . . . 0.0 110.361 178.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -98.13 38.63 3.02 Favored Glycine 0 N--CA 1.421 -2.363 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 176.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 8.5 mp 73.01 27.53 2.05 Favored 'General case' 0 CA--C 1.502 -0.903 0 C-N-CA 123.732 0.813 . . . . 0.0 110.282 175.045 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . 0.703 ' O ' ' HA3' ' B' ' 70' ' ' GLY . 32.0 mt-10 56.25 32.25 19.98 Favored 'General case' 0 CA--C 1.504 -0.817 0 CA-C-N 115.22 -0.9 . . . . 0.0 113.377 -177.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . 0.426 ' HD3' ' O ' ' B' ' 69' ' ' VAL . 70.1 mmtt -67.86 88.55 0.26 Allowed 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 122.324 1.059 . . . . 0.0 110.18 176.255 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 20.2 tp -87.47 159.11 18.78 Favored 'General case' 0 N--CA 1.413 -2.286 0 CA-C-N 113.808 -1.542 . . . . 0.0 107.674 -178.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -110.49 89.5 0.55 Allowed Glycine 0 N--CA 1.398 -3.849 0 C-N-CA 119.99 -1.1 . . . . 0.0 111.982 -176.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . . . . . . . . . 29.6 mm -90.21 78.4 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.212 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 171.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -86.05 167.63 14.83 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-N 113.911 -1.495 . . . . 0.0 109.137 -176.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.414 HG21 ' CG2' ' B' ' 54' ' ' ILE . 51.1 t -81.07 131.34 34.14 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 176.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 36.4 ttpt -91.9 -40.97 10.86 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.771 -175.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -156.63 162.73 39.84 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 -177.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 21.8 t -127.53 92.11 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 178.29 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 10.5 m -72.31 132.55 44.16 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 123.541 0.736 . . . . 0.0 111.672 -176.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . 0.45 ' HA ' ' HB3' ' B' ' 49' ' ' HIS . 11.3 pt-20 -67.83 -3.52 9.83 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 123.886 0.874 . . . . 0.0 113.208 -179.163 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.1 3.23 85.72 Favored Glycine 0 N--CA 1.44 -1.098 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.133 -177.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -139.36 170.94 23.94 Favored Glycine 0 N--CA 1.407 -3.273 0 C-N-CA 119.862 -1.161 . . . . 0.0 113.556 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.94 -35.05 44.54 Favored 'General case' 0 C--O 1.195 -1.812 0 C-N-CA 126.235 1.814 . . . . 0.0 114.726 -174.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -64.63 -45.28 87.53 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 120.284 -0.566 . . . . 0.0 112.348 -174.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . 0.45 ' HB3' ' HA ' ' B' ' 44' ' ' GLU . 5.1 t60 -73.44 -41.09 63.65 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 108.679 -0.859 . . . . 0.0 108.679 177.155 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -59.81 -42.76 94.2 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.71 -178.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . 0.601 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 9.7 t70 -78.19 -51.85 9.58 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.279 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.95 42.71 3.23 Favored Glycine 0 N--CA 1.434 -1.463 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.615 ' HA ' ' NE ' ' B' ' 53' ' ' ARG . 4.9 mmp_? -104.97 -82.77 0.51 Allowed 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -178.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.474 HD11 ' CE2' ' B' ' 89' ' ' PHE . 49.9 mt -61.28 122.94 13.1 Favored 'Isoleucine or valine' 0 C--O 1.244 0.785 0 C-N-CA 120.165 -0.614 . . . . 0.0 110.435 176.574 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . 0.419 ' HB2' ' OD1' ' B' ' 58' ' ' ASP . 48.0 mt-30 -100.81 173.45 6.5 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.845 0.355 . . . . 0.0 111.039 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.8 p -77.83 -1.97 4.36 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 CA-C-O 121.374 0.607 . . . . 0.0 112.388 -174.022 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -124.07 24.55 8.16 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-O 122.053 0.93 . . . . 0.0 109.584 -178.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . 0.419 ' OD1' ' HB2' ' B' ' 55' ' ' GLN . 11.1 m-20 -98.21 166.36 11.44 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 114.345 -1.298 . . . . 0.0 110.421 -177.411 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.577 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 24.8 tp -140.39 133.35 29.27 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 123.423 0.689 . . . . 0.0 109.851 -177.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 71.1 mt -82.72 99.75 9.83 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 177.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.472 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 25.1 t -85.02 -40.81 15.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 122.0 0.905 . . . . 0.0 110.676 178.51 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.481 ' HG2' ' HB2' ' B' ' 90' ' ' MET . 10.2 pt-20 -155.51 154.25 31.51 Favored 'General case' 0 C--N 1.27 -2.883 0 CA-C-N 115.17 -0.923 . . . . 0.0 109.633 173.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.538 HG12 ' HB ' ' B' ' 66' ' ' THR . 6.6 p -100.4 -171.86 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 N-CA-C 105.825 -1.917 . . . . 0.0 105.825 178.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.562 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 8.6 t70 -44.14 -55.21 4.95 Favored 'General case' 0 N--CA 1.482 1.125 0 C-N-CA 124.117 0.967 . . . . 0.0 112.959 177.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -136.21 43.39 1.24 Allowed Glycine 0 C--N 1.304 -1.234 0 C-N-CA 119.07 -1.538 . . . . 0.0 114.98 -179.214 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . 0.538 ' HB ' HG12 ' B' ' 63' ' ' VAL . 88.5 m -155.09 123.5 5.98 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 117.558 0.679 . . . . 0.0 109.326 177.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 5.7 m -87.58 125.02 34.11 Favored 'General case' 0 N--CA 1.441 -0.909 0 C-N-CA 123.091 0.557 . . . . 0.0 109.782 -177.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.472 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 25.1 mt -90.38 99.54 12.55 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 122.21 1.005 . . . . 0.0 110.856 179.327 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . 0.426 ' O ' ' HD3' ' B' ' 34' ' ' LYS . 58.1 t -69.22 -33.07 56.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-N 114.759 -1.109 . . . . 0.0 108.046 175.189 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . 0.703 ' HA3' ' O ' ' B' ' 33' ' ' GLU . . . 149.35 66.46 0.01 OUTLIER Glycine 0 CA--C 1.468 -2.845 0 N-CA-C 108.901 -1.68 . . . . 0.0 108.901 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 29.8 m -83.06 171.97 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.878 0 CA-C-N 113.694 -1.253 . . . . 0.0 109.188 -177.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 25.4 p -77.91 163.79 25.7 Favored 'General case' 0 N--CA 1.412 -2.339 0 C-N-CA 121.042 -0.263 . . . . 0.0 110.465 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -59.74 -37.53 79.22 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.314 0.578 . . . . 0.0 109.899 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 32.9 t -65.23 -41.36 94.48 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.776 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -64.57 -48.1 76.25 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.596 ' O ' ' HG ' ' B' ' 80' ' ' LEU . . . -55.78 -43.29 76.63 Favored 'General case' 0 C--O 1.217 -0.642 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.772 178.794 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -65.62 -39.1 91.12 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.28 0.562 . . . . 0.0 111.033 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.1 t -72.17 -29.41 63.99 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.9 -177.099 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.446 HG12 ' O ' ' B' ' 76' ' ' ALA . 9.8 p -75.69 -33.85 27.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 -176.173 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . 0.596 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 70.2 mt -68.19 -12.02 60.24 Favored 'General case' 0 C--O 1.214 -0.794 0 CA-C-N 114.517 -1.22 . . . . 0.0 110.789 176.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 96.6 mtt180 -106.16 -5.78 19.05 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.467 0.651 . . . . 0.0 111.036 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 13.0 m-80 -96.95 -24.04 16.02 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.546 177.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.791 ' HB ' HG11 ' B' ' 87' ' ' VAL . 3.9 p -68.44 179.74 1.57 Allowed 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -178.132 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 66.3 mmtt -72.03 -170.33 0.58 Allowed 'General case' 0 C--O 1.239 0.514 0 C-N-CA 123.462 0.705 . . . . 0.0 110.921 176.045 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.95 -36.09 47.99 Favored Glycine 0 N--CA 1.445 -0.759 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.648 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 26.3 ttm180 -127.52 122.48 33.45 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.791 HG11 ' HB ' ' B' ' 83' ' ' THR . 13.6 m -133.75 150.14 31.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.085 0 CA-C-O 121.085 0.469 . . . . 0.0 111.051 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 69.6 mtp85 -108.36 118.63 37.28 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.459 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.489 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 1.3 m-85 -98.73 170.74 8.56 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -177.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.481 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 48.5 mtt -113.54 116.88 30.24 Favored 'General case' 0 CA--C 1.473 -1.992 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 167.535 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.577 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.3 mp -94.49 121.72 45.34 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 177.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -112.67 96.45 0.83 Allowed Glycine 0 CA--C 1.461 -3.321 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 177.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . 0.522 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 36.6 ttm180 -96.51 120.36 36.67 Favored 'General case' 0 C--N 1.257 -3.435 0 CA-C-N 114.761 -0.719 . . . . 0.0 110.512 -176.077 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -85.6 79.03 9.51 Favored 'General case' 0 N--CA 1.423 -1.808 0 N-CA-C 106.529 -1.656 . . . . 0.0 106.529 170.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 12.5 ttm180 -57.89 -62.31 5.69 Favored Pre-proline 0 CA--C 1.551 1.003 0 CA-C-N 113.572 -1.649 . . . . 0.0 112.535 -179.166 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -61.14 144.91 99.29 Favored 'Trans proline' 0 C--N 1.371 1.715 0 C-N-CA 121.613 1.542 . . . . 0.0 111.331 179.321 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 129.36 -50.43 0.89 Allowed Glycine 0 N--CA 1.419 -2.491 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -176.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -75.69 -35.51 60.31 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.689 0.28 . . . . 0.0 111.142 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 18.7 tt0 -78.65 106.76 10.84 Favored 'General case' 0 N--CA 1.436 -1.139 0 CA-C-O 121.127 0.489 . . . . 0.0 111.339 -174.013 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 29.2 m -78.37 -178.07 5.55 Favored 'General case' 0 N--CA 1.426 -1.664 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 172.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 69.4 mm-40 -81.08 55.0 2.36 Favored 'General case' 0 C--N 1.306 -1.307 0 CA-C-O 121.963 0.887 . . . . 0.0 111.601 -178.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 25.3 m -95.24 112.34 27.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 CA-C-N 114.887 -1.051 . . . . 0.0 109.031 176.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -121.86 33.91 5.35 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 114.941 -1.027 . . . . 0.0 108.685 -176.418 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . 0.455 ' HA ' ' OE1' ' B' ' 104' ' ' GLN . 5.6 tp60 79.49 117.34 0.06 Allowed 'General case' 0 CA--C 1.508 -0.669 0 C-N-CA 125.606 1.562 . . . . 0.0 110.403 -175.319 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 6.3 mp -87.17 -179.66 6.48 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.386 -175.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 1.7 mp -74.46 -56.26 9.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -138.3 125.05 20.98 Favored 'General case' 0 N--CA 1.429 -1.487 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 176.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 12.1 tp60 -87.0 92.9 9.2 Favored 'General case' 0 N--CA 1.434 -1.239 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 178.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 12.4 t -64.5 -17.67 64.08 Favored 'General case' 0 CA--C 1.551 0.982 0 N-CA-C 114.53 1.307 . . . . 0.0 114.53 -171.055 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 94.0 mt -108.56 14.06 24.85 Favored 'General case' 0 C--N 1.317 -0.844 0 O-C-N 121.923 -0.485 . . . . 0.0 110.895 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 63.1 -87.56 0.02 OUTLIER 'General case' 0 C--O 1.21 -0.974 0 C-N-CA 124.588 1.155 . . . . 0.0 110.592 -177.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 25.6 mt-30 -162.51 155.26 19.54 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 178.098 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 40.2 mt-10 . . . . . 0 C--N 1.294 -1.826 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 178.406 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.488 -1.627 0 N-CA-C 110.465 -1.054 . . . . 0.0 110.465 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 66.45 -163.86 0.23 Allowed 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.145 0.978 . . . . 0.0 110.483 178.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . 0.522 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 66.8 mtt -77.09 95.41 4.22 Favored 'General case' 0 CA--C 1.505 -0.765 0 CA-C-O 120.901 0.381 . . . . 0.0 110.734 178.777 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . 0.408 ' O ' ' HA2' ' B' ' 92' ' ' GLY . 19.7 mt-10 -84.85 105.6 15.75 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -85.34 93.59 8.75 Favored 'General case' 0 C--N 1.291 -1.949 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 174.517 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -117.02 141.5 28.47 Favored Pre-proline 0 C--N 1.288 -2.068 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.196 179.398 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . 0.51 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 61.0 Cg_endo -79.32 137.79 13.57 Favored 'Trans proline' 0 N--CA 1.444 -1.411 0 C-N-CA 122.379 2.052 . . . . 0.0 112.984 178.413 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 79.0 t -125.61 142.19 43.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 N-CA-C 106.855 -1.535 . . . . 0.0 106.855 177.659 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -127.97 123.2 34.24 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 118.659 0.663 . . . . 0.0 110.708 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.453 ' O ' ' HD3' ' B' ' 86' ' ' ARG . 1.2 mt -113.7 163.94 14.35 Favored 'General case' 0 CA--C 1.486 -1.503 0 CA-C-O 121.589 0.709 . . . . 0.0 111.478 178.812 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -124.88 145.89 49.58 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 174.309 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -91.02 164.14 14.07 Favored 'General case' 0 N--CA 1.418 -2.026 0 CA-C-O 121.874 0.845 . . . . 0.0 110.36 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . 0.567 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 25.3 t70 -111.44 -179.41 3.71 Favored 'General case' 0 C--N 1.274 -2.683 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 178.073 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 16.1 m -69.54 -25.92 64.25 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 176.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 8.3 tp10 -85.89 1.71 48.85 Favored 'General case' 0 CA--C 1.548 0.876 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.443 178.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.45 -138.75 14.6 Favored Glycine 0 N--CA 1.437 -1.285 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.573 179.751 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 93.9 mt -95.54 -177.94 4.25 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 177.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -138.42 58.04 0.63 Allowed Glycine 0 CA--C 1.478 -2.23 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.453 -178.356 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.561 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 7.0 pt -150.4 179.13 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 C-N-CA 123.52 0.728 . . . . 0.0 109.396 -177.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . 0.426 ' HB2' HG22 ' B' ' 41' ' ' THR . 70.0 m -150.97 160.92 43.61 Favored 'General case' 0 C--N 1.269 -2.93 0 N-CA-C 105.14 -2.171 . . . . 0.0 105.14 175.673 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.475 ' HB ' HG22 ' B' ' 37' ' ' ILE . 10.3 pt -130.73 159.96 42.32 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.621 0 CA-C-N 117.877 0.308 . . . . 0.0 110.226 -177.607 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.2 tp -136.5 135.86 48.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-O 120.985 0.421 . . . . 0.0 110.348 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . 0.412 ' HA2' ' CD1' ' B' ' 37' ' ' ILE . . . -83.63 99.16 2.16 Favored Glycine 0 N--CA 1.437 -1.24 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.591 -178.082 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 3.8 mmt -113.83 175.59 5.4 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.473 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.03 170.54 47.54 Favored Glycine 0 N--CA 1.435 -1.418 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 174.167 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . 0.455 ' HB3' ' HG3' ' B' ' 34' ' ' LYS . . . -123.96 164.96 18.26 Favored 'General case' 0 C--N 1.295 -1.775 0 CA-C-N 117.394 0.597 . . . . 0.0 109.879 179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.79 -28.74 41.26 Favored Glycine 0 N--CA 1.439 -1.153 0 C-N-CA 120.93 -0.652 . . . . 0.0 113.428 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.14 54.88 0.19 Allowed 'General case' 0 N--CA 1.484 1.248 0 N-CA-C 114.311 1.226 . . . . 0.0 114.311 -175.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' B' ' 33' ' ' GLU . 16.6 t70 -73.97 -33.26 63.81 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.659 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 13.0 ptp -60.6 -34.41 74.17 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 114.451 -1.25 . . . . 0.0 111.18 -177.543 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -105.88 -49.81 0.93 Allowed Glycine 0 N--CA 1.421 -2.327 0 C-N-CA 120.232 -0.985 . . . . 0.0 114.078 -175.199 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 93.9 mt -119.02 -10.56 9.81 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 114.323 1.231 . . . . 0.0 114.323 -171.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . 0.465 ' HA ' ' HA ' ' B' ' 29' ' ' ASP . 48.0 mt-10 52.13 41.69 30.19 Favored 'General case' 0 N--CA 1.481 1.099 0 CA-C-O 122.494 1.14 . . . . 0.0 108.436 -176.397 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . 0.455 ' HG3' ' HB3' ' B' ' 26' ' ' ALA . 21.8 ptmt -90.23 172.45 8.78 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-N 114.147 -1.388 . . . . 0.0 114.464 -167.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 94.7 mt -106.93 161.81 14.38 Favored 'General case' 0 N--CA 1.427 -1.588 0 CA-C-N 113.504 -1.68 . . . . 0.0 107.627 176.094 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -124.69 102.8 0.71 Allowed Glycine 0 N--CA 1.414 -2.803 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 -178.301 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.475 HG22 ' HB ' ' B' ' 21' ' ' ILE . 23.7 mm -88.18 88.84 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 178.297 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -83.9 163.46 20.03 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.689 -1.141 . . . . 0.0 109.342 -178.548 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 65.8 t -71.49 130.99 35.09 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 174.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -90.31 -48.73 6.96 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.42 -177.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . 0.426 HG22 ' HB2' ' B' ' 20' ' ' SER . 0.6 OUTLIER -150.05 163.86 37.04 Favored 'General case' 0 N--CA 1.428 -1.529 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -177.875 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.0 p -139.01 93.7 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 CA-C-O 122.693 1.235 . . . . 0.0 109.29 178.63 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.429 HG22 ' H ' ' B' ' 45' ' ' GLY . 10.3 m -75.6 130.91 39.55 Favored 'General case' 0 N--CA 1.44 -0.974 0 CA-C-N 113.443 -1.708 . . . . 0.0 112.72 -172.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -57.93 -24.12 56.45 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 124.22 1.008 . . . . 0.0 112.901 179.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . 0.429 ' H ' HG22 ' B' ' 43' ' ' THR . . . -78.47 -1.26 81.67 Favored Glycine 0 N--CA 1.436 -1.313 0 CA-C-N 115.97 -0.559 . . . . 0.0 113.465 -178.129 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -122.28 170.23 15.08 Favored Glycine 0 N--CA 1.421 -2.354 0 C-N-CA 120.229 -0.986 . . . . 0.0 112.733 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . 0.567 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -59.94 -39.41 85.45 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 114.261 1.208 . . . . 0.0 114.261 -173.877 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . 0.4 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -64.34 -39.82 94.65 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -173.003 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -72.36 -44.53 62.44 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.509 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 17.2 mtp180 -62.24 -45.49 93.1 Favored 'General case' 0 CA--C 1.511 -0.536 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.188 -177.047 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . 0.484 ' OD2' ' HD2' ' B' ' 53' ' ' ARG . 19.1 t70 -65.54 -51.4 60.2 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 176.692 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 95.04 39.48 4.56 Favored Glycine 0 CA--C 1.478 -2.278 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.553 ' HA ' ' NE ' ' B' ' 53' ' ' ARG . 0.0 OUTLIER -99.66 -73.18 0.64 Allowed 'General case' 0 N--CA 1.419 -2.023 0 CA-C-N 114.221 -0.989 . . . . 0.0 110.483 -170.965 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.555 HD11 ' CE2' ' B' ' 89' ' ' PHE . 47.1 mt -82.78 125.1 39.95 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 175.725 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . 0.512 ' HG2' ' OD2' ' B' ' 58' ' ' ASP . 24.2 pt20 -100.42 169.52 9.04 Favored 'General case' 0 C--N 1.309 -1.196 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -178.26 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.1 p -66.82 -2.28 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.507 0 C-N-CA 123.964 0.906 . . . . 0.0 113.361 -174.182 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -127.27 19.39 6.93 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.044 -1.035 . . . . 0.0 110.769 -178.349 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . 0.512 ' OD2' ' HG2' ' B' ' 55' ' ' GLN . 80.8 m-20 -84.66 168.24 15.46 Favored 'General case' 0 C--N 1.312 -1.038 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.595 176.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 28.6 tp -136.06 127.45 28.48 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.393 -176.303 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 82.5 mt -81.73 90.91 6.39 Favored 'General case' 0 N--CA 1.434 -1.236 0 CA-C-O 121.534 0.683 . . . . 0.0 109.875 178.401 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.643 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 10.9 t -74.25 -39.6 49.56 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.126 175.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.486 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 11.9 pt-20 -164.56 159.66 19.42 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.862 171.009 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.566 HG12 ' HB ' ' B' ' 66' ' ' THR . 3.0 p -96.95 178.19 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.606 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 19.9 t70 -42.59 -54.34 4.01 Favored 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 125.409 1.484 . . . . 0.0 113.762 -176.185 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -132.56 43.85 1.25 Allowed Glycine 0 C--N 1.304 -1.232 0 C-N-CA 119.581 -1.295 . . . . 0.0 113.682 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . 0.566 ' HB ' HG12 ' B' ' 63' ' ' VAL . 51.6 m -157.43 114.34 2.99 Favored 'General case' 0 C--O 1.247 0.923 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 175.867 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . 0.486 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 44.6 m -81.99 111.65 18.36 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 112.476 0.547 . . . . 0.0 112.476 -177.177 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.643 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 44.2 mt -79.52 110.48 14.88 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.887 176.496 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 14.7 p -75.84 -24.98 16.98 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 177.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 142.54 64.04 0.03 OUTLIER Glycine 0 CA--C 1.484 -1.87 0 N-CA-C 108.928 -1.669 . . . . 0.0 108.928 -177.172 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 32.9 m -82.26 -178.59 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 114.366 -0.917 . . . . 0.0 110.406 -176.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 40.4 p -82.89 166.29 19.04 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 120.926 0.393 . . . . 0.0 110.93 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.7 tt0 -59.55 -42.89 93.4 Favored 'General case' 0 C--N 1.324 -0.539 0 C-N-CA 123.237 0.615 . . . . 0.0 110.168 -179.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 23.2 t -66.49 -38.96 88.41 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.247 -178.632 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -63.13 -50.22 71.33 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.554 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -61.3 -37.59 83.75 Favored 'General case' 0 CA--C 1.539 0.526 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.261 178.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.34 -30.54 71.24 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.657 0.741 . . . . 0.0 110.502 177.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.4 m -82.36 -27.48 32.12 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.521 -178.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.554 HG12 ' O ' ' B' ' 76' ' ' ALA . 3.9 p -72.03 -31.34 39.88 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.453 0 CA-C-O 121.396 0.617 . . . . 0.0 109.56 -176.126 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 19.4 mt -67.12 -17.35 64.82 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.918 -1.037 . . . . 0.0 111.322 176.519 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 22.1 mtm180 -100.72 -7.9 23.34 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-O 121.292 0.568 . . . . 0.0 110.31 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -89.99 -15.01 32.78 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 121.744 0.783 . . . . 0.0 109.655 176.255 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.655 ' HB ' HG11 ' B' ' 87' ' ' VAL . 9.3 p -92.06 167.2 12.24 Favored 'General case' 0 N--CA 1.412 -2.351 0 CA-C-N 115.261 -0.881 . . . . 0.0 111.855 179.191 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -76.88 -167.49 0.86 Allowed 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.277 -0.874 . . . . 0.0 112.876 177.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.26 -13.33 79.09 Favored Glycine 0 C--O 1.207 -1.555 0 CA-C-N 114.738 -1.119 . . . . 0.0 112.732 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . 0.453 ' HD3' ' O ' ' B' ' 10' ' ' LEU . 4.4 tpp180 -137.74 116.3 12.08 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 175.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.655 HG11 ' HB ' ' B' ' 83' ' ' THR . 6.3 m -149.12 157.59 6.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 122.969 0.508 . . . . 0.0 110.534 -179.06 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 77.0 mtm180 -96.18 170.18 9.44 Favored 'General case' 0 C--N 1.287 -2.145 0 CA-C-N 114.545 -1.207 . . . . 0.0 108.246 176.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.555 ' CE2' HD11 ' B' ' 54' ' ' ILE . 3.4 m-85 -150.9 162.16 41.32 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 105.163 -2.162 . . . . 0.0 105.163 175.397 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.543 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 66.4 mtm -115.54 114.45 24.99 Favored 'General case' 0 C--N 1.286 -2.195 0 CA-C-O 121.721 0.772 . . . . 0.0 110.139 170.548 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.45 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -97.38 127.33 49.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.73 0 CA-C-N 113.819 -1.537 . . . . 0.0 108.024 -176.566 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . 0.408 ' HA2' ' O ' ' B' ' 4' ' ' GLU . . . -106.83 118.05 5.51 Favored Glycine 0 CA--C 1.466 -3.014 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 176.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . 0.522 ' O ' ' HA ' ' B' ' 3' ' ' MET . 9.9 tpp180 -72.94 91.23 1.53 Allowed 'General case' 0 C--N 1.288 -2.084 0 CA-C-N 115.067 -0.567 . . . . 0.0 110.416 178.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -85.2 73.53 10.59 Favored 'General case' 0 N--CA 1.424 -1.762 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 172.063 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . 0.522 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 36.6 ttt180 -81.09 -57.26 0.57 Allowed Pre-proline 0 N--CA 1.424 -1.762 0 CA-C-N 113.585 -1.643 . . . . 0.0 110.533 179.295 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . 0.522 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 60.5 Cg_endo -87.78 163.55 7.65 Favored 'Trans proline' 0 C--N 1.364 1.378 0 C-N-CA 122.289 1.993 . . . . 0.0 113.591 178.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -137.21 -75.75 0.07 OUTLIER Glycine 0 N--CA 1.423 -2.208 0 N-CA-C 108.457 -1.857 . . . . 0.0 108.457 174.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -82.35 68.8 8.93 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-O 122.479 1.133 . . . . 0.0 111.207 175.725 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 21.4 mm-40 -141.49 -160.36 1.07 Allowed 'General case' 0 N--CA 1.417 -2.085 0 C-N-CA 126.754 2.022 . . . . 0.0 106.473 176.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 7.4 m -62.32 158.5 17.21 Favored 'General case' 0 C--O 1.248 0.993 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 176.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 62.54 76.07 0.38 Allowed 'General case' 0 CA--C 1.506 -0.724 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 -170.616 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 15.8 m -71.9 86.86 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 114.44 -1.255 . . . . 0.0 112.871 -173.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -116.25 109.66 17.71 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.96 -176.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 8.1 tp-100 55.85 86.03 0.06 Allowed 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 124.404 1.082 . . . . 0.0 112.737 177.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -103.91 153.73 20.45 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 176.495 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 48.9 mm -81.02 -75.9 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 120.739 -0.384 . . . . 0.0 111.022 -177.726 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 56.87 101.24 0.02 OUTLIER 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.151 0.981 . . . . 0.0 111.537 -175.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 46.5 tt0 -96.61 1.87 51.66 Favored 'General case' 0 C--N 1.288 -2.096 0 CA-C-O 121.787 0.803 . . . . 0.0 109.554 -177.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 6.3 t -114.18 173.23 6.55 Favored 'General case' 0 C--N 1.305 -1.331 0 O-C-N 121.912 -0.492 . . . . 0.0 110.981 -176.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 95.5 mt 60.19 -94.78 0.05 OUTLIER 'General case' 0 N--CA 1.469 0.516 0 C-N-CA 125.14 1.376 . . . . 0.0 111.991 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -84.35 78.95 9.71 Favored 'General case' 0 N--CA 1.426 -1.658 0 CA-C-O 122.468 1.128 . . . . 0.0 108.969 175.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -105.95 22.57 15.4 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 114.234 -1.348 . . . . 0.0 110.653 -175.7 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 . . . . . 0 N--CA 1.432 -1.336 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 175.817 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.491 -1.461 0 N-CA-C 110.851 -0.899 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 76.52 156.27 0.17 Allowed 'General case' 0 C--O 1.246 0.918 0 C-N-CA 124.834 1.254 . . . . 0.0 111.777 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 68.5 mtm -73.86 129.71 38.44 Favored 'General case' 0 N--CA 1.424 -1.752 0 CA-C-N 115.236 -0.893 . . . . 0.0 109.161 178.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -76.03 102.12 5.53 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.507 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 0.6 OUTLIER -85.93 84.64 7.48 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.056 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -113.49 142.93 28.42 Favored Pre-proline 0 C--N 1.301 -1.522 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.906 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . 0.454 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 59.0 Cg_endo -80.0 131.59 9.03 Favored 'Trans proline' 0 N--CA 1.444 -1.391 0 C-N-CA 122.115 1.877 . . . . 0.0 113.396 179.238 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.469 HG13 ' HB3' ' B' ' 53' ' ' ARG . 75.9 t -119.08 141.23 39.97 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.998 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.502 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -129.82 139.67 51.18 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.496 HD12 HG13 ' B' ' 54' ' ' ILE . 1.0 OUTLIER -144.09 157.68 44.17 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.001 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.606 ' OE2' ' HD3' ' B' ' 86' ' ' ARG . 68.4 mm-40 -95.11 133.14 39.26 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 114.061 -1.427 . . . . 0.0 107.71 177.138 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . 0.429 ' HA ' HD13 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -80.73 135.3 35.97 Favored 'General case' 0 N--CA 1.426 -1.664 0 C-N-CA 118.928 -1.109 . . . . 0.0 108.491 173.815 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . 0.435 ' HB3' ' HB2' ' B' ' 47' ' ' ALA . 2.6 p30 -85.76 -178.12 6.54 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -174.059 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 18.9 m -68.93 -26.39 65.05 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.394 -175.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -81.91 -46.61 13.83 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 176.492 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 168.25 -85.07 0.09 OUTLIER Glycine 0 N--CA 1.423 -2.225 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 177.569 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.429 HD13 ' HA ' ' B' ' 12' ' ' LYS . 27.2 tp -164.15 108.28 0.97 Allowed 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 175.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . 0.479 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -67.7 59.22 0.33 Allowed Glycine 0 C--O 1.215 -1.077 0 C-N-CA 124.704 1.145 . . . . 0.0 115.581 -173.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.478 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.8 pt -144.8 -178.42 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.267 -3.006 0 C-N-CA 125.565 1.546 . . . . 0.0 107.365 173.265 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 48.4 m -156.69 161.68 39.84 Favored 'General case' 0 C--N 1.272 -2.804 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.141 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.443 ' HB ' HG22 ' B' ' 37' ' ' ILE . 26.3 pt -124.43 153.52 31.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-N 117.99 0.359 . . . . 0.0 110.278 -179.513 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.2 tp -137.64 135.15 46.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.676 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.87 103.63 2.93 Favored Glycine 0 N--CA 1.421 -2.311 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.179 -178.616 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 25.9 mmt -106.45 116.46 31.96 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 176.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 135.85 151.9 6.26 Favored Glycine 0 N--CA 1.414 -2.827 0 C-N-CA 120.22 -0.991 . . . . 0.0 112.14 179.087 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -143.86 106.67 4.47 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 175.095 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -171.92 32.4 0.13 Allowed Glycine 0 N--CA 1.436 -1.333 0 C-N-CA 119.729 -1.224 . . . . 0.0 113.55 -177.489 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.54 75.19 10.19 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 176.774 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -106.24 13.95 28.17 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 114.468 -1.242 . . . . 0.0 109.671 -174.613 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 89.2 mtp 64.19 9.16 4.56 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.118 0.967 . . . . 0.0 112.959 -178.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -157.13 29.61 0.53 Allowed Glycine 0 C--O 1.217 -0.922 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 75.1 mt -146.24 -69.37 0.26 Allowed 'General case' 0 CA--C 1.486 -1.506 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 179.617 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . 0.288 6.2 pt-20 40.43 70.79 0.22 Allowed 'General case' 0 C--N 1.352 0.699 0 O-C-N 124.862 1.351 . . . . 0.0 114.421 175.124 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -132.74 85.66 2.24 Favored 'General case' 0 N--CA 1.431 -1.403 0 CA-C-N 113.857 -1.519 . . . . 0.0 107.089 176.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -111.52 129.24 56.12 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-N 114.883 -1.053 . . . . 0.0 108.78 -179.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -94.68 87.64 1.1 Allowed Glycine 0 N--CA 1.4 -3.764 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.443 HG22 ' HB ' ' B' ' 21' ' ' ILE . 20.7 mm -82.99 78.38 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.362 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 173.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -81.56 169.77 16.67 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 114.193 -1.367 . . . . 0.0 109.371 -172.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 79.4 t -75.69 128.98 37.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-O 121.372 0.606 . . . . 0.0 109.814 176.231 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 9.2 tmtm? -84.5 -54.42 4.76 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.11 -177.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 7.9 t -145.7 175.2 10.56 Favored 'General case' 0 N--CA 1.429 -1.508 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 179.182 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.478 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.5 p -154.88 96.4 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 -179.378 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.425 HG22 ' H ' ' B' ' 45' ' ' GLY . 6.0 m -78.25 134.96 37.48 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 113.59 -1.641 . . . . 0.0 111.514 -170.621 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -61.87 -12.8 19.46 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.004 0.922 . . . . 0.0 113.238 178.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . 0.425 ' H ' HG22 ' B' ' 43' ' ' THR . . . -86.18 -2.05 85.98 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 116.528 -0.306 . . . . 0.0 112.455 177.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.479 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -115.88 169.97 13.15 Favored Glycine 0 N--CA 1.418 -2.544 0 C-N-CA 120.291 -0.957 . . . . 0.0 111.823 179.169 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . 0.435 ' HB2' ' HB3' ' B' ' 13' ' ' ASP . . . -69.28 -36.26 76.88 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 114.882 -0.659 . . . . 0.0 111.745 -175.088 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -57.03 -40.52 76.9 Favored 'General case' 0 CA--C 1.542 0.657 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -175.417 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -71.34 -42.46 68.51 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.213 0.53 . . . . 0.0 110.209 -179.081 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -75.09 -28.52 60.32 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.952 -175.345 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -80.75 -41.79 22.92 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.723 -177.582 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 83.78 43.24 7.33 Favored Glycine 0 C--N 1.309 -0.924 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.576 176.447 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.533 ' HA ' ' HE ' ' B' ' 53' ' ' ARG . 1.4 mmp_? -115.22 -69.72 0.84 Allowed 'General case' 0 C--N 1.301 -1.537 0 CA-C-O 119.091 -0.48 . . . . 0.0 110.848 178.847 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.601 HD11 ' CE2' ' B' ' 89' ' ' PHE . 77.7 mt -73.55 136.97 24.25 Favored 'Isoleucine or valine' 0 C--O 1.253 1.241 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 171.755 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 19.6 mt-30 -118.21 162.51 18.12 Favored 'General case' 0 C--N 1.289 -2.04 0 C-N-CA 123.909 0.884 . . . . 0.0 109.639 -174.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.478 ' HB ' HG12 ' B' ' 42' ' ' VAL . 9.7 p -73.6 -4.34 5.29 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-O 121.695 0.76 . . . . 0.0 111.075 -178.384 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -116.55 -5.49 11.68 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -176.144 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -91.39 -175.39 4.22 Favored 'General case' 0 C--O 1.247 0.958 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 -175.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.528 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 35.6 tp -139.35 128.07 23.29 Favored 'General case' 0 N--CA 1.435 -1.212 0 CA-C-N 114.775 -1.102 . . . . 0.0 109.883 -174.043 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 57.0 mt -87.09 95.38 9.93 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.455 -0.942 . . . . 0.0 108.455 178.141 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.441 ' HB ' ' O ' ' B' ' 90' ' ' MET . 36.3 t -75.65 -43.07 41.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 CA-C-O 121.843 0.83 . . . . 0.0 111.301 -178.445 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.419 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 12.2 pt-20 -146.63 160.95 41.53 Favored 'General case' 0 C--N 1.267 -2.997 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 173.511 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.554 HG21 HG21 ' B' ' 83' ' ' THR . 4.8 p -113.18 -177.44 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.505 ' H ' HG22 ' B' ' 63' ' ' VAL . 31.2 t70 -49.53 -45.73 47.75 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -176.369 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -132.29 31.33 3.03 Favored Glycine 0 CA--C 1.522 0.525 0 C-N-CA 119.687 -1.244 . . . . 0.0 114.607 -177.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . 0.411 ' HB ' HG12 ' B' ' 63' ' ' VAL . 36.1 m -159.73 135.47 8.51 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . 0.419 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 30.5 m -108.64 146.83 32.78 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.43 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 43.6 mt -104.31 115.05 29.7 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-O 120.938 0.399 . . . . 0.0 110.66 176.49 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 12.3 p -81.38 -20.39 10.95 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 N-CA-C 108.544 -0.909 . . . . 0.0 108.544 174.529 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 140.79 71.27 0.04 OUTLIER Glycine 0 CA--C 1.487 -1.672 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 -177.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.9 m -92.79 179.33 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 114.856 -0.672 . . . . 0.0 110.681 -175.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 43.5 p -82.86 165.28 19.93 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 177.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -59.45 -42.11 91.2 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.949 0.404 . . . . 0.0 110.108 179.37 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 48.5 m -66.5 -35.92 81.46 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.473 -179.413 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -66.61 -46.67 75.09 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.401 ' O ' ' HB ' ' B' ' 79' ' ' VAL . . . -60.52 -41.56 94.65 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.132 178.149 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.25 -34.96 75.99 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.072 178.268 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 24.5 m -76.9 -20.92 55.66 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.984 -179.018 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.401 ' HB ' ' O ' ' B' ' 76' ' ' ALA . 24.3 t -71.37 -57.11 8.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 16.6 mt -57.79 -18.59 22.74 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 125.325 1.45 . . . . 0.0 112.964 178.205 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 69.9 mtp180 -88.94 -18.09 28.2 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-O 121.279 0.561 . . . . 0.0 110.813 176.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -99.71 -6.19 27.54 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.729 0.776 . . . . 0.0 110.749 -176.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.554 HG21 HG21 ' B' ' 63' ' ' VAL . 18.9 p -82.41 165.96 19.81 Favored 'General case' 0 C--O 1.249 1.07 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 -178.482 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 57.7 mmtt -73.1 -167.58 0.41 Allowed 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 124.594 1.158 . . . . 0.0 112.012 179.052 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -74.05 -34.23 55.87 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-N 115.509 -0.769 . . . . 0.0 112.516 -179.307 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . 0.606 ' HD3' ' OE2' ' B' ' 11' ' ' GLU . 45.5 ttp180 -134.69 124.69 25.68 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 175.621 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.539 HG11 ' HB ' ' B' ' 83' ' ' THR . 13.7 m -137.13 160.32 36.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.915 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -102.15 163.11 12.42 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 176.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.601 ' CE2' HD11 ' B' ' 54' ' ' ILE . 4.9 m-85 -140.44 155.99 46.52 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 179.072 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.441 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 9.5 ttt -110.22 115.07 29.05 Favored 'General case' 0 C--N 1.275 -2.631 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 174.082 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.528 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -92.29 138.45 19.92 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.342 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -177.679 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.26 112.99 1.29 Allowed Glycine 0 CA--C 1.486 -1.742 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 175.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 18.1 tpp180 -148.87 125.92 11.34 Favored 'General case' 0 C--N 1.286 -2.156 0 CA-C-N 115.099 -0.55 . . . . 0.0 109.757 -179.126 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -92.36 78.03 5.09 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 173.484 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . 0.469 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 32.7 ttm180 -77.92 -59.96 0.73 Allowed Pre-proline 0 N--CA 1.421 -1.876 0 CA-C-N 114.331 -1.304 . . . . 0.0 110.056 178.078 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . 0.469 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 91.7 Cg_endo -84.46 169.53 10.94 Favored 'Trans proline' 0 C--N 1.363 1.338 0 C-N-CA 122.166 1.911 . . . . 0.0 111.285 177.567 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 99.14 18.57 24.0 Favored Glycine 0 N--CA 1.428 -1.855 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.476 -177.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -77.27 -58.57 3.2 Favored 'General case' 0 N--CA 1.442 -0.841 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 178.37 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 63.44 -71.71 0.06 Allowed 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.952 1.301 . . . . 0.0 112.597 178.322 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . 0.439 ' C ' ' H ' ' B' ' 102' ' ' VAL . 23.1 t -98.32 -155.06 0.48 Allowed 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -80.89 20.76 0.74 Allowed 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 123.626 0.77 . . . . 0.0 109.798 177.302 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . 0.439 ' H ' ' C ' ' B' ' 100' ' ' SER . 58.8 t -111.47 146.14 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 124.611 1.164 . . . . 0.0 108.374 -174.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -142.94 -77.17 0.25 Allowed 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 173.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -107.0 134.3 50.35 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 177.219 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 83.8 mt -115.24 109.78 18.47 Favored 'General case' 0 C--N 1.296 -1.731 0 CA-C-O 120.984 0.421 . . . . 0.0 111.259 179.344 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 1.7 mp -88.72 -62.24 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.073 178.14 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 5.5 pm0 -99.86 127.6 46.02 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 176.399 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 48.1 mt-30 -127.17 111.85 14.46 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 -178.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 11.5 t -104.93 -32.57 8.71 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 120.386 -0.525 . . . . 0.0 111.21 -178.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 96.2 mt -138.24 88.67 2.33 Favored 'General case' 0 C--O 1.242 0.684 0 CA-C-O 121.064 0.459 . . . . 0.0 112.064 -177.551 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 8.3 tp10 -92.36 -29.77 16.15 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 168.105 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 4.6 pp0? -158.33 158.83 35.08 Favored 'General case' 0 N--CA 1.43 -1.432 0 CA-C-N 113.839 -1.528 . . . . 0.0 107.163 174.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 . . . . . 0 C--N 1.294 -1.845 0 CA-C-O 118.786 -0.626 . . . . 0.0 110.618 -173.911 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.514 0 CA-C-O 120.007 -0.33 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 56.8 m80 -70.75 -42.14 70.86 Favored 'General case' 0 CA--C 1.507 -0.695 0 N-CA-C 107.409 -1.33 . . . . 0.0 107.409 175.705 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 64.4 mtm -125.85 133.08 52.07 Favored 'General case' 0 N--CA 1.423 -1.779 0 N-CA-C 104.466 -2.42 . . . . 0.0 104.466 171.272 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . 0.533 ' HB2' ' HB3' ' B' ' 93' ' ' ARG . 12.0 mt-10 -94.3 93.36 7.68 Favored 'General case' 0 C--N 1.289 -2.036 0 C-N-CA 118.46 -1.296 . . . . 0.0 110.4 -175.581 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -82.52 95.85 7.85 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 177.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 7.1 p90 -119.46 144.33 36.41 Favored Pre-proline 0 C--N 1.279 -2.48 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.128 176.575 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . 0.596 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 30.4 Cg_endo -72.87 129.46 14.39 Favored 'Trans proline' 0 N--CA 1.432 -2.099 0 C-N-CA 122.005 1.803 . . . . 0.0 112.242 176.719 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.492 ' HB ' HD13 ' B' ' 91' ' ' ILE . 70.5 t -115.02 122.02 68.28 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.046 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 177.527 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . 0.485 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 31.8 tt0 -105.58 132.22 52.0 Favored 'General case' 0 C--N 1.269 -2.895 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -176.574 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.601 HD11 ' HB2' ' B' ' 48' ' ' ALA . 0.6 OUTLIER -124.09 159.77 29.21 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 175.264 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.411 ' H ' HD23 ' B' ' 10' ' ' LEU . 4.5 pt-20 -132.12 125.81 32.2 Favored 'General case' 0 C--N 1.26 -3.322 0 CA-C-N 113.919 -1.491 . . . . 0.0 107.187 178.187 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt -66.14 151.88 45.98 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 121.938 0.875 . . . . 0.0 112.608 -178.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -102.66 178.34 4.6 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 14.7 m -67.79 -26.5 66.12 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 121.7 0.762 . . . . 0.0 109.035 175.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -72.74 -21.28 61.05 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-N 114.62 -1.173 . . . . 0.0 109.607 173.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.62 -105.12 2.7 Favored Glycine 0 N--CA 1.422 -2.236 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -176.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 94.8 mt -109.79 -176.87 3.12 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.1 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . 0.409 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -156.19 61.62 0.35 Allowed Glycine 0 CA--C 1.476 -2.383 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.22 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.586 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 3.1 pt -161.46 175.78 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.481 -1.693 0 C-N-CA 124.557 1.143 . . . . 0.0 108.157 -176.654 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . 0.443 ' HB2' HG22 ' B' ' 41' ' ' THR . 54.9 m -148.59 151.7 35.49 Favored 'General case' 0 C--N 1.262 -3.2 0 N-CA-C 105.854 -1.906 . . . . 0.0 105.854 174.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.494 ' HB ' HG22 ' B' ' 37' ' ' ILE . 16.6 pt -116.94 162.06 15.2 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.537 0 O-C-N 123.421 0.45 . . . . 0.0 110.613 -176.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.5 tp -146.84 137.61 17.92 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.19 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.98 111.41 3.73 Favored Glycine 0 N--CA 1.431 -1.668 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.482 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 85.9 mtp -105.74 138.62 41.63 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 176.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 152.39 155.02 6.88 Favored Glycine 0 C--N 1.297 -1.619 0 C-N-CA 119.74 -1.219 . . . . 0.0 112.305 179.252 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -165.34 98.62 0.71 Allowed 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 124.62 1.168 . . . . 0.0 108.666 179.179 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.08 161.06 20.71 Favored Glycine 0 CA--C 1.487 -1.699 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -176.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.602 ' HA ' ' O ' ' B' ' 33' ' ' GLU . . . -136.38 107.95 6.97 Favored 'General case' 0 N--CA 1.422 -1.869 0 CA-C-O 121.758 0.79 . . . . 0.0 112.628 179.304 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.629 ' HB3' ' HB2' ' B' ' 33' ' ' GLU . 22.4 t70 -92.38 -10.07 39.44 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 114.33 -1.304 . . . . 0.0 108.18 173.062 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . 0.337 21.5 ptm 59.27 -6.54 0.06 Allowed 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 128.083 2.553 . . . . 0.0 114.404 -173.175 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . 0.421 ' H ' ' C ' ' B' ' 29' ' ' ASP . . . -105.52 69.09 0.24 Allowed Glycine 0 N--CA 1.434 -1.483 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 174.263 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . 0.275 4.4 mm? 77.95 -8.76 1.62 Allowed 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 114.68 1.363 . . . . 0.0 114.68 179.473 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . 0.629 ' HB2' ' HB3' ' B' ' 29' ' ' ASP . 29.9 mm-40 -103.21 74.27 1.28 Allowed 'General case' 0 N--CA 1.413 -2.31 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 177.517 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 12.6 mtmt -144.95 -171.65 3.68 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.146 -2.168 . . . . 0.0 105.146 176.15 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . 0.594 ' O ' ' HA2' ' B' ' 70' ' ' GLY . 85.9 mt -63.75 115.94 5.26 Favored 'General case' 0 C--N 1.291 -1.95 0 CA-C-O 121.881 0.848 . . . . 0.0 111.764 177.265 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -101.7 115.48 5.27 Favored Glycine 0 N--CA 1.4 -3.722 0 N-CA-C 106.903 -2.479 . . . . 0.0 106.903 176.11 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.494 HG22 ' HB ' ' B' ' 21' ' ' ILE . 29.1 mm -89.03 88.17 2.9 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 -177.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.478 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 73.5 m-85 -83.32 171.72 13.26 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 114.716 -1.129 . . . . 0.0 109.419 -177.664 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 58.9 t -78.19 136.22 24.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.67 0.748 . . . . 0.0 110.053 176.448 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -92.68 -48.13 6.74 Favored 'General case' 0 N--CA 1.426 -1.672 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.131 177.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . 0.443 HG22 ' HB2' ' B' ' 20' ' ' SER . 1.0 OUTLIER -154.13 167.27 30.43 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -178.44 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.586 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.4 p -133.92 96.66 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.065 0 CA-C-O 122.389 1.09 . . . . 0.0 109.821 176.697 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 27.9 m -59.87 125.57 24.17 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 113.257 -1.792 . . . . 0.0 112.2 -175.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . 0.47 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 45.4 mt-10 -61.27 -35.07 76.31 Favored 'General case' 0 CA--C 1.516 -0.35 0 C-N-CA 124.21 1.004 . . . . 0.0 111.889 -176.122 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.79 -10.13 84.95 Favored Glycine 0 N--CA 1.441 -1.015 0 CA-C-N 115.861 -0.609 . . . . 0.0 113.415 -179.295 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.478 ' O ' ' HG3' ' B' ' 50' ' ' ARG . . . -106.23 171.2 17.38 Favored Glycine 0 N--CA 1.417 -2.629 0 C-N-CA 119.828 -1.177 . . . . 0.0 113.85 -175.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.26 -50.59 38.21 Favored 'General case' 0 C--O 1.208 -1.131 0 C-N-CA 125.213 1.405 . . . . 0.0 114.788 -173.52 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . 0.601 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -63.96 -32.44 73.97 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 113.88 1.067 . . . . 0.0 113.88 -172.018 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . 0.47 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 2.7 t60 -83.75 -38.8 20.89 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.128 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . 0.478 ' HG3' ' O ' ' B' ' 46' ' ' GLY . 74.9 mtp180 -70.32 -42.52 71.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.072 -178.683 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -74.09 -43.08 58.97 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 89.98 51.49 2.8 Favored Glycine 0 CA--C 1.504 -0.608 0 CA-C-N 115.113 -0.949 . . . . 0.0 112.406 175.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . . . . . . . . . 34.0 mmt180 -112.94 -82.84 0.59 Allowed 'General case' 0 N--CA 1.442 -0.868 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.053 -177.356 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.463 HD11 ' CE2' ' B' ' 89' ' ' PHE . 70.7 mt -65.52 134.87 29.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 O-C-N 123.774 0.671 . . . . 0.0 109.396 179.648 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 24.4 mm-40 -111.95 164.77 12.74 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.416 HG23 ' HA ' ' B' ' 41' ' ' THR . 14.9 p -65.0 -8.34 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.578 2.028 0 N-CA-C 113.093 0.775 . . . . 0.0 113.093 -175.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -115.3 -6.09 12.37 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 -172.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -94.25 179.2 5.38 Favored 'General case' 0 N--CA 1.432 -1.373 0 N-CA-C 114.998 1.481 . . . . 0.0 114.998 -178.513 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.478 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 25.8 tp -135.25 136.69 41.89 Favored 'General case' 0 C--O 1.247 0.933 0 CA-C-N 114.958 -1.019 . . . . 0.0 110.954 -172.269 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 52.6 mt -83.82 96.84 8.89 Favored 'General case' 0 N--CA 1.425 -1.69 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 176.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.501 ' HB ' ' O ' ' B' ' 90' ' ' MET . 35.0 t -69.74 -42.75 80.28 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-O 122.159 0.98 . . . . 0.0 109.752 179.314 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -156.94 158.87 37.43 Favored 'General case' 0 C--N 1.277 -2.572 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.821 173.056 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.449 HG23 ' CD1' ' B' ' 89' ' ' PHE . 5.0 p -106.36 -175.9 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.099 0 N-CA-C 104.796 -2.298 . . . . 0.0 104.796 178.297 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.524 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 8.9 t70 -52.44 -54.47 31.77 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 112.792 0.664 . . . . 0.0 112.792 178.459 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -122.29 35.73 3.4 Favored Glycine 0 CA--C 1.531 1.069 0 C-N-CA 119.81 -1.186 . . . . 0.0 115.277 -177.072 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . 0.448 ' HB ' HG12 ' B' ' 63' ' ' VAL . 19.2 m -160.9 141.64 11.5 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 177.45 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 47.3 t -107.02 151.37 25.42 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 -178.628 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.456 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.6 mm? -116.27 106.28 13.5 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 120.98 0.419 . . . . 0.0 110.434 178.609 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 42.6 t -103.51 -8.09 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-O 122.221 1.01 . . . . 0.0 109.096 176.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . 0.594 ' HA2' ' O ' ' B' ' 35' ' ' LEU . . . 131.52 78.02 0.16 Allowed Glycine 0 CA--C 1.484 -1.898 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -177.47 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.431 HG22 HD12 ' B' ' 68' ' ' LEU . 26.4 m -106.13 -175.08 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.098 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -175.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . 0.41 ' O ' HG23 ' B' ' 71' ' ' VAL . 45.7 p -83.86 159.8 21.28 Favored 'General case' 0 N--CA 1.426 -1.655 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 175.061 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 53.0 tt0 -63.26 -31.37 72.51 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-O 121.519 0.676 . . . . 0.0 109.567 178.564 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 9.7 m -64.89 -43.18 93.75 Favored 'General case' 0 C--O 1.247 0.948 0 CA-C-N 115.052 -0.977 . . . . 0.0 110.051 177.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -62.27 -51.89 65.9 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 115.212 -0.904 . . . . 0.0 108.782 177.46 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.673 ' O ' ' HB ' ' B' ' 79' ' ' VAL . . . -57.61 -37.55 73.45 Favored 'General case' 0 C--O 1.214 -0.814 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.434 -178.131 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.84 -32.64 73.31 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.174 0.512 . . . . 0.0 111.037 178.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 19.0 m -79.36 -19.65 49.71 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.767 179.535 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.673 ' HB ' ' O ' ' B' ' 76' ' ' ALA . 3.9 t -57.15 -57.46 9.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.447 1.099 . . . . 0.0 111.843 177.072 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . 0.511 HD22 ' H ' ' B' ' 80' ' ' LEU . 2.6 mm? -58.62 -30.15 67.04 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 122.822 0.449 . . . . 0.0 111.781 178.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 31.6 mtp85 -80.76 -16.76 52.99 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.785 -179.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -81.97 -27.91 32.97 Favored 'General case' 0 N--CA 1.44 -0.973 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.611 ' HB ' HG11 ' B' ' 87' ' ' VAL . 12.5 p -88.99 159.86 17.4 Favored 'General case' 0 N--CA 1.417 -2.088 0 CA-C-N 114.882 -1.054 . . . . 0.0 112.887 179.05 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 72.5 mttt -64.6 -174.91 0.15 Allowed 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 124.914 1.286 . . . . 0.0 113.682 -177.114 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.94 -42.53 94.78 Favored Glycine 0 N--CA 1.445 -0.762 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.985 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 56.9 ttm-85 -123.13 118.46 27.73 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 176.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.611 HG11 ' HB ' ' B' ' 83' ' ' THR . 6.2 m -146.41 156.3 11.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.786 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.256 -178.037 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . 0.485 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 95.5 mtt180 -105.71 125.54 51.11 Favored 'General case' 0 N--CA 1.423 -1.799 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.47 177.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.596 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 1.8 m-85 -100.32 166.79 10.79 Favored 'General case' 0 C--N 1.27 -2.856 0 N-CA-C 106.026 -1.842 . . . . 0.0 106.026 176.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.501 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 64.3 mtt -113.3 112.92 24.52 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 171.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.492 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.4 mp -97.25 128.77 48.18 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.346 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -101.39 100.89 2.15 Favored Glycine 0 CA--C 1.46 -3.356 0 N-CA-C 108.522 -1.831 . . . . 0.0 108.522 176.338 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . 0.533 ' HB3' ' HB2' ' B' ' 4' ' ' GLU . 21.2 tpp180 -69.39 118.79 12.72 Favored 'General case' 0 C--N 1.277 -2.547 0 CA-C-N 114.398 -0.901 . . . . 0.0 109.991 -177.218 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -87.06 79.99 8.51 Favored 'General case' 0 N--CA 1.409 -2.521 0 N-CA-C 104.826 -2.287 . . . . 0.0 104.826 172.035 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . 0.413 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 16.4 ttm180 -57.46 -59.48 12.75 Favored Pre-proline 0 CA--C 1.549 0.939 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.865 -179.206 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . 0.413 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 90.9 Cg_endo -82.92 -177.65 3.46 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.163 1.909 . . . . 0.0 111.625 175.167 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -121.99 -38.21 0.62 Allowed Glycine 0 C--N 1.297 -1.589 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 175.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 19.0 mt-10 -82.43 -14.51 55.01 Favored 'General case' 0 C--N 1.315 -0.892 0 C-N-CA 123.656 0.782 . . . . 0.0 108.974 178.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 58.9 tp60 63.32 -95.4 0.05 OUTLIER 'General case' 0 N--CA 1.439 -1.001 0 C-N-CA 125.384 1.473 . . . . 0.0 109.452 -173.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 72.5 m -170.46 166.18 8.46 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 126.084 1.754 . . . . 0.0 106.271 176.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -117.19 3.69 12.65 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 121.537 0.684 . . . . 0.0 110.857 177.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 21.1 m -120.14 144.72 27.97 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-N 115.038 -0.983 . . . . 0.0 109.506 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -152.96 -80.45 0.1 Allowed 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 177.162 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 5.9 tp-100 -130.61 115.1 16.26 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 107.213 -1.402 . . . . 0.0 107.213 -179.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 5.8 mp -96.76 69.74 2.48 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-O 121.527 0.68 . . . . 0.0 111.202 -175.665 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 31.9 mm -111.1 -59.99 3.03 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.796 178.103 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -72.2 -16.87 61.96 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.658 0.742 . . . . 0.0 109.355 177.528 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 54.9 mt-30 -73.76 79.88 1.57 Allowed 'General case' 0 N--CA 1.433 -1.306 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.168 178.778 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 15.3 t -129.71 -4.06 4.69 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 107.286 -1.375 . . . . 0.0 107.286 170.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 95.1 mt -134.37 83.24 2.02 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 114.546 -1.206 . . . . 0.0 107.924 177.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.27 149.58 33.64 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 -179.83 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 23.6 tt0 -90.85 87.45 6.66 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 179.405 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 . . . . . 0 C--N 1.296 -1.747 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.792 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.272 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . 0.493 ' O ' ' HB2' ' B' ' 94' ' ' GLU . 22.9 p-80 -138.89 165.97 25.69 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 -177.443 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 1.7 mpt? -88.95 121.72 31.59 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 176.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -75.97 98.55 4.3 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 177.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -81.28 88.97 6.04 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 175.77 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -109.92 145.31 31.78 Favored Pre-proline 0 C--N 1.288 -2.077 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.672 178.781 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -75.91 129.92 11.94 Favored 'Trans proline' 0 N--CA 1.44 -1.66 0 C-N-CA 122.19 1.926 . . . . 0.0 111.97 177.65 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.521 HG13 ' HB3' ' B' ' 53' ' ' ARG . 84.9 t -116.61 126.2 73.96 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.401 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.331 -179.071 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . 0.477 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 41.4 tt0 -120.81 128.78 53.18 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -178.675 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.557 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.5 OUTLIER -115.41 -162.59 0.84 Allowed 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 179.796 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.518 ' H ' HD22 ' B' ' 10' ' ' LEU . 2.3 mm-40 -156.67 167.69 29.69 Favored 'General case' 0 C--N 1.29 -1.998 0 C-N-CA 126.251 1.82 . . . . 0.0 106.145 176.353 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -92.81 -173.15 3.23 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 121.297 0.57 . . . . 0.0 111.35 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . 0.47 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 21.9 t70 -128.52 172.05 11.53 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 22.8 t -61.75 -30.98 71.14 Favored 'General case' 0 C--N 1.307 -1.251 0 O-C-N 123.789 0.681 . . . . 0.0 109.199 178.298 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -91.59 -51.95 5.0 Favored 'General case' 0 N--CA 1.446 -0.662 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 173.377 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.461 ' H ' ' HB3' ' B' ' 13' ' ' ASP . . . 126.47 133.27 3.83 Favored Glycine 0 N--CA 1.428 -1.848 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.977 178.043 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mm? 63.66 -168.66 0.2 Allowed 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 176.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.19 54.29 0.05 OUTLIER Glycine 0 C--O 1.209 -1.43 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 179.035 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.599 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 4.9 pt -166.91 177.62 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.493 -1.246 0 C-N-CA 125.068 1.347 . . . . 0.0 108.657 -173.707 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . 0.421 ' HB2' HG22 ' B' ' 41' ' ' THR . 39.1 m -151.95 144.92 24.47 Favored 'General case' 0 C--N 1.27 -2.853 0 N-CA-C 105.461 -2.051 . . . . 0.0 105.461 174.146 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.464 ' HB ' HG22 ' B' ' 37' ' ' ILE . 12.3 pt -111.1 160.76 10.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.054 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 -178.361 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.8 tp -138.75 138.17 42.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-O 120.939 0.399 . . . . 0.0 110.177 -178.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -85.72 98.7 2.3 Favored Glycine 0 N--CA 1.423 -2.221 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 177.453 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 86.4 mtp -91.97 157.24 16.91 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 178.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.3 173.36 14.68 Favored Glycine 1 N--CA 1.388 -4.555 0 N-CA-C 107.359 -2.296 . . . . 0.0 107.359 179.665 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . 64.94 73.12 0.42 Allowed 'General case' 0 C--N 1.287 -2.148 0 CA-C-O 122.192 0.996 . . . . 0.0 111.319 -177.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -128.16 60.98 0.66 Allowed Glycine 0 N--CA 1.428 -1.859 0 CA-C-N 114.923 -1.035 . . . . 0.0 111.014 -178.425 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.16 75.14 8.14 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 121.868 0.842 . . . . 0.0 109.626 178.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 11.7 p-10 -89.61 -9.66 48.88 Favored 'General case' 0 N--CA 1.42 -1.957 0 C-N-CA 125.049 1.34 . . . . 0.0 110.034 -176.66 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 61.1 mtt 67.56 73.78 0.32 Allowed 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 114.266 -1.334 . . . . 0.0 109.743 -172.63 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . 0.489 ' H ' ' HG3' ' B' ' 33' ' ' GLU . . . 168.51 -59.74 0.2 Allowed Glycine 0 N--CA 1.437 -1.256 0 CA-C-N 113.673 -1.603 . . . . 0.0 109.511 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . 0.448 ' HG ' ' HA ' ' B' ' 69' ' ' VAL . 9.3 mp -88.92 -53.31 4.66 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 176.527 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . 0.489 ' HG3' ' H ' ' B' ' 31' ' ' GLY . 47.5 mt-10 54.29 29.45 10.79 Favored 'General case' 0 C--N 1.349 0.555 0 C-N-CA 124.733 1.213 . . . . 0.0 112.241 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 37.2 mtmm -147.0 -168.79 3.14 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.15 -175.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 77.6 mt -47.54 129.92 13.69 Favored 'General case' 0 C--O 1.248 0.996 0 O-C-N 124.926 1.391 . . . . 0.0 111.483 177.303 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -113.59 123.42 6.13 Favored Glycine 0 N--CA 1.412 -2.935 0 N-CA-C 108.892 -1.683 . . . . 0.0 108.892 177.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.464 HG22 ' HB ' ' B' ' 21' ' ' ILE . 20.7 mm -93.81 89.21 2.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.375 -0.93 . . . . 0.0 108.91 -179.46 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.457 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 90.5 m-85 -89.69 169.6 11.17 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.598 -178.376 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 58.0 t -75.32 134.83 28.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 CA-C-O 121.29 0.567 . . . . 0.0 109.723 175.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -93.04 -45.71 7.79 Favored 'General case' 0 N--CA 1.435 -1.186 0 CA-C-N 115.337 -0.847 . . . . 0.0 108.835 -179.09 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . 0.433 ' HA ' HG23 ' B' ' 56' ' ' VAL . 2.5 t -155.21 169.2 24.72 Favored 'General case' 0 N--CA 1.419 -2.003 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.455 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.599 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.3 p -140.47 99.67 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.279 -2.496 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 -179.709 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 9.8 m -61.13 124.46 20.6 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-N 113.804 -1.543 . . . . 0.0 111.549 -175.095 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -69.92 -20.93 63.33 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.256 0.551 . . . . 0.0 111.863 -177.725 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.95 4.76 85.54 Favored Glycine 0 N--CA 1.437 -1.292 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.673 175.245 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -113.29 172.09 14.24 Favored Glycine 0 N--CA 1.425 -2.044 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.92 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . 0.47 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -64.86 -42.05 95.19 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -173.581 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . 0.557 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -58.85 -38.09 77.96 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 113.649 0.981 . . . . 0.0 113.649 -173.601 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -75.79 -41.07 53.95 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.244 0.545 . . . . 0.0 109.581 -177.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 64.4 mtp180 -68.18 -44.04 76.81 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.717 -178.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -63.21 -59.4 4.79 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.909 176.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 110.83 -15.53 28.78 Favored Glycine 0 N--CA 1.437 -1.233 0 C-N-CA 120.286 -0.959 . . . . 0.0 114.279 176.171 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.521 ' HB3' HG13 ' B' ' 8' ' ' VAL . 30.4 mmt180 -62.85 -52.33 63.55 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 114.131 1.16 . . . . 0.0 114.131 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.522 HD11 ' CE2' ' B' ' 89' ' ' PHE . 39.0 mt -95.7 119.01 43.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 C-N-CA 119.634 -0.826 . . . . 0.0 109.901 178.57 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 85.0 mm-40 -107.69 -179.92 4.05 Favored 'General case' 0 N--CA 1.433 -1.317 0 CA-C-O 121.269 0.557 . . . . 0.0 109.881 177.22 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.433 HG23 ' HA ' ' B' ' 41' ' ' THR . 12.7 p -71.02 -5.46 5.75 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.329 0 N-CA-C 113.087 0.773 . . . . 0.0 113.087 -174.681 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -117.12 4.24 12.7 Favored 'General case' 0 C--N 1.313 -0.996 0 O-C-N 121.06 -1.025 . . . . 0.0 111.354 -175.214 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -79.09 164.22 24.47 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.504 -175.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.457 ' HB2' ' CD2' ' B' ' 38' ' ' PHE . 23.2 tp -136.69 128.34 28.81 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 123.078 0.551 . . . . 0.0 110.349 -176.587 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 70.3 mt -79.78 92.36 5.43 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.749 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.529 ' HB ' ' O ' ' B' ' 90' ' ' MET . 40.8 t -76.31 -42.24 36.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-O 122.066 0.936 . . . . 0.0 109.749 178.394 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.415 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 8.6 pt-20 -154.23 147.49 24.84 Favored 'General case' 0 C--N 1.274 -2.697 0 CA-C-N 114.843 -1.072 . . . . 0.0 109.348 174.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.41 HG12 ' O ' ' B' ' 66' ' ' THR . 5.3 p -97.61 -174.98 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 104.349 -2.463 . . . . 0.0 104.349 174.524 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.55 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 28.8 t70 -56.37 -44.11 79.83 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 118.643 0.656 . . . . 0.0 112.563 -179.259 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -103.88 -66.57 0.72 Allowed Glycine 0 CA--C 1.528 0.85 0 C-N-CA 120.391 -0.909 . . . . 0.0 113.277 178.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . 0.41 ' O ' HG12 ' B' ' 63' ' ' VAL . 14.2 m -66.87 129.86 41.27 Favored 'General case' 0 CA--C 1.547 0.849 0 CA-C-O 121.135 0.493 . . . . 0.0 112.124 -177.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 4.4 m -95.15 139.48 31.43 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 177.157 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.512 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.3 mm? -101.44 125.97 48.15 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.696 0.76 . . . . 0.0 111.39 -179.009 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . 0.448 ' HA ' ' HG ' ' B' ' 32' ' ' LEU . 8.8 p -125.13 9.57 4.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 CA-C-N 115.163 -0.926 . . . . 0.0 109.104 178.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 120.09 87.89 1.05 Allowed Glycine 0 CA--C 1.499 -0.942 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -177.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.0 m -121.94 -179.11 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -177.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 32.3 p -83.88 164.16 19.62 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 175.543 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 49.3 tt0 -60.89 -41.23 95.63 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.278 0.561 . . . . 0.0 110.246 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 12.9 t -66.74 -36.41 82.38 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.282 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . 0.416 ' O ' HG13 ' B' ' 79' ' ' VAL . 38.0 t80 -62.29 -52.29 64.26 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -179.65 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.698 ' O ' HG22 ' B' ' 79' ' ' VAL . . . -65.93 -31.32 72.18 Favored 'General case' 0 C--O 1.218 -0.574 0 CA-C-O 120.978 0.418 . . . . 0.0 110.383 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.4 -34.54 77.96 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.757 0.789 . . . . 0.0 109.603 175.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 21.4 m -84.18 -17.14 40.94 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 115.194 -0.912 . . . . 0.0 112.112 -177.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.698 HG22 ' O ' ' B' ' 76' ' ' ALA . 23.5 m -68.81 -38.87 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 CA-C-O 121.53 0.681 . . . . 0.0 109.588 -178.439 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 23.5 mt -65.56 -21.31 66.59 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 125.193 1.397 . . . . 0.0 110.884 176.728 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 80.7 mtt180 -92.94 -14.36 27.65 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.491 -177.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -94.79 -22.28 18.17 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.669 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.705 ' HB ' HG11 ' B' ' 87' ' ' VAL . 6.6 p -80.77 -177.37 6.3 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.707 177.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -67.8 -171.48 0.21 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 123.484 0.714 . . . . 0.0 111.217 178.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -73.15 -42.05 44.94 Favored Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.134 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . 0.483 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 16.0 ttp180 -121.99 124.13 43.29 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 175.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.705 HG11 ' HB ' ' B' ' 83' ' ' THR . 5.2 m -137.86 165.58 25.93 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 CA-C-O 121.055 0.455 . . . . 0.0 110.858 178.084 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 51.8 mtp85 -106.52 147.91 28.84 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.405 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.522 ' CE2' HD11 ' B' ' 54' ' ' ILE . 0.7 OUTLIER -129.83 170.38 13.97 Favored 'General case' 0 C--N 1.277 -2.578 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 -179.224 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.529 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 59.8 mtt -121.16 122.93 41.06 Favored 'General case' 0 C--N 1.292 -1.923 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 168.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 1.3 mp -105.7 133.31 50.4 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 CA-C-N 114.194 -1.366 . . . . 0.0 107.446 -178.307 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -117.69 101.14 0.9 Allowed Glycine 0 CA--C 1.48 -2.113 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 177.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 19.2 tpp180 -147.98 128.21 13.83 Favored 'General case' 0 C--N 1.274 -2.685 0 CA-C-N 114.435 -0.883 . . . . 0.0 110.099 -176.18 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . 0.493 ' HB2' ' O ' ' B' ' 2' ' ' HIS . 45.1 tt0 -101.29 84.57 2.65 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 172.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . 0.409 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 46.4 ttt180 -80.28 -57.15 0.66 Allowed Pre-proline 0 C--N 1.295 -1.765 0 CA-C-N 114.722 -1.127 . . . . 0.0 110.995 178.63 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . 0.409 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 65.8 Cg_endo -86.54 -178.48 2.7 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 122.2 1.933 . . . . 0.0 110.888 176.284 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -105.67 -33.97 3.43 Favored Glycine 0 C--N 1.295 -1.702 0 C-N-CA 120.441 -0.885 . . . . 0.0 110.956 176.018 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -144.1 -28.88 0.5 Allowed 'General case' 0 N--CA 1.425 -1.695 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -178.591 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 -84.86 79.83 9.49 Favored 'General case' 0 N--CA 1.426 -1.648 0 CA-C-O 122.012 0.911 . . . . 0.0 112.413 -178.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 19.5 m -105.94 170.64 7.79 Favored 'General case' 0 C--N 1.288 -2.069 0 CA-C-N 114.28 -1.327 . . . . 0.0 108.178 177.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -98.12 -39.16 9.03 Favored 'General case' 0 CA--C 1.485 -1.527 0 C-N-CA 119.219 -0.993 . . . . 0.0 110.074 175.473 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 20.5 t -94.46 78.38 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.262 -3.204 0 CA-C-N 114.255 -1.339 . . . . 0.0 108.069 -179.64 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -102.75 -68.91 0.81 Allowed 'General case' 0 C--N 1.264 -3.115 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.036 178.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 76.1 mm-40 -106.69 19.79 19.96 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.19 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -91.45 21.35 4.61 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.295 0.569 . . . . 0.0 111.184 -179.136 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 36.5 mm -78.41 -60.24 2.43 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 178.234 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . 0.534 HE21 ' HA ' ' B' ' 107' ' ' GLN . 0.0 OUTLIER 35.86 91.24 0.01 OUTLIER 'General case' 0 C--O 1.235 0.329 0 C-N-CA 127.314 2.246 . . . . 0.0 114.264 173.241 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . 0.431 HE21 ' HB2' ' B' ' 112' ' ' GLN . 49.8 tp60 -141.85 97.73 3.2 Favored 'General case' 0 C--N 1.311 -1.093 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.457 -179.25 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 5.7 t -153.04 161.12 42.9 Favored 'General case' 0 N--CA 1.427 -1.591 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 176.328 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 96.0 mt 63.09 30.23 16.18 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 123.835 0.854 . . . . 0.0 111.121 174.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -158.34 -50.77 0.06 Allowed 'General case' 0 C--N 1.313 -0.978 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -176.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . 0.431 ' HB2' HE21 ' B' ' 108' ' ' GLN . 32.7 tt0 -94.82 -59.36 1.93 Allowed 'General case' 0 C--N 1.308 -1.204 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 176.068 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 11.2 tp10 . . . . . 0 N--CA 1.414 -2.257 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 175.363 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.488 -1.609 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 76.5 m-70 58.5 -89.23 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.406 1.082 . . . . 0.0 109.669 -175.1 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . 0.46 ' O ' HD22 ' B' ' 5' ' ' LEU . 25.5 mmt -95.03 97.6 10.07 Favored 'General case' 0 N--CA 1.432 -1.34 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 169.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -83.38 92.3 7.52 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 -175.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.46 HD22 ' O ' ' B' ' 3' ' ' MET . 0.7 OUTLIER -88.49 93.99 9.72 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 176.585 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -111.77 142.89 27.54 Favored Pre-proline 0 C--N 1.281 -2.395 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.539 179.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . 0.498 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 57.8 Cg_endo -78.64 132.82 11.17 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 122.319 2.013 . . . . 0.0 113.316 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.503 HG13 ' HB3' ' B' ' 53' ' ' ARG . 71.6 t -117.69 122.59 70.16 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -106.77 132.25 52.96 Favored 'General case' 0 C--N 1.289 -2.042 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.192 -175.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.434 HD21 ' HA ' ' B' ' 48' ' ' ALA . 1.0 OUTLIER -135.51 158.57 44.04 Favored 'General case' 0 N--CA 1.427 -1.607 0 CA-C-O 121.293 0.568 . . . . 0.0 110.743 176.606 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -145.37 161.37 39.82 Favored 'General case' 0 C--N 1.278 -2.515 0 CA-C-N 114.105 -1.407 . . . . 0.0 107.228 175.198 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 60.6 mttp -86.71 156.64 19.88 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-O 122.029 0.919 . . . . 0.0 113.259 -172.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -71.55 -69.95 0.35 Allowed 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 113.69 -1.595 . . . . 0.0 110.744 178.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 47.0 t -176.55 -39.62 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 105.398 -2.075 . . . . 0.0 105.398 -175.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -78.3 -57.02 4.0 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 172.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 161.61 -142.54 8.1 Favored Glycine 0 N--CA 1.428 -1.887 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 179.354 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -91.59 -174.47 3.88 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.392 0.615 . . . . 0.0 110.003 176.31 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -133.98 -113.78 1.42 Allowed Glycine 0 N--CA 1.419 -2.475 0 N-CA-C 108.411 -1.876 . . . . 0.0 108.411 176.443 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.56 HG22 ' HA ' ' B' ' 42' ' ' VAL . 24.0 pt 45.04 -177.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 C-N-CA 125.573 1.549 . . . . 0.0 114.993 178.22 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 43.8 m -157.87 146.39 19.13 Favored 'General case' 0 C--N 1.274 -2.709 0 N-CA-C 104.823 -2.288 . . . . 0.0 104.823 173.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.525 ' HB ' HG22 ' B' ' 37' ' ' ILE . 12.5 pt -119.58 161.02 19.27 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.364 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . 0.415 ' HB ' ' CG ' ' B' ' 40' ' ' LYS . 8.7 tp -136.75 135.32 48.61 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.303 0 CA-C-O 120.964 0.412 . . . . 0.0 110.446 -176.363 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.33 103.24 3.02 Favored Glycine 0 N--CA 1.426 -2.011 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.025 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 68.6 mtm -129.3 107.48 9.56 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.266 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -163.15 154.09 24.88 Favored Glycine 0 N--CA 1.42 -2.397 0 C-N-CA 120.34 -0.933 . . . . 0.0 111.568 -177.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -136.15 94.2 3.01 Favored 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 176.637 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -176.42 33.85 0.09 OUTLIER Glycine 0 N--CA 1.43 -1.732 0 C-N-CA 120.633 -0.794 . . . . 0.0 113.222 -177.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -76.96 117.63 18.75 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 174.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -143.12 30.59 1.41 Allowed 'General case' 0 C--N 1.288 -2.081 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -173.375 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 15.6 ptt? 45.48 44.31 9.6 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 125.021 1.328 . . . . 0.0 112.973 -179.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.09 -51.3 0.26 Allowed Glycine 0 N--CA 1.443 -0.865 0 CA-C-N 114.98 -1.009 . . . . 0.0 112.126 -179.12 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 91.1 mt -66.57 -48.55 69.26 Favored 'General case' 0 CA--C 1.512 -0.512 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 178.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . 0.63 ' O ' ' HA3' ' B' ' 70' ' ' GLY . 5.0 mm-40 46.49 40.88 8.78 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 126.185 1.794 . . . . 0.0 113.472 177.81 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 56.9 pttt -76.71 82.07 3.34 Favored 'General case' 0 N--CA 1.438 -1.069 0 CA-C-O 122.195 0.998 . . . . 0.0 113.21 -175.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 97.6 mt -108.15 142.59 38.14 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 114.065 -1.425 . . . . 0.0 108.142 176.528 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -108.54 114.15 4.01 Favored Glycine 0 N--CA 1.422 -2.269 0 C-N-CA 120.235 -0.984 . . . . 0.0 111.571 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.525 HG22 ' HB ' ' B' ' 21' ' ' ILE . 20.7 mm -95.32 88.19 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.521 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 175.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.411 ' CD2' ' HB2' ' B' ' 59' ' ' LEU . 96.1 m-85 -82.07 172.1 13.6 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 114.901 -1.045 . . . . 0.0 108.686 -178.192 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 45.5 t -79.17 142.58 13.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 175.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . 0.415 ' CG ' ' HB ' ' B' ' 22' ' ' ILE . 0.1 OUTLIER -103.08 -42.63 5.72 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 -178.363 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . 0.452 ' HA ' HG23 ' B' ' 56' ' ' VAL . 1.5 t -155.78 164.8 38.08 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 179.108 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.56 ' HA ' HG22 ' B' ' 19' ' ' ILE . 16.9 t -124.63 94.73 2.91 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.512 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 6.3 m -54.61 124.9 17.71 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 123.34 0.656 . . . . 0.0 111.517 179.752 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -62.09 -30.6 71.11 Favored 'General case' 0 C--O 1.222 -0.345 0 O-C-N 124.415 1.072 . . . . 0.0 112.26 -177.298 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.46 -23.46 77.05 Favored Glycine 0 N--CA 1.438 -1.172 0 C-N-CA 121.221 -0.514 . . . . 0.0 112.464 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.08 159.79 30.36 Favored Glycine 0 N--CA 1.416 -2.669 0 C-N-CA 119.692 -1.242 . . . . 0.0 113.158 -175.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -56.01 -38.31 70.34 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.27 -1.465 . . . . 0.0 112.458 -176.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . 0.434 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -59.03 -35.32 73.09 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -175.645 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 4.2 t60 -78.17 -40.69 36.99 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.491 0.663 . . . . 0.0 109.38 -179.223 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 65.6 mtp180 -73.86 -39.46 63.95 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 114.508 -1.223 . . . . 0.0 110.072 -174.484 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . 0.462 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 9.9 t70 -68.06 -60.08 2.76 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 173.174 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 97.69 11.38 50.82 Favored Glycine 0 N--CA 1.427 -1.919 0 CA-C-O 119.073 -0.849 . . . . 0.0 114.964 175.101 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.567 ' HA ' ' NE ' ' B' ' 53' ' ' ARG . 3.6 mmp_? -76.09 -50.25 15.21 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 118.655 1.227 . . . . 0.0 112.492 174.551 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.487 HD11 ' CE2' ' B' ' 89' ' ' PHE . 33.4 mt -77.36 141.02 16.14 Favored 'Isoleucine or valine' 0 C--O 1.249 1.072 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 175.538 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 72.5 mm-40 -114.54 -177.17 3.06 Favored 'General case' 0 N--CA 1.433 -1.315 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 -178.159 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.452 HG23 ' HA ' ' B' ' 41' ' ' THR . 8.4 p -90.45 3.55 6.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 CA-C-O 121.436 0.636 . . . . 0.0 111.416 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -119.38 -16.4 8.98 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 -174.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -76.39 178.65 6.39 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 114.491 1.293 . . . . 0.0 114.491 -173.43 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.47 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 27.8 tp -133.79 121.9 22.51 Favored 'General case' 0 N--CA 1.437 -1.113 0 CA-C-N 114.933 -1.03 . . . . 0.0 110.911 -172.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 74.6 mt -80.67 91.66 5.89 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.458 179.128 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.583 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 10.8 t -72.5 -37.43 57.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 123.189 0.596 . . . . 0.0 111.078 179.076 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.558 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 12.8 pt-20 -160.43 157.64 28.08 Favored 'General case' 0 C--N 1.28 -2.413 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.001 171.806 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.461 HG12 ' HB ' ' B' ' 66' ' ' THR . 5.6 p -101.82 -178.35 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 105.484 -2.043 . . . . 0.0 105.484 178.434 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.415 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 9.4 t70 -55.94 -53.64 54.39 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -178.556 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -112.17 22.14 18.71 Favored Glycine 0 C--N 1.318 -0.425 0 C-N-CA 120.151 -1.023 . . . . 0.0 114.703 -175.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . 0.461 ' HB ' HG12 ' B' ' 63' ' ' VAL . 32.3 m -153.89 115.19 4.13 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 117.859 0.83 . . . . 0.0 109.709 178.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . 0.558 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 45.6 m -87.09 138.05 31.82 Favored 'General case' 0 N--CA 1.433 -1.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.751 178.322 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.583 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 52.5 mt -107.71 101.54 10.84 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-O 120.918 0.39 . . . . 0.0 111.695 -178.294 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 12.2 p -71.39 -26.63 26.97 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 172.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . 0.63 ' HA3' ' O ' ' B' ' 33' ' ' GLU . . . 151.62 85.77 0.05 OUTLIER Glycine 0 N--CA 1.424 -2.165 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -178.406 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 33.0 m -105.72 -177.56 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 CA-C-N 115.141 -0.53 . . . . 0.0 109.82 -177.056 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 71.6 p -81.37 166.68 20.21 Favored 'General case' 0 N--CA 1.428 -1.559 0 CA-C-O 121.236 0.541 . . . . 0.0 110.112 177.148 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -62.18 -39.85 94.09 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.584 -0.735 . . . . 0.0 109.935 178.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 20.3 t -69.77 -39.02 76.9 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.092 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . 0.437 ' O ' HG13 ' B' ' 79' ' ' VAL . 17.8 t80 -60.4 -51.57 68.91 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 -179.611 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.631 ' O ' HG22 ' B' ' 79' ' ' VAL . . . -64.38 -33.56 76.13 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.113 179.426 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -63.46 -37.44 87.3 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.622 0.725 . . . . 0.0 109.709 176.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 23.6 p -79.1 -18.06 54.0 Favored 'General case' 0 N--CA 1.427 -1.592 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 178.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.631 HG22 ' O ' ' B' ' 76' ' ' ALA . 32.9 m -73.67 -36.17 46.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 121.976 0.894 . . . . 0.0 109.703 -178.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 51.9 mt -66.1 -26.69 67.58 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 114.245 -1.343 . . . . 0.0 110.914 177.151 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 23.0 mtp180 -96.1 -8.0 34.53 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -176.523 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 25.7 m-80 -102.28 -13.77 17.24 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 120.852 0.358 . . . . 0.0 111.634 178.072 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.604 ' HB ' HG11 ' B' ' 87' ' ' VAL . 2.6 p -81.79 173.29 12.42 Favored 'General case' 0 N--CA 1.426 -1.665 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.108 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 66.5 mmtt -65.06 -172.36 0.09 Allowed 'General case' 0 C--O 1.242 0.679 0 C-N-CA 124.151 0.98 . . . . 0.0 113.347 -176.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.06 -49.12 63.88 Favored Glycine 0 N--CA 1.443 -0.888 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.635 179.691 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 -125.51 121.27 33.21 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -178.208 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.604 HG11 ' HB ' ' B' ' 83' ' ' THR . 12.5 m -138.78 154.55 26.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 123.945 0.778 . . . . 0.0 111.396 -175.521 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 89.5 mtt180 -110.48 124.37 51.66 Favored 'General case' 0 N--CA 1.429 -1.521 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.917 178.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.498 ' O ' ' HA ' ' B' ' 7' ' ' PRO . 4.8 m-85 -97.27 160.66 14.2 Favored 'General case' 0 C--N 1.28 -2.423 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 179.446 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.487 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 63.1 mtt -110.5 117.35 33.31 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 171.64 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.47 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.4 mp -100.77 129.92 50.9 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.128 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -114.97 119.15 4.54 Favored Glycine 0 CA--C 1.473 -2.574 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.376 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 -107.72 114.57 28.63 Favored 'General case' 0 C--N 1.278 -2.526 0 CA-C-N 114.728 -0.736 . . . . 0.0 110.551 177.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -82.21 86.35 6.66 Favored 'General case' 0 N--CA 1.424 -1.744 0 N-CA-C 105.996 -1.853 . . . . 0.0 105.996 168.005 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . 0.419 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 59.1 ttt180 -70.14 -59.34 4.32 Favored Pre-proline 0 C--N 1.294 -1.84 0 CA-C-N 114.094 -1.412 . . . . 0.0 111.183 -178.794 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . 0.56 ' HB2' ' O ' ' B' ' 99' ' ' GLN . 98.3 Cg_endo -79.95 -169.37 0.78 Allowed 'Trans proline' 0 N--CA 1.437 -1.825 0 C-N-CA 121.88 1.72 . . . . 0.0 112.218 175.556 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 153.03 -58.4 0.41 Allowed Glycine 0 C--N 1.288 -2.135 0 N-CA-C 108.181 -1.968 . . . . 0.0 108.181 -175.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -74.19 -27.05 60.63 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 171.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . 0.56 ' O ' ' HB2' ' B' ' 96' ' ' PRO . 8.3 tt0 -94.73 111.9 23.66 Favored 'General case' 0 N--CA 1.422 -1.851 0 N-CA-C 105.734 -1.95 . . . . 0.0 105.734 170.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . 0.464 ' OG ' HG12 ' B' ' 102' ' ' VAL . 12.1 p -92.48 -162.98 0.98 Allowed 'General case' 0 C--N 1.292 -1.934 0 CA-C-O 120.596 0.236 . . . . 0.0 111.258 -176.304 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -87.74 5.25 40.86 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 121.087 0.47 . . . . 0.0 111.325 -177.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . 0.464 HG12 ' OG ' ' B' ' 100' ' ' SER . 7.1 p -82.25 110.57 17.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 CA-C-O 122.755 1.264 . . . . 0.0 111.513 -178.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -154.63 37.79 0.42 Allowed 'General case' 0 C--N 1.283 -2.289 0 CA-C-N 113.08 -1.873 . . . . 0.0 107.316 -177.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 36.4 tt0 69.36 93.74 0.08 Allowed 'General case' 0 C--O 1.243 0.726 0 CA-C-N 114.194 -1.366 . . . . 0.0 109.698 -171.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 6.0 mp -77.72 146.17 36.12 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 115.025 -0.988 . . . . 0.0 109.683 -178.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 35.3 mm -84.32 -62.24 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 176.252 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . 0.539 ' HG2' HG22 ' B' ' 109' ' ' THR . 23.8 tt0 51.87 94.66 0.02 OUTLIER 'General case' 0 C--O 1.242 0.678 0 C-N-CA 125.579 1.551 . . . . 0.0 111.553 176.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 28.9 pt20 -66.47 -13.55 60.99 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -173.57 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . 0.539 HG22 ' HG2' ' B' ' 107' ' ' GLN . 11.7 t -83.19 -13.41 55.48 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 120.3 -0.56 . . . . 0.0 110.644 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 41.6 mt 61.54 29.78 18.45 Favored 'General case' 0 N--CA 1.477 0.884 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 172.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 49.7 mt-10 -89.47 -9.18 51.04 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 112.449 0.537 . . . . 0.0 112.449 -177.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 25.4 pt20 -76.32 144.39 40.22 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.167 178.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 56.7 mm-40 . . . . . 0 C--N 1.302 -1.463 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 175.52 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.636 0 N-CA-C 112.32 -0.312 . . . . 0.0 112.32 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 11.6 p80 -143.8 -172.54 3.76 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -178.47 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . 0.474 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 25.4 ptp -65.05 117.31 7.49 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 121.421 0.629 . . . . 0.0 110.092 175.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -106.07 104.7 14.46 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -88.55 89.58 8.05 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 178.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -118.51 144.47 35.34 Favored Pre-proline 0 C--N 1.297 -1.699 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -178.518 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . 0.414 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 28.7 Cg_endo -80.95 127.8 6.3 Favored 'Trans proline' 0 N--CA 1.445 -1.38 0 C-N-CA 122.337 2.024 . . . . 0.0 112.629 177.531 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.561 HG13 ' HB3' ' B' ' 53' ' ' ARG . 76.0 t -112.49 134.73 54.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.032 0 CA-C-N 114.913 -1.039 . . . . 0.0 108.214 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . 0.46 ' OE2' ' HD3' ' B' ' 86' ' ' ARG . 34.9 tt0 -121.75 130.79 53.68 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -178.087 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.56 HD23 ' H ' ' B' ' 11' ' ' GLU . 0.5 OUTLIER -143.78 162.66 35.45 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.116 0.484 . . . . 0.0 111.075 -179.606 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.56 ' H ' HD23 ' B' ' 10' ' ' LEU . 6.7 mm-40 -86.97 156.75 19.66 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 125.172 1.389 . . . . 0.0 107.414 179.585 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 15.8 ptpt -79.28 -167.59 1.23 Allowed 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 122.11 0.957 . . . . 0.0 109.961 172.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . 0.433 ' HB3' ' N ' ' B' ' 17' ' ' LEU . 6.9 t70 -126.18 162.65 24.91 Favored 'General case' 0 C--N 1.285 -2.206 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 -179.036 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 31.0 t -61.54 -33.7 74.27 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 124.057 0.848 . . . . 0.0 110.658 -176.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -88.78 -51.86 5.43 Favored 'General case' 0 N--CA 1.437 -1.082 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 176.47 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 145.79 94.48 0.16 Allowed Glycine 0 N--CA 1.43 -1.7 0 CA-C-N 115.266 -0.879 . . . . 0.0 111.417 179.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.433 ' N ' ' HB3' ' B' ' 13' ' ' ASP . 3.8 mm? 59.64 98.02 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 124.605 1.162 . . . . 0.0 113.941 178.203 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -83.15 59.9 4.94 Favored Glycine 0 C--O 1.219 -0.843 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.576 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 6.7 pt -148.79 -175.51 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 C-N-CA 126.416 1.887 . . . . 0.0 107.072 179.024 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 66.7 m -151.27 146.99 26.43 Favored 'General case' 0 C--N 1.261 -3.271 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 176.293 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.44 ' HB ' HG22 ' B' ' 37' ' ' ILE . 13.9 pt -113.49 157.86 14.04 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 O-C-N 123.405 0.44 . . . . 0.0 110.072 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . 0.444 ' HB ' ' HB2' ' B' ' 40' ' ' LYS . 8.5 tp -131.94 130.24 61.22 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.84 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.67 89.85 1.62 Allowed Glycine 0 N--CA 1.408 -3.186 0 C-N-CA 120.926 -0.654 . . . . 0.0 111.819 -177.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 25.4 mmt -72.86 108.41 5.79 Favored 'General case' 0 N--CA 1.434 -1.262 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 176.146 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.02 67.56 3.37 Favored Glycine 0 CA--C 1.465 -3.063 0 CA-C-O 122.291 0.94 . . . . 0.0 112.928 -174.726 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -111.68 75.75 0.94 Allowed 'General case' 1 C--N 1.239 -4.22 0 CA-C-N 112.628 -1.786 . . . . 0.0 106.242 174.447 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.73 104.2 1.34 Allowed Glycine 0 N--CA 1.426 -2.032 0 CA-C-N 114.382 -1.281 . . . . 0.0 111.748 -175.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.61 105.56 3.17 Favored 'General case' 0 C--O 1.256 1.403 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 177.722 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -82.8 67.44 8.87 Favored 'General case' 0 N--CA 1.434 -1.267 0 CA-C-O 122.988 1.375 . . . . 0.0 110.555 -176.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 24.4 ptm -112.83 26.59 10.37 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 112.916 -1.947 . . . . 0.0 109.28 178.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.06 10.34 59.86 Favored Glycine 0 CA--C 1.495 -1.204 0 CA-C-N 114.901 -1.045 . . . . 0.0 111.595 179.271 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 88.9 mt -132.19 -19.19 2.53 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 119.336 -0.364 . . . . 0.0 111.867 -177.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 42.11 36.93 0.75 Allowed 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 125.036 1.334 . . . . 0.0 111.355 -172.05 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -62.91 122.18 15.35 Favored 'General case' 0 N--CA 1.437 -1.094 0 CA-C-N 114.226 -1.352 . . . . 0.0 112.687 -174.225 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 88.3 mt -85.58 160.54 19.61 Favored 'General case' 0 C--N 1.3 -1.567 0 CA-C-N 114.404 -1.271 . . . . 0.0 108.147 175.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -112.44 95.01 0.76 Allowed Glycine 0 N--CA 1.429 -1.815 0 C-N-CA 120.021 -1.085 . . . . 0.0 110.882 179.409 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.44 HG22 ' HB ' ' B' ' 21' ' ' ILE . 16.4 mm -87.84 85.33 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 CA-C-O 121.905 0.86 . . . . 0.0 109.237 179.65 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -84.71 175.47 9.17 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.898 -178.544 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 48.5 t -79.92 142.35 14.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 175.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . 0.444 ' HB2' ' HB ' ' B' ' 22' ' ' ILE . 87.5 tttt -100.82 -51.84 3.46 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.654 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -149.53 162.88 39.29 Favored 'General case' 0 N--CA 1.417 -2.102 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -175.537 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.576 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.4 p -140.84 105.48 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.04 0 CA-C-O 121.836 0.826 . . . . 0.0 109.839 178.271 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 16.5 m -62.95 125.97 25.77 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-N 114.355 -1.293 . . . . 0.0 111.566 -175.414 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . 0.449 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 11.1 pt-20 -65.47 -23.2 66.85 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.395 -178.063 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -83.65 3.96 83.57 Favored Glycine 0 N--CA 1.441 -0.992 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.23 177.033 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -108.07 164.49 12.82 Favored Glycine 0 N--CA 1.424 -2.156 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.208 179.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -65.57 -36.33 83.46 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-N 114.279 -0.96 . . . . 0.0 112.357 -176.501 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.72 -38.44 90.49 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -175.046 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . 0.449 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 7.9 t60 -69.91 -41.9 74.08 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 121.499 0.666 . . . . 0.0 109.713 -178.398 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 23.9 mtp180 -75.49 -35.76 60.74 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.697 -174.74 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . 0.439 ' CB ' HD21 ' B' ' 10' ' ' LEU . 16.8 t70 -64.4 -63.64 1.08 Allowed 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.088 175.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 117.88 -20.25 10.86 Favored Glycine 0 N--CA 1.428 -1.9 0 C-N-CA 119.871 -1.157 . . . . 0.0 114.027 178.185 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.561 ' HB3' HG13 ' B' ' 8' ' ' VAL . 12.9 mmt180 -62.11 -62.83 1.5 Allowed 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 113.718 1.006 . . . . 0.0 113.718 179.588 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.644 HD11 ' CE2' ' B' ' 89' ' ' PHE . 62.9 mt -77.36 109.0 11.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 C-N-CA 119.374 -0.93 . . . . 0.0 109.137 174.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 79.6 mm-40 -102.01 173.89 6.18 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 121.163 0.506 . . . . 0.0 110.549 175.012 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.5 p -63.88 -12.97 12.6 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 114.165 1.172 . . . . 0.0 114.165 -173.381 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 20.2 t-20 -125.62 16.89 8.15 Favored 'General case' 0 C--N 1.311 -1.091 0 O-C-N 120.976 -1.078 . . . . 0.0 111.145 -176.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 25.7 m-20 -83.22 172.6 12.44 Favored 'General case' 0 C--N 1.317 -0.812 0 O-C-N 121.362 -0.836 . . . . 0.0 111.084 179.098 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.494 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 29.7 tp -128.51 116.06 19.11 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 120.563 0.221 . . . . 0.0 110.808 -175.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 32.8 mt -93.17 95.29 9.31 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 179.126 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.709 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 96.3 t -73.19 -65.3 0.68 Allowed 'Isoleucine or valine' 0 C--O 1.175 -2.845 0 C-N-CA 120.607 -0.437 . . . . 0.0 109.83 178.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.461 ' O ' ' HA ' ' B' ' 89' ' ' PHE . 8.6 pt-20 -129.05 157.26 42.22 Favored 'General case' 0 C--N 1.272 -2.787 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -177.019 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.559 HG21 HG21 ' B' ' 83' ' ' THR . 5.0 p -103.51 -176.19 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.554 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 -178.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.516 ' H ' HG22 ' B' ' 63' ' ' VAL . 27.5 t70 -51.25 -54.9 21.44 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 114.174 1.176 . . . . 0.0 114.174 -177.082 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -121.53 27.67 6.22 Favored Glycine 0 C--N 1.315 -0.591 0 C-N-CA 120.252 -0.975 . . . . 0.0 114.486 -175.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 51.4 m -152.57 120.67 6.22 Favored 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 176.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . . . . . . . . . 19.7 m -94.21 111.38 23.11 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.168 -175.61 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.709 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 51.3 mt -89.57 121.36 31.7 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 176.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 14.8 p -83.74 -22.18 8.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.372 0.605 . . . . 0.0 109.565 177.451 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 145.88 69.16 0.01 OUTLIER Glycine 0 CA--C 1.487 -1.706 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 -177.318 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 34.9 m -90.6 -178.66 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 CA-C-N 114.563 -0.819 . . . . 0.0 109.742 -177.125 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 32.3 p -78.19 164.66 24.75 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 120.825 0.345 . . . . 0.0 111.066 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 50.3 tt0 -58.9 -40.43 84.45 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 123.429 0.692 . . . . 0.0 110.15 179.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 30.3 t -66.83 -36.48 82.45 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.323 -179.386 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -68.37 -47.84 66.35 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -179.649 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.539 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -62.6 -39.31 93.35 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.929 178.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -61.33 -39.77 91.76 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-O 121.178 0.513 . . . . 0.0 111.153 178.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 13.3 p -82.1 -10.76 59.09 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -177.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.539 HG12 ' O ' ' B' ' 76' ' ' ALA . 5.3 p -86.18 -34.65 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.383 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 58.9 mt -69.87 -20.22 63.4 Favored 'General case' 0 C--O 1.213 -0.848 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.437 176.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 77.0 mtp180 -94.57 4.11 54.26 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.588 0.709 . . . . 0.0 110.244 177.429 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.2 t30 -113.6 0.86 14.76 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.734 0.778 . . . . 0.0 110.424 -176.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.559 HG21 HG21 ' B' ' 63' ' ' VAL . 23.1 p -91.78 170.76 9.63 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.001 1.112 . . . . 0.0 114.001 -174.117 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 69.7 mmtt -73.88 -167.38 0.47 Allowed 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 124.795 1.238 . . . . 0.0 111.82 176.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -67.09 -33.93 84.95 Favored Glycine 0 C--O 1.225 -0.434 0 CA-C-N 115.628 -0.714 . . . . 0.0 113.274 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . 0.46 ' HD3' ' OE2' ' B' ' 9' ' ' GLU . 16.6 ttm180 -140.99 133.48 28.47 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 178.173 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.468 HG11 ' HB ' ' B' ' 83' ' ' THR . 11.9 m -139.02 164.51 25.27 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.031 0 CA-C-O 121.167 0.508 . . . . 0.0 111.591 178.886 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . 0.473 ' H ' ' HB2' ' B' ' 64' ' ' ASP . 54.3 mtm180 -100.01 159.03 15.4 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-N 114.649 -1.159 . . . . 0.0 108.221 176.448 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.644 ' CE2' HD11 ' B' ' 54' ' ' ILE . 4.9 m-85 -141.82 152.92 44.13 Favored 'General case' 0 C--N 1.283 -2.306 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 175.551 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.402 ' HB2' ' HG2' ' B' ' 62' ' ' GLU . 87.3 mmm -98.41 112.89 24.75 Favored 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 120.101 -0.64 . . . . 0.0 109.913 173.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.555 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.5 mp -101.8 117.2 46.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -179.159 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.89 101.28 2.07 Favored Glycine 0 CA--C 1.458 -3.498 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 174.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . 0.474 ' O ' ' HA ' ' B' ' 3' ' ' MET . 19.9 tpp180 -76.09 93.74 3.36 Favored 'General case' 0 C--N 1.276 -2.59 0 CA-C-N 114.478 -0.861 . . . . 0.0 109.884 178.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . 0.422 ' HG3' ' O ' ' B' ' 96' ' ' PRO . 7.8 tp10 -83.71 80.67 9.05 Favored 'General case' 0 N--CA 1.403 -2.783 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 173.774 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . 0.429 ' HB3' ' HD3' ' B' ' 96' ' ' PRO . 31.7 ttm180 -62.91 -58.24 17.5 Favored Pre-proline 0 C--N 1.304 -1.401 0 CA-C-N 114.086 -1.415 . . . . 0.0 110.796 176.135 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . 0.429 ' HD3' ' HB3' ' B' ' 95' ' ' ARG . 83.5 Cg_endo -82.35 -159.01 0.1 OUTLIER 'Trans proline' 0 C--N 1.357 0.993 0 C-N-CA 122.252 1.968 . . . . 0.0 111.254 173.425 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 121.36 35.85 0.78 Allowed Glycine 0 C--N 1.29 -2.014 0 C-N-CA 120.781 -0.724 . . . . 0.0 111.853 176.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 54.55 15.21 0.98 Allowed 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 115.834 1.791 . . . . 0.0 115.834 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 7.1 tp-100 -77.72 -29.86 51.43 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 173.205 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 23.9 m -128.27 158.87 36.96 Favored 'General case' 0 N--CA 1.414 -2.253 0 N-CA-C 105.289 -2.115 . . . . 0.0 105.289 174.09 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -108.9 75.34 0.95 Allowed 'General case' 0 C--N 1.291 -1.954 0 CA-C-O 122.091 0.948 . . . . 0.0 110.799 -173.541 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 20.7 t -90.82 119.25 37.64 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.539 0 N-CA-C 104.706 -2.331 . . . . 0.0 104.706 170.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -139.18 102.77 4.59 Favored 'General case' 0 C--N 1.283 -2.316 0 O-C-N 123.238 0.336 . . . . 0.0 111.839 -172.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 7.1 tp60 59.49 97.61 0.03 OUTLIER 'General case' 0 C--O 1.249 1.034 0 C-N-CA 125.025 1.33 . . . . 0.0 112.874 178.196 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 89.7 mt -85.64 119.05 25.56 Favored 'General case' 0 C--N 1.278 -2.543 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 176.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 40.1 mm -61.81 -60.56 2.51 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.697 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 60.26 95.54 0.03 OUTLIER 'General case' 0 N--CA 1.435 -1.194 0 O-C-N 125.029 1.456 . . . . 0.0 112.422 174.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . 0.483 ' HB3' ' HA ' ' B' ' 111' ' ' GLU . 98.2 mt-30 -66.71 103.64 1.14 Allowed 'General case' 0 N--CA 1.437 -1.121 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 174.223 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 12.7 t -70.07 -27.99 65.06 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.018 -172.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 58.3 mt -98.11 -27.35 14.23 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 176.083 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . 0.483 ' HA ' ' HB3' ' B' ' 108' ' ' GLN . 29.1 tt0 64.24 78.95 0.27 Allowed 'General case' 0 C--O 1.251 1.137 0 CA-C-N 113.78 -1.555 . . . . 0.0 110.988 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 66.0 mt-30 65.78 -177.31 0.19 Allowed 'General case' 0 C--O 1.242 0.703 0 CA-C-N 113.827 -1.533 . . . . 0.0 110.736 -179.589 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 15.4 mm-40 . . . . . 0 C--N 1.303 -1.433 0 CA-C-O 118.765 -0.636 . . . . 0.0 109.403 179.718 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.201 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -79.13 -50.17 11.44 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 178.406 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . 0.491 ' HA ' ' O ' ' B' ' 93' ' ' ARG . 66.2 mtt -125.58 125.98 44.05 Favored 'General case' 0 N--CA 1.427 -1.605 0 CA-C-N 114.235 -1.348 . . . . 0.0 110.045 178.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -94.54 101.55 13.45 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.276 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.46 90.71 8.47 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.33 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -119.29 144.59 36.66 Favored Pre-proline 0 C--N 1.29 -1.985 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.109 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . 0.433 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 56.4 Cg_endo -75.49 139.23 22.83 Favored 'Trans proline' 0 N--CA 1.446 -1.297 0 C-N-CA 122.271 1.981 . . . . 0.0 111.767 177.36 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.463 ' HB ' HD13 ' B' ' 91' ' ' ILE . 87.5 t -129.73 128.99 66.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -179.298 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . 0.52 ' HB2' ' HG2' ' B' ' 88' ' ' ARG . 38.6 tt0 -114.99 123.26 48.65 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.48 HD21 ' HA ' ' B' ' 48' ' ' ALA . 1.1 mt -132.93 164.05 27.79 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 178.143 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -123.56 137.49 54.75 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 174.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . 0.415 ' HB2' ' O ' ' B' ' 16' ' ' GLY . 18.3 ptmt -74.96 162.48 28.56 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.189 179.143 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -134.78 -166.13 1.77 Allowed 'General case' 0 C--N 1.291 -1.965 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.5 m -66.49 -22.31 66.19 Favored 'General case' 0 C--N 1.313 -1.003 0 C-N-CA 123.666 0.786 . . . . 0.0 111.598 -178.279 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -86.06 2.34 46.89 Favored 'General case' 0 CA--C 1.55 0.952 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 177.543 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.415 ' O ' ' HB2' ' B' ' 12' ' ' LYS . . . 85.06 -91.57 1.7 Allowed Glycine 0 N--CA 1.417 -2.58 0 N-CA-C 107.34 -2.304 . . . . 0.0 107.34 -175.077 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.405 ' HB3' HG12 ' B' ' 19' ' ' ILE . 3.5 mm? -124.75 134.14 52.91 Favored 'General case' 0 C--N 1.281 -2.396 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 174.719 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -83.45 53.3 4.84 Favored Glycine 0 C--O 1.216 -1.005 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.531 HG22 ' HA ' ' B' ' 42' ' ' VAL . 8.0 pt -161.87 176.56 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 C-N-CA 126.126 1.77 . . . . 0.0 107.491 -177.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . 0.402 ' HB2' HG22 ' B' ' 41' ' ' THR . 27.3 m -143.41 146.21 33.28 Favored 'General case' 0 C--N 1.268 -2.951 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 173.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.475 ' HB ' HG22 ' B' ' 37' ' ' ILE . 10.1 pt -114.31 162.56 12.33 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.461 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -179.164 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . 0.43 ' HB ' ' HB2' ' B' ' 40' ' ' LYS . 10.8 tp -137.89 138.37 44.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-O 121.041 0.448 . . . . 0.0 110.362 -177.714 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -88.54 108.58 3.45 Favored Glycine 0 N--CA 1.427 -1.94 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.662 178.304 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 22.7 mmt -124.33 149.36 46.67 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 177.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 135.1 168.4 11.62 Favored Glycine 0 N--CA 1.426 -1.979 0 C-N-CA 120.205 -0.998 . . . . 0.0 111.612 178.4 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -171.77 161.51 5.96 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 179.685 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . 144.51 -149.11 21.17 Favored Glycine 0 N--CA 1.426 -2.031 0 C-N-CA 120.297 -0.954 . . . . 0.0 111.984 178.7 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.38 101.17 2.33 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-O 121.204 0.526 . . . . 0.0 111.133 179.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.437 ' HA ' ' HA ' ' B' ' 33' ' ' GLU . 18.8 t70 -100.43 -7.58 24.16 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-O 121.962 0.886 . . . . 0.0 109.186 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 24.0 ptm -60.09 -33.97 72.82 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 114.255 -1.339 . . . . 0.0 112.949 -178.552 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -171.22 56.25 0.18 Allowed Glycine 0 N--CA 1.445 -0.737 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 177.57 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 65.5 tp -171.01 -51.45 0.02 OUTLIER 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 -178.19 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . 0.437 ' HA ' ' HA ' ' B' ' 29' ' ' ASP 0.356 10.0 pt-20 51.8 68.66 0.77 Allowed 'General case' 0 CA--C 1.504 -0.804 0 O-C-N 125.22 1.575 . . . . 0.0 113.387 -178.813 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.11 101.91 8.15 Favored 'General case' 0 N--CA 1.42 -1.937 0 CA-C-N 113.341 -1.754 . . . . 0.0 110.271 179.037 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . 0.434 HD23 ' O ' ' B' ' 71' ' ' VAL . 14.5 tp -135.35 165.42 25.49 Favored 'General case' 0 C--N 1.282 -2.34 0 N-CA-C 104.797 -2.297 . . . . 0.0 104.797 179.348 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -138.94 120.36 1.9 Allowed Glycine 0 C--N 1.273 -2.929 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.051 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.475 HG22 ' HB ' ' B' ' 21' ' ' ILE . 32.0 mm -96.84 89.22 2.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 179.23 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -84.31 170.88 13.2 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.55 -1.204 . . . . 0.0 108.192 -179.176 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 49.8 t -75.86 145.22 10.92 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 174.151 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . 0.43 ' HB2' ' HB ' ' B' ' 22' ' ' ILE . 2.0 tmmm? -105.08 -41.26 5.63 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 -179.522 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . 0.424 ' HA ' HG23 ' B' ' 56' ' ' VAL . 1.0 OUTLIER -158.39 164.15 36.58 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 -179.533 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.531 ' HA ' HG22 ' B' ' 19' ' ' ILE . 15.3 t -119.0 95.15 3.46 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 175.634 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.45 ' H ' ' HA ' ' B' ' 19' ' ' ILE . 7.0 m -64.09 121.03 13.21 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 123.976 0.91 . . . . 0.0 112.159 -175.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -69.59 -18.18 63.6 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.18 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.45 -11.77 84.09 Favored Glycine 0 N--CA 1.436 -1.313 0 C-N-CA 120.978 -0.629 . . . . 0.0 112.354 178.094 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -115.69 172.43 14.21 Favored Glycine 0 N--CA 1.426 -1.982 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.303 -178.591 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -67.53 -27.03 66.63 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 114.698 1.37 . . . . 0.0 114.698 -172.171 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . 0.48 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -63.72 -41.89 98.0 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 112.486 0.551 . . . . 0.0 112.486 -175.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -70.83 -38.01 73.23 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 121.807 0.813 . . . . 0.0 109.276 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 -72.7 -34.08 66.89 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 114.197 -1.365 . . . . 0.0 110.626 -174.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . 0.542 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 15.5 t0 -75.81 -52.87 9.44 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 175.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.82 29.62 8.03 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.546 -177.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.542 ' HG2' ' OD1' ' B' ' 51' ' ' ASP . 32.6 mmt180 -90.0 -81.74 0.28 Allowed 'General case' 0 CA--C 1.513 -0.478 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.455 HD11 ' CE2' ' B' ' 89' ' ' PHE . 81.3 mt -67.01 125.41 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 O-C-N 123.293 0.37 . . . . 0.0 110.197 176.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . 0.495 ' NE2' HH12 ' B' ' 93' ' ' ARG . 0.9 OUTLIER -104.39 161.61 13.93 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.635 -176.677 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.424 HG23 ' HA ' ' B' ' 41' ' ' THR . 7.3 p -62.43 -21.32 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 N-CA-C 115.771 1.767 . . . . 0.0 115.771 -168.22 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.658 ' ND2' ' HA ' ' B' ' 98' ' ' GLU . 15.6 t-20 -122.57 22.63 9.85 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.936 -1.106 . . . . 0.0 109.066 -176.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . 0.445 ' OD2' ' HB2' ' B' ' 55' ' ' GLN . 78.5 m-20 -87.96 170.9 10.74 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.976 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . . . . . . . . . 28.2 tp -132.12 131.22 42.12 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.626 -178.157 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 78.9 mt -83.2 95.03 8.0 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 176.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.478 ' HB ' ' O ' ' B' ' 90' ' ' MET . 21.4 t -74.0 -40.96 52.7 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.886 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.448 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 11.3 pt-20 -160.56 149.66 17.07 Favored 'General case' 0 C--N 1.283 -2.307 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.482 176.22 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.407 HG12 ' O ' ' B' ' 66' ' ' THR . 4.8 p -98.27 -179.27 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 105.037 -2.209 . . . . 0.0 105.037 176.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.57 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 16.6 t70 -53.52 -53.33 53.04 Favored 'General case' 0 C--N 1.311 -1.076 0 N-CA-C 114.081 1.141 . . . . 0.0 114.081 -177.567 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -105.23 -1.77 41.4 Favored Glycine 0 C--N 1.312 -0.768 0 C-N-CA 119.408 -1.377 . . . . 0.0 115.509 -175.632 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . 0.407 ' O ' HG12 ' B' ' 63' ' ' VAL . 13.8 m -142.89 133.29 24.82 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 118.163 0.982 . . . . 0.0 110.011 -175.344 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . 0.448 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 13.0 t -94.15 157.15 16.21 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.72 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.45 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 3.3 mm? -118.25 115.21 24.27 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.956 0.408 . . . . 0.0 111.062 -179.075 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 13.8 p -97.52 -20.28 5.7 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-O 121.918 0.866 . . . . 0.0 109.497 175.437 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 143.52 86.15 0.08 OUTLIER Glycine 0 CA--C 1.485 -1.791 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -178.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.434 ' O ' HD23 ' B' ' 35' ' ' LEU . 33.5 m -109.46 -179.04 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.301 0 CA-C-N 115.032 -0.584 . . . . 0.0 109.515 -175.665 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 71.2 p -75.24 159.56 31.41 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 109.173 -0.676 . . . . 0.0 109.173 176.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.6 tt0 -62.17 -33.38 74.41 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.469 0.652 . . . . 0.0 110.046 -179.116 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 22.3 m -73.24 -37.37 66.38 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.004 178.159 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -62.41 -46.1 90.12 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 178.334 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.477 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -62.6 -42.42 99.57 Favored 'General case' 0 C--O 1.209 -1.075 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.747 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -62.0 -31.02 71.35 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 121.719 0.771 . . . . 0.0 111.057 178.788 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 33.4 t -90.47 -4.85 56.68 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.893 -179.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.477 HG12 ' O ' ' B' ' 76' ' ' ALA . 1.2 p -76.27 -31.98 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 C-N-CA 119.776 -0.77 . . . . 0.0 109.494 -177.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -67.86 -30.81 70.27 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.574 174.388 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -82.09 -7.59 59.62 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.648 -178.278 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -92.17 -23.11 19.49 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.989 178.259 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.516 ' HB ' HG11 ' B' ' 87' ' ' VAL . 11.6 p -97.46 -178.76 4.25 Favored 'General case' 0 N--CA 1.428 -1.535 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.241 177.479 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 65.3 mmtt -70.93 -171.56 0.56 Allowed 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 123.245 0.618 . . . . 0.0 111.387 177.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -78.39 -35.71 32.5 Favored Glycine 0 N--CA 1.442 -0.932 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.716 -178.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 29.5 ttt180 -123.13 117.33 25.15 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 176.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.57 ' HB ' ' HB2' ' B' ' 64' ' ' ASP . 7.8 m -148.5 160.02 6.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 123.878 0.736 . . . . 0.0 110.009 -177.371 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . 0.52 ' HG2' ' HB2' ' B' ' 9' ' ' GLU . 96.3 mtt180 -103.49 134.12 47.38 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.708 177.761 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.455 ' CE2' HD11 ' B' ' 54' ' ' ILE . 0.7 OUTLIER -112.93 166.37 11.46 Favored 'General case' 0 C--N 1.281 -2.407 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 178.879 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.478 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 85.0 mtp -111.66 114.55 27.65 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 171.381 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.463 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.4 mp -97.76 130.0 47.11 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.188 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -118.65 95.23 0.61 Allowed Glycine 0 CA--C 1.45 -3.97 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 177.003 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . 0.495 HH12 ' NE2' ' B' ' 55' ' ' GLN . 24.4 ttp180 -84.93 125.93 33.08 Favored 'General case' 0 C--N 1.268 -2.953 0 CA-C-N 114.322 -0.939 . . . . 0.0 111.716 -178.256 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -87.04 89.86 8.15 Favored 'General case' 0 N--CA 1.406 -2.655 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 170.177 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 24.0 ttt180 -39.17 -58.46 1.82 Allowed Pre-proline 0 CA--C 1.554 1.116 0 C-N-CA 126.282 1.833 . . . . 0.0 112.956 -177.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -70.39 139.05 37.19 Favored 'Trans proline' 0 N--CA 1.449 -1.093 0 C-N-CA 122.005 1.803 . . . . 0.0 110.888 174.324 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . 0.428 ' HA2' ' OG ' ' B' ' 100' ' ' SER . . . 118.73 7.29 10.75 Favored Glycine 0 C--N 1.286 -2.211 0 C-N-CA 120.059 -1.067 . . . . 0.0 112.299 -177.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . 0.658 ' HA ' ' ND2' ' B' ' 57' ' ' ASN . 5.4 pt-20 -82.22 -41.86 19.71 Favored 'General case' 0 N--CA 1.438 -1.042 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.381 176.766 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . 0.433 ' HG2' ' HG3' ' B' ' 98' ' ' GLU . 81.5 mm-40 -92.04 -60.91 1.74 Allowed 'General case' 0 N--CA 1.421 -1.897 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . 0.428 ' OG ' ' HA2' ' B' ' 97' ' ' GLY . 73.5 m 53.12 -175.64 0.03 OUTLIER 'General case' 0 C--O 1.246 0.888 0 C-N-CA 125.117 1.367 . . . . 0.0 113.821 -179.567 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -121.31 72.12 0.98 Allowed 'General case' 0 N--CA 1.423 -1.796 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 175.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . 0.537 ' HB ' HD11 ' B' ' 105' ' ' LEU . 14.2 m -126.53 97.72 4.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.686 -178.575 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -113.42 -54.22 2.63 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.943 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 22.3 mt-30 -122.7 95.01 4.46 Favored 'General case' 0 C--N 1.29 -1.989 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 178.543 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . 0.537 HD11 ' HB ' ' B' ' 102' ' ' VAL . 5.7 mp -78.93 76.87 5.41 Favored 'General case' 0 C--N 1.31 -1.12 0 CA-C-O 121.261 0.553 . . . . 0.0 110.895 -177.683 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 45.9 mm -101.66 -71.67 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 175.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -159.82 115.07 2.39 Favored 'General case' 0 N--CA 1.438 -1.046 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 176.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 80.2 mt-30 -87.0 102.09 14.07 Favored 'General case' 0 N--CA 1.425 -1.708 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 177.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 7.4 t -82.59 -22.81 34.67 Favored 'General case' 0 N--CA 1.431 -1.386 0 CA-C-N 114.661 -1.154 . . . . 0.0 108.093 -177.49 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 92.3 mt -96.68 91.35 5.67 Favored 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 174.687 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -69.48 115.28 8.56 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 176.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 29.2 tt0 -111.82 -57.18 2.29 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.136 -174.196 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 55.9 mm-40 . . . . . 0 N--CA 1.432 -1.367 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.541 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.503 -0.696 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . 0.437 ' O ' ' HD2' ' B' ' 96' ' ' PRO . 42.9 t-80 -72.18 -46.83 54.71 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 176.452 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 22.3 ptt? -103.31 115.99 31.61 Favored 'General case' 0 N--CA 1.421 -1.884 0 CA-C-N 114.601 -1.181 . . . . 0.0 107.813 172.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . 0.502 ' OE2' ' HD2' ' B' ' 93' ' ' ARG . 15.4 mt-10 -87.07 101.3 13.33 Favored 'General case' 0 C--N 1.294 -1.831 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.038 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -90.34 88.49 7.22 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 174.09 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -110.82 145.15 31.78 Favored Pre-proline 0 C--N 1.29 -1.985 0 CA-C-N 116.119 -0.491 . . . . 0.0 112.027 -177.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . 0.53 ' HA ' ' O ' ' B' ' 89' ' ' PHE . 60.1 Cg_endo -81.89 134.65 8.45 Favored 'Trans proline' 0 N--CA 1.439 -1.707 0 C-N-CA 122.142 1.894 . . . . 0.0 113.526 178.09 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 65.4 t -121.97 130.76 74.31 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 176.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -115.22 132.95 56.45 Favored 'General case' 0 C--N 1.294 -1.84 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.165 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.424 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -121.15 161.21 22.21 Favored 'General case' 0 CA--C 1.493 -1.231 0 CA-C-O 121.403 0.62 . . . . 0.0 111.251 179.562 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -132.94 132.99 42.61 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 107.41 -1.329 . . . . 0.0 107.41 174.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . 0.502 ' HA ' ' CB ' ' B' ' 47' ' ' ALA . 36.0 mtmm -97.43 160.31 14.4 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 121.467 0.651 . . . . 0.0 112.468 -171.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 m-20 -113.27 -168.27 1.31 Allowed 'General case' 0 C--N 1.308 -1.2 0 CA-C-N 114.882 -1.054 . . . . 0.0 109.652 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 15.1 m -60.27 -35.93 76.67 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 113.618 0.969 . . . . 0.0 113.618 -174.624 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -79.6 -22.08 44.15 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-O 121.641 0.734 . . . . 0.0 109.364 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.06 -132.02 10.78 Favored Glycine 0 N--CA 1.423 -2.205 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.139 178.623 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.423 ' HG ' HG12 ' B' ' 19' ' ' ILE . 24.0 tp -82.83 169.71 15.81 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -178.804 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . 0.514 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -149.54 66.24 0.38 Allowed Glycine 0 CA--C 1.48 -2.122 0 C-N-CA 119.805 -1.188 . . . . 0.0 112.442 -177.647 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.468 HG22 ' HA ' ' B' ' 42' ' ' VAL . 8.4 pt -160.14 172.17 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.486 -1.482 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 179.488 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . 0.424 ' HB2' HG22 ' B' ' 41' ' ' THR . 56.7 m -133.39 151.57 51.84 Favored 'General case' 0 C--N 1.257 -3.444 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 174.578 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.519 ' HB ' HG22 ' B' ' 37' ' ' ILE . 13.2 pt -121.59 148.2 25.15 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.681 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 -178.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.6 tp -119.02 132.49 68.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -179.374 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -96.56 97.97 2.11 Favored Glycine 0 N--CA 1.427 -1.951 0 C-N-CA 120.231 -0.985 . . . . 0.0 113.689 -174.408 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 82.3 mtp -95.89 112.94 24.54 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.083 -1.081 . . . . 0.0 108.083 175.672 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.524 ' HA3' ' HG ' ' B' ' 35' ' ' LEU . . . 149.95 173.26 20.15 Favored Glycine 0 N--CA 1.414 -2.809 0 C-N-CA 120.367 -0.921 . . . . 0.0 111.935 -178.374 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -152.76 -168.79 3.15 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 -178.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.36 113.55 5.42 Favored Glycine 0 N--CA 1.437 -1.234 0 O-C-N 123.673 0.608 . . . . 0.0 112.924 -178.25 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -132.85 45.0 2.79 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 105.748 -1.945 . . . . 0.0 105.748 176.783 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -79.63 2.5 22.27 Favored 'General case' 0 C--N 1.301 -1.529 0 CA-C-N 112.433 -2.167 . . . . 0.0 111.777 -171.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 26.5 ptm -75.45 11.71 1.18 Allowed 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.476 177.607 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 111.22 27.06 4.36 Favored Glycine 0 N--CA 1.435 -1.375 0 C-N-CA 121.369 -0.443 . . . . 0.0 112.818 177.602 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 95.3 mt -124.89 -69.99 0.77 Allowed 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 116.936 0.368 . . . . 0.0 110.536 -178.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . 0.295 10.4 pt-20 43.02 62.74 1.71 Allowed 'General case' 0 C--O 1.213 -0.821 0 C-N-CA 125.086 1.354 . . . . 0.0 114.285 -176.504 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 9.3 mtpm? -107.06 89.13 2.9 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 175.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . 0.524 ' HG ' ' HA3' ' B' ' 25' ' ' GLY . 9.4 mp -113.75 155.22 26.02 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.748 -175.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -116.18 97.77 0.79 Allowed Glycine 0 N--CA 1.413 -2.858 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.917 -177.095 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.519 HG22 ' HB ' ' B' ' 21' ' ' ILE . 23.3 mm -92.98 87.69 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 174.771 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -85.17 164.44 18.11 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.614 -175.238 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 94.2 t -77.65 128.31 38.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 174.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -93.45 -37.45 11.95 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.123 0.487 . . . . 0.0 110.556 -176.003 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . 0.424 HG22 ' HB2' ' B' ' 20' ' ' SER . 0.6 OUTLIER -158.4 163.46 37.22 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 -178.51 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.468 ' HA ' HG22 ' B' ' 19' ' ' ILE . 19.4 t -120.54 96.22 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.71 0 N-CA-C 106.468 -1.679 . . . . 0.0 106.468 176.441 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 17.1 m -59.99 124.31 19.8 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 124.186 0.995 . . . . 0.0 112.183 -175.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . 0.576 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 36.0 mt-10 -55.14 -33.83 63.25 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 124.767 1.227 . . . . 0.0 112.628 -176.709 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.67 -18.79 78.87 Favored Glycine 0 N--CA 1.438 -1.214 0 CA-C-N 115.674 -0.694 . . . . 0.0 114.521 -177.016 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.514 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -106.03 170.37 16.74 Favored Glycine 0 N--CA 1.423 -2.228 0 C-N-CA 118.497 -1.811 . . . . 0.0 114.719 -173.602 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . 0.502 ' CB ' ' HA ' ' B' ' 12' ' ' LYS . . . -59.53 -33.64 71.65 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 113.605 -1.298 . . . . 0.0 114.401 -174.14 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . 0.424 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -65.69 -33.0 74.86 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.243 -176.596 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . 0.576 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 12.2 t60 -77.31 -40.6 43.75 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.532 178.147 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 40.0 mtp-105 -66.97 -39.61 87.25 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.602 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . 0.528 ' OD1' ' HG2' ' B' ' 53' ' ' ARG . 12.0 t70 -78.0 -58.22 3.38 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.136 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.71 -4.87 36.9 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.628 -0.796 . . . . 0.0 113.662 179.146 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.528 ' HG2' ' OD1' ' B' ' 51' ' ' ASP . 0.4 OUTLIER -54.16 -62.13 1.86 Allowed 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 179.183 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.55 HD11 ' CE2' ' B' ' 89' ' ' PHE . 35.1 mt -81.31 126.46 39.8 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.227 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -103.29 168.51 9.12 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.162 177.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 7.1 p -73.53 4.46 0.84 Allowed 'Isoleucine or valine' 0 CA--C 1.57 1.725 0 CA-C-O 121.981 0.896 . . . . 0.0 111.533 -177.109 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -117.85 5.58 12.21 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.281 1.039 . . . . 0.0 109.529 -177.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -87.34 161.68 17.79 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.701 -177.536 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.626 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 25.5 tp -138.31 127.21 23.88 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 123.494 0.717 . . . . 0.0 109.742 -175.471 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 66.0 mt -88.01 97.48 10.98 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.619 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 0.8 OUTLIER -92.9 -21.42 6.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-O 122.219 1.009 . . . . 0.0 109.5 -177.277 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.561 ' HG2' ' O ' ' B' ' 63' ' ' VAL . 30.9 tt0 -164.64 150.99 10.65 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 113.133 -1.848 . . . . 0.0 108.701 175.013 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.561 ' O ' ' HG2' ' B' ' 62' ' ' GLU . 6.2 p -93.18 -162.6 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.202 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 176.367 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.587 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 11.7 t70 -56.59 -54.31 47.41 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 123.277 0.631 . . . . 0.0 111.687 -178.749 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -113.64 -54.18 0.44 Allowed Glycine 0 N--CA 1.439 -1.162 0 C-N-CA 120.478 -0.868 . . . . 0.0 113.213 -178.643 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 25.6 m -62.87 115.25 4.2 Favored 'General case' 0 C--O 1.246 0.909 0 CA-C-O 121.744 0.783 . . . . 0.0 112.731 -175.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . 0.506 ' HA ' ' HG3' ' B' ' 62' ' ' GLU . 25.1 m -77.72 109.87 12.09 Favored 'General case' 0 N--CA 1.424 -1.75 0 C-N-CA 124.992 1.317 . . . . 0.0 113.397 -176.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.619 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 54.8 mt -90.88 -164.74 1.22 Allowed 'General case' 0 N--CA 1.421 -1.911 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 174.003 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 p 175.73 -30.86 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 106.236 -1.765 . . . . 0.0 106.236 178.368 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . 0.498 ' HA3' ' H ' ' B' ' 35' ' ' LEU . . . 169.02 77.06 0.04 OUTLIER Glycine 1 N--CA 1.39 -4.373 0 CA-C-N 114.48 -1.236 . . . . 0.0 111.227 -179.279 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 27.0 m -99.74 178.1 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.277 -2.581 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 34.6 p -76.84 161.74 28.19 Favored 'General case' 0 C--N 1.291 -1.95 0 C-N-CA 120.415 -0.514 . . . . 0.0 109.892 175.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -57.99 -40.77 81.55 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 123.829 0.851 . . . . 0.0 109.614 178.675 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 22.3 m -68.46 -38.57 81.22 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.077 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -62.93 -47.92 81.13 Favored 'General case' 0 C--O 1.24 0.566 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 178.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.572 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -58.75 -45.37 89.86 Favored 'General case' 0 C--O 1.208 -1.105 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.845 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -59.91 -36.82 77.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.982 0.42 . . . . 0.0 111.749 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 15.4 p -77.88 -14.83 59.43 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 112.967 0.729 . . . . 0.0 112.967 -179.5 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.572 HG12 ' O ' ' B' ' 76' ' ' ALA . 2.8 p -73.31 -37.3 51.36 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.952 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.071 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -59.64 -18.81 44.76 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.97 0.908 . . . . 0.0 112.433 176.541 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 6.6 mtp180 -100.21 -6.66 25.73 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 121.213 0.53 . . . . 0.0 111.918 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -114.95 10.69 16.37 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.41 0.624 . . . . 0.0 111.245 179.153 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.724 ' HB ' HG11 ' B' ' 87' ' ' VAL . 7.9 p -92.46 -173.42 3.38 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 115.491 -0.777 . . . . 0.0 112.298 178.513 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 44.9 mttm -76.67 -169.0 1.12 Allowed 'General case' 0 N--CA 1.437 -1.111 0 C-N-CA 123.506 0.722 . . . . 0.0 111.113 175.163 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -73.37 -49.69 14.52 Favored Glycine 0 N--CA 1.437 -1.274 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.056 176.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 16.2 ttm180 -118.38 121.44 40.37 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 176.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.724 HG11 ' HB ' ' B' ' 83' ' ' THR . 8.8 m -130.13 151.98 36.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 71.7 mtm180 -94.96 169.66 9.97 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 113.788 -1.551 . . . . 0.0 108.006 173.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.55 ' CE2' HD11 ' B' ' 54' ' ' ILE . 4.7 m-85 -144.14 151.1 39.1 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 176.053 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . . . . . . . . . 48.0 mtm -100.43 115.12 29.3 Favored 'General case' 0 N--CA 1.425 -1.698 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 173.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.626 ' HA ' ' O ' ' B' ' 59' ' ' LEU . 1.5 mp -96.93 127.84 48.72 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.002 -179.142 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -108.36 120.87 6.1 Favored Glycine 0 N--CA 1.427 -1.962 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 177.312 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . 0.502 ' HD2' ' OE2' ' B' ' 4' ' ' GLU . 35.5 ttm180 -120.85 123.25 42.1 Favored 'General case' 0 C--N 1.281 -2.377 0 CA-C-N 115.207 -0.497 . . . . 0.0 109.731 178.218 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -87.88 81.72 7.47 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 171.445 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 13.8 ttm-85 -63.05 -64.38 3.08 Favored Pre-proline 0 CA--C 1.556 1.192 0 CA-C-N 115.136 -0.938 . . . . 0.0 113.387 -178.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . 0.437 ' HD2' ' O ' ' B' ' 2' ' ' HIS . 30.9 Cg_endo -67.13 159.92 49.86 Favored 'Trans proline' 0 C--N 1.364 1.368 0 C-N-CA 122.015 1.81 . . . . 0.0 113.952 -176.313 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . 155.33 -47.21 0.51 Allowed Glycine 0 N--CA 1.436 -1.366 0 CA-C-N 114.716 -1.129 . . . . 0.0 110.34 -178.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -68.58 -32.49 72.44 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.308 -0.446 . . . . 0.0 111.056 178.427 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 8.9 tp-100 52.32 74.56 0.27 Allowed 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 124.856 1.262 . . . . 0.0 110.838 -177.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 71.0 m -93.45 158.43 15.72 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.524 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -87.68 -21.48 25.22 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-O 122.708 1.242 . . . . 0.0 109.798 -176.544 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 12.9 m -114.68 71.01 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.269 -2.918 0 CA-C-N 113.946 -1.479 . . . . 0.0 112.721 178.477 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -139.99 13.3 2.45 Favored 'General case' 0 C--N 1.282 -2.333 0 CA-C-N 113.342 -1.754 . . . . 0.0 108.078 175.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 55.2 tp60 -161.48 93.64 0.94 Allowed 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 -179.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 3.8 mp -121.63 93.8 4.12 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 120.957 0.408 . . . . 0.0 110.269 -176.139 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 32.7 mm -96.94 -61.87 2.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 175.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 29.8 tt0 68.54 -33.39 0.24 Allowed 'General case' 0 CA--C 1.548 0.89 0 C-N-CA 125.828 1.651 . . . . 0.0 114.486 174.64 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . 0.426 ' HA ' ' OE1' ' B' ' 108' ' ' GLN . 12.5 mm-40 64.34 78.08 0.3 Allowed 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 124.075 0.95 . . . . 0.0 110.614 -179.562 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 5.2 t -81.17 -48.85 11.55 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.061 -177.365 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 89.7 mt -91.19 -14.31 31.27 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-O 121.277 0.561 . . . . 0.0 110.467 -178.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -96.78 102.6 14.41 Favored 'General case' 0 N--CA 1.418 -2.052 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.435 179.444 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.22 103.59 8.87 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 174.703 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 . . . . . 0 N--CA 1.42 -1.972 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -177.336 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.505 -0.552 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 14.9 p-80 -103.84 160.6 14.66 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 116.809 0.305 . . . . 0.0 110.841 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 66.8 mtt -81.82 137.0 35.35 Favored 'General case' 0 N--CA 1.431 -1.377 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 172.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . . . . . . . . . 14.0 mt-10 -90.81 97.77 11.38 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 120.43 -0.508 . . . . 0.0 109.931 -173.044 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -86.87 93.56 9.34 Favored 'General case' 0 N--CA 1.439 -0.977 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 177.339 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -114.59 143.56 30.18 Favored Pre-proline 0 C--N 1.283 -2.286 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.851 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -74.21 132.89 17.11 Favored 'Trans proline' 0 N--CA 1.45 -1.054 0 C-N-CA 122.331 2.02 . . . . 0.0 113.493 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.517 ' HB ' HD13 ' B' ' 91' ' ' ILE . 77.6 t -124.66 123.82 66.79 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 CA-C-N 114.783 -1.099 . . . . 0.0 108.316 178.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -111.3 123.62 50.58 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -176.192 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.468 HD11 ' HB2' ' B' ' 48' ' ' ALA . 1.6 mt -117.46 177.01 4.9 Favored 'General case' 0 CA--C 1.489 -1.389 0 CA-C-O 121.233 0.539 . . . . 0.0 111.218 177.22 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -155.18 166.55 33.21 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . 0.435 ' HG2' ' CD1' ' B' ' 17' ' ' LEU . 10.1 mtmp? -116.11 160.72 19.96 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 118.407 0.549 . . . . 0.0 112.264 -176.157 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -97.79 -160.22 0.79 Allowed 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 169.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 17.6 m -69.6 -27.06 64.76 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 120.993 0.425 . . . . 0.0 110.221 177.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -75.9 -64.42 1.09 Allowed 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.96 75.63 0.68 Allowed Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.209 -0.996 . . . . 0.0 112.628 179.683 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.435 ' CD1' ' HG2' ' B' ' 12' ' ' LYS . 10.7 mp 71.92 172.82 0.31 Allowed 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 124.309 1.044 . . . . 0.0 112.916 179.289 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . 0.486 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . -172.59 88.88 0.08 OUTLIER Glycine 0 CA--C 1.488 -1.612 0 N-CA-C 107.806 -2.118 . . . . 0.0 107.806 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.549 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 9.8 pt -157.62 -173.65 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 -176.421 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . 0.493 ' HB2' HG22 ' B' ' 41' ' ' THR . 40.5 m -152.72 144.61 23.67 Favored 'General case' 0 C--N 1.257 -3.452 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 173.656 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.511 ' HB ' HG22 ' B' ' 37' ' ' ILE . 16.3 pt -116.74 162.93 14.34 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.584 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 179.282 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 8.1 tp -140.81 136.77 35.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 CA-C-O 120.98 0.419 . . . . 0.0 110.665 -178.806 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . 0.464 ' HA2' ' CD1' ' B' ' 37' ' ' ILE . . . -67.13 101.92 0.73 Allowed Glycine 0 N--CA 1.435 -1.372 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.1 178.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . . . . . . . . . 91.7 mtp -145.93 159.37 43.34 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 -178.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 167.68 -148.51 13.0 Favored Glycine 0 N--CA 1.42 -2.421 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 -177.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -142.97 168.68 19.15 Favored 'General case' 0 C--N 1.289 -2.059 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.38 69.75 2.73 Favored Glycine 0 N--CA 1.442 -0.922 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 174.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.81 81.05 6.13 Favored 'General case' 0 N--CA 1.42 -1.934 0 N-CA-C 113.129 0.788 . . . . 0.0 113.129 -173.39 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -72.5 -24.64 61.19 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 123.059 1.409 . . . . 0.0 107.32 173.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 25.6 ptt? -80.8 4.3 19.56 Favored 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 112.318 -2.219 . . . . 0.0 110.057 176.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -153.68 40.93 0.67 Allowed Glycine 0 C--O 1.206 -1.603 0 C-N-CA 119.973 -1.108 . . . . 0.0 113.839 -177.485 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 2.8 mm? 62.6 26.09 15.49 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 112.727 0.64 . . . . 0.0 112.727 171.602 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 61.84 26.58 16.13 Favored 'General case' 0 C--O 1.243 0.733 0 C-N-CA 124.622 1.169 . . . . 0.0 111.529 -179.071 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -71.0 126.46 29.64 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 114.788 1.403 . . . . 0.0 114.788 -172.214 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 91.1 mt -100.0 129.2 46.03 Favored 'General case' 0 N--CA 1.417 -2.083 0 N-CA-C 104.174 -2.528 . . . . 0.0 104.174 167.052 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . 0.462 ' HA3' HD11 ' B' ' 59' ' ' LEU . . . -99.67 -13.78 36.72 Favored Glycine 0 C--N 1.291 -1.968 0 C-N-CA 118.881 -1.628 . . . . 0.0 111.048 -175.223 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.511 HG22 ' HB ' ' B' ' 21' ' ' ILE . 31.2 mm 64.64 98.02 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.557 1.241 0 C-N-CA 124.396 1.078 . . . . 0.0 111.08 -179.145 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 62.4 m-85 -76.36 164.91 25.56 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.823 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 47.8 t -76.61 142.54 14.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 177.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . . . . . . . . . 31.9 ttmt -98.36 -46.34 5.82 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.331 -179.614 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . 0.536 ' HA ' HG23 ' B' ' 56' ' ' VAL . 1.1 t -161.15 166.79 27.36 Favored 'General case' 0 N--CA 1.428 -1.55 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -178.355 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.549 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 1.8 p -137.71 97.26 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.282 -2.342 0 CA-C-O 122.102 0.953 . . . . 0.0 109.381 177.694 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 12.8 m -54.61 129.67 37.31 Favored 'General case' 0 N--CA 1.435 -1.2 0 CA-C-N 113.453 -1.703 . . . . 0.0 111.1 -176.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . 0.461 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 38.7 mt-10 -60.55 -27.17 67.45 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 123.537 0.735 . . . . 0.0 111.407 -177.13 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.63 -7.85 88.13 Favored Glycine 0 N--CA 1.434 -1.434 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.843 178.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.486 ' HA3' ' HA3' ' B' ' 18' ' ' GLY . . . -93.02 161.08 25.37 Favored Glycine 0 CA--C 1.485 -1.788 0 C-N-CA 120.326 -0.94 . . . . 0.0 114.243 -175.516 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -62.57 -34.6 77.3 Favored 'General case' 0 C--N 1.305 -1.34 0 CA-C-N 113.614 -1.293 . . . . 0.0 111.642 -178.103 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . 0.468 ' HB2' HD11 ' B' ' 10' ' ' LEU . . . -66.15 -31.89 73.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.762 -0.199 . . . . 0.0 111.36 -177.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . 0.461 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 4.6 t60 -80.46 -42.6 22.32 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.568 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . 0.414 ' HG3' ' O ' ' B' ' 46' ' ' GLY . 82.5 mtp180 -64.59 -42.63 95.48 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.836 -179.632 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -76.52 -43.42 39.46 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 88.24 52.48 2.88 Favored Glycine 0 CA--C 1.503 -0.657 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.787 178.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.463 ' HB3' ' CG1' ' B' ' 8' ' ' VAL . 30.8 mmt180 -118.76 -74.29 0.61 Allowed 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -175.4 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.406 HD11 ' CE2' ' B' ' 89' ' ' PHE . 60.9 mt -72.24 107.81 3.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 176.586 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -97.25 153.52 17.97 Favored 'General case' 0 N--CA 1.425 -1.709 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.703 -175.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.536 HG23 ' HA ' ' B' ' 41' ' ' THR . 10.0 p -55.05 -24.07 14.0 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.56 0 N-CA-C 115.747 1.758 . . . . 0.0 115.747 -171.236 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -114.43 9.31 16.77 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 120.966 -1.084 . . . . 0.0 111.54 -172.304 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . 0.41 ' HB3' ' CG2' ' B' ' 91' ' ' ILE . 5.9 m-20 -99.49 -177.74 3.68 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 119.804 -0.759 . . . . 0.0 112.559 -176.85 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.482 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 29.3 tp -133.67 139.26 46.34 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 112.445 0.535 . . . . 0.0 112.445 -170.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . 0.407 ' O ' HD12 ' B' ' 68' ' ' LEU . 67.1 mt -89.27 101.76 14.43 Favored 'General case' 0 C--O 1.208 -1.104 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 176.781 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.552 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 24.8 t -83.46 -42.91 17.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-O 121.84 0.828 . . . . 0.0 111.509 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.494 ' CG ' ' HB2' ' B' ' 90' ' ' MET . 11.8 pt-20 -154.98 150.12 27.01 Favored 'General case' 0 C--N 1.272 -2.8 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.559 176.653 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.438 HG22 ' H ' ' B' ' 64' ' ' ASP . 5.0 p -96.1 -178.51 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.07 0 N-CA-C 105.909 -1.885 . . . . 0.0 105.909 178.623 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.47 ' HB2' ' HB ' ' B' ' 87' ' ' VAL . 14.8 t70 -49.47 -54.89 15.34 Favored 'General case' 0 C--N 1.315 -0.919 0 C-N-CA 124.16 0.984 . . . . 0.0 113.344 -176.381 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -121.12 24.2 7.46 Favored Glycine 0 C--N 1.32 -0.354 0 C-N-CA 119.372 -1.394 . . . . 0.0 114.254 -177.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . 0.431 ' HB ' HG12 ' B' ' 63' ' ' VAL . 25.8 m -152.61 126.54 9.02 Favored 'General case' 0 C--N 1.316 -0.889 0 O-C-N 121.732 -0.864 . . . . 0.0 109.693 179.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . 0.42 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 23.4 m -91.82 132.19 36.62 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 120.889 0.376 . . . . 0.0 110.757 -179.531 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.552 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 26.9 mt -81.69 95.66 7.29 Favored 'General case' 0 N--CA 1.431 -1.4 0 CA-C-O 121.374 0.607 . . . . 0.0 110.509 177.326 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . . . . . . . . . 10.3 p -92.56 16.73 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 CA-C-O 122.317 1.056 . . . . 0.0 108.943 178.581 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . . . . . . . . . . . 117.54 87.46 1.24 Allowed Glycine 0 CA--C 1.474 -2.493 0 C-N-CA 120.328 -0.939 . . . . 0.0 111.543 178.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 15.5 m -120.44 174.2 5.57 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 -178.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 62.9 p -85.51 164.62 17.71 Favored 'General case' 0 N--CA 1.42 -1.928 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 176.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -60.97 -38.28 85.4 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 177.12 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 17.1 m -64.15 -41.28 97.23 Favored 'General case' 0 N--CA 1.433 -1.324 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.951 178.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -65.62 -46.72 78.18 Favored 'General case' 0 CA--C 1.521 -0.138 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.529 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.515 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -56.82 -43.43 81.03 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-O 120.999 0.428 . . . . 0.0 110.773 179.121 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.18 -24.54 66.65 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.605 0.716 . . . . 0.0 111.056 178.173 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 32.6 m -85.79 -26.43 25.78 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.821 -178.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.515 HG12 ' O ' ' B' ' 76' ' ' ALA . 9.0 p -73.69 -32.54 35.54 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.679 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . 0.428 ' HG ' ' O ' ' B' ' 76' ' ' ALA . 64.5 mt -65.78 -23.12 66.64 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.485 177.04 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 59.7 mtm180 -99.53 -0.4 40.65 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.834 179.457 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -100.78 -29.38 12.29 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.203 177.497 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.727 ' HB ' HG11 ' B' ' 87' ' ' VAL . 7.8 p -74.38 164.03 27.08 Favored 'General case' 0 N--CA 1.425 -1.699 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.87 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 68.5 mmtt -68.83 -166.78 0.08 Allowed 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.102 1.361 . . . . 0.0 112.771 -179.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.93 -39.18 93.27 Favored Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.562 -0.744 . . . . 0.0 113.186 -179.161 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . 0.426 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 41.7 ttm180 -128.19 124.56 37.06 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 -179.614 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.727 HG11 ' HB ' ' B' ' 83' ' ' THR . 13.6 m -135.2 147.68 29.06 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 CA-C-O 121.138 0.494 . . . . 0.0 111.448 178.075 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 36.2 mtp85 -108.87 120.37 42.31 Favored 'General case' 0 N--CA 1.428 -1.536 0 CA-C-N 114.925 -1.034 . . . . 0.0 109.086 -179.08 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.443 ' HB2' ' CD1' ' B' ' 91' ' ' ILE . 2.9 m-85 -103.82 159.36 15.7 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 -177.124 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.494 ' HB2' ' CG ' ' B' ' 62' ' ' GLU . 0.5 OUTLIER -104.34 109.35 21.16 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 168.939 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.517 HD13 ' HB ' ' B' ' 8' ' ' VAL . 1.3 mp -89.79 129.92 39.92 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.158 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 178.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . 0.466 ' O ' ' HB3' ' B' ' 59' ' ' LEU . . . -112.38 104.31 1.59 Allowed Glycine 0 CA--C 1.458 -3.483 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 178.512 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 2.5 tpp180 -73.87 118.43 16.82 Favored 'General case' 0 C--N 1.27 -2.849 0 CA-C-N 114.913 -0.644 . . . . 0.0 109.664 178.566 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -76.46 75.74 3.2 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 173.582 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 31.5 ttt180 -71.05 -56.42 5.63 Favored Pre-proline 0 C--N 1.294 -1.814 0 CA-C-N 113.312 -1.767 . . . . 0.0 111.354 177.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.95 167.31 27.53 Favored 'Trans proline' 0 C--N 1.364 1.358 0 C-N-CA 121.855 1.704 . . . . 0.0 112.038 177.429 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -146.89 66.88 0.4 Allowed Glycine 0 N--CA 1.435 -1.385 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.348 -178.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 49.33 25.15 1.19 Allowed 'General case' 0 CA--C 1.539 0.522 0 N-CA-C 115.287 1.588 . . . . 0.0 115.287 177.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 23.9 tp60 -95.7 -17.8 20.98 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 178.471 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 28.5 m -77.68 157.98 29.9 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.952 -178.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 52.94 81.78 0.08 Allowed 'General case' 0 C--O 1.251 1.144 0 C-N-CA 125.584 1.554 . . . . 0.0 112.46 178.059 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 4.0 p -114.79 132.48 63.85 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.044 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.194 176.025 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -101.21 -74.5 0.61 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.495 -179.084 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -154.69 99.0 2.12 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-O 121.691 0.758 . . . . 0.0 110.92 -177.04 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 78.0 mt -100.84 -13.82 18.23 Favored 'General case' 0 CA--C 1.502 -0.885 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.871 -177.106 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . . . . . . . . . 38.3 mm -88.17 -60.43 2.28 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.017 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.272 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . . . . . . . . . 28.1 tt0 -102.14 105.17 15.83 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.943 177.454 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . 0.42 HE21 ' HB2' ' B' ' 111' ' ' GLU . 24.5 mt-30 -105.26 112.38 25.47 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.394 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 9.2 t -80.28 -41.55 24.75 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 120.59 -0.444 . . . . 0.0 111.397 -176.071 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 96.5 mt -133.53 -24.32 1.79 Allowed 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.121 -179.544 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . 0.42 ' HB2' HE21 ' B' ' 108' ' ' GLN . 41.4 tt0 68.91 123.16 0.03 OUTLIER 'General case' 0 C--O 1.235 0.325 0 C-N-CA 124.914 1.285 . . . . 0.0 112.073 -177.83 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 89.4 mt-30 -115.66 -76.34 0.58 Allowed 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 105.842 -1.91 . . . . 0.0 105.842 175.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 . . . . . 0 N--CA 1.434 -1.245 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 169.017 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.241 0.583 0 N-CA-C 111.489 -0.645 . . . . 0.0 111.489 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 2' ' ' HIS . . . . . . . . . . . . . 57.9 m80 -90.57 -56.76 3.07 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 179.104 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 3' ' ' MET . . . . . . . . . . . . . 67.8 mtm -127.31 151.98 48.05 Favored 'General case' 0 N--CA 1.432 -1.347 0 CA-C-N 115.254 -0.884 . . . . 0.0 109.0 178.194 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 4' ' ' GLU . . . . . 0.463 ' HG3' ' HA ' ' B' ' 94' ' ' GLU . 18.7 mt-10 -85.26 108.34 17.72 Favored 'General case' 0 N--CA 1.426 -1.652 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 179.136 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.522 ' HA ' ' O ' ' B' ' 91' ' ' ILE . 1.1 mm? -85.35 89.46 7.68 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 174.219 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 6' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -111.7 142.6 26.93 Favored Pre-proline 0 C--N 1.288 -2.094 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.295 -179.37 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 7' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -75.8 132.88 14.83 Favored 'Trans proline' 0 N--CA 1.44 -1.632 0 C-N-CA 122.223 1.949 . . . . 0.0 111.878 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.498 HG13 ' HB3' ' B' ' 53' ' ' ARG . 76.4 t -120.83 120.77 63.39 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.389 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.178 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 9' ' ' GLU . . . . . 0.414 ' O ' ' HG3' ' B' ' 53' ' ' ARG . 38.4 tt0 -115.29 120.18 38.8 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.704 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.554 HD21 ' HA ' ' B' ' 48' ' ' ALA . 0.9 OUTLIER -108.34 -173.58 2.31 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 178.832 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -158.83 155.85 28.59 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 105.046 -2.205 . . . . 0.0 105.046 176.528 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 10.6 ptpp? -84.96 163.38 18.95 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-O 121.743 0.782 . . . . 0.0 112.991 -173.346 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 13' ' ' ASP . . . . . 0.515 ' HB2' ' HB2' ' B' ' 47' ' ' ALA . 14.0 t70 -111.34 -176.35 2.93 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 104.697 -2.334 . . . . 0.0 104.697 170.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 34.3 m -63.8 -30.33 71.44 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 119.278 0.944 . . . . 0.0 111.575 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -88.91 -13.0 40.12 Favored 'General case' 0 CA--C 1.539 0.541 0 CA-C-O 121.711 0.767 . . . . 0.0 109.64 178.12 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.01 -108.11 2.43 Favored Glycine 0 N--CA 1.433 -1.505 0 C-N-CA 120.862 -0.685 . . . . 0.0 111.78 179.55 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -95.63 172.63 7.93 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 120.954 0.407 . . . . 0.0 110.105 -178.285 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 18' ' ' GLY . . . . . . . . . . . . . . . -137.12 53.86 0.73 Allowed Glycine 0 CA--C 1.486 -1.744 0 N-CA-C 109.944 -1.263 . . . . 0.0 109.944 -179.519 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.518 ' HA ' ' HA ' ' B' ' 42' ' ' VAL . 6.9 pt -157.95 -178.64 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.489 -1.369 0 C-N-CA 124.84 1.256 . . . . 0.0 108.282 -174.204 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . 0.433 ' HB2' ' HB3' ' B' ' 40' ' ' LYS . 46.8 m -152.58 156.21 38.87 Favored 'General case' 0 C--N 1.27 -2.853 0 N-CA-C 105.106 -2.183 . . . . 0.0 105.106 174.361 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 21' ' ' ILE . . . . . 0.419 ' HB ' HG22 ' B' ' 37' ' ' ILE . 29.5 pt -117.3 158.96 17.71 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 CA-C-N 118.181 0.446 . . . . 0.0 110.287 -177.045 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 9.1 tp -148.48 136.26 14.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 CA-C-O 121.422 0.629 . . . . 0.0 110.181 178.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -75.19 122.15 6.78 Favored Glycine 0 N--CA 1.423 -2.232 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.044 178.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 24' ' ' MET . . . . . 0.67 ' HB2' ' CD1' ' B' ' 38' ' ' PHE . 64.6 mtt -126.34 144.75 50.7 Favored 'General case' 0 CA--C 1.491 -1.298 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 174.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 145.08 -170.37 26.53 Favored Glycine 0 N--CA 1.42 -2.389 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 -177.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -138.98 169.41 17.84 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.98 69.41 1.88 Allowed Glycine 0 N--CA 1.449 -0.467 0 O-C-N 123.412 0.445 . . . . 0.0 113.669 -176.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -99.34 54.1 0.96 Allowed 'General case' 0 C--N 1.298 -1.663 0 CA-C-O 122.193 0.997 . . . . 0.0 109.142 177.53 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.411 ' HA ' ' HG3' ' B' ' 33' ' ' GLU . 6.2 p-10 -84.05 19.94 1.67 Allowed 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 113.97 -1.468 . . . . 0.0 111.618 -175.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 30' ' ' MET . . . . . . . . . . . . . 23.5 ptp -88.75 23.72 2.23 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 123.428 0.691 . . . . 0.0 110.597 -178.149 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.04 36.27 3.71 Favored Glycine 0 N--CA 1.437 -1.247 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 -178.66 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 48.6 tp -140.63 -77.11 0.31 Allowed 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.061 -177.566 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . 0.627 ' O ' ' HA3' ' B' ' 70' ' ' GLY . 45.7 mt-10 47.66 42.41 15.19 Favored 'General case' 0 C--O 1.215 -0.726 0 C-N-CA 124.922 1.289 . . . . 0.0 114.472 -179.355 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 34' ' ' LYS . . . . . 0.442 ' HA ' ' O ' ' B' ' 69' ' ' VAL . 65.2 mttm -73.46 87.16 1.57 Allowed 'General case' 0 CA--C 1.512 -0.492 0 CA-C-O 122.366 1.079 . . . . 0.0 112.847 178.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 35' ' ' LEU . . . . . . . . . . . . . 10.8 mp -125.84 -171.47 2.39 Favored 'General case' 0 C--N 1.296 -1.749 0 CA-C-N 113.181 -1.827 . . . . 0.0 106.662 178.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 36' ' ' GLY . . . . . . . . . . . . . . . -170.99 1.63 0.03 OUTLIER Glycine 0 C--N 1.292 -1.892 0 C-N-CA 119.817 -1.183 . . . . 0.0 111.067 174.409 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 37' ' ' ILE . . . . . 0.419 HG22 ' HB ' ' B' ' 21' ' ' ILE . 40.9 mm 65.39 114.64 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 CA-C-O 122.495 1.141 . . . . 0.0 110.543 -173.649 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.67 ' CD1' ' HB2' ' B' ' 24' ' ' MET . 29.0 m-85 -88.55 176.19 7.25 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.103 -0.953 . . . . 0.0 108.881 -175.205 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 64.6 t -83.93 142.9 12.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-O 121.654 0.74 . . . . 0.0 110.759 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 40' ' ' LYS . . . . . 0.433 ' HB3' ' HB2' ' B' ' 20' ' ' SER . 16.3 ttmm -94.34 -47.03 6.78 Favored 'General case' 0 N--CA 1.434 -1.261 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.769 -179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 41' ' ' THR . . . . . . . . . . . . . 3.1 t -162.32 171.76 16.73 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 -178.64 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.518 ' HA ' ' HA ' ' B' ' 19' ' ' ILE . 2.2 p -147.9 91.51 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.861 0 CA-C-O 122.35 1.071 . . . . 0.0 109.193 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 8.2 m -59.3 128.94 39.61 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 113.557 -1.656 . . . . 0.0 111.528 -176.518 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 44' ' ' GLU . . . . . 0.576 ' HA ' ' CG ' ' B' ' 49' ' ' HIS . 8.1 pt-20 -68.01 -17.2 64.35 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 112.558 0.577 . . . . 0.0 112.558 -177.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.26 -0.04 85.27 Favored Glycine 0 N--CA 1.436 -1.351 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.486 177.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . -111.14 169.59 13.36 Favored Glycine 0 N--CA 1.418 -2.503 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.923 -177.492 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . 0.515 ' HB2' ' HB2' ' B' ' 13' ' ' ASP . . . -55.08 -54.67 40.11 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 113.911 -1.144 . . . . 0.0 113.651 -174.198 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 48' ' ' ALA . . . . . 0.554 ' HA ' HD21 ' B' ' 10' ' ' LEU . . . -56.24 -35.37 67.29 Favored 'General case' 0 C--O 1.243 0.75 0 N-CA-C 114.051 1.13 . . . . 0.0 114.051 -172.246 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 49' ' ' HIS . . . . . 0.576 ' CG ' ' HA ' ' B' ' 44' ' ' GLU . 6.6 t60 -75.39 -46.8 30.71 Favored 'General case' 0 C--N 1.312 -1.037 0 O-C-N 123.656 0.597 . . . . 0.0 109.953 -177.003 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 65.7 mtp180 -73.49 -34.98 65.57 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.422 -175.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -66.01 -51.36 59.06 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.419 178.549 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 95.13 52.77 1.7 Allowed Glycine 0 N--CA 1.432 -1.571 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 53' ' ' ARG . . . . . 0.498 ' HB3' HG13 ' B' ' 8' ' ' VAL . 21.6 mmt180 -129.78 -72.78 0.57 Allowed 'General case' 0 N--CA 1.432 -1.328 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -178.629 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.596 HD11 ' CE2' ' B' ' 89' ' ' PHE . 45.4 mt -80.06 129.15 38.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 C-N-CA 119.288 -0.965 . . . . 0.0 108.925 178.278 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 55' ' ' GLN . . . . . 0.741 ' HB2' ' OD1' ' B' ' 58' ' ' ASP . 6.9 mt-30 -116.78 164.15 15.09 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 -176.624 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 14.8 p -59.14 -33.95 52.01 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.276 0 N-CA-C 115.949 1.833 . . . . 0.0 115.949 -171.511 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -105.52 5.46 31.47 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.112 -0.993 . . . . 0.0 112.421 -172.721 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 58' ' ' ASP . . . . . 0.741 ' OD1' ' HB2' ' B' ' 55' ' ' GLN . 5.2 m-20 -82.01 171.09 14.8 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-O 121.318 0.58 . . . . 0.0 111.984 -175.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 59' ' ' LEU . . . . . 0.473 ' O ' ' HA ' ' B' ' 91' ' ' ILE . 23.1 tp -131.54 133.11 44.72 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.312 -174.318 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 60' ' ' LEU . . . . . . . . . . . . . 66.0 mt -87.25 96.36 10.31 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 178.095 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 61' ' ' VAL . . . . . 0.621 ' O ' ' HB2' ' B' ' 68' ' ' LEU . 16.1 t -73.94 -38.46 49.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 CA-C-O 121.589 0.709 . . . . 0.0 110.928 179.092 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.565 ' CB ' ' HA ' ' B' ' 67' ' ' SER . 10.0 pt-20 -159.95 156.67 27.56 Favored 'General case' 0 C--N 1.282 -2.357 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.653 174.662 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 63' ' ' VAL . . . . . 0.468 HG22 ' H ' ' B' ' 64' ' ' ASP . 6.2 p -100.53 177.35 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 177.479 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 64' ' ' ASP . . . . . 0.468 ' H ' HG22 ' B' ' 63' ' ' VAL . 27.3 t70 -46.65 -56.67 5.74 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 114.156 1.169 . . . . 0.0 114.156 -173.808 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 65' ' ' GLY . . . . . . . . . . . . . . . -117.98 27.44 7.44 Favored Glycine 0 C--N 1.31 -0.877 0 C-N-CA 119.392 -1.385 . . . . 0.0 114.072 -177.504 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . 0.43 ' HB ' HG12 ' B' ' 63' ' ' VAL . 29.6 m -154.11 123.86 6.71 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 117.754 0.777 . . . . 0.0 109.788 179.193 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 67' ' ' SER . . . . . 0.565 ' HA ' ' CB ' ' B' ' 62' ' ' GLU . 11.1 t -96.46 129.19 43.87 Favored 'General case' 0 N--CA 1.426 -1.671 0 CA-C-O 121.078 0.466 . . . . 0.0 110.607 -177.25 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.621 ' HB2' ' O ' ' B' ' 61' ' ' VAL . 62.7 mt -92.03 124.2 35.95 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.081 179.212 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 69' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' B' ' 34' ' ' LYS . 14.4 p -93.05 -25.39 4.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 174.164 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 70' ' ' GLY . . . . . 0.627 ' HA3' ' O ' ' B' ' 33' ' ' GLU . . . 149.26 75.13 0.02 OUTLIER Glycine 0 N--CA 1.423 -2.176 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 -176.648 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 31.3 m -93.15 178.45 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 CA-C-N 114.912 -0.644 . . . . 0.0 110.691 -175.368 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 72' ' ' THR . . . . . . . . . . . . . 36.6 p -80.88 160.98 24.6 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 175.482 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 73' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -62.59 -35.42 79.47 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 120.944 0.402 . . . . 0.0 110.307 -178.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 74' ' ' SER . . . . . . . . . . . . . 19.2 m -66.41 -40.18 89.42 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.279 178.122 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 75' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -64.31 -46.35 83.95 Favored 'General case' 0 C--N 1.338 0.101 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 76' ' ' ALA . . . . . 0.413 ' O ' HG12 ' B' ' 79' ' ' VAL . . . -57.89 -46.91 84.2 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.382 178.293 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 77' ' ' ALA . . . . . . . . . . . . . . . -58.49 -42.01 86.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.005 0.431 . . . . 0.0 110.687 178.345 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 78' ' ' SER . . . . . . . . . . . . . 22.8 t -68.73 -32.68 72.64 Favored 'General case' 0 N--CA 1.431 -1.377 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.736 -178.565 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 79' ' ' VAL . . . . . 0.413 HG12 ' O ' ' B' ' 76' ' ' ALA . 9.8 p -78.09 -39.13 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 C-N-CA 119.582 -0.847 . . . . 0.0 109.921 -174.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 80' ' ' LEU . . . . . . . . . . . . . 45.6 mt -63.93 -34.02 77.02 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.822 177.647 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 81' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -87.66 -5.02 58.9 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.344 179.446 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 82' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -89.07 -37.04 15.41 Favored 'General case' 0 N--CA 1.431 -1.387 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 175.609 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 83' ' ' THR . . . . . 0.68 ' HB ' HG11 ' B' ' 87' ' ' VAL . 12.8 p -77.11 172.24 13.54 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.463 177.058 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 84' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt -69.11 -173.74 0.55 Allowed 'General case' 0 N--CA 1.444 -0.748 0 CA-C-O 121.738 0.78 . . . . 0.0 111.725 177.607 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 85' ' ' GLY . . . . . . . . . . . . . . . -81.4 -28.66 43.16 Favored Glycine 0 N--CA 1.431 -1.661 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 175.634 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . 0.459 ' HG3' ' O ' ' B' ' 10' ' ' LEU . 21.9 ttm-85 -106.76 111.3 23.76 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 121.406 0.622 . . . . 0.0 110.162 175.804 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 87' ' ' VAL . . . . . 0.68 HG11 ' HB ' ' B' ' 83' ' ' THR . 2.6 m -147.63 151.68 13.44 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-N 114.58 -1.191 . . . . 0.0 109.679 178.348 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . 0.431 ' HA ' ' O ' ' B' ' 8' ' ' VAL . 10.3 mtm-85 -101.28 110.31 22.3 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 123.992 0.808 . . . . 0.0 109.726 -179.718 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 89' ' ' PHE . . . . . 0.596 ' CE2' HD11 ' B' ' 54' ' ' ILE . 3.0 m-85 -95.23 158.97 15.23 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 179.426 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 90' ' ' MET . . . . . 0.479 ' O ' ' HB ' ' B' ' 61' ' ' VAL . 86.3 mtp -107.8 114.04 27.71 Favored 'General case' 0 C--N 1.29 -1.993 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 170.273 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.522 ' O ' ' HA ' ' B' ' 5' ' ' LEU . 1.4 mp -95.45 136.78 25.39 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 -179.006 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 92' ' ' GLY . . . . . . . . . . . . . . . -121.93 100.9 0.73 Allowed Glycine 0 CA--C 1.474 -2.506 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 175.283 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 16.4 tpp180 -163.61 132.78 3.96 Favored 'General case' 0 C--N 1.275 -2.652 0 CA-C-N 113.824 -1.188 . . . . 0.0 108.726 -178.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 94' ' ' GLU . . . . . 0.469 ' HG2' ' O ' ' B' ' 96' ' ' PRO . 41.6 tt0 -99.39 91.14 4.8 Favored 'General case' 0 N--CA 1.415 -2.19 0 N-CA-C 106.352 -1.721 . . . . 0.0 106.352 170.066 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 95' ' ' ARG . . . . . . . . . . . . . 45.0 ttt180 -58.13 -59.15 14.24 Favored Pre-proline 0 CA--C 1.554 1.12 0 CA-C-N 114.209 -1.36 . . . . 0.0 111.881 -177.633 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 96' ' ' PRO . . . . . 0.469 ' O ' ' HG2' ' B' ' 94' ' ' GLU . 41.6 Cg_endo -87.96 -172.38 0.8 Allowed 'Trans proline' 0 N--CA 1.448 -1.181 0 C-N-CA 122.005 1.804 . . . . 0.0 109.993 174.755 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 97' ' ' GLY . . . . . . . . . . . . . . . -106.34 -85.45 1.8 Allowed Glycine 0 C--N 1.28 -2.537 0 N-CA-C 107.436 -2.266 . . . . 0.0 107.436 171.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 98' ' ' GLU . . . . . . . . . . . . . 30.0 mt-10 -115.06 80.64 1.45 Allowed 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 174.065 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 99' ' ' GLN . . . . . . . . . . . . . 35.0 tt0 -72.06 148.84 45.41 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.942 -178.022 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 100' ' ' SER . . . . . . . . . . . . . 64.5 m 62.79 152.66 0.03 OUTLIER 'General case' 0 N--CA 1.437 -1.087 0 C-N-CA 126.514 1.925 . . . . 0.0 114.948 179.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 101' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -124.87 20.6 8.38 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-N 114.976 -1.011 . . . . 0.0 109.584 -174.549 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 102' ' ' VAL . . . . . . . . . . . . . 66.7 t -120.5 124.97 73.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 CA-C-O 122.075 0.941 . . . . 0.0 112.805 -171.725 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 103' ' ' ALA . . . . . . . . . . . . . . . -94.02 -76.33 0.48 Allowed 'General case' 0 C--N 1.277 -2.583 0 CA-C-N 114.639 -1.164 . . . . 0.0 108.346 173.215 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 104' ' ' GLN . . . . . . . . . . . . . 20.9 mm-40 -127.08 24.52 6.36 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.093 176.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 105' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -82.4 61.26 5.49 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 177.443 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 106' ' ' ILE . . . . . 0.414 ' HB ' ' OE1' ' B' ' 107' ' ' GLN . 38.2 mm -126.48 -60.44 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 N-CA-C 106.345 -1.724 . . . . 0.0 106.345 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . 0.414 ' OE1' ' HB ' ' B' ' 106' ' ' ILE . 0.3 OUTLIER -74.0 159.13 33.15 Favored 'General case' 0 N--CA 1.44 -0.953 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 172.879 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 108' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -140.73 138.34 34.11 Favored 'General case' 0 C--N 1.274 -2.711 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 176.192 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 109' ' ' THR . . . . . . . . . . . . . 10.2 t -74.73 124.18 26.31 Favored 'General case' 0 N--CA 1.417 -2.106 0 CA-C-O 121.711 0.767 . . . . 0.0 109.707 179.23 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 110' ' ' LEU . . . . . . . . . . . . . 31.3 mt -105.35 5.48 31.88 Favored 'General case' 0 C--N 1.281 -2.39 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 179.558 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 111' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -102.21 66.93 1.03 Allowed 'General case' 0 N--CA 1.417 -2.112 0 N-CA-C 105.649 -1.982 . . . . 0.0 105.649 174.32 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 112' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -144.8 93.2 2.37 Favored 'General case' 0 N--CA 1.427 -1.619 0 CA-C-N 114.376 -1.283 . . . . 0.0 107.726 -178.126 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 113' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 . . . . . 0 C--N 1.286 -2.158 0 CA-C-N 114.519 -1.219 . . . . 0.0 108.553 -176.217 . . . . . . . . 0 0 . 1 stop_ save_